-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 Dh71oPFdchNDwFtDvdpQhxUjdAbEzUiP6rCw9rwCRlVVvq00wLJUMsVCKV80GDVQ
 mFqQKO8/zdi1IivjjBEO2w==

<SEC-DOCUMENT>0000891092-04-002887.txt : 20040614
<SEC-HEADER>0000891092-04-002887.hdr.sgml : 20040611
<ACCEPTANCE-DATETIME>20040614143435
ACCESSION NUMBER:		0000891092-04-002887
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		9
CONFORMED PERIOD OF REPORT:	20040331
FILED AS OF DATE:		20040614

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ABAXIS INC
		CENTRAL INDEX KEY:			0000881890
		STANDARD INDUSTRIAL CLASSIFICATION:	IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835]
		IRS NUMBER:				770213001
		STATE OF INCORPORATION:			CA
		FISCAL YEAR END:			0331

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-19720
		FILM NUMBER:		04861059

	BUSINESS ADDRESS:	
		STREET 1:		3240 WHIPPLE
		STREET 2:		ROAD
		CITY:			UNION CITY
		STATE:			CA
		ZIP:			94587
		BUSINESS PHONE:		(510) 675-6500

	MAIL ADDRESS:	
		STREET 1:		3240 WHIPPLE
		STREET 2:		ROAD
		CITY:			UNION CITY
		STATE:			CA
		ZIP:			94587
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>e18184_10k.htm
<DESCRIPTION>FORM 10-K
<TEXT>
<HTML>
<HEAD>
<TITLE></TITLE>
     <!-- Created by EDGAR Ease Plus (EDGAR Ease+ 1.6a) -->
     <!-- Project:        N:\02_EDGAR\18184-ABAXIS\e18184.eep                              -->
     <!-- Control Number: 18184                                                            -->
     <!-- Rev Number:     1                                                                -->
     <!-- Client Name:    Abaxis (PRN)                                                     -->
     <!-- Project Name:   Form 10-K                                                        -->
     <!-- Firm Name:      Doremus Financial Printing                                       -->
</HEAD>

<BODY><H1 align=center><FONT face="Times New Roman, Times, Serif" size=4>UNITED STATES<BR></FONT><FONT face="Times New Roman, Times, Serif" size=4>SECURITIES AND EXCHANGE COMMISSION<BR></FONT><FONT face="Times New Roman, Times, Serif" size=3>Washington, DC 20549 </FONT></H1>

<H1 align=center><FONT face="Times New Roman, Times, Serif" size=4>FORM 10-K </FONT></H1>


<P>
<TABLE width="100%">
<TR>
<TD vAlign=top width="10%">&nbsp;</TD>
<TD vAlign=top align=center width="12%"><FONT size=2><I>(Mark One)<BR>|X| </I></FONT></TD>
<TD width="80%"><FONT size=2><BR>Annual report pursuant to Section&nbsp;13 or 15(d) of the Securities Exchange Act of 1934 For the fiscal year ended March&nbsp;31, 2004</FONT></TD></TR>
</TABLE>


<P align=center><FONT face="Times New Roman, Times, Serif" size=2>OR </FONT></P>


<P>
<TABLE width="100%">
<TR>
<TD vAlign=top width="10%">&nbsp;</TD>
<TD vAlign=top align=center width="12%"><FONT size=2>|_| </FONT></TD>
<TD width="78%"><FONT size=2>Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934</FONT></TD></TR>
</TABLE>


<H1 align=center><FONT face="Times New Roman, Times, Serif" size=3>Commission file number 000-19720 </FONT></H1>

<H1 align=center><FONT face="Times New Roman, Times, Serif" size=4>ABAXIS, INC. <BR></FONT><FONT face="Times New Roman, Times, Serif" size=2>(Exact name of registrant as specified in its charter) </FONT></H1>

<TABLE cellSpacing=0 cellPadding=0 width="100%" border=0>
<TR vAlign=bottom>
<TH colSpan=2>&nbsp;</TH>
<TH colSpan=2>&nbsp;</TH></TR>
<TR vAlign=bottom>
<TD align=left width="8%"><FONT size=2>&nbsp;</FONT></TD>
<TD align=center width="37%"><B><FONT size=2>California</FONT></B></TD>
<TD align=left width="4%"><B><FONT size=2>&nbsp;</FONT></B></TD>
<TD align=center width="49%"><B><FONT size=2>77-0213001</FONT></B></TD>
<TD align=left width="2%"><FONT size=2>&nbsp;</FONT></TD></TR>
<TR vAlign=bottom>
<TD align=left><FONT size=2>&nbsp;</FONT></TD>
<TD align=center><FONT size=2>(State of Incorporation)</FONT></TD>
<TD align=left><FONT size=2>&nbsp;</FONT></TD>
<TD align=center><FONT size=2>(I.R.S. Employer Identification No.)</FONT></TD>
<TD align=left><FONT size=2>&nbsp;</FONT></TD></TR>
</TABLE>


<H1 align=center><FONT face="Times New Roman, Times, Serif" size=3>3240 Whipple Road<BR>Union City, CA 94587<BR></FONT><FONT face="Times New Roman, Times, Serif" size=2>(Address of principal executive offices) </FONT></H1>

<P align=center><FONT face="Times New Roman, Times, Serif" size=3>Telephone number: <B>(510) 675-6500 </B><BR></FONT><FONT face="Times New Roman, Times, Serif" size=2>(Registrant&#146;s telephone number including area code) </FONT></P>

<P align=center><FONT face="Times New Roman, Times, Serif" size=2>Securities registered pursuant to Section&nbsp;12(b) of the Act: <B>None </B></FONT></P>

<P align=center><FONT face="Times New Roman, Times, Serif" size=2>Securities registered pursuant to Section&nbsp;12(g) of the Act: <BR></FONT><FONT face="Times New Roman, Times, Serif" size=3><B>Common Stock, No par value </B><BR></FONT><FONT face="Times New Roman, Times, Serif" size=2>(Title of Class) </FONT></P>


<P><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section&nbsp;13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes |X| No |_| </FONT></P>


<P><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K is not contained herein, and will not be contained, to the best of registrant&#146;s knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10-K or any amendment to this Form 10-K |_|. </FONT></P>


<P><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Indicate by check mark whether the registrant is an accelerated filer as defined in Rule 12b-2 of the Act. Yes |X| No |_| </FONT></P>


<P><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The aggregate market value of the voting stock held by non-affiliates of Abaxis, as of June&nbsp;7, 2004 was $343,084,646 based upon the closing sale price reported for such date on the NASDAQ National Market. For purposes of this disclosure, shares of common stock held by persons who hold more than 5% of the outstanding shares of common stock and shares held by officers and directors of the registrant have been excluded because such persons may be deemed to be affiliates. This determination of affiliate status is not necessarily conclusive for any other purpose. </FONT></P>


<P><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We had 19,597,815 shares of Common Stock outstanding on June 7, 2004. </FONT></P>


<P>&nbsp;
<TABLE width="100%">
<TR>
<TD align=center>&nbsp;</TD></TR>
</TABLE>



<P>
<HR align=left width="100%" noshade SIZE=5>


<P>&nbsp;
<!-- *************************************************************************** -->
<!-- MARKER PAGE="sheet: 12; page: 12" -->
<P align=center><FONT face="Times New Roman, Times, Serif" size=3><B>Abaxis, Inc.</B><BR></FONT><FONT face="Times New Roman, Times, Serif" size=2>Annual Report on Form 10-K <BR>For The Fiscal Year Ended March 31, 2004 <BR>TABLE OF CONTENTS </FONT></P>

<TABLE cellSpacing=0 cellPadding=0 width="100%" border=0>
<TR vAlign=bottom>
<TD align=left width="8%"><FONT size=2>&nbsp;</FONT></TD>
<TD align=center width="5%"><FONT size=2>&nbsp;</FONT></TD>
<TD align=left width="76%"><FONT size=2>&nbsp;</FONT></TD>
<TD align=left width="2%"><FONT size=2>&nbsp;</FONT></TD>
<TD align=right width="7%"><FONT size=2>Page</FONT></TD>
<TD align=left width="2%"><FONT size=2>&nbsp;</FONT></TD></TR>
<TR vAlign=bottom>
<TD align=left><FONT size=2>&nbsp;</FONT></TD>
<TD align=center width="5%"><FONT size=2>&nbsp;</FONT></TD>
<TD align=center><FONT size=2><B>PART I</B></FONT></TD>
<TD align=left><FONT size=2>&nbsp;</FONT></TD></TR>
<TR vAlign=bottom>
<TD align=left><FONT size=2>Item 1</FONT></TD>
<TD align=center width="5%"><FONT size=2>&nbsp;</FONT></TD>
<TD align=left><FONT size=2>Business</FONT></TD>
<TD align=left><FONT size=2>&nbsp;</FONT></TD>
<TD align=right><FONT size=2>3</FONT></TD>
<TD align=left><FONT size=2>&nbsp;</FONT></TD></TR>
<TR vAlign=bottom>
<TD align=left><FONT size=2>Item 2</FONT></TD>
<TD align=center width="5%"><FONT size=2>&nbsp;</FONT></TD>
<TD align=left><FONT size=2>Properties</FONT></TD>
<TD align=left><FONT size=2>&nbsp;</FONT></TD>
<TD align=right><FONT size=2>13</FONT></TD>
<TD align=left><FONT size=2>&nbsp;</FONT></TD></TR>
<TR vAlign=bottom>
<TD align=left><FONT size=2>Item 3</FONT></TD>
<TD align=center width="5%"><FONT size=2>&nbsp;</FONT></TD>
<TD align=left><FONT size=2>Legal Proceedings</FONT></TD>
<TD align=left><FONT size=2>&nbsp;</FONT></TD>
<TD align=right><FONT size=2>13</FONT></TD>
<TD align=left><FONT size=2>&nbsp;</FONT></TD></TR>
<TR vAlign=bottom>
<TD align=left><FONT size=2>Item 4</FONT></TD>
<TD align=center width="5%"><FONT size=2>&nbsp;</FONT></TD>
<TD align=left><FONT size=2>Submission of Matters to a Vote of Security Holders</FONT></TD>
<TD align=left><FONT size=2>&nbsp;</FONT></TD>
<TD align=right><FONT size=2>13</FONT></TD>
<TD align=left><FONT size=2>&nbsp;</FONT></TD></TR>
<TR vAlign=bottom>
<TD align=left><FONT size=2>&nbsp;</FONT></TD>
<TD align=center width="5%"><FONT size=2>&nbsp;</FONT></TD>
<TD align=center><FONT size=2><B>PART II</B></FONT></TD>
<TD align=left><FONT size=2>&nbsp;</FONT></TD></TR>
<TR vAlign=bottom>
<TD align=left><FONT size=2>Item 5</FONT></TD>
<TD align=center width="5%"><FONT size=2>&nbsp;</FONT></TD>
<TD align=left><FONT size=2>Market for the Registrant's Common Equity and Related Stockholder Matters</FONT></TD>
<TD align=left><FONT size=2>&nbsp;</FONT></TD>
<TD align=right><FONT size=2>13</FONT></TD>
<TD align=left><FONT size=2>&nbsp;</FONT></TD></TR>
<TR vAlign=bottom>
<TD align=left><FONT size=2>Item 6</FONT></TD>
<TD align=center width="5%"><FONT size=2>&nbsp;</FONT></TD>
<TD align=left><FONT size=2>Selected Financial Data</FONT></TD>
<TD align=left><FONT size=2>&nbsp;</FONT></TD>
<TD align=right><FONT size=2>14</FONT></TD>
<TD align=left><FONT size=2>&nbsp;</FONT></TD></TR>
<TR vAlign=bottom>
<TD align=left><FONT size=2>Item 7</FONT></TD>
<TD align=center width="5%"><FONT size=2>&nbsp;</FONT></TD>
<TD align=left><FONT size=2>Management's Discussion and Analysis of Financial Condition and Results of Operations</FONT></TD>
<TD align=left><FONT size=2>&nbsp;</FONT></TD>
<TD align=right><FONT size=2>16</FONT></TD>
<TD align=left><FONT size=2>&nbsp;</FONT></TD></TR>
<TR vAlign=bottom>
<TD align=left><FONT size=2>Item 7A</FONT></TD>
<TD align=center width="5%"><FONT size=2>&nbsp;</FONT></TD>
<TD align=left><FONT size=2>Quantitative and Qualitative Disclosure About Market Risk</FONT></TD>
<TD align=left><FONT size=2>&nbsp;</FONT></TD>
<TD align=right><FONT size=2>33</FONT></TD>
<TD align=left><FONT size=2>&nbsp;</FONT></TD></TR>
<TR vAlign=bottom>
<TD align=left><FONT size=2>Item 8</FONT></TD>
<TD align=center width="5%"><FONT size=2>&nbsp;</FONT></TD>
<TD align=left><FONT size=2>Financial Statements and Supplementary Data</FONT></TD>
<TD align=left><FONT size=2>&nbsp;</FONT></TD>
<TD align=right><FONT size=2>34</FONT></TD>
<TD align=left><FONT size=2>&nbsp;</FONT></TD></TR>
<TR vAlign=bottom>
<TD align=left><FONT size=2>&nbsp;</FONT></TD>
<TD align=center width="5%"><FONT size=2>&nbsp;</FONT></TD>
<TD align=left><FONT size=2>&nbsp;&nbsp;&nbsp;&nbsp;Report of Independent Registered Public Accounting Firm</FONT></TD>
<TD align=left><FONT size=2>&nbsp;</FONT></TD>
<TD align=right><FONT size=2>35</FONT></TD>
<TD align=left><FONT size=2>&nbsp;</FONT></TD></TR>
<TR vAlign=bottom>
<TD align=left><FONT size=2>&nbsp;</FONT></TD>
<TD align=center width="5%"><FONT size=2>&nbsp;</FONT></TD>
<TD align=left><FONT size=2>&nbsp;&nbsp;&nbsp;&nbsp;Balance Sheets at March 31, 2004 and 2003</FONT></TD>
<TD align=left><FONT size=2>&nbsp;</FONT></TD>
<TD align=right><FONT size=2>36</FONT></TD>
<TD align=left><FONT size=2>&nbsp;</FONT></TD></TR>
<TR vAlign=bottom>
<TD align=left><FONT size=2>&nbsp;</FONT></TD>
<TD align=center width="5%"><FONT size=2>&nbsp;</FONT></TD>
<TD align=left><FONT size=2>&nbsp;&nbsp;&nbsp;&nbsp;Statements of Operations for the Years Ended March 31, 2004, 2003 and 2002</FONT></TD>
<TD align=left><FONT size=2>&nbsp;</FONT></TD>
<TD align=right><FONT size=2>37</FONT></TD>
<TD align=left><FONT size=2>&nbsp;</FONT></TD></TR>
<TR vAlign=bottom>
<TD align=left><FONT size=2>&nbsp;</FONT></TD>
<TD align=center width="5%"><FONT size=2>&nbsp;</FONT></TD>
<TD align=left><FONT size=2>&nbsp;&nbsp;&nbsp;&nbsp;Statements of Shareholders' Equity for the Years Ended March 31, 2004, 2003</FONT></TD>
<TD align=left><FONT size=2>&nbsp;</FONT></TD>
<TD align=right><FONT size=2>38</FONT></TD>
<TD align=left><FONT size=2>&nbsp;</FONT></TD></TR>
<TR vAlign=bottom>
<TD align=left><FONT size=2>&nbsp;</FONT></TD>
<TD align=center width="5%"><FONT size=2>&nbsp;</FONT></TD>
<TD align=left><FONT size=2>&nbsp;&nbsp;&nbsp;&nbsp;and 2002</FONT></TD>
<TD align=left><FONT size=2>&nbsp;</FONT></TD></TR>
<TR vAlign=bottom>
<TD align=left><FONT size=2>&nbsp;</FONT></TD>
<TD align=center width="5%"><FONT size=2>&nbsp;</FONT></TD>
<TD align=left><FONT size=2>&nbsp;&nbsp;&nbsp;&nbsp;Statements of Cash Flows for the Years Ended March 31, 2004, 2003 and 2002</FONT></TD>
<TD align=left><FONT size=2>&nbsp;</FONT></TD>
<TD align=right><FONT size=2>39</FONT></TD>
<TD align=left><FONT size=2>&nbsp;</FONT></TD></TR>
<TR vAlign=bottom>
<TD align=left><FONT size=2>&nbsp;</FONT></TD>
<TD align=center width="5%"><FONT size=2>&nbsp;</FONT></TD>
<TD align=left><FONT size=2>&nbsp;&nbsp;&nbsp;&nbsp;Notes to Financial Statements</FONT></TD>
<TD align=left><FONT size=2>&nbsp;</FONT></TD>
<TD align=right><FONT size=2>40</FONT></TD>
<TD align=left><FONT size=2>&nbsp;</FONT></TD></TR>
<TR vAlign=bottom>
<TD align=left><FONT size=2>Item 9</FONT></TD>
<TD align=center width="5%"><FONT size=2>&nbsp;</FONT></TD>
<TD align=left><FONT size=2>Changes In and Disagreements with Accountants on Accounting and Financial Disclosure</FONT></TD>
<TD align=left><FONT size=2>&nbsp;</FONT></TD>
<TD align=right><FONT size=2>53</FONT></TD>
<TD align=left><FONT size=2>&nbsp;</FONT></TD></TR>
<TR vAlign=bottom>
<TD align=left><FONT size=2>Item 9A</FONT></TD>
<TD align=center width="5%"><FONT size=2>&nbsp;</FONT></TD>
<TD align=left><FONT size=2>Controls and Procedures</FONT></TD>
<TD align=left><FONT size=2>&nbsp;</FONT></TD>
<TD align=right><FONT size=2>53</FONT></TD>
<TD align=left><FONT size=2>&nbsp;</FONT></TD></TR>
<TR vAlign=bottom>
<TD align=left><FONT size=2>Item 9B</FONT></TD>
<TD align=center width="5%"><FONT size=2>&nbsp;</FONT></TD>
<TD align=left><FONT size=2>Other Information</FONT></TD>
<TD align=left><FONT size=2>&nbsp;</FONT></TD>
<TD align=right><FONT size=2>53</FONT></TD>
<TD align=left><FONT size=2>&nbsp;</FONT></TD></TR>
<TR vAlign=bottom>
<TD align=left><FONT size=2>&nbsp;</FONT></TD>
<TD align=center width="5%"><FONT size=2>&nbsp;</FONT></TD>
<TD align=center><FONT size=2><B>PART III</B></FONT></TD>
<TD align=left><FONT size=2>&nbsp;</FONT></TD></TR>
<TR vAlign=bottom>
<TD align=left><FONT size=2>Item 10</FONT></TD>
<TD align=center width="5%"><FONT size=2>&nbsp;</FONT></TD>
<TD align=left><FONT size=2>Directors and Executive Officers of the Registrant</FONT></TD>
<TD align=left><FONT size=2>&nbsp;</FONT></TD>
<TD align=right><FONT size=2>54</FONT></TD>
<TD align=left><FONT size=2>&nbsp;</FONT></TD></TR>
<TR vAlign=bottom>
<TD align=left><FONT size=2>Item 11</FONT></TD>
<TD align=center width="5%"><FONT size=2>&nbsp;</FONT></TD>
<TD align=left><FONT size=2>Executive Compensation and Other Matters</FONT></TD>
<TD align=left><FONT size=2>&nbsp;</FONT></TD>
<TD align=right><FONT size=2>56</FONT></TD>
<TD align=left><FONT size=2>&nbsp;</FONT></TD></TR>
<TR vAlign=bottom>
<TD align=left><FONT size=2>Item 12</FONT></TD>
<TD align=center width="5%"><FONT size=2>&nbsp;</FONT></TD>
<TD align=left><FONT size=2>Security Ownership of Certain Beneficial Owners and Management</FONT></TD>
<TD align=left><FONT size=2>&nbsp;</FONT></TD>
<TD align=right><FONT size=2>58</FONT></TD>
<TD align=left><FONT size=2>&nbsp;</FONT></TD></TR>
<TR vAlign=bottom>
<TD align=left><FONT size=2>Item 13</FONT></TD>
<TD align=center width="5%"><FONT size=2>&nbsp;</FONT></TD>
<TD align=left><FONT size=2>Certain Relationships and Related Transactions</FONT></TD>
<TD align=left><FONT size=2>&nbsp;</FONT></TD>
<TD align=right><FONT size=2>60</FONT></TD>
<TD align=left><FONT size=2>&nbsp;</FONT></TD></TR>
<TR vAlign=bottom>
<TD align=left><FONT size=2>Item 14</FONT></TD>
<TD align=center width="5%"><FONT size=2>&nbsp;</FONT></TD>
<TD align=left><FONT size=2>Principal Accountant Fees and Services</FONT></TD>
<TD align=left><FONT size=2>&nbsp;</FONT></TD>
<TD align=right><FONT size=2>60</FONT></TD>
<TD align=left><FONT size=2>&nbsp;</FONT></TD></TR>
<TR vAlign=bottom>
<TD align=left><FONT size=2>&nbsp;</FONT></TD>
<TD align=center width="5%"><FONT size=2>&nbsp;</FONT></TD>
<TD align=center><FONT size=2><B>PART IV</B></FONT></TD>
<TD align=left><FONT size=2>&nbsp;</FONT></TD></TR>
<TR vAlign=bottom>
<TD align=left><FONT size=2>Item 15</FONT></TD>
<TD align=center width="5%"><FONT size=2>&nbsp;</FONT></TD>
<TD align=left><FONT size=2>Exhibits, Financial Statement Schedules and Reports on Form 8-K</FONT></TD>
<TD align=left><FONT size=2>&nbsp;</FONT></TD>
<TD align=right><FONT size=2>60</FONT></TD>
<TD align=left><FONT size=2>&nbsp;</FONT></TD></TR>
<TR vAlign=bottom>
<TD align=left><FONT size=2>&nbsp;</FONT></TD>
<TD align=center width="5%"><FONT size=2>(a)</FONT></TD>
<TD align=left><FONT size=2>1. Financial Statements</FONT></TD>
<TD align=left><FONT size=2>&nbsp;</FONT></TD>
<TD align=right><FONT size=2>60</FONT></TD>
<TD align=left><FONT size=2>&nbsp;</FONT></TD></TR>
<TR vAlign=bottom>
<TD align=left><FONT size=2>&nbsp;</FONT></TD>
<TD align=center width="5%"><FONT size=2>&nbsp;</FONT></TD>
<TD align=left><FONT size=2>2. Financial Statement Schedules</FONT></TD>
<TD align=left><FONT size=2>&nbsp;</FONT></TD>
<TD align=right><FONT size=2>60</FONT></TD>
<TD align=right>&nbsp;</TD>
<TD align=left><FONT size=2>&nbsp;</FONT></TD></TR>
<TR vAlign=bottom>
<TD align=left><FONT size=2>&nbsp;</FONT></TD>
<TD align=center width="5%"><FONT size=2>&nbsp;</FONT></TD>
<TD align=left><FONT size=2>3. Exhibits filed with this Report on Form 10-K</FONT></TD>
<TD align=left><FONT size=2>&nbsp;</FONT></TD>
<TD align=right><FONT size=2>61</FONT></TD>
<TD align=left><FONT size=2>&nbsp;</FONT></TD>
<TD align=right>&nbsp;</TD>
<TD align=left><FONT size=2>&nbsp;</FONT></TD></TR>
<TR vAlign=bottom>
<TD align=left><FONT size=2>&nbsp;</FONT></TD>
<TD align=center width="5%"><FONT size=2>(b)</FONT></TD>
<TD align=left><FONT size=2>Reports on Form 8-K</FONT></TD>
<TD align=left><FONT size=2>&nbsp;</FONT></TD>
<TD align=right><FONT size=2>61</FONT></TD>
<TD align=left><FONT size=2>&nbsp;</FONT></TD></TR>
<TR vAlign=bottom>
<TD align=left><FONT size=2>Signatures</FONT></TD>
<TD align=center width="5%"><FONT size=2>&nbsp;</FONT></TD>
<TD align=left><FONT size=2>&nbsp;</FONT></TD>
<TD align=left><FONT size=2>&nbsp;</FONT></TD>
<TD align=right><FONT size=2>62</FONT></TD>
<TD align=left><FONT size=2>&nbsp;</FONT></TD></TR>
<TR vAlign=bottom>
<TD align=left><FONT size=2>Exhibits Index</FONT></TD>
<TD align=center width="5%"><FONT size=2>&nbsp;</FONT></TD>
<TD align=left><FONT size=2>&nbsp;</FONT></TD>
<TD align=left><FONT size=2>&nbsp;</FONT></TD>
<TD align=right><FONT size=2>64</FONT></TD>
<TD align=left><FONT size=2>&nbsp;</FONT></TD></TR>
<TR vAlign=bottom>
<TD align=left><FONT size=2>Certifications</FONT></TD>
<TD align=center width="5%"><FONT size=2>&nbsp;</FONT></TD>
<TD align=left><FONT size=2>&nbsp;</FONT></TD>
<TD align=left><FONT size=2>&nbsp;</FONT></TD>
<TD align=right><FONT size=2>68</FONT></TD>
<TD align=left><FONT size=2>&nbsp;</FONT></TD></TR>
<TR vAlign=bottom>
<TD align=left>&nbsp;</TD>
<TD align=center width="5%"><FONT size=2>&nbsp;</FONT></TD></TR>
</TABLE>



<P>&nbsp;
<TABLE width="100%">
<TR>
<TD align=center><FONT size=2>2</FONT></TD></TR>
</TABLE>



<P>
<HR align=left width="100%" noshade SIZE=5>


<P>&nbsp;
<!-- *************************************************************************** -->
<!-- MARKER PAGE="sheet: 13; page: 13" -->
<H1 align=center><FONT face="Times New Roman, Times, Serif" size=2>PART I </FONT></H1>


<P><FONT face="Times New Roman, Times, Serif" size=2>This report contains forward-looking statements within the meaning of Sections 21E of the Securities Exchange Act of 1934 that reflect Abaxis&#146; current view with respect to future events and financial performance. In this report, the words &#147;will,&#148; &#147;anticipates,&#148; &#147;believes,&#148; &#147;expects,&#148; &#147;intends,&#148; &#147;plans,&#148; &#147;future,&#148; and similar expressions identify forward-looking statements. These forward-looking statements are subject to certain risks and uncertainties, including but not limited to those discussed below, that could cause actual results to differ materially from historical results or those anticipated. Such risks and uncertainties include the market acceptance of our products and the continuing development of our products, required United States Food and Drug Administration (&#147;FDA&#148;) clearance and other government approvals, risks associated with manufacturing and
distributing our products on a commercial scale, free of defects, risk related to the introduction of new instruments manufactured by third parties, risks associated with entering the human diagnostic market on a larger scale, risks related to the protection of the our intellectual property or claims of infringement of intellectual property asserted by third parties, risks involved in carrying of inventory, risks associated with the ability to attract, train and retain competent sales personnel, general market conditions and competition. </FONT></P>


<P><FONT face="Times New Roman, Times, Serif" size=2>Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. Abaxis assumes no obligation to update any forward-looking statements as circumstances change. Readers are advised to read this Annual Report on Form 10-K in its entirety paying careful attention to the risk factors set forth in this and other reports or documents the Company files from time to time with the Securities and Exchange Commission, particularly the Quarterly Reports on Form 10-Q and any current reports on Form 8-K, copies of which may be obtained from Abaxis or from the Securities and Exchange Commission at its website at <I>www.sec.gov</I>. </FONT></P>

<H1 align=left><FONT face="Times New Roman, Times, Serif" size=2>ITEM 1. &nbsp;&nbsp;BUSINESS </FONT></H1>

<H1 align=left><FONT face="Times New Roman, Times, Serif" size=2>General </FONT></H1>


<P><FONT face="Times New Roman, Times, Serif" size=2>Abaxis, Inc. (&#147;us&#148; or &#147;we&#148;), incorporated in California in 1989, develops, manufactures and markets portable blood analysis systems for use in any veterinary or human patient-care setting to provide clinicians with rapid blood constituent measurements. Our principal offices are located at 3240 Whipple Road, Union City, California 94587 and our telephone number at that location is (510) 675-6500. Our Internet address is <I>www.abaxis.com</I>. We make available free of charge on or through our Internet website our annual reports on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K and all amendments to those reports as soon as reasonably practicable after such material is electronically filed with or furnished to the Securities and Exchange Commission. Our common stock trades on the Nasdaq National Market under the symbol &#147;ABAX.&#148; </FONT></P>


<P><FONT face="Times New Roman, Times, Serif" size=2>Our primary product is a blood analysis system, consisting of a compact 6.9 kilogram (15 pounds) analyzer and a series of single-use plastic discs, called reagent discs, containing all the chemicals required to perform a panel of up to 13 tests on veterinary patients and 14 tests on human patients. The system can be operated with minimal training and performs multiple routine tests on whole blood, serum or plasma samples. The system provides test results in less than 14 minutes with the precision and accuracy equivalent to a clinical laboratory analyzer. We currently market this system for veterinary use under the name VetScan&#174; and in the human medical market under the name Piccolo&#174;. </FONT></P>


<P><FONT face="Times New Roman, Times, Serif" size=2>Through April 2004, we marketed a veterinary hematology analyzer under the name VetScan HMT, which provided a complete blood count including three-part white blood cell differential in less than 2 minutes and required only 12 &#181;L (microliter) of whole blood. It provided results for eight selectable species, plus two user configurable programs. We marketed one type of reagent kit with this analyzer. We purchased the hematology analyzer and reagent kits from Melet Schloesing Laboratoires of France. We will continue to support and service our current population of VetScan HMT hematology customers. </FONT></P>


<P><FONT face="Times New Roman, Times, Serif" size=2>In May 2004, we introduced a hematology instrument (&#147;VetScan HMII&#148;) that offers an 18-parameter CBC (complete blood count) analysis, including a three-part white blood cell differential for the diagnostic assessment of patients by the veterinarian in their clinic. We entered into an original equipment manufacturing (&#147;OEM&#148;) agreement with Diatron Messtechnik GmbH (DIATRON) of Austria to purchase the DIATRON hematology instruments commencing in the fiscal quarter that the instruments were qualified, which was the first quarter of fiscal 2005. We market the combination of the VetScan and the VetScan HMII under the name VetScan DXS. </FONT></P>


<P><FONT face="Times New Roman, Times, Serif" size=2>We offer our point-of-care blood chemistry analyzer system with a total of 25 diagnostic tests. Our repertoire of tests includes alanine aminotransferase (ALT), albumin (ALB), alkaline phosphatase (ALP), amylase (AMY), aspartate aminotransferase (AST), calcium (CA++), creatine kinase (CK), chloride (CL-), creatinine (CRE), direct bilirubin (DBIL), gamma glutamyl </FONT></P>


<P>&nbsp;
<TABLE width="100%">
<TR>
<TD align=center><FONT size=2>3</FONT></TD></TR>
</TABLE>



<P>
<HR align=left noshade SIZE=5>


<P>&nbsp;
<!-- *************************************************************************** -->
<!-- MARKER PAGE="sheet: 14; page: 14" -->

<P><FONT face="Times New Roman, Times, Serif" size=2>transferase (GGT), glucose (GLU), high-density lipoprotein cholesterol (HDL), magnesium (MG), phosphorous (PHOS), potassium (K+), sodium (NA+), thyroxine (T4), total bilirubin (TBIL), total carbon dioxide (TCO2), total cholesterol (CHOL), total protein (TP), triglycerides (TRIG), urea nitrogen (BUN) and uric acid (UA). Nineteen of these tests are marketed for both human and veterinary markets. Tests for MG and T4 are currently marketed exclusively in the veterinary market. The tests for CL-, DBIL, HDL and TRIG are marketed exclusively in the human market. We market our reagent products by configuring these 25 test methods in panels that are designed to meet a variety of clinical diagnostic needs. We currently offer 11 multi-test reagent disc products in the human medical market and 8 multi-test reagent disc products in the veterinary market. </FONT></P>


<P><FONT face="Times New Roman, Times, Serif" size=2>Our focus in fiscal 2005 will be continued growth in the veterinary market where we believe we can receive immediate economic rewards, while at the same time expanding our presence in the human in vitro diagnostic point of care market. We intend to continue our marketing efforts of our Piccolo systems to the U.S. military. Internationally, we will continue to focus our sales efforts in Asia, Europe and Latin America. </FONT></P>

<H1 align=left><FONT face="Times New Roman, Times, Serif" size=2>Our Industry: In Vitro Diagnostic Testing </FONT></H1>


<P><FONT face="Times New Roman, Times, Serif" size=2>We believe that a key element of the patient-centered, cost-constrained health care system in the current year and beyond will be the availability of blood analysis systems in the patient care setting that are easily and reliably operated by caregivers and provide accurate, real time results for enabling rapid clinical decisions. The optimal system uses whole blood, has built-in calibration and quality control, provides quick turnaround time, is portable and low cost. In addition, the optimal near-patient system should be easy to use by people with no special training and capable of transmitting test results instantly to caregivers and patient information management systems. </FONT></P>


<P><FONT face="Times New Roman, Times, Serif" size=2>Abaxis has developed a blood analysis system incorporating all of these criteria into a 6.9 kilogram (15 pounds) analyzer and a series of menu-specific, multi-test single-use reagent discs. The system is essentially a compact portable laboratory that can be easily located near the patient. Each reagent disc is pre-configured with multiple analytes and contains all the reagents necessary to perform a fixed menu of tests. Taking the system to the patient care site instead of shipping the sample to a central laboratory makes blood testing and analysis as easy as measuring the patient&#146;s blood pressure, temperature, and heart rate and eliminates the necessity of multiple visits to the doctor&#146;s office. Additional advantages of near-patient testing include eliminating errors from sample handling, transcription and transportation. We have adapted this blood analysis system in both the veterinary and human medical markets in order to bring the same
advantages to all healthcare professionals and patients. </FONT></P>

<H1 align=left><FONT face="Times New Roman, Times, Serif" size=2>Abaxis Products </FONT></H1>

<P align=left><FONT face="Times New Roman, Times, Serif" size=2><I>Point-of-Care Blood Chemistry Analyzers</I> </FONT></P>


<P><FONT face="Times New Roman, Times, Serif" size=2>We currently manufacture and market our point-of-care blood chemistry analyzers for veterinary use under the name VetScan&#174; and in the human medical market under the name Piccolo&#174;. The blood analysis system is a portable spectrophotometer, which is a device that measures the absorption of light at various wavelengths. A variable speed motor is used to spin a reagent disc for sample processing. The chemical reactions in the disc&#146;s cuvettes are measured optically by detecting the light absorbance of the solutions in the cuvettes at pre-determined wavelengths. The absorbances are converted to clinically relevant units by a measurement microprocessor. Results are stored by the analyzer&#146;s interface microprocessor, sent to an RS232 port and printed on result cards by an internal thermal printer or transmitted to a patient data management system. The features of the analyzer include a small required sample size (100 &#181;L) of whole
blood, serum or plasma, an intelligent quality control system that includes many self-test functions to ensure quality results, a built-in instrument self calibration, a built-in printer, a quick turn-around time of less than 14 minutes, minimal operational training and ease of information transmission using a computer port on the analyzer. </FONT></P>

<P align=left><FONT face="Times New Roman, Times, Serif" size=2><I>Hematology</I> </FONT></P>


<P><FONT face="Times New Roman, Times, Serif" size=2>From March 1999 to April 2004, we entered into an original equipment manufacturing (OEM) and distribution agreement with MELET SCHLOESING Laboratoires (MELET) under which we marketed and sold the MELET hematology instrument and reagents and MELET marketed and sold the VetScan and Piccolo products. We marketed the MELET hematology instrument as the VetScan&#174; HMT in the veterinary market. </FONT></P>


<P><FONT face="Times New Roman, Times, Serif" size=2>In May 2004, we introduced the VetScan HMII, a hematology instrument that offers an 18-parameter CBC (complete blood count) analysis, including a three-part white blood cell differential for the diagnostic assessment of patients by the veterinarian in their clinic. We entered into an original equipment manufacturing (&#147;OEM&#148;) agreement with Diatron Messtechnik GmbH (DIATRON) of Austria to purchase the DIATRON hematology instruments commencing in the fiscal quarter that the </FONT></P>

<TABLE width="100%">
<TR>
<TD align=center><FONT size=2>4</FONT></TD></TR>
</TABLE>



<P>
<HR align=left noshade SIZE=5>


<P>&nbsp;
<!-- *************************************************************************** -->
<!-- MARKER PAGE="sheet: 14; page: 14" -->

<P><FONT face="Times New Roman, Times, Serif" size=2>instruments were qualified, which was the first quarter of fiscal 2005. We market the combination of the VetScan and the VetScan HMII under the name VetScan DXS. </FONT></P>

<P align=left><FONT face="Times New Roman, Times, Serif" size=2><I>Reagent Discs</I> </FONT></P>


<P><FONT face="Times New Roman, Times, Serif" size=2>The reagent discs, used with the blood chemistry analyzers, are designed to handle almost all technical steps of blood chemistry testing automatically. The discs first separate a whole blood sample into plasma and blood cells, meter the required quantity of plasma and diluent, mix the plasma and diluent, and deliver the mixture to the reagent chambers, called cuvettes, along the disc perimeter. The diluted plasma dissolves and mixes with the reagent beads initiating the chemical reactions, which are monitored by the analyzer. The discs are 8-cm diameter, single-use devices constructed from three ultrasonically welded injection-molded plastic parts. The base and the middle piece create the chambers, cuvettes and passageways for processing the whole blood and mixing plasma with diluent and reagents. The top piece, referred to as the bar code ring, is imprinted with bar codes that contain disc-specific calibration information. In the center of the disc
is a plastic diluent container sealed with polyethylene-laminated foil. Spherical lyophilized reagent beads are placed in the cuvettes during disc manufacturing. Upon completion of the analysis, used discs may be placed back into their foil pouches to minimize human contact with blood prior to proper disposal. </FONT></P>


<P><FONT face="Times New Roman, Times, Serif" size=2>To perform a panel of tests, the operator collects a blood sample. The operator then transfers the sample into the reagent disc. The operator places the disc into the analyzer drawer, and enters patient, physician, and operator identification numbers. The analyzer spins the disc to separate cells from plasma, meters and mixes plasma with diluent, distributes diluted plasma to the cuvettes, and monitors chemical reactions. In less than 14 minutes, results are printed out on a result card with an adhesive backing or can be transmitted to a patient data management system for inclusion in the patient&#146;s medical record. A computer port enables transmission of patient results to external computers for patient data management. </FONT></P>


<P><FONT face="Times New Roman, Times, Serif" size=2>The VetScan system was introduced in the U.S. veterinary market in July 1994. We initially launched the system with the Diagnostic Profile, a nine-test reagent product. Since then, we have added new test methods and new reagent disc products targeted to fulfill different veterinary diagnostic needs. The following is a list of the current VetScan reagents offered: </FONT></P>

<TABLE cellSpacing=0 cellPadding=0 width="100%" border=0>
<TR vAlign=bottom>
<TD align=left><FONT size=2><B>VetScan Profile</B></FONT>
<HR width="100%" color=black noshade SIZE=1>
</TD>
<TD align=left><FONT size=2><B>Description of the Test Panels</B></FONT>
<HR width="100%" color=black noshade SIZE=1>
</TD></TR>
<TR vAlign=bottom>
<TD align=left width="34%"><FONT size=2>Comprehensive Diagnostic Profile</FONT></TD>
<TD align=left width="66%"><FONT size=2>ALB, ALP, ALT, AMY, BUN, CA++, CRE, GLOB, GLU, K+, NA+, PHOS, TBIL, TP.</FONT></TD></TR>
<TR>
<TD>&nbsp;</TD>
<TD>&nbsp;</TD></TR>
<TR vAlign=bottom>
<TD align=left><FONT size=2>Diagnostic Profile Plus</FONT></TD>
<TD align=left><FONT size=2>ALB, ALP, ALT, AMY, BUN, CA++, CHOL, CRE, GLOB, GLU, K+, TBIL, TP.</FONT></TD></TR>
<TR>
<TD>&nbsp;</TD>
<TD>&nbsp;</TD></TR>
<TR vAlign=bottom>
<TD align=left><FONT size=2>Prep Profile II</FONT></TD>
<TD align=left><FONT size=2>ALP, ALT, BUN, CRE, GLU, TP.</FONT></TD></TR>
<TR>
<TD>&nbsp;</TD>
<TD>&nbsp;</TD></TR>
<TR vAlign=bottom>
<TD align=left><FONT size=2>Critical Care Profile</FONT></TD>
<TD align=left><FONT size=2>ALT, BUN, CRE, GLU, K+, NA+, tCO2.</FONT></TD></TR>
<TR>
<TD>&nbsp;</TD>
<TD>&nbsp;</TD></TR>
<TR vAlign=bottom>
<TD align=left><FONT size=2>Equine Profile</FONT></TD>
<TD align=left><FONT size=2>ALB, AST, BUN, CA++, CK, CRE, GGT, GLOB, GLU, TBIL, TP.</FONT></TD></TR>
<TR>
<TD>&nbsp;</TD>
<TD>&nbsp;</TD></TR>
<TR vAlign=bottom>
<TD align=left><FONT size=2>Large Animal Profile</FONT></TD>
<TD align=left><FONT size=2>ALB, ALP, AST, BUN, CA++, CK, GGT, GLOB, MG++, PHOS, TP.</FONT></TD></TR>
<TR>
<TD>&nbsp;</TD>
<TD>&nbsp;</TD></TR>
<TR vAlign=bottom>
<TD align=left><FONT size=2>T4-Cholesterol Profile</FONT></TD>
<TD align=left><FONT size=2>CHOL, T4.</FONT></TD></TR>
<TR>
<TD>&nbsp;</TD>
<TD>&nbsp;</TD></TR>
<TR vAlign=bottom>
<TD align=left><FONT size=2>Avian-Reptilian Profile</FONT></TD>
<TD align=left><FONT size=2>ALB, AST, BUN, CA++, CK, GLOB, GLU, K+, NA+, PHOS, TP, UA.</FONT></TD></TR>
<TR>
<TD>&nbsp;</TD>
<TD>&nbsp;</TD></TR>
<TR vAlign=bottom>
<TD align=left>&nbsp;</TD></TR>
</TABLE>



<P><FONT face="Times New Roman, Times, Serif" size=2>We introduced our Piccolo system to the human medical market in November 1995 with two reagent discs, General Health Panel 8 and General Health Panel 11. Since that time we have introduced new panels to aid conventional disease diagnosis or monitor disease treatment. The following is a list of the current Piccolo reagents offered: </FONT></P>

<TABLE cellSpacing=0 cellPadding=0 width="100%" border=0>
<TR vAlign=bottom>
<TD align=left><FONT size=2><B>Piccolo Panels</B></FONT>
<HR width="100%" color=black noshade SIZE=1>
</TD>
<TD align=left><FONT size=2><B>Description of the Test Panels</B></FONT>
<HR width="100%" color=black noshade SIZE=1>
</TD></TR>
<TR vAlign=bottom>
<TD align=left width="34%"><FONT size=2>General Chemistry 12</FONT></TD>
<TD align=left width="66%"><FONT size=2>ALB, ALP, ALT, AMY, AST, BUN, CA++, CHOL, CRE, GLU, TBIL, TP.</FONT></TD></TR>
<TR>
<TD>&nbsp;</TD>
<TD>&nbsp;</TD></TR>
<TR vAlign=bottom>
<TD align=left><FONT size=2>Liver Panel Plus</FONT></TD>
<TD align=left><FONT size=2>ALB, ALP, ALT, AMY, AST, GGT, TBIL, TP.</FONT></TD></TR>
<TR>
<TD>&nbsp;</TD>
<TD>&nbsp;</TD></TR>
<TR vAlign=bottom>
<TD align=left><FONT size=2>General Chemistry 7</FONT></TD>
<TD align=left><FONT size=2>BUN, CA++, CHOL, CRE, GLU, TBIL, UA.</FONT></TD></TR>
<TR vAlign=bottom>
<TD align=left>&nbsp;</TD></TR>
</TABLE>

<BR>
<TABLE width="100%">
<TR>
<TD align=center><FONT size=2>5</FONT></TD></TR>
</TABLE>



<P>
<HR align=left noshade SIZE=5>


<P>&nbsp;
<!-- *************************************************************************** -->
<!-- MARKER PAGE="sheet: 14; page: 14" --><BR>
<TABLE cellSpacing=0 cellPadding=0 width="100%" border=0>
<TR>
<TD>&nbsp;</TD>
<TD>&nbsp;</TD></TR>
<TR vAlign=bottom>
<TD align=left width="36%"><FONT size=2>General Chemistry 6</FONT></TD>
<TD align=left width="64%"><FONT size=2>ALT, AST, BUN, CRE, GGT, GLU.</FONT></TD></TR>
<TR>
<TD>&nbsp;</TD>
<TD>&nbsp;</TD></TR>
<TR vAlign=bottom>
<TD align=left><FONT size=2>Electrolyte Panel</FONT></TD>
<TD align=left><FONT size=2>CL- ,K+, Na+, tCO2.</FONT></TD></TR>
<TR>
<TD>&nbsp;</TD>
<TD>&nbsp;</TD></TR>
<TR vAlign=bottom>
<TD align=left><FONT size=2>MetLyte 8</FONT></TD>
<TD align=left><FONT size=2>BUN, CK, CL-, CRE, GLU, K+, Na+, tCO2.</FONT></TD></TR>
<TR>
<TD>&nbsp;</TD>
<TD>&nbsp;</TD></TR>
<TR vAlign=bottom>
<TD align=left><FONT size=2>Basic Metabolic Panel</FONT></TD>
<TD align=left><FONT size=2>BUN, CA++, CL-, CRE, GLU, K+, NA+, tCO2.</FONT></TD></TR>
<TR>
<TD>&nbsp;</TD>
<TD>&nbsp;</TD></TR>
<TR vAlign=bottom>
<TD align=left><FONT size=2>Lipid Panel</FONT></TD>
<TD align=left><FONT size=2>TOTAL CHOL, TOTAL CHOL/HDL RATIO, HDL, LDL, TRIG, VLDL.</FONT></TD></TR>
<TR>
<TD>&nbsp;</TD>
<TD>&nbsp;</TD></TR>
<TR vAlign=bottom>
<TD align=left><FONT size=2>Renal Panel</FONT></TD>
<TD align=left><FONT size=2>ALB, BUN, CA++, CL-, CRE, GLU, K+, NA+, PHOS, tCO2.</FONT></TD></TR>
<TR>
<TD>&nbsp;</TD>
<TD>&nbsp;</TD></TR>
<TR vAlign=bottom>
<TD align=left><FONT size=2>Comprehensive Metabolic</FONT></TD>
<TD align=left><FONT size=2>ALB, ALP, ALT, AST, BUN, CA++, CL-, CRE, GLU, K+, NA+, TBIL, tCO2, TP.</FONT></TD></TR>
<TR>
<TD>&nbsp;</TD>
<TD>&nbsp;</TD></TR>
<TR vAlign=bottom>
<TD align=left><FONT size=2>Hepatic Panel</FONT></TD>
<TD align=left><FONT size=2>ALB, ALP, ALT, AST, DBIL, TBIL, TP.</FONT></TD></TR>
<TR>
<TD>&nbsp;</TD>
<TD>&nbsp;</TD></TR>
<TR vAlign=bottom>
<TD align=left>&nbsp;</TD></TR>
</TABLE>

<BR>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2><I>Orbos Process</I> </FONT></P>


<P><FONT face="Times New Roman, Times, Serif" size=2>The dry reagents used in our reagent discs are produced using a proprietary technology called the Orbos&#174; Discrete Lyophilization Process. This process allows the production of an accurate, precise amount of active chemical ingredient in the form of a soluble bead. The Orbos process involves flash-freezing a drop of liquid reagent to form a solid bead and then freeze-drying the bead to remove water. The Orbos beads are stable in dry form and dissolve rapidly in aqueous solutions. We believe that the Orbos process has broad applications in products where delivery of active ingredients in a stable, pre-metered format is desired. We have licensed the technology underlying the Orbos process to Amersham Biosciences Corp. (formerly Pharmacia Biotech, Inc.) and we have a supply contract with Becton Dickinson Immunocytometry Systems for products using the Orbos process. Revenues from these arrangements, however, are unpredictable. We continue to explore
potential applications with other companies, although there can be no assurance that we will be able to develop any new applications for the Orbos process. </FONT></P>

<P align=left><FONT face="Times New Roman, Times, Serif" size=2><I>VetScan Canine Heartworm Antigen Test</I> </FONT></P>


<P><FONT face="Times New Roman, Times, Serif" size=2>In December 2001, we introduced and launched the VetScan Canine Heartworm Antigen Test. We purchased the VetScan Canine Heartworm Antigen Test from S.A. Scientific, Inc., of San Antonio, Texas, a privately-held leader in the development and manufacturing of a wide-range of one-step rapid tests for various diseases. In March 2002, Idexx Laboratories, Inc. sued both Abaxis and S.A. Scientific for infringement upon patents issued to Idexx. On December 6, 2002, the case was settled under the terms of an out-of-court agreement between the parties. Among other terms, Abaxis paid Idexx $249,500 in cash damages and ceased the selling of the particular canine heartworm antigen test referenced in the complaint. Although we subsequently sold a limited number of redesigned canine heartworm tests manufactured by S.A. Scientific, we have subsequently terminated our relationship with S.A. Scientific. We are exploring whether or not we will introduce another canine
heartworm antigen test in the near future, although there can be no assurance that we would be successful in any such efforts or that any party will not claim patent infringement on us or file suit upon other grounds. </FONT></P>

<P align=left><FONT face="Times New Roman, Times, Serif" size=2><I>Future Products</I> </FONT></P>


<P><FONT face="Times New Roman, Times, Serif" size=2>We continue to develop new products that we believe will provide further opportunities for growth in the human and veterinary markets. For the human medical market, we completed and released the developments of the Renal Function, Hepatic Function and Comprehensive Metabolic Panels during fiscal 2004. Additionally, we have begun working on the feasibility of a second generation Lipid Panel Disc that would add liver function and glucose tests to the lipid panel. Development of tests for other disc products will be targeted at specific applications based on fulfilling clinical needs. Our current focus of test methods development is in general clinical chemistry. In addition to general clinical chemistry, we have demonstrated our ability to perform immunoassay tests on our blood analysis system by successfully developing the Thyroxine (T4) test in the veterinary market. We believe other immunoassay methods can be performed with our discs to measure a
wide assortment of blood analytes, including cardiac markers. Although there can be no assurance that we will be able to develop any of these potential products, we believe that our technology and expertise will allow us to develop reagent disc products in the future to provide a variety of additional blood tests. </FONT></P>

<TABLE width="100%">
<TR>
<TD align=center><FONT size=2>6</FONT></TD></TR>
</TABLE>



<P>
<HR align=left noshade SIZE=5>


<P>&nbsp;
<!-- *************************************************************************** -->
<!-- MARKER PAGE="sheet: 14; page: 14" -->
<H1 align=left><FONT face="Times New Roman, Times, Serif" size=2><B>Customers and Distribution</B> </FONT></H1>

<P align=left><FONT face="Times New Roman, Times, Serif" size=2><I>Customers</I> </FONT></P>


<P><FONT face="Times New Roman, Times, Serif" size=2>Our point-of-care blood analyzer products and reagent discs are sold either directly or through distributors depending on the needs of the customer segment. In the delivery of human or veterinary care there are many kinds of providers and a multitude of sites where Abaxis products could be used as an alternative to relying on a central laboratory for blood test information. </FONT></P>


<P><FONT face="Times New Roman, Times, Serif" size=2>We believe that our current Piccolo system menu of 24 reagent test results is suitable for a wide variety of the human medical market segments. These market segments include military installations (ships, field hospitals and mobile care units), physicians office practices, urgent care and walk-in clinics (free-standing or hospital-connected), home care providers (national, regional or local), nursing homes, ambulance companies, dialysis centers, hospital labs and draw stations. </FONT></P>


<P><FONT face="Times New Roman, Times, Serif" size=2>We believe that our current veterinary reagent product offerings meet a substantial part of the clinical diagnostic needs of veterinarians. Potential customers for the VetScan DXS are primarily companion animal hospitals, animal clinics with mixed practices of small animals, birds and reptiles, equine practitioners, veterinary referral hospitals, private toxicology laboratories and university and government toxicology research laboratories. </FONT></P>

<P align=left><FONT face="Times New Roman, Times, Serif" size=2><I>Distribution Within North America </I></FONT></P>


<P><FONT face="Times New Roman, Times, Serif" size=2>We sell our human-oriented products directly to those customers who serve large human patient populations with employed caregivers such as the military, hospitals and managed care organizations. As a result of health care reform, we anticipate a consolidation of providers with more centralized purchasing of medical products based on the standardization of care and the use of patient outcome studies to influence purchase decisions. We plan to achieve our direct sales objectives by employing highly skilled sales specialists and eventually sales teams which will work closely with providers in performing studies to show that the use of the Piccolo point-of-care blood chemistry analyzer rather than laboratory alternatives can provide better outcomes at a lower cost. </FONT></P>


<P><FONT face="Times New Roman, Times, Serif" size=2>In the future, we will be exploring distribution alternatives with local and national organizations. These distributors can contribute to identifying potential customers and introducing the product, but often need the support of our personnel in closing the sale. Product distributors are generally of two types: large companies that primarily serve hospitals, clinics and large health maintenance organizations (HMOs) nationwide using multiple warehouses and extensive transportation systems and smaller companies that provide the daily supplies needed by office-based physicians. However, several large distributors have acquired local and regional companies to service the office-based physicians market segment as well. In the human market, national firms sell thousands of products, including furniture, capital equipment, surgical instruments and a myriad of consumables. The smaller companies generally direct their product offerings to those items a
physician uses daily in caring for primarily ambulatory patients. These firms also may sell lower priced equipment such as diagnostic instruments, which are used in conjunction with consumable reagents. </FONT></P>


<P><FONT face="Times New Roman, Times, Serif" size=2>Veterinarians are served typically by local distributors, some with national affiliations. Our largest volume purchaser is Vedco, Inc., which is a national network of independent distributors through which six member distributors represent our products. We also work with ten additional independent distributors of which DVM Resources is our fastest growing partner in instrument and consumable sales. In addition to selling through distributors, we directly supply our VetScan products to Veterinary Centers of America (VCA), the nation&#146;s largest veterinary hospital chain. In April 2004, we signed a distributor agreement with the Veterinary Division of Henry Schein, Inc., a distributor of animal healthcare products and services to veterinary practitioners to sell and distribute the VetScan DXS, along with the associated reagent discs and kits. We intend to enter into arrangements with additional veterinary distributors as well as pursue direct
veterinary sales where appropriate. </FONT></P>

<P align=left><FONT face="Times New Roman, Times, Serif" size=2><I>Distribution Outside of North America</I> </FONT></P>


<P><FONT face="Times New Roman, Times, Serif" size=2>Our international sales and marketing objectives include identifying and defining the market segments in each country by product and then focusing on specific objectives for each segment in each country. These specific objectives include modification and expansion of distribution and distributor training and monitoring to ensure the attainment of sales goals. </FONT></P>


<P><FONT face="Times New Roman, Times, Serif" size=2>We currently have distribution agreements in the following countries: Argentina, Australia, Austria, Bahrain, Belgium, France, Germany, Greece, Israel, Italy, Japan, Korea, Kuwait, Mexico, New Zealand, Nigeria, Norway, Poland, Portugal, South Africa, Spain, Switzerland, United Arab Emirates, the United Kingdom and Venezuela. Each distributor agreement contains a number of requirements that must be met to retain exclusivity, including minimum order quantity commitments, trade show and promotion requirements and a specified number of demonstration analyzer requirements. In most cases, the foreign distributors need to either go through a FDA-equivalent approval process with national regulators or clinical trials/market evaluations with </FONT></P>

<TABLE width="100%">
<TR>
<TD align=center><FONT size=2>7</FONT></TD></TR>
</TABLE>



<P>
<HR align=left noshade SIZE=5>


<P>&nbsp;
<!-- *************************************************************************** -->
<!-- MARKER PAGE="sheet: 14; page: 14" -->

<P><FONT face="Times New Roman, Times, Serif" size=2>their local opinion leaders
  in the medical field. Each distributor is responsible for obtaining the required
  approvals. There can be no assurance that any of our distributors will be successful
  in obtaining proper approvals for Abaxis products in their respective countries
  or that these distributors will be successful in marketing Abaxis products.
  In August 2001, we signed a non-exclusive agreement with Scil Animal Care Company
  GmbH of Germany, a leading supplier of veterinary technology and supplies, to
  distribute the VetScan in defined European countries. In August 2002, we entered
  into an exclusive distribution agreement to distribute our VetScan products
  in Japan with T. Chatani &amp; Co. We plan to continue to enter into additional
  distribution agreements to enhance our international distribution base and solidify
  our international presence.</FONT></P>

<H1 align=left><FONT face="Times New Roman, Times, Serif" size=2>Competition </FONT></H1>


<P><FONT face="Times New Roman, Times, Serif" size=2>Competition in the human and veterinary diagnostic markets is intense. Blood analysis is a well established field in which there are a number of competitors that have substantially greater financial resources and larger, more established marketing, sales and service organizations than we do. We compete with the following organizations: commercial clinical laboratories, hospitals&#146; clinical laboratories and manufacturers of bench top multi-test blood analyzers and other testing systems that health care providers can use &#147;on-site.&#148; </FONT></P>


<P><FONT face="Times New Roman, Times, Serif" size=2>Historically, hospitals and commercial laboratories perform most of the human medical testing, and commercial laboratories perform the most veterinary medical testing. We have identified five principal factors that customers typically use to evaluate our products and those of our competitors. These factors are as follows: range of tests offered; the immediacy of results; cost effectiveness; ease of use and reliability of results. We believe that we compete effectively on each of these factors except for the range of tests offered. Clinical laboratories are effective at processing both a wide range and high volumes of discrete tests using skilled technicians and complex equipment. While our current offering of reagent discs cannot provide the same broad range of tests, we believe that in our targeted market segments, our products provide a sufficient breadth of test menus to compete successfully with clinical laboratories given the advantages of our
products with respect to the other four factors. </FONT></P>


<P><FONT face="Times New Roman, Times, Serif" size=2>Our principal competitors in the human blood-analyzer market are Alfa Wassermann S.P.A., Hemagen Diagnostics, Inc., i-STAT Corporation (which was recently purchased by Abbott Laboratories), Johnson &amp; Johnson (including its subsidiary, Ortho-Clinical Diagnostics, Inc.), Novitron International, Inc. and Roche. Our principal competitors in the veterinary blood-analyzer market are Idexx Laboratories, Inc. and Heska Corporation. Most of our competitors have significantly greater financial and other resources than we do. In particular, many of our competitors have large sales forces and well-established distribution channels. Consequently, we are developing our distribution network and expanding our direct sales force in order to compete in these markets. </FONT></P>

<H1 align=left><FONT face="Times New Roman, Times, Serif" size=2>Manufacturing </FONT></H1>


<P><FONT face="Times New Roman, Times, Serif" size=2>We manufacture our Piccolo and VetScan products from our facilities located in Union City, California. The VetScan HMII is manufactured by DIATRON in Austria and is purchased by us as a completed instrument. </FONT></P>


<P><FONT face="Times New Roman, Times, Serif" size=2>Our Piccolo products are regulated under the 1976 Medical Device Amendments to the Food, Drug and Cosmetic Act, which is administered by the Food and Drug Administration. To produce and commercially ship Piccolo products, we must have a license to manufacture medical products in the State of California, where we conduct our principal manufacturing activities, and have approval from the FDA as a medical device manufacturer. The 1976 Medical Device Amendment requires us to manufacture our Piccolo products in accordance with current Good Manufacturing Practices (&#147;cGMP&#148;) guidelines. Current Good Manufacturing Practice requirements are set forth in the 21 CFR820 Quality System Regulation. These requirements regulate the methods used in, and the facilities and controls used for, the design, manufacture, packaging, storage, installation and servicing of our medical devices intended for human use. In addition, various state regulatory agencies may
regulate the manufacture of our products. For example, we have obtained a license from the State of California to manufacture our products. In April 2001, the State of California Food and Drug Branch granted our manufacturing facility &#147;in compliance&#148; status, based on the regulations for Good Manufacturing Practices for medical devices. In May 2001, the State of California Food and Drug Branch granted licensing for our Union City facility. In May 2002, we received our ISO 9001 certification, expanding our compliance with international quality standards. In March 2003 the U.S. FDA conducted a facilities inspection and verified our compliance with the 21 CFR 820 Regulation. Although we are not required to comply with all of the government regulations applicable to the human market when manufacturing the VetScan DXS products, we have established all of our manufacturing operations to be compliant with the Quality System Regulation as this ensures product quality and integrity regardless of end
use or patient. </FONT></P>

<TABLE width="100%">
<TR>
<TD align=center><FONT size=2>8</FONT></TD></TR>
</TABLE>



<P>
<HR align=left noshade SIZE=5>


<P>&nbsp;
<!-- *************************************************************************** -->
<!-- MARKER PAGE="sheet: 14; page: 14" -->

<P><FONT face="Times New Roman, Times, Serif" size=2>In addition to the development of standardized manufacturing processes and quality control programs for the entire manufacturing process, our manufacturing activities are concentrated in the following three primary areas: </FONT></P>

<TABLE cellSpacing=0 cellPadding=0 width="100%">
<TR vAlign=top>
<TD width="3%"><FONT face="Times New Roman, Times, Serif" size=2>&nbsp; </FONT></TD>
<TD width="3%"><FONT face="Times New Roman, Times, Serif" size=2>&#149; </FONT></TD>
<TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp; </FONT></TD>
<TD width="94%"><FONT face="Times New Roman, Times, Serif" size=2><I>Point-of-Care Blood Chemistry Analyzer</I>: The analyzer used in the Piccolo and VetScan system employs a variety of components designed or specified by Abaxis, including a variable speed motor, microprocessors, a liquid crystal display, a result card printer, a spectrophotometer and other electronic components. These components are manufactured by several third party vendors that have been qualified and approved by Abaxis and then assembled by contract manufacturers for Abaxis. The components are assembled at the Abaxis facility into the finished product and completely tested to ensure that the finished product meets product specifications. The analyzer uses technologically advanced components, many of which are available only from single source vendors. Currently, the technologically advanced components are purchased from two single source vendors, PerkinElmer, Inc. and Electro-Alliance, Inc., neither of which have a written supply
agreement with us and thus both of which are not contractually obligated to continue supplying us with components in the quantities or at the prices that both companies have performed historically. </FONT></TD></TR>
</TABLE>

<BR>
<TABLE cellSpacing=0 cellPadding=0 width="100%">
<TR vAlign=top>
<TD width="3%"><FONT face="Times New Roman, Times, Serif" size=2>&nbsp; </FONT></TD>
<TD width="3%"><FONT face="Times New Roman, Times, Serif" size=2>&#149; </FONT></TD>
<TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp; </FONT></TD>
<TD width="94%"><FONT face="Times New Roman, Times, Serif" size=2><I>Reagent Disc: </I>The molded plastic discs used in the manufacture of the reagent disc are manufactured to our specifications by an established injection-molding manufacturer. To achieve the precision required for accurate test results, the discs must be molded to very narrow tolerances. To date, we have only qualified two manufacturers, C. Brewer &amp; Co. and Nypro Oregon, Inc. to mold the discs. We have also qualified a second manufacturing site with Nypro Oregon, Inc. We do not have supply agreements with any of these companies and they are under no contractual obligation to continue supplying us with discs either in the quantities or at the prices that such companies have done historically. We are also working with our suppliers to improve yields and increase capacity on the existing production molds. While we have increased the number of disc molding tools to strengthen and better protect our line of supply, an inability by our
injection-molding manufacturers to supply sufficient discs would have a material adverse impact on our results of operations. </FONT></TD></TR>
</TABLE>

<BR>
<TABLE cellSpacing=0 cellPadding=0 width="100%">
<TR vAlign=top>
<TD width="6%"><FONT face="Times New Roman, Times, Serif" size=2>&nbsp; </FONT></TD>
<TD width="94%"><FONT face="Times New Roman, Times, Serif" size=2>We assemble the reagent discs by using the molded plastic discs, loading the disc with reagents and then ultrasonically welding together the top and bottom pieces. In fiscal 2002, we completed our development of a semi-automated disc assembly line (&#147;semi-autoline&#148;) to provide anticipated capacity for future demand and to improve production efficiency. This semi-autoline was placed into service during fiscal 2003. </FONT></TD></TR>
</TABLE>

<BR>
<TABLE cellSpacing=0 cellPadding=0 width="100%">
<TR vAlign=top>
<TD width="3%"><FONT face="Times New Roman, Times, Serif" size=2>&nbsp; </FONT></TD>
<TD width="3%"><FONT face="Times New Roman, Times, Serif" size=2>&#149; </FONT></TD>
<TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp; </FONT></TD>
<TD width="94%"><FONT face="Times New Roman, Times, Serif" size=2><I>Reagent Beads: </I>The reagent discs contain diluent and all the dry reagent chemistry beads necessary to perform blood analyses. We purchase chemicals from third party suppliers and formulate the raw materials, using proprietary processes, into beads at the proper concentration and consistency to facilitate placement in the reagent disc and provide homogeneous dissolution and mixing when contacted by the diluted plasma. We are dependent on the following companies who are our sole source providers of one or more chemicals that we use in the reagent production process: Amano Enzyme USA Co, LTD, Genzyme Corporation, Kikkoman Corporation Biochemical Division, Microgenics Corporation, Roche Molecular Biochemicals of Roche Diagnostics Corporation, a division of F. Hoffman-La Roche, Ltd., Shinko American Inc., and Sigma Aldrich Inc. We do not have supply agreements with any of these companies and they are under no contractual obligation to
continue supplying us in the quantities or at the price such companies have done historically. Although we believe all of the chemicals provided by these companies would be readily available elsewhere and we continue to evaluate vendor sources to protect and improve our lines of supply, the loss of any of these companies as a supplier could materially adversely affect our manufacturing activities and results of operations. </FONT></TD></TR>
</TABLE>

<BR>
<H1 align=left><FONT face="Times New Roman, Times, Serif" size=2>Material Relationships with Suppliers and Other Third Parties </FONT></H1>

<P align=left><FONT face="Times New Roman, Times, Serif" size=2><I>Amersham Biosciences Corp. (formerly Pharmacia Biotech, Inc.)</I> </FONT></P>


<P><FONT face="Times New Roman, Times, Serif" size=2>Under our 1994 agreement with Amersham Biosciences Corp. (formerly Pharmacia Biotech), we licensed our Orbos bead technology to Amersham Biosciences Corp. (formerly Pharmacia Biotech) for use in various medical tests. This agreement was amended in June 1997 to include DNA/RN and Human Leukocyte Antigen testing. We receive royalty payments equal to 5% of net sales, as defined in the agreement, of Amersham&#146;s products that use our technology. </FONT></P>

<P align=left><FONT face="Times New Roman, Times, Serif" size=2><I>Becton Dickinson</I> </FONT></P>


<P><FONT face="Times New Roman, Times, Serif" size=2>Under our 1994 agreement with Becton Dickinson, Becton Dickinson has agreed to purchase from us certain minimum quantities of our Orbos chemical beads in return for compensation and our agreeing not to license or otherwise use the Orbos bead process with any other party. In June 1997, Becton Dickinson failed to purchase the minimum quantities specified in the agreement and thus the exclusivity terms of the agreement have lapsed. The contract with Becton Dickinson will expire in </FONT></P>

<TABLE width="100%">
<TR>
<TD align=center><FONT size=2>9</FONT></TD></TR>
</TABLE>



<P>
<HR align=left noshade SIZE=5>


<P>&nbsp;
<!-- *************************************************************************** -->
<!-- MARKER PAGE="sheet: 14; page: 14" -->

<P><FONT face="Times New Roman, Times, Serif" size=2>September 2009 and, in the event that prior to that date we decide to cease manufacturing Orbos beads, we must give Becton Dickinson at least one year&#146;s notice. </FONT></P>

<P align=left><FONT face="Times New Roman, Times, Serif" size=2><I>Diatron Messtechnik GmbH</I> </FONT></P>


<P><FONT face="Times New Roman, Times, Serif" size=2>Under our agreement with DIATRON, we acquired the exclusive right to distribute DIATRON&#146;s veterinary hematology analyzers in Australia, Canada, Japan, New Zealand and the United States. The agreement has a five year term, but is also subject to certain minimum purchase quantities during the first five years of the contract term. </FONT></P>

<P align=left><FONT face="Times New Roman, Times, Serif" size=2><I>DVM Resources</I> </FONT></P>


<P><FONT face="Times New Roman, Times, Serif" size=2>We do not have any contractual relationship with DVM Resources, one of our distributors that accounted for 16% of our revenue in fiscal 2004. Consequently, DVM Resources may at any time cease to purchase our products without any penalty. </FONT></P>

<P align=left><FONT face="Times New Roman, Times, Serif" size=2><I>S.A. Scientific, Inc. </I></FONT></P>


<P><FONT face="Times New Roman, Times, Serif" size=2>In November 2001, we signed a term sheet with S.A. Scientific, Inc. of San Antonio, Texas, under which S.A. Scientific agreed to provide us with canine heartworm antigen tests that we would distribute and sell using the Abaxis brand. The term sheet did not include any reference to indemnification by S.A. Scientific in the event that Abaxis was sued for patent infringement with respect to the canine heartworm antigen test. In March 2002, Idexx Laboratories, Inc. sued both Abaxis and S.A. Scientific for infringement upon patents issued to Idexx. The case was settled under the terms of an out-of-court agreement on December 6, 2002. Among other terms, Abaxis agreed to pay Idexx $249,500 in cash damages and to cease the selling of the particular canine heartworm antigen test referenced in the complaint. Although we subsequently sold a limited number of redesigned canine heartworm tests manufactured by S.A. Scientific, we have subsequently terminated our
relationship with S.A. Scientific. </FONT></P>

<P align=left><FONT face="Times New Roman, Times, Serif" size=2><I>Scil Animal Care Gmbh</I> </FONT></P>


<P><FONT face="Times New Roman, Times, Serif" size=2>In September 2001, we entered into a five-year non-exclusive distribution agreement with Scil Animal Care Company GmbH of Germany, under which Scil will distribute our VetScan products in Belgium, Denmark, Finland, Germany, Norway, Sweden and the Netherlands. </FONT></P>

<P align=left><FONT face="Times New Roman, Times, Serif" size=2><I>Vedco, Inc.</I> </FONT></P>


<P><FONT face="Times New Roman, Times, Serif" size=2>We do not have any contractual relationship with Vedco, Inc., one of our distributors that accounted for 27% of our revenue in fiscal 2004. Consequently, Vedco may at any time cease to purchase our products without any penalty. </FONT></P>

<H1 align=left><FONT face="Times New Roman, Times, Serif" size=2>Government Regulation </FONT></H1>

<P align=left><FONT face="Times New Roman, Times, Serif" size=2><I>Piccolo System</I> </FONT></P>

<P align=left><FONT face="Times New Roman, Times, Serif" size=2><I>Food and Drug Administration Clearance</I> </FONT></P>


<P><FONT face="Times New Roman, Times, Serif" size=2>Our Piccolo products are regulated under the 1976 Medical Device Amendments to the Food, Drug and Cosmetic Act, which is administered by the Food and Drug Administration. The FDA has classified our Piccolo products as &#147;Class I&#148; and &#147;Class II&#148; devices. These classifications require us to submit to the FDA a pre-market notification form or 510(k). The FDA uses the 510(k) to substantiate product claims that are made by medical device manufacturers prior to marketing. In our 510(k) notification, we must, among other things, establish that the product we plan to market is &#147;substantially equivalent&#148; to (1) a product that was on the market prior to the adoption of the 1976 Medical Device Amendment or (2) to a product that the FDA has previously cleared under the 510(k) process. The FDA review process of a 510(k) notification can last anywhere from three to six months, and the FDA must issue a written order finding
&#147;substantial equivalence&#148; before a company can market a medical device. To date, we have received market clearance from the FDA for our Piccolo System and 24 reagent tests that we have on eleven reagent discs. We are currently developing additional tests that the FDA will have to clear through the 510(k) notification procedures. These new test products are crucial for our success in the human diagnostic market. If we do not receive 510(k) clearance for a particular product, we will not be able to sell that product in the United States. </FONT></P>

<P align=left><FONT face="Times New Roman, Times, Serif" size=2><I>Clinical Laboratory Improvements Act Regulations </I></FONT></P>


<P><FONT face="Times New Roman, Times, Serif" size=2>Our Piccolo products are affected by the Clinical Laboratory Improvement Amendments of 1988. The Clinical Laboratory Improvement Amendments are intended to insure the quality and reliability of all medical testing in the United States regardless </FONT></P>

<TABLE width="100%">
<TR>
<TD align=center><FONT size=2>10</FONT></TD></TR>
</TABLE>



<P>
<HR align=left noshade SIZE=5>


<P>&nbsp;
<!-- *************************************************************************** -->
<!-- MARKER PAGE="sheet: 14; page: 14" -->

<P><FONT face="Times New Roman, Times, Serif" size=2>of where tests are performed. The current Clinical Laboratory Improvement Amendments divide laboratory tests into three categories: &#147;simple,&#148; &#147;moderately complex&#148; and &#147;highly complex.&#148; Tests performed using the Piccolo system are in the &#147;moderately complex&#148; category. This category requires that any location in which testing is performed be certified as a laboratory. Hence, we can only sell our Piccolo products to customers who meet the standards of a laboratory. To receive &#147;laboratory&#148; certification, a testing facility must be certified by the Centers for Medicare and Medicaid Services. After the testing facility receives a &#147;laboratory&#148; certification, it must then meet the Clinical Laboratory Improvement Amendments regulations. Because we can only sell our Piccolo products to testing facilities that are certified &#147;laboratories,&#148; the market for our products is correspondingly
constrained. During the third quarter of fiscal 2004, we submitted a petition for &#147;waived status&#148; to the Food and Drug Administration (FDA) after we conducted clinical studies designed to demonstrate the ability of untrained personnel to use the Piccolo and obtain reliable results from the Piccolo Lipid Panel Reagent Disc (Total Cholesterol, HDL, and Triglycerides). Waived status would permit untrained personnel to run the Piccolo using the Lipid Panel and, thus, extending the sites (doctors&#146; offices and other point-of-care environments) that can use the Piccolo. Currently, this petition is under evaluation by the FDA. We cannot assure you that we will successfully receive the waived status from the FDA. Consequently, the market for our Piccolo products may be confined to those testing facilities that are certified as &#147;laboratories&#148; and our growth will be limited accordingly. </FONT></P>

<P align=left><FONT face="Times New Roman, Times, Serif" size=2><I>Other Regulations</I> </FONT></P>


<P><FONT face="Times New Roman, Times, Serif" size=2>We are subject to a variety of federal, state, local and international regulations regarding the manufacture and sale of our products. For example, in December 2003, we received certification from the British Standards Institute to the ISO 13485:1996 quality system standard for medical devices. This quality system certification, along with successful completion of product testing to current European standards and the translation of Piccolo product documentation into the required languages, enabled us to meet the compliance requirements of the CE Mark and the current European In Vitro Device Directive. As we continue to sell in foreign markets, we may have to obtain additional governmental clearances in those markets. We cannot predict what impact, if any, such current or future regulatory changes would have on our business. </FONT></P>

<P align=left><FONT face="Times New Roman, Times, Serif" size=2><I>VetScan DXS</I> </FONT></P>


<P><FONT face="Times New Roman, Times, Serif" size=2>The government regulations discussed above generally do not apply to our VetScan DXS products in the U.S. Internationally, among the countries where we currently have established distribution arrangements, to our knowledge, Japan is the only market where VetScan DXS products are subject to government approvals. In Japan, the Ministry of Agriculture, Forestry and Fishery regulates veterinary diagnostic devices, and thus the DXS System must be approved by such Ministry prior to being marketed in Japan. </FONT></P>


<P><FONT face="Times New Roman, Times, Serif" size=2>In order to maintain high quality standards for all products, we are using the same manufacturing facilities to manufacture all point-of-care blood chemistry analyzers whether they be for the Piccolo or VetScan system products and therefore is following the same manufacturing processes and procedures where practical. </FONT></P>

<H1 align=left><FONT face="Times New Roman, Times, Serif" size=2>Intellectual Property </FONT></H1>


<P><FONT face="Times New Roman, Times, Serif" size=2>We have pursued the development of a patent portfolio to protect our technology. As of June 14, 2004, 33 patent applications have been filed on behalf of Abaxis with the United States Patent and Trademark Office, of which the following 27 have been issued: </FONT></P>

<TABLE cellSpacing=0 cellPadding=0 width="100%" border=0>
<TR vAlign=bottom>
<TH align=left width="12%"><FONT size=2>Patent No.</FONT>
<HR width="100%" color=black noshade SIZE=1>
</TH>
<TH align=left width="58%"><FONT size=2>Description</FONT>
<HR width="100%" color=black noshade SIZE=1>
</TH>
<TH align=left width="16%"><FONT size=2>Issue Date</FONT>
<HR width="100%" color=black noshade SIZE=1>
</TH>
<TH align=left width="14%"><FONT size=2>Expiration Date</FONT>
<HR width="100%" color=black noshade SIZE=1>
</TH></TR>
<TR vAlign=bottom>
<TD align=left width="12%"><FONT size=2>5,061,381&nbsp;</FONT></TD>
<TD align=left width="58%"><FONT size=2>Apparatus and Method for Separating Cells from Biological Fluids</FONT></TD>
<TD align=left width="16%"><FONT size=2>October 29, 1991</FONT></TD>
<TD align=left width="14%"><FONT size=2>June 4, 2010</FONT></TD></TR>
<TR>
<TD>&nbsp; </TD>
<TD>&nbsp; </TD>
<TD>&nbsp; </TD>
<TD>&nbsp; </TD></TR>
<TR vAlign=bottom>
<TD align=left width="12%"><FONT size=2>5,122,284&nbsp;</FONT></TD>
<TD align=left><FONT size=2>Apparatus and Method for Optically Analyzing Biological Fluids</FONT></TD>
<TD align=left><FONT size=2>June 16, 1992</FONT></TD>
<TD align=left><FONT size=2>April 1, 2011</FONT></TD></TR>
<TR>
<TD>&nbsp; </TD>
<TD>&nbsp; </TD>
<TD>&nbsp; </TD>
<TD>&nbsp; </TD></TR>
<TR vAlign=bottom>
<TD align=left width="12%"><FONT size=2>5,173,193&nbsp;</FONT></TD>
<TD align=left><FONT size=2>Centrifugal Rotor Having Flow Partition</FONT></TD>
<TD align=left><FONT size=2>December 22, 1992</FONT></TD>
<TD align=left><FONT size=2>April 1, 2011</FONT></TD></TR>
<TR>
<TD>&nbsp; </TD>
<TD>&nbsp; </TD>
<TD>&nbsp; </TD>
<TD>&nbsp; </TD></TR>
<TR vAlign=bottom>
<TD align=left width="12%"><FONT size=2>5,186,844&nbsp;</FONT></TD>
<TD align=left><FONT size=2>Apparatus and Method for Continuous Centrifugal Blood Cell Separation</FONT></TD>
<TD align=left><FONT size=2>February 16, 1993</FONT></TD>
<TD align=left><FONT size=2>April 1, 2011</FONT></TD></TR>
<TR>
<TD>&nbsp; </TD>
<TD>&nbsp; </TD>
<TD>&nbsp; </TD>
<TD>&nbsp; </TD></TR>
<TR vAlign=bottom>
<TD align=left width="12%"><FONT size=2>5,242,606&nbsp;</FONT></TD>
<TD align=left><FONT size=2>Sample Metering Port for Analytical Rotor Having Overflow Chamber</FONT></TD>
<TD align=left><FONT size=2>September 7, 1993</FONT></TD>
<TD align=left><FONT size=2>September 7, 2010</FONT></TD></TR>
<TR>
<TD>&nbsp; </TD>
<TD>&nbsp; </TD>
<TD>&nbsp; </TD>
<TD>&nbsp; </TD></TR>
<TR vAlign=bottom>
<TD align=left width="12%">&nbsp;</TD></TR>
</TABLE>


<TABLE width="100%">
<TR>
<TD align=center><FONT size=2>11</FONT></TD></TR>
</TABLE>



<P>
<HR align=left noshade SIZE=5>


<P>&nbsp;
<!-- *************************************************************************** -->
<!-- MARKER PAGE="sheet: 14; page: 14" -->
<TABLE cellSpacing=0 cellPadding=0 width="100%" border=0>
<TR>
<TD>&nbsp; </TD>
<TD>&nbsp; </TD>
<TD>&nbsp; </TD>
<TD>&nbsp; </TD></TR>
<TR vAlign=bottom>
<TD align=left width="12%"><FONT size=2>5,275,016</FONT></TD>
<TD align=left width="58%"><FONT size=2>Cryogenic Apparatus</FONT></TD>
<TD align=left width="16%"><FONT size=2>January 4, 1994</FONT></TD>
<TD align=left width="14%"><FONT size=2>April 24, 2012</FONT></TD></TR>
<TR>
<TD>&nbsp; </TD>
<TD>&nbsp; </TD>
<TD>&nbsp; </TD>
<TD>&nbsp; </TD></TR>
<TR vAlign=bottom>
<TD align=left><FONT size=2>5,304,348</FONT></TD>
<TD align=left><FONT size=2>Reagent Container for Analytical Rotor</FONT></TD>
<TD align=left><FONT size=2>April 19, 1994</FONT></TD>
<TD align=left><FONT size=2>February 11, 2012</FONT></TD></TR>
<TR>
<TD>&nbsp; </TD>
<TD>&nbsp; </TD>
<TD>&nbsp; </TD>
<TD>&nbsp; </TD></TR>
<TR vAlign=bottom>
<TD align=left><FONT size=2>5,384,247</FONT></TD>
<TD align=left><FONT size=2>Determination of Sodium Ions in Fluids</FONT></TD>
<TD align=left><FONT size=2>January 24, 1995</FONT></TD>
<TD align=left><FONT size=2>January 24, 2012</FONT></TD></TR>
<TR>
<TD>&nbsp; </TD>
<TD>&nbsp; </TD>
<TD>&nbsp; </TD>
<TD>&nbsp; </TD></TR>
<TR vAlign=bottom>
<TD align=left><FONT size=2>5,403,415</FONT></TD>
<TD align=left><FONT size=2>Method and Device for Ultrasonic Welding</FONT></TD>
<TD align=left><FONT size=2>April 4, 1995</FONT></TD>
<TD align=left><FONT size=2>November 17, 2013</FONT></TD></TR>
<TR>
<TD>&nbsp; </TD>
<TD>&nbsp; </TD>
<TD>&nbsp; </TD>
<TD>&nbsp; </TD></TR>
<TR vAlign=bottom>
<TD align=left><FONT size=2>5,409,665</FONT></TD>
<TD align=left><FONT size=2>Simultaneous Cuvette Filling with Means to Isolate Cuvettes</FONT></TD>
<TD align=left><FONT size=2>April 25, 1995</FONT></TD>
<TD align=left><FONT size=2>September 1, 2013</FONT></TD></TR>
<TR>
<TD>&nbsp; </TD>
<TD>&nbsp; </TD>
<TD>&nbsp; </TD>
<TD>&nbsp; </TD></TR>
<TR vAlign=bottom>
<TD align=left><FONT size=2>5,409,814</FONT></TD>
<TD align=left><FONT size=2>Determination of Ions in Fluids</FONT></TD>
<TD align=left><FONT size=2>April 25, 1995</FONT></TD>
<TD align=left><FONT size=2>April 25, 2012</FONT></TD></TR>
<TR>
<TD>&nbsp; </TD>
<TD>&nbsp; </TD>
<TD>&nbsp; </TD>
<TD>&nbsp; </TD></TR>
<TR vAlign=bottom>
<TD align=left><FONT size=2>5,413,732</FONT></TD>
<TD align=left><FONT size=2>Reagent Compositions for Analytical Testing</FONT></TD>
<TD align=left><FONT size=2>May 9, 1995</FONT></TD>
<TD align=left><FONT size=2>May 9, 2012</FONT></TD></TR>
<TR>
<TD>&nbsp; </TD>
<TD>&nbsp; </TD>
<TD>&nbsp; </TD>
<TD>&nbsp; </TD></TR>
<TR vAlign=bottom>
<TD align=left><FONT size=2>5,457,053</FONT></TD>
<TD align=left><FONT size=2>Reagent Container for Analytical Rotor</FONT></TD>
<TD align=left><FONT size=2>October 10, 1995</FONT></TD>
<TD align=left><FONT size=2>October 10, 2012</FONT></TD></TR>
<TR>
<TD>&nbsp; </TD>
<TD>&nbsp; </TD>
<TD>&nbsp; </TD>
<TD>&nbsp; </TD></TR>
<TR vAlign=bottom>
<TD align=left><FONT size=2>5,472,603</FONT></TD>
<TD align=left><FONT size=2>Analytical Rotor with Dye Mixing Chamber</FONT></TD>
<TD align=left><FONT size=2>December 5, 1995</FONT></TD>
<TD align=left><FONT size=2>December 5, 2012</FONT></TD></TR>
<TR>
<TD>&nbsp; </TD>
<TD>&nbsp; </TD>
<TD>&nbsp; </TD>
<TD>&nbsp; </TD></TR>
<TR vAlign=bottom>
<TD align=left><FONT size=2>5,478,750</FONT></TD>
<TD align=left><FONT size=2>Methods for Photometric Analysis</FONT></TD>
<TD align=left><FONT size=2>December 26, 1995</FONT></TD>
<TD align=left><FONT size=2>March 31, 2013</FONT></TD></TR>
<TR>
<TD>&nbsp; </TD>
<TD>&nbsp; </TD>
<TD>&nbsp; </TD>
<TD>&nbsp; </TD></TR>
<TR vAlign=bottom>
<TD align=left><FONT size=2>5,501,958</FONT></TD>
<TD align=left><FONT size=2>Determination of Potassium Ions in Fluids</FONT></TD>
<TD align=left><FONT size=2>March 26, 1996</FONT></TD>
<TD align=left><FONT size=2>March 26, 2013</FONT></TD></TR>
<TR>
<TD>&nbsp; </TD>
<TD>&nbsp; </TD>
<TD>&nbsp; </TD>
<TD>&nbsp; </TD></TR>
<TR vAlign=bottom>
<TD align=left><FONT size=2>5,518,930</FONT></TD>
<TD align=left><FONT size=2>Simultaneous Cuvette Filling with Means to Isolate Cuvettes</FONT></TD>
<TD align=left><FONT size=2>May 21, 1996</FONT></TD>
<TD align=left><FONT size=2>September 1, 2013</FONT></TD></TR>
<TR>
<TD>&nbsp; </TD>
<TD>&nbsp; </TD>
<TD>&nbsp; </TD>
<TD>&nbsp; </TD></TR>
<TR vAlign=bottom>
<TD align=left><FONT size=2>5,590,052</FONT></TD>
<TD align=left><FONT size=2>Error Checking in Blood Analyzer</FONT></TD>
<TD align=left><FONT size=2>December 31, 1996</FONT></TD>
<TD align=left><FONT size=2>April 14, 2014</FONT></TD></TR>
<TR>
<TD>&nbsp; </TD>
<TD>&nbsp; </TD>
<TD>&nbsp; </TD>
<TD>&nbsp; </TD></TR>
<TR vAlign=bottom>
<TD align=left><FONT size=2>5,591,643</FONT></TD>
<TD align=left><FONT size=2>Simplified Inlet Channels</FONT></TD>
<TD align=left><FONT size=2>January 7, 1997</FONT></TD>
<TD align=left><FONT size=2>January 7, 2014</FONT></TD></TR>
<TR>
<TD>&nbsp; </TD>
<TD>&nbsp; </TD>
<TD>&nbsp; </TD>
<TD>&nbsp; </TD></TR>
<TR vAlign=bottom>
<TD align=left><FONT size=2>5,599,411</FONT></TD>
<TD align=left><FONT size=2>Method and Device for Ultrasonic Welding</FONT></TD>
<TD align=left><FONT size=2>February 4, 1997</FONT></TD>
<TD align=left><FONT size=2>November 17, 2013</FONT></TD></TR>
<TR>
<TD>&nbsp; </TD>
<TD>&nbsp; </TD>
<TD>&nbsp; </TD>
<TD>&nbsp; </TD></TR>
<TR vAlign=bottom>
<TD align=left><FONT size=2>5,624,597</FONT></TD>
<TD align=left><FONT size=2>Reagent Compositions for Analytical Testing</FONT></TD>
<TD align=left><FONT size=2>April 29, 1997</FONT></TD>
<TD align=left><FONT size=2>April 29, 2014</FONT></TD></TR>
<TR>
<TD>&nbsp; </TD>
<TD>&nbsp; </TD>
<TD>&nbsp; </TD>
<TD>&nbsp; </TD></TR>
<TR vAlign=bottom>
<TD align=left><FONT size=2>5,693,233</FONT></TD>
<TD align=left><FONT size=2>Methods of Transporting Fluids Within An Analytical Rotor</FONT></TD>
<TD align=left><FONT size=2>December 2, 1997</FONT></TD>
<TD align=left><FONT size=2>April 2, 2012</FONT></TD></TR>
<TR>
<TD>&nbsp; </TD>
<TD>&nbsp; </TD>
<TD>&nbsp; </TD>
<TD>&nbsp; </TD></TR>
<TR vAlign=bottom>
<TD align=left><FONT size=2>5,776,563</FONT></TD>
<TD align=left><FONT size=2>Dried Chemical Compositions</FONT></TD>
<TD align=left><FONT size=2>July 7, 1998</FONT></TD>
<TD align=left><FONT size=2>July 7, 2015</FONT></TD></TR>
<TR>
<TD>&nbsp; </TD>
<TD>&nbsp; </TD>
<TD>&nbsp; </TD>
<TD>&nbsp; </TD></TR>
<TR vAlign=bottom>
<TD align=left><FONT size=2>5,998,031</FONT></TD>
<TD align=left><FONT size=2>Dried Chemical Compositions</FONT></TD>
<TD align=left><FONT size=2>December 7, 1999</FONT></TD>
<TD align=left><FONT size=2>August 19, 2011</FONT></TD></TR>
<TR>
<TD>&nbsp; </TD>
<TD>&nbsp; </TD>
<TD>&nbsp; </TD>
<TD>&nbsp; </TD></TR>
<TR vAlign=bottom>
<TD align=left><FONT size=2>6,068,971</FONT></TD>
<TD align=left><FONT size=2>Process for Determination of Ions in Fluids by Masking of Interfering Ions</FONT></TD>
<TD align=left><FONT size=2>May 30, 2000</FONT></TD>
<TD align=left><FONT size=2>May 30, 2017</FONT></TD></TR>
<TR>
<TD>&nbsp; </TD>
<TD>&nbsp; </TD>
<TD>&nbsp; </TD>
<TD>&nbsp; </TD></TR>
<TR vAlign=bottom>
<TD align=left><FONT size=2>6,235,531</FONT></TD>
<TD align=left><FONT size=2>Modified Siphons for Improved Metering Precision</FONT></TD>
<TD align=left><FONT size=2>May 22, 2001</FONT></TD>
<TD align=left><FONT size=2>September 1, 2013</FONT></TD></TR>
<TR>
<TD>&nbsp; </TD>
<TD>&nbsp; </TD>
<TD>&nbsp; </TD>
<TD>&nbsp; </TD></TR>
<TR vAlign=bottom>
<TD align=left><FONT size=2>6,251,684</FONT></TD>
<TD align=left><FONT size=2>Dried Chemical Compositions</FONT></TD>
<TD align=left><FONT size=2>June 26, 2001</FONT></TD>
<TD align=left><FONT size=2>August 18, 2011</FONT></TD></TR>
<TR vAlign=bottom>
<TD align=left><FONT size=2>&nbsp;</FONT></TD>
<TD align=left><FONT size=2>&nbsp;</FONT></TD>
<TD align=left><FONT size=2>&nbsp;</FONT></TD>
<TD align=left>&nbsp;</TD></TR>
</TABLE>



<P><FONT face="Times New Roman, Times, Serif" size=2>Our policy is to file patent applications to protect technology, inventions and improvements that are important to the development of our business. We also rely upon trade secrets, know-how, continuing technological innovations and licensing opportunities to develop and maintain competitive position. Fourteen international applications have been filed on behalf of Abaxis under the Patent Cooperation Treaty (PCT) and we are selectively filing patent applications in countries where we anticipate to market our products. Under the fourteen PCT applications, 72 national foreign applications were filed on behalf of Abaxis in various countries and forty-two of them have been granted. Of these forty-two, one is being opposed by the European Patent Office, and we are in the process of responding to their concerns. </FONT></P>

<H1 align=left><FONT face="Times New Roman, Times, Serif" size=2>Employees </FONT></H1>


<P><FONT face="Times New Roman, Times, Serif" size=2>As of March&nbsp;31, 2004, we had 171 full-time employees distributed across the following divisions: </FONT></P>

<TABLE width="100%">
<TR>
<TD align=center><FONT size=2>12</FONT></TD></TR>
</TABLE>



<P>
<HR align=left noshade SIZE=5>


<P>&nbsp;
<!-- *************************************************************************** -->
<!-- MARKER PAGE="sheet: 14; page: 14" -->

<P>
<TABLE width=600>
<TR>
<TD vAlign=top width="5%">&nbsp;</TD>
<TD vAlign=top width="5%">&nbsp;</TD>
<TD vAlign=top width="5%"><FONT size=2>&#149; </FONT></TD>
<TD width="85%"><FONT size=2>24 in research and development;</FONT></TD></TR>
</TABLE>


<!-- MARKER FORMAT-SHEET="Hang 2 [15/85]" FSL="Workstation" -->

<P>
<TABLE width=600>
<TR>
<TD vAlign=top width="5%">&nbsp;</TD>
<TD vAlign=top width="5%">&nbsp;</TD>
<TD vAlign=top width="5%"><FONT size=2>&#149; </FONT></TD>
<TD width="85%"><FONT size=2>87 in manufacturing operations;</FONT></TD></TR>
</TABLE>


<!-- MARKER FORMAT-SHEET="Hang 2 [15/85]" FSL="Workstation" -->

<P>
<TABLE width=600>
<TR>
<TD vAlign=top width="5%">&nbsp;</TD>
<TD vAlign=top width="5%">&nbsp;</TD>
<TD vAlign=top width="5%"><FONT size=2>&#149; </FONT></TD>
<TD width="85%"><FONT size=2>50 in sales and marketing (including customer support); and</FONT></TD></TR>
</TABLE>



<P>
<TABLE width=600>
<TR>
<TD vAlign=top width="5%">&nbsp;</TD>
<TD vAlign=top width="5%">&nbsp;</TD>
<TD vAlign=top width="5%"><FONT size=2>&#149; </FONT></TD>
<TD width="85%"><FONT size=2>10 in general and administrative.</FONT></TD></TR>
</TABLE>



<P><FONT face="Times New Roman, Times, Serif" size=2>We also use temporary help to assist in carrying out certain operational duties. As of March&nbsp;31, 2004, we had 6 temporary employees with most of them assisting in manufacturing operations. None of our employees are covered by collective bargaining agreements and management considers its relations with employees to be good. </FONT></P>

<H1 align=left><FONT face="Times New Roman, Times, Serif" size=2>ITEM 2. PROPERTIES </FONT></H1>


<P><FONT face="Times New Roman, Times, Serif" size=2>We occupy approximately 91,124 square feet of office, research and development and manufacturing space in a building in Union City, California. The lease agreement is for ten years commencing January 2001 with an option to extend the lease for five additional years. Our Germany office consists of approximately 900 square feet located in Darmstadt, Germany. The lease agreement for the Germany office is terminable upon three months notice. We believe that our current facilities are suitable and adequate to meet our needs for the foreseeable future. </FONT></P>

<H1 align=left><FONT face="Times New Roman, Times, Serif" size=2>ITEM 3. LEGAL PROCEEDINGS </FONT></H1>


<P><FONT face="Times New Roman, Times, Serif" size=2>We are from time to time involved in various litigation matters in the normal course of business. We believe that the ultimate resolution of these matters will not have a material effect on our financial position or results of operations. </FONT></P>

<H1 align=left><FONT face="Times New Roman, Times, Serif" size=2>ITEM 4. SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS </FONT></H1>


<P><FONT face="Times New Roman, Times, Serif" size=2>No items were submitted to a vote of security holders during the quarter ended March&nbsp;31, 2004. </FONT></P>

<H1 align=center><FONT face="Times New Roman, Times, Serif" size=2>PART II </FONT></H1>

<H1 align=left><FONT face="Times New Roman, Times, Serif" size=2>ITEM 5. MARKET FOR THE REGISTRANT&#146;S COMMON EQUITY AND RELATED STOCKHOLDER MATTERS </FONT></H1>


<P><FONT face="Times New Roman, Times, Serif" size=2>Our initial public offering of common stock was completed in January 1992. Since that date, our common stock has been traded on the NASDAQ National Market under the symbol &#147;ABAX&#148;. </FONT></P>


<P><FONT face="Times New Roman, Times, Serif" size=2>The high and low prices for our common stock during each quarter since April&nbsp;1, 2002 are exhibited in the table below, as represented by the high and low daily trade closing sales prices as reported by the NASDAQ National Market: </FONT></P>

<TABLE cellSpacing=0 cellPadding=0 width="100%" border=0>
<TR>
<TH colSpan=2>&nbsp;</TH>
<TH align=center width="6%" colSpan=4><FONT size=2>High</FONT>
<HR width="95%" color=black noshade SIZE=1>
</TH>
<TH>&nbsp;</TH>
<TH align=center width="6%" colSpan=4><FONT size=2>Low</FONT>
<HR width="95%" color=black noshade SIZE=1>
</TH>
<TH>&nbsp;</TH></TR>
<TR>
<TH>&nbsp;</TH>
<TH align=left colSpan=2><FONT size=2>Year Ended March 31, 2003 </FONT>
<HR align=left width="55%" color=black noshade SIZE=1>
</TH>
<TH colSpan=6>&nbsp;</TH></TR>
<TR>
<TD align=left width="15%"><FONT size=2>&nbsp;</FONT></TD>
<TD align=left width="38%"><FONT size=2>Quarter ended June 30</FONT></TD>
<TD align=center width="6%"><FONT size=2>$&nbsp;</FONT></TD>
<TD align=right width="3%"><FONT size=2>6</FONT></TD>
<TD align=left width="2%"><FONT size=2>.510</FONT></TD>
<TD width="3%"><FONT size=2>&nbsp;</FONT></TD>
<TD width="5%"><FONT size=2>&nbsp;</FONT></TD>
<TD align=center width="6%"><FONT size=2>$&nbsp;</FONT></TD>
<TD align=right width="3%"><FONT size=2>4</FONT></TD>
<TD align=left width="2%"><FONT size=2>.360</FONT></TD></TR>
<TR>
<TD width="3%"><FONT size=2>&nbsp;</FONT></TD>
<TD width="14%"><FONT size=2>&nbsp;</FONT></TD>
<TR>
<TD align=left><FONT size=2>&nbsp;</FONT></TD>
<TD align=left><FONT size=2>Quarter ended September 30</FONT></TD>
<TD align=center width="6%"><FONT size=2>$&nbsp;</FONT></TD>
<TD align=right><FONT size=2>4</FONT></TD>
<TD align=left><FONT size=2>.520</FONT></TD>
<TD>&nbsp;</TD>
<TD>&nbsp;</TD>
<TD align=center width="6%"><FONT size=2>$&nbsp;</FONT></TD>
<TD align=right><FONT size=2>3</FONT></TD>
<TD align=left><FONT size=2>.000</FONT></TD></TR>
<TR>
<TD>&nbsp;</TD>
<TD align=left><FONT size=2>&nbsp;</FONT></TD>
<TR>
<TD align=left><FONT size=2>&nbsp;</FONT></TD>
<TD align=left><FONT size=2>Quarter ended December 31</FONT></TD>
<TD align=center width="6%"><FONT size=2>$&nbsp;</FONT></TD>
<TD align=right><FONT size=2>4</FONT></TD>
<TD align=left><FONT size=2>.294</FONT></TD>
<TD>&nbsp;</TD>
<TD width="2%"><FONT size=2>&nbsp;</FONT></TD>
<TD align=center width="6%"><FONT size=2>$&nbsp;</FONT></TD>
<TD align=right><FONT size=2>3</FONT></TD>
<TD align=left><FONT size=2>.190</FONT></TD></TR>
<TR>
<TD>&nbsp;</TD>
<TD align=left><FONT size=2>&nbsp;</FONT></TD>
<TR>
<TD align=left><FONT size=2>&nbsp;</FONT></TD>
<TD align=left><FONT size=2>Quarter ended March 31</FONT></TD>
<TD align=center width="6%"><FONT size=2>$&nbsp;</FONT></TD>
<TD align=right><FONT size=2>4</FONT></TD>
<TD align=left><FONT size=2>.039</FONT></TD>
<TD>&nbsp;</TD>
<TD width="2%"><FONT size=2>&nbsp;</FONT></TD>
<TD align=center width="6%"><FONT size=2>$&nbsp;</FONT></TD>
<TD align=right><FONT size=2>3</FONT></TD>
<TD align=left><FONT size=2>.290</FONT></TD></TR>
<TR>
<TD>&nbsp;</TD>
<TD align=left><FONT size=2>&nbsp;</FONT></TD>
<TR>
<TD colSpan=2></TD>
<TD align=center width="6%" colSpan=2></TD>
<TD colSpan=3></TD></TR>
<TR>
<TH>&nbsp;</TH>
<TH align=left colSpan=2><FONT size=2>Year Ended March 31, 2004 </FONT>
<HR align=left width="55%" color=black noshade SIZE=1>
</TH>
<TH colSpan=6>&nbsp;</TH></TR>
<TR>
<TD align=left><FONT size=2>&nbsp;</FONT></TD>
<TD align=left><FONT size=2>Quarter ended June 30</FONT></TD>
<TD align=center width="6%"><FONT size=2>$&nbsp;</FONT></TD>
<TD align=right><FONT size=2>6</FONT></TD>
<TD align=left><FONT size=2>.670</FONT></TD>
<TD>&nbsp;</TD>
<TD width="2%"><FONT size=2>&nbsp;</FONT></TD>
<TD align=center width="6%"><FONT size=2>$&nbsp;</FONT></TD>
<TD align=right><FONT size=2>3</FONT></TD>
<TD align=left><FONT size=2>.660</FONT></TD></TR>
<TR>
<TD>&nbsp;</TD>
<TD align=left><FONT size=2>&nbsp;</FONT></TD>
<TR>
<TD align=left><FONT size=2>&nbsp;</FONT></TD>
<TD align=left><FONT size=2>Quarter ended September 30</FONT></TD>
<TD align=center width="6%"><FONT size=2>$&nbsp;</FONT></TD>
<TD align=right><FONT size=2>13</FONT></TD>
<TD align=left><FONT size=2>.900</FONT></TD>
<TD>&nbsp;</TD>
<TD width="2%"><FONT size=2>&nbsp;</FONT></TD>
<TD align=center width="6%"><FONT size=2>$&nbsp;</FONT></TD>
<TD align=right><FONT size=2>6</FONT></TD>
<TD align=left><FONT size=2>.400</FONT></TD></TR>
<TR>
<TD>&nbsp;</TD>
<TD align=left><FONT size=2>&nbsp;</FONT></TD>
<TR>
<TD align=left><FONT size=2>&nbsp;</FONT></TD>
<TD align=left><FONT size=2>Quarter ended December 31</FONT></TD>
<TD align=center width="6%"><FONT size=2>$&nbsp;</FONT></TD>
<TD align=right><FONT size=2>21</FONT></TD>
<TD align=left><FONT size=2>.500</FONT></TD>
<TD>&nbsp;</TD>
<TD width="2%"><FONT size=2>&nbsp;</FONT></TD>
<TD align=center width="6%"><FONT size=2>$&nbsp;</FONT></TD>
<TD align=right><FONT size=2>14</FONT></TD>
<TD align=left><FONT size=2>.260</FONT></TD></TR>
<TR>
<TD>&nbsp;</TD>
<TD align=left><FONT size=2>&nbsp;</FONT></TD>
<TR>
<TD align=left><FONT size=2>&nbsp;</FONT></TD>
<TD align=left><FONT size=2>Quarter ended March 31</FONT></TD>
<TD align=center width="6%"><FONT size=2>$&nbsp;</FONT></TD>
<TD align=right><FONT size=2>22</FONT></TD>
<TD align=left><FONT size=2>.800</FONT></TD>
<TD>&nbsp;</TD>
<TD width="2%"><FONT size=2>&nbsp;</FONT></TD>
<TD align=center width="6%"><FONT size=2>$&nbsp;</FONT></TD>
<TD align=right><FONT size=2>15</FONT></TD>
<TD align=left><FONT size=2>.560</FONT></TD></TR>
<TR>
<TD>&nbsp;</TD>
<TD align=left><FONT size=2>&nbsp;</FONT></TD></TR>
</TABLE>

<BR>
<TABLE width="100%">
<TR>
<TD align=center><FONT size=2>13</FONT></TD></TR>
</TABLE>



<P>
<HR align=left noshade SIZE=5>


<P>&nbsp;
<!-- *************************************************************************** -->
<!-- MARKER PAGE="sheet: 14; page: 14" -->

<P><FONT face="Times New Roman, Times, Serif" size=2>As of June&nbsp;7, 2004, there were 19,597,815 shares of our Common Stock issued and outstanding and held by 224 shareholders of record. </FONT></P>


<P><FONT face="Times New Roman, Times, Serif" size=2>Under our debt agreements, we are restricted from paying aggregate cash dividends on our stock in excess of 50% of our net income on an annual basis. We have never paid dividends on our common stock and do not anticipate paying cash dividends in the foreseeable future. </FONT></P>


<P><FONT face="Times New Roman, Times, Serif" size=2><B>Stock Purchase Rights</B><I> </I>&#150; On April 22, 2003, the Board of Directors of the Company approved the adoption of a Shareholder Rights Plan. Under the terms of the plan, shareholders of record on May 8, 2003, received one preferred stock purchase right for each outstanding share of Common Stock held. Each right entitled the registered holder to purchase from the Company one one-thousandth of a share of the Company&#146;s Series RP Preferred Stock, $0.001 par value, at a price of $24.00 per share and becomes exercisable when a person or group acquires 15% or more of the Company&#146;s Common Stock without prior approval by the Board of Directors. </FONT></P>

<H1 align=left><FONT face="Times New Roman, Times, Serif" size=2>Securities Authorized for Issuance Under Equity Compensation Plans </FONT></H1>


<P><FONT face="Times New Roman, Times, Serif" size=2>Abaxis has two equity incentive plans under which our equity securities are or have been authorized for issuance to our employees or directors: the 1989 Stock Option Plan, which was amended and restated as the 1998 Stock Option Plan, and the 1992 Outside Directors&#146; Stock Option Plan. Both the 1998 Stock Option Plan and the 1992 Outside Directors&#146; Stock Option Plan have been approved by our shareholders. In June 2002, the time period for granting options under the Directors&#146; Plan expired in accordance with the terms of the plan. From time to time we issue warrants to purchase shares of our common stock to non-employees, such as service providers and purchasers of our preferred stock. </FONT></P>


<P><FONT face="Times New Roman, Times, Serif" size=2>The following table provides aggregate information through March 31, 2004 regarding (i) grants under both of our equity incentive plans and (ii) outstanding warrants to purchase our common stock. </FONT></P>

<!-- MARKER FORMAT-SHEET="Head Major Center Bold 1" FSL="Default" -->
<H1 align=center><FONT face="Times New Roman, Times, Serif" size=2>EQUITY COMPENSATION INFORMATION </FONT></H1>

<TABLE cellSpacing=0 cellPadding=0 width="100%" border=0>
<TR vAlign=bottom align=left>
<TH colSpan=2><FONT size=2>Plan Category</FONT>
<HR width="100%" color=black noshade SIZE=1>
</TH>
<TH width="16%"><FONT size=2>Number of securities to be<BR>issued upon exercise of <BR>outstanding options,<BR>warrants and rights</FONT>
<HR width="100%" color=black noshade SIZE=1>
</TH>
<TH width="6%">
<HR width="100%" color=black noshade SIZE=1>
</TH>
<TH width="13%"><FONT size=2>Weighted-average <BR>exercise price of <BR>outstanding options,<BR>warrants and rights</FONT>
<HR width="100%" color=black noshade SIZE=1>
</TH>
<TH width="6%">
<HR width="100%" color=black noshade SIZE=1>
</TH>
<TH width="13%"><FONT size=2>Number of securities <BR>remaining available <BR>for future issuance<BR>under equity <BR>compensation plans</FONT>
<HR width="100%" color=black noshade SIZE=1>
</TH>
<TH width="6%">
<HR width="100%" color=black noshade SIZE=1>
</TH></TR>
<TR vAlign=baseline>
<TD align=left width="37%"><B><FONT size=2>Equity compensation plans approved by our</FONT></B></TD>
<TD align=left width="3%"><FONT size=2>&nbsp;</FONT></TD>
<TD align=left width="16%">&nbsp;</TD>
<TD align=left width="6%"><FONT size=2>&nbsp;</FONT></TD>
<TD align=left width="13%">&nbsp;</TD>
<TD align=left width="6%"><FONT size=2>&nbsp;</FONT></TD>
<TD align=left width="13%">&nbsp;</TD>
<TD align=left width="6%"><FONT size=2>&nbsp;</FONT></TD></TR>
<TR vAlign=baseline>
<TD align=left width="37%"><B><FONT size=2>shareholders:</FONT></B></TD>
<TD align=left width="3%"><FONT size=2>&nbsp;</FONT></TD></TR>
<TR vAlign=baseline>
<TD align=left width="37%"><FONT size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1998 Stock Option Plan</FONT></TD>
<TD align=left width="3%"><FONT size=2>&nbsp;</FONT></TD>
<TD align=right width="16%"><FONT size=2>2,578,224</FONT></TD>
<TD align=left width="6%"><FONT size=2>&nbsp;</FONT></TD>
<TD align=right width="13%"><FONT size=2>$4.91</FONT></TD>
<TD align=left width="6%"><FONT size=2>&nbsp;</FONT></TD>
<TD align=right width="13%"><FONT size=2>610,932</FONT></TD>
<TD align=left width="6%"><FONT size=2>&nbsp;</FONT></TD></TR>
<TR vAlign=baseline>
<TD align=left width="37%"><FONT size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1992 Outside Directors' Stock Option Plan</FONT></TD>
<TD align=left width="3%"><FONT size=2>&nbsp;</FONT></TD>
<TD align=right width="16%"><FONT size=2>86,000</FONT></TD>
<TD align=left width="6%"><FONT size=2>&nbsp;</FONT></TD>
<TD align=right width="13%"><FONT size=2>$4.23</FONT></TD>
<TD align=left width="6%"><FONT size=2>&nbsp;</FONT></TD>
<TD align=right width="13%"><FONT size=2>&#151;</FONT></TD>
<TD align=left width="6%"><FONT size=2>&nbsp;</FONT></TD></TR>
<TR>
<TD colSpan=8>
<HR color=black noshade SIZE=1>
</TD></TR>
<TR vAlign=baseline>
<TD align=left width="37%"><B><FONT size=2>Equity securities not approved by our</FONT></B></TD>
<TD align=left width="3%"><FONT size=2>&nbsp;</FONT></TD></TR>
<TR vAlign=baseline>
<TD align=left width="37%"><B><FONT size=2>shareholders:</FONT></B></TD>
<TD align=left width="3%"><FONT size=2>&nbsp;</FONT></TD></TR>
<TR vAlign=baseline>
<TD align=left width="37%"><FONT size=2>&nbsp;&nbsp;&nbsp;&nbsp;Warrants to purchase our common stock <SUP>(1)</SUP></FONT></TD>
<TD align=left width="3%"><FONT size=2>&nbsp;</FONT></TD>
<TD align=right width="16%"><FONT size=2>567,135</FONT></TD>
<TD align=left width="6%"><FONT size=2>&nbsp;</FONT></TD>
<TD align=right width="13%"><FONT size=2>$6.78</FONT></TD>
<TD align=left width="6%"><FONT size=2>&nbsp;</FONT></TD>
<TD align=right width="13%"><FONT size=2>&#151;</FONT></TD>
<TD align=left width="6%"><FONT size=2>&nbsp;</FONT></TD></TR>
<TR>
<TD colSpan=8>
<HR color=black noshade SIZE=2>
</TD></TR>
<TR vAlign=baseline>
<TD align=left width="37%"><FONT size=2><B>Total:</B></FONT></TD>
<TD align=left width="3%"><FONT size=2>&nbsp;</FONT></TD>
<TD align=right width="16%"><FONT size=2>3,231,359</FONT></TD>
<TD align=left width="6%"><FONT size=2>&nbsp;</FONT></TD>
<TD align=right width="13%"><FONT size=2>$5.22</FONT></TD>
<TD align=left width="6%"><FONT size=2>&nbsp;</FONT></TD>
<TD align=right width="13%"><FONT size=2>610,932</FONT></TD>
<TD align=left width="6%"><FONT size=2>&nbsp;</FONT></TD></TR>
<TR vAlign=baseline>
<TD align=left width="37%">&nbsp;</TD>
<TD align=left width="3%"><FONT size=2>&nbsp;</FONT></TD></TR>
</TABLE>



<P><FONT face="Times New Roman, Times, Serif" size=2><SUP>(1)</SUP>&nbsp;&nbsp;&nbsp;&nbsp; Consists of warrants that have a five year term in which they may be exercised. All warrants were issued to service providers, except for warrants to purchase an aggregate of 88,750 and 115,000 shares of our common stock at a per share exercise price of $7.00 issued to purchasers of our Series D and Series E convertible preferred stock, respectively. </FONT></P>

<!-- MARKER FORMAT-SHEET="Head Sub 1 Left" FSL="Default" -->
<H1 align=left><FONT face="Times New Roman, Times, Serif" size=2>ITEM 6. SELECTED FINANCIAL DATA</FONT></H1>


<P><FONT face="Times New Roman, Times, Serif" size=2>The following selected financial data is qualified by reference to and should be read in conjunction with &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations&#148; and with the financial statements, related notes and other financial information included elsewhere in this Annual Report on Form 10-K. </FONT></P>

<TABLE width="100%">
<TR>
<TD align=center><FONT size=2>14</FONT></TD></TR>
</TABLE>



<P>
<HR align=left noshade SIZE=5>


<P>&nbsp;
<!-- *************************************************************************** -->
<!-- MARKER PAGE="sheet: 14; page: 14" -->
<TABLE cellSpacing=0 cellPadding=0 width="100%" border=0>
<TR vAlign=bottom>
<TH colSpan=3></TH>
<TH colSpan=15><FONT size=2>Years Ended March 31,</FONT>
<HR width="100%" color=black noshade SIZE=1>
</TH></TR>
<TR vAlign=bottom>
<TH colSpan=3></TH>
<TH colSpan=3><FONT size=2>2004</FONT>
<HR width="100%" color=black noshade SIZE=1>
</TH>
<TH colSpan=3><FONT size=2>2003</FONT>
<HR width="100%" color=black noshade SIZE=1>
</TH>
<TH colSpan=3><FONT size=2>2002</FONT>
<HR width="100%" color=black noshade SIZE=1>
</TH>
<TH colSpan=3><FONT size=2>2001</FONT>
<HR width="100%" color=black noshade SIZE=1>
</TH>
<TH colSpan=3><FONT size=2>2000</FONT>
<HR width="100%" color=black noshade SIZE=1>
</TH></TR>
<TR vAlign=bottom>
<TD align=left width="39%"><FONT size=2><B>Statement of Operations Data:</B></FONT></TD>
<TD align=left width="1%"><FONT size=2>&nbsp;</FONT></TD>
<TD align=left width="1%"><FONT size=2>&nbsp;</FONT></TD>
<TD align=right width="1%"><FONT size=2>&nbsp;</FONT></TD>
<TD align=right width="8%">&nbsp;</TD>
<TD align=left width="3%"><FONT size=2>&nbsp;</FONT></TD>
<TD align=right width="1%"><FONT size=2>&nbsp;</FONT></TD>
<TD align=right width="8%">&nbsp;</TD>
<TD align=left width="3%"><FONT size=2>&nbsp;</FONT></TD>
<TD align=right width="1%"><FONT size=2>&nbsp;</FONT></TD>
<TD align=right width="8%">&nbsp;</TD>
<TD align=left width="3%"><FONT size=2>&nbsp;</FONT></TD>
<TD align=right width="1%"><FONT size=2>&nbsp;</FONT></TD>
<TD align=right width="8%">&nbsp;</TD>
<TD align=left width="3%"><FONT size=2>&nbsp;</FONT></TD>
<TD align=right width="1%"><FONT size=2>&nbsp;</FONT></TD>
<TD align=right width="8%">&nbsp;</TD>
<TD align=left width="2%"><FONT size=2>&nbsp;</FONT></TD></TR>
<TR vAlign=bottom>
<TD align=left><FONT size=2>Product sales, net</FONT></TD>
<TD align=left><FONT size=2>&nbsp;</FONT></TD>
<TD align=left><FONT size=2>&nbsp;</FONT></TD>
<TD align=right><FONT size=2>$</FONT></TD>
<TD align=right><FONT size=2>46,599,000</FONT></TD>
<TD align=left><FONT size=2>&nbsp;</FONT></TD>
<TD align=right><FONT size=2>$</FONT></TD>
<TD align=right><FONT size=2>34,532,000</FONT></TD>
<TD align=left><FONT size=2>&nbsp;</FONT></TD>
<TD align=right><FONT size=2>$</FONT></TD>
<TD align=right><FONT size=2>30,418,000</FONT></TD>
<TD align=left><FONT size=2>&nbsp;</FONT></TD>
<TD align=right><FONT size=2>$</FONT></TD>
<TD align=right><FONT size=2>29,536,000</FONT></TD>
<TD align=left><FONT size=2>&nbsp;</FONT></TD>
<TD align=right><FONT size=2>$</FONT></TD>
<TD align=right><FONT size=2>23,236,000</FONT></TD>
<TD align=left><FONT size=2>&nbsp;</FONT></TD></TR>
<TR vAlign=bottom>
<TD align=left><FONT size=2>Development and licensing revenue</FONT></TD>
<TD align=left><FONT size=2>&nbsp;</FONT></TD>
<TD align=left><FONT size=2>&nbsp;</FONT></TD>
<TD align=right><FONT size=2>&nbsp;</FONT></TD>
<TD align=right><FONT size=2>275,000</FONT></TD>
<TD align=left><FONT size=2>&nbsp;</FONT></TD>
<TD align=right><FONT size=2>&nbsp;</FONT></TD>
<TD align=right><FONT size=2>248,000</FONT></TD>
<TD align=left><FONT size=2>&nbsp;</FONT></TD>
<TD align=right><FONT size=2>&nbsp;</FONT></TD>
<TD align=right><FONT size=2>213,000</FONT></TD>
<TD align=left><FONT size=2>&nbsp;</FONT></TD>
<TD align=right><FONT size=2>&nbsp;</FONT></TD>
<TD align=right><FONT size=2>237,000</FONT></TD>
<TD align=left><FONT size=2>&nbsp;</FONT></TD>
<TD align=right><FONT size=2>&nbsp;</FONT></TD>
<TD align=right><FONT size=2>140,000</FONT></TD>
<TD align=left><FONT size=2>&nbsp;</FONT></TD></TR>
<TR>
<TD colSpan=3></TD>
<TD align=right colSpan=15>
<HR color=black noshade SIZE=1>
</TD></TR>
<TR vAlign=bottom>
<TD align=left><FONT size=2>Total revenues</FONT></TD>
<TD align=left><FONT size=2>&nbsp;</FONT></TD>
<TD align=left><FONT size=2>&nbsp;</FONT></TD>
<TD align=right><FONT size=2>&nbsp;</FONT></TD>
<TD align=right><FONT size=2>46,874,000</FONT></TD>
<TD align=left><FONT size=2>&nbsp;</FONT></TD>
<TD align=right><FONT size=2>&nbsp;</FONT></TD>
<TD align=right><FONT size=2>34,780,000</FONT></TD>
<TD align=left><FONT size=2>&nbsp;</FONT></TD>
<TD align=right><FONT size=2>&nbsp;</FONT></TD>
<TD align=right><FONT size=2>30,631,000</FONT></TD>
<TD align=left><FONT size=2>&nbsp;</FONT></TD>
<TD align=right><FONT size=2>&nbsp;</FONT></TD>
<TD align=right><FONT size=2>29,773,000</FONT></TD>
<TD align=left><FONT size=2>&nbsp;</FONT></TD>
<TD align=right><FONT size=2>&nbsp;</FONT></TD>
<TD align=right><FONT size=2>23,376,000</FONT></TD>
<TD align=left><FONT size=2>&nbsp;</FONT></TD></TR>
<TR>
<TD colSpan=3></TD>
<TD align=right colSpan=15>
<HR color=black noshade SIZE=1>
</TD></TR>
<TR vAlign=bottom>
<TD align=left><FONT size=2>Costs and operating expenses:</FONT></TD>
<TD align=left><FONT size=2>&nbsp;</FONT></TD>
<TD align=left><FONT size=2>&nbsp;</FONT></TD></TR>
<TR vAlign=bottom>
<TD align=left><FONT size=2>&nbsp;&nbsp;&nbsp;Cost of product sales</FONT></TD>
<TD align=left><FONT size=2>&nbsp;</FONT></TD>
<TD align=left><FONT size=2>&nbsp;</FONT></TD>
<TD align=right><FONT size=2>&nbsp;</FONT></TD>
<TD align=right><FONT size=2>22,966,000</FONT></TD>
<TD align=left><FONT size=2>&nbsp;</FONT></TD>
<TD align=right><FONT size=2>&nbsp;</FONT></TD>
<TD align=right><FONT size=2>17,755,000</FONT></TD>
<TD align=left><FONT size=2>&nbsp;</FONT></TD>
<TD align=right><FONT size=2>&nbsp;</FONT></TD>
<TD align=right><FONT size=2>15,966,000</FONT></TD>
<TD align=left><FONT size=2>&nbsp;</FONT></TD>
<TD align=right><FONT size=2>&nbsp;</FONT></TD>
<TD align=right><FONT size=2>16,560,000</FONT></TD>
<TD align=left><FONT size=2>&nbsp;</FONT></TD>
<TD align=right><FONT size=2>&nbsp;</FONT></TD>
<TD align=right><FONT size=2>12,695,000</FONT></TD>
<TD align=left><FONT size=2>&nbsp;</FONT></TD></TR>
<TR vAlign=bottom>
<TD align=left><FONT size=2>&nbsp;&nbsp;&nbsp;Selling, general and administrative</FONT></TD>
<TD align=left><FONT size=2>&nbsp;</FONT></TD>
<TD align=left><FONT size=2>&nbsp;</FONT></TD>
<TD align=right><FONT size=2>&nbsp;</FONT></TD>
<TD align=right><FONT size=2>14,431,000</FONT></TD>
<TD align=left><FONT size=2>&nbsp;</FONT></TD>
<TD align=right><FONT size=2>&nbsp;</FONT></TD>
<TD align=right><FONT size=2>11,564,000</FONT></TD>
<TD align=left><FONT size=2>&nbsp;</FONT></TD>
<TD align=right><FONT size=2>&nbsp;</FONT></TD>
<TD align=right><FONT size=2>9,333,000</FONT></TD>
<TD align=left><FONT size=2>&nbsp;</FONT></TD>
<TD align=right><FONT size=2>&nbsp;</FONT></TD>
<TD align=right><FONT size=2>9,641,000</FONT></TD>
<TD align=left><FONT size=2>&nbsp;</FONT></TD>
<TD align=right><FONT size=2>&nbsp;</FONT></TD>
<TD align=right><FONT size=2>7,765,000</FONT></TD>
<TD align=left><FONT size=2>&nbsp;</FONT></TD></TR>
<TR vAlign=bottom>
<TD align=left><FONT size=2>&nbsp;&nbsp;&nbsp;Research and development</FONT></TD>
<TD align=left><FONT size=2>&nbsp;</FONT></TD>
<TD align=left><FONT size=2>&nbsp;</FONT></TD>
<TD align=right><FONT size=2>&nbsp;</FONT></TD>
<TD align=right><FONT size=2>4,757,000</FONT></TD>
<TD align=left><FONT size=2>&nbsp;</FONT></TD>
<TD align=right><FONT size=2>&nbsp;</FONT></TD>
<TD align=right><FONT size=2>3,888,000</FONT></TD>
<TD align=left><FONT size=2>&nbsp;</FONT></TD>
<TD align=right><FONT size=2>&nbsp;</FONT></TD>
<TD align=right><FONT size=2>3,834,000</FONT></TD>
<TD align=left><FONT size=2>&nbsp;</FONT></TD>
<TD align=right><FONT size=2>&nbsp;</FONT></TD>
<TD align=right><FONT size=2>3,458,000</FONT></TD>
<TD align=left><FONT size=2>&nbsp;</FONT></TD>
<TD align=right><FONT size=2>&nbsp;</FONT></TD>
<TD align=right><FONT size=2>3,534,000</FONT></TD>
<TD align=left><FONT size=2>&nbsp;</FONT></TD></TR>
<TR>
<TD colSpan=3></TD>
<TD align=right colSpan=15>
<HR color=black noshade SIZE=1>
</TD></TR>
<TR vAlign=bottom>
<TD align=left><FONT size=2>Total costs and operating expenses</FONT></TD>
<TD align=left><FONT size=2>&nbsp;</FONT></TD>
<TD align=left><FONT size=2>&nbsp;</FONT></TD>
<TD align=right><FONT size=2>&nbsp;</FONT></TD>
<TD align=right><FONT size=2>42,154,000</FONT></TD>
<TD align=left><FONT size=2>&nbsp;</FONT></TD>
<TD align=right><FONT size=2>&nbsp;</FONT></TD>
<TD align=right><FONT size=2>33,207,000</FONT></TD>
<TD align=left><FONT size=2>&nbsp;</FONT></TD>
<TD align=right><FONT size=2>&nbsp;</FONT></TD>
<TD align=right><FONT size=2>29,133,000</FONT></TD>
<TD align=left><FONT size=2>&nbsp;</FONT></TD>
<TD align=right><FONT size=2>&nbsp;</FONT></TD>
<TD align=right><FONT size=2>29,659,000</FONT></TD>
<TD align=left><FONT size=2>&nbsp;</FONT></TD>
<TD align=right><FONT size=2>&nbsp;</FONT></TD>
<TD align=right><FONT size=2>23,994,000</FONT></TD>
<TD align=left><FONT size=2>&nbsp;</FONT></TD></TR>
<TR>
<TD colSpan=3></TD>
<TD align=right colSpan=15>
<HR color=black noshade SIZE=1>
</TD></TR>
<TR vAlign=bottom>
<TD align=left><FONT size=2>Income (loss) from operations</FONT></TD>
<TD align=left><FONT size=2>&nbsp;</FONT></TD>
<TD align=left><FONT size=2>&nbsp;</FONT></TD>
<TD align=right><FONT size=2>&nbsp;</FONT></TD>
<TD align=right><FONT size=2>4,720,000</FONT></TD>
<TD align=left><FONT size=2>&nbsp;</FONT></TD>
<TD align=right><FONT size=2>&nbsp;</FONT></TD>
<TD align=right><FONT size=2>1,573,000</FONT></TD>
<TD align=left><FONT size=2>&nbsp;</FONT></TD>
<TD align=right><FONT size=2>&nbsp;</FONT></TD>
<TD align=right><FONT size=2>1,498,000</FONT></TD>
<TD align=left><FONT size=2>&nbsp;</FONT></TD>
<TD align=right><FONT size=2>&nbsp;</FONT></TD>
<TD align=right><FONT size=2>114,000</FONT></TD>
<TD align=left><FONT size=2>&nbsp;</FONT></TD>
<TD align=right><FONT size=2>&nbsp;</FONT></TD>
<TD align=right><FONT size=2>(618,000</FONT></TD>
<TD align=left><FONT size=2>)</FONT></TD></TR>
<TR vAlign=bottom>
<TD align=left><FONT size=2>Interest and other income</FONT></TD>
<TD align=left><FONT size=2>&nbsp;</FONT></TD>
<TD align=left><FONT size=2>&nbsp;</FONT></TD>
<TD align=right><FONT size=2>&nbsp;</FONT></TD>
<TD align=right><FONT size=2>173,000</FONT></TD>
<TD align=left><FONT size=2>&nbsp;</FONT></TD>
<TD align=right><FONT size=2>&nbsp;</FONT></TD>
<TD align=right><FONT size=2>217,000</FONT></TD>
<TD align=left><FONT size=2>&nbsp;</FONT></TD>
<TD align=right><FONT size=2>&nbsp;</FONT></TD>
<TD align=right><FONT size=2>91,000</FONT></TD>
<TD align=left><FONT size=2>&nbsp;</FONT></TD>
<TD align=right><FONT size=2>&nbsp;</FONT></TD>
<TD align=right><FONT size=2>140,000</FONT></TD>
<TD align=left><FONT size=2>&nbsp;</FONT></TD>
<TD align=right><FONT size=2>&nbsp;</FONT></TD>
<TD align=right><FONT size=2>187,000</FONT></TD>
<TD align=left><FONT size=2>&nbsp;</FONT></TD></TR>
<TR vAlign=bottom>
<TD align=left><FONT size=2>Interest and other expense</FONT></TD>
<TD align=left><FONT size=2>&nbsp;</FONT></TD>
<TD align=left><FONT size=2>&nbsp;</FONT></TD>
<TD align=right><FONT size=2>&nbsp;</FONT></TD>
<TD align=right><FONT size=2>(68,000</FONT></TD>
<TD align=left><FONT size=2>)</FONT></TD>
<TD align=right><FONT size=2>&nbsp;</FONT></TD>
<TD align=right><FONT size=2>(149,000</FONT></TD>
<TD align=left><FONT size=2>)</FONT></TD>
<TD align=right><FONT size=2>&nbsp;</FONT></TD>
<TD align=right><FONT size=2>(269,000</FONT></TD>
<TD align=left><FONT size=2>)</FONT></TD>
<TD align=right><FONT size=2>&nbsp;</FONT></TD>
<TD align=right><FONT size=2>(45,000</FONT></TD>
<TD align=left><FONT size=2>)</FONT></TD>
<TD align=right><FONT size=2>&nbsp;</FONT></TD>
<TD align=right><FONT size=2>(170,000</FONT></TD>
<TD align=left><FONT size=2>)</FONT></TD></TR>
<TR>
<TD colSpan=3></TD>
<TD align=right colSpan=15>
<HR color=black noshade SIZE=1>
</TD></TR>
<TR vAlign=bottom>
<TD align=left><FONT size=2>Net income (loss) before income taxes</FONT></TD>
<TD align=left><FONT size=2>&nbsp;</FONT></TD>
<TD align=left><FONT size=2>&nbsp;</FONT></TD>
<TD align=right><FONT size=2>&nbsp;</FONT></TD>
<TD align=right><FONT size=2>4,825,000</FONT></TD>
<TD align=left><FONT size=2>&nbsp;</FONT></TD>
<TD align=right><FONT size=2>&nbsp;</FONT></TD>
<TD align=right><FONT size=2>1,641,000</FONT></TD>
<TD align=left><FONT size=2>&nbsp;</FONT></TD>
<TD align=right><FONT size=2>&nbsp;</FONT></TD>
<TD align=right><FONT size=2>1,320,000</FONT></TD>
<TD align=left><FONT size=2>&nbsp;</FONT></TD>
<TD align=right><FONT size=2>&nbsp;</FONT></TD>
<TD align=right><FONT size=2>209,000</FONT></TD>
<TD align=left><FONT size=2>&nbsp;</FONT></TD>
<TD align=right><FONT size=2>&nbsp;</FONT></TD>
<TD align=right><FONT size=2>(601,000</FONT></TD>
<TD align=left><FONT size=2>)</FONT></TD></TR>
<TR vAlign=bottom>
<TD align=left><FONT size=2>Income tax provision (benefit)</FONT></TD>
<TD align=left><FONT size=2>&nbsp;</FONT></TD>
<TD align=left><FONT size=2>&nbsp;</FONT></TD>
<TD align=right><FONT size=2>&nbsp;</FONT></TD>
<TD align=right><FONT size=2>(19,208,000</FONT></TD>
<TD align=left><FONT size=2>)</FONT></TD>
<TD align=right><FONT size=2>&nbsp;</FONT></TD>
<TD align=right><FONT size=2>5,000</FONT></TD>
<TD align=left><FONT size=2>&nbsp;</FONT></TD>
<TD align=right><FONT size=2>&nbsp;</FONT></TD>
<TD align=right><FONT size=2>16,000</FONT></TD>
<TD align=left><FONT size=2>&nbsp;</FONT></TD>
<TD align=right><FONT size=2>&nbsp;</FONT></TD>
<TD align=right><FONT size=2>21,000</FONT></TD>
<TD align=left><FONT size=2>&nbsp;</FONT></TD>
<TD align=right><FONT size=2>&nbsp;</FONT></TD>
<TD align=right><FONT size=2>(24,000</FONT></TD>
<TD align=left><FONT size=2>)</FONT></TD></TR>
<TR>
<TD colSpan=3></TD>
<TD align=right colSpan=15>
<HR color=black noshade SIZE=1>
</TD></TR>
<TR vAlign=bottom>
<TD align=left><FONT size=2>Net income (loss)</FONT></TD>
<TD align=left><FONT size=2>&nbsp;</FONT></TD>
<TD align=left><FONT size=2>&nbsp;</FONT></TD>
<TD align=right><FONT size=2>&nbsp;</FONT></TD>
<TD align=right><FONT size=2>24,033,000</FONT></TD>
<TD align=left><FONT size=2>&nbsp;</FONT></TD>
<TD align=right><FONT size=2>&nbsp;</FONT></TD>
<TD align=right><FONT size=2>1,636,000</FONT></TD>
<TD align=left><FONT size=2>&nbsp;</FONT></TD>
<TD align=right><FONT size=2>&nbsp;</FONT></TD>
<TD align=right><FONT size=2>1,304,000</FONT></TD>
<TD align=left><FONT size=2>&nbsp;</FONT></TD>
<TD align=right><FONT size=2>&nbsp;</FONT></TD>
<TD align=right><FONT size=2>188,000</FONT></TD>
<TD align=left><FONT size=2>&nbsp;</FONT></TD>
<TD align=right><FONT size=2>&nbsp;</FONT></TD>
<TD align=right><FONT size=2>(577,000</FONT></TD>
<TD align=left><FONT size=2>)</FONT></TD></TR>
<TR>
<TD colSpan=3></TD>
<TD align=right colSpan=15>
<HR color=black noshade SIZE=1>
</TD></TR>
<TR vAlign=bottom>
<TD align=left><FONT size=2>Preferred dividends and accretion (a)</FONT></TD>
<TD align=left><FONT size=2>&nbsp;</FONT></TD>
<TD align=left><FONT size=2>&nbsp;</FONT></TD>
<TD align=right><FONT size=2>&nbsp;</FONT></TD>
<TD align=right><FONT size=2>(419,000</FONT></TD>
<TD align=left><FONT size=2>)</FONT></TD>
<TD align=right><FONT size=2>&nbsp;</FONT></TD>
<TD align=right><FONT size=2>(1,235,000</FONT></TD>
<TD align=left><FONT size=2>)</FONT></TD>
<TD align=right><FONT size=2>&nbsp;</FONT></TD>
<TD align=right><FONT size=2>(1,033,000</FONT></TD>
<TD align=left><FONT size=2>)</FONT></TD>
<TD align=right><FONT size=2>&nbsp;</FONT></TD>
<TD align=right><FONT size=2>(1,648,000</FONT></TD>
<TD align=left><FONT size=2>)</FONT></TD>
<TD align=right><FONT size=2>&nbsp;</FONT></TD>
<TD align=right><FONT size=2>(151,000</FONT></TD>
<TD align=left><FONT size=2>)</FONT></TD></TR>
<TR>
<TD colSpan=3></TD>
<TD align=right colSpan=15>
<HR color=black noshade SIZE=1>
</TD></TR>
<TR vAlign=bottom>
<TD align=left><FONT size=2>Net income (loss) attributable to common shareholders</FONT></TD>
<TD align=left><FONT size=2>&nbsp;</FONT></TD>
<TD align=left><FONT size=2>&nbsp;</FONT></TD>
<TD align=right><FONT size=2>$</FONT></TD>
<TD align=right><FONT size=2>23,614,000</FONT></TD>
<TD align=left><FONT size=2>&nbsp;</FONT></TD>
<TD align=right><FONT size=2>$</FONT></TD>
<TD align=right><FONT size=2>401,000</FONT></TD>
<TD align=left><FONT size=2>&nbsp;</FONT></TD>
<TD align=right><FONT size=2>$</FONT></TD>
<TD align=right><FONT size=2>271,000</FONT></TD>
<TD align=left><FONT size=2>&nbsp;</FONT></TD>
<TD align=right><FONT size=2>$</FONT></TD>
<TD align=right><FONT size=2>(1,460,000</FONT></TD>
<TD align=left><FONT size=2>)</FONT></TD>
<TD align=right><FONT size=2>$</FONT></TD>
<TD align=right><FONT size=2>(728,000</FONT></TD>
<TD align=left><FONT size=2>)</FONT></TD></TR>
<TR>
<TD colSpan=3></TD>
<TD align=right colSpan=15>
<HR color=black noshade SIZE=2>
</TD></TR>
<TR vAlign=bottom>
<TD align=left><FONT size=2>Basic net income (loss) per share</FONT></TD>
<TD align=left><FONT size=2>&nbsp;</FONT></TD>
<TD align=left><FONT size=2>&nbsp;</FONT></TD>
<TD align=right><FONT size=2>$</FONT></TD>
<TD align=right><FONT size=2>1.30</FONT></TD>
<TD align=left><FONT size=2>&nbsp;</FONT></TD>
<TD align=right><FONT size=2>$</FONT></TD>
<TD align=right><FONT size=2>0.02</FONT></TD>
<TD align=left><FONT size=2>&nbsp;</FONT></TD>
<TD align=right><FONT size=2>$</FONT></TD>
<TD align=right><FONT size=2>0.02</FONT></TD>
<TD align=left><FONT size=2>&nbsp;</FONT></TD>
<TD align=right><FONT size=2>$</FONT></TD>
<TD align=right><FONT size=2>(0.09</FONT></TD>
<TD align=left><FONT size=2>)</FONT></TD>
<TD align=right><FONT size=2>$</FONT></TD>
<TD align=right><FONT size=2>(0.05</FONT></TD>
<TD align=left><FONT size=2>)</FONT></TD></TR>
<TR>
<TD colSpan=3></TD>
<TD align=right colSpan=15>
<HR color=black noshade SIZE=2>
</TD></TR>
<TR vAlign=bottom>
<TD align=left><FONT size=2>Diluted net income (loss) per share</FONT></TD>
<TD align=left><FONT size=2>&nbsp;</FONT></TD>
<TD align=left><FONT size=2>&nbsp;</FONT></TD>
<TD align=right><FONT size=2>$</FONT></TD>
<TD align=right><FONT size=2>1.16</FONT></TD>
<TD align=left><FONT size=2>&nbsp;</FONT></TD>
<TD align=right><FONT size=2>$</FONT></TD>
<TD align=right><FONT size=2>0.02</FONT></TD>
<TD align=left><FONT size=2>&nbsp;</FONT></TD>
<TD align=right><FONT size=2>$</FONT></TD>
<TD align=right><FONT size=2>0.02</FONT></TD>
<TD align=left><FONT size=2>&nbsp;</FONT></TD>
<TD align=right><FONT size=2>$</FONT></TD>
<TD align=right><FONT size=2>(0.09</FONT></TD>
<TD align=left><FONT size=2>)</FONT></TD>
<TD align=right><FONT size=2>$</FONT></TD>
<TD align=right><FONT size=2>(0.05</FONT></TD>
<TD align=left><FONT size=2>)</FONT></TD></TR>
<TR>
<TD colSpan=3></TD>
<TD align=right colSpan=15>
<HR color=black noshade SIZE=2>
</TD></TR>
<TR vAlign=bottom>
<TD align=left><FONT size=2>Shares used in computing basic per share amounts</FONT></TD>
<TD align=left><FONT size=2>&nbsp;</FONT></TD>
<TD align=left><FONT size=2>&nbsp;</FONT></TD>
<TD align=right><FONT size=2>&nbsp;</FONT></TD>
<TD align=right><FONT size=2>18,128,181</FONT></TD>
<TD align=left><FONT size=2>&nbsp;</FONT></TD>
<TD align=right><FONT size=2>&nbsp;</FONT></TD>
<TD align=right><FONT size=2>16,634,447</FONT></TD>
<TD align=left><FONT size=2>&nbsp;</FONT></TD>
<TD align=right><FONT size=2>&nbsp;</FONT></TD>
<TD align=right><FONT size=2>16,264,153</FONT></TD>
<TD align=left><FONT size=2>&nbsp;</FONT></TD>
<TD align=right><FONT size=2>&nbsp;</FONT></TD>
<TD align=right><FONT size=2>15,994,438</FONT></TD>
<TD align=left><FONT size=2>&nbsp;</FONT></TD>
<TD align=right><FONT size=2>&nbsp;</FONT></TD>
<TD align=right><FONT size=2>14,295,748</FONT></TD>
<TD align=left><FONT size=2>&nbsp;</FONT></TD></TR>
<TR>
<TD colSpan=3></TD>
<TD align=right colSpan=15>
<HR color=black noshade SIZE=2>
</TD></TR>
<TR vAlign=bottom>
<TD align=left><FONT size=2>Shares used in computing diluted per share amounts</FONT></TD>
<TD align=left><FONT size=2>&nbsp;</FONT></TD>
<TD align=left><FONT size=2>&nbsp;</FONT></TD>
<TD align=right><FONT size=2>&nbsp;</FONT></TD>
<TD align=right><FONT size=2>20,387,167</FONT></TD>
<TD align=left><FONT size=2>&nbsp;</FONT></TD>
<TD align=right><FONT size=2>&nbsp;</FONT></TD>
<TD align=right><FONT size=2>17,014,313</FONT></TD>
<TD align=left><FONT size=2>&nbsp;</FONT></TD>
<TD align=right><FONT size=2>&nbsp;</FONT></TD>
<TD align=right><FONT size=2>16,811,326</FONT></TD>
<TD align=left><FONT size=2>&nbsp;</FONT></TD>
<TD align=right><FONT size=2>&nbsp;</FONT></TD>
<TD align=right><FONT size=2>15,994,438</FONT></TD>
<TD align=left><FONT size=2>&nbsp;</FONT></TD>
<TD align=right><FONT size=2>&nbsp;</FONT></TD>
<TD align=right><FONT size=2>14,295,748</FONT></TD>
<TD align=left><FONT size=2>&nbsp;</FONT></TD></TR>
<TR>
<TD colSpan=3></TD>
<TD align=right colSpan=15>
<HR color=black noshade SIZE=2>
</TD></TR>
<TR vAlign=bottom>
<TD align=left>&nbsp;</TD>
<TD align=left><FONT size=2>&nbsp;</FONT></TD>
<TD align=left><FONT size=2>&nbsp;</FONT></TD></TR>
</TABLE>


<TABLE cellSpacing=0 cellPadding=0 width="100%">
<TR vAlign=top>
<TD align=left width="3%"><FONT face="Times New Roman, Times, Serif" size=2>(a) </FONT></TD>
<TD width="97%">
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>For fiscal 2004, includes preferred dividends of $419,000. For fiscal 2003, includes preferred dividends of $865,000 and a non-cash preferred dividend charge of $370,000 related to the beneficial conversion feature contained in our Series E Preferred Stock issued in April 2002. For fiscal 2002, includes preferred dividends of $446,000 and a non-cash preferred dividend charge of $587,000 related to the beneficial conversion feature contained in our Series E Preferred Stock issued in March 2002. For fiscal 2001, includes preferred dividends of $230,000 and a non-cash preferred dividend charge of $1,418,000 related to the beneficial conversion feature contained in our Series D Preferred Stock issued in October 2000. For fiscal 2000, includes preferred dividends of $151,000. </FONT></P>
</TD></TR>
</TABLE>

<BR>
<TABLE width="100%">
<TR>
<TD align=center><FONT size=2>15</FONT></TD></TR>
</TABLE>



<P>
<HR align=left noshade SIZE=5>


<P>&nbsp;
<!-- *************************************************************************** -->
<!-- MARKER PAGE="sheet: 14; page: 14" -->
<TABLE cellSpacing=0 cellPadding=0 width="100%" border=0>
<TR vAlign=bottom>
<TH colSpan=3></TH>
<TH colSpan=15><FONT size=2>March 31,</FONT>
<HR width="100%" color=black noshade SIZE=1>
</TH></TR>
<TR vAlign=bottom>
<TH colSpan=3></TH>
<TH colSpan=3><FONT size=2>2004</FONT>
<HR width="100%" color=black noshade SIZE=1>
</TH>
<TH colSpan=3><FONT size=2>2003</FONT>
<HR width="100%" color=black noshade SIZE=1>
</TH>
<TH colSpan=3><FONT size=2>2002</FONT>
<HR width="100%" color=black noshade SIZE=1>
</TH>
<TH colSpan=3><FONT size=2>2001</FONT>
<HR width="100%" color=black noshade SIZE=1>
</TH>
<TH colSpan=3><FONT size=2>2000</FONT>
<HR width="100%" color=black noshade SIZE=1>
</TH></TR>
<TR vAlign=bottom>
<TD align=left width="43%"><FONT size=2><B>Balance Sheet Data:</B></FONT></TD>
<TD align=left width="1%"><FONT size=2>&nbsp;</FONT></TD>
<TD align=left width="1%"><FONT size=2>&nbsp;</FONT></TD>
<TD align=right width="1%"><FONT size=2>&nbsp;</FONT></TD>
<TD align=right width="8%">&nbsp;</TD>
<TD align=left width="2%"><FONT size=2>&nbsp;</FONT></TD>
<TD align=right width="1%"><FONT size=2>&nbsp;</FONT></TD>
<TD align=right width="8%">&nbsp;</TD>
<TD align=left width="2%"><FONT size=2>&nbsp;</FONT></TD>
<TD align=right width="1%"><FONT size=2>&nbsp;</FONT></TD>
<TD align=right width="8%">&nbsp;</TD>
<TD align=left width="2%"><FONT size=2>&nbsp;</FONT></TD>
<TD align=right width="1%"><FONT size=2>&nbsp;</FONT></TD>
<TD align=right width="8%">&nbsp;</TD>
<TD align=left width="2%"><FONT size=2>&nbsp;</FONT></TD>
<TD align=right width="1%"><FONT size=2>&nbsp;</FONT></TD>
<TD align=right width="8%">&nbsp;</TD>
<TD align=left width="2%"><FONT size=2>&nbsp;</FONT></TD></TR>
<TR vAlign=bottom>
<TD align=left><FONT size=2>Cash, cash equivalents, and short-term investments</FONT></TD>
<TD align=left><FONT size=2>&nbsp;</FONT></TD>
<TD align=left><FONT size=2>&nbsp;</FONT></TD>
<TD align=right><FONT size=2>$</FONT></TD>
<TD align=right><FONT size=2>17,322,000</FONT></TD>
<TD align=left><FONT size=2>&nbsp;</FONT></TD>
<TD align=right><FONT size=2>$</FONT></TD>
<TD align=right><FONT size=2>10,430,000</FONT></TD>
<TD align=left><FONT size=2>&nbsp;</FONT></TD>
<TD align=right><FONT size=2>$</FONT></TD>
<TD align=right><FONT size=2>4,098,000</FONT></TD>
<TD align=left><FONT size=2>&nbsp;</FONT></TD>
<TD align=right><FONT size=2>$</FONT></TD>
<TD align=right><FONT size=2>2,012,000</FONT></TD>
<TD align=left><FONT size=2>&nbsp;</FONT></TD>
<TD align=right><FONT size=2>$</FONT></TD>
<TD align=right><FONT size=2>2,049,000</FONT></TD>
<TD align=left><FONT size=2>&nbsp;</FONT></TD></TR>
<TR vAlign=bottom>
<TD align=left><FONT size=2>Working capital</FONT></TD>
<TD align=left><FONT size=2>&nbsp;</FONT></TD>
<TD align=left><FONT size=2>&nbsp;</FONT></TD>
<TD align=right><FONT size=2>&nbsp;</FONT></TD>
<TD align=right><FONT size=2>25,865,000</FONT></TD>
<TD align=left><FONT size=2>&nbsp;</FONT></TD>
<TD align=right><FONT size=2>&nbsp;</FONT></TD>
<TD align=right><FONT size=2>17,855,000</FONT></TD>
<TD align=left><FONT size=2>&nbsp;</FONT></TD>
<TD align=right><FONT size=2>&nbsp;</FONT></TD>
<TD align=right><FONT size=2>13,282,000</FONT></TD>
<TD align=left><FONT size=2>&nbsp;</FONT></TD>
<TD align=right><FONT size=2>&nbsp;</FONT></TD>
<TD align=right><FONT size=2>7,811,000</FONT></TD>
<TD align=left><FONT size=2>&nbsp;</FONT></TD>
<TD align=right><FONT size=2>&nbsp;</FONT></TD>
<TD align=right><FONT size=2>4,019,000</FONT></TD>
<TD align=left><FONT size=2>&nbsp;</FONT></TD></TR>
<TR vAlign=bottom>
<TD align=left><FONT size=2>Total assets</FONT></TD>
<TD align=left><FONT size=2>&nbsp;</FONT></TD>
<TD align=left><FONT size=2>&nbsp;</FONT></TD>
<TD align=right><FONT size=2>&nbsp;</FONT></TD>
<TD align=right><FONT size=2>61,898,000</FONT></TD>
<TD align=left><FONT size=2>&nbsp;</FONT></TD>
<TD align=right><FONT size=2>&nbsp;</FONT></TD>
<TD align=right><FONT size=2>32,368,000</FONT></TD>
<TD align=left><FONT size=2>&nbsp;</FONT></TD>
<TD align=right><FONT size=2>&nbsp;</FONT></TD>
<TD align=right><FONT size=2>29,680,000</FONT></TD>
<TD align=left><FONT size=2>&nbsp;</FONT></TD>
<TD align=right><FONT size=2>&nbsp;</FONT></TD>
<TD align=right><FONT size=2>26,001,000</FONT></TD>
<TD align=left><FONT size=2>&nbsp;</FONT></TD>
<TD align=right><FONT size=2>&nbsp;</FONT></TD>
<TD align=right><FONT size=2>14,098,000</FONT></TD>
<TD align=left><FONT size=2>&nbsp;</FONT></TD></TR>
<TR vAlign=bottom>
<TD align=left><FONT size=2>Long-term obligations, excluding current portion</FONT></TD>
<TD align=left><FONT size=2>&nbsp;</FONT></TD>
<TD align=left><FONT size=2>&nbsp;</FONT></TD>
<TD align=right><FONT size=2>&nbsp;</FONT></TD>
<TD align=right><FONT size=2>938,000</FONT></TD>
<TD align=left><FONT size=2>&nbsp;</FONT></TD>
<TD align=right><FONT size=2>&nbsp;</FONT></TD>
<TD align=right><FONT size=2>1,218,000</FONT></TD>
<TD align=left><FONT size=2>&nbsp;</FONT></TD>
<TD align=right><FONT size=2>&nbsp;</FONT></TD>
<TD align=right><FONT size=2>1,747,000</FONT></TD>
<TD align=left><FONT size=2>&nbsp;</FONT></TD>
<TD align=right><FONT size=2>&nbsp;</FONT></TD>
<TD align=right><FONT size=2>2,191,000</FONT></TD>
<TD align=left><FONT size=2>&nbsp;</FONT></TD>
<TD align=right><FONT size=2>&nbsp;</FONT></TD>
<TD align=right><FONT size=2>878,000</FONT></TD>
<TD align=left><FONT size=2>&nbsp;</FONT></TD></TR>
<TR vAlign=bottom>
<TD align=left><FONT size=2>Convertible preferred stock</FONT></TD>
<TD align=left><FONT size=2>&nbsp;</FONT></TD>
<TD align=left><FONT size=2>&nbsp;</FONT></TD>
<TD align=right><FONT size=2>&nbsp;</FONT></TD>
<TD align=right><FONT size=2>--</FONT></TD>
<TD align=left><FONT size=2>&nbsp;</FONT></TD>
<TD align=right><FONT size=2>&nbsp;</FONT></TD>
<TD align=right><FONT size=2>3,176,000</FONT></TD>
<TD align=left><FONT size=2>&nbsp;</FONT></TD>
<TD align=right><FONT size=2>&nbsp;</FONT></TD>
<TD align=right><FONT size=2>2,561,000</FONT></TD>
<TD align=left><FONT size=2>&nbsp;</FONT></TD>
<TD align=right><FONT size=2>&nbsp;</FONT></TD>
<TD align=right><FONT size=2>--</FONT></TD>
<TD align=left><FONT size=2>&nbsp;</FONT></TD>
<TD align=right><FONT size=2>&nbsp;</FONT></TD>
<TD align=right><FONT size=2>--</FONT></TD>
<TD align=left><FONT size=2>&nbsp;</FONT></TD></TR>
<TR vAlign=bottom>
<TD align=left><FONT size=2>Total shareholders' equity</FONT></TD>
<TD align=left><FONT size=2>&nbsp;</FONT></TD>
<TD align=left><FONT size=2>&nbsp;</FONT></TD>
<TD align=right><FONT size=2>&nbsp;</FONT></TD>
<TD align=right><FONT size=2>54,572,000</FONT></TD>
<TD align=left><FONT size=2>&nbsp;</FONT></TD>
<TD align=right><FONT size=2>&nbsp;</FONT></TD>
<TD align=right><FONT size=2>22,268,000</FONT></TD>
<TD align=left><FONT size=2>&nbsp;</FONT></TD>
<TD align=right><FONT size=2>&nbsp;</FONT></TD>
<TD align=right><FONT size=2>18,152,000</FONT></TD>
<TD align=left><FONT size=2>&nbsp;</FONT></TD>
<TD align=right><FONT size=2>&nbsp;</FONT></TD>
<TD align=right><FONT size=2>15,495,000</FONT></TD>
<TD align=left><FONT size=2>&nbsp;</FONT></TD>
<TD align=right><FONT size=2>&nbsp;</FONT></TD>
<TD align=right><FONT size=2>7,237,000</FONT></TD>
<TD align=left><FONT size=2>&nbsp;</FONT></TD></TR>
</TABLE>


<!-- MARKER FORMAT-SHEET="APP HANG1" FSL="Workstation" -->

<P>
<H1><FONT size=2>ITEM 7.&nbsp;&nbsp; MANAGEMENT&#146;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS </FONT></H1>

<H1 align=left><FONT face="Times New Roman, Times, Serif" size=2>Overview </FONT></H1>


<P><FONT face="Times New Roman, Times, Serif" size=2>Abaxis, Inc. (&#147;us&#148; or &#147;we&#148;), incorporated in California in 1989, develops, manufactures and markets portable blood analysis systems for use in any veterinary or human patient-care setting to provide clinicians with rapid blood constituent measurements. Our primary product is a system consisting of a compact 6.9 kilogram (15 pounds) analyzer and a series of single-use plastic discs, called reagent discs, containing all the chemicals required to perform a panel of up to 13 tests on veterinary patients and 14 tests on human patients. </FONT></P>


<P><FONT face="Times New Roman, Times, Serif" size=2>Sales for any future periods are not predictable with a significant degree of certainty. We generally operate with limited order backlog because our products typically are shipped shortly after orders are received. As a result, product sales in any quarter are generally dependent on orders booked and shipped in that quarter. Our expense levels, which are to a large extent fixed, are based in part on our expectations of future revenues. Accordingly, we may be unable to adjust spending in a timely manner to compensate for any unexpected revenue shortfall. As a result, any such shortfall would negatively affect our operating results and financial condition. Our sales may be adversely impacted by pricing pressure from competitors. Our ability to be consistently profitable will depend, in part, on our ability to increase our sales volumes of our VetScan DXS and Piccolo products and to compete with other competitors successfully. We believe that period to
period comparisons of our results of operations are not necessarily meaningful. </FONT></P>

<H1 align=left><FONT face="Times New Roman, Times, Serif" size=2>Results of Operations </FONT></H1>

<P align=left><FONT face="Times New Roman, Times, Serif" size=2><B><I>Total Revenues </I></B></FONT></P>

<TABLE cellSpacing=0 cellPadding=0 width="100%" border=0>
<TR vAlign=bottom>
<TH></TH>
<TH colSpan=9><FONT size=2>Years Ended March 31,</FONT>
<HR width="95%" color=black noshade SIZE=1>
</TH>
<TH colSpan=6><FONT size=2>Percentage Change</FONT>
<HR width="95%" color=black noshade SIZE=1>
</TH></TR>
<TR vAlign=bottom>
<TH></TH>
<TH colSpan=3><FONT size=2>2004</FONT>
<HR width="35%" color=black noshade SIZE=1>
</TH>
<TH colSpan=3><FONT size=2>2003</FONT>
<HR width="35%" color=black noshade SIZE=1>
</TH>
<TH colSpan=3><FONT size=2>2002</FONT>
<HR width="35%" color=black noshade SIZE=1>
</TH>
<TH colSpan=3><FONT size=2>2003 to 2004</FONT>
<HR width="75%" color=black noshade SIZE=1>
</TH>
<TH colSpan=3><FONT size=2>2002 to 2003</FONT>
<HR width="80%" color=black noshade SIZE=1>
</TH></TR>
<TR vAlign=bottom>
<TD align=left width="30%"><FONT size=2>Product sales, net</FONT></TD>
<TD align=right width="1%"><FONT size=2>$</FONT></TD>
<TD align=right width="11%"><FONT size=2>46,599,000</FONT></TD>
<TD align=left width="4%"><FONT size=2>&nbsp;</FONT></TD>
<TD align=right width="1%"><FONT size=2>$</FONT></TD>
<TD align=right width="11%"><FONT size=2>34,532,000</FONT></TD>
<TD align=left width="4%"><FONT size=2>&nbsp;</FONT></TD>
<TD align=right width="1%"><FONT size=2>$</FONT></TD>
<TD align=right width="11%"><FONT size=2>30,418,000</FONT></TD>
<TD align=left width="4%"><FONT size=2>&nbsp;</FONT></TD>
<TD align=right width="1%"><FONT size=2>&nbsp;</FONT></TD>
<TD align=right width="7%"><FONT size=2>35</FONT></TD>
<TD align=left width="4%"><FONT size=2>%</FONT></TD>
<TD align=right width="1%"><FONT size=2>&nbsp;</FONT></TD>
<TD align=right width="7%"><FONT size=2>14</FONT></TD>
<TD align=left width="2%"><FONT size=2>%</FONT></TD></TR>
<TR vAlign=bottom>
<TD align=left><FONT size=2>&nbsp;&nbsp;Percentage of total revenues</FONT></TD>
<TD align=right><FONT size=2>&nbsp;</FONT></TD>
<TD align=right><FONT size=2>99</FONT></TD>
<TD align=left><FONT size=2>%</FONT></TD>
<TD align=right><FONT size=2>&nbsp;</FONT></TD>
<TD align=right><FONT size=2>99</FONT></TD>
<TD align=left><FONT size=2>%</FONT></TD>
<TD align=right><FONT size=2>&nbsp;</FONT></TD>
<TD align=right><FONT size=2>99</FONT></TD>
<TD align=left><FONT size=2>%</FONT></TD></TR>
<TR>
<TD colSpan=16>&nbsp; </TD></TR>
<TR vAlign=bottom>
<TD align=left><FONT size=2>Development and licensing revenue</FONT></TD>
<TD align=right><FONT size=2>&nbsp;</FONT></TD>
<TD align=right><FONT size=2>275,000</FONT></TD>
<TD align=left><FONT size=2>&nbsp;</FONT></TD>
<TD align=right><FONT size=2>&nbsp;</FONT></TD>
<TD align=right><FONT size=2>248,000</FONT></TD>
<TD align=left><FONT size=2>&nbsp;</FONT></TD>
<TD align=right><FONT size=2>&nbsp;</FONT></TD>
<TD align=right><FONT size=2>213,000</FONT></TD>
<TD align=left><FONT size=2>&nbsp;</FONT></TD>
<TD align=right><FONT size=2>&nbsp;</FONT></TD>
<TD align=right><FONT size=2>11</FONT></TD>
<TD align=left><FONT size=2>%</FONT></TD>
<TD align=right><FONT size=2>&nbsp;</FONT></TD>
<TD align=right><FONT size=2>16</FONT></TD>
<TD align=left><FONT size=2>%</FONT></TD></TR>
<TR vAlign=bottom>
<TD align=left><FONT size=2>&nbsp;&nbsp;Percentage of total revenues</FONT></TD>
<TD align=right><FONT size=2>&nbsp;</FONT></TD>
<TD align=right><FONT size=2>1</FONT></TD>
<TD align=left><FONT size=2>%</FONT></TD>
<TD align=right><FONT size=2>&nbsp;</FONT></TD>
<TD align=right><FONT size=2>1</FONT></TD>
<TD align=left><FONT size=2>%</FONT></TD>
<TD align=right><FONT size=2>&nbsp;</FONT></TD>
<TD align=right><FONT size=2>1</FONT></TD>
<TD align=left><FONT size=2>%</FONT></TD></TR>
<TR>
<TD colSpan=16>&nbsp; </TD></TR>
<TR>
<TD></TD>
<TD colSpan=9>
<HR color=black noshade SIZE=1>
</TD>
<TD align=right colSpan=6></TD></TR>
<TR vAlign=bottom>
<TD align=left><FONT size=2>Total revenues</FONT></TD>
<TD align=right><FONT size=2>$</FONT></TD>
<TD align=right><FONT size=2>46,874,000</FONT></TD>
<TD align=left><FONT size=2>&nbsp;</FONT></TD>
<TD align=right><FONT size=2>$</FONT></TD>
<TD align=right><FONT size=2>34,780,000</FONT></TD>
<TD align=left><FONT size=2>&nbsp;</FONT></TD>
<TD align=right><FONT size=2>$</FONT></TD>
<TD align=right><FONT size=2>30,631,000</FONT></TD>
<TD align=left><FONT size=2>&nbsp;</FONT></TD>
<TD align=right><FONT size=2>&nbsp;</FONT></TD>
<TD align=right><FONT size=2>35</FONT></TD>
<TD align=left><FONT size=2>%</FONT></TD>
<TD align=right><FONT size=2>&nbsp;</FONT></TD>
<TD align=right><FONT size=2>14</FONT></TD>
<TD align=left><FONT size=2>%</FONT></TD></TR>
<TR>
<TD></TD>
<TD colSpan=9>
<HR color=black noshade SIZE=2>
</TD>
<TD align=right colSpan=6></TD></TR>
<TR vAlign=bottom>
<TD align=left>&nbsp;</TD></TR>
</TABLE>



<P><FONT face="Times New Roman, Times, Serif" size=2>Total revenues increased 35% from $34,780,000 in fiscal 2003 to $46,874,000 in fiscal 2004. The growth in revenue was primarily due to an increase in total instrument sales of 51% or $5,459,000 from fiscal 2003 to fiscal 2004 and an increase of reagent discs and kits of 29% or $6,251,000 from fiscal 2003 to fiscal 2004. Revenues from the medical market increased by $4,082,000 from $3,037,000 in fiscal 2003 to $7,119,000 in fiscal 2004. Revenues from the veterinary market increased by $7,562,000 from $30,313,000 in fiscal 2003 to $37,875,000 in fiscal 2004. Other sales of $2,261,000 in fiscal 2004 primarily consisted of $1,061,000 related to sales of our Orbos technology. Although we sold a limited number of redesigned canine heartworm tests manufactured by S.A. Scientific in fiscal 2004, we have subsequently terminated our relationship with S.A. Scientifc. </FONT></P>

<TABLE width="100%">
<TR>
<TD align=center><FONT size=2>16</FONT></TD></TR>
</TABLE>



<P>
<HR align=left noshade SIZE=5>


<P>&nbsp;
<!-- *************************************************************************** -->
<!-- MARKER PAGE="sheet: 14; page: 14" -->

<P><FONT face="Times New Roman, Times, Serif" size=2>Total revenues increased 14% from $30,631,000 in fiscal 2002 to $34,780,000 in fiscal 2003. The growth in revenue was primarily due to an increase in total instrument sales of 8% or $840,000 from fiscal 2002 to fiscal 2003 and an increase of total reagent discs and kits of 20% or $3,687,000 from fiscal 2002 to fiscal 2003. Revenues from the medical market increased by $1,451,000 from $1,586,000 in fiscal 2002 to $3,037,000 in fiscal 2003. Revenues from the veterinary market increased by $3,001,000 from $27,312,000 in fiscal 2002 to $30,313,000 in fiscal 2003. Other sales decreased $413,000 from $2,317,000 in fiscal 2002 to $1,904,000 in fiscal 2003. Other sales included a decrease of $618,000 in Orbos sales and an increase of $16,000 in sales from the VetScan Canine Heartworm Test, which we ceased selling in December 2002 as a result of an out-of-court settlement. </FONT></P>


<P><FONT face="Times New Roman, Times, Serif" size=2>The increase in revenues from fiscal 2003 to fiscal 2004 is attributable to increased worldwide demand in both the medical and veterinary markets and driven by increased unit sales of our reagent discs and kits due to a higher consumption rate of users and to the expanded installed base of our Piccolo and VetScan systems. In September 2003, we completed and released the developments of the Renal Function, Hepatic Function and Comprehensive Metabolic Panels, which are key Piccolo medical panels which, together with existing panels, completes the full array of the Center for Medicare and Medicaid Services reimbursement panels. In February 2004, we received Food and Drug Administration (FDA) market clearance for our magnesium assay for use in the Piccolo blood chemistry analyzers. In fiscal 2004, 2003 and 2002, sales in the United States represented 85%, 84% and 86%, respectively, of our total revenues. In spite of the increase of total revenues in
absolute dollars from prior periods, our growth rate has remained consistent in both the United States and international markets during fiscal 2004, 2003 and 2002. </FONT></P>


<P><FONT face="Times New Roman, Times, Serif" size=2>Development and licensing revenue consists of royalty payments from Amersham Biosciences (formerly Pharmacia Biotech) equal to 5% of net sales, as defined in our agreement, of Amersham&#146;s products that use our technology. Our development and licensing revenue during fiscal 2004, 2003 and 2002 are based on our customers&#146; use of the Orbos technology. The usage by our customer is unpredictable. </FONT></P>

<P align=left><FONT face="Times New Roman, Times, Serif" size=2><B><I>Revenues by Geographical Location</I></B> </FONT></P>

<TABLE cellSpacing=0 cellPadding=0 width="100%" border=0>
<TR vAlign=bottom>
<TH colSpan=3>&nbsp;</TH>
<TH colSpan=9><FONT size=2>Year Ended March 31,</FONT>
<HR width="100%" color=black noshade SIZE=1>
</TH>
<TH>&nbsp;</TH>
<TH colSpan=5><FONT size=2>Percentage Change</FONT>
<HR width="95%" color=black noshade SIZE=1>
</TH></TR>
<TR vAlign=bottom>
<TH colSpan=3>&nbsp;</TH>
<TH colSpan=3><FONT size=2>2004</FONT>
<HR width="35%" color=black noshade SIZE=1>
</TH>
<TH colSpan=3><FONT size=2>2003</FONT>
<HR width="35%" color=black noshade SIZE=1>
</TH>
<TH colSpan=3><FONT size=2>2002</FONT>
<HR width="35%" color=black noshade SIZE=1>
</TH>
<TH colSpan=3><FONT size=2>2003 to 2004</FONT>
<HR width="75%" color=black noshade SIZE=1>
</TH>
<TH colSpan=3><FONT size=2>2002 to 2003</FONT>
<HR width="80%" color=black noshade SIZE=1>
</TH></TR>
<TR vAlign=bottom>
<TD align=left width="24%"><FONT size=2>United States</FONT></TD>
<TD align=left width="1%"><FONT size=2>&nbsp;</FONT></TD>
<TD align=left width="2%"><FONT size=2>&nbsp;</FONT></TD>
<TD align=right width="1%"><FONT size=2>$</FONT></TD>
<TD align=right width="13%"><FONT size=2>40,000,000</FONT></TD>
<TD align=left width="3%"><FONT size=2>&nbsp;</FONT></TD>
<TD align=right width="1%"><FONT size=2>$</FONT></TD>
<TD align=right width="13%"><FONT size=2>29,029,000</FONT></TD>
<TD align=left width="3%"><FONT size=2>&nbsp;</FONT></TD>
<TD align=right width="1%"><FONT size=2>$</FONT></TD>
<TD align=right width="13%"><FONT size=2>26,463,000</FONT></TD>
<TD align=left width="3%"><FONT size=2>&nbsp;</FONT></TD>
<TD align=right width="1%"><FONT size=2>&nbsp;</FONT></TD>
<TD align=right width="5%"><FONT size=2>38</FONT></TD>
<TD align=left width="6%"><FONT size=2>%</FONT></TD>
<TD align=right width="1%"><FONT size=2>&nbsp;</FONT></TD>
<TD align=right width="7%"><FONT size=2>10</FONT></TD>
<TD align=left width="2%"><FONT size=2>%</FONT></TD></TR>
<TR vAlign=bottom>
<TD align=left><FONT size=2>Europe</FONT></TD>
<TD align=left><FONT size=2>&nbsp;</FONT></TD>
<TD align=left><FONT size=2>&nbsp;</FONT></TD>
<TD align=right><FONT size=2>&nbsp;</FONT></TD>
<TD align=right><FONT size=2>5,005,000</FONT></TD>
<TD align=left><FONT size=2>&nbsp;</FONT></TD>
<TD align=right><FONT size=2>&nbsp;</FONT></TD>
<TD align=right><FONT size=2>3,866,000</FONT></TD>
<TD align=left><FONT size=2>&nbsp;</FONT></TD>
<TD align=right><FONT size=2>&nbsp;</FONT></TD>
<TD align=right><FONT size=2>2,780,000</FONT></TD>
<TD align=left><FONT size=2>&nbsp;</FONT></TD>
<TD align=right><FONT size=2>&nbsp;</FONT></TD>
<TD align=right><FONT size=2>29</FONT></TD>
<TD align=left><FONT size=2>%</FONT></TD>
<TD align=right><FONT size=2>&nbsp;</FONT></TD>
<TD align=right><FONT size=2>39</FONT></TD>
<TD align=left><FONT size=2>%</FONT></TD></TR>
<TR vAlign=bottom>
<TD align=left><FONT size=2>Asia and Latin America</FONT></TD>
<TD align=left><FONT size=2>&nbsp;</FONT></TD>
<TD align=left><FONT size=2>&nbsp;</FONT></TD>
<TD align=right><FONT size=2>&nbsp;</FONT></TD>
<TD align=right><FONT size=2>1,869,000</FONT></TD>
<TD align=left><FONT size=2>&nbsp;</FONT></TD>
<TD align=right><FONT size=2>&nbsp;</FONT></TD>
<TD align=right><FONT size=2>1,885,000</FONT></TD>
<TD align=left><FONT size=2>&nbsp;</FONT></TD>
<TD align=right><FONT size=2>&nbsp;</FONT></TD>
<TD align=right><FONT size=2>1,388,000</FONT></TD>
<TD align=left><FONT size=2>&nbsp;</FONT></TD>
<TD align=right><FONT size=2>&nbsp;</FONT></TD>
<TD align=right><FONT size=2>(1</FONT></TD>
<TD align=left><FONT size=2>)%</FONT></TD>
<TD align=right><FONT size=2>&nbsp;</FONT></TD>
<TD align=right><FONT size=2>36</FONT></TD>
<TD align=left><FONT size=2>%</FONT></TD></TR>
<TR>
<TD colSpan=3></TD>
<TD colSpan=3>
<HR width="95%" color=black noshade SIZE=1>
</TD>
<TD colSpan=3>
<HR width="95%" color=black noshade SIZE=1>
</TD>
<TD colSpan=3>
<HR width="95%" color=black noshade SIZE=1>
</TD>
<TD align=right colSpan=6></TD></TR>
<TR vAlign=bottom>
<TD align=left><FONT size=2>Total revenues</FONT></TD>
<TD align=left><FONT size=2>&nbsp;</FONT></TD>
<TD align=left><FONT size=2>&nbsp;</FONT></TD>
<TD align=right><FONT size=2>$</FONT></TD>
<TD align=right><FONT size=2>46,874,000</FONT></TD>
<TD align=left><FONT size=2>&nbsp;</FONT></TD>
<TD align=right><FONT size=2>$</FONT></TD>
<TD align=right><FONT size=2>34,780,000</FONT></TD>
<TD align=left><FONT size=2>&nbsp;</FONT></TD>
<TD align=right><FONT size=2>$</FONT></TD>
<TD align=right><FONT size=2>30,631,000</FONT></TD>
<TD align=left><FONT size=2>&nbsp;</FONT></TD>
<TD align=right><FONT size=2>&nbsp;</FONT></TD>
<TD align=right><FONT size=2>35</FONT></TD>
<TD align=left><FONT size=2>%</FONT></TD>
<TD align=right><FONT size=2>&nbsp;</FONT></TD>
<TD align=right><FONT size=2>14</FONT></TD>
<TD align=left><FONT size=2>%</FONT></TD></TR>
<TR>
<TD colSpan=3></TD>
<TD colSpan=3>
<HR width="95%" color=black noshade SIZE=2>
</TD>
<TD colSpan=3>
<HR width="95%" color=black noshade SIZE=2>
</TD>
<TD colSpan=3>
<HR width="95%" color=black noshade SIZE=2>
</TD>
<TD align=right colSpan=6></TD></TR>
</TABLE>


<!-- MARKER FORMAT-SHEET="Para Default" FSL="Default" -->

<P><FONT face="Times New Roman, Times, Serif" size=2>Total revenues in the United States increased by 38% or $10,971,000 from fiscal 2003 to fiscal 2004 and by 10% or $2,566,000 from fiscal 2002 to fiscal 2003. The increase in the United States in fiscal 2004 was primarily due to increases of instrument sales of $5,114,000 (including an increase in U.S. military sales of $1,123,000) and reagent discs of $5,477,000 (including an increase in U.S. military sales of $637,000). </FONT></P>


<P><FONT face="Times New Roman, Times, Serif" size=2>Total revenues in the United States increased by 10% or $2,566,000 from fiscal 2002 to fiscal 2003. In fiscal 2003, total United States instrument sales decreased by $29,000 offset by an increase in instrument sales to the U.S. military of $219,000. In fiscal 2003, reagent disc sales in the United States increased by $3,010,000 (including an increase in U.S. military sales of $271,000). </FONT></P>


<P><FONT face="Times New Roman, Times, Serif" size=2>In the United States, two distributors, Vedco Inc. and DVM Resources accounted for 27% and 16%, respectively, of total revenues for fiscal 2004, 36% and 11%, respectively, of total revenues for fiscal 2003, and 41% and 8%, respectively, of total revenues for fiscal 2002. In April 2004, we signed a distributor agreement with the Veterinary Division of Henry Schein, Inc., a distributor of animal healthcare products and services to veterinary practitioners to sell and distribute the VetScan DXS, along with the associated reagent discs and kits. </FONT></P>


<P><FONT face="Times New Roman, Times, Serif" size=2>Total revenues in Europe increased by 29% or $1,139,000 from fiscal 2003 to fiscal 2004 and by 39% or $1,086,000 from fiscal 2002 to fiscal 2003. The increase in Europe in fiscal 2004 was primarily due to increases of instrument sales of $479,000 and reagent disc sales of $666,000. The increase in Europe in fiscal 2003 was primarily due to increases of instrument sales of $289,000 and reagent disc sales of $770,000. </FONT></P>


<P><FONT face="Times New Roman, Times, Serif" size=2>Total revenues in Asia and Latin America decreased by 1% or $16,000 from fiscal 2003 to fiscal 2004 and increased by 36% or $497,000 from fiscal 2002 to fiscal 2003. The slight decrease in Asia and Latin America in fiscal 2004 was primarily due to a </FONT></P>

<TABLE width="100%">
<TR>
<TD align=center><FONT size=2>17</FONT></TD></TR>
</TABLE>



<P>
<HR align=left noshade SIZE=5>


<P>&nbsp;
<!-- *************************************************************************** -->
<!-- MARKER PAGE="sheet: 14; page: 14" -->

<P><FONT face="Times New Roman, Times, Serif" size=2>decrease in instrument sales of $134,000 offset by an increase in reagent disc sales of $108,000. The increase in Asia and Latin America in fiscal 2003 was primarily due to increases of instrument sales of $580,000 offset by a decrease of reagent disc sales of $93,000. </FONT></P>


<P><FONT face="Times New Roman, Times, Serif" size=2>Our goal for fiscal 2005 is to continue the increase in instrument sales by allocating resources to product selling and marketing. We intend to introduce marketing programs emphasizing instrument sales. We also plan to increase our sales force and offer incentive programs to retain highly skilled sales professionals. The increase of 29% or $6,251,000 in reagent disc sales during our fiscal 2004 compared to fiscal 2003 is consistent with our belief that there will be recurring reagent disc revenue as our product lines mature. This growth is mostly attributable to the expanded installed base of Piccolo and VetScan systems and higher consumption rates of users. </FONT></P>

<P align=left><FONT face="Times New Roman, Times, Serif" size=2><I><B>Cost of Product Sales</B></I> </FONT></P>

<TABLE cellSpacing=0 cellPadding=0 width="100%" border=0>
<TR vAlign=bottom>
<TD width="45%">&nbsp;</TD>
<TD align=center colSpan=6><B><FONT size=2>Years Ended March 31,</FONT> </B>
<HR width=320 noshade SIZE=1>
</TD>
<TD align=center colSpan=4><B><FONT size=2>Percentage Change</FONT></B>
<HR width=190 noshade SIZE=1>
</TD></TR>
<TR vAlign=bottom>
<TD width="45%">&nbsp;</TD>
<TD align=center colSpan=2><FONT size=2><B>2004</B></FONT>
<HR width=70 noshade SIZE=1>
</TD>
<TD align=center colSpan=2><FONT size=2><B>2003</B></FONT>
<HR width=70 noshade SIZE=1>
</TD>
<TD align=center colSpan=2><FONT size=2><B>2002</B></FONT>
<HR width=70 noshade SIZE=1>
</TD>
<TD align=center colSpan=2><FONT size=2><B>2003 to 2004</B></FONT>
<HR width=80 noshade SIZE=1>
</TD>
<TD align=center colSpan=2><FONT size=2><B>2002 to 2003</B></FONT>
<HR width=80 noshade SIZE=1>
</TD></TR>
<TR vAlign=bottom>
<TD width="45%"><FONT size=2>Cost of product sales</FONT></TD>
<TD align=right width="9%"><FONT size=2>$22,966,000</FONT></TD>
<TD width="3%">&nbsp;</TD>
<TD align=right width="9%"><FONT size=2>$17,755,000</FONT></TD>
<TD width="3%">&nbsp;</TD>
<TD align=right width="8%"><FONT size=2>$15,966,000</FONT></TD>
<TD width="2%">&nbsp;</TD>
<TD align=right width="6%"><FONT size=2>29</FONT></TD>
<TD width="5%"><FONT size=2>%</FONT></TD>
<TD align=right width="5%"><FONT size=2>11</FONT></TD>
<TD width="5%"><FONT size=2>%</FONT></TD></TR>
<TR vAlign=bottom>
<TD width="45%"><FONT size=2>Percentage of total revenues</FONT></TD>
<TD align=right width="9%"><FONT size=2>49</FONT></TD>
<TD width="3%"><FONT size=2>%</FONT></TD>
<TD align=right width="9%"><FONT size=2>51</FONT></TD>
<TD width="3%"><FONT size=2>%</FONT></TD>
<TD align=right width="8%"><FONT size=2>52</FONT></TD>
<TD width="2%"><FONT size=2>%</FONT></TD>
<TD align=right width="6%">&nbsp;</TD>
<TD width="5%">&nbsp;</TD>
<TD align=right width="5%">&nbsp;</TD>
<TD width="5%">&nbsp;</TD></TR>
</TABLE>



<P><FONT face="Times New Roman, Times, Serif" size=2>Cost of product sales includes the costs associated with manufacturing, assembly, package, warranty repairs, test and quality assurance for our instrument analyzers and reagent discs and manufacturing overhead, including costs of personnel and equipment associated with manufacturing support. The decrease in cost of product sales as a percent of revenue from fiscal 2002 to fiscal 2003 and from fiscal 2003 to fiscal 2004 were attributable to continued increases in sales volume of reagent discs and lower unit costs resulting from improved manufacturing processes and absorption of fixed costs of our current facilities. The increase in cost of product sales in absolute dollars from fiscal 2002 to fiscal 2003 and from fiscal 2003 to fiscal 2004 were primarily attributable to an increase in instrument sales of 51% or $5,459,000 from fiscal 2003 to fiscal 2004 and 8% or $840,000 from fiscal 2002 to fiscal 2003 and an increase of reagent discs of 29% or
$6,251,000 from fiscal 2003 to fiscal 2004 and 20% or $3,687,000 from fiscal 2002 to fiscal 2003. </FONT></P>

<P align=left><FONT face="Times New Roman, Times, Serif" size=2><B><I>Selling, General and Administrative Expense </I></B></FONT></P>

<TABLE cellSpacing=0 cellPadding=0 width="100%" border=0>
<TR vAlign=bottom>
<TD width="45%">&nbsp;</TD>
<TD align=center colSpan=6><B><FONT size=2>Years Ended March 31,</FONT> </B>
<HR width=320 noshade SIZE=1>
</TD>
<TD align=center colSpan=4><B><FONT size=2>Percentage Change</FONT></B>
<HR width=190 noshade SIZE=1>
</TD></TR>
<TR vAlign=bottom>
<TD width="45%">&nbsp;</TD>
<TD align=center colSpan=2><FONT size=2><B>2004</B></FONT>
<HR width=70 noshade SIZE=1>
</TD>
<TD align=center colSpan=2><FONT size=2><B>2003</B></FONT>
<HR width=70 noshade SIZE=1>
</TD>
<TD align=center colSpan=2><FONT size=2><B>2002</B></FONT>
<HR width=70 noshade SIZE=1>
</TD>
<TD align=center colSpan=2><FONT size=2><B>2003 to 2004</B></FONT>
<HR width=80 noshade SIZE=1>
</TD>
<TD align=center colSpan=2><FONT size=2><B>2002 to 2003</B></FONT>
<HR width=80 noshade SIZE=1>
</TD></TR>
<TR vAlign=bottom>
<TD width="45%"><FONT size=2>Selling, general and administrative</FONT></TD>
<TD align=right width="9%"><FONT size=2>$14,431,000</FONT></TD>
<TD width="3%">&nbsp;</TD>
<TD align=right width="9%"><FONT size=2>$11,564,000</FONT></TD>
<TD width="3%">&nbsp;</TD>
<TD align=right width="8%"><FONT size=2>$9,333,000</FONT></TD>
<TD width="2%">&nbsp;</TD>
<TD align=right width="6%"><FONT size=2>25</FONT></TD>
<TD width="5%"><FONT size=2>%</FONT></TD>
<TD align=right width="5%"><FONT size=2>24</FONT></TD>
<TD width="5%"><FONT size=2>%</FONT></TD></TR>
<TR vAlign=bottom>
<TD width="45%"><FONT size=2>Percentage of total revenues</FONT></TD>
<TD align=right width="9%"><FONT size=2>31</FONT></TD>
<TD width="3%"><FONT size=2>%</FONT></TD>
<TD align=right width="9%"><FONT size=2>33</FONT></TD>
<TD width="3%"><FONT size=2>%</FONT></TD>
<TD align=right width="8%"><FONT size=2>30</FONT></TD>
<TD width="2%"><FONT size=2>%</FONT></TD>
<TD align=right width="6%">&nbsp;</TD>
<TD width="5%">&nbsp;</TD>
<TD align=right width="5%">&nbsp;</TD>
<TD width="5%">&nbsp;</TD></TR>
</TABLE>



<P><FONT face="Times New Roman, Times, Serif" size=2>Selling, general and administrative expenses consist primarily of salaries and benefits, commissions and related expenses for personnel engaged in marketing, advertising, costs associated with promotional and other marketing expenses, customer service and technical service, general corporate functions, including accounting, human resources and legal. Selling, general and administrative expenses increased 25% or $2,867,000 in fiscal 2004 from fiscal 2003 primarily due to increased expenses of $841,000 devoted to sales and marketing resources in the medical market and $1,410,000 devoted to sales and marketing resources in the veterinary market. Selling, general and administrative expenses increased 24% or $2,231,000 in fiscal 2003 from fiscal 2002 primarily due to increased expenses of $1,024,000 devoted to sales and marketing resources in the medical market and $890,000 of costs related to legal action filed by Idexx, which resulted in an
out-of-court settlement in December 2002. </FONT></P>


<P><FONT face="Times New Roman, Times, Serif" size=2>Selling, general and administrative activities accounted for 31%, 33% and 30% of total revenues during fiscal 2004, 2003 and 2002. We anticipate the dollar amount of selling, general and administrative expenses to increase in fiscal 2005 from fiscal 2004 but remain consistent as a percentage of total revenues due to our plan to increase our sales force and offer incentive programs to retain highly skilled sales professionals. In addition, we expect an increase in expenses due to accounting services relating to Sarbanes-Oxley compliance and an increase in premiums for our general business insurance. </FONT></P>

<P align=left><FONT face="Times New Roman, Times, Serif" size=2><B><I>Research and Development</I></B> </FONT></P>

<TABLE cellSpacing=0 cellPadding=0 width="100%" border=0>
<TR vAlign=bottom>
<TD width="45%">&nbsp;</TD>
<TD align=center colSpan=6><B><FONT size=2>Years Ended March 31,</FONT> </B>
<HR width=320 noshade SIZE=1>
</TD>
<TD align=center colSpan=4><B><FONT size=2>Percentage Change</FONT></B>
<HR width=190 noshade SIZE=1>
</TD></TR>
<TR vAlign=bottom>
<TD width="45%">&nbsp;</TD>
<TD align=center colSpan=2><FONT size=2><B>2004</B></FONT>
<HR width=70 noshade SIZE=1>
</TD>
<TD align=center colSpan=2><FONT size=2><B>2003</B></FONT>
<HR width=70 noshade SIZE=1>
</TD>
<TD align=center colSpan=2><FONT size=2><B>2002</B></FONT>
<HR width=70 noshade SIZE=1>
</TD>
<TD align=center colSpan=2><FONT size=2><B>2003 to 2004</B></FONT>
<HR width=80 noshade SIZE=1>
</TD>
<TD align=center colSpan=2><FONT size=2><B>2002 to 2003</B></FONT>
<HR width=80 noshade SIZE=1>
</TD></TR>
<TR vAlign=bottom>
<TD width="45%"><FONT size=2>Research and development</FONT></TD>
<TD align=right width="9%"><FONT size=2>$4,757,000</FONT></TD>
<TD width="3%">&nbsp;</TD>
<TD align=right width="9%"><FONT size=2>$3,888,000</FONT></TD>
<TD width="3%">&nbsp;</TD>
<TD align=right width="8%"><FONT size=2>$3,834,000</FONT></TD>
<TD width="2%">&nbsp;</TD>
<TD align=right width="6%"><FONT size=2>22</FONT></TD>
<TD width="5%"><FONT size=2>%</FONT></TD>
<TD align=right width="5%"><FONT size=2>1</FONT></TD>
<TD width="5%"><FONT size=2>%</FONT></TD></TR>
<TR vAlign=bottom>
<TD width="45%"><FONT size=2>Percentage of total revenues</FONT></TD>
<TD align=right width="9%"><FONT size=2>10</FONT></TD>
<TD width="3%"><FONT size=2>%</FONT></TD>
<TD align=right width="9%"><FONT size=2>11</FONT></TD>
<TD width="3%"><FONT size=2>%</FONT></TD>
<TD align=right width="8%"><FONT size=2>13</FONT></TD>
<TD width="2%"><FONT size=2>%</FONT></TD>
<TD align=right width="6%">&nbsp;</TD>
<TD width="5%">&nbsp;</TD>
<TD align=right width="5%">&nbsp;</TD>
<TD width="5%">&nbsp;</TD></TR>
</TABLE>

<BR>
<TABLE width="100%">
<TR>
<TD align=center><FONT size=2>18</FONT></TD></TR>
</TABLE>



<P>
<HR align=left noshade SIZE=5>


<P>&nbsp;
<!-- *************************************************************************** -->
<!-- MARKER PAGE="sheet: 14; page: 14" -->

<P><FONT face="Times New Roman, Times, Serif" size=2>Research and development expenses consist of salaries and benefits, related expenses associated with the development of clinical trials of new test methods and the enhancement of existing products. Research and development expenses increased by 22% or $869,000 in fiscal 2004 from fiscal 2003 primarily due to product development in the medical market. Research and development expenses increased by 1% or $54,000 in fiscal 2003 from fiscal 2002 primarily related to the completion of clinical trials and Food and Drug Administration (FDA) clearance on our Lipid Panel for use in the Piccolo diagnostic system and completion of the VetScan Comprehensive Diagnostic Profile rotor for use in the veterinary market. </FONT></P>


<P><FONT face="Times New Roman, Times, Serif" size=2>Research and development activities accounted for 10%, 11% and 13% of total revenues during fiscal 2004, 2003 and 2002. We anticipate the dollar amount of research and development expenses to increase in fiscal 2005 from fiscal 2004 but remain consistent as a percentage of total revenues, as we complete new products for both the human medical and veterinary markets. There can be no assurance, however, that we will undertake such research and development activities in future periods or, if we do, that such activities will be successful. </FONT></P>

<P align=left><FONT face="Times New Roman, Times, Serif" size=2><B><I>Interest and Other, Net</I></B> </FONT></P>


<P><FONT face="Times New Roman, Times, Serif" size=2>The following table sets forth our interest and other income, net for fiscal 2004, 2003 and 2002: </FONT></P>

<TABLE cellSpacing=0 cellPadding=0 width="100%" border=0>
<TR vAlign=bottom>
<TD width="45%">&nbsp;</TD>
<TD align=center colSpan=6><B><FONT size=2>Years Ended March 31,</FONT> </B>
<HR width=320 noshade SIZE=1>
</TD>
<TD align=center colSpan=4><B><FONT size=2>Percentage Change</FONT></B>
<HR width=190 noshade SIZE=1>
</TD></TR>
<TR vAlign=bottom>
<TD width="45%">&nbsp;</TD>
<TD align=center colSpan=2><FONT size=2><B>2004</B></FONT>
<HR width=70 noshade SIZE=1>
</TD>
<TD align=center colSpan=2><FONT size=2><B>2003</B></FONT>
<HR width=70 noshade SIZE=1>
</TD>
<TD align=center colSpan=2><FONT size=2><B>2002</B></FONT>
<HR width=70 noshade SIZE=1>
</TD>
<TD align=center colSpan=2><FONT size=2><B>2003 to 2004</B></FONT>
<HR width=80 noshade SIZE=1>
</TD>
<TD align=center colSpan=2><FONT size=2><B>2002 to 2003</B></FONT>
<HR width=80 noshade SIZE=1>
</TD></TR>
<TR vAlign=bottom>
<TD width="45%"><FONT size=2>Interest income</FONT></TD>
<TD align=right width="9%"><FONT size=2>$&nbsp;173,000</FONT></TD>
<TD width="3%"><FONT size=2></FONT></TD>
<TD align=right width="9%"><FONT size=2>$&nbsp;217,000</FONT></TD>
<TD width="3%"><FONT size=2></FONT></TD>
<TD align=right width="8%"><FONT size=2>$&nbsp;&nbsp;&nbsp;91,000</FONT></TD>
<TD width="2%"><FONT size=2></FONT></TD>
<TD align=right width="6%"><FONT size=2>(20</FONT></TD>
<TD width="5%"><FONT size=2>)%</FONT></TD>
<TD align=right width="5%"><FONT size=2>138</FONT></TD>
<TD width="5%"><FONT size=2>%</FONT></TD></TR>
<TR vAlign=bottom>
<TD width="45%"><FONT size=2>Interest expense and other income (expense), net</FONT></TD>
<TD align=right width="9%"><FONT size=2>(68,000</FONT></TD>
<TD align=left width="3%"><FONT size=2>)</FONT></TD>
<TD align=right width="9%"><FONT size=2>(149,000</FONT></TD>
<TD align=left width="3%"><FONT size=2>)</FONT></TD>
<TD align=right width="8%"><FONT size=2>(269,000</FONT></TD>
<TD align=left width="2%"><FONT size=2>)</FONT></TD>
<TD align=right width="6%"><FONT size=2>(54</FONT></TD>
<TD align=left width="5%"><FONT size=2>)%</FONT></TD>
<TD align=right width="5%"><FONT size=2>(45</FONT></TD>
<TD align=left width="5%"><FONT size=2>)%</FONT></TD></TR>
<TR vAlign=bottom>
<TD width="45%">&nbsp;</TD>
<TD align=right width="9%">
<HR align=right width=50 color=black noshade SIZE=1>
</TD>
<TD align=left width="3%">&nbsp;</TD>
<TD align=right width="9%">
<HR align=right width=50 color=black noshade SIZE=1>
</TD>
<TD align=left width="3%">&nbsp;</TD>
<TD align=right width="8%">
<HR align=right width=50 color=black noshade SIZE=1>
</TD>
<TD align=left width="2%">&nbsp;</TD>
<TD align=right width="6%"><FONT size=2></FONT></TD>
<TD align=left width="5%"><FONT size=2></FONT></TD>
<TD align=right width="5%"><FONT size=2></FONT></TD>
<TD align=left width="5%"><FONT size=2></FONT></TD></TR>
<TR vAlign=bottom>
<TD width="45%">&nbsp;</TD>
<TD vAlign=bottom align=right width="9%"><FONT size=2>$&nbsp;105,000</FONT></TD>
<TD vAlign=bottom align=left width="3%"><FONT size=2></FONT></TD>
<TD vAlign=bottom align=right width="9%"><FONT size=2>$&nbsp;&nbsp;&nbsp;68,000</FONT></TD>
<TD vAlign=bottom align=left width="3%"><FONT size=2></FONT></TD>
<TD vAlign=bottom align=right width="8%"><FONT size=2>$(178,000</FONT></TD>
<TD vAlign=bottom align=left width="2%"><FONT size=2>)</FONT></TD>
<TD align=right width="6%"><FONT size=2>54</FONT></TD>
<TD align=left width="5%"><FONT size=2>%</FONT></TD>
<TD align=right width="5%"><FONT size=2>138</FONT></TD>
<TD align=left width="5%"><FONT size=2>%</FONT></TD></TR>
<TR vAlign=bottom>
<TD width="45%">&nbsp;</TD>
<TD align=right width="9%">
<HR align=right width=50 color=black noshade SIZE=2>
<FONT size=2></FONT></TD>
<TD align=left width="3%"><FONT size=2></FONT></TD>
<TD align=right width="9%">
<HR align=right width=50 color=black noshade SIZE=2>
<FONT size=2></FONT></TD>
<TD align=left width="3%"><FONT size=2></FONT></TD>
<TD align=right width="8%">
<HR align=right width=50 color=black noshade SIZE=2>
<FONT size=2></FONT></TD>
<TD align=left width="2%"><FONT size=2></FONT></TD>
<TD align=right width="6%"><FONT size=2></FONT></TD>
<TD align=left width="5%"><FONT size=2></FONT></TD>
<TD align=right width="5%"><FONT size=2></FONT></TD>
<TD align=left width="5%"><FONT size=2></FONT></TD></TR>
</TABLE>


<P align=left><FONT face="Times New Roman, Times, Serif" size=2><B><I>Interest Income</I></B> </FONT></P>


<P><FONT face="Times New Roman, Times, Serif" size=2>Interest income was $173,000, $217,000 and $91,000 for fiscal 2004, 2003 and 2002, respectively. Interest and other income primarily consisted of interest earned on cash and cash equivalents. The decrease of 20% or $44,000, in fiscal 2004 from fiscal 2003, was primarily due to lower interest rates obtained on our cash, cash equivalents and short-term investments. The increase of $126,000 in fiscal 2003 from fiscal 2002 was primarily due to higher average invested balances. </FONT></P>

<P align=left><FONT face="Times New Roman, Times, Serif" size=2><B><I>Interest Expense and Other Income (Expense), Net</I></B> </FONT></P>


<P><FONT face="Times New Roman, Times, Serif" size=2>Interest and other expense for fiscal 2004, included a total of $43,000 of interest on our capital equipment loan and capital leases and $10,000 on our co-promotion agreement with Abbott Laboratories. In fiscal 2004, we recorded a net loss of $12,000 on foreign currency transactions. Interest and other expense for fiscal 2003, included a total of $107,000 of interest on our capital equipment loan and line of credit, $26,000 on our capital leases and $10,000 on our co-promotion agreement with Abbott Laboratories. Interest and other expense for fiscal 2002, included $210,000 on equipment and working capital loans and $87,000 on our building and capital leases, net of capitalized interest of $74,000 on the purchase and installation of our semi-automated disc production line. Also included in interest and other expense in fiscal 2002, was a cancellation fee of $32,000 related to the termination of our previous equipment and working capital loans when we
signed our new agreements with Comerica Bank-California in March 2002. We incurred other expense of $6,000 for currency losses during fiscal 2002. These decreases in interest expense were primarily attributable to reduced balances on our equipment loan, capital leases and other outstanding debt. </FONT></P>

<P align=left><FONT face="Times New Roman, Times, Serif" size=2><B><I>Income Tax Provision (Benefit)</I></B> </FONT></P>


<P><FONT face="Times New Roman, Times, Serif" size=2>Income tax benefit totaled $19,208,000 in fiscal 2004, which included a one-time income tax benefit of $19,450,000 related to existing deferred tax assets (principally net operating loss carryforwards) because we concluded that it is more likely than not that these assets will be realized. Prior to the fourth quarter of fiscal 2004, these deferred tax assets had been fully reserved. The $19,450,000 income tax benefit is partially offset by a current tax provision of $242,000 related to taxes for various state tax jurisdictions and federal alternative minimum tax for fiscal 2004. For fiscal 2003 and 2002, income tax expense totaled $5,000 and $16,000, respectively, which primarily related to taxes for various state tax jurisdictions. We expect our effective tax rate will be approximately 39% for federal and various state tax jurisdictions in the near term. </FONT></P>

<P align=left><FONT face="Times New Roman, Times, Serif" size=2><B><I>Preferred Dividends and Accretion</I></B> </FONT></P>


<P><FONT face="Times New Roman, Times, Serif" size=2>In fiscal 2004, preferred dividends totaled $419,000. In fiscal 2003, we recorded preferred dividends and accretion related to the beneficial conversion feature of our preferred stock of $865,000 and $370,000, respectively, compared to $446,000 and $587,000, respectively, in fiscal 2002. In October 2003, under the terms of our respective Certificate of Determination with </FONT></P>

<TABLE width="100%">
<TR>
<TD align=center><FONT size=2>19</FONT></TD></TR>
</TABLE>



<P>
<HR align=left noshade SIZE=5>


<P>&nbsp;
<!-- *************************************************************************** -->
<!-- MARKER PAGE="sheet: 14; page: 14" -->

<P><FONT face="Times New Roman, Times, Serif" size=2>respect to both the Series D Preferred Stock and Series E Preferred Stock, the Series D Preferred and the Series E Preferred automatically converted into shares of common stock after twenty consecutive trading days where the per share closing price of our common stock as reported on the Nasdaq National Market exceeded $14.00 and $12.00, respectively. Consequently, we have eliminated our obligation to pay an ongoing annual dividend to the holders of the Series D Preferred and Series E Preferred. </FONT></P>

<H1 align=left><FONT face="Times New Roman, Times, Serif" size=2><B>Liquidity and Capital Resources</B> </FONT></H1>


<P><FONT face="Times New Roman, Times, Serif" size=2>As of March&nbsp;31, 2004, we had $17,322,000 in cash, cash equivalents and short-term investments as compared to $10,430,000 at March 31, 2003. </FONT></P>


<P><FONT face="Times New Roman, Times, Serif" size=2>Cash provided (used) in fiscal 2004, 2003 and 2002 was as follows: </FONT></P>

<TABLE cellSpacing=0 cellPadding=0 width="100%" border=0>
<TR vAlign=bottom>
<TH colSpan=2>&nbsp;</TH>
<TH colSpan=6><FONT size=2>Year Ended March 31,</FONT>
<HR width="95%" color=black noshade SIZE=1>
</TH></TR>
<TR vAlign=bottom>
<TH colSpan=2>&nbsp;</TH>
<TH colSpan=2><FONT size=2>2004</FONT>
<HR width="65%" color=black noshade SIZE=1>
</TH>
<TH colSpan=2><FONT size=2>2003</FONT>
<HR width="65%" color=black noshade SIZE=1>
</TH>
<TH colSpan=2><FONT size=2>2002</FONT>
<HR width="65%" color=black noshade SIZE=1>
</TH></TR>
<TR vAlign=bottom>
<TD align=left width="53%"><FONT size=2>Cash provided by operating activities</FONT></TD>
<TD align=left width="3%"><FONT size=2>&nbsp;</FONT></TD>
<TD align=right width="12%"><FONT size=2>$&nbsp;&nbsp;&nbsp;7,198,000</FONT></TD>
<TD align=left width="4%"><FONT size=2>&nbsp;</FONT></TD>
<TD align=right width="11%"><FONT size=2>$&nbsp;3,525,000</FONT></TD>
<TD align=left width="4%"><FONT size=2>&nbsp;</FONT></TD>
<TD align=right width="10%"><FONT size=2>$&nbsp;3,102,000</FONT></TD>
<TD align=left width="3%"><FONT size=2>&nbsp;</FONT></TD></TR>
<TR vAlign=bottom>
<TD align=left width="53%"><FONT size=2>Cash (used in) investing activities</FONT></TD>
<TD align=left width="3%"><FONT size=2>&nbsp;</FONT></TD>
<TD align=right width="12%"><FONT size=2>(10,029,000</FONT></TD>
<TD align=left width="4%"><FONT size=2>)</FONT></TD>
<TD align=right width="11%"><FONT size=2>(1,157,000</FONT></TD>
<TD align=left width="4%"><FONT size=2>)</FONT></TD>
<TD align=right width="10%"><FONT size=2>(873,000</FONT></TD>
<TD align=left width="3%"><FONT size=2>)</FONT></TD></TR>
<TR vAlign=bottom>
<TD align=left width="53%"><FONT size=2>Cash provided by (used in) financing activities</FONT></TD>
<TD align=left width="3%"><FONT size=2>&nbsp;</FONT></TD>
<TD align=right width="12%"><FONT size=2>1,725,000</FONT></TD>
<TD align=left width="4%"><FONT size=2>&nbsp;</FONT></TD>
<TD align=right width="11%"><FONT size=2>3,964,000</FONT></TD>
<TD align=left width="4%"><FONT size=2>&nbsp;</FONT></TD>
<TD align=right width="10%"><FONT size=2>(143,000</FONT></TD>
<TD align=left width="3%"><FONT size=2>)</FONT></TD></TR>
<TR vAlign=bottom>
<TD align=left width="53%">&nbsp;</TD>
<TD align=left width="3%">&nbsp;</TD>
<TD align=right width="12%">
<HR align=right width="70%" noshade SIZE=1>
</TD>
<TD align=left width="4%">&nbsp;</TD>
<TD align=right width="11%">
<HR align=right width="70%" noshade SIZE=1>
</TD>
<TD align=left width="4%">&nbsp;</TD>
<TD align=right width="10%">
<HR align=right width="70%" noshade SIZE=1>
</TD>
<TD align=left width="3%">&nbsp;</TD></TR>
<TR vAlign=bottom>
<TD align=left width="53%"><FONT size=2>&nbsp;&nbsp;Net increase (decrease) in cash and cash equivalents</FONT></TD>
<TD align=left width="3%"><FONT size=2>&nbsp;</FONT></TD>
<TD align=right width="12%"><FONT size=2>$(1,106,000</FONT></TD>
<TD align=left width="4%"><FONT size=2>)</FONT></TD>
<TD align=right width="11%"><FONT size=2>$&nbsp;6,332,000</FONT></TD>
<TD align=left width="4%"><FONT size=2>&nbsp;</FONT></TD>
<TD align=right width="10%"><FONT size=2>$&nbsp;2,086,000</FONT></TD>
<TD align=left width="3%"><FONT size=2>&nbsp;</FONT></TD></TR>
<TR vAlign=bottom>
<TD align=left width="53%">&nbsp;</TD>
<TD align=left width="3%">&nbsp;</TD>
<TD align=right width="12%">
<HR align=right width="70%" noshade SIZE=2>
</TD>
<TD align=left width="4%">&nbsp;</TD>
<TD align=right width="11%">
<HR align=right width="70%" noshade SIZE=2>
</TD>
<TD align=left width="4%">&nbsp;</TD>
<TD align=right width="10%">
<HR align=right width="70%" noshade SIZE=2>
</TD>
<TD align=left width="3%">&nbsp;</TD></TR>
</TABLE>



<P><FONT face="Times New Roman, Times, Serif" size=2><B><I>Operating Activities</I> &#151;</B> Net cash provided by operating activities in fiscal 2004 was $7,198,000. This was primarily the result of net income of $24,033,000 offset by the effects of non-cash expenses including depreciation and amortization of $1,708,000, common stock issued for employee benefits plan of $73,000, stock based compensation of $24,000, stock option income tax benefits of $1,902,000 and an increase in net deferred tax assets of $21,233,000. Additional cash was generated from a decrease of $355,000 in prepaid expenses, deposits and other assets, increases of $637,000 in accounts payable, $1,042,000 in accrued payroll and related expenses, $88,000 in deferred rent and $42,000 in deferred revenue. Uses of cash from operating activities included increases totaling $1,437,000 in trade receivables and in inventories and a decrease of long-term commission obligation of $36,000. </FONT></P>


<P><FONT face="Times New Roman, Times, Serif" size=2>Net income in fiscal 2004 included a one-time income tax benefit of $19,450,000 related to existing deferred tax assets (principally net operating loss carryforwards) because we concluded that it is more likely than not that these assets will be realized. Prior to the fourth quarter of fiscal 2004, the net deferred tax assets had been fully reserved. The increase in trade receivable of $720,000 is primarily due to sales made in the last month of the quarter. The increase in inventory of $717,000, which mainly consists of finished reagent discs, is primarily due to higher sales forecast. </FONT></P>


<P><FONT face="Times New Roman, Times, Serif" size=2>Net cash provided by operating activities in fiscal 2003 was $3,525,000. This was primarily the result of net income of $1,636,000 offset by the effects of non-cash expenses including depreciation and amortization of $1,634,000, common stock issued for employee benefits plan of $197,000 and stock based compensation of $16,000. Additional cash was generated from a decrease inventories of $600,000 and increases totaling $664,000 in accounts payable, accrued payroll and related expenses and deferred rent. The decrease in inventory was due to lower inventory levels as of March 31, 2003 resulting from better inventory management. The increase in accrued payroll and related expenses is primarily due to an increase in our headcount during fiscal 2003. Uses of cash from operating activities included increases totaling $869,000 in trade receivables, prepaid expenses, deposits and other assets and decreases totaling $314,000 in warranty reserve, other accrued
liabilities, deferred revenue and long-term commission obligation. </FONT></P>


<P><FONT face="Times New Roman, Times, Serif" size=2>We anticipate to incur incremental additional costs to support our future operations, including further commercialization of our products and development of new test methods that will allow us to expand our veterinary market and further penetrate the human diagnostic market; acquisition of capital equipment for our manufacturing facilities, which includes the ongoing costs related to continuing development of our current and future products; additional pre-clinical testing and clinical trials for our current and future products; and the design and production of our next generation blood chemistry analyzers. </FONT></P>


<P><FONT face="Times New Roman, Times, Serif" size=2>We anticipate that our existing capital resources, debt financing, and anticipated revenue from the sales of our products will be adequate to satisfy our currently planned operating and financial requirements through the next twelve months. Our future capital requirements will largely depend upon the increased market acceptance of our point-of-care blood analyzer products. However, our sales for any future periods are not predictable with a significant degree of certainty. Regardless, we may seek to raise additional funds to leverage our internal expansion into the human medical market or pursue strategic acquisition opportunities. </FONT></P>

<TABLE width="100%">
<TR>
<TD align=center><FONT size=2>20</FONT></TD></TR>
</TABLE>



<P>
<HR align=left noshade SIZE=5>


<P>&nbsp;
<!-- *************************************************************************** -->
<!-- MARKER PAGE="sheet: 14; page: 14" -->

<P><FONT face="Times New Roman, Times, Serif" size=2><B><I>Investing Activities</I></B> &#151; Net cash used in investing activities for fiscal 2004 was $10,029,000, and was primarily related to purchases of short-term investments of $7,998,000 and $1,281,000 of property and equipment and $750,000 of intellectual property relating to patents. Net cash used in investing activities for fiscal 2003 was $1,157,000, and was primarily related to $1,168,000 of purchases in property and equipment. </FONT></P>


<P><FONT face="Times New Roman, Times, Serif" size=2>Our short-term investments consist of various certificate of deposits with maturities greater than three months at the balance sheet date and less than twelve months. Our short-term investment objective is to maximize yields without significantly increased risk. </FONT></P>


<P><FONT face="Times New Roman, Times, Serif" size=2>We anticipate that we will continue to purchase property and equipment necessary in the normal course of our business. </FONT></P>


<P><FONT face="Times New Roman, Times, Serif" size=2><B><I>Financing Activities</I></B> &#150; Net cash provided by financing activities of $1,725,000 included $2,716,000 of proceeds from the exercise of stock options and warrants, partially offset by repayments of $991,000 on our equipment loan finance and capital leases. During fiscal 2004, we paid off the outstanding balance of our equipment financing loan of $933,000. </FONT></P>


<P><FONT face="Times New Roman, Times, Serif" size=2>Net cash provided by financing activities of $3,964,000 included $6,812,000 of net proceeds from the issuance of Series E preferred stock, net borrowings of $1,000,000 from our line of credit, offset by cash dividends of $457,000 and repayments on our line of credit, equipment financing loan and capital leases totaling $3,571,000. </FONT></P>


<P><FONT face="Times New Roman, Times, Serif" size=2><B><I>Preferred Stock</I></B> &#150; In October 2003, under the terms of our respective Certificate of Determination with respect to both the Series D Preferred Stock (the &#147;Series D Preferred&#148;) and Series E Preferred Stock (the &#147;Series E Preferred&#148;), the Series D Preferred and the Series E Preferred automatically converted into shares of common stock after twenty consecutive trading days where the per share closing price of our common stock as reported on the Nasdaq National Market exceeded $14.00 and $12.00, respectively. Elective conversions, coupled with the automatic conversion of all remaining outstanding Series E Preferred Stock, resulted in the conversion of 5,570 shares of Series E Preferred Stock into 856,907 shares of common stock during fiscal 2004. Elective conversions, coupled with the automatic conversion of all remaining outstanding Series D Preferred Stock, resulted in the conversion of 6,508 shares of Series D
Preferred Stock into 929,699 shares of common stock during fiscal 2004. Consequently, we have eliminated our obligation to pay an ongoing annual dividend that the holders of the Series D Preferred and Series E Preferred would have otherwise received in either cash or shares of our common stock. </FONT></P>


<P><FONT face="Times New Roman, Times, Serif" size=2><B><I>Line of Credit and Long-Term Debt</I></B> &#150; In September 2003, we terminated our existing line of credit with Comerica Bank-California and entered into a new line of credit with Comerica Bank-California, which provides for borrowings of up to $2,000,000, bears interest at the bank&#146;s prime rate minus 0.25%, which totaled 3.75% at March 31, 2004, and is payable monthly. Of the $2,000,000 available, $820,000 was committed to secure a letter of credit for our facilities lease. The letter of credit will be reduced to $410,000 if we meet certain requirements as outlined in the terms of our facilities lease agreement, which among other stipulations, includes a minimum cumulative net income requirement of $2,000,000 for four consecutive quarters. The new line of credit terminates upon notification by either party and the outstanding balance is payable upon demand. At March 31, 2004, there was no amount outstanding under our line of credit.
The weighted average interest rate on the line of credit during 2004 and 2003 was 3.92% and 4.55%, respectively. In September 2003, our foreign line of credit expired. </FONT></P>


<P><FONT face="Times New Roman, Times, Serif" size=2>We also had an equipment financing loan, which bore interest at the prime rate plus 1%, which totaled 5.00% at March 31, 2004, and is payable in monthly installments of $42,000 in principal and interest. In March 2004, we paid off the remaining outstanding balance of our equipment financing loan. Total repayments in fiscal 2004 were $933,000. At March 31, 2004, there was no amount outstanding under our equipment financing loan. At March 31, 2003, the outstanding balance on our equipment financing loan totaled $933,000. The weighted average interest rate on equipment financing loans during fiscal 2004 and 2003 was 5.00% and 5.55%, respectively. </FONT></P>


<P><FONT face="Times New Roman, Times, Serif" size=2>The line of credit agreement contain certain financial covenants, which are evaluated on a quarterly basis. Included in these financial covenants, among other stipulations, is a requirement that we have a minimum net income of $25,000 before preferred stock dividends and accretion in any three quarters of a fiscal year, provided that any loss before preferred stock dividends and accretion incurred in the remaining quarter is not to exceed $250,000. We are also required to be profitable, as defined, on a fiscal year to date basis beginning with the six month period ending September 30, 2003 and to have net income before preferred stock dividends and accretion on preferred stock of $1,150,000 for the fiscal year ending March 31, 2004. In addition, we are required to have a quick ratio, as defined, of not less than 1.00 to 1.00, cash flow coverage, as defined, of not less than 1.25 to 1.00, debt to net worth ratio, as defined, not greater than 1.00 to
1.00 and to maintain a tangible effective net worth, as defined, of not less than $25,731,000. At March 31, 2004, we were in compliance with these covenants. </FONT></P>

<TABLE width="100%">
<TR>
<TD align=center><FONT size=2>21</FONT></TD></TR>
</TABLE>



<P>
<HR align=left noshade SIZE=5>


<P>&nbsp;
<!-- *************************************************************************** -->
<!-- MARKER PAGE="sheet: 14; page: 14" -->

<P><FONT face="Times New Roman, Times, Serif" size=2>Borrowings under the line of credit are collateralized by our net book value of assets of $54.6 million at March 31, 2004 including our intellectual property. </FONT></P>


<P><FONT face="Times New Roman, Times, Serif" size=2><B>Critical Accounting Policies</B> &#151; We have identified the policies below as critical to our business operations and the understanding of our results of operations. The impact and any associated risks related to these policies on our business operations are discussed below. For a more detailed discussion on the application of these and other accounting policies, see the Notes to Financial Statements included in this Annual Report on Form 10-K. The preparation of financial statements in accordance with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. There can be no assurance that actual results will not differ from those estimates.
</FONT></P>

<H1 align=left><FONT face="Times New Roman, Times, Serif" size=2>Revenue Recognition </FONT></H1>


<P><FONT face="Times New Roman, Times, Serif" size=2>Revenues from product sales, net of estimated sales allowances and rebates, are recognized upon shipment when a purchase order has been received, the sales price is fixed and determinable and collection of the resulting receivable is reasonably assured. Rights of return are not provided and provisions are made at the time the related revenue is recognized for the estimated future costs to be incurred under initial standard warranty obligations of one year. Revenues received for, or allocated to extended warranty arrangements are recognized ratably over the related warranty period. Instrument revenues under cross-distribution agreements (where we and another party purchase each other&#146;s products for resale) are recognized upon sale of the products to the end user. Development and licensing revenue is recognized in accordance with the related contract terms. </FONT></P>


<P><FONT face="Times New Roman, Times, Serif" size=2>We make estimates to adjust revenues for estimated sales allowances and rebates based on historical data and terms of current promotions, including cash rebates and trade-in programs in which we issue credit to customers as incentives for purchasing our products. Although we believe these estimates are reliable, it is possible that actual allowance or rebate amounts realized could vary from our estimates and that the amounts of such differences could affect our operating results. </FONT></P>

<H1 align=left><FONT face="Times New Roman, Times, Serif" size=2>Reserves and Accruals </FONT></H1>


<P><FONT face="Times New Roman, Times, Serif" size=2>We maintain allowances for doubtful accounts based on our assessment of the collectibility of amounts owed us by customers which is mostly determined by the customer&#146;s payment history and the outstanding period of accounts. In addition, we provide provisions for the estimated future costs to be incurred under our standard warranty obligations of one year. Actual amounts realized could vary from our estimates and affect our operating results. </FONT></P>

<H1 align=left><FONT face="Times New Roman, Times, Serif" size=2>Income Taxes </FONT></H1>


<P><FONT face="Times New Roman, Times, Serif" size=2>As of March 31, 2004, we had net deferred tax assets of $21,233,000 primarily resulting from net operating loss carryforwards (&#147;NOLs&#148;), which consist of $48,468,000 of Federal NOLs that expire at various times through 2023, and $6,631,000 of state NOLs that expire at various times through 2007. At March 31, 2004, the Company eliminated the valuation allowance previously maintained against deferred tax assets to the extent that it is more likely than not that it will generate sufficient taxable income in the future to realize the deferred tax assets. We will continue to evaluate our deferred tax assets in the future to determine whether a deferred tax asset valuation allowance is required at some future point. </FONT></P>

<H1 align=left><FONT face="Times New Roman, Times, Serif" size=2>Contractual Obligations </FONT></H1>


<P><FONT face="Times New Roman, Times, Serif" size=2>As of March&nbsp;31, 2004, we have the following outstanding contractual obligations: </FONT></P>


<P><FONT face="Times New Roman, Times, Serif" size=2>In September 1999, we entered into a co-promotion agreement with Abbott Laboratories. The agreement was for an initial term of two years. As of September&nbsp;30, 2000, the co-promotion agreement with Abbott Laboratories was terminated in accordance with its terms. While this agreement was in effect, we incurred commission obligations to Abbott Laboratories totaling $103,000 at March 31, 2004, payable over a four-year period. The present value of such obligations were recorded concurrent with the respective sales using a discount rate of 9.75%. </FONT></P>


<P><FONT face="Times New Roman, Times, Serif" size=2>At March 31, 2004, there was no outstanding balance on our line of credit, which is payable upon demand. </FONT></P>

<TABLE width="100%">
<TR>
<TD align=center><FONT size=2>22</FONT></TD></TR>
</TABLE>



<P>
<HR align=left noshade SIZE=5>


<P>&nbsp;
<!-- *************************************************************************** -->
<!-- MARKER PAGE="sheet: 14; page: 14" -->

<P><FONT face="Times New Roman, Times, Serif" size=2>At March 31, 2004, there was no outstanding balance on our equipment financing loan. In March 2004, we paid off the remaining outstanding balance of our equipment financing loan. Total repayments on our equipment financing loan during fiscal 2004 was $933,000. </FONT></P>


<P><FONT face="Times New Roman, Times, Serif" size=2>The future minimum payments under our capital and operating leases at March&nbsp;31, 2004 are as follows: </FONT></P>


<P>
<TABLE cellSpacing=0 cellPadding=0 width="100%" border=0>
<TR>
<TD vAlign=bottom nowrap width="74%">
<P align=left><FONT face="Times New Roman" size=2></FONT>&nbsp;</P>
</TD>
<TD vAlign=bottom nowrap width="9%">
<P align=center><FONT face="Times New Roman" size=2>Capital</FONT></P>
</TD>
<TD vAlign=bottom nowrap width="7%">&nbsp;</TD>
<TD vAlign=bottom nowrap width="10%">
<P align=center><FONT face="Times New Roman" size=2>Operating </FONT></P>
</TD></TR>
<TR>
<TD vAlign=bottom nowrap width="74%">
<P align=left><FONT face="Times New Roman" size=2></FONT>&nbsp;</P>
</TD>
<TD vAlign=bottom nowrap width="9%">
<P align=center><FONT face="Times New Roman" size=2>Leases</FONT></P>
</TD>
<TD vAlign=bottom nowrap width="7%">&nbsp;</TD>
<TD vAlign=bottom nowrap width="10%">
<P align=center><FONT face="Times New Roman" size=2>Leases</FONT></P>
</TD></TR>
<TR>
<TD vAlign=bottom nowrap width="74%">&nbsp;</TD>
<TD vAlign=bottom nowrap width="9%">
<HR noshade SIZE=1>
</TD>
<TD vAlign=bottom nowrap width="7%">&nbsp;</TD>
<TD vAlign=bottom nowrap width="10%">
<HR noshade SIZE=1>
</TD></TR>
<TR>
<TD vAlign=bottom nowrap width="74%">
<P align=left><FONT face="Times New Roman" size=2>Fiscal Year Ending March 31,&nbsp; </FONT></P>
</TD>
<TD vAlign=bottom nowrap width="9%">
<P align=center><FONT face="Times New Roman" size=2></FONT>&nbsp;</P>
</TD>
<TD vAlign=bottom nowrap width="7%">&nbsp;</TD>
<TD vAlign=bottom nowrap width="10%">
<P align=right><FONT face="Times New Roman" size=2></FONT>&nbsp;</P>
</TD></TR>
<TR>
<TD vAlign=bottom nowrap width="74%">
<P align=left><FONT face="Times New Roman" size=2>&nbsp;&nbsp; 2005</FONT></P>
</TD>
<TD vAlign=bottom nowrap width="9%">
<P align=right><FONT face="Times New Roman" size=2>&nbsp;$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 24,000 </FONT></P>
</TD>
<TD vAlign=bottom nowrap width="7%">&nbsp;</TD>
<TD vAlign=bottom nowrap align=right width="10%">
<P align=right><FONT face="Times New Roman" size=2>&nbsp;$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 953,000 </FONT></P>
</TD></TR>
<TR>
<TD vAlign=bottom nowrap width="74%">
<P align=left><FONT face="Times New Roman" size=2>&nbsp;&nbsp; 2006</FONT></P>
</TD>
<TD vAlign=bottom nowrap width="9%">
<P align=right><FONT face="Times New Roman" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 17,000 </FONT></P>
</TD>
<TD vAlign=bottom nowrap width="7%">&nbsp;</TD>
<TD vAlign=bottom nowrap align=right width="10%">
<P align=right><FONT face="Times New Roman" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;975,000 </FONT></P>
</TD></TR>
<TR>
<TD vAlign=bottom nowrap width="74%">
<P align=left><FONT face="Times New Roman" size=2>&nbsp;&nbsp; 2007</FONT></P>
</TD>
<TD vAlign=bottom nowrap width="9%">
<P align=right><FONT face="Times New Roman" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &#151; </FONT></P>
</TD>
<TD vAlign=bottom nowrap width="7%">&nbsp;</TD>
<TD vAlign=bottom nowrap align=right width="10%">
<P align=right><FONT face="Times New Roman" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 1,008,000 </FONT></P>
</TD></TR>
<TR>
<TD vAlign=bottom nowrap width="74%">
<P align=left><FONT face="Times New Roman" size=2>&nbsp;&nbsp; 2008</FONT></P>
</TD>
<TD vAlign=bottom nowrap width="9%">
<P align=right><FONT face="Times New Roman" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &#151; </FONT></P>
</TD>
<TD vAlign=bottom nowrap width="7%">&nbsp;</TD>
<TD vAlign=bottom nowrap align=right width="10%">
<P align=right><FONT face="Times New Roman" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 1,048,000 </FONT></P>
</TD></TR>
<TR>
<TD vAlign=bottom nowrap width="74%">
<P align=left><FONT face="Times New Roman" size=2>&nbsp;&nbsp; 2009</FONT></P>
</TD>
<TD vAlign=bottom nowrap width="9%">
<P align=right><FONT face="Times New Roman" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &#151; </FONT></P>
</TD>
<TD vAlign=bottom nowrap width="7%">&nbsp;</TD>
<TD vAlign=bottom nowrap align=right width="10%">
<P align=right><FONT face="Times New Roman" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 1,090,000 </FONT></P>
</TD></TR>
<TR>
<TD vAlign=bottom nowrap width="74%">
<P align=left><FONT face="Times New Roman" size=2>&nbsp;&nbsp; Thereafter</FONT></P>
</TD>
<TD vAlign=bottom nowrap width="9%">
<P align=right><FONT face="Times New Roman" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &#151; </FONT></P>
</TD>
<TD vAlign=bottom nowrap width="7%">&nbsp;</TD>
<TD vAlign=bottom nowrap align=right width="10%">
<P align=right><FONT face="Times New Roman" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2,009,000 </FONT></P>
</TD></TR>
<TR>
<TD vAlign=bottom nowrap width="74%">&nbsp;</TD>
<TD vAlign=bottom nowrap width="9%">
<HR align=right noshade SIZE=1>
</TD>
<TD vAlign=bottom nowrap width="7%">&nbsp;</TD>
<TD vAlign=bottom nowrap align=right width="10%">
<HR align=right noshade SIZE=1>
</TD></TR>
<TR>
<TD vAlign=bottom nowrap width="74%">
<P align=left><FONT face="Times New Roman" size=2>Total minimum lease payments</FONT></P>
</TD>
<TD vAlign=bottom nowrap width="9%">
<P align=right><FONT face="Times New Roman" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 41,000 </FONT></P>
</TD>
<TD vAlign=bottom nowrap width="7%">&nbsp;</TD>
<TD vAlign=bottom nowrap align=right width="10%">
<P align=right><FONT face="Times New Roman" size=2>&nbsp;$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 7,083,000 </FONT></P>
</TD></TR>
<TR>
<TD vAlign=bottom nowrap width="74%">
<P align=left><FONT face="Times New Roman" size=2>Less amounts representing interest (9.9% to 26.7%)</FONT></P>
</TD>
<TD vAlign=bottom nowrap width="9%">
<P align=right><FONT face="Times New Roman" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 3,000 </FONT></P>
</TD>
<TD vAlign=bottom nowrap width="7%">&nbsp;</TD>
<TD vAlign=bottom nowrap align=right width="10%">
<HR align=right noshade SIZE=2>
</TD></TR>
<TR>
<TD vAlign=bottom nowrap width="74%">&nbsp;</TD>
<TD vAlign=bottom nowrap width="9%">
<HR align=right noshade SIZE=1>
</TD>
<TD vAlign=bottom nowrap width="7%">&nbsp;</TD>
<TD vAlign=bottom nowrap align=right width="10%">&nbsp;</TD></TR>
<TR>
<TD vAlign=bottom nowrap width="74%">
<P align=left><FONT face="Times New Roman" size=2>Present value of minimum lease payments</FONT></P>
</TD>
<TD vAlign=bottom nowrap width="9%">
<P align=right><FONT face="Times New Roman" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 38,000 </FONT></P>
</TD>
<TD vAlign=bottom nowrap width="7%">&nbsp;</TD>
<TD vAlign=bottom nowrap align=right width="10%">
<P align=right><FONT face="Times New Roman" size=2></FONT>&nbsp;</P>
</TD></TR>
<TR>
<TD vAlign=bottom nowrap width="74%">
<P align=left><FONT face="Times New Roman" size=2>Less amounts due within one year</FONT></P>
</TD>
<TD vAlign=bottom nowrap width="9%">
<P align=right><FONT face="Times New Roman" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 22,000 </FONT></P>
</TD>
<TD vAlign=bottom nowrap width="7%">&nbsp;</TD>
<TD vAlign=bottom nowrap align=right width="10%">
<P align=right><FONT face="Times New Roman" size=2></FONT>&nbsp;</P>
</TD></TR>
<TR>
<TD vAlign=bottom nowrap width="74%">&nbsp;</TD>
<TD vAlign=bottom nowrap width="9%">
<HR align=right noshade SIZE=1>
</TD>
<TD vAlign=bottom nowrap width="7%">&nbsp;</TD>
<TD vAlign=bottom nowrap align=right width="10%">&nbsp;</TD></TR>
<TR>
<TD vAlign=bottom nowrap width="74%">
<P align=left><FONT face="Times New Roman" size=2>Long-term portion</FONT></P>
</TD>
<TD vAlign=bottom nowrap width="9%">
<P align=right><FONT face="Times New Roman" size=2>&nbsp;$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 16,000 </FONT></P>
</TD>
<TD vAlign=bottom nowrap width="7%">&nbsp;</TD>
<TD vAlign=bottom nowrap align=right width="10%">
<P align=right><FONT face="Times New Roman" size=2></FONT>&nbsp;</P>
</TD></TR>
<TR>
<TD vAlign=bottom nowrap width="74%">&nbsp;</TD>
<TD vAlign=bottom nowrap width="9%">
<HR align=right noshade SIZE=2>
</TD>
<TD vAlign=bottom nowrap width="7%">&nbsp;</TD>
<TD vAlign=bottom nowrap align=right width="10%">&nbsp;</TD></TR>
</TABLE>



<P><FONT face="Times New Roman, Times, Serif" size=2>In connection with our facility lease agreement, we have established a letter of credit for $820,000, which is secured by our line of credit. The letter of credit will be reduced to $410,000 if we meet certain requirements as outlined in the terms of our facilities lease agreement, which among other stipulations, includes a minimum cumulative net income requirement of $2,000,000 for four consecutive quarters. </FONT></P>

<H1 align=left><FONT face="Times New Roman, Times, Serif" size=2>Purchase Commitments </FONT></H1>


<P><FONT face="Times New Roman, Times, Serif" size=2>In November 2003, we entered into an OEM agreement with Diatron Messtechnik GmbH (DIATRON) of Austria to purchase DIATRON hematology instruments. Under the terms of the agreement, we are commited to purchase a minimum number of hematology units from DIATRON once their product was qualified for sale. Qualification occurred in May 2004 and accordingly, we have minimum purchase commitments. The outstanding commitment for fiscal 2005 through 2009 was $2,376,000, $2,592,000, $2,592,000, $2,592,000 and $2,592,000, respectively. </FONT></P>


<P><FONT face="Times New Roman, Times, Serif" size=2>In November 2001, we arrived at general terms with S.A. Scientific, Inc., of San Antonio, Texas, to purchase canine heartworm antigen tests over a period of four years. In December 2002, we reached an out-of-court settlement with one of our competitors, Idexx Laboratories, Inc., which alleged in an action filed with the United States District Court for the District Court of Maine that the canine heartworm antigen test supplied to us by S.A. Scientific infringed on two of Idexx&#146;s patents. In light of the terms of this settlement, we do not believe, based on the general terms that we have agreed to with S.A. Scientific, that we will be obligated to purchase any of the canine heartworm antigen tests. Although we subsequently sold a limited number of redesigned canine heartworm tests manufactured by S.A. Scientific, we have subsequently terminated our relationship with S.A. Scientific. </FONT></P>

<H1 align=left><FONT face="Times New Roman, Times, Serif" size=2>Contingencies </FONT></H1>


<P><FONT face="Times New Roman, Times, Serif" size=2>We are from time to time involved in various litigation matters in the normal course of business. We believe that the ultimate resolution of these matters will not have a material effect on our financial position or results of operations. </FONT></P>


<P><FONT face="Times New Roman, Times, Serif" size=2><B>New Accounting Pronouncements</B> &#151; In December 2002, the FASB issued SFAS No. 148, &#147;Accounting for Stock-Based Compensation &#151; Transition and Disclosure.&#148; SFAS No. 148 amends FASB Statement No. 123, &#147;Accounting for Stock-Based Compensation,&#148; to provide alternative methods of transition for a voluntary change to the fair value based method of accounting for stock-based employee compensation. In addition, SFAS No. 148 amends the disclosure requirements of SFAS No. 123 to require prominent disclosures in both annual and interim financial statements of the method of accounting for stock-based employee compensation and the effect of the method used on reported results. We adopted the disclosure provisions of SFAS No. 148 on January 1, 2003. We did not change to using the fair value based method of accounting for stock-based employee </FONT></P>

<TABLE width="100%">
<TR>
<TD align=center><FONT size=2>23</FONT></TD></TR>
</TABLE>



<P>
<HR align=left noshade SIZE=5>


<P>&nbsp;
<!-- *************************************************************************** -->
<!-- MARKER PAGE="sheet: 14; page: 14" -->

<P><FONT face="Times New Roman, Times, Serif" size=2>compensation as permitted by the voluntary transition provisions of SFAS 148; and therefore, adoption of SFAS No. 148 did not have an impact on our financial position, results of operations or cash flows in the financial statements. </FONT></P>


<P><FONT face="Times New Roman, Times, Serif" size=2>In April 2003, the FASB issued SFAS No. 149, &#147;Amendment of Statement 133 on Derivative Instruments and Hedging Activities.&#148; This statement amends and clarifies financial accounting and reporting for derivative instruments, including certain derivative instruments embedded in other contracts (collectively referred to as derivatives) and for hedging activities under FASB Statement No. 133, &#147;Accounting for Derivative Instruments and Hedging Activities.&#148; This statement is effective for contracts entered into or modified after June 30, 2003. The adoption of this statement did not have an impact on our financial position, results of operations or cash flows. </FONT></P>


<P><FONT face="Times New Roman, Times, Serif" size=2>In May 2003, the FASB issued SFAS No. 150, &#147;Accounting for Certain Financial Instruments with Characteristics of both Liabilities and Equity.&#148; This statement establishes standards for how an issuer classifies and measures certain financial instruments with characteristics of both liabilities and equity. This statement is effective for financial instruments entered into or modified after May 31, 2003 and otherwise is effective at the beginning of the first interim period beginning after June 15, 2003. The adoption of this statement did not have an impact on our financial position, results of operations or cash flows. </FONT></P>


<P><FONT face="Times New Roman, Times, Serif" size=2>The Financial Accounting Standards Board (&#147;FASB&#148;) issued Interpretation No. 46 (&#147;FIN 46&#148;), &#147;Consolidation of Variable Interest Entities,&#148; in January 2003, and a revised interpretation of FIN 46 (&#147;FIN 46-R&#148;) in December 2003. FIN 46 requires certain variable interest entities (&#147;VIEs&#148;) to be consolidated by the primary beneficiary of the entity if the equity investors in the entity do not have the characteristics of a controlling financial interest or do not have sufficient equity at risk for the entity to finance its activities without additional subordinated financial support from other parties. The provisions of FIN 46 are effective immediately for all arrangements entered into after January 31, 2003. Since January 31, 2003, we have not invested in any entities that we believe are variable interest entities for which we are the primary beneficiary. For all arrangements entered into after January 31,
2003, we are required to continue to apply FIN 46 through the end of the fourth quarter of fiscal 2004. We are required to adopt the provisions of FIN 46-R for those arrangements in the first quarter of fiscal 2005. For arrangements entered into prior to February 1, 2003, we are required to adopt the provisions of FIN 46-R in the first quarter of fiscal 2005. We do not expect the adoption of FIN 46-R to have an impact on our financial position, results of operations or cash flows. </FONT></P>

<H1 align=left><FONT face="Times New Roman, Times, Serif" size=2>RISK FACTORS THAT MAY AFFECT OUR PERFORMANCE </FONT></H1>


<P><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our future performance is subject to a number of risks. If any of the following risks actually occur, our business could be harmed and the trading price of our common stock could decline. </FONT></P>


<P><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;When used in these risk factors, the words &#147;anticipates,&#148; &#147;believes,&#148; &#147;expects,&#148; &#147;intends,&#148; &#147;plans,&#148; &#147;future,&#148; and similar expressions identify forward-looking statements. Our actual results could differ materially from those that we project in the forward-looking statements as a result of factors that we have set forth throughout this document as well as factors of which we are currently not aware. </FONT></P>

<H1 align=left><FONT face="Times New Roman, Times, Serif" size=2>We Have Not Been Consistently Profitable; We Must Increase Sales Of Our Piccolo And Vetscan DXS Products To Maintain Consistent Profitability </FONT></H1>


<P><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We recognized a net loss attributable to common shareholders in four of the last twelve fiscal quarters ended March 31, 2004. There can be no assurance that we will experience profitability in the future. As of March&nbsp;31, 2004, we have incurred cumulative net losses of $38 million. Our ability to be consistently profitable will depend, in part, on our ability to increase our sales volumes of our VetScan DXS and Piccolo products. Increasing our sales volume of our products will depend upon our ability to: </FONT></P>

<!-- MARKER FORMAT-SHEET="Para Hang Level 1" FSL="Default" -->
<TABLE cellSpacing=0 cellPadding=0 width="100%">
<TR vAlign=top>
<TD width="5%"><FONT face="Times New Roman, Times, Serif" size=2>&nbsp; </FONT></TD>
<TD width="5%"><FONT face="Times New Roman, Times, Serif" size=2>&#149;</FONT></TD>
<TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp; </FONT></TD>
<TD width="90%"><FONT face="Times New Roman, Times, Serif" size=2>continue to develop our products; </FONT></TD></TR>
</TABLE>

<BR>
<!-- MARKER FORMAT-SHEET="Para Hang Level 1" FSL="Default" -->
<TABLE cellSpacing=0 cellPadding=0 width="100%">
<TR vAlign=top>
<TD width="5%"><FONT face="Times New Roman, Times, Serif" size=2>&nbsp; </FONT></TD>
<TD width="5%">&#149;</TD>
<TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp; </FONT></TD>
<TD width="90%"><FONT face="Times New Roman, Times, Serif" size=2>increase our sales and marketing activities; </FONT></TD></TR>
</TABLE>

<BR>
<!-- MARKER FORMAT-SHEET="Para Hang Level 1" FSL="Default" -->
<TABLE cellSpacing=0 cellPadding=0 width="100%">
<TR vAlign=top>
<TD width="5%"><FONT face="Times New Roman, Times, Serif" size=2>&nbsp; </FONT></TD>
<TD width="5%">&#149;</TD>
<TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp; </FONT></TD>
<TD width="90%"><FONT face="Times New Roman, Times, Serif" size=2>effectively manage our manufacturing activities; and </FONT></TD></TR>
</TABLE>

<BR>
<!-- MARKER FORMAT-SHEET="Para Hang Level 1" FSL="Default" -->
<TABLE cellSpacing=0 cellPadding=0 width="100%">
<TR vAlign=top>
<TD width="5%"><FONT face="Times New Roman, Times, Serif" size=2>&nbsp; </FONT></TD>
<TD width="5%">&#149;</TD>
<TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp; </FONT></TD>
<TD width="90%"><FONT face="Times New Roman, Times, Serif" size=2>effectively compete against current and future competitors. </FONT></TD></TR>
</TABLE>



<P><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We cannot assure you that we will be able to successfully increase our sales volumes of our products to achieve sustained profitability. </FONT></P>

<TABLE width="100%">
<TR>
<TD align=center><FONT size=2>24</FONT></TD></TR>
</TABLE>



<P>
<HR align=left noshade SIZE=5>


<P>&nbsp;
<!-- *************************************************************************** -->
<!-- MARKER PAGE="sheet: 14; page: 14" -->
<H1 align=left><FONT face="Times New Roman, Times, Serif" size=2>We Are Not Able To Predict Sales In Future Quarters And A Number Of Factors Affect Our Periodic Results </FONT></H1>


<P><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We are not able to accurately predict our sales in future quarters. In any quarter, we derive almost half of our revenues from two distributors who resell our products to the ultimate user. While we are better able to predict sales of our reagent discs, as we sell these discs primarily for use with blood chemistry analyzers that we sold in prior periods, we generally are unable to predict with much certainty sales of our analyzers, as we typically sell our analyzers to new users. Accordingly, our sales in any one quarter are not indicative of our sales in any future period. In addition, we generally operate with limited order backlog, because we ship our products shortly after we receive the orders from our customers. As a result, our product sales in any quarter are generally dependent on orders that we receive and ship in that quarter. We base our expense levels, which are to a large extent fixed, in
part on our expectations as to future revenues. We may be unable to reduce our spending in a timely manner to compensate for any unexpected revenue shortfall. As a result, any such shortfall would immediately materially and adversely impact our operating results and financial condition. In addition, we have historically experienced a decrease in our sales, especially in Europe, in our second and third quarters, ending in September and December of each year, which we believe is due to seasonal patterns in the decision making processes to acquire our products. Accordingly, we believe that period to period comparisons of our results of operations are not necessarily meaningful. </FONT></P>


<P><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our periodic operating results have varied in the past. In the future, we anticipate our periodic operating results to vary significantly depending on, but not limited to, a number of factors, including, in addition to those factors discussed elsewhere in this section: </FONT><FONT face="Times New Roman, Times, Serif" size=2>
<!-- MARKER FORMAT-SHEET="Para Hang Level 1" FSL="Default" --></FONT></P>

<TABLE cellSpacing=0 cellPadding=0 width="100%">
<TR vAlign=top>
<TD width="5%"><FONT face="Times New Roman, Times, Serif" size=2>&nbsp; </FONT></TD>
<TD width="5%">&#149;</TD>
<TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp; </FONT></TD>
<TD width="90%"><FONT face="Times New Roman, Times, Serif" size=2>new product announcements made by us or our competitors; &nbsp; </FONT></TD></TR>
</TABLE>

<BR>
<!-- MARKER FORMAT-SHEET="Para Hang Level 1" FSL="Default" -->
<TABLE cellSpacing=0 cellPadding=0 width="100%">
<TR vAlign=top>
<TD width="5%"><FONT face="Times New Roman, Times, Serif" size=2>&nbsp; </FONT></TD>
<TD width="5%"><FONT face="Times New Roman, Times, Serif" size=2>&#149;</FONT></TD>
<TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp; </FONT></TD>
<TD width="90%"><FONT face="Times New Roman, Times, Serif" size=2>changes in our pricing structures or the pricing structures of our competitors; </FONT></TD></TR>
</TABLE>

<BR>
<!-- MARKER FORMAT-SHEET="Para Hang Level 1" FSL="Default" -->
<TABLE cellSpacing=0 cellPadding=0 width="100%">
<TR vAlign=top>
<TD width="5%"><FONT face="Times New Roman, Times, Serif" size=2>&nbsp; </FONT></TD>
<TD width="5%"><FONT face="Times New Roman, Times, Serif" size=2>&#149;</FONT></TD>
<TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp; </FONT></TD>
<TD width="90%"><FONT face="Times New Roman, Times, Serif" size=2>our ability to develop, introduce and market new products on a timely basis; </FONT></TD></TR>
</TABLE>

<BR>
<!-- MARKER FORMAT-SHEET="Para Hang Level 1" FSL="Default" -->
<TABLE cellSpacing=0 cellPadding=0 width="100%">
<TR vAlign=top>
<TD width="5%"><FONT face="Times New Roman, Times, Serif" size=2>&nbsp; </FONT></TD>
<TD width="5%"><FONT face="Times New Roman, Times, Serif" size=2>&#149;</FONT></TD>
<TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp; </FONT></TD>
<TD width="90%"><FONT face="Times New Roman, Times, Serif" size=2>our manufacturing capacities and our ability to increase the scale of these capacities; </FONT></TD></TR>
</TABLE>

<BR>
<!-- MARKER FORMAT-SHEET="Para Hang Level 1" FSL="Default" -->
<TABLE cellSpacing=0 cellPadding=0 width="100%">
<TR vAlign=top>
<TD width="5%"><FONT face="Times New Roman, Times, Serif" size=2>&nbsp; </FONT></TD>
<TD width="5%"><FONT face="Times New Roman, Times, Serif" size=2>&#149;</FONT></TD>
<TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp; </FONT></TD>
<TD width="90%"><FONT face="Times New Roman, Times, Serif" size=2>the mix of product sales between our analyzer and our reagent disc products; </FONT></TD></TR>
</TABLE>

<BR>
<!-- MARKER FORMAT-SHEET="Para Hang Level 1" FSL="Default" -->
<TABLE cellSpacing=0 cellPadding=0 width="100%">
<TR vAlign=top>
<TD width="5%" height=14><FONT face="Times New Roman, Times, Serif" size=2>&nbsp; </FONT></TD>
<TD width="5%" height=14><FONT face="Times New Roman, Times, Serif" size=2>&#149;</FONT></TD>
<TD height=14><FONT face="Times New Roman, Times, Serif" size=2>&nbsp; </FONT></TD>
<TD width="90%" height=14><FONT face="Times New Roman, Times, Serif" size=2>the amount we spend on research and development; and </FONT></TD></TR>
</TABLE>

<BR>
<!-- MARKER FORMAT-SHEET="Para Hang Level 1" FSL="Default" -->
<TABLE cellSpacing=0 cellPadding=0 width="100%">
<TR vAlign=top>
<TD width="5%"><FONT face="Times New Roman, Times, Serif" size=2>&nbsp; </FONT></TD>
<TD width="5%"><FONT face="Times New Roman, Times, Serif" size=2>&#149;</FONT></TD>
<TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp; </FONT></TD>
<TD width="90%"><FONT face="Times New Roman, Times, Serif" size=2>changes in our strategy. </FONT></TD></TR>
</TABLE>


<H1 align=left><FONT face="Times New Roman, Times, Serif" size=2>We Could Fail to Achieve Anticipated Revenue If The Market Does Not Accept Our Products </FONT></H1>


<P><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our core compact blood chemistry analyzer product differs substantially from current blood chemistry analyzers on the market. Our primary competition is from centralized laboratories that offer a greater number of tests than our products, but do so at greater cost and requiring more time. We also compete with other point-of-care analyzers that cost more, require more maintenance and offer a narrower range of tests. However, these point-of-care analyzers are generally marketed by larger companies which have greater resources for sales and marketing, in addition to a recognized brand name and established distribution relationships. </FONT></P>


<P><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Historically we have marketed our VetScan analyzer to veterinarians and we have relatively limited experience in large scale sales of our Piccolo analyzer into the human medical market. We continue to develop new animal blood tests that we cannot be assured will be accepted by the veterinary market. Although we believe that our blood analyzers offer consumers many advantages, including according to our analyses substantial cost savings, in terms of the actual product and implementation of it procedurally, these advantages involve changes to current standard practices, such as using large clinical laboratories, that will require changes in both the procedures and mindset of care providers. The human medical market in particular is highly regulated, structured and often slow to adopt new product offerings. If we are unable to convince large numbers of medical clinics, hospitals and other point-of-care
environments of the benefits of our products, we will suffer lost sales and could fail to achieve anticipated revenue. </FONT></P>

<H1 align=left><FONT face="Times New Roman, Times, Serif" size=2>We are Dependent Upon Our Profitability, and If We Cannot Remain Profitable We May Need Additional Funding In The Future And These Funds May Not Be Available To Us </FONT></H1>


<P><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; We believe that our existing capital resources, available line of credit and anticipated revenue from the sales of our products will be adequate to satisfy our currently planned operating and financial requirements through March 31, 2005, although no assurances can be given. Our bank financing documents contain a number of covenants concerning financial tests </FONT></P>

<TABLE width="100%">
<TR>
<TD align=center><FONT size=2>25</FONT></TD></TR>
</TABLE>



<P>
<HR align=left noshade SIZE=5>


<P>&nbsp;
<!-- *************************************************************************** -->
<!-- MARKER PAGE="sheet: 14; page: 14" -->

<P><FONT face="Times New Roman, Times, Serif" size=2>that we must meet that are more fully detailed in the agreements that we have filed with the SEC as exhibits to our periodic reports. We may need additional funds if we are unable to meet requirements for continuing access to bank financing or if we do not achieve anticipated revenues from the sale of our Piccolo and VetScan products. </FONT></P>


<P><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Further, we expect to incur incremental additional costs to support our future operations, including: </FONT></P>

<TABLE cellSpacing=0 cellPadding=0 width="100%">
<TR vAlign=top>
<TD width="5%"><FONT face="Times New Roman, Times, Serif" size=2>&nbsp; </FONT></TD>
<TD width="5%"><FONT face="Times New Roman, Times, Serif" size=2>&#149; </FONT></TD>
<TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp; </FONT></TD>
<TD width="90%"><FONT face="Times New Roman, Times, Serif" size=2>further commercialization of our products and development of new test methods to allow us to further penetrate the human diagnostic market and the veterinary diagnostic market; </FONT></TD></TR>
</TABLE>

<BR>
<TABLE cellSpacing=0 cellPadding=0 width="100%">
<TR vAlign=top>
<TD width="5%"><FONT face="Times New Roman, Times, Serif" size=2>&nbsp; </FONT></TD>
<TD width="5%"><FONT face="Times New Roman, Times, Serif" size=2>&#149; </FONT></TD>
<TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp; </FONT></TD>
<TD width="90%"><FONT face="Times New Roman, Times, Serif" size=2>our need to acquire capital equipment for our manufacturing facilities, which includes the ongoing implementation of our semi-automated manufacturing lines to provide capacity for the production of commercial volumes of our products; </FONT></TD></TR>
</TABLE>

<BR>
<TABLE cellSpacing=0 cellPadding=0 width="100%">
<TR vAlign=top>
<TD width="5%"><FONT face="Times New Roman, Times, Serif" size=2>&nbsp; </FONT></TD>
<TD width="5%"><FONT face="Times New Roman, Times, Serif" size=2>&#149; </FONT></TD>
<TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp; </FONT></TD>
<TD width="90%"><FONT face="Times New Roman, Times, Serif" size=2>research and design costs related to the continuing development of our current and future products; and </FONT></TD></TR>
<TR vAlign=top>
<TD width="5%">&nbsp;</TD>
<TD width="5%">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD width="90%">&nbsp;</TD></TR>
<TR vAlign=top>
<TD width="5%">&nbsp;</TD>
<TD width="5%"><FONT face="Times New Roman, Times, Serif" size=2>&#149; </FONT></TD>
<TD>&nbsp;</TD>
<TD width="90%"><FONT face="Times New Roman, Times, Serif" size=2>additional pre-clinical testing and clinical trials for our current and future products. </FONT></TD></TR>
</TABLE>



<P><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;To the extent that our existing resources and anticipated revenue from the sale of our products are insufficient to fund our activities or if we are unable to meet the financial tests contained in our bank financing documents, we may have to raise additional funds from the issuance of public or private securities. In the event that we cannot maintain compliance with the financial covenants of our bank financing agreements, we may also be subject to increased interest rate expenses. We may not be able to raise additional funding, or if we are able to, we may not be able to raise funding on acceptable terms. We may also dilute then-existing shareholders if we raise additional funds by issuing new equity securities. Alternately, we may have to relinquish rights to certain of our technologies, products and/or sales territories if we are required to obtain funds through arrangements with collaborative
partners. If we are unable to raise needed funds, we may be required to curtail our operations significantly. This would materially adversely affect our operating results and financial condition. </FONT></P>

<H1 align=left><FONT face="Times New Roman, Times, Serif" size=2>We Rely On Patents And Other Proprietary Information, The Loss Of Any Of Which Would Negatively Affect Our Business </FONT></H1>


<P><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As of June 2004, 33 patent applications have been filed on behalf of Abaxis with the United States Patent and Trademark Office, of which 27 have been issued. Additionally, we have filed several international patent applications covering the same subject matter as our domestic applications. The patent position of any medical device manufacturer, including Abaxis, is uncertain and may involve complex legal and factual issues. Consequently, we may not be issued any additional patents, either domestically or internationally. Furthermore, our patents may not provide significant proprietary protection because there is a chance that they will be circumvented or invalidated. We cannot be certain that we were the first creator of the inventions covered by our issued patents or pending patent applications, or that we were the first to file patent applications for these inventions, because (1) the United States
Patent and Trademark Office maintains all patent applications that are not filed in any foreign jurisdictions in secrecy until it issues the patents (unless a patent application owner files a request for publication) and (2) publications of discoveries in the scientific or patent literature tend to lag behind actual discoveries by several months. We may have to participate in interference proceedings, which are proceedings in front of the U.S. Patent and Trademark Office, to determine who will be issued a patent. These proceedings could be costly and could be decided against us. </FONT></P>


<P><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We also rely upon copyrights, trademarks and unpatented trade secrets. Others may independently develop substantially equivalent proprietary information and techniques that would undermine our proprietary technologies. Further, others may gain access to our trade secrets or disclose such technology. Although we require our employees, consultants and advisors to execute agreements that require that our corporate information be kept confidential and that any inventions by these individuals are property of Abaxis, there can be no assurance that these agreements will provide meaningful protection or adequate remedies for our trade secrets in the event of unauthorized use or disclosure of such information. The unauthorized dissemination of our confidential information would negatively impact our business. </FONT></P>

<H1 align=left><FONT face="Times New Roman, Times, Serif" size=2>We Continue to Develop Our Marketing And Distribution Experience In the Human Diagnostic Market </FONT></H1>


<P><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Although we have gained experience marketing our VetScan System products for the past eight years in the veterinary diagnostic market, we have much less experience in marketing the Piccolo System in the human diagnostic market. Accordingly, we have limited sales, marketing and distribution experience, especially in the human diagnostic market. We cannot assure you that: </FONT></P>

<TABLE width="100%">
<TR>
<TD align=center><FONT size=2>26</FONT></TD></TR>
</TABLE>



<P>
<HR align=left noshade SIZE=5>


<P>&nbsp;
<!-- *************************************************************************** -->
<!-- MARKER PAGE="sheet: 14; page: 14" -->
<!-- MARKER FORMAT-SHEET="Para Hang Level 1" FSL="Default" -->
<TABLE cellSpacing=0 cellPadding=0 width="100%">
<TR vAlign=top>
<TD width="5%"><FONT face="Times New Roman, Times, Serif" size=2>&nbsp; </FONT></TD>
<TD width="5%"><FONT face="Times New Roman, Times, Serif" size=2>&#149; </FONT></TD>
<TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp; </FONT></TD>
<TD width="90%"><FONT face="Times New Roman, Times, Serif" size=2>we will be able to establish and maintain effective distribution arrangements in the human medical market; </FONT></TD></TR>
</TABLE>

<BR>
<!-- MARKER FORMAT-SHEET="Para Hang Level 1" FSL="Default" -->
<TABLE cellSpacing=0 cellPadding=0 width="100%">
<TR vAlign=top>
<TD width="5%"><FONT face="Times New Roman, Times, Serif" size=2>&nbsp; </FONT></TD>
<TD width="5%"><FONT face="Times New Roman, Times, Serif" size=2>&#149; </FONT></TD>
<TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp; </FONT></TD>
<TD width="90%"><FONT face="Times New Roman, Times, Serif" size=2>any distribution arrangements that we are able to establish will be successful in marketing our products; or </FONT></TD></TR>
</TABLE>

<BR>
<!-- MARKER FORMAT-SHEET="Para Hang Level 1" FSL="Default" -->
<TABLE cellSpacing=0 cellPadding=0 width="100%">
<TR vAlign=top>
<TD width="5%"><FONT face="Times New Roman, Times, Serif" size=2>&nbsp; </FONT></TD>
<TD width="5%"><FONT face="Times New Roman, Times, Serif" size=2>&#149; </FONT></TD>
<TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp; </FONT></TD>
<TD width="90%"><FONT face="Times New Roman, Times, Serif" size=2>the costs associated with marketing and distributing our products will not be excessive. </FONT></TD></TR>
</TABLE>



<P><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Should we fail to effectively develop our marketing and distribution efforts, our growth will be limited and our results of operations will be adversely affected. </FONT></P>

<H1 align=left><FONT face="Times New Roman, Times, Serif" size=2>We May Inadvertently Produce Defective Products, Which May Subject Us to Significant Warranty Liabilities or Product Liability Claims And We May Have Insufficient Product Liability Insurance </FONT></H1>


<P><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our business exposes us to potential warranty and product liability risks which are inherent in the testing, manufacturing and marketing of human and veterinary medical products. We strive to apply sophisticated methods to raw materials and produce defect-free medical test equipment. Although we have established procedures for quality control on both the raw materials that we receive from suppliers and our manufactured final products, these procedures may prove inadequate to detect a defect that either occurs in limited quantities or that we have not anticipated. We believe that our Piccolo and VetScan systems detect the vast majority of errors that occur on our reagent discs and automatically reject such tests, prompting the medical provider to retest the patient. However, our Piccolo and VetScan systems may be unable to detect errors which could result in the misdiagnosis of human or veterinary
patients. </FONT></P>


<P><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Should we inadvertently ship defective products, we may be subject to substantial claims under our warranty policy or product liability law. In addition, our policy is to credit medical providers for any defective product that we produce, including those reagent discs that are rejected by our Piccolo and VetScan systems. Therefore, even if a mass defect within a lot or lots of reagent discs were detected by our Piccolo and VetScan systems, our need to replace such reagent discs free of charge would materially harm our financial condition. Further, in the event that a product defect is not detected by our Piccolo system, our relatively recent expansion into the human medical market greatly increases the risk that the amount of damages involved with just one product defect would be material to our operations. We currently maintain limited product liability insurance that we believe is adequate for our
needs, taking into account the risks involved and cost of coverage. However, our product liability insurance and cash may be insufficient to cover potential liabilities. In addition, in the future the coverage that we require may be unavailable on commercially reasonable terms, if at all. Even with our current insurance coverage, a mass product defect, product liability claim or recall would materially adversely affect our business or our financial condition. </FONT></P>

<H1 align=left><FONT face="Times New Roman, Times, Serif" size=2>Many of Our Sales Force Have Been Employed by Us for Less Than One Year And We Must Effectively Train And Integrate Our Sales Team In Order To Achieve Our Anticipated Revenue </FONT></H1>


<P><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We have thirty-three full-time sales personnel involved in our sales and marketing activities, many of whom have been employed by us for a limited period of time. While these individuals work with our distribution partners both domestically and internationally to extend our market reach, the primary selling activities are often done by these individuals. If we are to increase our sales, we will need to train new salespeople and supervise them closely. We also will continue hiring additional sales personnel. If we are unable to retain our existing personnel, or attract and train additional qualified personnel, our growth may be limited due to our lack of capacity to market our products. </FONT></P>

<H1 align=left><FONT face="Times New Roman, Times, Serif" size=2>We Need to Successfully Manufacture and Market Additional, Recently Approved Reagent Discs For The Human Diagnostic Market If We Are To Compete In That Market </FONT></H1>


<P><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We have developed a blood analysis system that consists of a portable blood analyzer and single-use reagent discs. Each reagent disc performs a series of standard blood tests. We believe that it is necessary to develop additional series of reagent discs with various tests for use with the Piccolo and VetScan DXS. Historically, we primarily developed reagent discs suitable for the veterinary diagnostic market. We recently received approval from the U.S. Food and Drug Administration to begin selling additional tests, namely magnesium assay, HDL and triglycerides, for the more lucrative human diagnostic market. These tests are included in standard tests for which the medical community receives reimbursements from third party payors such as HMOs and Medicare. We may not be able to successfully manufacture or market these newly developed reagent discs. Our failure to meet these challenges will materially
adversely affect our operating results and financial condition. </FONT></P>

<H1 align=left><FONT face="Times New Roman, Times, Serif" size=2>We Rely On Distributors To Sell Our Products; We Rely On Sole Distributor Arrangements In A Number Of Countries </FONT></H1>


<P><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We distribute our products primarily through distributors. As a result, we are dependent upon these distributors to sell our products and to assist us in promoting and creating a demand for our products. We have a number of distributors in the </FONT></P>

<TABLE width="100%">
<TR>
<TD align=center><FONT size=2>27</FONT></TD></TR>
</TABLE>



<P>
<HR align=left noshade SIZE=5>


<P>&nbsp;
<!-- *************************************************************************** -->
<!-- MARKER PAGE="sheet: 14; page: 14" -->

<P><FONT face="Times New Roman, Times, Serif" size=2>United States who distribute our VetScan products. Two distributors, Vedco Inc. and DVM Resources accounted for 27% and 16%, respectively, of total revenues for fiscal 2004, 36% and 11%, respectively, of total revenues for fiscal 2003 and 41% and 8%, respectively, of total revenues for fiscal 2002. We believe that our future growth depends on the efforts of these distributors. If one of our distributors, particularly Vedco, Inc., were to stop selling our products we may not be able to replace such lost revenue. We operate on a purchase order basis with Vedco, Inc. and DVM Resources and each of these distributors is under no contractual obligation to continue carrying our products. Further, many of our distributors may carry our competitors&#146; products, and may promote our competitors&#146; products over our own products. Finally, we do not have at this time distribution partners in the United States who distribute our products for the human
diagnostic market. Internationally, we have one distributor in Japan for our products in both the human and veterinary diagnostic markets. </FONT></P>


<P><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; We currently have distribution agreements for our VetScan products in Argentina, Australia, Austria, Bahrain, Belgium, France, Germany, Greece, Israel, Italy, Japan, Korea, Kuwait, Mexico, New Zealand, Nigeria, Norway, Poland, Portugal, South Africa, Spain, Switzerland, United Arab Emirates, the United Kingdom and Venezuela. Our distributor in each of these countries is responsible for obtaining the necessary approvals to sell our products. These distributors may not be successful in obtaining proper approvals for our products in their respective countries, and they may not be successful in marketing our products. We plan to enter into additional distribution agreements to expand our international distribution base and solidify our international presence. However, we may not be successful in entering into additional distributor agreements. Our distributors may terminate
their relationship with us at any time. Historically, we have experienced a high degree of turnover among our international distributors. This high degree of turnover makes it difficult for us to establish a steady distribution network overseas. Consequently, we may not be successful in marketing our Piccolo System and VetScan products internationally. </FONT></P>

<H1 align=left><FONT face="Times New Roman, Times, Serif" size=2>We Depend On Sole Suppliers For Several Key Components To Our Products, Many of Whom We Have Not Entered Into Contractual Relationships With </FONT></H1>


<P><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We use several key<B> </B>components that are currently available from limited or sole sources as discussed below: </FONT></P>


<P><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#149; <I>Reagent Discs:</I> Two injection molding manufacturers, C.&nbsp;Brewer &amp;&nbsp;Co. and Nypro Oregon, Inc., currently make the molded plastic discs which, when loaded with reagents and welded together, form our reagent disc products. We believe that only a few manufacturers are capable of producing these discs to the narrow tolerances that we require; to date, we have only qualified these two manufacturers, with Nypro Oregon, Inc. being qualified at two separate facilities, to manufacture the molded plastic discs. </FONT></P>


<P><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#149; <I>Reagent Chemicals: </I>We currently depend on the following single source vendors for some of the chemicals that we use to produce the dry reagent chemistry beads that are either inserted in our reagent discs or sold as a stand-alone product: Amano Enzyme USA&nbsp;Co., Ltd., Genzyme Corporation, Kikkoman Corporation Biochemical Division, Microgenics Corporation, Roche Molecular Biochemicals of Roche Diagnostics Corporatioin, a division of F.&nbsp;Hoffmann-La Roche, Ltd., Shinko American Inc., and Sigma Aldrich Inc. </FONT></P>


<P><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#149; <I>Blood Analyzer Components: </I>Our analyzer products use several technologically advanced components that we currently purchase from two single source vendors, PerkinElmer, Inc. and Electro Alliance, Inc. Our analyzers use a printer that is only made by Seiko North America Corporation. The loss of the supply of any of these components could force us to redesign our analyzers. </FONT></P>


<P><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#149; Hematology Instrument and Reagents: We purchase the HMII instruments from DIATRON of Austria. To date, we have qualified these two suppliers to produce the reagents for the hematology instruments: Mallinckrodt Baker BV and Clinical Diagnostic Solutions, Inc. </FONT></P>


<P><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We operate on a purchase order basis with all of the suppliers of our molded plastic reagent discs, reagent chemicals, and blood analyzer components and thus these suppliers are under no contractual obligation to supply us with their products or to do so at specified prices. Although we believe that there are potential alternate suppliers available for these critical components, to date we have not qualified additional vendors beyond those referenced above. </FONT></P>


<P><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Because we are dependent on a limited number of suppliers and manufacturers for critical components to our products, we are particularly susceptible to any interruption in the supply of these products or the viability of our assembly arrangements. The loss of any one of these suppliers or a disruption in our manufacturing arrangements could materially adversely affect our business and financial condition. </FONT></P>

<TABLE width="100%">
<TR>
<TD align=center><FONT size=2>28</FONT></TD></TR>
</TABLE>



<P>
<HR align=left noshade SIZE=5>


<P>&nbsp;
<!-- *************************************************************************** -->
<!-- MARKER PAGE="sheet: 14; page: 14" -->
<H1 align=left><FONT face="Times New Roman, Times, Serif" size=2>We Compete With Larger, Better Established Entities Such As Hospitals And Commercial Laboratories </FONT></H1>


<P><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Blood analysis is a well established field in which there are a number of competitors that have substantially greater financial resources and larger, more established marketing, sales and service organizations than we do. We compete with the following organizations: </FONT><FONT face="Times New Roman, Times, Serif" size=2>
<!-- MARKER FORMAT-SHEET="Para Flush Level 1" FSL="Default" --></FONT></P>

<!-- MARKER FORMAT-SHEET="Para Hang Level 1" FSL="Default" -->
<TABLE cellSpacing=0 cellPadding=0 width="100%">
<TR vAlign=top>
<TD width="5%"><FONT face="Times New Roman, Times, Serif" size=2>&nbsp; </FONT></TD>
<TD width="5%"><FONT face="Times New Roman, Times, Serif" size=2>&#149; </FONT></TD>
<TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp; </FONT></TD>
<TD width="90%"><FONT face="Times New Roman, Times, Serif" size=2>commercial clinical laboratories; </FONT></TD></TR>
</TABLE>

<BR>
<!-- MARKER FORMAT-SHEET="Para Hang Level 1" FSL="Default" -->
<TABLE cellSpacing=0 cellPadding=0 width="100%">
<TR vAlign=top>
<TD width="5%"><FONT face="Times New Roman, Times, Serif" size=2>&nbsp; </FONT></TD>
<TD width="5%"><FONT face="Times New Roman, Times, Serif" size=2>&#149;</FONT></TD>
<TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp; </FONT></TD>
<TD width="90%"><FONT face="Times New Roman, Times, Serif" size=2>hospitals' clinical laboratories; and </FONT></TD></TR>
</TABLE>

<BR>
<!-- MARKER FORMAT-SHEET="Para Hang Level 1" FSL="Default" -->
<TABLE cellSpacing=0 cellPadding=0 width="100%">
<TR vAlign=top>
<TD width="5%"><FONT face="Times New Roman, Times, Serif" size=2>&nbsp; </FONT></TD>
<TD width="5%"><FONT face="Times New Roman, Times, Serif" size=2>&#149;</FONT></TD>
<TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp; </FONT></TD>
<TD width="90%"><FONT face="Times New Roman, Times, Serif" size=2>manufacturers of bench top multi-test blood analyzers and other testing systems that health care providers can use &#147;on-site.&#148; </FONT></TD></TR>
</TABLE>

<BR>
<H1 align=left><FONT face="Times New Roman, Times, Serif" size=2>We May Not Be Able To Compete With These Organizations Or Their Products Or With Future Organizations Or Future Products </FONT></H1>


<P><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Historically, hospitals and commercial laboratories perform the most human diagnostic testing, and commercial laboratories perform the most veterinary diagnostic testing. We have identified five principal factors that customers typically use to evaluate our products and those of our competitors. These factors are: </FONT><FONT face="Times New Roman, Times, Serif" size=2>
<!-- MARKER FORMAT-SHEET="Para Flush Level 1" FSL="Default" --></FONT></P>

<!-- MARKER FORMAT-SHEET="Para Hang Level 1" FSL="Default" -->
<TABLE cellSpacing=0 cellPadding=0 width="100%">
<TR vAlign=top>
<TD width="5%"><FONT face="Times New Roman, Times, Serif" size=2>&nbsp; </FONT></TD>
<TD width="5%"><FONT face="Times New Roman, Times, Serif" size=2>&#149;</FONT></TD>
<TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp; </FONT></TD>
<TD width="90%"><FONT face="Times New Roman, Times, Serif" size=2>range of tests offered; </FONT></TD></TR>
</TABLE>

<BR>
<!-- MARKER FORMAT-SHEET="Para Hang Level 1" FSL="Default" -->
<TABLE cellSpacing=0 cellPadding=0 width="100%">
<TR vAlign=top>
<TD width="5%"><FONT face="Times New Roman, Times, Serif" size=2>&nbsp; </FONT></TD>
<TD width="5%"><FONT face="Times New Roman, Times, Serif" size=2>&#149;</FONT></TD>
<TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp; </FONT></TD>
<TD width="90%"><FONT face="Times New Roman, Times, Serif" size=2>the immediacy of results; </FONT></TD></TR>
</TABLE>

<BR>
<!-- MARKER FORMAT-SHEET="Para Hang Level 1" FSL="Default" -->
<TABLE cellSpacing=0 cellPadding=0 width="100%">
<TR vAlign=top>
<TD width="5%"><FONT face="Times New Roman, Times, Serif" size=2>&nbsp; </FONT></TD>
<TD width="5%"><FONT face="Times New Roman, Times, Serif" size=2>&#149;</FONT></TD>
<TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp; </FONT></TD>
<TD width="90%"><FONT face="Times New Roman, Times, Serif" size=2>cost effectiveness; </FONT></TD></TR>
</TABLE>

<BR>
<!-- MARKER FORMAT-SHEET="Para Hang Level 1" FSL="Default" -->
<TABLE cellSpacing=0 cellPadding=0 width="100%">
<TR vAlign=top>
<TD width="5%"><FONT face="Times New Roman, Times, Serif" size=2>&nbsp; </FONT></TD>
<TD width="5%"><FONT face="Times New Roman, Times, Serif" size=2>&#149;</FONT></TD>
<TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp; </FONT></TD>
<TD width="90%"><FONT face="Times New Roman, Times, Serif" size=2>ease of use; and </FONT></TD></TR>
</TABLE>

<BR>
<!-- MARKER FORMAT-SHEET="Para Hang Level 1" FSL="Default" -->
<TABLE cellSpacing=0 cellPadding=0 width="100%">
<TR vAlign=top>
<TD width="5%"><FONT face="Times New Roman, Times, Serif" size=2>&nbsp; </FONT></TD>
<TD width="5%"><FONT face="Times New Roman, Times, Serif" size=2>&#149;</FONT></TD>
<TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp; </FONT></TD>
<TD width="90%"><FONT face="Times New Roman, Times, Serif" size=2>reliability of results. </FONT></TD></TR>
</TABLE>

<BR>

<P><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We believe that we compete effectively on each of these factors except for the range of tests offered. Clinical laboratories are effective at processing large panels of tests using skilled technicians and complex equipment. While our current offering of reagent discs cannot provide the same broad range of tests, we believe that in certain limited markets our products provide a sufficient breadth of test menus to compete successfully with clinical laboratories given the advantages of our products with respect to the other four factors. However, we cannot assure you that we will continue to be able to compete effectively on cost effectiveness, ease of use, immediacy of results or reliability of results. We also cannot assure you that we will ever be able to compete effectively solely on the basis of range of tests offered. </FONT></P>


<P><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Competition in the human and veterinary diagnostic markets is intense. Our principal competitors in the human blood analyzer market are Alfa Wassermann S.P.A., Hemagen Diagnostics, Inc., i-STAT Corporation (which was recently purchased by Abbott Laboratories), Johnson &amp; Johnson (including its subsidiary, Ortho-Clinical Diagnostics, Inc.), Novitron International, Inc. and Roche. Our principal competitors in the veterinary blood analyzer market are Idexx Laboratories, Inc. and Heska Corporation. Most of our competitors have significantly greater financial and other resources than we do. In particular, many of our competitors have large sales forces and well-established distribution channels. Consequently, we must develop our distribution channels and improve our direct sales force in order to compete in these markets. </FONT></P>

<H1 align=left><FONT face="Times New Roman, Times, Serif" size=2>Changes In Third Party Payor Reimbursement Regulations Can Negatively Affect Our Business </FONT></H1>


<P><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;By regulating the maximum amount of reimbursement they will provide for blood testing services, third party payors, such as HMOs, pay-per-service insurance plans, Medicare and Medicaid, can indirectly affect the pricing or the relative attractiveness of our human testing products. For example, the Centers for Medicare and Medicaid Services (&#147;CMS&#148;) sets the level of reimbursement of fees for blood testing services for Medicare beneficiaries. If third party payors decrease the reimbursement amounts for blood testing services, it may decrease the amount that physicians and hospitals are able to charge patients for such services. Consequently, we will need to charge less for our products. If the government and third party payors do not provide for adequate coverage and reimbursement levels to allow health care providers to use our products, the demand for our products will decrease. </FONT></P>

<TABLE width="100%">
<TR>
<TD align=center><FONT size=2>29</FONT></TD></TR>
</TABLE>



<P>
<HR align=left noshade SIZE=5>


<P>&nbsp;
<!-- *************************************************************************** -->
<!-- MARKER PAGE="sheet: 14; page: 14" -->
<H1 align=left><FONT face="Times New Roman, Times, Serif" size=2>We Are Subject To Numerous Governmental Regulations </FONT></H1>

<!-- MARKER FORMAT-SHEET="Head Sub 2 Left" FSL="Default" -->
<P align=left><FONT face="Times New Roman, Times, Serif" size=2><I>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</I>&#149;<I> Need for FDA Clearance for Our Medical Device Products</I> </FONT></P>


<P><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our Piccolo products are regulated under the 1976 Medical Device Amendments to the Food, Drug and Cosmetic Act, which is administered by the Food and Drug Administration. The FDA has classified our Piccolo products as &#147;Class I&#148; and &#147;Class II&#148; devices. These classifications require us to submit to the FDA a pre-market notification form or 510(k). The FDA uses the 510(k) to substantiate product claims that are made by medical device manufacturers prior to marketing. In our 510(k) notification, we must, among other things, establish that the product we plan to market is &#147;substantially equivalent&#148; to (1) a product that was on the market prior to the adoption of the 1976 Medical Device Amendment or (2) to a product that the FDA has previously cleared under the 510(k) process. The FDA review process of a 510(k) notification can last anywhere from three to six months, and the FDA
must issue a written order finding &#147;substantial equivalence&#148; before a company can market a medical device. To date, we have received market clearance from the FDA for our Piccolo System and 24 reagent tests that we have on eleven reagent discs. We are currently developing additional tests that the FDA will have to clear through the 510(k) notification procedures. These new test products are crucial for our success in the human diagnostic market. If we do not receive 510(k) clearance for a particular product, we will not be able to sell that product in the United States. </FONT></P>

<!-- MARKER FORMAT-SHEET="Head Sub 2 Left" FSL="Default" -->
<P align=left><FONT face="Times New Roman, Times, Serif" size=2><I>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</I>&#149;<I> Need to Comply with Manufacturing Regulations</I> </FONT></P>


<P><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The 1976 Medical Device Amendment also requires us to manufacture our Piccolo products in accordance with Good Manufacturing Practices guidelines. Current Good Manufacturing Practice requirements are set forth in the 21 CFR820 Quality System Regulation. These requirements regulate the methods used in, and the facilities and controls used for, the design, manufacture, packaging, storage, installation and servicing of our medical devices intended for human use. Our manufacturing facility is subject to periodic audits. In addition, various state regulatory agencies may regulate the manufacture of our products. For example, we have obtained a license from the State of California to manufacture our products. In April 2001, the State of California Food and Drug Branch granted our manufacturing facility &#147;in compliance&#148; status, based on the regulations for Good Manufacturing Practices for medical
devices. In May 2001, the State of California Food and Drug Branch granted licensing for our new Union City facility. The most recent inspection was in March 2003 when the U.S. FDA conducted a facilities inspection and verified our compliance with the 21 CFR 820 Regulation. We cannot assure you that we will successfully pass a re-inspection by the FDA or the State of California. In addition, we cannot assure you that we can comply with all current or future government manufacturing requirements and regulations. If we are unable to comply with the regulations, or if we do not pass routine inspections, our business and results of operations will be materially adversely affected. </FONT></P>

<!-- MARKER FORMAT-SHEET="Head Sub 2 Left" FSL="Default" -->
<P align=left><FONT face="Times New Roman, Times, Serif" size=2><I>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</I>&#149;<I> Effects of the Clinical Laboratory Improvement Amendments on Our Products</I> </FONT></P>


<P><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our Piccolo products are affected by the Clinical Laboratory Improvement Amendments of 1988. The Clinical Laboratory Improvement Amendments are intended to insure the quality and reliability of all medical testing in the United States regardless of where tests are performed. The current Clinical Laboratory Improvement Amendments divide laboratory tests into three categories: &#147;simple,&#148; &#147;moderately complex&#148; and &#147;highly complex.&#148; Tests performed using the Piccolo system are in the &#147;moderately complex&#148; category. This category requires that any location in which testing is performed be certified as a laboratory. Hence, we can only sell our Piccolo products to customers who meet the standards of a laboratory. To receive &#147;laboratory&#148; certification, a testing facility must be certified by the Centers for Medicare and Medicaid Services. After the testing
facility receives a &#147;laboratory&#148; certification, it must then meet the Clinical Laboratory Improvement Amendments regulations. Because we can only sell our Piccolo products to testing facilities that are certified &#147;laboratories,&#148; the market for our products is correspondingly constrained. During the third quarter of fiscal 2004, we submitted a petition for &#147;waived status&#148; to the Food and Drug Administration (FDA) after we conducted clinical studies designed to demonstrate the ability of untrained personnel to use the Piccolo and obtain reliable results from the Piccolo Lipid Panel Reagent Disc (Total Cholesterol, HDL, and Triglycerides). Waived status would permit untrained personnel to run the Piccolo using the Lipid Panel and, thus, extending the sites (doctors&#146; offices and other point-of-care environments) that can use the Piccolo. Currently, this petition is under evaluation by the FDA. We cannot assure you that we will successfully receive the waived status from
the FDA. Consequently, the market for our Piccolo products may be confined to those testing facilities that are certified as &#147;laboratories&#148; and our growth will be limited accordingly. </FONT></P>

<!-- MARKER FORMAT-SHEET="Head Sub 2 Left" FSL="Default" -->
<P align=left><FONT face="Times New Roman, Times, Serif" size=2><I>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</I>&#149;<I> &nbsp;We Are Subject to Various Federal, State and Local Regulations</I> </FONT></P>


<P><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Federal and state regulations regarding the manufacture and sale of health care products and diagnostic devices may change. In addition, as we continue to sell in foreign markets, we may have to obtain additional governmental clearances in those markets. For example, in December 2003, we received certification from the British Standards Institute to the ISO 13485:1996 quality system standard for medical devices. This quality system certification, along with successful completion of product testing to current European standards and the translation of Piccolo product documentation into the required languages, </FONT></P>

<TABLE width="100%">
<TR>
<TD align=center><FONT size=2>30</FONT></TD></TR>
</TABLE>



<P>
<HR align=left noshade SIZE=5>


<P>&nbsp;
<!-- *************************************************************************** -->
<!-- MARKER PAGE="sheet: 14; page: 14" -->

<P><FONT face="Times New Roman, Times, Serif" size=2>enabled us to meet the compliance requirements of the CE Mark and the current European In Vitro Device Directive. We cannot predict what impact, if any, such current or future regulatory changes would have on our business. We may not be able to obtain regulatory clearances for our products in the United States or in foreign markets, and the failure to obtain these regulatory clearances will materially adversely affect our business and results of operations. </FONT></P>


<P><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Although we believe that we will be able to comply with all applicable regulations of the Food and Drug Administration and of the State of California, including the Quality System Regulation, current regulations depend on administrative interpretations. Future interpretations made by the Food and Drug Administration, the Centers for Medicare and Medicaid Services (CMS) or other regulatory bodies may adversely affect our business. </FONT></P>

<H1 align=left><FONT face="Times New Roman, Times, Serif" size=2>We Depend On Key Members Of Our Management And Scientific Staff, And We Must Retain And Recruit Qualified Individuals If We Are To Be Competitive </FONT></H1>


<P><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We are highly dependent on the principal members of our management and scientific staff. The loss of any of these key personnel, including in particular Clinton H. Severson, our President, Chief Executive Officer and Chairman of our Board of Directors, might impede the achievement of our business objectives. Mr. Severson&#146;s amended and restated employment agreement with us was filed with the SEC on August 14, 2001 as an exhibit to our quarterly report for the quarter ended June 30, 2001. We are not aware of any member of our executive management team who intends to retire within one year of the date of this filing. We currently do not maintain key man life insurance on any of our employees. Although historically we have been relatively successful both in retaining our current management and scientific staff and attracting and retaining skilled and experienced marketing, sales and manufacturing
personnel, we may not be able to employ such personnel on acceptable terms in the future because numerous medical products and other high technology companies compete for the services of these qualified individuals. </FONT></P>

<H1 align=left><FONT face="Times New Roman, Times, Serif" size=2>Legislative Actions, Higher Insurance Cost And Potential New Accounting Pronouncements Are Likely To Cause Our General And Administrative Expenses To Increase And Impact Our Future Financial Position And Results Of Operations </FONT></H1>


<P><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In order to comply with the newly adopted Sarbanes-Oxley Act of 2002, as well as proposed changes to listing standards by Nasdaq, and proposed accounting changes by the Securities and Exchange Commission, we may be required to enhance our internal controls, hire additional personnel and utilize additional outside legal, accounting and advisory services, all of which will cause our general and administrative costs to increase. Insurers are also likely to increase premiums as a result of the high claims rates incurred over the past year, and so our premiums for our various insurance policies, including our directors&#146; and officers&#146; insurance policies, are likely to increase. Proposed changes in the accounting rules, including legislative and other proposals to account for employee stock options as a compensation expense among others, could materially increase the expenses that we report under
generally accepted accounting principles and adversely affect our operating results. </FONT></P>

<H1 align=left><FONT face="Times New Roman, Times, Serif" size=2>We Must Comply With Strict And Potentially Costly Environmental Regulations </FONT></H1>


<P><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We are subject to stringent federal, state and local laws, rules, regulations and policies that govern the use, generation, manufacture, storage, air emission, effluent discharge, handling and disposal of certain materials and wastes. In particular, we are subject to laws, rules and regulations governing the handling and disposal of biohazardous materials used in the development and testing of our products. We handle and dispose of human and veterinary blood samples for testing (whole blood, plasma, serum) and we pay approximately $54,000 per year to comply with applicable environmental regulations. Although we believe that we have complied with applicable laws and regulations in all material respects and have not been required to take any action to correct any noncompliance, we may have to incur significant costs to comply with environmental regulations if our manufacturing to commercial levels
continues to increase. In addition, if a government agency determines that we have not complied with these laws, rules and regulations, we may have to pay significant fines and/or take remedial action that would be expensive and we do not carry environmental-related insurance coverage. </FONT></P>

<H1 align=left><FONT face="Times New Roman, Times, Serif" size=2>System Failures Or Delays May Harm Our Business And Our Facilities And Manufacturing Operations Are Vulnerable To Natural Disasters And Other Unexpected Losses </FONT></H1>


<P><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our success depends on the efficient and uninterrupted operation of our manufacturing operations, which are co-located with our corporate headquarters in Union City, California. A failure of manufacturing operations, be it in the development and manufacturing of our Piccolo or VetScan analyzers or the reagent discs used in the analyzers could result in our inability to supply customer demand. </FONT></P>

<TABLE width="100%">
<TR>
<TD align=center><FONT size=2>31</FONT></TD></TR>
</TABLE>



<P>
<HR align=left noshade SIZE=5>


<P>&nbsp;
<!-- *************************************************************************** -->
<!-- MARKER PAGE="sheet: 14; page: 14" -->

<P><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We do not have a backup facility to provide redundant manufacturing capacity in the event of a system failure. Accordingly, if our Union City location experienced a system failure, or regulatory problem that temporarily shut-down our manufacturing facility, our manufacturing ability would become unavailable until we were able to bring an alternative facility online, a process which could take several weeks or even months. These manufacturing operations are also vulnerable to damage from earthquakes, fire, floods, power loss, telecommunications failures, break-ins and similar events. Although we carry property and business interruption insurance, our coverage may not be adequate to compensate us for all losses that may occur. Additionally, our computer servers may be vulnerable to computer viruses, physical or electronic break-ins and similar disruptions. </FONT></P>

<H1 align=left><FONT face="Times New Roman, Times, Serif" size=2>Fluctuations In Foreign Exchange Rates And The Possible Lack Of Financial Stability In Foreign Countries Could Prevent Overseas Sales Growth </FONT></H1>


<P><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our international sales are overwhelmingly currently U.S. dollar-denominated. As a result, an increase in the value of the U.S. dollar relative to foreign currencies could make our products less competitive in international markets. For the limited amount of our sales denominated in local currencies, we are subject to fluctuations in exchange rates between the U.S. dollar and the particular local currency. Our operating results could also be adversely affected by the seasonality of international sales and the economic conditions of our overseas markets. </FONT></P>

<H1 align=left><FONT face="Times New Roman, Times, Serif" size=2>Our Stock Price Is Highly Volatile And Investing In Our Stock Involves A High Degree Of Risk </FONT></H1>


<P><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The market price of our common stock, like the securities of many other medical products companies, fluctuates over a wide range, and will continue to be highly volatile in the future. During the past two fiscal years, our stock price closed at a high of $22.80 on January 26, 2004 and a low of $3.00 on August 19, 2002. The following factors may affect the market price of our common stock: </FONT><FONT face="Times New Roman, Times, Serif" size=2>
<!-- MARKER FORMAT-SHEET="Para Hang Level 1" FSL="Default" --></FONT></P>

<TABLE cellSpacing=0 cellPadding=0 width="100%">
<TR vAlign=top>
<TD width="5%"><FONT face="Times New Roman, Times, Serif" size=2>&nbsp; </FONT></TD>
<TD width="5%"><FONT face="Times New Roman, Times, Serif" size=2>&#149; </FONT></TD>
<TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp; </FONT></TD>
<TD width="90%"><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;fluctuation in our operating results; </FONT></TD></TR>
</TABLE>

<BR>
<!-- MARKER FORMAT-SHEET="Para Hang Level 1" FSL="Default" -->
<TABLE cellSpacing=0 cellPadding=0 width="100%">
<TR vAlign=top>
<TD width="5%"><FONT face="Times New Roman, Times, Serif" size=2>&nbsp; </FONT></TD>
<TD width="5%"><FONT face="Times New Roman, Times, Serif" size=2>&#149;</FONT></TD>
<TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp; </FONT></TD>
<TD width="90%"><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;announcements of technological innovations or new commercial products by us or our competitors; </FONT></TD></TR>
</TABLE>

<BR>
<!-- MARKER FORMAT-SHEET="Para Hang Level 1" FSL="Default" -->
<TABLE cellSpacing=0 cellPadding=0 width="100%">
<TR vAlign=top>
<TD width="5%"><FONT face="Times New Roman, Times, Serif" size=2>&nbsp; </FONT></TD>
<TD width="5%"><FONT face="Times New Roman, Times, Serif" size=2>&#149;</FONT></TD>
<TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp; </FONT></TD>
<TD width="90%"><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;changes in governmental regulation; </FONT></TD></TR>
</TABLE>

<BR>
<!-- MARKER FORMAT-SHEET="Para Hang Level 1" FSL="Default" -->
<TABLE cellSpacing=0 cellPadding=0 width="100%">
<TR vAlign=top>
<TD width="5%"><FONT face="Times New Roman, Times, Serif" size=2>&nbsp; </FONT></TD>
<TD width="5%"><FONT face="Times New Roman, Times, Serif" size=2>&#149;</FONT></TD>
<TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp; </FONT></TD>
<TD width="90%"><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;prospects and proposals for health care reform; </FONT></TD></TR>
</TABLE>

<BR>
<!-- MARKER FORMAT-SHEET="Para Hang Level 1" FSL="Default" -->
<TABLE cellSpacing=0 cellPadding=0 width="100%">
<TR vAlign=top>
<TD width="5%"><FONT face="Times New Roman, Times, Serif" size=2>&nbsp; </FONT></TD>
<TD width="5%"><FONT face="Times New Roman, Times, Serif" size=2>&#149;</FONT></TD>
<TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp; </FONT></TD>
<TD width="90%"><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;governmental or third party payors' controls on prices that our customers may pay for our products; </FONT></TD></TR>
</TABLE>

<BR>
<!-- MARKER FORMAT-SHEET="Para Hang Level 1" FSL="Default" -->
<TABLE cellSpacing=0 cellPadding=0 width="100%">
<TR vAlign=top>
<TD width="5%"><FONT face="Times New Roman, Times, Serif" size=2>&nbsp; </FONT></TD>
<TD width="5%"><FONT face="Times New Roman, Times, Serif" size=2>&#149;</FONT></TD>
<TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp; </FONT></TD>
<TD width="90%"><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;developments or disputes concerning patent or our other proprietary rights; </FONT></TD></TR>
</TABLE>

<BR>
<!-- MARKER FORMAT-SHEET="Para Hang Level 1" FSL="Default" -->
<TABLE cellSpacing=0 cellPadding=0 width="100%">
<TR vAlign=top>
<TD width="5%"><FONT face="Times New Roman, Times, Serif" size=2>&nbsp; </FONT></TD>
<TD width="5%"><FONT face="Times New Roman, Times, Serif" size=2>&#149;</FONT></TD>
<TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp; </FONT></TD>
<TD width="90%"><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;public concern as to the safety of our devices or similar devices developed by our competitors; and </FONT></TD></TR>
</TABLE>

<BR>
<!-- MARKER FORMAT-SHEET="Para Hang Level 1" FSL="Default" -->
<TABLE cellSpacing=0 cellPadding=0 width="100%">
<TR vAlign=top>
<TD width="5%"><FONT face="Times New Roman, Times, Serif" size=2>&nbsp; </FONT></TD>
<TD width="5%"><FONT face="Times New Roman, Times, Serif" size=2>&#149;</FONT></TD>
<TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp; </FONT></TD>
<TD width="90%"><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;general market conditions. </FONT></TD></TR>
</TABLE>



<P><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Because our stock price is so volatile, investing in our common stock is highly risky. A potential investor must be able to withstand the loss of his entire investment in our common stock. </FONT></P>

<H1 align=left><FONT face="Times New Roman, Times, Serif" size=2>Our Shareholders Rights Plan And Our Ability To Issue Preferred Stock May Delay Or Prevent A Change Of Control Of Abaxis </FONT></H1>


<P><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our Shareholder Rights Plan, adopted by our board of directors on April 22, 2003 may make it more difficult for a third party to acquire, or discourage a third party from attempting to acquire, control of Abaxis. The Shareholder Rights Plan could limit the price that investors might be willing to pay in the future for shares of our common stock. </FONT></P>


<P><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In addition, our board of directors has the authority to issue up to 5,000,000 shares of preferred stock and to determine the price, rights, preferences, privileges and restrictions, including voting rights, of those shares without any further vote or action by the stockholders, except to the extent required by NASDAQ rules. The issuance of preferred stock, while providing flexibility in connection with possible financings or acquisitions or other corporate purposes, could have the effect of making it more difficult for a third party to acquire a majority of our outstanding voting stock. </FONT></P>

<TABLE width="100%">
<TR>
<TD align=center><FONT size=2>32</FONT></TD></TR>
</TABLE>



<P>
<HR align=left noshade SIZE=5>


<P>&nbsp;
<!-- *************************************************************************** -->
<!-- MARKER PAGE="sheet: 14; page: 14" -->
<!-- MARKER FORMAT-SHEET="Head Sub 2 Left" FSL="Default" -->
<H1 align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;ITEM 7A. &nbsp;&nbsp;QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK </FONT></H1>


<P><FONT face="Times New Roman, Times, Serif" size=2>We are exposed to financial market risks with respect to interest rates on our line of credit and cash equivalent investments. </FONT></P>


<P><FONT face="Times New Roman, Times, Serif" size=2>For our line of credit, which provides for borrowings of up to $2,000,000, the interest rate is equal to the prime rate minus 0.25%, which totaled 3.75% at March 31, 2004. Consequently, an increase in the prime rate would expose us to higher interest expenses. There was no outstanding balance on our line of credit at March&nbsp;31, 2004. </FONT></P>


<P><FONT face="Times New Roman, Times, Serif" size=2>For our equipment loan, the interest rate was equal to 1.00% over the prime rate. There was no outstanding balance on our equipment loan at March&nbsp;31, 2004. </FONT></P>


<P><FONT face="Times New Roman, Times, Serif" size=2>All of our sales are denominated in U.S. dollars, except for sales under our terminated OEM agreement to provide VetScan systems to MELET which were denominated in Euros. During fiscal 2004, our sales to MELET were 2% of our total revenues. At March&nbsp;31, 2004, the net receivable from MELET was $53,000. </FONT></P>


<P><FONT face="Times New Roman, Times, Serif" size=2>As a matter of management policy, we do not currently enter into transactions involving derivative financial instruments. In the event we do enter into such transactions in the future, such items will be accounted for in accordance with Statement of Financial Accounting Standards No. 133, &#147;Accounting for Derivative Instruments and Hedging Activities&#148;, in which case we will formally document all relationships between hedging instruments and hedged items, as well as our risk management objective and strategy for undertaking such hedge transactions. </FONT></P>

<TABLE width="100%">
<TR>
<TD align=center><FONT size=2>33</FONT></TD></TR>
</TABLE>



<P>
<HR align=left noshade SIZE=5>


<P>&nbsp;
<!-- *************************************************************************** -->
<!-- MARKER PAGE="sheet: 14; page: 14" -->
<H1 align=left><FONT face="Times New Roman, Times, Serif" size=2>ITEM 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA </FONT></H1>


<P><FONT size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Report of Independent Registered Public Accounting Firm</FONT></P>


<P><FONT size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Balance Sheets at March 31, 2004 and 2003</FONT></P>


<P><FONT size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Statements of Operations for the Years Ended March 31, 2004, 2003 and 2002</FONT></P>


<P><FONT size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Statements of Shareholders' Equity for the Years Ended March 31, 2004, 2003 and 2002</FONT></P>


<P><FONT size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Statements of Cash Flows for the Years Ended March 31, 2004, 2003 and 2002</FONT></P>


<P><FONT size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Notes to Financial Statements </FONT></P>

<TABLE width="100%">
<TR>
<TD align=center><FONT size=2>34</FONT></TD></TR>
</TABLE>



<P>
<HR align=left noshade SIZE=5>


<P>&nbsp;
<!-- *************************************************************************** -->
<!-- MARKER PAGE="sheet: 14; page: 14" -->
<H1 align=left><FONT face="Times New Roman, Times, Serif" size=2>REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM </FONT></H1>


<P><FONT face="Times New Roman, Times, Serif" size=2>To the Board of Directors and Shareholders of Abaxis, Inc.: </FONT></P>


<P><FONT face="Times New Roman, Times, Serif" size=2>We have audited the accompanying balance sheets of Abaxis, Inc. (the &#147;Company&#148;) as of March&nbsp;31, 2004 and 2003, and the related statements of operations, shareholders&#146; equity, and cash flows for each of the three years in the period ended March&nbsp;31, 2004. These financial statements are the responsibility of the Company&#146;s management. Our responsibility is to express an opinion on these financial statements based on our audits. </FONT></P>


<P><FONT face="Times New Roman, Times, Serif" size=2>We conducted our audits in accordance with the standards of the Public Company Accounting Oversight Board (United States). Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement. An audit includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements. An audit also includes assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall financial statement presentation. We believe that our audits provide a reasonable basis for our opinion. </FONT></P>


<P><FONT face="Times New Roman, Times, Serif" size=2>In our opinion, such financial statements present fairly, in all material respects, the financial position of the Company as of March&nbsp;31, 2004 and 2003, and the results of its operations and its cash flows for each of the three years in the period ended March&nbsp;31, 2004 in conformity with accounting principles generally accepted in the United States of America. </FONT></P>

<P align=left><FONT face="Times New Roman, Times, Serif" size=2>/s/ DELOITTE &amp; TOUCHE LLP<BR></FONT><FONT face="Times New Roman, Times, Serif" size=2>San Jose, California<BR>June 11, 2004 </FONT></P>

<TABLE width="100%">
<TR>
<TD align=center><FONT size=2>35</FONT></TD></TR>
</TABLE>



<P>
<HR align=left noshade SIZE=5>

<H1>&nbsp;
<!-- *************************************************************************** -->
<!-- MARKER PAGE="sheet: 14; page: 14" -->
<!-- MARKER FORMAT-SHEET="Head Sub 3 Left" FSL="Default" --></H1>


<P>
<TABLE cellSpacing=0 cellPadding=0 width="100%" border=0>
<TR>
<TD vAlign=bottom nowrap colSpan=4>
<DIV align=center><FONT face="Times New Roman" size=3><B>ABAXIS, INC.</B></FONT></DIV></TD></TR>
<TR>
<TD vAlign=bottom nowrap colSpan=4>
<DIV align=center><FONT face="Times New Roman" size=2><B>BALANCE SHEETS</B></FONT></DIV></TD></TR>
<TR>
<TD vAlign=bottom nowrap width="75%"><FONT face="Times New Roman" size=1><B></B></FONT></TD>
<TD vAlign=bottom nowrap width="10%"><FONT face="Times New Roman" size=1><B>&nbsp;</B></FONT></TD>
<TD vAlign=bottom nowrap width="6%">&nbsp;</TD>
<TD vAlign=bottom nowrap width="9%"><FONT face="Times New Roman" size=1><B>&nbsp;</B></FONT></TD></TR>
<TR>
<TD vAlign=bottom nowrap width="75%"><FONT face="Times New Roman" size=1><B>&nbsp;</B></FONT></TD>
<TD vAlign=bottom nowrap align=center colSpan=3><FONT face="Times New Roman" size=1><B>March 31,</B></FONT>
<HR noshade SIZE=1>
</TD></TR>
<TR>
<TD vAlign=bottom nowrap width="75%" height=18><FONT face="Times New Roman" size=2><B>ASSETS</B></FONT></TD>
<TD vAlign=bottom nowrap align=center width="10%" height=18><FONT face="Times New Roman" size=1><B>2004</B></FONT>
<HR noshade SIZE=1>
</TD>
<TD vAlign=bottom nowrap align=center width="6%" height=18>&nbsp;</TD>
<TD vAlign=bottom nowrap align=center width="9%" height=18><FONT face="Times New Roman" size=1><B>2003</B></FONT>
<HR noshade SIZE=1>
</TD></TR>
<TR>
<TD vAlign=bottom nowrap width="75%"><FONT face="Times New Roman" size=2>Current assets:</FONT></TD>
<TD vAlign=bottom nowrap width="10%"><FONT face="Times New Roman" size=2>&nbsp;</FONT></TD>
<TD vAlign=bottom nowrap width="6%">&nbsp;</TD>
<TD vAlign=bottom nowrap width="9%"><FONT face="Times New Roman" size=2>&nbsp;</FONT></TD></TR>
<TR>
<TD vAlign=bottom nowrap width="75%"><FONT face="Times New Roman" size=2>Cash and cash equivalents</FONT></TD>
<TD vAlign=bottom nowrap align=right width="10%"><FONT face="Times New Roman" size=2>&nbsp;$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 9,324,000 </FONT></TD>
<TD vAlign=bottom nowrap align=right width="6%">&nbsp;</TD>
<TD vAlign=bottom nowrap align=right width="9%"><FONT face="Times New Roman" size=2>&nbsp;$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 10,430,000 </FONT></TD></TR>
<TR>
<TD vAlign=bottom nowrap width="75%"><FONT face="Times New Roman" size=2>Short-term investments</FONT></TD>
<TD vAlign=bottom nowrap align=right width="10%"><FONT face="Times New Roman" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 7,998,000 </FONT></TD>
<TD vAlign=bottom nowrap align=right width="6%">&nbsp;</TD>
<TD vAlign=bottom nowrap align=right width="9%"><FONT face="Times New Roman" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &#151; </FONT></TD></TR>
<TR>
<TD vAlign=bottom nowrap width="75%"><FONT face="Times New Roman" size=2>Trade receivables (net of allowances of $257,000 in 2004 and $267,000 in 2003)</FONT></TD>
<TD vAlign=bottom nowrap align=right width="10%"><FONT face="Times New Roman" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 8,202,000 </FONT></TD>
<TD vAlign=bottom nowrap align=right width="6%">&nbsp;</TD>
<TD vAlign=bottom nowrap align=right width="9%"><FONT face="Times New Roman" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 7,482,000 </FONT></TD></TR>
<TR>
<TD vAlign=bottom nowrap width="75%"><FONT face="Times New Roman" size=2>Inventories</FONT></TD>
<TD vAlign=bottom nowrap align=right width="10%"><FONT face="Times New Roman" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 5,736,000 </FONT></TD>
<TD vAlign=bottom nowrap align=right width="6%">&nbsp;</TD>
<TD vAlign=bottom nowrap align=right width="9%"><FONT face="Times New Roman" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 4,982,000 </FONT></TD></TR>
<TR>
<TD vAlign=bottom nowrap width="75%"><FONT face="Times New Roman" size=2>Prepaid expenses</FONT></TD>
<TD vAlign=bottom nowrap align=right width="10%"><FONT face="Times New Roman" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 384,000 </FONT></TD>
<TD vAlign=bottom nowrap align=right width="6%">&nbsp;</TD>
<TD vAlign=bottom nowrap align=right width="9%"><FONT face="Times New Roman" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 667,000 </FONT></TD></TR>
<TR>
<TD vAlign=bottom nowrap width="75%"><FONT face="Times New Roman" size=2>Net deferred tax asset - current</FONT></TD>
<TD vAlign=bottom nowrap align=right width="10%"><FONT face="Times New Roman" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 609,000 </FONT></TD>
<TD vAlign=bottom nowrap align=right width="6%">&nbsp;</TD>
<TD vAlign=bottom nowrap align=right width="9%"><FONT face="Times New Roman" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &#151; </FONT></TD></TR>
<TR>
<TD vAlign=bottom nowrap width="75%">&nbsp;</TD>
<TD vAlign=bottom nowrap align=right width="10%">
<HR noshade SIZE=1>
</TD>
<TD vAlign=bottom nowrap align=right width="6%">&nbsp;</TD>
<TD vAlign=bottom nowrap align=right width="9%">
<HR noshade SIZE=1>
</TD></TR>
<TR>
<TD vAlign=bottom nowrap width="75%"><FONT face="Times New Roman" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Total current assets</FONT></TD>
<TD vAlign=bottom nowrap align=right width="10%"><FONT face="Times New Roman" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 32,253,000 </FONT></TD>
<TD vAlign=bottom nowrap align=right width="6%">&nbsp;</TD>
<TD vAlign=bottom nowrap align=right width="9%"><FONT face="Times New Roman" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 23,561,000 </FONT></TD></TR>
<TR>
<TD vAlign=bottom nowrap width="75%"><FONT face="Times New Roman" size=2>Property and equipment, net</FONT></TD>
<TD vAlign=bottom nowrap align=right width="10%"><FONT face="Times New Roman" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 8,191,000 </FONT></TD>
<TD vAlign=bottom nowrap align=right width="6%">&nbsp;</TD>
<TD vAlign=bottom nowrap align=right width="9%"><FONT face="Times New Roman" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 8,580,000 </FONT></TD></TR>
<TR>
<TD vAlign=bottom nowrap width="75%"><FONT face="Times New Roman" size=2>Intangible assets, net</FONT></TD>
<TD vAlign=bottom nowrap align=right width="10%"><FONT face="Times New Roman" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 675,000 </FONT></TD>
<TD vAlign=bottom nowrap align=right width="6%">&nbsp;</TD>
<TD vAlign=bottom nowrap align=right width="9%"><FONT face="Times New Roman" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &#151; </FONT></TD></TR>
<TR>
<TD vAlign=bottom nowrap width="75%"><FONT face="Times New Roman" size=2>Deposits and other assets</FONT></TD>
<TD vAlign=bottom nowrap align=right width="10%"><FONT face="Times New Roman" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 155,000 </FONT></TD>
<TD vAlign=bottom nowrap align=right width="6%">&nbsp;</TD>
<TD vAlign=bottom nowrap align=right width="9%"><FONT face="Times New Roman" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 227,000 </FONT></TD></TR>
<TR>
<TD vAlign=bottom nowrap width="75%"><FONT face="Times New Roman" size=2>Net deferred tax asset - non-current</FONT></TD>
<TD vAlign=bottom nowrap align=right width="10%"><FONT face="Times New Roman" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 20,624,000 </FONT></TD>
<TD vAlign=bottom nowrap align=right width="6%">&nbsp;</TD>
<TD vAlign=bottom nowrap align=right width="9%"><FONT face="Times New Roman" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#151; </FONT></TD></TR>
<TR>
<TD vAlign=bottom nowrap width="75%">&nbsp;</TD>
<TD vAlign=bottom nowrap align=right width="10%">
<HR noshade SIZE=1>
</TD>
<TD vAlign=bottom nowrap align=right width="6%">&nbsp;</TD>
<TD vAlign=bottom nowrap align=right width="9%">
<HR noshade SIZE=1>
</TD></TR>
<TR>
<TD vAlign=bottom nowrap width="75%"><FONT face="Times New Roman" size=2>Total assets</FONT></TD>
<TD vAlign=bottom nowrap align=right width="10%"><FONT face="Times New Roman" size=2>&nbsp;$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 61,898,000 </FONT></TD>
<TD vAlign=bottom nowrap align=right width="6%">&nbsp;</TD>
<TD vAlign=bottom nowrap align=right width="9%"><FONT face="Times New Roman" size=2>&nbsp;$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 32,368,000 </FONT></TD></TR>
<TR>
<TD vAlign=bottom nowrap width="75%">&nbsp;</TD>
<TD vAlign=bottom nowrap align=right width="10%">
<HR noshade>
</TD>
<TD vAlign=bottom nowrap align=right width="6%">&nbsp;</TD>
<TD vAlign=bottom nowrap align=right width="9%">
<HR noshade>
</TD></TR>
<TR>
<TD vAlign=bottom nowrap width="75%"><FONT face="Times New Roman" size=2><B>LIABILITIES, CONVERTIBLE PREFERRED STOCK&nbsp; AND&nbsp; SHAREHOLDERS'&nbsp; EQUITY</B></FONT></TD>
<TD vAlign=bottom nowrap align=right width="10%"><FONT face="Times New Roman" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT></TD>
<TD vAlign=bottom nowrap align=right width="6%">&nbsp;</TD>
<TD vAlign=bottom nowrap align=right width="9%"><FONT face="Times New Roman" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT></TD></TR>
<TR>
<TD vAlign=bottom nowrap width="75%"><FONT face="Times New Roman" size=2>Current liabilities:</FONT></TD>
<TD vAlign=bottom nowrap align=right width="10%"><FONT face="Times New Roman" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT></TD>
<TD vAlign=bottom nowrap align=right width="6%">&nbsp;</TD>
<TD vAlign=bottom nowrap align=right width="9%"><FONT face="Times New Roman" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT></TD></TR>
<TR>
<TD vAlign=bottom nowrap width="75%"><FONT face="Times New Roman" size=2>Accounts payable</FONT></TD>
<TD vAlign=bottom nowrap align=right width="10%"><FONT face="Times New Roman" size=2>&nbsp;$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 2,721,000 </FONT></TD>
<TD vAlign=bottom nowrap align=right width="6%">&nbsp;</TD>
<TD vAlign=bottom nowrap align=right width="9%"><FONT face="Times New Roman" size=2>&nbsp;$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 2,084,000 </FONT></TD></TR>
<TR>
<TD vAlign=bottom nowrap width="75%"><FONT face="Times New Roman" size=2>Dividends payable</FONT></TD>
<TD vAlign=bottom nowrap align=right width="10%"><FONT face="Times New Roman" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 28,000 </FONT></TD>
<TD vAlign=bottom nowrap align=right width="6%">&nbsp;</TD>
<TD vAlign=bottom nowrap align=right width="9%"><FONT face="Times New Roman" size=2>&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;408,000 </FONT></TD></TR>
<TR>
<TD vAlign=bottom nowrap width="75%"><FONT face="Times New Roman" size=2>Accrued payroll and related expenses</FONT></TD>
<TD vAlign=bottom nowrap align=right width="10%"><FONT face="Times New Roman" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 2,853,000 </FONT></TD>
<TD vAlign=bottom nowrap align=right width="6%">&nbsp;</TD>
<TD vAlign=bottom nowrap align=right width="9%"><FONT face="Times New Roman" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 1,811,000 </FONT></TD></TR>
<TR>
<TD vAlign=bottom nowrap width="75%"><FONT face="Times New Roman" size=2>Other accrued liabilities</FONT></TD>
<TD vAlign=bottom nowrap align=right width="10%"><FONT face="Times New Roman" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 319,000 </FONT></TD>
<TD vAlign=bottom nowrap align=right width="6%">&nbsp;</TD>
<TD vAlign=bottom nowrap align=right width="9%"><FONT face="Times New Roman" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 377,000 </FONT></TD></TR>
<TR>
<TD vAlign=bottom nowrap width="75%"><FONT face="Times New Roman" size=2>Warranty reserve</FONT></TD>
<TD vAlign=bottom nowrap align=right width="10%"><FONT face="Times New Roman" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 181,000 </FONT></TD>
<TD vAlign=bottom nowrap align=right width="6%">&nbsp;</TD>
<TD vAlign=bottom nowrap align=right width="9%"><FONT face="Times New Roman" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 123,000 </FONT></TD></TR>
<TR>
<TD vAlign=bottom nowrap width="75%"><FONT face="Times New Roman" size=2>Deferred revenue</FONT></TD>
<TD vAlign=bottom nowrap align=right width="10%"><FONT face="Times New Roman" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 264,000 </FONT></TD>
<TD vAlign=bottom nowrap align=right width="6%">&nbsp;</TD>
<TD vAlign=bottom nowrap align=right width="9%"><FONT face="Times New Roman" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 378,000 </FONT></TD></TR>
<TR>
<TD vAlign=bottom nowrap width="75%"><FONT face="Times New Roman" size=2>Current portion of capital lease obligations</FONT></TD>
<TD vAlign=bottom nowrap align=right width="10%"><FONT face="Times New Roman" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 22,000 </FONT></TD>
<TD vAlign=bottom nowrap align=right width="6%">&nbsp;</TD>
<TD vAlign=bottom nowrap align=right width="9%"><FONT face="Times New Roman" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 58,000 </FONT></TD></TR>
<TR>
<TD vAlign=bottom nowrap width="75%"><FONT face="Times New Roman" size=2>Current portion of long-term debt</FONT></TD>
<TD vAlign=bottom nowrap align=right width="10%"><FONT face="Times New Roman" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &#151; </FONT></TD>
<TD vAlign=bottom nowrap align=right width="6%">&nbsp;</TD>
<TD vAlign=bottom nowrap align=right width="9%"><FONT face="Times New Roman" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 467,000 </FONT></TD></TR>
<TR>
<TD vAlign=bottom nowrap width="75%">&nbsp;</TD>
<TD vAlign=bottom nowrap align=right width="10%">
<HR noshade SIZE=1>
</TD>
<TD vAlign=bottom nowrap align=right width="6%">&nbsp;</TD>
<TD vAlign=bottom nowrap align=right width="9%">
<HR noshade SIZE=1>
</TD></TR>
<TR>
<TD vAlign=bottom nowrap width="75%"><FONT face="Times New Roman" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Total current liabilities</FONT></TD>
<TD vAlign=bottom nowrap align=right width="10%"><FONT face="Times New Roman" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 6,388,000 </FONT></TD>
<TD vAlign=bottom nowrap align=right width="6%">&nbsp;</TD>
<TD vAlign=bottom nowrap align=right width="9%"><FONT face="Times New Roman" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 5,706,000 </FONT></TD></TR>
<TR>
<TD vAlign=bottom nowrap width="75%">&nbsp;</TD>
<TD vAlign=bottom nowrap align=right width="10%">
<HR noshade SIZE=1>
</TD>
<TD vAlign=bottom nowrap align=right width="6%">&nbsp;</TD>
<TD vAlign=bottom nowrap align=right width="9%">
<HR noshade SIZE=1>
</TD></TR>
<TR>
<TD vAlign=bottom nowrap width="75%"><FONT face="Times New Roman" size=2>&nbsp;</FONT></TD>
<TD vAlign=bottom nowrap align=right width="10%"><FONT face="Times New Roman" size=2>&nbsp;</FONT></TD>
<TD vAlign=bottom nowrap align=right width="6%">&nbsp;</TD>
<TD vAlign=bottom nowrap align=right width="9%"><FONT face="Times New Roman" size=2>&nbsp;</FONT></TD></TR>
<TR>
<TD vAlign=bottom nowrap width="75%"><FONT face="Times New Roman" size=2>Capital lease obligations, less current portion</FONT></TD>
<TD vAlign=bottom nowrap align=right width="10%"><FONT face="Times New Roman" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 16,000 </FONT></TD>
<TD vAlign=bottom nowrap align=right width="6%">&nbsp;</TD>
<TD vAlign=bottom nowrap align=right width="9%"><FONT face="Times New Roman" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 38,000 </FONT></TD></TR>
<TR>
<TD vAlign=bottom nowrap width="75%"><FONT face="Times New Roman" size=2>Long-term debt, less current portion </FONT></TD>
<TD vAlign=bottom nowrap align=right width="10%"><FONT face="Times New Roman" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &#151; </FONT></TD>
<TD vAlign=bottom nowrap align=right width="6%">&nbsp;</TD>
<TD vAlign=bottom nowrap align=right width="9%"><FONT face="Times New Roman" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 466,000 </FONT></TD></TR>
<TR>
<TD vAlign=bottom nowrap width="75%"><FONT face="Times New Roman" size=2>Deferred rent</FONT></TD>
<TD vAlign=bottom nowrap align=right width="10%"><FONT face="Times New Roman" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 409,000 </FONT></TD>
<TD vAlign=bottom nowrap align=right width="6%">&nbsp;</TD>
<TD vAlign=bottom nowrap align=right width="9%"><FONT face="Times New Roman" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 321,000 </FONT></TD></TR>
<TR>
<TD vAlign=bottom nowrap width="75%"><FONT face="Times New Roman" size=2>Deferred revenue, less current portion</FONT></TD>
<TD vAlign=bottom nowrap align=right width="10%"><FONT face="Times New Roman" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 474,000 </FONT></TD>
<TD vAlign=bottom nowrap align=right width="6%">&nbsp;</TD>
<TD vAlign=bottom nowrap align=right width="9%"><FONT face="Times New Roman" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 318,000 </FONT></TD></TR>
<TR>
<TD vAlign=bottom nowrap width="75%"><FONT face="Times New Roman" size=2>Commission obligation, less current portion</FONT></TD>
<TD vAlign=bottom nowrap align=right width="10%"><FONT face="Times New Roman" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 39,000 </FONT></TD>
<TD vAlign=bottom nowrap align=right width="6%">&nbsp;</TD>
<TD vAlign=bottom nowrap align=right width="9%"><FONT face="Times New Roman" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 75,000 </FONT></TD></TR>
<TR>
<TD vAlign=bottom nowrap width="75%">&nbsp;</TD>
<TD vAlign=bottom nowrap align=right width="10%">
<HR noshade SIZE=1>
</TD>
<TD vAlign=bottom nowrap align=right width="6%">&nbsp;</TD>
<TD vAlign=bottom nowrap align=right width="9%">
<HR noshade SIZE=1>
</TD></TR>
<TR>
<TD vAlign=bottom nowrap width="75%"><FONT face="Times New Roman" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Total non-current liabilities</FONT></TD>
<TD vAlign=bottom nowrap align=right width="10%"><FONT face="Times New Roman" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 938,000 </FONT></TD>
<TD vAlign=bottom nowrap align=right width="6%">&nbsp;</TD>
<TD vAlign=bottom nowrap align=right width="9%"><FONT face="Times New Roman" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 1,218,000 </FONT></TD></TR>
<TR>
<TD vAlign=bottom nowrap width="75%">&nbsp;</TD>
<TD vAlign=bottom nowrap align=right width="10%">
<HR noshade SIZE=1>
</TD>
<TD vAlign=bottom nowrap align=right width="6%">&nbsp;</TD>
<TD vAlign=bottom nowrap align=right width="9%">
<HR noshade SIZE=1>
</TD></TR>
<TR>
<TD vAlign=bottom nowrap width="75%"><FONT face="Times New Roman" size=2>Commitments and contingencies (Note 8)</FONT></TD>
<TD vAlign=bottom nowrap align=right width="10%"><FONT face="Times New Roman" size=2>&nbsp;</FONT></TD>
<TD vAlign=bottom nowrap align=right width="6%">&nbsp;</TD>
<TD vAlign=bottom nowrap align=right width="9%"><FONT face="Times New Roman" size=2>&nbsp;</FONT></TD></TR>
<TR>
<TD vAlign=bottom nowrap width="75%"><FONT face="Times New Roman" size=2>Redeemable convertible preferred stock, Series E, no par value:</FONT></TD>
<TD vAlign=bottom nowrap align=right width="10%"><FONT face="Times New Roman" size=2>&nbsp;</FONT></TD>
<TD vAlign=bottom nowrap align=right width="6%">&nbsp;</TD>
<TD vAlign=bottom nowrap align=right width="9%"><FONT face="Times New Roman" size=2>&nbsp;</FONT></TD></TR>
<TR>
<TD vAlign=bottom nowrap width="75%"><FONT face="Times New Roman" size=2>&nbsp;issued and outstanding shares - 0 in 2004 and 5,570 in 2003,</FONT></TD>
<TD vAlign=bottom nowrap align=right width="10%"><FONT face="Times New Roman" size=2>&nbsp;</FONT></TD>
<TD vAlign=bottom nowrap align=right width="6%">&nbsp;</TD>
<TD vAlign=bottom nowrap align=right width="9%"><FONT face="Times New Roman" size=2>&nbsp;</FONT></TD></TR>
<TR>
<TD vAlign=bottom nowrap width="75%"><FONT face="Times New Roman" size=2>&nbsp;(liquidation preference of $0 in 2004 and $5,570,000 in 2003)</FONT></TD>
<TD vAlign=bottom nowrap align=right width="10%"><FONT face="Times New Roman" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#151; </FONT></TD>
<TD vAlign=bottom nowrap align=right width="6%">&nbsp;</TD>
<TD vAlign=bottom nowrap align=right width="9%"><FONT face="Times New Roman" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 3,176,000 </FONT></TD></TR>
<TR>
<TD vAlign=bottom nowrap width="75%">&nbsp;</TD>
<TD vAlign=bottom nowrap align=right width="10%">
<HR noshade SIZE=1>
</TD>
<TD vAlign=bottom nowrap align=right width="6%">&nbsp;</TD>
<TD vAlign=bottom nowrap align=right width="9%">
<HR noshade SIZE=1>
</TD></TR>
<TR>
<TD vAlign=bottom nowrap width="75%"><FONT face="Times New Roman" size=2>Shareholders' equity:</FONT></TD>
<TD vAlign=bottom nowrap align=right width="10%"><FONT face="Times New Roman" size=2>&nbsp;</FONT></TD>
<TD vAlign=bottom nowrap align=right width="6%">&nbsp;</TD>
<TD vAlign=bottom nowrap align=right width="9%"><FONT face="Times New Roman" size=2>&nbsp;</FONT></TD></TR>
<TR>
<TD vAlign=bottom nowrap width="75%"><FONT face="Times New Roman" size=2>&nbsp; Convertible preferred stock, Series D, no par value:&nbsp; authorized shares - 5,000,000; </FONT></TD>
<TD vAlign=bottom nowrap align=right width="10%"><FONT face="Times New Roman" size=2>&nbsp;</FONT></TD>
<TD vAlign=bottom nowrap align=right width="6%">&nbsp;</TD>
<TD vAlign=bottom nowrap align=right width="9%"><FONT face="Times New Roman" size=2>&nbsp;</FONT></TD></TR>
<TR>
<TD vAlign=bottom nowrap width="75%"><FONT face="Times New Roman" size=2>&nbsp; issued and outstanding shares - 0 in 2004 and 6,508 in 2003</FONT></TD>
<TD vAlign=bottom nowrap align=right width="10%"><FONT face="Times New Roman" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#151; </FONT></TD>
<TD vAlign=bottom nowrap align=right width="6%">&nbsp;</TD>
<TD vAlign=bottom nowrap align=right width="9%"><FONT face="Times New Roman" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 3,143,000 </FONT></TD></TR>
<TR>
<TD vAlign=bottom nowrap width="75%"><FONT face="Times New Roman" size=2>&nbsp; Common stock, no par value: authorized shares - 35,000,000; issued and outstanding</FONT></TD>
<TD vAlign=bottom nowrap align=right width="10%"><FONT face="Times New Roman" size=2>&nbsp;</FONT></TD>
<TD vAlign=bottom nowrap align=right width="6%">&nbsp;</TD>
<TD vAlign=bottom nowrap align=right width="9%"><FONT face="Times New Roman" size=2>&nbsp;</FONT></TD></TR>
<TR>
<TD vAlign=bottom nowrap width="75%"><FONT face="Times New Roman" size=2>&nbsp;&nbsp;&nbsp; shares - 19,520,237 in 2004 and 16,816,095 in 2003</FONT></TD>
<TD vAlign=bottom nowrap align=right width="10%"><FONT face="Times New Roman" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 92,441,000 </FONT></TD>
<TD vAlign=bottom nowrap align=right width="6%">&nbsp;</TD>
<TD vAlign=bottom nowrap align=right width="9%"><FONT face="Times New Roman" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 80,608,000 </FONT></TD></TR>
<TR>
<TD vAlign=bottom nowrap width="75%"><FONT face="Times New Roman" size=2>&nbsp;Accumulated deficit</FONT></TD>
<TD vAlign=bottom nowrap align=right width="10%"><FONT face="Times New Roman" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (37,869,000)</FONT></TD>
<TD vAlign=bottom nowrap align=right width="6%">&nbsp;</TD>
<TD vAlign=bottom nowrap align=right width="9%"><FONT face="Times New Roman" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (61,483,000)</FONT></TD></TR>
<TR>
<TD vAlign=bottom nowrap width="75%">&nbsp;</TD>
<TD vAlign=bottom nowrap align=right width="10%">
<HR noshade SIZE=1>
</TD>
<TD vAlign=bottom nowrap align=right width="6%">&nbsp;</TD>
<TD vAlign=bottom nowrap align=right width="9%">
<HR noshade SIZE=1>
</TD></TR>
<TR>
<TD vAlign=bottom nowrap width="75%"><FONT face="Times New Roman" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Total shareholders' equity</FONT></TD>
<TD vAlign=bottom nowrap align=right width="10%"><FONT face="Times New Roman" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 54,572,000 </FONT></TD>
<TD vAlign=bottom nowrap align=right width="6%">&nbsp;</TD>
<TD vAlign=bottom nowrap align=right width="9%"><FONT face="Times New Roman" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 22,268,000 </FONT></TD></TR>
<TR>
<TD vAlign=bottom nowrap width="75%">&nbsp;</TD>
<TD vAlign=bottom nowrap align=right width="10%">
<HR noshade SIZE=1>
</TD>
<TD vAlign=bottom nowrap align=right width="6%">&nbsp;</TD>
<TD vAlign=bottom nowrap align=right width="9%">
<HR noshade SIZE=1>
</TD></TR>
<TR>
<TD vAlign=bottom nowrap width="75%"><FONT face="Times New Roman" size=2>Total liabilities, convertible preferred stock and shareholders' equity</FONT></TD>
<TD vAlign=bottom nowrap align=right width="10%"><FONT face="Times New Roman" size=2>&nbsp;$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 61,898,000 </FONT></TD>
<TD vAlign=bottom nowrap align=right width="6%">&nbsp;</TD>
<TD vAlign=bottom nowrap align=right width="9%"><FONT face="Times New Roman" size=2>&nbsp;$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 32,368,000 </FONT></TD></TR>
<TR>
<TD vAlign=bottom nowrap width="75%">&nbsp;</TD>
<TD vAlign=bottom nowrap align=right width="10%">
<HR noshade>
</TD>
<TD vAlign=bottom nowrap align=right width="6%">&nbsp;</TD>
<TD vAlign=bottom nowrap align=right width="9%">
<HR noshade>
</TD></TR>
<TR>
<TD vAlign=bottom nowrap width="75%"><FONT face="Times New Roman" size=2>&nbsp;</FONT></TD>
<TD vAlign=bottom nowrap align=right width="10%"><FONT face="Times New Roman" size=2>&nbsp;</FONT></TD>
<TD vAlign=bottom nowrap align=right width="6%">&nbsp;</TD>
<TD vAlign=bottom nowrap align=right width="9%"><FONT face="Times New Roman" size=2>&nbsp;</FONT></TD></TR>
<TR>
<TD vAlign=bottom nowrap width="75%"><FONT face="Times New Roman" size=2>See notes to financial statements.</FONT></TD>
<TD vAlign=bottom nowrap align=right width="10%"><FONT face="Times New Roman" size=2>&nbsp;</FONT></TD>
<TD vAlign=bottom nowrap align=right width="6%">&nbsp;</TD>
<TD vAlign=bottom nowrap align=right width="9%"><FONT face="Times New Roman" size=2>&nbsp;</FONT></TD></TR>
</TABLE>



<P></P>

<TABLE width="100%">
<TR>
<TD align=center><FONT size=2>36</FONT></TD></TR>
</TABLE>



<P>
<HR align=left noshade SIZE=5>


<P>&nbsp;
<!-- *************************************************************************** -->
<!-- MARKER PAGE="sheet: 14; page: 14" -->

<P>
<TABLE cellSpacing=0 cellPadding=0 width="85%" border=0>
<TR>
<TD vAlign=bottom colSpan=6>
<DIV align=center><FONT face="Times New Roman" size=2><B>ABAXIS,&nbsp; INC.</B></FONT></DIV></TD></TR>
<TR>
<TD vAlign=bottom colSpan=6>
<DIV align=center><FONT face="Times New Roman" size=2><B>STATEMENTS&nbsp; OF&nbsp; OPERATIONS</B></FONT></DIV></TD></TR>
<TR>
<TD vAlign=bottom width=497><FONT face="Times New Roman" size=2><B>&nbsp;</B></FONT></TD>
<TD vAlign=bottom width=93><FONT face="Times New Roman" size=2><B>&nbsp;</B></FONT></TD>
<TD vAlign=bottom width=38>&nbsp;</TD>
<TD vAlign=bottom width=89><FONT face="Times New Roman" size=2><B>&nbsp;</B></FONT></TD>
<TD vAlign=bottom width=28>&nbsp;</TD>
<TD vAlign=bottom width=95><FONT face="Times New Roman" size=2><B>&nbsp;</B></FONT></TD></TR>
<TR>
<TD vAlign=bottom width=497><FONT face="Times New Roman" size=2><B>&nbsp;</B></FONT></TD>
<TD vAlign=bottom align=center colSpan=5><FONT face="Times New Roman" size=2><B>Year Ended March 31,</B></FONT>
<HR align=center noshade SIZE=1>
</TD></TR>
<TR>
<TD vAlign=bottom width=497><FONT face="Times New Roman" size=2><B>&nbsp;</B></FONT></TD>
<TD vAlign=bottom width=93>
<DIV align=center><FONT size=2><B>2004</B></FONT> </DIV>
<HR align=center noshade SIZE=1>
</TD>
<TD vAlign=bottom width=38>
<DIV align=center></DIV></TD>
<TD vAlign=bottom align=center width=89><FONT size=2><B>2003</B> </FONT>
<HR align=center noshade SIZE=1>
</TD>
<TD vAlign=bottom width=28>
<DIV align=center></DIV></TD>
<TD vAlign=bottom align=center width=95><FONT size=2><B>2002</B></FONT>
<HR align=center noshade SIZE=1>
</TD></TR>
<TR>
<TD vAlign=bottom width=497><FONT face="Times New Roman" size=2>Product sales, net</FONT></TD>
<TD vAlign=bottom align=right width=93><FONT face="Times New Roman" size=2>&nbsp;$&nbsp;&nbsp;&nbsp;46,599,000 </FONT></TD>
<TD vAlign=bottom align=right width=38>&nbsp;</TD>
<TD vAlign=bottom align=right width=89><FONT face="Times New Roman" size=2>&nbsp;$&nbsp;&nbsp;&nbsp;34,532,000 </FONT></TD>
<TD vAlign=bottom align=right width=28>&nbsp;</TD>
<TD vAlign=bottom align=right width=95><FONT face="Times New Roman" size=2>&nbsp;$&nbsp;&nbsp;&nbsp;&nbsp; 30,418,000 </FONT></TD></TR>
<TR>
<TD vAlign=bottom width=497><FONT face="Times New Roman" size=2>Development and licensing revenue</FONT></TD>
<TD vAlign=bottom align=right width=93><FONT face="Times New Roman" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 275,000 </FONT></TD>
<TD vAlign=bottom align=right width=38>&nbsp;</TD>
<TD vAlign=bottom align=right width=89><FONT face="Times New Roman" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 248,000 </FONT></TD>
<TD vAlign=bottom align=right width=28>&nbsp;</TD>
<TD vAlign=bottom align=right width=95><FONT face="Times New Roman" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 213,000 </FONT></TD></TR>
<TR>
<TD vAlign=bottom width=497>&nbsp;</TD>
<TD vAlign=bottom align=right width=93>
<HR noshade SIZE=1>
</TD>
<TD vAlign=bottom align=right width=38>&nbsp;</TD>
<TD vAlign=bottom align=right width=89>
<HR noshade SIZE=1>
</TD>
<TD vAlign=bottom align=right width=28>&nbsp;</TD>
<TD vAlign=bottom align=right width=95>
<HR noshade SIZE=1>
</TD></TR>
<TR>
<TD vAlign=bottom width=497><FONT face="Times New Roman" size=2>Total revenues</FONT></TD>
<TD vAlign=bottom align=right width=93><FONT face="Times New Roman" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 46,874,000 </FONT></TD>
<TD vAlign=bottom align=right width=38>&nbsp;</TD>
<TD vAlign=bottom align=right width=89><FONT face="Times New Roman" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 34,780,000 </FONT></TD>
<TD vAlign=bottom align=right width=28>&nbsp;</TD>
<TD vAlign=bottom align=right width=95><FONT face="Times New Roman" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 30,631,000 </FONT></TD></TR>
<TR>
<TD vAlign=bottom width=497>&nbsp;</TD>
<TD vAlign=bottom align=right width=93>
<HR noshade SIZE=1>
</TD>
<TD vAlign=bottom align=right width=38>&nbsp;</TD>
<TD vAlign=bottom align=right width=89>
<HR noshade SIZE=1>
</TD>
<TD vAlign=bottom align=right width=28>&nbsp;</TD>
<TD vAlign=bottom align=right width=95>
<HR noshade SIZE=1>
</TD></TR>
<TR>
<TD vAlign=bottom width=497><FONT face="Times New Roman" size=2>Costs and operating expenses:</FONT></TD>
<TD vAlign=bottom align=right width=93><FONT face="Times New Roman" size=2>&nbsp;</FONT></TD>
<TD vAlign=bottom align=right width=38>&nbsp;</TD>
<TD vAlign=bottom align=right width=89><FONT face="Times New Roman" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD vAlign=bottom align=right width=28>&nbsp;</TD>
<TD vAlign=bottom align=right width=95><FONT face="Times New Roman" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT></TD></TR>
<TR>
<TD vAlign=bottom width=497><FONT face="Times New Roman" size=2>&nbsp; Cost of product sales</FONT></TD>
<TD vAlign=bottom align=right width=93><FONT face="Times New Roman" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 22,966,000 </FONT></TD>
<TD vAlign=bottom align=right width=38>&nbsp;</TD>
<TD vAlign=bottom align=right width=89><FONT face="Times New Roman" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 17,755,000 </FONT></TD>
<TD vAlign=bottom align=right width=28>&nbsp;</TD>
<TD vAlign=bottom align=right width=95><FONT face="Times New Roman" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 15,966,000 </FONT></TD></TR>
<TR>
<TD vAlign=bottom width=497><FONT face="Times New Roman" size=2>&nbsp; Selling, general and administrative</FONT></TD>
<TD vAlign=bottom align=right width=93><FONT face="Times New Roman" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 14,431,000 </FONT></TD>
<TD vAlign=bottom align=right width=38>&nbsp;</TD>
<TD vAlign=bottom align=right width=89><FONT face="Times New Roman" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 11,564,000 </FONT></TD>
<TD vAlign=bottom align=right width=28>&nbsp;</TD>
<TD vAlign=bottom align=right width=95><FONT face="Times New Roman" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 9,333,000 </FONT></TD></TR>
<TR>
<TD vAlign=bottom width=497><FONT face="Times New Roman" size=2>&nbsp; Research and development</FONT></TD>
<TD vAlign=bottom align=right width=93><FONT face="Times New Roman" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 4,757,000 </FONT></TD>
<TD vAlign=bottom align=right width=38>&nbsp;</TD>
<TD vAlign=bottom align=right width=89><FONT face="Times New Roman" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 3,888,000 </FONT></TD>
<TD vAlign=bottom align=right width=28>&nbsp;</TD>
<TD vAlign=bottom align=right width=95><FONT face="Times New Roman" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 3,834,000 </FONT></TD></TR>
<TR>
<TD vAlign=bottom width=497>&nbsp;</TD>
<TD vAlign=bottom align=right width=93>
<HR noshade SIZE=1>
</TD>
<TD vAlign=bottom align=right width=38>&nbsp;</TD>
<TD vAlign=bottom align=right width=89>
<HR noshade SIZE=1>
</TD>
<TD vAlign=bottom align=right width=28>&nbsp;</TD>
<TD vAlign=bottom align=right width=95>
<HR noshade SIZE=1>
</TD></TR>
<TR>
<TD vAlign=bottom width=497><FONT face="Times New Roman" size=2>Total costs and operating expenses</FONT></TD>
<TD vAlign=bottom align=right width=93><FONT face="Times New Roman" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 42,154,000 </FONT></TD>
<TD vAlign=bottom align=right width=38>&nbsp;</TD>
<TD vAlign=bottom align=right width=89><FONT face="Times New Roman" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 33,207,000 </FONT></TD>
<TD vAlign=bottom align=right width=28>&nbsp;</TD>
<TD vAlign=bottom align=right width=95><FONT face="Times New Roman" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 29,133,000 </FONT></TD></TR>
<TR>
<TD vAlign=bottom width=497>&nbsp;</TD>
<TD vAlign=bottom align=right width=93>
<HR noshade SIZE=1>
</TD>
<TD vAlign=bottom align=right width=38>&nbsp;</TD>
<TD vAlign=bottom align=right width=89>
<HR noshade SIZE=1>
</TD>
<TD vAlign=bottom align=right width=28>&nbsp;</TD>
<TD vAlign=bottom align=right width=95>
<HR noshade SIZE=1>
</TD></TR>
<TR>
<TD vAlign=bottom width=497><FONT face="Times New Roman" size=2>Income from operations</FONT></TD>
<TD vAlign=bottom align=right width=93><FONT face="Times New Roman" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 4,720,000 </FONT></TD>
<TD vAlign=bottom align=right width=38>&nbsp;</TD>
<TD vAlign=bottom align=right width=89><FONT face="Times New Roman" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 1,573,000 </FONT></TD>
<TD vAlign=bottom align=right width=28>&nbsp;</TD>
<TD vAlign=bottom align=right width=95><FONT face="Times New Roman" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 1,498,000 </FONT></TD></TR>
<TR>
<TD vAlign=bottom width=497><FONT face="Times New Roman" size=2>Interest and other income</FONT></TD>
<TD vAlign=bottom align=right width=93><FONT face="Times New Roman" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 173,000 </FONT></TD>
<TD vAlign=bottom align=right width=38>&nbsp;</TD>
<TD vAlign=bottom align=right width=89><FONT face="Times New Roman" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 217,000 </FONT></TD>
<TD vAlign=bottom align=right width=28>&nbsp;</TD>
<TD vAlign=bottom align=right width=95><FONT face="Times New Roman" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 91,000 </FONT></TD></TR>
<TR>
<TD vAlign=bottom width=497><FONT face="Times New Roman" size=2>Interest and other expense</FONT></TD>
<TD vAlign=bottom align=right width=93><FONT face="Times New Roman" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (68,000)</FONT></TD>
<TD vAlign=bottom align=right width=38>&nbsp;</TD>
<TD vAlign=bottom align=right width=89><FONT face="Times New Roman" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (149,000)</FONT></TD>
<TD vAlign=bottom align=right width=28>&nbsp;</TD>
<TD vAlign=bottom align=right width=95><FONT face="Times New Roman" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (269,000)</FONT></TD></TR>
<TR>
<TD vAlign=bottom width=497>&nbsp;</TD>
<TD vAlign=bottom align=right width=93>
<HR noshade SIZE=1>
</TD>
<TD vAlign=bottom align=right width=38>&nbsp;</TD>
<TD vAlign=bottom align=right width=89>
<HR noshade SIZE=1>
</TD>
<TD vAlign=bottom align=right width=28>&nbsp;</TD>
<TD vAlign=bottom align=right width=95>
<HR noshade SIZE=1>
</TD></TR>
<TR>
<TD vAlign=bottom width=497><FONT face="Times New Roman" size=2>Income before income taxes</FONT></TD>
<TD vAlign=bottom align=right width=93><FONT face="Times New Roman" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 4,825,000 </FONT></TD>
<TD vAlign=bottom align=right width=38>&nbsp;</TD>
<TD vAlign=bottom align=right width=89><FONT face="Times New Roman" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 1,641,000 </FONT></TD>
<TD vAlign=bottom align=right width=28>&nbsp;</TD>
<TD vAlign=bottom align=right width=95><FONT face="Times New Roman" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 1,320,000 </FONT></TD></TR>
<TR>
<TD vAlign=bottom width=497><FONT face="Times New Roman" size=2>Income tax provision (benefit)</FONT></TD>
<TD vAlign=bottom align=right width=93><FONT face="Times New Roman" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (19,208,000)</FONT></TD>
<TD vAlign=bottom align=right width=38>&nbsp;</TD>
<TD vAlign=bottom align=right width=89><FONT face="Times New Roman" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 5,000 </FONT></TD>
<TD vAlign=bottom align=right width=28>&nbsp;</TD>
<TD vAlign=bottom align=right width=95><FONT face="Times New Roman" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 16,000 </FONT></TD></TR>
<TR>
<TD vAlign=bottom width=497>&nbsp;</TD>
<TD vAlign=bottom align=right width=93>
<HR noshade SIZE=1>
</TD>
<TD vAlign=bottom align=right width=38>&nbsp;</TD>
<TD vAlign=bottom align=right width=89>
<HR noshade SIZE=1>
</TD>
<TD vAlign=bottom align=right width=28>&nbsp;</TD>
<TD vAlign=bottom align=right width=95>
<HR noshade SIZE=1>
</TD></TR>
<TR>
<TD vAlign=bottom width=497><FONT face="Times New Roman" size=2>Net income</FONT></TD>
<TD vAlign=bottom align=right width=93><FONT face="Times New Roman" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 24,033,000 </FONT></TD>
<TD vAlign=bottom align=right width=38>&nbsp;</TD>
<TD vAlign=bottom align=right width=89><FONT face="Times New Roman" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 1,636,000 </FONT></TD>
<TD vAlign=bottom align=right width=28>&nbsp;</TD>
<TD vAlign=bottom align=right width=95><FONT face="Times New Roman" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 1,304,000 </FONT></TD></TR>
<TR>
<TD vAlign=bottom width=497><FONT face="Times New Roman" size=2>Preferred dividends and accretion (a)</FONT></TD>
<TD vAlign=bottom align=right width=93><FONT face="Times New Roman" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (419,000)</FONT></TD>
<TD vAlign=bottom align=right width=38>&nbsp;</TD>
<TD vAlign=bottom align=right width=89><FONT face="Times New Roman" size=2>&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1,235,000)</FONT></TD>
<TD vAlign=bottom align=right width=28>&nbsp;</TD>
<TD vAlign=bottom align=right width=95><FONT face="Times New Roman" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (1,033,000)</FONT></TD></TR>
<TR>
<TD vAlign=bottom width=497>&nbsp;</TD>
<TD vAlign=bottom align=right width=93>
<HR noshade SIZE=1>
</TD>
<TD vAlign=bottom align=right width=38>&nbsp;</TD>
<TD vAlign=bottom align=right width=89>
<HR noshade SIZE=1>
</TD>
<TD vAlign=bottom align=right width=28>&nbsp;</TD>
<TD vAlign=bottom align=right width=95>
<HR noshade SIZE=1>
</TD></TR>
<TR>
<TD vAlign=bottom width=497><FONT face="Times New Roman" size=2>Net income attributable to common shareholders</FONT></TD>
<TD vAlign=bottom align=right width=93><FONT face="Times New Roman" size=2>&nbsp;$&nbsp;&nbsp;&nbsp;23,614,000 </FONT></TD>
<TD vAlign=bottom align=right width=38>&nbsp;</TD>
<TD vAlign=bottom align=right width=89><FONT face="Times New Roman" size=2>&nbsp;$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 401,000 </FONT></TD>
<TD vAlign=bottom align=right width=28>&nbsp;</TD>
<TD vAlign=bottom align=right width=95><FONT face="Times New Roman" size=2>&nbsp;$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 271,000 </FONT></TD></TR>
<TR>
<TD vAlign=bottom width=497>&nbsp;</TD>
<TD vAlign=bottom align=right width=93>
<HR noshade>
</TD>
<TD vAlign=bottom align=right width=38>&nbsp;</TD>
<TD vAlign=bottom align=right width=89>
<HR noshade>
</TD>
<TD vAlign=bottom align=right width=28>&nbsp;</TD>
<TD vAlign=bottom align=right width=95>
<HR noshade>
</TD></TR>
<TR>
<TD vAlign=bottom width=497><FONT face="Times New Roman" size=2>Basic net income per share</FONT></TD>
<TD vAlign=bottom align=right width=93><FONT face="Times New Roman" size=2>&nbsp;$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 1.30 </FONT></TD>
<TD vAlign=bottom align=right width=38>&nbsp;</TD>
<TD vAlign=bottom align=right width=89><FONT face="Times New Roman" size=2>&nbsp;$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 0.02 </FONT></TD>
<TD vAlign=bottom align=right width=28>&nbsp;</TD>
<TD vAlign=bottom align=right width=95><FONT face="Times New Roman" size=2>&nbsp;$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 0.02 </FONT></TD></TR>
<TR>
<TD vAlign=bottom width=497>&nbsp;</TD>
<TD vAlign=bottom align=right width=93>
<HR noshade>
</TD>
<TD vAlign=bottom align=right width=38>&nbsp;</TD>
<TD vAlign=bottom align=right width=89>
<HR noshade>
</TD>
<TD vAlign=bottom align=right width=28>&nbsp;</TD>
<TD vAlign=bottom align=right width=95>
<HR noshade>
</TD></TR>
<TR>
<TD vAlign=bottom width=497><FONT face="Times New Roman" size=2>Diluted net income per share</FONT></TD>
<TD vAlign=bottom align=right width=93><FONT face="Times New Roman" size=2>&nbsp;$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 1.16 </FONT></TD>
<TD vAlign=bottom align=right width=38>&nbsp;</TD>
<TD vAlign=bottom align=right width=89><FONT face="Times New Roman" size=2>&nbsp;$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 0.02 </FONT></TD>
<TD vAlign=bottom align=right width=28>&nbsp;</TD>
<TD vAlign=bottom align=right width=95><FONT face="Times New Roman" size=2>&nbsp;$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 0.02 </FONT></TD></TR>
<TR>
<TD vAlign=bottom width=497>&nbsp;</TD>
<TD vAlign=bottom align=right width=93>
<HR noshade>
</TD>
<TD vAlign=bottom align=right width=38>&nbsp;</TD>
<TD vAlign=bottom align=right width=89>
<HR noshade>
</TD>
<TD vAlign=bottom align=right width=28>&nbsp;</TD>
<TD vAlign=bottom align=right width=95>
<HR noshade>
</TD></TR>
<TR>
<TD vAlign=bottom width=497><FONT face="Times New Roman" size=2>Weighted average common shares outstanding - basic</FONT></TD>
<TD vAlign=bottom align=right width=93><FONT face="Times New Roman" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 18,128,181 </FONT></TD>
<TD vAlign=bottom align=right width=38>&nbsp;</TD>
<TD vAlign=bottom align=right width=89><FONT face="Times New Roman" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 16,634,447 </FONT></TD>
<TD vAlign=bottom align=right width=28>&nbsp;</TD>
<TD vAlign=bottom align=right width=95><FONT face="Times New Roman" size=2>&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;16,264,153 </FONT></TD></TR>
<TR>
<TD vAlign=bottom width=497>&nbsp;</TD>
<TD vAlign=bottom align=right width=93>
<HR noshade>
</TD>
<TD vAlign=bottom align=right width=38>&nbsp;</TD>
<TD vAlign=bottom align=right width=89>
<HR noshade>
</TD>
<TD vAlign=bottom align=right width=28>&nbsp;</TD>
<TD vAlign=bottom align=right width=95>
<HR noshade>
</TD></TR>
<TR>
<TD vAlign=bottom width=497><FONT face="Times New Roman" size=2>Weighted average common shares outstanding - diluted</FONT></TD>
<TD vAlign=bottom align=right width=93><FONT face="Times New Roman" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 20,387,167 </FONT></TD>
<TD vAlign=bottom align=right width=38>&nbsp;</TD>
<TD vAlign=bottom align=right width=89><FONT face="Times New Roman" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 17,014,313 </FONT></TD>
<TD vAlign=bottom align=right width=28>&nbsp;</TD>
<TD vAlign=bottom align=right width=95><FONT face="Times New Roman" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 16,811,326 </FONT></TD></TR>
<TR>
<TD vAlign=bottom width=497>&nbsp;</TD>
<TD vAlign=bottom align=right width=93>
<HR noshade>
</TD>
<TD vAlign=bottom align=right width=38>&nbsp;</TD>
<TD vAlign=bottom align=right width=89>
<HR noshade>
</TD>
<TD vAlign=bottom align=right width=28>&nbsp;</TD>
<TD vAlign=bottom align=right width=95>
<HR noshade>
</TD></TR>
</TABLE>



<P><FONT face="Times New Roman, Times, Serif" size=2>(a)&nbsp;&nbsp;&nbsp;&nbsp; For fiscal 2004, includes preferred dividends of $419,000. For fiscal 2003, includes preferred dividends of $865,000 and a non-cash preferred dividend charge of $370,000 related to the beneficial conversion feature contained in the Company&#146;s Series E Preferred Stock issued in April 2002. For fiscal 2002, includes preferred dividends of $446,000 and a non-cash preferred dividend charge of $587,000 related to the beneficial conversion feature contained in the Company&#146;s Series E Preferred Stock issued in March 2002. See Notes 10 &amp; 11. </FONT></P>


<P><FONT face="Times New Roman, Times, Serif" size=2>See notes to financial statements. </FONT></P>

<TABLE width="100%">
<TR>
<TD align=center><FONT size=2>37</FONT></TD></TR>
</TABLE>



<P>
<HR align=left noshade SIZE=5>


<P>&nbsp;
<!-- *************************************************************************** -->
<!-- MARKER PAGE="sheet: 14; page: 14" -->

<P>
<TABLE cellSpacing=0 cellPadding=0 width="100%" border=0>
<TR align=center>
<TD vAlign=bottom colSpan=14><FONT face="Times New Roman" size=1><B>ABAXIS,&nbsp; INC.</B></FONT></TD></TR>
<TR align=center>
<TD vAlign=bottom colSpan=14><FONT face="Times New Roman" size=1><B>STATEMENTS&nbsp; OF&nbsp; SHAREHOLDERS'&nbsp; EQUITY</B></FONT></TD></TR>
<TR align=center>
<TD vAlign=bottom width="35%"><FONT face="Times New Roman" size=1><B>&nbsp;</B></FONT></TD>
<TD vAlign=bottom width="7%"><FONT face="Times New Roman" size=1><B>&nbsp;</B></FONT></TD>
<TD vAlign=bottom width="1%">&nbsp; </TD>
<TD vAlign=bottom width="9%"><FONT face="Times New Roman" size=1><B>&nbsp;</B></FONT></TD>
<TD vAlign=bottom width="1%">&nbsp; </TD>
<TD vAlign=bottom width="6%"><FONT face="Times New Roman" size=1>&nbsp;</FONT></TD>
<TD vAlign=bottom width="1%">&nbsp; </TD>
<TD vAlign=bottom width="9%"><FONT face="Times New Roman" size=1><B>&nbsp;</B></FONT></TD>
<TD vAlign=bottom width="1%">&nbsp; </TD>
<TD vAlign=bottom width="9%" rowSpan=3><FONT face="Times New Roman" size=1><B>Deferred <BR>Stock <BR>Compensation</B></FONT> </TD>
<TD vAlign=bottom width="1%" rowSpan=3>&nbsp;&nbsp; </TD>
<TD vAlign=bottom width="9%" rowSpan=3><FONT face="Times New Roman" size=1><B>Accumulated <BR>Deficit </B></FONT></TD>
<TD vAlign=bottom width="1%" rowSpan=3>&nbsp;&nbsp; </TD>
<TD vAlign=bottom width="10%" rowSpan=3><FONT face="Times New Roman" size=1><B>Shareholders&#146; <BR>Equity </B></FONT></TD></TR>
<TR align=center>
<TD vAlign=bottom width="35%"><FONT face="Times New Roman" size=1><B>&nbsp;</B></FONT></TD>
<TD vAlign=bottom colSpan=4><FONT face="Times New Roman" size=1><B>&nbsp;Convertible Preferred Stock </B></FONT>
<HR align=center noshade SIZE=1>
</TD>
<TD vAlign=bottom colSpan=4><FONT face="Times New Roman" size=1><B>&nbsp;Common Stock </B></FONT>
<HR align=center noshade SIZE=1>
</TD></TR>
<TR align=center>
<TD vAlign=bottom width="35%" height=10><FONT face="Times New Roman" size=1><B>&nbsp;</B></FONT></TD>
<TD vAlign=bottom width="7%" height=10><FONT face="Times New Roman" size=1><B>&nbsp;Shares </B></FONT><FONT face="Times New Roman" size=1><B></B></FONT></TD>
<TD vAlign=bottom width="1%" height=10>&nbsp;&nbsp; </TD>
<TD vAlign=bottom width="9%" height=10><FONT face="Times New Roman" size=1><B>Amount</B></FONT> </TD>
<TD vAlign=bottom width="1%" height=10>&nbsp;&nbsp; </TD>
<TD vAlign=bottom width="6%" height=10><FONT face="Times New Roman" size=1><B>&nbsp;Shares </B></FONT></TD>
<TD vAlign=bottom width="1%" height=10>&nbsp;&nbsp; </TD>
<TD vAlign=bottom width="9%" height=10><FONT face="Times New Roman" size=1><B>Amount</B></FONT> </TD>
<TD vAlign=bottom width="1%" height=10>&nbsp;&nbsp; </TD></TR>
<TR>
<TD vAlign=bottom width="35%"></TD>
<TD vAlign=bottom colSpan=13>
<HR align=center noshade SIZE=1>
</TD></TR>
<TR>
<TD vAlign=bottom width="35%"><FONT face="Times New Roman" size=1>Balances at April 1, 2001</FONT></TD>
<TD vAlign=bottom align=right width="7%"><FONT face="Times New Roman" size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 6,578 </FONT></TD>
<TD vAlign=bottom align=right width="1%"></TD>
<TD vAlign=bottom align=right width="9%"><FONT face="Times New Roman" size=1>&nbsp;$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 3,213,000 </FONT></TD>
<TD vAlign=bottom align=right width="1%"></TD>
<TD vAlign=bottom align=right width="6%"><FONT face="Times New Roman" size=1>&nbsp;&nbsp;&nbsp;&nbsp; 16,102,451 </FONT></TD>
<TD vAlign=bottom align=right width="1%"></TD>
<TD vAlign=bottom align=right width="9%"><FONT face="Times New Roman" size=1>&nbsp;$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 74,453,000 </FONT></TD>
<TD vAlign=bottom align=right width="1%"></TD>
<TD vAlign=bottom align=right width="9%"><FONT face="Times New Roman" size=1>&nbsp;$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (16,000)</FONT></TD>
<TD vAlign=bottom align=right width="1%"></TD>
<TD vAlign=bottom align=right width="9%"><FONT face="Times New Roman" size=1>&nbsp;$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (62,155,000)</FONT></TD>
<TD vAlign=bottom align=right width="1%"></TD>
<TD vAlign=bottom align=right width="10%"><FONT face="Times New Roman" size=1>&nbsp;$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 15,495,000 </FONT></TD></TR>
<TR>
<TD vAlign=bottom width="35%"><FONT face="Times New Roman" size=1>Option exercises and related tax benefits</FONT></TD>
<TD vAlign=bottom align=right width="7%"><FONT face="Times New Roman" size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &#151; </FONT></TD>
<TD vAlign=bottom align=right width="1%"></TD>
<TD vAlign=bottom align=right width="9%"><FONT face="Times New Roman" size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &#151; </FONT></TD>
<TD vAlign=bottom align=right width="1%"></TD>
<TD vAlign=bottom align=right width="6%"><FONT face="Times New Roman" size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 133,901 </FONT></TD>
<TD vAlign=bottom align=right width="1%"></TD>
<TD vAlign=bottom align=right width="9%"><FONT face="Times New Roman" size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 417,000 </FONT></TD>
<TD vAlign=bottom align=right width="1%"></TD>
<TD vAlign=bottom align=right width="9%"><FONT face="Times New Roman" size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &#151; </FONT></TD>
<TD vAlign=bottom align=right width="1%"></TD>
<TD vAlign=bottom align=right width="9%"><FONT face="Times New Roman" size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &#151; </FONT></TD>
<TD vAlign=bottom align=right width="1%"></TD>
<TD vAlign=bottom align=right width="10%"><FONT face="Times New Roman" size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 417,000 </FONT></TD></TR>
<TR>
<TD vAlign=bottom width="35%"><FONT face="Times New Roman" size=1>Amounts related to Series E convertible preferred stock issuance:</FONT></TD>
<TD vAlign=bottom align=right width="7%"><FONT face="Times New Roman" size=1>&nbsp;</FONT></TD>
<TD vAlign=bottom align=right width="1%"></TD>
<TD vAlign=bottom align=right width="9%"><FONT face="Times New Roman" size=1>&nbsp;</FONT></TD>
<TD vAlign=bottom align=right width="1%"></TD>
<TD vAlign=bottom align=right width="6%"><FONT face="Times New Roman" size=1>&nbsp;</FONT></TD>
<TD vAlign=bottom align=right width="1%"></TD>
<TD vAlign=bottom align=right width="9%"><FONT face="Times New Roman" size=1>&nbsp;</FONT></TD>
<TD vAlign=bottom align=right width="1%"></TD>
<TD vAlign=bottom align=right width="9%"><FONT face="Times New Roman" size=1>&nbsp;</FONT></TD>
<TD vAlign=bottom align=right width="1%"></TD>
<TD vAlign=bottom align=right width="9%"><FONT face="Times New Roman" size=1>&nbsp;</FONT></TD>
<TD vAlign=bottom align=right width="1%"></TD>
<TD vAlign=bottom align=right width="10%"><FONT face="Times New Roman" size=1>&nbsp;</FONT></TD></TR>
<TR>
<TD vAlign=bottom width="35%"><FONT face="Times New Roman" size=1>&nbsp;&nbsp;&nbsp;&nbsp; Proceeds allocated to common <BR>&nbsp;&nbsp;&nbsp;&nbsp; stock warrants</FONT></TD>
<TD vAlign=bottom align=right width="7%"><FONT face="Times New Roman" size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &#151; </FONT></TD>
<TD vAlign=bottom align=right width="1%"></TD>
<TD vAlign=bottom align=right width="9%"><FONT face="Times New Roman" size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &#151; </FONT></TD>
<TD vAlign=bottom align=right width="1%"></TD>
<TD vAlign=bottom align=right width="6%"><FONT face="Times New Roman" size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &#151; </FONT></TD>
<TD vAlign=bottom align=right width="1%"></TD>
<TD vAlign=bottom align=right width="9%"><FONT face="Times New Roman" size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 645,000 </FONT></TD>
<TD vAlign=bottom align=right width="1%"></TD>
<TD vAlign=bottom align=right width="9%"><FONT face="Times New Roman" size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &#151; </FONT></TD>
<TD vAlign=bottom align=right width="1%"></TD>
<TD vAlign=bottom align=right width="9%"><FONT face="Times New Roman" size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &#151; </FONT></TD>
<TD vAlign=bottom align=right width="1%"></TD>
<TD vAlign=bottom align=right width="10%"><FONT face="Times New Roman" size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 645,000 </FONT></TD></TR>
<TR>
<TD vAlign=bottom width="35%"><FONT face="Times New Roman" size=1>&nbsp;&nbsp;&nbsp;&nbsp; Non cash issuance costs-<BR>&nbsp;&nbsp;&nbsp;&nbsp; common stock warrants <BR>&nbsp;&nbsp;&nbsp;&nbsp; issued to advisors</FONT></TD>
<TD vAlign=bottom align=right width="7%"><FONT face="Times New Roman" size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &#151; </FONT></TD>
<TD vAlign=bottom align=right width="1%"></TD>
<TD vAlign=bottom align=right width="9%"><FONT face="Times New Roman" size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &#151; </FONT></TD>
<TD vAlign=bottom align=right width="1%"></TD>
<TD vAlign=bottom align=right width="6%"><FONT face="Times New Roman" size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &#151; </FONT></TD>
<TD vAlign=bottom align=right width="1%"></TD>
<TD vAlign=bottom align=right width="9%"><FONT face="Times New Roman" size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 240,000 </FONT></TD>
<TD vAlign=bottom align=right width="1%"></TD>
<TD vAlign=bottom align=right width="9%"><FONT face="Times New Roman" size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &#151; </FONT></TD>
<TD vAlign=bottom align=right width="1%"></TD>
<TD vAlign=bottom align=right width="9%"><FONT face="Times New Roman" size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &#151; </FONT></TD>
<TD vAlign=bottom align=right width="1%"></TD>
<TD vAlign=bottom align=right width="10%"><FONT face="Times New Roman" size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 240,000 </FONT></TD></TR>
<TR>
<TD vAlign=bottom width="35%"><FONT face="Times New Roman" size=1>&nbsp;&nbsp;&nbsp;&nbsp; Beneficial conversion<BR>&nbsp;&nbsp;&nbsp;&nbsp; feature, net of deemed <BR>&nbsp;&nbsp;&nbsp;&nbsp; dividend and accretion</FONT></TD>
<TD vAlign=bottom align=right width="7%"><FONT face="Times New Roman" size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &#151; </FONT></TD>
<TD vAlign=bottom align=right width="1%"></TD>
<TD vAlign=bottom align=right width="9%"><FONT face="Times New Roman" size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &#151; </FONT></TD>
<TD vAlign=bottom align=right width="1%"></TD>
<TD vAlign=bottom align=right width="6%"><FONT face="Times New Roman" size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &#151; </FONT></TD>
<TD vAlign=bottom align=right width="1%"></TD>
<TD vAlign=bottom align=right width="9%"><FONT face="Times New Roman" size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 587,000 </FONT></TD>
<TD vAlign=bottom align=right width="1%"></TD>
<TD vAlign=bottom align=right width="9%"><FONT face="Times New Roman" size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#151; </FONT></TD>
<TD vAlign=bottom align=right width="1%"></TD>
<TD vAlign=bottom align=right width="9%"><FONT face="Times New Roman" size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (587,000)</FONT></TD>
<TD vAlign=bottom align=right width="1%"></TD>
<TD vAlign=bottom align=right width="10%"><FONT face="Times New Roman" size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &#151; </FONT></TD></TR>
<TR>
<TD vAlign=bottom width="35%"><FONT face="Times New Roman" size=1>Accrued dividends on Series D convertible preferred stock</FONT></TD>
<TD vAlign=bottom align=right width="7%"><FONT face="Times New Roman" size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &#151; </FONT></TD>
<TD vAlign=bottom align=right width="1%"></TD>
<TD vAlign=bottom align=right width="9%"><FONT face="Times New Roman" size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &#151; </FONT></TD>
<TD vAlign=bottom align=right width="1%"></TD>
<TD vAlign=bottom align=right width="6%"><FONT face="Times New Roman" size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &#151; </FONT></TD>
<TD vAlign=bottom align=right width="1%"></TD>
<TD vAlign=bottom align=right width="9%"><FONT face="Times New Roman" size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#151; </FONT></TD>
<TD vAlign=bottom align=right width="1%"></TD>
<TD vAlign=bottom align=right width="9%"><FONT face="Times New Roman" size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &#151; </FONT></TD>
<TD vAlign=bottom align=right width="1%"></TD>
<TD vAlign=bottom align=right width="9%"><FONT face="Times New Roman" size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (446,000)</FONT></TD>
<TD vAlign=bottom align=right width="1%"></TD>
<TD vAlign=bottom align=right width="10%"><FONT face="Times New Roman" size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (446,000)</FONT></TD></TR>
<TR>
<TD vAlign=bottom width="35%"><FONT face="Times New Roman" size=1>Conversion of Series D convertible preferred stock into common stock</FONT></TD>
<TD vAlign=bottom align=right width="7%"><FONT face="Times New Roman" size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (20)</FONT></TD>
<TD vAlign=bottom align=right width="1%"></TD>
<TD vAlign=bottom align=right width="9%"><FONT face="Times New Roman" size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (20,000)</FONT></TD>
<TD vAlign=bottom align=right width="1%"></TD>
<TD vAlign=bottom align=right width="6%"><FONT face="Times New Roman" size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 2,857 </FONT></TD>
<TD vAlign=bottom align=right width="1%"></TD>
<TD vAlign=bottom align=right width="9%"><FONT face="Times New Roman" size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 20,000 </FONT></TD>
<TD vAlign=bottom align=right width="1%"></TD>
<TD vAlign=bottom align=right width="9%"><FONT face="Times New Roman" size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &#151; </FONT></TD>
<TD vAlign=bottom align=right width="1%"></TD>
<TD vAlign=bottom align=right width="9%"><FONT face="Times New Roman" size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &#151; </FONT></TD>
<TD vAlign=bottom align=right width="1%"></TD>
<TD vAlign=bottom align=right width="10%"><FONT face="Times New Roman" size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &#151; </FONT></TD></TR>
<TR>
<TD vAlign=bottom width="35%"><FONT face="Times New Roman" size=1>Common stock issued for dividends payable</FONT></TD>
<TD vAlign=bottom align=right width="7%"><FONT face="Times New Roman" size=1>&nbsp;</FONT></TD>
<TD vAlign=bottom align=right width="1%"></TD>
<TD vAlign=bottom align=right width="9%"><FONT face="Times New Roman" size=1>&nbsp;</FONT></TD>
<TD vAlign=bottom align=right width="1%"></TD>
<TD vAlign=bottom align=right width="6%"><FONT face="Times New Roman" size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 100,526 </FONT></TD>
<TD vAlign=bottom align=right width="1%"></TD>
<TD vAlign=bottom align=right width="9%"><FONT face="Times New Roman" size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 446,000 </FONT></TD>
<TD vAlign=bottom align=right width="1%"></TD>
<TD vAlign=bottom align=right width="9%"><FONT face="Times New Roman" size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#151; </FONT></TD>
<TD vAlign=bottom align=right width="1%"></TD>
<TD vAlign=bottom align=right width="9%"><FONT face="Times New Roman" size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &#151; </FONT></TD>
<TD vAlign=bottom align=right width="1%"></TD>
<TD vAlign=bottom align=right width="10%"><FONT face="Times New Roman" size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 446,000 </FONT></TD></TR>
<TR>
<TD vAlign=bottom width="35%"><FONT face="Times New Roman" size=1>Revaluation of non-employee options and warrants granted prior to fiscal 2001</FONT></TD>
<TD vAlign=bottom align=right width="7%"><FONT face="Times New Roman" size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &#151; </FONT></TD>
<TD vAlign=bottom align=right width="1%"></TD>
<TD vAlign=bottom align=right width="9%"><FONT face="Times New Roman" size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &#151; </FONT></TD>
<TD vAlign=bottom align=right width="1%"></TD>
<TD vAlign=bottom align=right width="6%"><FONT face="Times New Roman" size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#151; </FONT></TD>
<TD vAlign=bottom align=right width="1%"></TD>
<TD vAlign=bottom align=right width="9%"><FONT face="Times New Roman" size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (3,000)</FONT></TD>
<TD vAlign=bottom align=right width="1%"></TD>
<TD vAlign=bottom align=right width="9%"><FONT face="Times New Roman" size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 3,000 </FONT></TD>
<TD vAlign=bottom align=right width="1%"></TD>
<TD vAlign=bottom align=right width="9%"><FONT face="Times New Roman" size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &#151; </FONT></TD>
<TD vAlign=bottom align=right width="1%"></TD>
<TD vAlign=bottom align=right width="10%"><FONT face="Times New Roman" size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &#151; </FONT></TD></TR>
<TR>
<TD vAlign=bottom width="35%"><FONT face="Times New Roman" size=1>Amortization of deferred compensation</FONT></TD>
<TD vAlign=bottom align=right width="7%"><FONT face="Times New Roman" size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &#151; </FONT></TD>
<TD vAlign=bottom align=right width="1%"></TD>
<TD vAlign=bottom align=right width="9%"><FONT face="Times New Roman" size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&#151; </FONT></TD>
<TD vAlign=bottom align=right width="1%"></TD>
<TD vAlign=bottom align=right width="6%"><FONT face="Times New Roman" size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &#151; </FONT></TD>
<TD vAlign=bottom align=right width="1%"></TD>
<TD vAlign=bottom align=right width="9%"><FONT face="Times New Roman" size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &#151; </FONT></TD>
<TD vAlign=bottom align=right width="1%"></TD>
<TD vAlign=bottom align=right width="9%"><FONT face="Times New Roman" size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 13,000 </FONT></TD>
<TD vAlign=bottom align=right width="1%"></TD>
<TD vAlign=bottom align=right width="9%"><FONT face="Times New Roman" size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &#151; </FONT></TD>
<TD vAlign=bottom align=right width="1%"></TD>
<TD vAlign=bottom align=right width="10%"><FONT face="Times New Roman" size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 13,000 </FONT></TD></TR>
<TR>
<TD vAlign=bottom width="35%"><FONT face="Times New Roman" size=1>Compensation expense for non-employee options granted in fiscal 2001 and 2002</FONT></TD>
<TD vAlign=bottom align=right width="7%"><FONT face="Times New Roman" size=1>&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#151; </FONT></TD>
<TD vAlign=bottom align=right width="1%"></TD>
<TD vAlign=bottom align=right width="9%"><FONT face="Times New Roman" size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &#151; </FONT></TD>
<TD vAlign=bottom align=right width="1%"></TD>
<TD vAlign=bottom align=right width="6%"><FONT face="Times New Roman" size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &#151; </FONT></TD>
<TD vAlign=bottom align=right width="1%"></TD>
<TD vAlign=bottom align=right width="9%"><FONT face="Times New Roman" size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 38,000 </FONT></TD>
<TD vAlign=bottom align=right width="1%"></TD>
<TD vAlign=bottom align=right width="9%"><FONT face="Times New Roman" size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &#151; </FONT></TD>
<TD vAlign=bottom align=right width="1%"></TD>
<TD vAlign=bottom align=right width="9%"><FONT face="Times New Roman" size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &#151; </FONT></TD>
<TD vAlign=bottom align=right width="1%"></TD>
<TD vAlign=bottom align=right width="10%"><FONT face="Times New Roman" size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 38,000 </FONT></TD></TR>
<TR>
<TD vAlign=bottom width="35%"><FONT face="Times New Roman" size=1>Net income</FONT></TD>
<TD vAlign=bottom align=right width="7%"><FONT face="Times New Roman" size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#151; </FONT></TD>
<TD vAlign=bottom align=right width="1%"></TD>
<TD vAlign=bottom align=right width="9%"><FONT face="Times New Roman" size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &#151; </FONT></TD>
<TD vAlign=bottom align=right width="1%"></TD>
<TD vAlign=bottom align=right width="6%"><FONT face="Times New Roman" size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &#151; </FONT></TD>
<TD vAlign=bottom align=right width="1%"></TD>
<TD vAlign=bottom align=right width="9%"><FONT face="Times New Roman" size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &#151; </FONT></TD>
<TD vAlign=bottom align=right width="1%"></TD>
<TD vAlign=bottom align=right width="9%"><FONT face="Times New Roman" size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &#151; </FONT></TD>
<TD vAlign=bottom align=right width="1%"></TD>
<TD vAlign=bottom align=right width="9%"><FONT face="Times New Roman" size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 1,304,000 </FONT></TD>
<TD vAlign=bottom align=right width="1%"></TD>
<TD vAlign=bottom align=right width="10%"><FONT face="Times New Roman" size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 1,304,000 </FONT></TD></TR>
<TR>
<TD vAlign=bottom width="35%">&nbsp;</TD>
<TD vAlign=bottom align=right width="7%">
<HR noshade SIZE=1>
</TD>
<TD vAlign=bottom align=right width="1%"></TD>
<TD vAlign=bottom align=right width="9%">
<HR noshade SIZE=1>
</TD>
<TD vAlign=bottom align=right width="1%"></TD>
<TD vAlign=bottom align=right width="6%">
<HR noshade SIZE=1>
</TD>
<TD vAlign=bottom align=right width="1%"></TD>
<TD vAlign=bottom align=right width="9%">
<HR noshade SIZE=1>
</TD>
<TD vAlign=bottom align=right width="1%"></TD>
<TD vAlign=bottom align=right width="9%">
<HR noshade SIZE=1>
</TD>
<TD vAlign=bottom align=right width="1%"></TD>
<TD vAlign=bottom align=right width="9%">
<HR noshade SIZE=1>
</TD>
<TD vAlign=bottom align=right width="1%"></TD>
<TD vAlign=bottom align=right width="10%">
<HR noshade SIZE=1>
</TD></TR>
<TR>
<TD vAlign=bottom width="35%"><FONT face="Times New Roman" size=1>Balances at March 31, 2002</FONT></TD>
<TD vAlign=bottom align=right width="7%"><FONT face="Times New Roman" size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6,558 </FONT></TD>
<TD vAlign=bottom align=right width="1%"></TD>
<TD vAlign=bottom align=right width="9%"><FONT face="Times New Roman" size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 3,193,000 </FONT></TD>
<TD vAlign=bottom align=right width="1%"></TD>
<TD vAlign=bottom align=right width="6%"><FONT face="Times New Roman" size=1>&nbsp;&nbsp; 16,339,735 </FONT></TD>
<TD vAlign=bottom align=right width="1%"></TD>
<TD vAlign=bottom align=right width="9%"><FONT face="Times New Roman" size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 76,843,000 </FONT></TD>
<TD vAlign=bottom align=right width="1%"></TD>
<TD vAlign=bottom align=right width="9%"><FONT face="Times New Roman" size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &#151; </FONT></TD>
<TD vAlign=bottom align=right width="1%"></TD>
<TD vAlign=bottom align=right width="9%"><FONT face="Times New Roman" size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (61,884,000)</FONT></TD>
<TD vAlign=bottom align=right width="1%"></TD>
<TD vAlign=bottom align=right width="10%"><FONT face="Times New Roman" size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 18,152,000 </FONT></TD></TR>
<TR>
<TD vAlign=bottom width="35%"><FONT face="Times New Roman" size=1>Option exercises and related tax benefits</FONT></TD>
<TD vAlign=bottom align=right width="7%"><FONT face="Times New Roman" size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &#151; </FONT></TD>
<TD vAlign=bottom align=right width="1%"></TD>
<TD vAlign=bottom align=right width="9%"><FONT face="Times New Roman" size=1>&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#151; </FONT></TD>
<TD vAlign=bottom align=right width="1%"></TD>
<TD vAlign=bottom align=right width="6%"><FONT face="Times New Roman" size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 131,642 </FONT></TD>
<TD vAlign=bottom align=right width="1%"></TD>
<TD vAlign=bottom align=right width="9%"><FONT face="Times New Roman" size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 377,000 </FONT></TD>
<TD vAlign=bottom align=right width="1%"></TD>
<TD vAlign=bottom align=right width="9%"><FONT face="Times New Roman" size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &#151; </FONT></TD>
<TD vAlign=bottom align=right width="1%"></TD>
<TD vAlign=bottom align=right width="9%"><FONT face="Times New Roman" size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &#151; </FONT></TD>
<TD vAlign=bottom align=right width="1%"></TD>
<TD vAlign=bottom align=right width="10%"><FONT face="Times New Roman" size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 377,000 </FONT></TD></TR>
<TR>
<TD vAlign=bottom width="35%"><FONT face="Times New Roman" size=1>Accrued dividends on Series D convertible preferred stock</FONT></TD>
<TD vAlign=bottom align=right width="7%"><FONT face="Times New Roman" size=1>&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#151; </FONT></TD>
<TD vAlign=bottom align=right width="1%"></TD>
<TD vAlign=bottom align=right width="9%"><FONT face="Times New Roman" size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &#151; </FONT></TD>
<TD vAlign=bottom align=right width="1%"></TD>
<TD vAlign=bottom align=right width="6%"><FONT face="Times New Roman" size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &#151; </FONT></TD>
<TD vAlign=bottom align=right width="1%"></TD>
<TD vAlign=bottom align=right width="9%"><FONT face="Times New Roman" size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &#151; </FONT></TD>
<TD vAlign=bottom align=right width="1%"></TD>
<TD vAlign=bottom align=right width="9%"><FONT face="Times New Roman" size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &#151; </FONT></TD>
<TD vAlign=bottom align=right width="1%"></TD>
<TD vAlign=bottom align=right width="9%"><FONT face="Times New Roman" size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (456,000)</FONT></TD>
<TD vAlign=bottom align=right width="1%"></TD>
<TD vAlign=bottom align=right width="10%"><FONT face="Times New Roman" size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (456,000)</FONT></TD></TR>
<TR>
<TD vAlign=bottom width="35%"><FONT face="Times New Roman" size=1>Accrued dividends on Series E convertible preferred stock</FONT></TD>
<TD vAlign=bottom align=right width="7%"><FONT face="Times New Roman" size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &#151; </FONT></TD>
<TD vAlign=bottom align=right width="1%"></TD>
<TD vAlign=bottom align=right width="9%"><FONT face="Times New Roman" size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &#151; </FONT></TD>
<TD vAlign=bottom align=right width="1%"></TD>
<TD vAlign=bottom align=right width="6%"><FONT face="Times New Roman" size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &#151; </FONT></TD>
<TD vAlign=bottom align=right width="1%"></TD>
<TD vAlign=bottom align=right width="9%"><FONT face="Times New Roman" size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &#151; </FONT></TD>
<TD vAlign=bottom align=right width="1%"></TD>
<TD vAlign=bottom align=right width="9%"><FONT face="Times New Roman" size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &#151; </FONT></TD>
<TD vAlign=bottom align=right width="1%"></TD>
<TD vAlign=bottom align=right width="9%"><FONT face="Times New Roman" size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (409,000)</FONT></TD>
<TD vAlign=bottom align=right width="1%"></TD>
<TD vAlign=bottom align=right width="10%"><FONT face="Times New Roman" size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (409,000)</FONT></TD></TR>
<TR>
<TD vAlign=bottom width="35%"><FONT face="Times New Roman" size=1>Common stock issued for dividends payable</FONT></TD>
<TD vAlign=bottom align=right width="7%"><FONT face="Times New Roman" size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &#151; </FONT></TD>
<TD vAlign=bottom align=right width="1%"></TD>
<TD vAlign=bottom align=right width="9%"><FONT face="Times New Roman" size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &#151; </FONT></TD>
<TD vAlign=bottom align=right width="1%"></TD>
<TD vAlign=bottom align=right width="6%"><FONT face="Times New Roman" size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 35,654 </FONT></TD>
<TD vAlign=bottom align=right width="1%"></TD>
<TD vAlign=bottom align=right width="9%"><FONT face="Times New Roman" size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 230,000 </FONT></TD>
<TD vAlign=bottom align=right width="1%"></TD>
<TD vAlign=bottom align=right width="9%"><FONT face="Times New Roman" size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &#151; </FONT></TD>
<TD vAlign=bottom align=right width="1%"></TD>
<TD vAlign=bottom align=right width="9%"><FONT face="Times New Roman" size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &#151; </FONT></TD>
<TD vAlign=bottom align=right width="1%"></TD>
<TD vAlign=bottom align=right width="10%"><FONT face="Times New Roman" size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;230,000 </FONT></TD></TR>
<TR>
<TD vAlign=bottom width="35%"><FONT face="Times New Roman" size=1>Adjustment on issuance cost for Series D convertible preferred stock</FONT></TD>
<TD vAlign=bottom align=right width="7%"><FONT face="Times New Roman" size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &#151; </FONT></TD>
<TD vAlign=bottom align=right width="1%"></TD>
<TD vAlign=bottom align=right width="9%"><FONT face="Times New Roman" size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &#151; </FONT></TD>
<TD vAlign=bottom align=right width="1%"></TD>
<TD vAlign=bottom align=right width="6%"><FONT face="Times New Roman" size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &#151; </FONT></TD>
<TD vAlign=bottom align=right width="1%"></TD>
<TD vAlign=bottom align=right width="9%"><FONT face="Times New Roman" size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (29,000)</FONT></TD>
<TD vAlign=bottom align=right width="1%"></TD>
<TD vAlign=bottom align=right width="9%"><FONT face="Times New Roman" size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &#151; </FONT></TD>
<TD vAlign=bottom align=right width="1%"></TD>
<TD vAlign=bottom align=right width="9%"><FONT face="Times New Roman" size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#151; </FONT></TD>
<TD vAlign=bottom align=right width="1%"></TD>
<TD vAlign=bottom align=right width="10%"><FONT face="Times New Roman" size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (29,000)</FONT></TD></TR>
<TR>
<TD vAlign=bottom width="35%"><FONT face="Times New Roman" size=1>Conversion of Series D convertible preferred stock into common stock</FONT></TD>
<TD vAlign=bottom align=right width="7%"><FONT face="Times New Roman" size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (50)</FONT></TD>
<TD vAlign=bottom align=right width="1%"></TD>
<TD vAlign=bottom align=right width="9%"><FONT face="Times New Roman" size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (50,000)</FONT></TD>
<TD vAlign=bottom align=right width="1%"></TD>
<TD vAlign=bottom align=right width="6%"><FONT face="Times New Roman" size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 7,142 </FONT></TD>
<TD vAlign=bottom align=right width="1%"></TD>
<TD vAlign=bottom align=right width="9%"><FONT face="Times New Roman" size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 50,000 </FONT></TD>
<TD vAlign=bottom align=right width="1%"></TD>
<TD vAlign=bottom align=right width="9%"><FONT face="Times New Roman" size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#151; </FONT></TD>
<TD vAlign=bottom align=right width="1%"></TD>
<TD vAlign=bottom align=right width="9%"><FONT face="Times New Roman" size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &#151; </FONT></TD>
<TD vAlign=bottom align=right width="1%"></TD>
<TD vAlign=bottom align=right width="10%"><FONT face="Times New Roman" size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &#151; </FONT></TD></TR>
<TR>
<TD vAlign=bottom width="35%"><FONT face="Times New Roman" size=1>Conversion of Series E convertible preferred stock into common stock</FONT></TD>
<TD vAlign=bottom align=right width="7%"><FONT face="Times New Roman" size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &#151; </FONT></TD>
<TD vAlign=bottom align=right width="1%"></TD>
<TD vAlign=bottom align=right width="9%"><FONT face="Times New Roman" size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &#151; </FONT></TD>
<TD vAlign=bottom align=right width="1%"></TD>
<TD vAlign=bottom align=right width="6%"><FONT face="Times New Roman" size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 276,922 </FONT></TD>
<TD vAlign=bottom align=right width="1%"></TD>
<TD vAlign=bottom align=right width="9%"><FONT face="Times New Roman" size=1>&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1,800,000 </FONT></TD>
<TD vAlign=bottom align=right width="1%"></TD>
<TD vAlign=bottom align=right width="9%"><FONT face="Times New Roman" size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &#151; </FONT></TD>
<TD vAlign=bottom align=right width="1%"></TD>
<TD vAlign=bottom align=right width="9%"><FONT face="Times New Roman" size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &#151; </FONT></TD>
<TD vAlign=bottom align=right width="1%"></TD>
<TD vAlign=bottom align=right width="10%"><FONT face="Times New Roman" size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 1,800,000 </FONT></TD></TR>
<TR>
<TD vAlign=bottom width="35%"><FONT face="Times New Roman" size=1>Amounts related to Series E convertible preferred stock issuance:</FONT></TD>
<TD vAlign=bottom align=right width="7%"><FONT face="Times New Roman" size=1>&nbsp;</FONT></TD>
<TD vAlign=bottom align=right width="1%"></TD>
<TD vAlign=bottom align=right width="9%"><FONT face="Times New Roman" size=1>&nbsp;</FONT></TD>
<TD vAlign=bottom align=right width="1%"></TD>
<TD vAlign=bottom align=right width="6%"><FONT face="Times New Roman" size=1>&nbsp;</FONT></TD>
<TD vAlign=bottom align=right width="1%"></TD>
<TD vAlign=bottom align=right width="9%"><FONT face="Times New Roman" size=1>&nbsp;</FONT></TD>
<TD vAlign=bottom align=right width="1%"></TD>
<TD vAlign=bottom align=right width="9%"><FONT face="Times New Roman" size=1>&nbsp;</FONT></TD>
<TD vAlign=bottom align=right width="1%"></TD>
<TD vAlign=bottom align=right width="9%"><FONT face="Times New Roman" size=1>&nbsp;</FONT></TD>
<TD vAlign=bottom align=right width="1%"></TD>
<TD vAlign=bottom align=right width="10%"><FONT face="Times New Roman" size=1>&nbsp;</FONT></TD></TR>
<TR>
<TD vAlign=bottom width="35%"><FONT face="Times New Roman" size=1>&nbsp;&nbsp;&nbsp;&nbsp; Proceeds allocated to common <BR>&nbsp;&nbsp;&nbsp;&nbsp; stock warrants</FONT></TD>
<TD vAlign=bottom align=right width="7%"><FONT face="Times New Roman" size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &#151; </FONT></TD>
<TD vAlign=bottom align=right width="1%"></TD>
<TD vAlign=bottom align=right width="9%"><FONT face="Times New Roman" size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &#151; </FONT></TD>
<TD vAlign=bottom align=right width="1%"></TD>
<TD vAlign=bottom align=right width="6%"><FONT face="Times New Roman" size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &#151; </FONT></TD>
<TD vAlign=bottom align=right width="1%"></TD>
<TD vAlign=bottom align=right width="9%"><FONT face="Times New Roman" size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 590,000 </FONT></TD>
<TD vAlign=bottom align=right width="1%"></TD>
<TD vAlign=bottom align=right width="9%"><FONT face="Times New Roman" size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &#151; </FONT></TD>
<TD vAlign=bottom align=right width="1%"></TD>
<TD vAlign=bottom align=right width="9%"><FONT face="Times New Roman" size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &#151; </FONT></TD>
<TD vAlign=bottom align=right width="1%"></TD>
<TD vAlign=bottom align=right width="10%"><FONT face="Times New Roman" size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 590,000 </FONT></TD></TR>
<TR>
<TD vAlign=bottom width="35%"><FONT face="Times New Roman" size=1>&nbsp;&nbsp;&nbsp;&nbsp; Non cash issuance costs-<BR>&nbsp;&nbsp;&nbsp;&nbsp; common stock warrants <BR>&nbsp;&nbsp;&nbsp;&nbsp; issued to advisors</FONT></TD>
<TD vAlign=bottom align=right width="7%"><FONT face="Times New Roman" size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &#151; </FONT></TD>
<TD vAlign=bottom align=right width="1%"></TD>
<TD vAlign=bottom align=right width="9%"><FONT face="Times New Roman" size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &#151; </FONT></TD>
<TD vAlign=bottom align=right width="1%"></TD>
<TD vAlign=bottom align=right width="6%"><FONT face="Times New Roman" size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &#151; </FONT></TD>
<TD vAlign=bottom align=right width="1%"></TD>
<TD vAlign=bottom align=right width="9%"><FONT face="Times New Roman" size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 216,000 </FONT></TD>
<TD vAlign=bottom align=right width="1%"></TD>
<TD vAlign=bottom align=right width="9%"><FONT face="Times New Roman" size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &#151; </FONT></TD>
<TD vAlign=bottom align=right width="1%"></TD>
<TD vAlign=bottom align=right width="9%"><FONT face="Times New Roman" size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &#151; </FONT></TD>
<TD vAlign=bottom align=right width="1%"></TD>
<TD vAlign=bottom align=right width="10%"><FONT face="Times New Roman" size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;216,000 </FONT></TD></TR>
<TR>
<TD vAlign=bottom width="35%"><FONT face="Times New Roman" size=1>&nbsp;&nbsp;&nbsp;&nbsp; Common stock issued related to <BR>&nbsp;&nbsp;&nbsp;&nbsp; issuance costs</FONT></TD>
<TD vAlign=bottom align=right width="7%"><FONT face="Times New Roman" size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &#151; </FONT></TD>
<TD vAlign=bottom align=right width="1%"></TD>
<TD vAlign=bottom align=right width="9%"><FONT face="Times New Roman" size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &#151; </FONT></TD>
<TD vAlign=bottom align=right width="1%"></TD>
<TD vAlign=bottom align=right width="6%"><FONT face="Times New Roman" size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 25,000 </FONT></TD>
<TD vAlign=bottom align=right width="1%"></TD>
<TD vAlign=bottom align=right width="9%"><FONT face="Times New Roman" size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 145,000 </FONT></TD>
<TD vAlign=bottom align=right width="1%"></TD>
<TD vAlign=bottom align=right width="9%"><FONT face="Times New Roman" size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &#151; </FONT></TD>
<TD vAlign=bottom align=right width="1%"></TD>
<TD vAlign=bottom align=right width="9%"><FONT face="Times New Roman" size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#151; </FONT></TD>
<TD vAlign=bottom align=right width="1%"></TD>
<TD vAlign=bottom align=right width="10%"><FONT face="Times New Roman" size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 145,000 </FONT></TD></TR>
<TR>
<TD vAlign=bottom width="35%"><FONT face="Times New Roman" size=1>&nbsp;&nbsp;&nbsp;&nbsp; Beneficial conversion feature,<BR>&nbsp;&nbsp;&nbsp;&nbsp; net of deemed dividend <BR>&nbsp;&nbsp;&nbsp;&nbsp; and accretion</FONT></TD>
<TD vAlign=bottom align=right width="7%"><FONT face="Times New Roman" size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &#151; </FONT></TD>
<TD vAlign=bottom align=right width="1%"></TD>
<TD vAlign=bottom align=right width="9%"><FONT face="Times New Roman" size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &#151; </FONT></TD>
<TD vAlign=bottom align=right width="1%"></TD>
<TD vAlign=bottom align=right width="6%"><FONT face="Times New Roman" size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &#151; </FONT></TD>
<TD vAlign=bottom align=right width="1%"></TD>
<TD vAlign=bottom align=right width="9%"><FONT face="Times New Roman" size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 370,000 </FONT></TD>
<TD vAlign=bottom align=right width="1%"></TD>
<TD vAlign=bottom align=right width="9%"><FONT face="Times New Roman" size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#151; </FONT></TD>
<TD vAlign=bottom align=right width="1%"></TD>
<TD vAlign=bottom align=right width="9%"><FONT face="Times New Roman" size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (370,000)</FONT></TD>
<TD vAlign=bottom align=right width="1%"></TD>
<TD vAlign=bottom align=right width="10%"><FONT face="Times New Roman" size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &#151; </FONT></TD></TR>
<TR>
<TD vAlign=bottom width="35%"><FONT face="Times New Roman" size=1>Compensation expense for non-employee options</FONT></TD>
<TD vAlign=bottom align=right width="7%"><FONT face="Times New Roman" size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &#151; </FONT></TD>
<TD vAlign=bottom align=right width="1%"></TD>
<TD vAlign=bottom align=right width="9%"><FONT face="Times New Roman" size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &#151; </FONT></TD>
<TD vAlign=bottom align=right width="1%"></TD>
<TD vAlign=bottom align=right width="6%"><FONT face="Times New Roman" size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &#151; </FONT></TD>
<TD vAlign=bottom align=right width="1%"></TD>
<TD vAlign=bottom align=right width="9%"><FONT face="Times New Roman" size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;16,000 </FONT></TD>
<TD vAlign=bottom align=right width="1%"></TD>
<TD vAlign=bottom align=right width="9%"><FONT face="Times New Roman" size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &#151; </FONT></TD>
<TD vAlign=bottom align=right width="1%"></TD>
<TD vAlign=bottom align=right width="9%"><FONT face="Times New Roman" size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &#151; </FONT></TD>
<TD vAlign=bottom align=right width="1%"></TD>
<TD vAlign=bottom align=right width="10%"><FONT face="Times New Roman" size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 16,000 </FONT></TD></TR>
<TR>
<TD vAlign=bottom width="35%"><FONT face="Times New Roman" size=1>Net income</FONT></TD>
<TD vAlign=bottom align=right width="7%"><FONT face="Times New Roman" size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &#151; </FONT></TD>
<TD vAlign=bottom align=right width="1%"></TD>
<TD vAlign=bottom align=right width="9%"><FONT face="Times New Roman" size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &#151; </FONT></TD>
<TD vAlign=bottom align=right width="1%"></TD>
<TD vAlign=bottom align=right width="6%"><FONT face="Times New Roman" size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &#151; </FONT></TD>
<TD vAlign=bottom align=right width="1%"></TD>
<TD vAlign=bottom align=right width="9%"><FONT face="Times New Roman" size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#151; </FONT></TD>
<TD vAlign=bottom align=right width="1%"></TD>
<TD vAlign=bottom align=right width="9%"><FONT face="Times New Roman" size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &#151; </FONT></TD>
<TD vAlign=bottom align=right width="1%"></TD>
<TD vAlign=bottom align=right width="9%"><FONT face="Times New Roman" size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 1,636,000 </FONT></TD>
<TD vAlign=bottom align=right width="1%"></TD>
<TD vAlign=bottom align=right width="10%"><FONT face="Times New Roman" size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 1,636,000 </FONT></TD></TR>
<TR>
<TD vAlign=bottom width="35%">&nbsp;</TD>
<TD vAlign=bottom align=right width="7%">
<HR noshade SIZE=1>
</TD>
<TD vAlign=bottom align=right width="1%"></TD>
<TD vAlign=bottom align=right width="9%">
<HR noshade SIZE=1>
</TD>
<TD vAlign=bottom align=right width="1%"></TD>
<TD vAlign=bottom align=right width="6%">
<HR noshade SIZE=1>
</TD>
<TD vAlign=bottom align=right width="1%"></TD>
<TD vAlign=bottom align=right width="9%">
<HR noshade SIZE=1>
</TD>
<TD vAlign=bottom align=right width="1%"></TD>
<TD vAlign=bottom align=right width="9%">
<HR noshade SIZE=1>
</TD>
<TD vAlign=bottom align=right width="1%"></TD>
<TD vAlign=bottom align=right width="9%">
<HR noshade SIZE=1>
</TD>
<TD vAlign=bottom align=right width="1%"></TD>
<TD vAlign=bottom align=right width="10%">
<HR noshade SIZE=1>
</TD></TR>
<TR>
<TD vAlign=bottom width="35%"><FONT face="Times New Roman" size=1>Balances at March 31, 2003</FONT></TD>
<TD vAlign=bottom align=right width="7%"><FONT face="Times New Roman" size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 6,508 </FONT></TD>
<TD vAlign=bottom align=right width="1%"></TD>
<TD vAlign=bottom align=right width="9%"><FONT face="Times New Roman" size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 3,143,000 </FONT></TD>
<TD vAlign=bottom align=right width="1%"></TD>
<TD vAlign=bottom align=right width="6%"><FONT face="Times New Roman" size=1>&nbsp;&nbsp;&nbsp; 16,816,095 </FONT></TD>
<TD vAlign=bottom align=right width="1%"></TD>
<TD vAlign=bottom align=right width="9%"><FONT face="Times New Roman" size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 80,608,000 </FONT></TD>
<TD vAlign=bottom align=right width="1%"></TD>
<TD vAlign=bottom align=right width="9%"><FONT face="Times New Roman" size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#151; </FONT></TD>
<TD vAlign=bottom align=right width="1%"></TD>
<TD vAlign=bottom align=right width="9%"><FONT face="Times New Roman" size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (61,483,000)</FONT></TD>
<TD vAlign=bottom align=right width="1%"></TD>
<TD vAlign=bottom align=right width="10%"><FONT face="Times New Roman" size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 22,268,000 </FONT></TD></TR>
<TR>
<TD vAlign=bottom width="35%"><FONT face="Times New Roman" size=1>Option exercises and related tax benefits</FONT></TD>
<TD vAlign=bottom align=right width="7%"><FONT face="Times New Roman" size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &#151; </FONT></TD>
<TD vAlign=bottom align=right width="1%"></TD>
<TD vAlign=bottom align=right width="9%"><FONT face="Times New Roman" size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &#151; </FONT></TD>
<TD vAlign=bottom align=right width="1%"></TD>
<TD vAlign=bottom align=right width="6%"><FONT face="Times New Roman" size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 281,640 </FONT></TD>
<TD vAlign=bottom align=right width="1%"></TD>
<TD vAlign=bottom align=right width="9%"><FONT face="Times New Roman" size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 3,122,000 </FONT></TD>
<TD vAlign=bottom align=right width="1%"></TD>
<TD vAlign=bottom align=right width="9%"><FONT face="Times New Roman" size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#151; </FONT></TD>
<TD vAlign=bottom align=right width="1%"></TD>
<TD vAlign=bottom align=right width="9%"><FONT face="Times New Roman" size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &#151; </FONT></TD>
<TD vAlign=bottom align=right width="1%"></TD>
<TD vAlign=bottom align=right width="10%"><FONT face="Times New Roman" size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 3,122,000 </FONT></TD></TR>
<TR>
<TD vAlign=bottom width="35%"><FONT face="Times New Roman" size=1>Warrant exercises</FONT></TD>
<TD vAlign=bottom align=right width="7%"><FONT face="Times New Roman" size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &#151; </FONT></TD>
<TD vAlign=bottom align=right width="1%"></TD>
<TD vAlign=bottom align=right width="9%"><FONT face="Times New Roman" size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &#151; </FONT></TD>
<TD vAlign=bottom align=right width="1%"></TD>
<TD vAlign=bottom align=right width="6%"><FONT face="Times New Roman" size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 497,498 </FONT></TD>
<TD vAlign=bottom align=right width="1%"></TD>
<TD vAlign=bottom align=right width="9%"><FONT face="Times New Roman" size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 1,569,000 </FONT></TD>
<TD vAlign=bottom align=right width="1%"></TD>
<TD vAlign=bottom align=right width="9%"><FONT face="Times New Roman" size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &#151; </FONT></TD>
<TD vAlign=bottom align=right width="1%"></TD>
<TD vAlign=bottom align=right width="9%"><FONT face="Times New Roman" size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#151; </FONT></TD>
<TD vAlign=bottom align=right width="1%"></TD>
<TD vAlign=bottom align=right width="10%"><FONT face="Times New Roman" size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 1,569,000 </FONT></TD></TR>
<TR>
<TD vAlign=bottom width="35%"><FONT face="Times New Roman" size=1>Accrued dividends on Series D convertible preferred stock</FONT></TD>
<TD vAlign=bottom align=right width="7%"><FONT face="Times New Roman" size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &#151; </FONT></TD>
<TD vAlign=bottom align=right width="1%"></TD>
<TD vAlign=bottom align=right width="9%"><FONT face="Times New Roman" size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &#151; </FONT></TD>
<TD vAlign=bottom align=right width="1%"></TD>
<TD vAlign=bottom align=right width="6%"><FONT face="Times New Roman" size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &#151; </FONT></TD>
<TD vAlign=bottom align=right width="1%"></TD>
<TD vAlign=bottom align=right width="9%"><FONT face="Times New Roman" size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &#151; </FONT></TD>
<TD vAlign=bottom align=right width="1%"></TD>
<TD vAlign=bottom align=right width="9%"><FONT face="Times New Roman" size=1>&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#151; </FONT></TD>
<TD vAlign=bottom align=right width="1%"></TD>
<TD vAlign=bottom align=right width="9%"><FONT face="Times New Roman" size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (238,000)</FONT></TD>
<TD vAlign=bottom align=right width="1%"></TD>
<TD vAlign=bottom align=right width="10%"><FONT face="Times New Roman" size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (238,000)</FONT></TD></TR>
<TR>
<TD vAlign=bottom width="35%"><FONT face="Times New Roman" size=1>Accrued dividends on Series E convertible preferred stock</FONT></TD>
<TD vAlign=bottom align=right width="7%"><FONT face="Times New Roman" size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &#151; </FONT></TD>
<TD vAlign=bottom align=right width="1%"></TD>
<TD vAlign=bottom align=right width="9%"><FONT face="Times New Roman" size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &#151; </FONT></TD>
<TD vAlign=bottom align=right width="1%"></TD>
<TD vAlign=bottom align=right width="6%"><FONT face="Times New Roman" size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &#151; </FONT></TD>
<TD vAlign=bottom align=right width="1%"></TD>
<TD vAlign=bottom align=right width="9%"><FONT face="Times New Roman" size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#151; </FONT></TD>
<TD vAlign=bottom align=right width="1%"></TD>
<TD vAlign=bottom align=right width="9%"><FONT face="Times New Roman" size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &#151; </FONT></TD>
<TD vAlign=bottom align=right width="1%"></TD>
<TD vAlign=bottom align=right width="9%"><FONT face="Times New Roman" size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (181,000)</FONT></TD>
<TD vAlign=bottom align=right width="1%"></TD>
<TD vAlign=bottom align=right width="10%"><FONT face="Times New Roman" size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (181,000)</FONT></TD></TR>
<TR>
<TD vAlign=bottom width="35%"><FONT face="Times New Roman" size=1>Common stock issued for dividends payable</FONT></TD>
<TD vAlign=bottom align=right width="7%"><FONT face="Times New Roman" size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &#151; </FONT></TD>
<TD vAlign=bottom align=right width="1%"></TD>
<TD vAlign=bottom align=right width="9%"><FONT face="Times New Roman" size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &#151; </FONT></TD>
<TD vAlign=bottom align=right width="1%"></TD>
<TD vAlign=bottom align=right width="6%"><FONT face="Times New Roman" size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 138,398 </FONT></TD>
<TD vAlign=bottom align=right width="1%"></TD>
<TD vAlign=bottom align=right width="9%"><FONT face="Times New Roman" size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 799,000 </FONT></TD>
<TD vAlign=bottom align=right width="1%"></TD>
<TD vAlign=bottom align=right width="9%"><FONT face="Times New Roman" size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &#151; </FONT></TD>
<TD vAlign=bottom align=right width="1%"></TD>
<TD vAlign=bottom align=right width="9%"><FONT face="Times New Roman" size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &#151; </FONT></TD>
<TD vAlign=bottom align=right width="1%"></TD>
<TD vAlign=bottom align=right width="10%"><FONT face="Times New Roman" size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 799,000 </FONT></TD></TR>
<TR>
<TD vAlign=bottom width="35%"><FONT face="Times New Roman" size=1>Conversion of Series D convertible preferred stock into common stock</FONT></TD>
<TD vAlign=bottom align=right width="7%"><FONT face="Times New Roman" size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (6,508)</FONT></TD>
<TD vAlign=bottom align=right width="1%"></TD>
<TD vAlign=bottom align=right width="9%"><FONT face="Times New Roman" size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (3,143,000)</FONT></TD>
<TD vAlign=bottom align=right width="1%"></TD>
<TD vAlign=bottom align=right width="6%"><FONT face="Times New Roman" size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 929,699 </FONT></TD>
<TD vAlign=bottom align=right width="1%"></TD>
<TD vAlign=bottom align=right width="9%"><FONT face="Times New Roman" size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 3,143,000 </FONT></TD>
<TD vAlign=bottom align=right width="1%"></TD>
<TD vAlign=bottom align=right width="9%"><FONT face="Times New Roman" size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &#151; </FONT></TD>
<TD vAlign=bottom align=right width="1%"></TD>
<TD vAlign=bottom align=right width="9%"><FONT face="Times New Roman" size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &#151; </FONT></TD>
<TD vAlign=bottom align=right width="1%"></TD>
<TD vAlign=bottom align=right width="10%"><FONT face="Times New Roman" size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &#151; </FONT></TD></TR>
<TR>
<TD vAlign=bottom width="35%"><FONT face="Times New Roman" size=1>Conversion of Series E convertible preferred stock into common stock</FONT></TD>
<TD vAlign=bottom align=right width="7%"><FONT face="Times New Roman" size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#151; </FONT></TD>
<TD vAlign=bottom align=right width="1%"></TD>
<TD vAlign=bottom align=right width="9%"><FONT face="Times New Roman" size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &#151; </FONT></TD>
<TD vAlign=bottom align=right width="1%"></TD>
<TD vAlign=bottom align=right width="6%"><FONT face="Times New Roman" size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 856,907 </FONT></TD>
<TD vAlign=bottom align=right width="1%"></TD>
<TD vAlign=bottom align=right width="9%"><FONT face="Times New Roman" size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 3,176,000 </FONT></TD>
<TD vAlign=bottom align=right width="1%"></TD>
<TD vAlign=bottom align=right width="9%"><FONT face="Times New Roman" size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &#151; </FONT></TD>
<TD vAlign=bottom align=right width="1%"></TD>
<TD vAlign=bottom align=right width="9%"><FONT face="Times New Roman" size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &#151; </FONT></TD>
<TD vAlign=bottom align=right width="1%"></TD>
<TD vAlign=bottom align=right width="10%"><FONT face="Times New Roman" size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 3,176,000 </FONT></TD></TR>
<TR>
<TD vAlign=bottom width="35%"><FONT face="Times New Roman" size=1>Compensation expense for non-employee options</FONT></TD>
<TD vAlign=bottom align=right width="7%"><FONT face="Times New Roman" size=1>&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#151; </FONT></TD>
<TD vAlign=bottom align=right width="1%"></TD>
<TD vAlign=bottom align=right width="9%"><FONT face="Times New Roman" size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &#151; </FONT></TD>
<TD vAlign=bottom align=right width="1%"></TD>
<TD vAlign=bottom align=right width="6%"><FONT face="Times New Roman" size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &#151; </FONT></TD>
<TD vAlign=bottom align=right width="1%"></TD>
<TD vAlign=bottom align=right width="9%"><FONT face="Times New Roman" size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 24,000 </FONT></TD>
<TD vAlign=bottom align=right width="1%"></TD>
<TD vAlign=bottom align=right width="9%"><FONT face="Times New Roman" size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &#151; </FONT></TD>
<TD vAlign=bottom align=right width="1%"></TD>
<TD vAlign=bottom align=right width="9%"><FONT face="Times New Roman" size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &#151; </FONT></TD>
<TD vAlign=bottom align=right width="1%"></TD>
<TD vAlign=bottom align=right width="10%"><FONT face="Times New Roman" size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 24,000 </FONT></TD></TR>
<TR>
<TD vAlign=bottom width="35%"><FONT face="Times New Roman" size=1>Net income</FONT></TD>
<TD vAlign=bottom align=right width="7%"><FONT face="Times New Roman" size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#151; </FONT></TD>
<TD vAlign=bottom align=right width="1%"></TD>
<TD vAlign=bottom align=right width="9%"><FONT face="Times New Roman" size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &#151; </FONT></TD>
<TD vAlign=bottom align=right width="1%"></TD>
<TD vAlign=bottom align=right width="6%"><FONT face="Times New Roman" size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &#151; </FONT></TD>
<TD vAlign=bottom align=right width="1%"></TD>
<TD vAlign=bottom align=right width="9%"><FONT face="Times New Roman" size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &#151; </FONT></TD>
<TD vAlign=bottom align=right width="1%"></TD>
<TD vAlign=bottom align=right width="9%"><FONT face="Times New Roman" size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &#151; </FONT></TD>
<TD vAlign=bottom align=right width="1%"></TD>
<TD vAlign=bottom align=right width="9%"><FONT face="Times New Roman" size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 24,033,000 </FONT></TD>
<TD vAlign=bottom align=right width="1%"></TD>
<TD vAlign=bottom align=right width="10%"><FONT face="Times New Roman" size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 24,033,000 </FONT></TD></TR>
<TR>
<TD vAlign=bottom width="35%">&nbsp;</TD>
<TD vAlign=bottom align=right width="7%">
<HR noshade SIZE=1>
</TD>
<TD vAlign=bottom align=right width="1%"></TD>
<TD vAlign=bottom align=right width="9%">
<HR noshade SIZE=1>
</TD>
<TD vAlign=bottom align=right width="1%"></TD>
<TD vAlign=bottom align=right width="6%">
<HR noshade SIZE=1>
</TD>
<TD vAlign=bottom align=right width="1%"></TD>
<TD vAlign=bottom align=right width="9%">
<HR noshade SIZE=1>
</TD>
<TD vAlign=bottom align=right width="1%"></TD>
<TD vAlign=bottom align=right width="9%">
<HR noshade SIZE=1>
</TD>
<TD vAlign=bottom align=right width="1%"></TD>
<TD vAlign=bottom align=right width="9%">
<HR noshade SIZE=1>
</TD>
<TD vAlign=bottom align=right width="1%"></TD>
<TD vAlign=bottom align=right width="10%">
<HR noshade SIZE=1>
</TD></TR>
<TR>
<TD vAlign=bottom width="35%"><FONT face="Times New Roman" size=1>Balances at March 31, 2004</FONT></TD>
<TD vAlign=bottom align=right width="7%"><FONT face="Times New Roman" size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#151; </FONT></TD>
<TD vAlign=bottom align=right width="1%"></TD>
<TD vAlign=bottom align=right width="9%"><FONT face="Times New Roman" size=1>&nbsp;$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &#151; </FONT></TD>
<TD vAlign=bottom align=right width="1%"></TD>
<TD vAlign=bottom align=right width="6%"><FONT face="Times New Roman" size=1>&nbsp;&nbsp; 19,520,237 </FONT></TD>
<TD vAlign=bottom align=right width="1%"></TD>
<TD vAlign=bottom align=right width="9%"><FONT face="Times New Roman" size=1>&nbsp;$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 92,441,000 </FONT></TD>
<TD vAlign=bottom align=right width="1%"></TD>
<TD vAlign=bottom align=right width="9%"><FONT face="Times New Roman" size=1>&nbsp;$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &#151; </FONT></TD>
<TD vAlign=bottom align=right width="1%"></TD>
<TD vAlign=bottom align=right width="9%"><FONT face="Times New Roman" size=1>&nbsp;$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (37,869,000)</FONT></TD>
<TD vAlign=bottom align=right width="1%"></TD>
<TD vAlign=bottom align=right width="10%"><FONT face="Times New Roman" size=1>&nbsp;$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 54,572,000 </FONT></TD></TR>
<TR>
<TD vAlign=bottom width="35%">&nbsp;</TD>
<TD vAlign=bottom align=right width="7%">
<HR noshade>
</TD>
<TD vAlign=bottom align=right width="1%"></TD>
<TD vAlign=bottom align=right width="9%">
<HR noshade>
</TD>
<TD vAlign=bottom align=right width="1%"></TD>
<TD vAlign=bottom align=right width="6%">
<HR noshade>
</TD>
<TD vAlign=bottom align=right width="1%"></TD>
<TD vAlign=bottom align=right width="9%">
<HR noshade>
</TD>
<TD vAlign=bottom align=right width="1%"></TD>
<TD vAlign=bottom align=right width="9%">
<HR noshade>
</TD>
<TD vAlign=bottom align=right width="1%"></TD>
<TD vAlign=bottom align=right width="9%">
<HR noshade>
</TD>
<TD vAlign=bottom align=right width="1%"></TD>
<TD vAlign=bottom align=right width="10%">
<HR noshade>
</TD></TR>
<TR>
<TD vAlign=bottom width="35%"><FONT face="Times New Roman" size=1>&nbsp;</FONT></TD>
<TD vAlign=bottom align=right width="7%"><FONT face="Times New Roman" size=1>&nbsp;</FONT></TD>
<TD vAlign=bottom align=right width="1%"></TD>
<TD vAlign=bottom align=right width="9%"><FONT face="Times New Roman" size=1>&nbsp;</FONT></TD>
<TD vAlign=bottom align=right width="1%"></TD>
<TD vAlign=bottom align=right width="6%"><FONT face="Times New Roman" size=1>&nbsp;</FONT></TD>
<TD vAlign=bottom align=right width="1%"></TD>
<TD vAlign=bottom align=right width="9%"><FONT face="Times New Roman" size=1>&nbsp;</FONT></TD>
<TD vAlign=bottom align=right width="1%"></TD>
<TD vAlign=bottom align=right width="9%"><FONT face="Times New Roman" size=1>&nbsp;</FONT></TD>
<TD vAlign=bottom align=right width="1%"></TD>
<TD vAlign=bottom align=right width="9%"><FONT face="Times New Roman" size=1>&nbsp;</FONT></TD>
<TD vAlign=bottom align=right width="1%"></TD>
<TD vAlign=bottom align=right width="10%"><FONT face="Times New Roman" size=1>&nbsp;</FONT></TD></TR>
<TR>
<TD vAlign=bottom width="35%"><FONT face="Times New Roman" size=1>&nbsp;</FONT></TD>
<TD vAlign=bottom align=right width="7%"><FONT face="Times New Roman" size=1>&nbsp;</FONT></TD>
<TD vAlign=bottom align=right width="1%"></TD>
<TD vAlign=bottom align=right width="9%"><FONT face="Times New Roman" size=1>&nbsp;</FONT></TD>
<TD vAlign=bottom align=right width="1%"></TD>
<TD vAlign=bottom align=right width="6%"><FONT face="Times New Roman" size=1>&nbsp;</FONT></TD>
<TD vAlign=bottom align=right width="1%"></TD>
<TD vAlign=bottom align=right width="9%"><FONT face="Times New Roman" size=1>&nbsp;</FONT></TD>
<TD vAlign=bottom align=right width="1%"></TD>
<TD vAlign=bottom align=right width="9%"><FONT face="Times New Roman" size=1>&nbsp;</FONT></TD>
<TD vAlign=bottom align=right width="1%"></TD>
<TD vAlign=bottom align=right width="9%"><FONT face="Times New Roman" size=1>&nbsp;</FONT></TD>
<TD vAlign=bottom align=right width="1%"></TD>
<TD vAlign=bottom align=right width="10%"><FONT face="Times New Roman" size=1>&nbsp;</FONT></TD></TR>
<TR>
<TD vAlign=bottom width="35%"><FONT face="Times New Roman" size=1>See notes to financial statements.</FONT></TD>
<TD vAlign=bottom align=right width="7%"><FONT face="Times New Roman" size=1>&nbsp;</FONT></TD>
<TD vAlign=bottom align=right width="1%"></TD>
<TD vAlign=bottom align=right width="9%"><FONT face="Times New Roman" size=1>&nbsp;</FONT></TD>
<TD vAlign=bottom align=right width="1%"></TD>
<TD vAlign=bottom align=right width="6%"><FONT face="Times New Roman" size=1>&nbsp;</FONT></TD>
<TD vAlign=bottom align=right width="1%"></TD>
<TD vAlign=bottom align=right width="9%"><FONT face="Times New Roman" size=1>&nbsp;</FONT></TD>
<TD vAlign=bottom align=right width="1%"></TD>
<TD vAlign=bottom align=right width="9%"><FONT face="Times New Roman" size=1>&nbsp;</FONT></TD>
<TD vAlign=bottom align=right width="1%"></TD>
<TD vAlign=bottom align=right width="9%"><FONT face="Times New Roman" size=1>&nbsp;</FONT></TD>
<TD vAlign=bottom align=right width="1%"></TD>
<TD vAlign=bottom align=right width="10%"><FONT face="Times New Roman" size=1>&nbsp;</FONT></TD></TR>
</TABLE>



<P>&nbsp;
<TABLE width="100%">
<TR>
<TD align=center><FONT size=2>38</FONT></TD></TR>
</TABLE>



<P>
<HR align=left noshade SIZE=5>


<P>&nbsp;
<!-- *************************************************************************** -->
<!-- MARKER PAGE="sheet: 14; page: 14" -->

<P>
<TABLE cellSpacing=0 cellPadding=0 width="100%" border=0>
<TR align=center>
<TD vAlign=bottom nowrap colSpan=6><B><FONT size=1>ABAXIS, INC.</FONT></B></TD></TR>
<TR align=center>
<TD vAlign=bottom nowrap colSpan=6><B><FONT size=1>STATEMENTS&nbsp; OF&nbsp; CASH&nbsp; FLOWS</FONT></B></TD></TR>
<TR align=center>
<TD vAlign=bottom nowrap width="60%"><B><FONT size=1>&nbsp;</FONT></B></TD>
<TD vAlign=bottom nowrap colSpan=5><B><FONT size=1>Year Ended March 31,</FONT></B>
<HR noshade SIZE=1>
</TD></TR>
<TR align=center>
<TD vAlign=bottom nowrap width="60%"><B><FONT size=1>&nbsp;</FONT></B></TD>
<TD vAlign=bottom nowrap width="9%"><B><FONT size=1>2004</FONT></B>
<HR noshade SIZE=1>
</TD>
<TD vAlign=bottom nowrap width="6%">&nbsp;</TD>
<TD vAlign=bottom nowrap width="9%"><B><FONT size=1>2003</FONT></B>
<HR noshade SIZE=1>
</TD>
<TD vAlign=bottom nowrap width="7%">&nbsp;</TD>
<TD vAlign=bottom nowrap width="9%"><B><FONT size=1>2002</FONT></B>
<HR noshade SIZE=1>
</TD></TR>
<TR>
<TD vAlign=bottom nowrap width="60%"><FONT size=1>Operating activities:</FONT></TD>
<TD vAlign=bottom nowrap width="9%"><B><FONT size=1>&nbsp;</FONT></B></TD>
<TD vAlign=bottom nowrap width="6%"></TD>
<TD vAlign=bottom nowrap width="9%"><B><FONT size=1>&nbsp;</FONT></B></TD>
<TD vAlign=bottom nowrap width="7%"></TD>
<TD vAlign=bottom nowrap width="9%"><B><FONT size=1>&nbsp;</FONT></B></TD></TR>
<TR>
<TD vAlign=bottom nowrap width="60%"><FONT size=1>&nbsp; Net income</FONT></TD>
<TD vAlign=bottom nowrap align=right width="9%"><FONT size=1>&nbsp;$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 24,033,000 </FONT></TD>
<TD vAlign=bottom nowrap align=right width="6%"></TD>
<TD vAlign=bottom nowrap align=right width="9%"><FONT size=1>&nbsp;$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 1,636,000 </FONT></TD>
<TD vAlign=bottom nowrap align=right width="7%"></TD>
<TD vAlign=bottom nowrap align=right width="9%"><FONT size=1>&nbsp;$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 1,304,000 </FONT></TD></TR>
<TR>
<TD vAlign=bottom nowrap width="60%"><FONT size=1>&nbsp; Adjustments to reconcile net income to net cash provided by operating activities:</FONT></TD>
<TD vAlign=bottom nowrap align=right width="9%"><FONT size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT></TD>
<TD vAlign=bottom nowrap align=right width="6%"></TD>
<TD vAlign=bottom nowrap align=right width="9%"><FONT size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT></TD>
<TD vAlign=bottom nowrap align=right width="7%"></TD>
<TD vAlign=bottom nowrap align=right width="9%"><FONT size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT></TD></TR>
<TR>
<TD vAlign=bottom nowrap width="60%"><FONT size=1>&nbsp;&nbsp;&nbsp; Depreciation and amortization</FONT></TD>
<TD vAlign=bottom nowrap align=right width="9%"><FONT size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 1,708,000 </FONT></TD>
<TD vAlign=bottom nowrap align=right width="6%"></TD>
<TD vAlign=bottom nowrap align=right width="9%"><FONT size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 1,634,000 </FONT></TD>
<TD vAlign=bottom nowrap align=right width="7%"></TD>
<TD vAlign=bottom nowrap align=right width="9%"><FONT size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1,717,000 </FONT></TD></TR>
<TR>
<TD vAlign=bottom nowrap width="60%"><FONT size=1>&nbsp;&nbsp;&nbsp; (Gain) on sale of property and equipment</FONT></TD>
<TD vAlign=bottom nowrap align=right width="9%"><FONT size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &#151; </FONT></TD>
<TD vAlign=bottom nowrap align=right width="6%"></TD>
<TD vAlign=bottom nowrap align=right width="9%"><FONT size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (10,000)</FONT></TD>
<TD vAlign=bottom nowrap align=right width="7%"></TD>
<TD vAlign=bottom nowrap align=right width="9%"><FONT size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &#151; </FONT></TD></TR>
<TR>
<TD vAlign=bottom nowrap width="60%"><FONT size=1>&nbsp;&nbsp;&nbsp; Stock option income tax benefits</FONT></TD>
<TD vAlign=bottom nowrap align=right width="9%"><FONT size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 1,902,000 </FONT></TD>
<TD vAlign=bottom nowrap align=right width="6%"></TD>
<TD vAlign=bottom nowrap align=right width="9%"><FONT size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#151; </FONT></TD>
<TD vAlign=bottom nowrap align=right width="7%"></TD>
<TD vAlign=bottom nowrap align=right width="9%"><FONT size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &#151; </FONT></TD></TR>
<TR>
<TD vAlign=bottom nowrap width="60%"><FONT size=1>&nbsp;&nbsp;&nbsp; Common stock issued for employee benefit plans</FONT></TD>
<TD vAlign=bottom nowrap align=right width="9%"><FONT size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 73,000 </FONT></TD>
<TD vAlign=bottom nowrap align=right width="6%"></TD>
<TD vAlign=bottom nowrap align=right width="9%"><FONT size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 197,000 </FONT></TD>
<TD vAlign=bottom nowrap align=right width="7%"></TD>
<TD vAlign=bottom nowrap align=right width="9%"><FONT size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &#151; </FONT></TD></TR>
<TR>
<TD vAlign=bottom nowrap width="60%"><FONT size=1>&nbsp;&nbsp;&nbsp; Stock based compensation, including amortization of </FONT></TD>
<TD vAlign=bottom nowrap align=right width="9%"><FONT size=1>&nbsp;</FONT></TD>
<TD vAlign=bottom nowrap align=right width="6%"></TD>
<TD vAlign=bottom nowrap align=right width="9%"><FONT size=1>&nbsp;</FONT></TD>
<TD vAlign=bottom nowrap align=right width="7%"></TD>
<TD vAlign=bottom nowrap align=right width="9%"><FONT size=1>&nbsp;</FONT></TD></TR>
<TR>
<TD vAlign=bottom nowrap width="60%"><FONT size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; deferred stock compensation</FONT></TD>
<TD vAlign=bottom nowrap align=right width="9%"><FONT size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 24,000 </FONT></TD>
<TD vAlign=bottom nowrap align=right width="6%"></TD>
<TD vAlign=bottom nowrap align=right width="9%"><FONT size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 16,000 </FONT></TD>
<TD vAlign=bottom nowrap align=right width="7%"></TD>
<TD vAlign=bottom nowrap align=right width="9%"><FONT size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 51,000 </FONT></TD></TR>
<TR>
<TD vAlign=bottom nowrap width="60%"><FONT size=1>&nbsp;&nbsp;&nbsp; Adjustment for issuance cost on Series D convertible preferred stock</FONT></TD>
<TD vAlign=bottom nowrap align=right width="9%"><FONT size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#151; </FONT></TD>
<TD vAlign=bottom nowrap align=right width="6%"></TD>
<TD vAlign=bottom nowrap align=right width="9%"><FONT size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (29,000)</FONT></TD>
<TD vAlign=bottom nowrap align=right width="7%"></TD>
<TD vAlign=bottom nowrap align=right width="9%"><FONT size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &#151; </FONT></TD></TR>
<TR>
<TD vAlign=bottom nowrap width="60%"><FONT size=1>&nbsp;&nbsp;&nbsp; Changes in assets and liabilities:</FONT></TD>
<TD vAlign=bottom nowrap align=right width="9%"><FONT size=1>&nbsp;</FONT></TD>
<TD vAlign=bottom nowrap align=right width="6%"></TD>
<TD vAlign=bottom nowrap align=right width="9%"><FONT size=1>&nbsp;</FONT></TD>
<TD vAlign=bottom nowrap align=right width="7%"></TD>
<TD vAlign=bottom nowrap align=right width="9%"><FONT size=1>&nbsp;</FONT></TD></TR>
<TR>
<TD vAlign=bottom nowrap width="60%"><FONT size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Trade receivables</FONT></TD>
<TD vAlign=bottom nowrap align=right width="9%"><FONT size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (720,000)</FONT></TD>
<TD vAlign=bottom nowrap align=right width="6%"></TD>
<TD vAlign=bottom nowrap align=right width="9%"><FONT size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (558,000)</FONT></TD>
<TD vAlign=bottom nowrap align=right width="7%"></TD>
<TD vAlign=bottom nowrap align=right width="9%"><FONT size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 636,000 </FONT></TD></TR>
<TR>
<TD vAlign=bottom nowrap width="60%"><FONT size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Interest receivable</FONT></TD>
<TD vAlign=bottom nowrap align=right width="9%"><FONT size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &#151; </FONT></TD>
<TD vAlign=bottom nowrap align=right width="6%"></TD>
<TD vAlign=bottom nowrap align=right width="9%"><FONT size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &#151; </FONT></TD>
<TD vAlign=bottom nowrap align=right width="7%"></TD>
<TD vAlign=bottom nowrap align=right width="9%"><FONT size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 2,000 </FONT></TD></TR>
<TR>
<TD vAlign=bottom nowrap width="60%"><FONT size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Inventories</FONT></TD>
<TD vAlign=bottom nowrap align=right width="9%"><FONT size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (717,000)</FONT></TD>
<TD vAlign=bottom nowrap align=right width="6%"></TD>
<TD vAlign=bottom nowrap align=right width="9%"><FONT size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 600,000 </FONT></TD>
<TD vAlign=bottom nowrap align=right width="7%"></TD>
<TD vAlign=bottom nowrap align=right width="9%"><FONT size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 318,000 </FONT></TD></TR>
<TR>
<TD vAlign=bottom nowrap width="60%"><FONT size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Prepaid expenses</FONT></TD>
<TD vAlign=bottom nowrap align=right width="9%"><FONT size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 283,000 </FONT></TD>
<TD vAlign=bottom nowrap align=right width="6%"></TD>
<TD vAlign=bottom nowrap align=right width="9%"><FONT size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (191,000)</FONT></TD>
<TD vAlign=bottom nowrap align=right width="7%"></TD>
<TD vAlign=bottom nowrap align=right width="9%"><FONT size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (250,000)</FONT></TD></TR>
<TR>
<TD vAlign=bottom nowrap width="60%"><FONT size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Net deferred tax assets</FONT></TD>
<TD vAlign=bottom nowrap align=right width="9%"><FONT size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (21,233,000)</FONT></TD>
<TD vAlign=bottom nowrap align=right width="6%"></TD>
<TD vAlign=bottom nowrap align=right width="9%"><FONT size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &#151; </FONT></TD>
<TD vAlign=bottom nowrap align=right width="7%"></TD>
<TD vAlign=bottom nowrap align=right width="9%"><FONT size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#151; </FONT></TD></TR>
<TR>
<TD vAlign=bottom nowrap width="60%"><FONT size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Deposits and other assets</FONT></TD>
<TD vAlign=bottom nowrap align=right width="9%"><FONT size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 72,000 </FONT></TD>
<TD vAlign=bottom nowrap align=right width="6%"></TD>
<TD vAlign=bottom nowrap align=right width="9%"><FONT size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (120,000)</FONT></TD>
<TD vAlign=bottom nowrap align=right width="7%"></TD>
<TD vAlign=bottom nowrap align=right width="9%"><FONT size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 313,000 </FONT></TD></TR>
<TR>
<TD vAlign=bottom nowrap width="60%"><FONT size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Accounts payable</FONT></TD>
<TD vAlign=bottom nowrap align=right width="9%"><FONT size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 637,000 </FONT></TD>
<TD vAlign=bottom nowrap align=right width="6%"></TD>
<TD vAlign=bottom nowrap align=right width="9%"><FONT size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 170,000 </FONT></TD>
<TD vAlign=bottom nowrap align=right width="7%"></TD>
<TD vAlign=bottom nowrap align=right width="9%"><FONT size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (1,708,000)</FONT></TD></TR>
<TR>
<TD vAlign=bottom nowrap width="60%"><FONT size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Accrued payroll and related expenses</FONT></TD>
<TD vAlign=bottom nowrap align=right width="9%"><FONT size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 1,042,000 </FONT></TD>
<TD vAlign=bottom nowrap align=right width="6%"></TD>
<TD vAlign=bottom nowrap align=right width="9%"><FONT size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 371,000 </FONT></TD>
<TD vAlign=bottom nowrap align=right width="7%"></TD>
<TD vAlign=bottom nowrap align=right width="9%"><FONT size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 475,000 </FONT></TD></TR>
<TR>
<TD vAlign=bottom nowrap width="60%"><FONT size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Warranty reserve and other accrued liabilities </FONT></TD>
<TD vAlign=bottom nowrap align=right width="9%"><FONT size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &#151; </FONT></TD>
<TD vAlign=bottom nowrap align=right width="6%"></TD>
<TD vAlign=bottom nowrap align=right width="9%"><FONT size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(189,000)</FONT></TD>
<TD vAlign=bottom nowrap align=right width="7%"></TD>
<TD vAlign=bottom nowrap align=right width="9%"><FONT size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 73,000 </FONT></TD></TR>
<TR>
<TD vAlign=bottom nowrap width="60%"><FONT size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Deferred rent</FONT></TD>
<TD vAlign=bottom nowrap align=right width="9%"><FONT size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 88,000 </FONT></TD>
<TD vAlign=bottom nowrap align=right width="6%"></TD>
<TD vAlign=bottom nowrap align=right width="9%"><FONT size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 123,000 </FONT></TD>
<TD vAlign=bottom nowrap align=right width="7%"></TD>
<TD vAlign=bottom nowrap align=right width="9%"><FONT size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 157,000 </FONT></TD></TR>
<TR>
<TD vAlign=bottom nowrap width="60%"><FONT size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Deferred revenue</FONT></TD>
<TD vAlign=bottom nowrap align=right width="9%"><FONT size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 42,000 </FONT></TD>
<TD vAlign=bottom nowrap align=right width="6%"></TD>
<TD vAlign=bottom nowrap align=right width="9%"><FONT size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (104,000)</FONT></TD>
<TD vAlign=bottom nowrap align=right width="7%"></TD>
<TD vAlign=bottom nowrap align=right width="9%"><FONT size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 36,000 </FONT></TD></TR>
<TR>
<TD vAlign=bottom nowrap width="60%"><FONT size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Long-term commission obligation</FONT></TD>
<TD vAlign=bottom nowrap align=right width="9%"><FONT size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (36,000)</FONT></TD>
<TD vAlign=bottom nowrap align=right width="6%"></TD>
<TD vAlign=bottom nowrap align=right width="9%"><FONT size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (21,000)</FONT></TD>
<TD vAlign=bottom nowrap align=right width="7%"></TD>
<TD vAlign=bottom nowrap align=right width="9%"><FONT size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (22,000)</FONT></TD></TR>
<TR>
<TD vAlign=bottom nowrap width="60%">&nbsp;</TD>
<TD vAlign=bottom nowrap align=right width="9%">
<HR noshade SIZE=1>
</TD>
<TD vAlign=bottom nowrap align=right width="6%"></TD>
<TD vAlign=bottom nowrap align=right width="9%">
<HR noshade SIZE=1>
</TD>
<TD vAlign=bottom nowrap align=right width="7%"></TD>
<TD vAlign=bottom nowrap align=right width="9%">
<HR noshade SIZE=1>
</TD></TR>
<TR>
<TD vAlign=bottom nowrap width="60%"><FONT size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Net cash provided by operating activities</FONT></TD>
<TD vAlign=bottom nowrap align=right width="9%"><FONT size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 7,198,000 </FONT></TD>
<TD vAlign=bottom nowrap align=right width="6%"></TD>
<TD vAlign=bottom nowrap align=right width="9%"><FONT size=1>&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3,525,000 </FONT></TD>
<TD vAlign=bottom nowrap align=right width="7%"></TD>
<TD vAlign=bottom nowrap align=right width="9%"><FONT size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 3,102,000 </FONT></TD></TR>
<TR>
<TD vAlign=bottom nowrap width="60%">&nbsp;</TD>
<TD vAlign=bottom nowrap align=right width="9%">
<HR noshade SIZE=1>
</TD>
<TD vAlign=bottom nowrap align=right width="6%"></TD>
<TD vAlign=bottom nowrap align=right width="9%">
<HR noshade SIZE=1>
</TD>
<TD vAlign=bottom nowrap align=right width="7%"></TD>
<TD vAlign=bottom nowrap align=right width="9%">
<HR noshade SIZE=1>
</TD></TR>
<TR>
<TD vAlign=bottom nowrap width="60%"><FONT size=1>Investing activities:</FONT></TD>
<TD vAlign=bottom nowrap align=right width="9%"><FONT size=1>&nbsp;</FONT></TD>
<TD vAlign=bottom nowrap align=right width="6%"></TD>
<TD vAlign=bottom nowrap align=right width="9%"><FONT size=1>&nbsp;</FONT></TD>
<TD vAlign=bottom nowrap align=right width="7%"></TD>
<TD vAlign=bottom nowrap align=right width="9%"><FONT size=1>&nbsp;</FONT></TD></TR>
<TR>
<TD vAlign=bottom nowrap width="60%"><FONT size=1>&nbsp; Purchase of short-term investments</FONT></TD>
<TD vAlign=bottom nowrap align=right width="9%"><FONT size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (7,998,000)</FONT></TD>
<TD vAlign=bottom nowrap align=right width="6%"></TD>
<TD vAlign=bottom nowrap align=right width="9%"><FONT size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &#151; </FONT></TD>
<TD vAlign=bottom nowrap align=right width="7%"></TD>
<TD vAlign=bottom nowrap align=right width="9%"><FONT size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &#151; </FONT></TD></TR>
<TR>
<TD vAlign=bottom nowrap width="60%"><FONT size=1>&nbsp; Purchase of property and equipment</FONT></TD>
<TD vAlign=bottom nowrap align=right width="9%"><FONT size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (1,281,000)</FONT></TD>
<TD vAlign=bottom nowrap align=right width="6%"></TD>
<TD vAlign=bottom nowrap align=right width="9%"><FONT size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (1,168,000)</FONT></TD>
<TD vAlign=bottom nowrap align=right width="7%"></TD>
<TD vAlign=bottom nowrap align=right width="9%"><FONT size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (873,000)</FONT></TD></TR>
<TR>
<TD vAlign=bottom nowrap width="60%"><FONT size=1>&nbsp; Purchase of intangible assets</FONT></TD>
<TD vAlign=bottom nowrap align=right width="9%"><FONT size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (750,000)</FONT></TD>
<TD vAlign=bottom nowrap align=right width="6%"></TD>
<TD vAlign=bottom nowrap align=right width="9%"><FONT size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &#151; </FONT></TD>
<TD vAlign=bottom nowrap align=right width="7%"></TD>
<TD vAlign=bottom nowrap align=right width="9%"><FONT size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &#151; </FONT></TD></TR>
<TR>
<TD vAlign=bottom nowrap width="60%"><FONT size=1>&nbsp; Proceeds from sale of property and equipment</FONT></TD>
<TD vAlign=bottom nowrap align=right width="9%"><FONT size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &#151; </FONT></TD>
<TD vAlign=bottom nowrap align=right width="6%"></TD>
<TD vAlign=bottom nowrap align=right width="9%"><FONT size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 11,000 </FONT></TD>
<TD vAlign=bottom nowrap align=right width="7%"></TD>
<TD vAlign=bottom nowrap align=right width="9%"><FONT size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &#151; </FONT></TD></TR>
<TR>
<TD vAlign=bottom nowrap width="60%">&nbsp;</TD>
<TD vAlign=bottom nowrap align=right width="9%">
<HR noshade SIZE=1>
</TD>
<TD vAlign=bottom nowrap align=right width="6%"></TD>
<TD vAlign=bottom nowrap align=right width="9%">
<HR noshade SIZE=1>
</TD>
<TD vAlign=bottom nowrap align=right width="7%"></TD>
<TD vAlign=bottom nowrap align=right width="9%">
<HR noshade SIZE=1>
</TD></TR>
<TR>
<TD vAlign=bottom nowrap width="60%"><FONT size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Net cash used in investing activities</FONT></TD>
<TD vAlign=bottom nowrap align=right width="9%"><FONT size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (10,029,000)</FONT></TD>
<TD vAlign=bottom nowrap align=right width="6%"></TD>
<TD vAlign=bottom nowrap align=right width="9%"><FONT size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (1,157,000)</FONT></TD>
<TD vAlign=bottom nowrap align=right width="7%"></TD>
<TD vAlign=bottom nowrap align=right width="9%"><FONT size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (873,000)</FONT></TD></TR>
<TR>
<TD vAlign=bottom nowrap width="60%">&nbsp;</TD>
<TD vAlign=bottom nowrap align=right width="9%">
<HR noshade SIZE=1>
</TD>
<TD vAlign=bottom nowrap align=right width="6%"></TD>
<TD vAlign=bottom nowrap align=right width="9%">
<HR noshade SIZE=1>
</TD>
<TD vAlign=bottom nowrap align=right width="7%"></TD>
<TD vAlign=bottom nowrap align=right width="9%">
<HR noshade SIZE=1>
</TD></TR>
<TR>
<TD vAlign=bottom nowrap width="60%"><FONT size=1>Financing activities:</FONT></TD>
<TD vAlign=bottom nowrap align=right width="9%"><FONT size=1>&nbsp;</FONT></TD>
<TD vAlign=bottom nowrap align=right width="6%"></TD>
<TD vAlign=bottom nowrap align=right width="9%"><FONT size=1>&nbsp;</FONT></TD>
<TD vAlign=bottom nowrap align=right width="7%"></TD>
<TD vAlign=bottom nowrap align=right width="9%"><FONT size=1>&nbsp;</FONT></TD></TR>
<TR>
<TD vAlign=bottom nowrap width="60%"><FONT size=1>&nbsp; Proceeds from equipment financing</FONT></TD>
<TD vAlign=bottom nowrap align=right width="9%"><FONT size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &#151; </FONT></TD>
<TD vAlign=bottom nowrap align=right width="6%"></TD>
<TD vAlign=bottom nowrap align=right width="9%"><FONT size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &#151; </FONT></TD>
<TD vAlign=bottom nowrap align=right width="7%"></TD>
<TD vAlign=bottom nowrap align=right width="9%"><FONT size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 1,400,000 </FONT></TD></TR>
<TR>
<TD vAlign=bottom nowrap width="60%"><FONT size=1>&nbsp; Repayment of equipment financing</FONT></TD>
<TD vAlign=bottom nowrap align=right width="9%"><FONT size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(933,000)</FONT></TD>
<TD vAlign=bottom nowrap align=right width="6%"></TD>
<TD vAlign=bottom nowrap align=right width="9%"><FONT size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (467,000)</FONT></TD>
<TD vAlign=bottom nowrap align=right width="7%"></TD>
<TD vAlign=bottom nowrap align=right width="9%"><FONT size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (1,653,000)</FONT></TD></TR>
<TR>
<TD vAlign=bottom nowrap width="60%"><FONT size=1>&nbsp; Borrowings under line of credit</FONT></TD>
<TD vAlign=bottom nowrap align=right width="9%"><FONT size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &#151; </FONT></TD>
<TD vAlign=bottom nowrap align=right width="6%"></TD>
<TD vAlign=bottom nowrap align=right width="9%"><FONT size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 1,000,000 </FONT></TD>
<TD vAlign=bottom nowrap align=right width="7%"></TD>
<TD vAlign=bottom nowrap align=right width="9%"><FONT size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 2,600,000 </FONT></TD></TR>
<TR>
<TD vAlign=bottom nowrap width="60%"><FONT size=1>&nbsp; Repayment of line of credit</FONT></TD>
<TD vAlign=bottom nowrap align=right width="9%"><FONT size=1>&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#151; </FONT></TD>
<TD vAlign=bottom nowrap align=right width="6%"></TD>
<TD vAlign=bottom nowrap align=right width="9%"><FONT size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (3,000,000)</FONT></TD>
<TD vAlign=bottom nowrap align=right width="7%"></TD>
<TD vAlign=bottom nowrap align=right width="9%"><FONT size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (2,371,000)</FONT></TD></TR>
<TR>
<TD vAlign=bottom nowrap width="60%"><FONT size=1>&nbsp; Repayment of capital lease obligations</FONT></TD>
<TD vAlign=bottom nowrap align=right width="9%"><FONT size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (58,000)</FONT></TD>
<TD vAlign=bottom nowrap align=right width="6%"></TD>
<TD vAlign=bottom nowrap align=right width="9%"><FONT size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (104,000)</FONT></TD>
<TD vAlign=bottom nowrap align=right width="7%"></TD>
<TD vAlign=bottom nowrap align=right width="9%"><FONT size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (515,000)</FONT></TD></TR>
<TR>
<TD vAlign=bottom nowrap width="60%"><FONT size=1>&nbsp; Net cash proceeds from issuance of preferred stock, Series E</FONT></TD>
<TD vAlign=bottom nowrap align=right width="9%"><FONT size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &#151; </FONT></TD>
<TD vAlign=bottom nowrap align=right width="6%"></TD>
<TD vAlign=bottom nowrap align=right width="9%"><FONT size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 6,812,000 </FONT></TD>
<TD vAlign=bottom nowrap align=right width="7%"></TD>
<TD vAlign=bottom nowrap align=right width="9%"><FONT size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &#151; </FONT></TD></TR>
<TR>
<TD vAlign=bottom nowrap width="60%"><FONT size=1>&nbsp; Exercise of common stock options</FONT></TD>
<TD vAlign=bottom nowrap align=right width="9%"><FONT size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 1,147,000 </FONT></TD>
<TD vAlign=bottom nowrap align=right width="6%"></TD>
<TD vAlign=bottom nowrap align=right width="9%"><FONT size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 180,000 </FONT></TD>
<TD vAlign=bottom nowrap align=right width="7%"></TD>
<TD vAlign=bottom nowrap align=right width="9%"><FONT size=1>&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;396,000 </FONT></TD></TR>
<TR>
<TD vAlign=bottom nowrap width="60%"><FONT size=1>&nbsp; Exercise of common stock warrants</FONT></TD>
<TD vAlign=bottom nowrap align=right width="9%"><FONT size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 1,569,000 </FONT></TD>
<TD vAlign=bottom nowrap align=right width="6%"></TD>
<TD vAlign=bottom nowrap align=right width="9%"><FONT size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &#151; </FONT></TD>
<TD vAlign=bottom nowrap align=right width="7%"></TD>
<TD vAlign=bottom nowrap align=right width="9%"><FONT size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &#151; </FONT></TD></TR>
<TR>
<TD vAlign=bottom nowrap width="60%"><FONT size=1>&nbsp; Dividends paid</FONT></TD>
<TD vAlign=bottom nowrap align=right width="9%"><FONT size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &#151; </FONT></TD>
<TD vAlign=bottom nowrap align=right width="6%"></TD>
<TD vAlign=bottom nowrap align=right width="9%"><FONT size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (457,000)</FONT></TD>
<TD vAlign=bottom nowrap align=right width="7%"></TD>
<TD vAlign=bottom nowrap align=right width="9%"><FONT size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &#151; </FONT></TD></TR>
<TR>
<TD vAlign=bottom nowrap width="60%">&nbsp;</TD>
<TD vAlign=bottom nowrap align=right width="9%">
<HR noshade SIZE=1>
</TD>
<TD vAlign=bottom nowrap align=right width="6%"></TD>
<TD vAlign=bottom nowrap align=right width="9%">
<HR noshade SIZE=1>
</TD>
<TD vAlign=bottom nowrap align=right width="7%"></TD>
<TD vAlign=bottom nowrap align=right width="9%">
<HR noshade SIZE=1>
</TD></TR>
<TR>
<TD vAlign=bottom nowrap width="60%"><FONT size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Net cash provided by (used in) financing activities</FONT></TD>
<TD vAlign=bottom nowrap align=right width="9%"><FONT size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 1,725,000 </FONT></TD>
<TD vAlign=bottom nowrap align=right width="6%"></TD>
<TD vAlign=bottom nowrap align=right width="9%"><FONT size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 3,964,000 </FONT></TD>
<TD vAlign=bottom nowrap align=right width="7%"></TD>
<TD vAlign=bottom nowrap align=right width="9%"><FONT size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (143,000)</FONT></TD></TR>
<TR>
<TD vAlign=bottom nowrap width="60%">&nbsp;</TD>
<TD vAlign=bottom nowrap align=right width="9%">
<HR noshade SIZE=1>
</TD>
<TD vAlign=bottom nowrap align=right width="6%"></TD>
<TD vAlign=bottom nowrap align=right width="9%">
<HR noshade SIZE=1>
</TD>
<TD vAlign=bottom nowrap align=right width="7%"></TD>
<TD vAlign=bottom nowrap align=right width="9%">
<HR noshade SIZE=1>
</TD></TR>
<TR>
<TD vAlign=bottom nowrap width="60%"><FONT size=1>Net increase (decrease) in cash and cash equivalents</FONT></TD>
<TD vAlign=bottom nowrap align=right width="9%"><FONT size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (1,106,000)</FONT></TD>
<TD vAlign=bottom nowrap align=right width="6%"></TD>
<TD vAlign=bottom nowrap align=right width="9%"><FONT size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 6,332,000 </FONT></TD>
<TD vAlign=bottom nowrap align=right width="7%"></TD>
<TD vAlign=bottom nowrap align=right width="9%"><FONT size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 2,086,000 </FONT></TD></TR>
<TR>
<TD vAlign=bottom nowrap width="60%"><FONT size=1>Cash and cash equivalents at beginning of year</FONT></TD>
<TD vAlign=bottom nowrap align=right width="9%"><FONT size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 10,430,000 </FONT></TD>
<TD vAlign=bottom nowrap align=right width="6%"></TD>
<TD vAlign=bottom nowrap align=right width="9%"><FONT size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 4,098,000 </FONT></TD>
<TD vAlign=bottom nowrap align=right width="7%"></TD>
<TD vAlign=bottom nowrap align=right width="9%"><FONT size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 2,012,000 </FONT></TD></TR>
<TR>
<TD vAlign=bottom nowrap width="60%">&nbsp;</TD>
<TD vAlign=bottom nowrap align=right width="9%">
<HR noshade SIZE=1>
</TD>
<TD vAlign=bottom nowrap align=right width="6%"></TD>
<TD vAlign=bottom nowrap align=right width="9%">
<HR noshade SIZE=1>
</TD>
<TD vAlign=bottom nowrap align=right width="7%"></TD>
<TD vAlign=bottom nowrap align=right width="9%">
<HR noshade SIZE=1>
</TD></TR>
<TR>
<TD vAlign=bottom nowrap width="60%"><FONT size=1>Cash and cash equivalents at end of year</FONT></TD>
<TD vAlign=bottom nowrap align=right width="9%"><FONT size=1>&nbsp;$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 9,324,000 </FONT></TD>
<TD vAlign=bottom nowrap align=right width="6%"></TD>
<TD vAlign=bottom nowrap align=right width="9%"><FONT size=1>&nbsp;$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 10,430,000 </FONT></TD>
<TD vAlign=bottom nowrap align=right width="7%"></TD>
<TD vAlign=bottom nowrap align=right width="9%"><FONT size=1>&nbsp;$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 4,098,000 </FONT></TD></TR>
<TR>
<TD vAlign=bottom nowrap width="60%">&nbsp;</TD>
<TD vAlign=bottom nowrap align=right width="9%">
<HR noshade>
</TD>
<TD vAlign=bottom nowrap align=right width="6%"></TD>
<TD vAlign=bottom nowrap align=right width="9%">
<HR noshade>
</TD>
<TD vAlign=bottom nowrap align=right width="7%"></TD>
<TD vAlign=bottom nowrap align=right width="9%">
<HR noshade>
</TD></TR>
<TR>
<TD vAlign=bottom nowrap width="60%"><FONT size=1>Supplemental disclosures of cash flow information:</FONT></TD>
<TD vAlign=bottom nowrap align=right width="9%"><FONT size=1>&nbsp;</FONT></TD>
<TD vAlign=bottom nowrap align=right width="6%"></TD>
<TD vAlign=bottom nowrap align=right width="9%"><FONT size=1>&nbsp;</FONT></TD>
<TD vAlign=bottom nowrap align=right width="7%"></TD>
<TD vAlign=bottom nowrap align=right width="9%"><FONT size=1>&nbsp;</FONT></TD></TR>
<TR>
<TD vAlign=bottom nowrap width="60%"><FONT size=1>&nbsp; Cash paid for interest, net of interest capitalized</FONT></TD>
<TD vAlign=bottom nowrap align=right width="9%"><FONT size=1>&nbsp;$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 58,000 </FONT></TD>
<TD vAlign=bottom nowrap align=right width="6%"></TD>
<TD vAlign=bottom nowrap align=right width="9%"><FONT size=1>&nbsp;$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;146,000 </FONT></TD>
<TD vAlign=bottom nowrap align=right width="7%"></TD>
<TD vAlign=bottom nowrap align=right width="9%"><FONT size=1>&nbsp;$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 260,000 </FONT></TD></TR>
<TR>
<TD vAlign=bottom nowrap width="60%">&nbsp;</TD>
<TD vAlign=bottom nowrap align=right width="9%">
<HR noshade>
</TD>
<TD vAlign=bottom nowrap align=right width="6%"></TD>
<TD vAlign=bottom nowrap align=right width="9%">
<HR noshade>
</TD>
<TD vAlign=bottom nowrap align=right width="7%"></TD>
<TD vAlign=bottom nowrap align=right width="9%">
<HR noshade>
</TD></TR>
<TR>
<TD vAlign=bottom nowrap width="60%"><FONT size=1>&nbsp; Taxes paid</FONT></TD>
<TD vAlign=bottom nowrap align=right width="9%"><FONT size=1>&nbsp;$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 211,000 </FONT></TD>
<TD vAlign=bottom nowrap align=right width="6%"></TD>
<TD vAlign=bottom nowrap align=right width="9%"><FONT size=1>&nbsp;$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 5,000 </FONT></TD>
<TD vAlign=bottom nowrap align=right width="7%"></TD>
<TD vAlign=bottom nowrap align=right width="9%"><FONT size=1>&nbsp;$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &#151; </FONT></TD></TR>
<TR>
<TD vAlign=bottom nowrap width="60%">&nbsp;</TD>
<TD vAlign=bottom nowrap align=right width="9%">
<HR noshade>
</TD>
<TD vAlign=bottom nowrap align=right width="6%"></TD>
<TD vAlign=bottom nowrap align=right width="9%">
<HR noshade>
</TD>
<TD vAlign=bottom nowrap align=right width="7%"></TD>
<TD vAlign=bottom nowrap align=right width="9%">
<HR noshade>
</TD></TR>
<TR>
<TD vAlign=bottom nowrap width="60%"><FONT size=1>Noncash financing activities &#151; </FONT></TD>
<TD vAlign=bottom nowrap align=right width="9%"><FONT size=1>&nbsp;</FONT></TD>
<TD vAlign=bottom nowrap align=right width="6%"></TD>
<TD vAlign=bottom nowrap align=right width="9%"><FONT size=1>&nbsp;</FONT></TD>
<TD vAlign=bottom nowrap align=right width="7%"></TD>
<TD vAlign=bottom nowrap align=right width="9%"><FONT size=1>&nbsp;</FONT></TD></TR>
<TR>
<TD vAlign=bottom nowrap width="60%"><FONT size=1>&nbsp; Proceeds receivable from stock offering, net</FONT></TD>
<TD vAlign=bottom nowrap align=right width="9%"><FONT size=1>&nbsp;$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#151; </FONT></TD>
<TD vAlign=bottom nowrap align=right width="6%"></TD>
<TD vAlign=bottom nowrap align=right width="9%"><FONT size=1>&nbsp;$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &#151; </FONT></TD>
<TD vAlign=bottom nowrap align=right width="7%"></TD>
<TD vAlign=bottom nowrap align=right width="9%"><FONT size=1>&nbsp;$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 3,446,000 </FONT></TD></TR>
<TR>
<TD vAlign=bottom nowrap width="60%">&nbsp;</TD>
<TD vAlign=bottom nowrap align=right width="9%">
<HR noshade>
</TD>
<TD vAlign=bottom nowrap align=right width="6%"></TD>
<TD vAlign=bottom nowrap align=right width="9%">
<HR noshade>
</TD>
<TD vAlign=bottom nowrap align=right width="7%"></TD>
<TD vAlign=bottom nowrap align=right width="9%">
<HR noshade>
</TD></TR>
<TR>
<TD vAlign=bottom nowrap width="60%"><FONT size=1>&nbsp; Preferred stock dividends and accretion</FONT></TD>
<TD vAlign=bottom nowrap align=right width="9%"><FONT size=1>&nbsp;$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 419,000 </FONT></TD>
<TD vAlign=bottom nowrap align=right width="6%"></TD>
<TD vAlign=bottom nowrap align=right width="9%"><FONT size=1>&nbsp;$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 778,000 </FONT></TD>
<TD vAlign=bottom nowrap align=right width="7%"></TD>
<TD vAlign=bottom nowrap align=right width="9%"><FONT size=1>&nbsp;$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 1,033,000 </FONT></TD></TR>
<TR>
<TD vAlign=bottom nowrap width="60%">&nbsp;</TD>
<TD vAlign=bottom nowrap align=right width="9%">
<HR noshade>
</TD>
<TD vAlign=bottom nowrap align=right width="6%"></TD>
<TD vAlign=bottom nowrap align=right width="9%">
<HR noshade>
</TD>
<TD vAlign=bottom nowrap align=right width="7%"></TD>
<TD vAlign=bottom nowrap align=right width="9%">
<HR noshade>
</TD></TR>
<TR>
<TD vAlign=bottom nowrap width="60%"><FONT size=1>&nbsp; Issuance of common stock for conversion of preferred stock and </FONT></TD>
<TD vAlign=bottom nowrap align=right width="9%"><FONT size=1>&nbsp;</FONT></TD>
<TD vAlign=bottom nowrap align=right width="6%"></TD>
<TD vAlign=bottom nowrap align=right width="9%"><FONT size=1>&nbsp;</FONT></TD>
<TD vAlign=bottom nowrap align=right width="7%"></TD>
<TD vAlign=bottom nowrap align=right width="9%"><FONT size=1>&nbsp;</FONT></TD></TR>
<TR>
<TD vAlign=bottom nowrap width="60%"><FONT size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; payment of dividends payable</FONT></TD>
<TD vAlign=bottom nowrap align=right width="9%"><FONT size=1>&nbsp;$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 12,877,000 </FONT></TD>
<TD vAlign=bottom nowrap align=right width="6%"></TD>
<TD vAlign=bottom nowrap align=right width="9%"><FONT size=1>&nbsp;$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 2,080,000 </FONT></TD>
<TD vAlign=bottom nowrap align=right width="7%"></TD>
<TD vAlign=bottom nowrap align=right width="9%"><FONT size=1>&nbsp;$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 466,000 </FONT></TD></TR>
<TR>
<TD vAlign=bottom nowrap width="60%">&nbsp;</TD>
<TD vAlign=bottom nowrap align=right width="9%">
<HR noshade>
</TD>
<TD vAlign=bottom nowrap align=right width="6%"></TD>
<TD vAlign=bottom nowrap align=right width="9%">
<HR noshade>
</TD>
<TD vAlign=bottom nowrap align=right width="7%"></TD>
<TD vAlign=bottom nowrap align=right width="9%">
<HR noshade>
</TD></TR>
<TR>
<TD vAlign=bottom nowrap width="60%"><FONT size=1>&nbsp; Warrants and options issued for services and issuance costs</FONT></TD>
<TD vAlign=bottom nowrap align=right width="9%"><FONT size=1>&nbsp;$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#151; </FONT></TD>
<TD vAlign=bottom nowrap align=right width="6%"></TD>
<TD vAlign=bottom nowrap align=right width="9%"><FONT size=1>&nbsp;$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 361,000 </FONT></TD>
<TD vAlign=bottom nowrap align=right width="7%"></TD>
<TD vAlign=bottom nowrap align=right width="9%"><FONT size=1>&nbsp;$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 240,000 </FONT></TD></TR>
<TR>
<TD vAlign=bottom nowrap width="60%">&nbsp;</TD>
<TD vAlign=bottom nowrap align=right width="9%">
<HR noshade>
</TD>
<TD vAlign=bottom nowrap align=right width="6%"></TD>
<TD vAlign=bottom nowrap align=right width="9%">
<HR noshade>
</TD>
<TD vAlign=bottom nowrap align=right width="7%"></TD>
<TD vAlign=bottom nowrap align=right width="9%">
<HR noshade>
</TD></TR>
<TR>
<TD vAlign=bottom nowrap width="60%"><FONT size=1>&nbsp; Capital lease obligations incurred in connection with acquisition of fixed assets</FONT></TD>
<TD vAlign=bottom nowrap align=right width="9%"><FONT size=1>&nbsp;$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &#151; </FONT></TD>
<TD vAlign=bottom nowrap align=right width="6%"></TD>
<TD vAlign=bottom nowrap align=right width="9%"><FONT size=1>&nbsp;$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &#151; </FONT></TD>
<TD vAlign=bottom nowrap align=right width="7%"></TD>
<TD vAlign=bottom nowrap align=right width="9%"><FONT size=1>&nbsp;$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;10,000 </FONT></TD></TR>
<TR>
<TD vAlign=bottom nowrap width="60%">&nbsp;</TD>
<TD vAlign=bottom nowrap align=right width="9%">
<HR noshade>
</TD>
<TD vAlign=bottom nowrap align=right width="6%"></TD>
<TD vAlign=bottom nowrap align=right width="9%">
<HR noshade>
</TD>
<TD vAlign=bottom nowrap align=right width="7%"></TD>
<TD vAlign=bottom nowrap align=right width="9%">
<HR noshade>
</TD></TR>
<TR>
<TD vAlign=bottom nowrap width="60%"><FONT size=1>&nbsp;</FONT></TD>
<TD vAlign=bottom nowrap align=right width="9%"><FONT size=1>&nbsp;</FONT></TD>
<TD vAlign=bottom nowrap align=right width="6%"></TD>
<TD vAlign=bottom nowrap align=right width="9%"><FONT size=1>&nbsp;</FONT></TD>
<TD vAlign=bottom nowrap align=right width="7%"></TD>
<TD vAlign=bottom nowrap align=right width="9%"><FONT size=1>&nbsp;</FONT></TD></TR>
<TR>
<TD vAlign=bottom nowrap width="60%"><FONT size=1>See notes to financial statements.</FONT></TD>
<TD vAlign=bottom nowrap align=right width="9%"><FONT size=1>&nbsp;</FONT></TD>
<TD vAlign=bottom nowrap align=right width="6%"></TD>
<TD vAlign=bottom nowrap align=right width="9%"><FONT size=1>&nbsp;</FONT></TD>
<TD vAlign=bottom nowrap align=right width="7%"></TD>
<TD vAlign=bottom nowrap align=right width="9%"><FONT size=1>&nbsp;</FONT></TD></TR>
<TR>
<TD vAlign=bottom nowrap width="60%"><FONT size=1>&nbsp;</FONT></TD>
<TD vAlign=bottom nowrap align=right width="9%"><FONT size=1>&nbsp;</FONT></TD>
<TD vAlign=bottom nowrap align=right width="6%"></TD>
<TD vAlign=bottom nowrap align=right width="9%"><FONT size=1>&nbsp;</FONT></TD>
<TD vAlign=bottom nowrap align=right width="7%"></TD>
<TD vAlign=bottom nowrap align=right width="9%"><FONT size=1>&nbsp;</FONT></TD></TR>
</TABLE>

<BR>
<TABLE width="100%">
<TR>
<TD align=center><FONT size=2>39</FONT></TD></TR>
</TABLE>



<P>
<HR align=left noshade SIZE=5>


<P>&nbsp;
<!-- *************************************************************************** -->
<!-- MARKER PAGE="sheet: 14; page: 14" -->
<!-- MARKER FORMAT-SHEET="Head Major Center Bold 1" FSL="Default" -->
<H1 align=center><FONT face="Times New Roman, Times, Serif" size=2>ABAXIS, INC. </FONT></H1>

<H1 align=center><FONT face="Times New Roman, Times, Serif" size=2>NOTES TO FINANCIAL STATEMENTS <BR></FONT><FONT face="Times New Roman, Times, Serif" size=2>YEARS ENDED MARCH 31, 2004, 2003 AND 2002 </FONT></H1>

<H1 align=left>
<!-- MARKER FORMAT-SHEET="Para (List) Flush Level 1" FSL="Default" --></H1>

<!-- MARKER FORMAT-SHEET="Para Flush Level 1" FSL="Default" -->
<TABLE cellSpacing=0 cellPadding=0 width="100%">
<TR vAlign=top>
<TD align=left width="5%"><FONT face="Times New Roman, Times, Serif" size=2><B>1. </B></FONT></TD>
<TD width="95%"><FONT face="Times New Roman, Times, Serif" size=2><B>Organization and Summary of Significant Accounting Policies </B></FONT></TD></TR>
</TABLE>

<BR>
<!-- MARKER FORMAT-SHEET="Para Flush Level 1" FSL="Default" -->
<TABLE cellSpacing=0 cellPadding=0 width="100%">
<TR vAlign=top>
<TD width="5%"><FONT face="Times New Roman, Times, Serif" size=2>&nbsp; </FONT></TD>
<TD width="95%"><FONT face="Times New Roman, Times, Serif" size=2>Abaxis, Inc. (&#147;the Company&#148;) was incorporated in California in 1989 for the purpose of developing, manufacturing and marketing portable blood analysis systems for use in any veterinary or human patient-care setting to provide clinicians with rapid blood constituent measurements. </FONT></TD></TR>
</TABLE>

<BR>
<!-- MARKER FORMAT-SHEET="Para Flush Level 1" FSL="Default" -->
<TABLE cellSpacing=0 cellPadding=0 width="100%">
<TR vAlign=top>
<TD width="5%"><FONT face="Times New Roman, Times, Serif" size=2>&nbsp; </FONT></TD>
<TD width="95%"><FONT face="Times New Roman, Times, Serif" size=2><B><I>Use of Estimates in Preparation of Financial Statements </I></B>&#151; The preparation of financial statements in accordance with accounting principles generally accepted in the United States of America, requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Such management estimates include trade receivables allowances, certain accruals, warranty reserves and a valuation allowance for net deferred tax assets. Actual results could differ from those estimates. </FONT></TD></TR>
</TABLE>

<BR>
<!-- MARKER FORMAT-SHEET="Para Flush Level 1" FSL="Default" -->
<TABLE cellSpacing=0 cellPadding=0 width="100%">
<TR vAlign=top>
<TD width="5%"><FONT face="Times New Roman, Times, Serif" size=2>&nbsp; </FONT></TD>
<TD width="95%"><FONT face="Times New Roman, Times, Serif" size=2><B><I>Certain Significant Risks and Uncertainties </I></B>&#151; The Company operates in a dynamic industry, and accordingly, can be affected by a variety of factors. For example, management of the Company believes that changes in any of the following areas could have a negative effect on the Company in terms of its future financial position and results of operations: ability to obtain additional financing; continued Federal Drug Administration compliance or regulatory changes; uncertainty regarding health care reforms; fundamental changes in the technology underlying blood testing; the ability to develop new products that are accepted in the marketplace; competition, including, but not limited to pricing and products or product features and services; litigation or other claims against the Company; the adequate and timely sourcing of inventories; and the hiring, training and retention of key employees. </FONT></TD></TR>
</TABLE>

<BR>
<!-- MARKER FORMAT-SHEET="Para Flush Level 1" FSL="Default" -->
<TABLE cellSpacing=0 cellPadding=0 width="100%">
<TR vAlign=top>
<TD width="5%"><FONT face="Times New Roman, Times, Serif" size=2>&nbsp; </FONT></TD>
<TD width="95%"><FONT face="Times New Roman, Times, Serif" size=2><B><I>Cash, Cash Equivalents and Short-term Investments </I></B>&#151; Cash and cash equivalents consist primarily of money market accounts and short-term financial instruments with original maturities of less than 90&nbsp;days from the date of acquisition that are readily convertible into cash. The Company&#146;s short-term investments consist of various certificate of deposits with maturities greater than three months at the balance sheet date and less than twelve months. </FONT></TD></TR>
</TABLE>

<BR>
<!-- MARKER FORMAT-SHEET="Para Flush Level 1" FSL="Default" -->
<TABLE cellSpacing=0 cellPadding=0 width="100%">
<TR vAlign=top>
<TD width="5%"><FONT face="Times New Roman, Times, Serif" size=2>&nbsp; </FONT></TD>
<TD width="95%"><FONT face="Times New Roman, Times, Serif" size=2><B><I>Concentration of Credit Risk</I></B> &#151; Financial instruments that potentially subject the Company to a concentration of credit risk consist primarily of cash and cash equivalents, short-term investments and trade receivables. Cash and cash equivalents and short-term investments are placed with high quality financial institutions and are regularly monitored by management. </FONT></TD></TR>
</TABLE>

<BR>
<!-- MARKER FORMAT-SHEET="Para Flush Level 1" FSL="Default" -->
<TABLE cellSpacing=0 cellPadding=0 width="100%">
<TR vAlign=top>
<TD width="5%"><FONT face="Times New Roman, Times, Serif" size=2>&nbsp; </FONT></TD>
<TD width="95%"><FONT face="Times New Roman, Times, Serif" size=2>The Company sells its products primarily to organizations in Europe, Japan and in the United States. The Company monitors the credit status of its customers on an ongoing basis and generally does not require its customers to provide collateral for purchases on credit. The Company maintains allowances for estimated bad debt losses. At March&nbsp;31, 2004, two distributors accounted for 30% and 25%, respectively, of trade receivables. At March&nbsp;31, 2003, two distributors accounted for 36% and 18%, respectively, of trade receivables. At March&nbsp;31, 2002, two distributors accounted for 42% and 12%, respectively, of trade receivables. </FONT></TD></TR>
</TABLE>

<BR>
<TABLE cellSpacing=0 cellPadding=0 width="100%">
<TR vAlign=top>
<TD width="5%"><FONT face="Times New Roman, Times, Serif" size=2>&nbsp; </FONT></TD>
<TD width="95%"><FONT face="Times New Roman, Times, Serif" size=2><B><I>Inventories</I></B>&#151; Inventories are stated at the lower of cost (first-in, first-out method) or market. </FONT></TD></TR>
</TABLE>

<BR>
<!-- MARKER FORMAT-SHEET="Para Flush Level 1" FSL="Default" -->
<TABLE cellSpacing=0 cellPadding=0 width="100%">
<TR vAlign=top>
<TD width="5%"><FONT face="Times New Roman, Times, Serif" size=2>&nbsp; </FONT></TD>
<TD width="95%"><FONT face="Times New Roman, Times, Serif" size=2><B><I>Property and Equipment</I></B> &#151; Property and equipment are stated at cost. Depreciation and amortization are generally provided using the straight-line method over the estimated useful lives of the assets (two to five years). Leasehold improvements are amortized over the shorter of the estimated useful lives or the related lease term. No interest was capitalized on constructed assets during fiscal 2004 and 2003. During fiscal 2002, the Company capitalized $74,000, of interest on constructed assets. </FONT></TD></TR>
</TABLE>

<BR>
<!-- MARKER FORMAT-SHEET="Para Flush Level 1" FSL="Default" -->
<TABLE cellSpacing=0 cellPadding=0 width="100%">
<TR vAlign=top>
<TD width="5%"><FONT face="Times New Roman, Times, Serif" size=2>&nbsp; </FONT></TD>
<TD width="95%"><FONT face="Times New Roman, Times, Serif" size=2><B><I>Valuation of Long-lived Assets</I></B> &#151; The carrying value of the Company&#146;s long-lived assets is reviewed for impairment whenever events or changes in circumstances indicate that an asset may not be recoverable. The Company looks to current and future profitability, as well as current and future undiscounted cash flows, excluding financing costs, as primary indicators of recoverability. An impairment loss would be recognized when the sum of the undiscounted future net cash flows expected to result from the use of the asset and its eventual disposal is less than the carrying amount. If impairment is determined to exist, any related impairment loss is calculated based on fair value. The Company adopted SFAS No. 144, &#147;Accounting for the Impairment or Disposal of Long-Lived Assets,&#148; which did not impact its results of operations or financial position. </FONT></TD></TR>
</TABLE>

<BR>
<TABLE width="100%">
<TR>
<TD align=center><FONT size=2>40</FONT></TD></TR>
</TABLE>



<P>
<HR align=left noshade SIZE=5>


<P>&nbsp;
<!-- *************************************************************************** -->
<!-- MARKER PAGE="sheet: 14; page: 14" -->
<!-- MARKER FORMAT-SHEET="Para Flush Level 1" FSL="Default" -->
<TABLE cellSpacing=0 cellPadding=0 width="100%">
<TR vAlign=top>
<TD width="5%"><FONT face="Times New Roman, Times, Serif" size=2>&nbsp; </FONT></TD>
<TD width="95%"><FONT face="Times New Roman, Times, Serif" size=2><B><I>Other Intangible Assets</I> </B>&#151; Intangible assets, consisting of patents, are amortized using the straight-line method over the estimated useful life of ten years. In accordance with SFAS No. 142, &#147;Goodwill and Other Intangible Assets,&#148; issued in July 2001, goodwill and other indefinite-lived intangible assets are tested annually for impairment rather than amortized. See Note 4. </FONT></TD></TR>
</TABLE>

<BR>
<!-- MARKER FORMAT-SHEET="Para Flush Level 1" FSL="Default" -->
<TABLE cellSpacing=0 cellPadding=0 width="100%">
<TR vAlign=top>
<TD width="5%"><FONT face="Times New Roman, Times, Serif" size=2>&nbsp; </FONT></TD>
<TD width="95%"><FONT face="Times New Roman, Times, Serif" size=2><B><I>Fair Value of Financial Instruments</I></B> &#151; Financial instruments include cash and cash equivalents, short-term investments, customer receivables, accounts payable, certain other accrued liabilities and long-term debt. The fair value of long-term debt approximates the carrying amount based on the current rate offered to the Company for debt of similar remaining maturities. The carrying values of all other financial instruments are reasonable estimates of their values. </FONT></TD></TR>
</TABLE>

<BR>
<!-- MARKER FORMAT-SHEET="Para Flush Level 1" FSL="Default" -->
<TABLE cellSpacing=0 cellPadding=0 width="100%">
<TR vAlign=top>
<TD width="5%"><FONT face="Times New Roman, Times, Serif" size=2>&nbsp; </FONT></TD>
<TD width="95%"><FONT face="Times New Roman, Times, Serif" size=2><B><I>Revenue Recognition</I></B> &#150; Revenues from product sales, net of estimated sales allowances and rebates, are recognized upon shipment when a purchase order has been received, the sales price is fixed and determinable and collection of the resulting receivable is reasonably assured. Rights of return are not provided and provisions are made at the time the related revenue is recognized for the estimated future costs to be incurred under initial standard warranty obligations of one year. Revenues received for, or allocated to extended warranty arrangements are recognized ratably over the related warranty period. Instrument revenues under cross-distribution agreements (where the Company and another party purchase each other&#146;s products for resale) are recognized upon sale of the products to the end user. Development and licensing revenue is recognized in accordance with the related contract terms. </FONT></TD></TR>
</TABLE>

<BR>
<!-- MARKER FORMAT-SHEET="Para Flush Level 1" FSL="Default" -->
<TABLE cellSpacing=0 cellPadding=0 width="100%">
<TR vAlign=top>
<TD width="5%"><FONT face="Times New Roman, Times, Serif" size=2>&nbsp; </FONT></TD>
<TD width="95%"><FONT face="Times New Roman, Times, Serif" size=2><B><I>Research and Development &#150; </I></B>Research and development costs, including internally generated software costs, are expensed as incurred and include expenses associated with new product research and regulatory activities. The Company&#146;s products include certain software applications that are resident in the product. The costs to develop such software have not been capitalized as the Company believes its current software development process is completed concurrent with the establishment of technological feasibility of the software. </FONT></TD></TR>
</TABLE>

<BR>
<!-- MARKER FORMAT-SHEET="Para Flush Level 1" FSL="Default" -->
<TABLE cellSpacing=0 cellPadding=0 width="100%">
<TR vAlign=top>
<TD width="5%"><FONT face="Times New Roman, Times, Serif" size=2>&nbsp; </FONT></TD>
<TD width="95%"><FONT face="Times New Roman, Times, Serif" size=2><B><I>Advertising Expenses &#150;</I></B><I> </I>Costs of advertising, which also includes promotional expenses, are expensed as incurred. Advertising expenses for fiscal 2004, 2003 and 2002 were $1,529,000, $1,181,000 and $1,023,000 respectively. </FONT></TD></TR>
</TABLE>

<BR>
<!-- MARKER FORMAT-SHEET="Para Flush Level 1" FSL="Default" -->
<TABLE cellSpacing=0 cellPadding=0 width="100%">
<TR vAlign=top>
<TD width="5%"><FONT face="Times New Roman, Times, Serif" size=2>&nbsp; </FONT></TD>
<TD width="95%"><FONT face="Times New Roman, Times, Serif" size=2><B><I>Shipping and Handling &#150;</I></B>The cost of shipping products to customers is included in cost of goods sold. Amounts billed to a customer in a sale transaction related to shipping and handling is classified as revenue. </FONT></TD></TR>
</TABLE>

<BR>
<!-- MARKER FORMAT-SHEET="Para Flush Level 1" FSL="Default" -->
<TABLE cellSpacing=0 cellPadding=0 width="100%">
<TR vAlign=top>
<TD width="5%"><FONT face="Times New Roman, Times, Serif" size=2>&nbsp; </FONT></TD>
<TD width="95%"><FONT face="Times New Roman, Times, Serif" size=2><B><I>Income Taxes</I></B> <B><I>&#150;</I></B><I> </I>The Company accounts for income taxes under the provisions of SFAS No. 109, &#147;Accounting for Income Taxes.&#148; Under this method, deferred tax assets and liabilities are determined based on the differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amounts to be recovered. </FONT></TD></TR>
</TABLE>

<BR>
<!-- MARKER FORMAT-SHEET="Para Flush Level 1" FSL="Default" -->
<TABLE cellSpacing=0 cellPadding=0 width="100%">
<TR vAlign=top>
<TD width="5%"><FONT face="Times New Roman, Times, Serif" size=2>&nbsp; </FONT></TD>
<TD width="95%"><FONT face="Times New Roman, Times, Serif" size=2><B><I>Stock-Based Compensation</I></B> &#151; The Company accounts for stock-based awards to employees using the intrinsic value method in accordance with Accounting Principles Board Opinion No.&nbsp;25, &#147;Accounting for Stock Issued to Employees&#148; (&#147;APB No.&nbsp;25&#148;) and other related guidance. Stock-based awards to consultants and other non-employees are accounted for based upon estimated fair values in accordance with Statement of Financial Accounting Standards No. 123 &#147;Accounting for Stock-Based Compensation.&#148; </FONT></TD></TR>
</TABLE>

<BR>
<!-- MARKER FORMAT-SHEET="Para Flush Level 1" FSL="Default" -->
<TABLE cellSpacing=0 cellPadding=0 width="100%">
<TR vAlign=top>
<TD width="5%"><FONT face="Times New Roman, Times, Serif" size=2>&nbsp; </FONT></TD>
<TD width="95%"><FONT face="Times New Roman, Times, Serif" size=2>Statement of Financial Accounting Standards No.&nbsp;123, &#147;Accounting for Stock-Based Compensation&#148; (SFAS&nbsp;No. 123), requires the disclosure of pro&nbsp;forma net loss and loss per share as if the Company had adopted the fair value method. Under SFAS&nbsp;No. 123, the fair value of stock-based awards to employees is calculated through the use of option pricing models, even though such models were developed to estimate the fair value of freely tradable, fully transferable options without vesting restrictions, which significantly differ from the Company&#146;s stock option awards. These models also require subjective assumptions, including future stock price volatility and expected time to exercise, which greatly affect the calculated values. </FONT></TD></TR>
</TABLE>

<BR>

<P><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Had compensation cost been recognized based on the fair value at the grant date, the Company&#146;s net income (loss) and basic and diluted net income (loss) per share would have been as follows: </FONT></P>

<TABLE width="100%">
<TR>
<TD align=center><FONT size=2>41</FONT></TD></TR>
</TABLE>



<P>
<HR align=left noshade SIZE=5>


<P>&nbsp;
<!-- *************************************************************************** -->
<!-- MARKER PAGE="sheet: 14; page: 14" -->
<TABLE cellSpacing=0 cellPadding=0 width="100%" border=0>
<TR>
<TD vAlign=bottom nowrap width="61%"><FONT face="Times New Roman" size=2><B>&nbsp;</B></FONT></TD>
<TD vAlign=bottom nowrap align=center colSpan=5><FONT face="Times New Roman" size=2><B>Year Ended March 31,</B></FONT>
<HR noshade SIZE=1>
</TD></TR>
<TR>
<TD vAlign=bottom nowrap width="61%"><FONT face="Times New Roman" size=2><B>&nbsp;</B></FONT></TD>
<TD vAlign=bottom nowrap align=center width="9%"><FONT face="Times New Roman" size=2><B>2004</B></FONT>
<HR noshade SIZE=1>
</TD>
<TD vAlign=bottom nowrap align=center width="7%"><FONT face="Times New Roman" size=2><B>&nbsp;&nbsp;&nbsp;</B></FONT></TD>
<TD vAlign=bottom nowrap align=center width="8%"><FONT face="Times New Roman" size=2><B>2003</B></FONT>
<HR noshade SIZE=1>
</TD>
<TD vAlign=bottom nowrap align=center width="6%"><FONT face="Times New Roman" size=2><B>&nbsp;&nbsp;&nbsp;</B></FONT></TD>
<TD vAlign=bottom nowrap align=center width="9%"><FONT face="Times New Roman" size=2><B>2002</B></FONT>
<HR noshade SIZE=1>
</TD></TR>
<TR>
<TD vAlign=bottom nowrap width="61%"><FONT face="Times New Roman" size=2><B>&nbsp;</B></FONT></TD>
<TD vAlign=bottom nowrap width="9%"><FONT face="Times New Roman" size=2>&nbsp;</FONT></TD>
<TD vAlign=bottom nowrap width="7%"><FONT face="Times New Roman" size=2><B>&nbsp;</B></FONT></TD>
<TD vAlign=bottom nowrap width="8%"><FONT face="Times New Roman" size=2><B>&nbsp;</B></FONT></TD>
<TD vAlign=bottom nowrap width="6%"><FONT face="Times New Roman" size=2><B>&nbsp;</B></FONT></TD>
<TD vAlign=bottom nowrap width="9%"><FONT face="Times New Roman" size=2><B>&nbsp;</B></FONT></TD></TR>
<TR>
<TD vAlign=bottom nowrap width="61%"><FONT face="Times New Roman" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net income:</FONT></TD>
<TD vAlign=bottom nowrap width="9%"><FONT face="Times New Roman" size=2>&nbsp;</FONT></TD>
<TD vAlign=bottom nowrap width="7%"><FONT face="Times New Roman" size=2><B>&nbsp;</B></FONT></TD>
<TD vAlign=bottom nowrap width="8%"><FONT face="Times New Roman" size=2><B>&nbsp;</B></FONT></TD>
<TD vAlign=bottom nowrap width="6%"><FONT face="Times New Roman" size=2><B>&nbsp;</B></FONT></TD>
<TD vAlign=bottom nowrap width="9%"><FONT face="Times New Roman" size=2><B>&nbsp;</B></FONT></TD></TR>
<TR>
<TD vAlign=bottom nowrap width="61%"><FONT face="Times New Roman" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; As reported</FONT></TD>
<TD vAlign=bottom nowrap align=right width="9%"><FONT face="Times New Roman" size=2>&nbsp; $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 24,033,000&nbsp; </FONT></TD>
<TD vAlign=bottom nowrap align=right width="7%"><FONT face="Times New Roman" size=2>&nbsp;</FONT></TD>
<TD vAlign=bottom nowrap align=right width="8%"><FONT face="Times New Roman" size=2>&nbsp; $&nbsp;&nbsp;&nbsp;&nbsp; 1,636,000&nbsp; </FONT></TD>
<TD vAlign=bottom nowrap align=right width="6%"><FONT face="Times New Roman" size=2>&nbsp;</FONT></TD>
<TD vAlign=bottom nowrap align=right width="9%"><FONT face="Times New Roman" size=2>&nbsp; $&nbsp;&nbsp;&nbsp;&nbsp; 1,304,000&nbsp; </FONT></TD></TR>
<TR>
<TD vAlign=bottom nowrap width="61%"><FONT face="Times New Roman" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Less stock-based compensation expense determined under the</FONT></TD>
<TD vAlign=bottom nowrap align=right width="9%"><FONT face="Times New Roman" size=2>&nbsp;</FONT></TD>
<TD vAlign=bottom nowrap align=right width="7%"><FONT face="Times New Roman" size=2>&nbsp;</FONT></TD>
<TD vAlign=bottom nowrap align=right width="8%"><FONT face="Times New Roman" size=2>&nbsp;</FONT></TD>
<TD vAlign=bottom nowrap align=right width="6%"><FONT face="Times New Roman" size=2>&nbsp;</FONT></TD>
<TD vAlign=bottom nowrap align=right width="9%"><FONT face="Times New Roman" size=2>&nbsp;</FONT></TD></TR>
<TR>
<TD vAlign=bottom nowrap width="61%"><FONT face="Times New Roman" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;fair value method for all awards, net of related tax effects</FONT></TD>
<TD vAlign=bottom nowrap align=right width="9%"><FONT face="Times New Roman" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (1,538,000) </FONT></TD>
<TD vAlign=bottom nowrap align=right width="7%"><FONT face="Times New Roman" size=2>&nbsp;</FONT></TD>
<TD vAlign=bottom nowrap align=right width="8%"><FONT face="Times New Roman" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (1,202,000) </FONT></TD>
<TD vAlign=bottom nowrap align=right width="6%"><FONT face="Times New Roman" size=2>&nbsp;</FONT></TD>
<TD vAlign=bottom nowrap align=right width="9%"><FONT face="Times New Roman" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (2,263,000) </FONT></TD></TR>
<TR>
<TD vAlign=bottom nowrap width="61%"><FONT face="Times New Roman" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD vAlign=bottom nowrap align=right width="9%">
<HR noshade SIZE=1>
</TD>
<TD vAlign=bottom nowrap align=right width="7%">&nbsp;</TD>
<TD vAlign=bottom nowrap align=right width="8%">
<HR noshade SIZE=1>
</TD>
<TD vAlign=bottom nowrap align=right width="6%">&nbsp;</TD>
<TD vAlign=bottom nowrap align=right width="9%">
<HR noshade SIZE=1>
</TD></TR>
<TR>
<TD vAlign=bottom nowrap width="61%"><FONT face="Times New Roman" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Pro forma net income (loss)</FONT></TD>
<TD vAlign=bottom nowrap align=right width="9%"><FONT face="Times New Roman" size=2>&nbsp; $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 22,495,000&nbsp; </FONT></TD>
<TD vAlign=bottom nowrap align=right width="7%"><FONT face="Times New Roman" size=2>&nbsp;</FONT></TD>
<TD vAlign=bottom nowrap align=right width="8%"><FONT face="Times New Roman" size=2>&nbsp; $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 434,000&nbsp; </FONT></TD>
<TD vAlign=bottom nowrap align=right width="6%"><FONT face="Times New Roman" size=2>&nbsp;</FONT></TD>
<TD vAlign=bottom nowrap align=right width="9%"><FONT face="Times New Roman" size=2>&nbsp; $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (959,000) </FONT></TD></TR>
<TR>
<TD vAlign=bottom nowrap width="61%">&nbsp;</TD>
<TD vAlign=bottom nowrap align=right width="9%">
<HR noshade>
</TD>
<TD vAlign=bottom nowrap align=right width="7%">&nbsp;</TD>
<TD vAlign=bottom nowrap align=right width="8%">
<HR noshade>
</TD>
<TD vAlign=bottom nowrap align=right width="6%">&nbsp;</TD>
<TD vAlign=bottom nowrap align=right width="9%">
<HR noshade>
</TD></TR>
<TR>
<TD vAlign=bottom nowrap width="61%"><FONT face="Times New Roman" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Basic and diluted net income (loss) per share:</FONT></TD>
<TD vAlign=bottom nowrap align=right width="9%"><FONT face="Times New Roman" size=2>&nbsp;</FONT></TD>
<TD vAlign=bottom nowrap align=right width="7%"><FONT face="Times New Roman" size=2>&nbsp;</FONT></TD>
<TD vAlign=bottom nowrap align=right width="8%"><FONT face="Times New Roman" size=2>&nbsp;</FONT></TD>
<TD vAlign=bottom nowrap align=right width="6%"><FONT face="Times New Roman" size=2>&nbsp;</FONT></TD>
<TD vAlign=bottom nowrap align=right width="9%"><FONT face="Times New Roman" size=2>&nbsp;</FONT></TD></TR>
<TR>
<TD vAlign=bottom nowrap width="61%"><FONT face="Times New Roman" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; As reported - basic</FONT></TD>
<TD vAlign=bottom nowrap align=right width="9%"><FONT face="Times New Roman" size=2>&nbsp; $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 1.30&nbsp; </FONT></TD>
<TD vAlign=bottom nowrap align=right width="7%"><FONT face="Times New Roman" size=2>&nbsp;</FONT></TD>
<TD vAlign=bottom nowrap align=right width="8%"><FONT face="Times New Roman" size=2>&nbsp; $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 0.02&nbsp; </FONT></TD>
<TD vAlign=bottom nowrap align=right width="6%"><FONT face="Times New Roman" size=2>&nbsp;</FONT></TD>
<TD vAlign=bottom nowrap align=right width="9%"><FONT face="Times New Roman" size=2>&nbsp; $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 0.02&nbsp; </FONT></TD></TR>
<TR>
<TD vAlign=bottom nowrap width="61%"><FONT face="Times New Roman" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Pro forma - basic</FONT></TD>
<TD vAlign=bottom nowrap align=right width="9%"><FONT face="Times New Roman" size=2>&nbsp; $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 1.24&nbsp; </FONT></TD>
<TD vAlign=bottom nowrap align=right width="7%"><FONT face="Times New Roman" size=2>&nbsp;</FONT></TD>
<TD vAlign=bottom nowrap align=right width="8%"><FONT face="Times New Roman" size=2>&nbsp; $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 0.03&nbsp; </FONT></TD>
<TD vAlign=bottom nowrap align=right width="6%"><FONT face="Times New Roman" size=2>&nbsp;</FONT></TD>
<TD vAlign=bottom nowrap align=right width="9%"><FONT face="Times New Roman" size=2>&nbsp; $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (0.06) </FONT></TD></TR>
<TR>
<TD vAlign=bottom nowrap width="61%"><FONT face="Times New Roman" size=2>&nbsp;</FONT></TD>
<TD vAlign=bottom nowrap align=right width="9%"><FONT face="Times New Roman" size=2>&nbsp;</FONT></TD>
<TD vAlign=bottom nowrap align=right width="7%"><FONT face="Times New Roman" size=2>&nbsp;</FONT></TD>
<TD vAlign=bottom nowrap align=right width="8%"><FONT face="Times New Roman" size=2>&nbsp;</FONT></TD>
<TD vAlign=bottom nowrap align=right width="6%"><FONT face="Times New Roman" size=2>&nbsp;</FONT></TD>
<TD vAlign=bottom nowrap align=right width="9%"><FONT face="Times New Roman" size=2>&nbsp;</FONT></TD></TR>
<TR>
<TD vAlign=bottom nowrap width="61%"><FONT face="Times New Roman" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; As reported - diluted</FONT></TD>
<TD vAlign=bottom nowrap align=right width="9%"><FONT face="Times New Roman" size=2>&nbsp; $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 1.16&nbsp; </FONT></TD>
<TD vAlign=bottom nowrap align=right width="7%"><FONT face="Times New Roman" size=2>&nbsp;</FONT></TD>
<TD vAlign=bottom nowrap align=right width="8%"><FONT face="Times New Roman" size=2>&nbsp; $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 0.02&nbsp; </FONT></TD>
<TD vAlign=bottom nowrap align=right width="6%"><FONT face="Times New Roman" size=2>&nbsp;</FONT></TD>
<TD vAlign=bottom nowrap align=right width="9%"><FONT face="Times New Roman" size=2>&nbsp; $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 0.02&nbsp; </FONT></TD></TR>
<TR>
<TD vAlign=bottom nowrap width="61%"><FONT face="Times New Roman" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Pro forma - diluted</FONT></TD>
<TD vAlign=bottom nowrap align=right width="9%"><FONT face="Times New Roman" size=2>&nbsp; $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 1.10&nbsp; </FONT></TD>
<TD vAlign=bottom nowrap align=right width="7%"><FONT face="Times New Roman" size=2>&nbsp;</FONT></TD>
<TD vAlign=bottom nowrap align=right width="8%"><FONT face="Times New Roman" size=2>&nbsp; $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 0.03&nbsp; </FONT></TD>
<TD vAlign=bottom nowrap align=right width="6%"><FONT face="Times New Roman" size=2>&nbsp;</FONT></TD>
<TD vAlign=bottom nowrap align=right width="9%"><FONT face="Times New Roman" size=2>&nbsp; $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (0.06) </FONT></TD></TR>
</TABLE>

<BR>
<!-- MARKER FORMAT-SHEET="Para Flush Level 1" FSL="Default" -->
<TABLE cellSpacing=0 cellPadding=0 width="100%">
<TR vAlign=top>
<TD width="5%"><FONT face="Times New Roman, Times, Serif" size=2>&nbsp; </FONT></TD>
<TD width="95%"><FONT face="Times New Roman, Times, Serif" size=2>The Company&#146;s calculations were made using the Black-Scholes option pricing model, based on a multiple option valuation approach, and forfeitures were recognized as they occurred. The following are the weighted average assumptions: </FONT></TD></TR>
</TABLE>



<P>
<TABLE cellSpacing=0 cellPadding=0 width="100%" border=0>
<TR>
<TD vAlign=bottom nowrap width="70%">&nbsp; </TD>
<TD vAlign=bottom nowrap align=center colSpan=8><FONT face="Times New Roman" size=2><B>Year Ended March 31,</B></FONT>
<HR noshade SIZE=1>
</TD></TR>
<TR>
<TD vAlign=bottom nowrap width="70%">&nbsp; </TD>
<TD vAlign=bottom nowrap align=center colSpan=2><FONT face="Times New Roman" size=2><B>2004</B></FONT>
<HR noshade SIZE=1>
</TD>
<TD vAlign=bottom nowrap align=center width="3%">&nbsp;&nbsp; </TD>
<TD vAlign=bottom nowrap align=center colSpan=2><FONT face="Times New Roman" size=2><B>2003</B></FONT>
<HR noshade SIZE=1>
</TD>
<TD vAlign=bottom nowrap align=center width="2%"><FONT face="Times New Roman" size=2><B>&nbsp;&nbsp;&nbsp;</B></FONT></TD>
<TD vAlign=bottom nowrap align=center colSpan=2><FONT face="Times New Roman" size=2><B>2002</B></FONT>
<HR noshade SIZE=1>
</TD></TR>
<TR>
<TD vAlign=bottom nowrap width="70%"><FONT face="Times New Roman" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Expected life of option</FONT></TD>
<TD vAlign=bottom nowrap align=right width="6%"><FONT face="Times New Roman" size=2>6 years</FONT></TD>
<TD vAlign=bottom nowrap align=right width="3%">&nbsp; </TD>
<TD vAlign=bottom nowrap align=right width="3%">&nbsp; </TD>
<TD vAlign=bottom nowrap align=right width="5%"><FONT face="Times New Roman" size=2>6 years</FONT></TD>
<TD vAlign=bottom nowrap align=right width="3%">&nbsp; </TD>
<TD vAlign=bottom nowrap align=right width="2%">&nbsp; </TD>
<TD vAlign=bottom nowrap align=right width="5%"><FONT face="Times New Roman" size=2>6 years</FONT></TD>
<TD vAlign=bottom nowrap align=right width="3%">&nbsp; </TD></TR>
<TR>
<TD vAlign=bottom nowrap width="70%"><FONT face="Times New Roman" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Risk-free interest rate</FONT></TD>
<TD vAlign=bottom nowrap align=right width="6%"><FONT face="Times New Roman" size=2>2.78-3.53</FONT></TD>
<TD vAlign=bottom nowrap width="3%"><FONT face="Times New Roman" size=2>%</FONT></TD>
<TD vAlign=bottom nowrap width="3%">&nbsp; </TD>
<TD vAlign=bottom nowrap align=right width="5%"><FONT face="Times New Roman" size=2>3.17</FONT></TD>
<TD vAlign=bottom nowrap width="3%"><FONT face="Times New Roman" size=2>%</FONT></TD>
<TD vAlign=bottom nowrap width="2%">&nbsp; </TD>
<TD vAlign=bottom nowrap align=right width="5%"><FONT face="Times New Roman" size=2>5.20</FONT></TD>
<TD vAlign=bottom nowrap width="3%"><FONT face="Times New Roman" size=2>%</FONT></TD></TR>
<TR>
<TD vAlign=bottom nowrap width="70%"><FONT face="Times New Roman" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Dividend yield</FONT></TD>
<TD vAlign=bottom nowrap align=right width="6%"><FONT face="Times New Roman" size=2>0.00 </FONT></TD>
<TD vAlign=bottom nowrap width="3%"><FONT face="Times New Roman" size=2>%</FONT></TD>
<TD vAlign=bottom nowrap width="3%">&nbsp; </TD>
<TD vAlign=bottom nowrap align=right width="5%"><FONT face="Times New Roman" size=2>0.00 </FONT></TD>
<TD vAlign=bottom nowrap width="3%"><FONT face="Times New Roman" size=2>%</FONT></TD>
<TD vAlign=bottom nowrap width="2%">&nbsp; </TD>
<TD vAlign=bottom nowrap align=right width="5%"><FONT face="Times New Roman" size=2>0.00 </FONT></TD>
<TD vAlign=bottom nowrap width="3%"><FONT face="Times New Roman" size=2>%</FONT></TD></TR>
<TR>
<TD vAlign=bottom nowrap width="70%"><FONT face="Times New Roman" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Volatility</FONT></TD>
<TD vAlign=bottom nowrap align=right width="6%"><FONT face="Times New Roman" size=2>58-61</FONT></TD>
<TD vAlign=bottom nowrap width="3%"><FONT face="Times New Roman" size=2>%</FONT></TD>
<TD vAlign=bottom nowrap width="3%">&nbsp; </TD>
<TD vAlign=bottom nowrap align=right width="5%"><FONT face="Times New Roman" size=2>62</FONT></TD>
<TD vAlign=bottom nowrap width="3%"><FONT face="Times New Roman" size=2>%</FONT></TD>
<TD vAlign=bottom nowrap width="2%">&nbsp; </TD>
<TD vAlign=bottom nowrap align=right width="5%"><FONT face="Times New Roman" size=2>79</FONT></TD>
<TD vAlign=bottom nowrap width="3%"><FONT face="Times New Roman" size=2>%</FONT></TD></TR>
</TABLE>

<BR>
<!-- MARKER FORMAT-SHEET="Para Flush Level 1" FSL="Default" -->
<TABLE cellSpacing=0 cellPadding=0 width="100%">
<TR vAlign=top>
<TD width="5%"><FONT face="Times New Roman, Times, Serif" size=2>&nbsp; </FONT></TD>
<TD width="95%"><FONT face="Times New Roman, Times, Serif" size=2><B><I>Net Income Per Share Information</I></B> &#151; Basic net income per share is computed by dividing the net income attributable to common shareholders by the weighted average number of shares of common stock outstanding. Diluted net income per share is computed by dividing net income attributable to common shareholders by the weighted average number of common shares that would have been outstanding during the period assuming the issuance of common shares for all dilutive potential common shares outstanding. <BR>See Note 12. </FONT></TD></TR>
</TABLE>

<BR>
<!-- MARKER FORMAT-SHEET="Para Flush Level 1" FSL="Default" -->
<TABLE cellSpacing=0 cellPadding=0 width="100%">
<TR vAlign=top>
<TD width="5%"><FONT face="Times New Roman, Times, Serif" size=2>&nbsp; </FONT></TD>
<TD width="95%"><FONT face="Times New Roman, Times, Serif" size=2><B><I>Comprehensive Income (Loss)</I></B> &#151; Comprehensive income was the same as net income for fiscal 2004, 2003 and 2002. </FONT></TD></TR>
</TABLE>

<BR>
<TABLE cellSpacing=0 cellPadding=0 width="100%">
<TR vAlign=top>
<TD width="5%"><FONT face="Times New Roman, Times, Serif" size=2>&nbsp; </FONT></TD>
<TD width="95%"><FONT face="Times New Roman, Times, Serif" size=2><B><I>New Accounting Pronouncements</I></B> &#151; In December 2002, the FASB issued SFAS No. 148, &#147;Accounting for Stock-Based Compensation &#151; Transition and Disclosure.&#148; SFAS No. 148 amends FASB Statement No. 123, &#147;Accounting for Stock-Based Compensation,&#148; to provide alternative methods of transition for a voluntary change to the fair value based method of accounting for stock-based employee compensation. In addition, SFAS 148 amends the disclosure requirements of SFAS 123 to require prominent disclosures in both annual and interim financial statements of the method of accounting for stock-based employee compensation and the effect of the method used on reported results. The Company adopted the disclosure provisions of SFAS No. 148 on January 1, 2003. The Company did not change to using the fair value based method of accounting for stock-based employee compensation as permitted by the voluntary transition
provisions of SFAS 148; and therefore, adoption of SFAS No. 148 did not have an impact on the financial position, results of operations or cash flows of the Company. </FONT></TD></TR>
</TABLE>

<BR>
<!-- MARKER FORMAT-SHEET="Para Flush Level 1" FSL="Default" -->
<TABLE cellSpacing=0 cellPadding=0 width="100%">
<TR vAlign=top>
<TD width="5%"><FONT face="Times New Roman, Times, Serif" size=2>&nbsp; </FONT></TD>
<TD width="95%"><FONT face="Times New Roman, Times, Serif" size=2>In April 2003, the FASB issued SFAS No. 149, &#147;Amendment of Statement 133 on Derivative Instruments and Hedging Activities.&#148; This statement amends and clarifies financial accounting and reporting for derivative instruments, including certain derivative instruments embedded in other contracts (collectively referred to as derivatives) and for hedging activities under FASB Statement No. 133, &#147;Accounting for Derivative Instruments and Hedging Activities.&#148; This statement is effective for contracts entered into or modified after June 30, 2003. The adoption of this statement did not have an impact on the Company&#146;s financial position, results of operations or cash flows. </FONT></TD></TR>
</TABLE>

<BR>
<!-- MARKER FORMAT-SHEET="Para Flush Level 1" FSL="Default" -->
<TABLE cellSpacing=0 cellPadding=0 width="100%">
<TR vAlign=top>
<TD width="5%"><FONT face="Times New Roman, Times, Serif" size=2>&nbsp; </FONT></TD>
<TD width="95%"><FONT face="Times New Roman, Times, Serif" size=2>In May 2003, the FASB issued SFAS No. 150, &#147;Accounting for Certain Financial Instruments with Characteristics of both Liabilities and Equity.&#148; This statement establishes standards for how an issuer classifies and measures certain financial instruments with characteristics of both liabilities and equity. This statement is effective for financial instruments entered into or </FONT></TD></TR>
</TABLE>

<BR>
<TABLE width="100%">
<TR>
<TD align=center><FONT size=2>42</FONT></TD></TR>
</TABLE>



<P>
<HR align=left noshade SIZE=5>


<P>&nbsp;
<!-- *************************************************************************** -->
<!-- MARKER PAGE="sheet: 14; page: 14" -->
<!-- MARKER FORMAT-SHEET="Para Flush Level 1" FSL="Default" -->
<TABLE cellSpacing=0 cellPadding=0 width="100%">
<TR vAlign=top>
<TD width="5%"><FONT face="Times New Roman, Times, Serif" size=2>&nbsp; </FONT></TD>
<TD width="95%"><FONT face="Times New Roman, Times, Serif" size=2>modified after May 31, 2003 and otherwise is effective at the beginning of the first interim period beginning after June 15, 2003. The adoption of this statement did not have an impact on the Company&#146;s financial position, results of operations or cash flows. </FONT></TD></TR>
</TABLE>

<BR>
<!-- MARKER FORMAT-SHEET="Para Flush Level 1" FSL="Default" -->
<TABLE cellSpacing=0 cellPadding=0 width="100%">
<TR vAlign=top>
<TD width="5%"><FONT face="Times New Roman, Times, Serif" size=2>&nbsp; </FONT></TD>
<TD width="95%"><FONT face="Times New Roman, Times, Serif" size=2>The Financial Accounting Standards Board (&#147;FASB&#148;) issued Interpretation No. 46 (&#147;FIN 46&#148;), &#147;Consolidation of Variable Interest Entities,&#148; in January 2003, and a revised interpretation of FIN 46 (&#147;FIN 46-R&#148;) in December 2003. FIN 46 requires certain variable interest entities (&#147;VIEs&#148;) to be consolidated by the primary beneficiary of the entity if the equity investors in the entity do not have the characteristics of a controlling financial interest or do not have sufficient equity at risk for the entity to finance its activities without additional subordinated financial support from other parties. The provisions of FIN 46 are effective immediately for all arrangements entered into after January 31, 2003. Since January 31, 2003, the Company has not invested in any entities it believes are variable interest entities for which the Company is the primary beneficiary. For all arrangements
entered into after January 31, 2003, the Company is required to continue to apply FIN 46 through the end of the fourth quarter of fiscal 2004. The Company is required to adopt the provisions of FIN 46-R for those arrangements in the first quarter of fiscal 2005. For arrangements entered into prior to February 1, 2003, the Company is required to adopt the provisions of FIN 46-R in the first quarter of fiscal 2005. The Company does not expect the adoption of FIN 46-R to have an impact on the financial position, results of operations or cash flows of the Company. </FONT></TD></TR>
</TABLE>

<BR>
<!-- MARKER FORMAT-SHEET="Para Flush Level 1" FSL="Default" -->
<TABLE cellSpacing=0 cellPadding=0 width="100%">
<TR vAlign=top>
<TD width="5%"><FONT face="Times New Roman, Times, Serif" size=2>&nbsp; </FONT></TD>
<TD width="95%"><FONT face="Times New Roman, Times, Serif" size=2><B><I>Reclassification</I></B><I>&#150;</I>Certain amounts in the fiscal years ended March 31, 2003 and 2002 financial statements have been reclassified to conform to the fiscal year ended March 31, 2004 presentation. </FONT></TD></TR>
</TABLE>

<BR>
<TABLE cellSpacing=0 cellPadding=0 width="100%">
<TR vAlign=top>
<TD width="5%"><B><FONT face="Times New Roman, Times, Serif" size=2>2. &nbsp;&nbsp;</FONT></B></TD>
<TD width="95%"><B><FONT face="Times New Roman, Times, Serif" size=2>Inventories </FONT></B></TD></TR>
</TABLE>


<H1 align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Inventories at March&nbsp;31 consist of the following: </FONT></H1>


<P>
<TABLE cellSpacing=0 cellPadding=0 width="100%" border=0>
<TR>
<TD vAlign=bottom nowrap width="78%"><FONT face="Times New Roman" size=2><B>&nbsp;</B></FONT></TD>
<TD vAlign=bottom nowrap align=center width="9%"><FONT face="Times New Roman" size=2><B>2004</B></FONT>
<HR noshade SIZE=1>
</TD>
<TD vAlign=bottom nowrap align=center width="4%">&nbsp;</TD>
<TD vAlign=bottom nowrap align=center width="9%"><FONT face="Times New Roman" size=2><B>2003</B></FONT>
<HR noshade SIZE=1>
</TD></TR>
<TR>
<TD vAlign=bottom nowrap width="78%"><FONT face="Times New Roman" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Raw materials</FONT></TD>
<TD vAlign=bottom nowrap align=right width="9%"><FONT face="Times New Roman" size=2>&nbsp; $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 2,886,000&nbsp; </FONT></TD>
<TD vAlign=bottom nowrap align=right width="4%">&nbsp; </TD>
<TD vAlign=bottom nowrap align=right width="9%"><FONT face="Times New Roman" size=2>&nbsp; $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 2,317,000&nbsp; </FONT></TD></TR>
<TR>
<TD vAlign=bottom nowrap width="78%"><FONT face="Times New Roman" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Work-in-process</FONT></TD>
<TD vAlign=bottom nowrap align=right width="9%"><FONT face="Times New Roman" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 1,654,000&nbsp; </FONT></TD>
<TD vAlign=bottom nowrap align=right width="4%">&nbsp; </TD>
<TD vAlign=bottom nowrap align=right width="9%"><FONT face="Times New Roman" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 2,071,000&nbsp; </FONT></TD></TR>
<TR>
<TD vAlign=bottom nowrap width="78%"><FONT face="Times New Roman" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Finished goods</FONT></TD>
<TD vAlign=bottom nowrap align=right width="9%"><FONT face="Times New Roman" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 1,196,000&nbsp; </FONT></TD>
<TD vAlign=bottom nowrap align=right width="4%">&nbsp; </TD>
<TD vAlign=bottom nowrap align=right width="9%"><FONT face="Times New Roman" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 594,000&nbsp; </FONT></TD></TR>
<TR>
<TD vAlign=bottom nowrap width="78%">&nbsp;</TD>
<TD vAlign=bottom nowrap align=right width="9%">
<HR noshade SIZE=1>
</TD>
<TD vAlign=bottom nowrap align=right width="4%">&nbsp;</TD>
<TD vAlign=bottom nowrap align=right width="9%">
<HR noshade SIZE=1>
</TD></TR>
<TR>
<TD vAlign=bottom nowrap width="78%"><FONT face="Times New Roman" size=2>&nbsp;</FONT></TD>
<TD vAlign=bottom nowrap align=right width="9%"><FONT face="Times New Roman" size=2>&nbsp; $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 5,736,000&nbsp; </FONT></TD>
<TD vAlign=bottom nowrap align=right width="4%">&nbsp; </TD>
<TD vAlign=bottom nowrap align=right width="9%"><FONT face="Times New Roman" size=2>&nbsp; $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 4,982,000&nbsp; </FONT></TD></TR>
<TR>
<TD vAlign=bottom nowrap width="78%">&nbsp;</TD>
<TD vAlign=bottom nowrap align=right width="9%">
<HR noshade>
</TD>
<TD vAlign=bottom nowrap align=right width="4%">&nbsp;</TD>
<TD vAlign=bottom nowrap align=right width="9%">
<HR noshade>
</TD></TR>
</TABLE>

<BR>
<TABLE cellSpacing=0 cellPadding=0 width="100%">
<TR vAlign=top>
<TD width="5%"><B><FONT face="Times New Roman, Times, Serif" size=2>3. &nbsp;&nbsp;</FONT></B></TD>
<TD width="95%"><B><FONT face="Times New Roman, Times, Serif" size=2>Property and Equipment </FONT></B></TD></TR>
</TABLE>



<P><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Property and equipment at March&nbsp;31 consists of the following: </FONT></P>


<P>
<TABLE cellSpacing=0 cellPadding=0 width="100%" border=0>
<TR>
<TD vAlign=bottom nowrap width="78%"><FONT face="Times New Roman" size=2>&nbsp;</FONT></TD>
<TD vAlign=bottom nowrap align=center width="10%"><FONT face="Times New Roman" size=2><B>2004</B></FONT>
<HR noshade SIZE=1>
</TD>
<TD vAlign=bottom nowrap align=center width="2%">&nbsp;</TD>
<TD vAlign=bottom nowrap align=center width="10%"><FONT face="Times New Roman" size=2><B>2003</B></FONT>
<HR noshade SIZE=1>
</TD></TR>
<TR>
<TD vAlign=bottom nowrap width="78%"><FONT face="Times New Roman" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Machinery and equipment</FONT></TD>
<TD vAlign=bottom nowrap align=right width="10%"><FONT face="Times New Roman" size=2>&nbsp; $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 10,210,000&nbsp; </FONT></TD>
<TD vAlign=bottom nowrap align=right width="2%">&nbsp;</TD>
<TD vAlign=bottom nowrap align=right width="10%"><FONT face="Times New Roman" size=2>&nbsp; $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 8,828,000&nbsp; </FONT></TD></TR>
<TR>
<TD vAlign=bottom nowrap width="78%"><FONT face="Times New Roman" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Furniture and fixtures</FONT></TD>
<TD vAlign=bottom nowrap align=right width="10%"><FONT face="Times New Roman" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 1,111,000&nbsp; </FONT></TD>
<TD vAlign=bottom nowrap align=right width="2%">&nbsp;</TD>
<TD vAlign=bottom nowrap align=right width="10%"><FONT face="Times New Roman" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 1,075,000&nbsp; </FONT></TD></TR>
<TR>
<TD vAlign=bottom nowrap width="78%"><FONT face="Times New Roman" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Computers and computer equipment</FONT></TD>
<TD vAlign=bottom nowrap align=right width="10%"><FONT face="Times New Roman" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 1,014,000&nbsp; </FONT></TD>
<TD vAlign=bottom nowrap align=right width="2%">&nbsp;</TD>
<TD vAlign=bottom nowrap align=right width="10%"><FONT face="Times New Roman" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 907,000&nbsp; </FONT></TD></TR>
<TR>
<TD vAlign=bottom nowrap width="78%"><FONT face="Times New Roman" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Leasehold improvements</FONT></TD>
<TD vAlign=bottom nowrap align=right width="10%"><FONT face="Times New Roman" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 5,453,000&nbsp; </FONT></TD>
<TD vAlign=bottom nowrap align=right width="2%">&nbsp;</TD>
<TD vAlign=bottom nowrap align=right width="10%"><FONT face="Times New Roman" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 5,356,000&nbsp; </FONT></TD></TR>
<TR>
<TD vAlign=bottom nowrap width="78%"><FONT face="Times New Roman" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Construction in progress</FONT></TD>
<TD vAlign=bottom nowrap align=right width="10%"><FONT face="Times New Roman" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 396,000&nbsp; </FONT></TD>
<TD vAlign=bottom nowrap align=right width="2%">&nbsp;</TD>
<TD vAlign=bottom nowrap align=right width="10%"><FONT face="Times New Roman" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 818,000&nbsp; </FONT></TD></TR>
<TR>
<TD vAlign=bottom nowrap width="78%">&nbsp;</TD>
<TD vAlign=bottom nowrap align=right width="10%">
<HR noshade SIZE=1>
</TD>
<TD vAlign=bottom nowrap align=right width="2%">&nbsp;</TD>
<TD vAlign=bottom nowrap align=right width="10%">
<HR noshade SIZE=1>
</TD></TR>
<TR>
<TD vAlign=bottom nowrap width="78%"><FONT face="Times New Roman" size=2>&nbsp;</FONT></TD>
<TD vAlign=bottom nowrap align=right width="10%"><FONT face="Times New Roman" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 18,184,000&nbsp; </FONT></TD>
<TD vAlign=bottom nowrap align=right width="2%">&nbsp;</TD>
<TD vAlign=bottom nowrap align=right width="10%"><FONT face="Times New Roman" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 16,984,000&nbsp; </FONT></TD></TR>
<TR>
<TD vAlign=bottom nowrap width="78%"><FONT face="Times New Roman" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accumulated depreciation and amortization</FONT></TD>
<TD vAlign=bottom nowrap align=right width="10%"><FONT face="Times New Roman" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (9,993,000) </FONT></TD>
<TD vAlign=bottom nowrap align=right width="2%">&nbsp;</TD>
<TD vAlign=bottom nowrap align=right width="10%"><FONT face="Times New Roman" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (8,404,000) </FONT></TD></TR>
<TR>
<TD vAlign=bottom nowrap width="78%">&nbsp;</TD>
<TD vAlign=bottom nowrap align=right width="10%">
<HR noshade SIZE=1>
</TD>
<TD vAlign=bottom nowrap align=right width="2%">&nbsp;</TD>
<TD vAlign=bottom nowrap align=right width="10%">
<HR noshade SIZE=1>
</TD></TR>
<TR>
<TD vAlign=bottom nowrap width="78%"><FONT face="Times New Roman" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Property and equipment, net</FONT></TD>
<TD vAlign=bottom nowrap align=right width="10%"><FONT face="Times New Roman" size=2>&nbsp; $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 8,191,000&nbsp; </FONT></TD>
<TD vAlign=bottom nowrap align=right width="2%">&nbsp;</TD>
<TD vAlign=bottom nowrap align=right width="10%"><FONT face="Times New Roman" size=2>&nbsp; $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 8,580,000&nbsp; </FONT></TD></TR>
<TR>
<TD vAlign=bottom nowrap width="78%">&nbsp;</TD>
<TD vAlign=bottom nowrap align=right width="10%">
<HR noshade>
</TD>
<TD vAlign=bottom nowrap align=right width="2%">&nbsp;</TD>
<TD vAlign=bottom nowrap align=right width="10%">
<HR noshade>
</TD></TR>
</TABLE>



<P><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Depreciation and amortization expense for property and equipment for fiscal 2004, 2003 and 2002 was $1,633,000, $1,634,000 and $1,537,000, respectively. </FONT></P>

<!-- MARKER FORMAT-SHEET="Para Flush Level 1" FSL="Default" -->
<TABLE cellSpacing=0 cellPadding=0 width="100%">
<TR vAlign=top>
<TD width="5%"><B><FONT face="Times New Roman, Times, Serif" size=2>4. &nbsp;</FONT></B></TD>
<TD width="95%"><B><FONT face="Times New Roman, Times, Serif" size=2>Intangible Assets </FONT></B></TD></TR>
</TABLE>



<P><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Intangible assets at March 31 consist of the following: </FONT></P>

<TABLE width="100%">
<TR>
<TD align=center><FONT size=2>43</FONT></TD></TR>
</TABLE>



<P>
<HR align=left noshade SIZE=5>


<P>&nbsp;
<!-- *************************************************************************** -->
<!-- MARKER PAGE="sheet: 14; page: 14" -->

<P>
<TABLE cellSpacing=0 cellPadding=0 width="100%" border=0>
<TR>
<TD vAlign=bottom nowrap width="81%"><FONT face="Times New Roman" size=2><B>&nbsp;</B></FONT></TD>
<TD vAlign=bottom nowrap width="9%">
<DIV align=center><FONT face="Times New Roman" size=2><B>2004</B></FONT></DIV>
<HR align=center noshade SIZE=1>
</TD>
<TD vAlign=bottom nowrap width="1%">&nbsp;</TD>
<TD vAlign=bottom nowrap width="9%">
<DIV align=center><FONT face="Times New Roman" size=2><B>2003</B></FONT></DIV>
<HR align=center noshade SIZE=1>
</TD></TR>
<TR>
<TD vAlign=bottom nowrap width="81%"><FONT face="Times New Roman" size=2>Cost</FONT></TD>
<TD vAlign=bottom nowrap width="9%"><FONT face="Times New Roman" size=2>&nbsp; $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 750,000&nbsp; </FONT></TD>
<TD vAlign=bottom nowrap width="1%">&nbsp;</TD>
<TD vAlign=bottom nowrap width="9%"><FONT face="Times New Roman" size=2>&nbsp;$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &#151; </FONT></TD></TR>
<TR>
<TD vAlign=bottom nowrap width="81%"><FONT face="Times New Roman" size=2>Less accumulated amortization</FONT></TD>
<TD vAlign=bottom nowrap width="9%"><FONT face="Times New Roman" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (75,000) </FONT></TD>
<TD vAlign=bottom nowrap width="1%">&nbsp;</TD>
<TD vAlign=bottom nowrap width="9%"><FONT face="Times New Roman" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &#151; </FONT></TD></TR>
<TR>
<TD vAlign=bottom nowrap width="81%">&nbsp;</TD>
<TD vAlign=bottom nowrap width="9%">
<HR noshade SIZE=1>
</TD>
<TD vAlign=bottom nowrap width="1%">&nbsp;</TD>
<TD vAlign=bottom nowrap width="9%">
<HR noshade SIZE=1>
</TD></TR>
<TR>
<TD vAlign=bottom nowrap width="81%"><FONT face="Times New Roman" size=2>&nbsp;</FONT></TD>
<TD vAlign=bottom nowrap width="9%"><FONT face="Times New Roman" size=2>&nbsp; $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 675,000&nbsp; </FONT></TD>
<TD vAlign=bottom nowrap width="1%">&nbsp;</TD>
<TD vAlign=bottom nowrap width="9%"><FONT face="Times New Roman" size=2>&nbsp;$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#151; </FONT></TD></TR>
<TR>
<TD vAlign=bottom nowrap width="81%">&nbsp;</TD>
<TD vAlign=bottom nowrap width="9%">
<HR noshade SIZE=2>
</TD>
<TD vAlign=bottom nowrap width="1%">&nbsp;</TD>
<TD vAlign=bottom nowrap width="9%">
<HR noshade SIZE=2>
</TD></TR>
</TABLE>



<P><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;For fiscal 2004, amortization expense for intangible assets, consisting of patents, was $75,000. </FONT></P>

<!-- MARKER FORMAT-SHEET="Para Flush Level 1" FSL="Default" -->
<TABLE cellSpacing=0 cellPadding=0 width="100%">
<TR vAlign=top>
<TD width="5%"><B><FONT face="Times New Roman, Times, Serif" size=2>5. </FONT></B></TD>
<TD width="95%"><B><FONT face="Times New Roman, Times, Serif" size=2>Warranty Reserves </FONT></B></TD></TR>
</TABLE>

<BR>
<!-- MARKER FORMAT-SHEET="Para Flush Level 1" FSL="Default" -->
<TABLE cellSpacing=0 cellPadding=0 width="100%">
<TR vAlign=top>
<TD width="5%"><FONT face="Times New Roman, Times, Serif" size=2>&nbsp; </FONT></TD>
<TD width="95%"><FONT face="Times New Roman, Times, Serif" size=2>The Company provides for the estimated future costs to be incurred under the Company&#146;s standard warranty obligations of one year. Estimated contractual warranty obligations are recorded when related sales are recognized and any additional amounts are recorded when such costs are probable and can be reasonably estimated. </FONT></TD></TR>
</TABLE>

<BR>
<!-- MARKER FORMAT-SHEET="Para Flush Level 1" FSL="Default" -->
<TABLE cellSpacing=0 cellPadding=0 width="100%">
<TR vAlign=top>
<TD width="5%"><FONT face="Times New Roman, Times, Serif" size=2>&nbsp; </FONT></TD>
<TD width="95%"><FONT face="Times New Roman, Times, Serif" size=2>The warranty reserve activity is summarized as follows for fiscal 2004, 2003 and 2002: </FONT></TD></TR>
</TABLE>

<BR>

<P>
<TABLE cellSpacing=0 cellPadding=0 width="100%" border=0>
<TR>
<TD vAlign=bottom nowrap width="69%"><FONT face="Times New Roman" size=2>&nbsp;</FONT></TD>
<TD vAlign=bottom nowrap colSpan=5>
<DIV align=center><FONT face="Times New Roman" size=2><B>Year Ended March 31,</B></FONT></DIV>
<HR align=center noshade SIZE=1>
</TD></TR>
<TR>
<TD vAlign=bottom nowrap width="69%"><FONT face="Times New Roman" size=2><B>&nbsp;</B></FONT></TD>
<TD vAlign=bottom nowrap width="9%">
<DIV align=center><FONT face="Times New Roman" size=2><B>2004</B></FONT></DIV></TD>
<TD vAlign=bottom nowrap width="2%">&nbsp; </TD>
<TD vAlign=bottom nowrap width="9%">
<DIV align=center><FONT face="Times New Roman" size=2><B>2003</B></FONT></DIV></TD>
<TD vAlign=bottom nowrap width="2%">&nbsp; </TD>
<TD vAlign=bottom nowrap width="9%">
<DIV align=center><FONT face="Times New Roman" size=2><B>2002</B></FONT></DIV></TD></TR>
<TR>
<TD vAlign=bottom nowrap width="69%">&nbsp;</TD>
<TD vAlign=bottom nowrap width="9%">
<HR noshade SIZE=1>
</TD>
<TD vAlign=bottom nowrap width="2%">&nbsp;</TD>
<TD vAlign=bottom nowrap width="9%">
<HR noshade SIZE=1>
</TD>
<TD vAlign=bottom nowrap width="2%">&nbsp;</TD>
<TD vAlign=bottom nowrap width="9%">
<HR noshade SIZE=1>
</TD></TR>
<TR>
<TD vAlign=bottom nowrap width="69%"><FONT face="Times New Roman" size=2>Balance beginning of period</FONT></TD>
<TD vAlign=bottom nowrap width="9%"><FONT face="Times New Roman" size=2>&nbsp; $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 123,000&nbsp; </FONT></TD>
<TD vAlign=bottom nowrap width="2%">&nbsp;&nbsp;</TD>
<TD vAlign=bottom nowrap width="9%"><FONT face="Times New Roman" size=2>&nbsp; $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 192,000&nbsp; </FONT></TD>
<TD vAlign=bottom nowrap width="2%">&nbsp;&nbsp;</TD>
<TD vAlign=bottom nowrap width="9%"><FONT face="Times New Roman" size=2>&nbsp; $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 240,000&nbsp; </FONT></TD></TR>
<TR>
<TD vAlign=bottom nowrap width="69%"><FONT face="Times New Roman" size=2>Provision for warranty expense</FONT></TD>
<TD vAlign=bottom nowrap width="9%"><FONT face="Times New Roman" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 726,000&nbsp; </FONT></TD>
<TD vAlign=bottom nowrap width="2%">&nbsp;</TD>
<TD vAlign=bottom nowrap width="9%"><FONT face="Times New Roman" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 344,000&nbsp; </FONT></TD>
<TD vAlign=bottom nowrap width="2%">&nbsp;</TD>
<TD vAlign=bottom nowrap width="9%"><FONT face="Times New Roman" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 349,000&nbsp; </FONT></TD></TR>
<TR>
<TD vAlign=bottom nowrap width="69%"><FONT face="Times New Roman" size=2>Warranty costs incurred</FONT></TD>
<TD vAlign=bottom nowrap width="9%"><FONT face="Times New Roman" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(668,000) </FONT></TD>
<TD vAlign=bottom nowrap width="2%">&nbsp;</TD>
<TD vAlign=bottom nowrap width="9%"><FONT face="Times New Roman" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (413,000) </FONT></TD>
<TD vAlign=bottom nowrap width="2%">&nbsp;</TD>
<TD vAlign=bottom nowrap width="9%"><FONT face="Times New Roman" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (397,000) </FONT></TD></TR>
<TR>
<TD vAlign=bottom nowrap width="69%">&nbsp;</TD>
<TD vAlign=bottom nowrap width="9%">
<HR noshade SIZE=1>
</TD>
<TD vAlign=bottom nowrap width="2%">&nbsp;</TD>
<TD vAlign=bottom nowrap width="9%">
<HR noshade SIZE=1>
</TD>
<TD vAlign=bottom nowrap width="2%">&nbsp;</TD>
<TD vAlign=bottom nowrap width="9%">
<HR noshade SIZE=1>
</TD></TR>
<TR>
<TD vAlign=bottom nowrap width="69%"><FONT face="Times New Roman" size=2>Balance end of period</FONT></TD>
<TD vAlign=bottom nowrap width="9%"><FONT face="Times New Roman" size=2>&nbsp; $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 181,000&nbsp; </FONT></TD>
<TD vAlign=bottom nowrap width="2%">&nbsp;</TD>
<TD vAlign=bottom nowrap width="9%"><FONT face="Times New Roman" size=2>&nbsp; $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 123,000&nbsp; </FONT></TD>
<TD vAlign=bottom nowrap width="2%">&nbsp;</TD>
<TD vAlign=bottom nowrap width="9%"><FONT face="Times New Roman" size=2>&nbsp; $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 192,000&nbsp; </FONT></TD></TR>
<TR>
<TD vAlign=bottom nowrap width="69%">&nbsp;</TD>
<TD vAlign=bottom nowrap width="9%">
<HR noshade SIZE=2>
</TD>
<TD vAlign=bottom nowrap width="2%">&nbsp;</TD>
<TD vAlign=bottom nowrap width="9%">
<HR noshade SIZE=2>
</TD>
<TD vAlign=bottom nowrap width="2%">&nbsp;</TD>
<TD vAlign=bottom nowrap width="9%">
<HR noshade SIZE=2>
</TD></TR>
</TABLE>

<BR>
<TABLE cellSpacing=0 cellPadding=0 width="100%">
<TR vAlign=top>
<TD width="5%"><B><FONT face="Times New Roman, Times, Serif" size=2>6. </FONT></B></TD>
<TD width="95%"><B><FONT face="Times New Roman, Times, Serif" size=2>Line of Credit and Long-Term Debt </FONT></B></TD></TR>
</TABLE>

<BR>
<!-- MARKER FORMAT-SHEET="Para Flush Level 1" FSL="Default" -->
<TABLE cellSpacing=0 cellPadding=0 width="100%">
<TR vAlign=top>
<TD width="5%"><FONT face="Times New Roman, Times, Serif" size=2>&nbsp; </FONT></TD>
<TD width="95%"><FONT face="Times New Roman, Times, Serif" size=2>In September 2003, the Company terminated its existing line of credit with Comerica Bank-California and entered into a new line of credit with Comerica Bank-California which provides for borrowings of up to $2,000,000, bears interest at the bank&#146;s prime rate minus 0.25%, which totaled 3.75% at March 31, 2004, and is payable monthly. Of the $2,000,000 available, $820,000 was committed to secure a letter of credit for the Company&#146;s facilities lease. The letter of credit will be reduced to $410,000 if the Company meets certain requirements as outlined in the terms of the Company&#146;s facilities lease agreement, which among other stipulations, includes a minimum cumulative net income requirement of $2,000,000 for four consecutive quarters. The new line of credit terminates upon notification by either party and the outstanding balance is payable upon demand. At March 31, 2004, there was no amount outstanding under the
Company&#146;s line of credit. The weighted average interest rate on the line of credit during fiscal 2004 and 2003 was 3.92% and 4.55%, respectively. In September 2003, the Company&#146;s foreign line of credit expired. </FONT></TD></TR>
</TABLE>

<BR>
<!-- MARKER FORMAT-SHEET="Para Flush Level 1" FSL="Default" -->
<TABLE cellSpacing=0 cellPadding=0 width="100%">
<TR vAlign=top>
<TD width="5%"><FONT face="Times New Roman, Times, Serif" size=2>&nbsp; </FONT></TD>
<TD width="95%"><FONT face="Times New Roman, Times, Serif" size=2>During fiscal 2004, the Company had an equipment financing loan, which bore interest at the prime rate plus 1%, which totaled 5.00% at March 31, 2004, and is payable in monthly installments of $42,000 in principal and interest. In March 2004, the Company paid off the remaining outstanding balance of its equipment financing loan. Total repayments in fiscal 2004 were $933,000. At March 31, 2004, there was no amount outstanding under the Company&#146;s equipment financing loan. At March 31, 2003, the outstanding balance on the equipment financing loan totaled $933,000. The weighted average interest rate on equipment financing loans during fiscal 2004 and 2003 was 5.06% and 5.55%, respectively. </FONT></TD></TR>
</TABLE>

<BR>
<!-- MARKER FORMAT-SHEET="Para Flush Level 1" FSL="Default" -->
<TABLE cellSpacing=0 cellPadding=0 width="100%">
<TR vAlign=top>
<TD width="5%"><FONT face="Times New Roman, Times, Serif" size=2>&nbsp; </FONT></TD>
<TD width="95%"><FONT face="Times New Roman, Times, Serif" size=2>The line of credit agreement contains certain financial covenants, which are evaluated on a quarterly basis. Included in these financial covenants, among other stipulations, is a requirement that the Company have a minimum net income of $25,000 before preferred stock dividends and accretion in any three quarters of a fiscal year, provided that any loss before preferred stock dividends and accretion incurred in the remaining quarter is not to exceed $250,000. The Company is also required to be profitable, as defined, on a fiscal year to date basis beginning with the six month period ending September 30, 2003 and to have net income before preferred stock dividends and accretion on preferred stock of $1,150,000 for the fiscal year ending March 31, 2004. In addition, the Company is required to have a quick ratio, as defined, of not less than 1.00 to 1.00, cash flow coverage, as defined, of not less than 1.25 to 1.00, debt to net worth
ratio, as defined, not greater than 1.00 to 1.00 and to maintain a tangible effective net worth, as defined, of not less than $25,731,000. At March 31, 2004, the Company was in compliance with these covenants. </FONT></TD></TR>
</TABLE>



<P><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Borrowings under the line of credit are collateralized by the Company&#146;s net book value of assets of $54.6 million at March 31, 2004 including its intellectual property. </FONT></P>

<TABLE width="100%">
<TR>
<TD align=center><FONT size=2>44</FONT></TD></TR>
</TABLE>



<P>
<HR align=left noshade SIZE=5>


<P>&nbsp;
<!-- *************************************************************************** -->
<!-- MARKER PAGE="sheet: 14; page: 14" -->
<TABLE cellSpacing=0 cellPadding=0 width="100%">
<TR vAlign=top>
<TD width="5%"><B><FONT face="Times New Roman, Times, Serif" size=2>7. </FONT></B></TD>
<TD width="95%"><B><FONT face="Times New Roman, Times, Serif" size=2>Co-Promotion Agreement </FONT></B></TD></TR>
</TABLE>

<BR>
<!-- MARKER FORMAT-SHEET="Para Flush Level 1" FSL="Default" -->
<TABLE cellSpacing=0 cellPadding=0 width="100%">
<TR vAlign=top>
<TD width="5%"><FONT face="Times New Roman, Times, Serif" size=2>&nbsp; </FONT></TD>
<TD width="95%"><FONT face="Times New Roman, Times, Serif" size=2>In September 1999, the Company entered into a co-promotion agreement with Abbott Laboratories. The agreement was for an initial term of two years. As of September&nbsp;30, 2000, the co-promotion agreement with Abbott Laboratories was terminated in accordance with its terms. While this agreement was in effect, the Company incurred commission obligations to Abbott Laboratories totaling $103,000 at March 31, 2004, payable over a four-year period. The present value of such obligations were recorded concurrent with the respective sales using a discount rate of 9.75%. </FONT></TD></TR>
</TABLE>

<BR>
<TABLE cellSpacing=0 cellPadding=0 width="100%">
<TR vAlign=top>
<TD width="5%"><B><FONT face="Times New Roman, Times, Serif" size=2>8. </FONT></B></TD>
<TD width="95%"><B><FONT face="Times New Roman, Times, Serif" size=2>Commitments and Contingencies </FONT></B></TD></TR>
</TABLE>

<BR>
<!-- MARKER FORMAT-SHEET="Para Flush Level 1" FSL="Default" -->
<TABLE cellSpacing=0 cellPadding=0 width="100%">
<TR vAlign=top>
<TD width="5%"><FONT face="Times New Roman, Times, Serif" size=2>&nbsp; </FONT></TD>
<TD width="95%"><FONT face="Times New Roman, Times, Serif" size=2><B><I>Lease</I></B> &#151; The Company leases its principal facility and certain computer and office equipment under non-cancelable operating lease agreements, which expire on various dates through fiscal 2011. Monthly rental payments increase based on a predetermined schedule. The Company recognizes rent expense on a straight-line basis over the life of the leases. </FONT></TD></TR>
</TABLE>

<BR>
<TABLE cellSpacing=0 cellPadding=0 width="100%">
<TR vAlign=top>
<TD width="5%"><FONT face="Times New Roman, Times, Serif" size=2>&nbsp; </FONT></TD>
<TD width="95%"><FONT face="Times New Roman, Times, Serif" size=2>At March&nbsp;31, 2004 and 2003, property and equipment held under capital leases were $103,000 and $235,000, respectively (with accumulated amortization of $70,000 and $152,000, respectively). </FONT></TD></TR>
</TABLE>

<BR>
<TABLE cellSpacing=0 cellPadding=0 width="100%">
<TR vAlign=top>
<TD width="5%"><FONT face="Times New Roman, Times, Serif" size=2>&nbsp; </FONT></TD>
<TD width="95%"><FONT face="Times New Roman, Times, Serif" size=2>The future minimum payments under the leases at March&nbsp;31, 2004 are as follows: </FONT></TD></TR>
</TABLE>



<P><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></P>


<P>
<TABLE cellSpacing=0 cellPadding=0 width="100%" border=0>
<TR align=center>
<TD vAlign=bottom nowrap align=left width="80%"><FONT face="Times New Roman" size=2>Fiscal Year Ending March 31,</FONT></TD>
<TD vAlign=bottom nowrap width="9%"><FONT face="Times New Roman" size=2><B>Capital<BR>Leases</B></FONT></TD>
<TD vAlign=bottom nowrap width="2%">&nbsp;</TD>
<TD vAlign=bottom nowrap width="9%"><FONT face="Times New Roman" size=2><B>Operating<BR>Lease</B></FONT></TD></TR>
<TR>
<TD vAlign=bottom nowrap colSpan=4>
<HR noshade SIZE=1>
</TD></TR>
<TR>
<TD vAlign=bottom nowrap width="80%"><FONT face="Times New Roman" size=2>&nbsp;&nbsp; 2005</FONT></TD>
<TD vAlign=bottom nowrap width="9%"><FONT face="Times New Roman" size=2>&nbsp;$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 24,000 </FONT></TD>
<TD vAlign=bottom nowrap width="2%">&nbsp;</TD>
<TD vAlign=bottom nowrap width="9%"><FONT face="Times New Roman" size=2>&nbsp;$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 953,000 </FONT></TD></TR>
<TR>
<TD vAlign=bottom nowrap width="80%"><FONT face="Times New Roman" size=2>&nbsp;&nbsp; 2006</FONT></TD>
<TD vAlign=bottom nowrap width="9%"><FONT face="Times New Roman" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 17,000 </FONT></TD>
<TD vAlign=bottom nowrap width="2%">&nbsp;</TD>
<TD vAlign=bottom nowrap width="9%"><FONT face="Times New Roman" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 975,000 </FONT></TD></TR>
<TR>
<TD vAlign=bottom nowrap width="80%"><FONT face="Times New Roman" size=2>&nbsp;&nbsp; 2007</FONT></TD>
<TD vAlign=bottom nowrap width="9%"><FONT face="Times New Roman" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &#151; </FONT></TD>
<TD vAlign=bottom nowrap width="2%">&nbsp;</TD>
<TD vAlign=bottom nowrap width="9%"><FONT face="Times New Roman" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 1,008,000 </FONT></TD></TR>
<TR>
<TD vAlign=bottom nowrap width="80%"><FONT face="Times New Roman" size=2>&nbsp;&nbsp; 2008</FONT></TD>
<TD vAlign=bottom nowrap width="9%"><FONT face="Times New Roman" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &#151; </FONT></TD>
<TD vAlign=bottom nowrap width="2%">&nbsp;</TD>
<TD vAlign=bottom nowrap width="9%"><FONT face="Times New Roman" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 1,048,000 </FONT></TD></TR>
<TR>
<TD vAlign=bottom nowrap width="80%"><FONT face="Times New Roman" size=2>&nbsp;&nbsp; 2009</FONT></TD>
<TD vAlign=bottom nowrap width="9%"><FONT face="Times New Roman" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &#151; </FONT></TD>
<TD vAlign=bottom nowrap width="2%">&nbsp;</TD>
<TD vAlign=bottom nowrap width="9%"><FONT face="Times New Roman" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 1,090,000 </FONT></TD></TR>
<TR>
<TD vAlign=bottom nowrap width="80%"><FONT face="Times New Roman" size=2>&nbsp;&nbsp; Thereafter</FONT></TD>
<TD vAlign=bottom nowrap width="9%"><FONT face="Times New Roman" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &#151; </FONT></TD>
<TD vAlign=bottom nowrap width="2%">&nbsp;</TD>
<TD vAlign=bottom nowrap width="9%"><FONT face="Times New Roman" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 2,009,000 </FONT></TD></TR>
<TR>
<TD vAlign=bottom nowrap width="80%">&nbsp;</TD>
<TD vAlign=bottom nowrap width="9%">
<HR noshade SIZE=1>
</TD>
<TD vAlign=bottom nowrap width="2%">&nbsp;</TD>
<TD vAlign=bottom nowrap width="9%">
<HR noshade SIZE=1>
</TD></TR>
<TR>
<TD vAlign=bottom nowrap width="80%"><FONT face="Times New Roman" size=2>Total minimum lease payments</FONT></TD>
<TD vAlign=bottom nowrap width="9%"><FONT face="Times New Roman" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 41,000 </FONT></TD>
<TD vAlign=bottom nowrap width="2%">&nbsp;</TD>
<TD vAlign=bottom nowrap width="9%"><FONT face="Times New Roman" size=2>&nbsp;$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 7,083,000 </FONT></TD></TR>
<TR>
<TD vAlign=bottom nowrap width="80%">&nbsp;</TD>
<TD vAlign=bottom nowrap width="9%">&nbsp;</TD>
<TD vAlign=bottom nowrap width="2%">&nbsp;</TD>
<TD vAlign=bottom nowrap width="9%">
<HR noshade SIZE=2>
</TD></TR>
<TR>
<TD vAlign=bottom nowrap width="80%"><FONT face="Times New Roman" size=2>Less amounts representing interest (9.9% to 26.7%)</FONT></TD>
<TD vAlign=bottom nowrap width="9%"><FONT face="Times New Roman" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 3,000 </FONT></TD>
<TD vAlign=bottom nowrap width="2%">&nbsp;</TD>
<TD vAlign=bottom nowrap width="9%"><FONT face="Times New Roman" size=2>&nbsp;</FONT></TD></TR>
<TR>
<TD vAlign=bottom nowrap width="80%">&nbsp;</TD>
<TD vAlign=bottom nowrap width="9%">
<HR noshade SIZE=1>
</TD>
<TD vAlign=bottom nowrap width="2%">&nbsp;</TD>
<TD vAlign=bottom nowrap width="9%">&nbsp;</TD></TR>
<TR>
<TD vAlign=bottom nowrap width="80%"><FONT face="Times New Roman" size=2>Present value of minimum lease payments</FONT></TD>
<TD vAlign=bottom nowrap width="9%"><FONT face="Times New Roman" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 38,000 </FONT></TD>
<TD vAlign=bottom nowrap width="2%">&nbsp;</TD>
<TD vAlign=bottom nowrap width="9%"><FONT face="Times New Roman" size=2>&nbsp;</FONT></TD></TR>
<TR>
<TD vAlign=bottom nowrap width="80%"><FONT face="Times New Roman" size=2>Less amounts due within one year</FONT></TD>
<TD vAlign=bottom nowrap width="9%"><FONT face="Times New Roman" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 22,000 </FONT></TD>
<TD vAlign=bottom nowrap width="2%">&nbsp;</TD>
<TD vAlign=bottom nowrap width="9%"><FONT face="Times New Roman" size=2>&nbsp;</FONT></TD></TR>
<TR>
<TD vAlign=bottom nowrap width="80%">&nbsp;</TD>
<TD vAlign=bottom nowrap width="9%">
<HR noshade SIZE=1>
</TD>
<TD vAlign=bottom nowrap width="2%">&nbsp;</TD>
<TD vAlign=bottom nowrap width="9%">&nbsp;</TD></TR>
<TR>
<TD vAlign=bottom nowrap width="80%"><FONT face="Times New Roman" size=2>Long-term portion</FONT></TD>
<TD vAlign=bottom nowrap width="9%"><FONT face="Times New Roman" size=2>&nbsp;$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 16,000 </FONT></TD>
<TD vAlign=bottom nowrap width="2%">&nbsp;</TD>
<TD vAlign=bottom nowrap width="9%"><FONT face="Times New Roman" size=2>&nbsp;</FONT></TD></TR>
<TR>
<TD vAlign=bottom nowrap width="80%">&nbsp;</TD>
<TD vAlign=bottom nowrap width="9%">
<HR noshade SIZE=2>
</TD>
<TD vAlign=bottom nowrap width="2%">&nbsp;</TD>
<TD vAlign=bottom nowrap width="9%">&nbsp;</TD></TR>
</TABLE>

<BR>
<!-- MARKER FORMAT-SHEET="Para Flush Level 1" FSL="Default" -->
<TABLE cellSpacing=0 cellPadding=0 width="100%">
<TR vAlign=top>
<TD width="5%"><FONT face="Times New Roman, Times, Serif" size=2>&nbsp; </FONT></TD>
<TD width="95%"><FONT face="Times New Roman, Times, Serif" size=2>Rent expense under operating leases was $1,050,000, $1,024,000 and $1,019,000 for fiscal 2004, 2003 and 2002, respectively. In connection with its facilities lease agreement, the Company established a letter of credit for $820,000, which is secured by its line of credit. The letter of credit will be reduced to $410,000 if the Company meets certain requirements as outlined in the terms of its facilities lease agreement, which among other stipulations, includes a minimum cumulative net income requirement of $2,000,000 for four consecutive quarters. See Note 6. </FONT></TD></TR>
</TABLE>

<BR>
<!-- MARKER FORMAT-SHEET="Para Flush Level 1" FSL="Default" -->
<TABLE cellSpacing=0 cellPadding=0 width="100%">
<TR vAlign=top>
<TD width="5%"><FONT face="Times New Roman, Times, Serif" size=2>&nbsp; </FONT></TD>
<TD width="95%"><FONT face="Times New Roman, Times, Serif" size=2><B><I>Purchase Commitments </I></B>&#150; In November 2003, the Company entered into an OEM agreement with Diatron Messtechnik GmbH (DIATRON) of Austria to purchase DIATRON hematology instruments. Under the terms of the agreement, the Company is commited to purchase a minimum number of hematology units from DIATRON once the product was qualified for sale. Qualification occurred in May 2004 and accordingly, the Company has minimum purchase commitments. The outstanding commitment for fiscal 2005 through 2009 was $2,376,000, $2,592,000, $2,592,000, $2,592,000 and $2,592,000, respectively. </FONT></TD></TR>
</TABLE>

<BR>
<!-- MARKER FORMAT-SHEET="Para Flush Level 1" FSL="Default" -->
<TABLE cellSpacing=0 cellPadding=0 width="100%">
<TR vAlign=top>
<TD width="5%"><FONT face="Times New Roman, Times, Serif" size=2>&nbsp; </FONT></TD>
<TD width="95%"><FONT face="Times New Roman, Times, Serif" size=2>In November 2001, the Company arrived at general terms with S.A. Scientific, Inc., of San Antonio, Texas, to purchase canine heartworm antigen tests over a period of four years. In December 2002, the Company reached an out-of-court settlement with one of our competitors, Idexx Laboratories, Inc., which alleged in an action filed with the United States District Court for the District Court of Maine that the canine heartworm antigen test supplied to the Company by S.A. Scientific infringed on two of Idexx&#146;s patents. In light of the terms of this settlement, the Company does not believe, based on the general terms that the Company have agreed to with S.A. Scientific, that the Company will be obligated to purchase any of the canine heartworm antigen tests. Although we subsequently sold a limited number of redesigned canine heartworm tests manufactured by S.A. Scientific, we have subsequently terminated our relationship with S.A.
Scientific. </FONT></TD></TR>
</TABLE>

<BR>
<TABLE width="100%">
<TR>
<TD align=center><FONT size=2>45</FONT></TD></TR>
</TABLE>



<P>
<HR align=left noshade SIZE=5>


<P>&nbsp;
<!-- *************************************************************************** -->
<!-- MARKER PAGE="sheet: 14; page: 14" -->
<!-- MARKER FORMAT-SHEET="Para Flush Level 1" FSL="Default" -->
<TABLE cellSpacing=0 cellPadding=0 width="100%">
<TR vAlign=top>
<TD width="5%"><FONT face="Times New Roman, Times, Serif" size=2>&nbsp; </FONT></TD>
<TD width="95%"><FONT face="Times New Roman, Times, Serif" size=2><B><I>Litigation </I></B>&#150; On March 28, 2002, Idexx Laboratories, Inc., the Company&#146;s principal competitor in the veterinary diagnostic market, filed a complaint in the United States District Court for the District of Maine (Civil Action Docket No. 02-69-P-H) alleging that a canine heartworm test produced for the Company by a third party, S.A. Scientific, Inc., and sold using the Abaxis brand infringed on U.S. Patents Nos. 4,965,187 and 4,939,096 held by Idexx. On December 6, 2002, the Company and S.A. Scientific, Inc. entered into an out-of-court settlement agreement with Idexx under which, among other terms, the Company paid Idexx $249,500 in cash damages and ceased the selling of the particular canine heartworm antigen test referenced in the complaint. </FONT></TD></TR>
</TABLE>

<BR>
<!-- MARKER FORMAT-SHEET="Para Flush Level 1" FSL="Default" -->
<TABLE cellSpacing=0 cellPadding=0 width="100%">
<TR vAlign=top>
<TD width="5%"><FONT face="Times New Roman, Times, Serif" size=2>&nbsp; </FONT></TD>
<TD width="95%"><FONT face="Times New Roman, Times, Serif" size=2>The Company is involved from time to time in various other litigation matters in the normal course of business. The Company believes that the ultimate resolution of these matters will not have a material effect on its financial position or results of operations. </FONT></TD></TR>
</TABLE>

<BR>
<TABLE cellSpacing=0 cellPadding=0 width="100%">
<TR vAlign=top>
<TD width="5%"><B><FONT face="Times New Roman, Times, Serif" size=2>9. </FONT></B></TD>
<TD colSpan=2><B><FONT face="Times New Roman, Times, Serif" size=2>Retirement Plan </FONT></B></TD></TR>
</TABLE>

<BR>
<!-- MARKER FORMAT-SHEET="Para Flush Level 1" FSL="Default" -->
<TABLE cellSpacing=0 cellPadding=0 width="100%">
<TR vAlign=top>
<TD width="5%"><FONT face="Times New Roman, Times, Serif" size=2>&nbsp; </FONT></TD>
<TD width="95%"><FONT face="Times New Roman, Times, Serif" size=2>The Company has a tax deferred savings plan for the benefit of qualified employees. The plan is designed to provide employees with an accumulation of funds at retirement. Qualified employees may elect to have salary reduction contributions made to the plan on a bi-weekly basis. The Company may make quarterly contributions to the plan at the discretion of the Board of Directors of the Company either in cash or in common stock. Contributions to the deferred savings plan were $162,000, $127,000 and $107,000 in fiscal 2004, 2003 and 2002, respectively. </FONT></TD></TR>
</TABLE>

<BR>
<!-- MARKER FORMAT-SHEET="Para Hang" FSL="Default" -->
<TABLE cellSpacing=0 cellPadding=0 width="100%">
<TR vAlign=top>
<TD width="5%"><B><FONT face="Times New Roman, Times, Serif" size=2>10. </FONT></B></TD>
<TD colSpan=2><B><FONT face="Times New Roman, Times, Serif" size=2>Redeemable Convertible Preferred Stock &#151; Series E </FONT></B></TD></TR>
</TABLE>

<BR>
<!-- MARKER FORMAT-SHEET="Para Flush Level 1" FSL="Default" -->
<TABLE cellSpacing=0 cellPadding=0 width="100%">
<TR vAlign=top>
<TD width="5%"><FONT face="Times New Roman, Times, Serif" size=2>&nbsp; </FONT></TD>
<TD width="95%"><FONT face="Times New Roman, Times, Serif" size=2><I>Redeemable Convertible Preferred Stock</I> <I>Series E </I>&#150; In March 2002 and April 2002, the Company sold 3,750 and 3,620 shares, respectively, of Series E convertible preferred stock (the &#147;Series E Preferred&#148;) at $1,000 per share, resulting in net cash proceeds to the Company of $6,812,000. The Company recorded stock offering proceeds receivable of $3,446,000 for the first closing of Series E Preferred at March 31, 2002. The proceeds were received by the Company on April 3, 2002. The Series E Preferred is non-voting and pays an annual cumulative dividend of 6.5% of the original issue price per share, payable semiannually in cash or shares of common stock at the Company&#146;s election. Upon the liquidation of, dissolution of, winding-up of, or change of control in Abaxis, holders of the Series E Preferred are entitled to receive $1,000 per share, the original issue price, plus any accrued but unpaid dividends, as a
liquidation preference prior to Abaxis making any distributions to holders of common stock. Accordingly, the Series E preferred stock is classified as a redeemable convertible preferred stock and is included outside of shareholders&#146; equity in the accompanying balance sheets. </FONT></TD></TR>
</TABLE>

<BR>
<!-- MARKER FORMAT-SHEET="Para Flush Level 1" FSL="Default" -->
<TABLE cellSpacing=0 cellPadding=0 width="100%">
<TR vAlign=top>
<TD width="5%"><FONT face="Times New Roman, Times, Serif" size=2>&nbsp; </FONT></TD>
<TD width="95%"><FONT face="Times New Roman, Times, Serif" size=2>During fiscal 2004, 5,570 shares of Series E convertible preferred stock were converted into 856,907 shares of common stock in accordance with the specified exchange ratio. Elective conversions during fiscal 2004 resulted in the conversion of 3,820 shares of Series E preferred stock into 587,683 shares of common stock. In October 2003, under the terms of the Company&#146;s Certificate of Determination with respect to the Series E Preferred Stock (the &#147;Series E Preferred&#148;), the remaining outstanding Series E convertible preferred stock automatically converted into shares of common stock after twenty consecutive trading days where the per share closing price of the Company&#146;s common stock as reported on the Nasdaq National Market exceeded $12.00. Automatic conversions resulted in the conversion of 1,750 shares of Series E Preferred Stock into 269,224 shares of common stock. During fiscal 2004, total dividends related to the
Series E convertible preferred stock of $181,000, included $7,000 accrued at March&nbsp;31, 2004 and $174,000 of common stock issued. </FONT></TD></TR>
</TABLE>

<BR>
<!-- MARKER FORMAT-SHEET="Para Flush Level 1" FSL="Default" -->
<TABLE cellSpacing=0 cellPadding=0 width="100%">
<TR vAlign=top>
<TD width="5%"><FONT face="Times New Roman, Times, Serif" size=2>&nbsp; </FONT></TD>
<TD width="95%"><FONT face="Times New Roman, Times, Serif" size=2>Each Series E preferred stock investor received a warrant to purchase 50 shares of common stock for each preferred share acquired. The common stock warrants are valid for five years and exercisable at $7.00 per share. Approximately $1,235,000 of the proceeds were attributed to the value of the warrants and allocated to common stock. The fair value of the warrants was determined using the Black-Scholes option-pricing model with the following assumptions: contractual life of five years, volatility of 78.6%, risk free interest rate of 4.57%-4.92% and no dividends during the contractual term. In connection with the sale of the Series E convertible preferred stock, the Company issued to advisors for services a fully-vested warrant to purchase 113,385 shares of its common stock at an exercise price of $6.50 per share and 25,000 shares of its common stock. The aggregate value of these warrants and shares of common stock of $601,000 was
recorded as a stock issuance cost. The value of the warrants was determined using the Black-Scholes option pricing model with assumptions substantially consistent with those used for valuing the warrants issued to the investors. </FONT></TD></TR>
</TABLE>

<BR>
<!-- MARKER FORMAT-SHEET="Para Flush Level 1" FSL="Default" -->
<TABLE cellSpacing=0 cellPadding=0 width="100%">
<TR vAlign=top>
<TD width="5%"><FONT face="Times New Roman, Times, Serif" size=2>&nbsp; </FONT></TD>
<TD width="95%"><FONT face="Times New Roman, Times, Serif" size=2>In accordance with the provisions of Emerging Issues Task Force (EITF) Issue 00-27, &#147;Application of EITF Issue No. 98-5, &#145;Accounting for Convertible Securities with Beneficial Conversion Features of Contingently Adjustable Conversion Ratios,&#146; to Certain Convertible Securities,&#148; which became effective in November 2000, the allocated value of the Series E convertible preferred stock contained a beneficial conversion feature calculated based on the difference between the effective conversion </FONT></TD></TR>
</TABLE>

<BR>
<TABLE width="100%">
<TR>
<TD align=center><FONT size=2>46</FONT></TD></TR>
</TABLE>



<P>
<HR align=left noshade SIZE=5>


<P>&nbsp;
<!-- *************************************************************************** -->
<!-- MARKER PAGE="sheet: 14; page: 14" -->
<!-- MARKER FORMAT-SHEET="Para Flush Level 1" FSL="Default" -->
<TABLE cellSpacing=0 cellPadding=0 width="100%">
<TR vAlign=top>
<TD width="5%"><FONT face="Times New Roman, Times, Serif" size=2>&nbsp; </FONT></TD>
<TD width="95%"><FONT face="Times New Roman, Times, Serif" size=2>price of the proceeds allocated to the Series E convertible preferred stock and the fair market value of the common stock at the date of issuance. The Company determined an aggregate dividend charge of $957,000 representing the value of the beneficial conversion feature. </FONT></TD></TR>
</TABLE>

<BR>
<!-- MARKER FORMAT-SHEET="Para Flush Level 1" FSL="Default" -->
<TABLE cellSpacing=0 cellPadding=0 width="100%">
<TR vAlign=top>
<TD width="5%"><FONT face="Times New Roman, Times, Serif" size=2>&nbsp; </FONT></TD>
<TD width="95%"><FONT face="Times New Roman, Times, Serif" size=2>The amounts recorded in the Company&#146;s financial statements during fiscal 2003, representing the amounts attributed to the closings in April 2002, were as follows: net cash proceeds &#151; $3,366,000 ($254,000 of issuance costs incurred), allocation to warrants issued to investors &#151; $590,000, warrants issued to advisors for services &#151; $361,000, and the amount of the dividend charge related to the value of beneficial conversion feature &#151; $370,000. </FONT></TD></TR>
</TABLE>

<BR>
<!-- MARKER FORMAT-SHEET="Para Flush Level 1" FSL="Default" -->
<TABLE cellSpacing=0 cellPadding=0 width="100%">
<TR vAlign=top>
<TD width="5%"><FONT face="Times New Roman, Times, Serif" size=2>&nbsp; </FONT></TD>
<TD width="95%"><FONT face="Times New Roman, Times, Serif" size=2>During fiscal 2003, dividends related to the Series E convertible preferred stock of $409,000, included $180,000 accrued at March&nbsp;31, 2003 and $229,000 of cash dividends. In addition, 1,800 shares of Series E convertible preferred stock were converted into 276,922 shares of common stock in accordance with the specified exchange ratio. At March 31, 2003, the outstanding shares of Series E convertible preferred stock were convertible into 856,924 shares of common stock. </FONT></TD></TR>
</TABLE>

<BR>
<!-- MARKER FORMAT-SHEET="Para Flush Level 1" FSL="Default" -->
<TABLE cellSpacing=0 cellPadding=0 width="100%">
<TR vAlign=top>
<TD width="5%"><B><FONT face="Times New Roman, Times, Serif" size=2>11. </FONT></B></TD>
<TD width="95%"><B><FONT face="Times New Roman, Times, Serif" size=2>Shareholders&#146;Equity </FONT></B></TD></TR>
</TABLE>

<BR>
<!-- MARKER FORMAT-SHEET="Para Flush Level 1" FSL="Default" -->
<TABLE cellSpacing=0 cellPadding=0 width="100%">
<TR vAlign=top>
<TD width="5%"><FONT face="Times New Roman, Times, Serif" size=2>&nbsp; </FONT></TD>
<TD width="95%"><FONT face="Times New Roman, Times, Serif" size=2><I>Series D Convertible Preferred Stock</I> &#150; In October 2000 and November 2000, the Company sold 6,578 shares of Series D convertible preferred stock (&#147;Series D Preferred&#148;) at $1,000 per share, resulting in net cash proceeds to the Company of $6,433,000. The Series D convertible preferred stock is non-voting and pays an annual cumulative dividend of 7.0% of the original issue price per share, payable semiannually in cash or shares of common stock at the Company&#146;s election. During fiscal 2004, 6,508 shares of Series D convertible preferred stock were converted into 929,699 shares of common stock in accordance with the specified exchange ratio. Elective conversions during fiscal 2004 resulted in the conversion of 3,708 shares of Series D preferred stock into 529,711 shares of common stock. In October 2003, under the terms of the Company&#146;s Certificate of Determination with respect to the Series D preferred stock,
the remaining outstanding Series D convertible preferred stock automatically converted into shares of common stock after twenty consecutive trading days where the per share closing price of the Company&#146;s common stock as reported on the Nasdaq National Market exceeded $14.00. Automatic conversions resulted in the conversion of 2,800 shares of Series D preferred stock into 399,988 shares of common stock. During fiscal 2004, total dividends related to the Series D convertible preferred stock of $238,000, included $21,000 accrued at March&nbsp;31, 2004 and $217,000 of common stock issued. </FONT></TD></TR>
</TABLE>

<BR>
<!-- MARKER FORMAT-SHEET="Para Flush Level 1" FSL="Default" -->
<TABLE cellSpacing=0 cellPadding=0 width="100%">
<TR vAlign=top>
<TD width="5%"><FONT face="Times New Roman, Times, Serif" size=2>&nbsp; </FONT></TD>
<TD width="95%"><FONT face="Times New Roman, Times, Serif" size=2>Each Series D convertible preferred stock investor received a warrant to purchase 50 shares of common stock for each preferred share acquired. The common stock warrants are exercisable at $7.00 per share at various dates through November&nbsp;17, 2005. Approximately $1,418,000 of the proceeds were attributed to the value of the warrants and allocated to common stock. The fair value of the warrants was determined using the Black-Scholes option-pricing model with the following assumptions: contractual life of six years, volatility of 84.2%, risk free interest rate of 5.45% and no dividends during the contractual term. In connection with the sale of the Series D convertible preferred stock the Company issued, to advisors for services, fully vested five year warrants to purchase 377,500 shares of common stock at exercise prices ranging from $6.00-$7.00 per share. The aggregate value of these warrants of $1,802,000 was recorded as a stock
issuance cost and was determined using the Black-Scholes option pricing model with assumptions substantially consistent with those used for valuing the warrants issued to the investors. </FONT></TD></TR>
</TABLE>

<BR>
<!-- MARKER FORMAT-SHEET="Para Flush Level 1" FSL="Default" -->
<TABLE cellSpacing=0 cellPadding=0 width="100%">
<TR vAlign=top>
<TD width="5%"><FONT face="Times New Roman, Times, Serif" size=2>&nbsp; </FONT></TD>
<TD width="95%"><FONT face="Times New Roman, Times, Serif" size=2>In accordance with the provisions of Emerging Issues Task Force (EITF) Issue 00-27, &#147;Application of EITF Issue No. 98-5. &#145;Accounting for Convertible Securities with Beneficial Conversion Features of Contingently Adjustable Conversion Ratios,&#146; to Certain Convertible Securities&#148;, which became effective in November 2000, the allocated value of the Series D convertible preferred stock contained a beneficial conversion feature calculated based on the difference between the effective conversion price of the proceeds allocated to the Series D convertible preferred stock and the fair market value of the common stock at the date of issuance. As a result, in fiscal 2001, the Company recorded a dividend charge of $1,418,000 representing the value of the beneficial conversion feature. </FONT></TD></TR>
</TABLE>

<BR>
<!-- MARKER FORMAT-SHEET="Para Flush Level 1" FSL="Default" -->
<TABLE cellSpacing=0 cellPadding=0 width="100%">
<TR vAlign=top>
<TD width="5%"><FONT face="Times New Roman, Times, Serif" size=2>&nbsp; </FONT></TD>
<TD width="95%"><FONT face="Times New Roman, Times, Serif" size=2>During fiscal 2003, dividends related to the Series D preferred stock of $456,000, included $228,000 accrued at March&nbsp;31, 2003, issuance of 35,654 shares of common stock and $228,000 in cash. In addition, 50 shares of Series D preferred stock were converted into 7,142 shares of common stock in accordance with the specified exchange ratio. At March 31, 2003, the outstanding shares of Series D preferred stock were convertible into 929,715 shares of common stock. </FONT></TD></TR>
</TABLE>

<BR>
<!-- MARKER FORMAT-SHEET="Para Flush Level 1" FSL="Default" -->
<TABLE cellSpacing=0 cellPadding=0 width="100%">
<TR vAlign=top>
<TD width="5%"><FONT face="Times New Roman, Times, Serif" size=2>&nbsp; </FONT></TD>
<TD width="95%"><FONT face="Times New Roman, Times, Serif" size=2>During fiscal 2002, dividends related to the Series D preferred stock of $446,000, including $230,000 accrued at March&nbsp;31, 2001, were paid through the issuance of 100,526 shares of common stock. In addition, 20 shares of Series D preferred stock were converted into 2,857 shares of common stock in accordance with the specified exchange ratio. At March 31, 2002, the outstanding shares of Series D preferred stock were convertible into 936,857 shares of common stock. </FONT></TD></TR>
</TABLE>

<BR>
<TABLE width="100%">
<TR>
<TD align=center><FONT size=2>47</FONT></TD></TR>
</TABLE>



<P>
<HR align=left noshade SIZE=5>


<P>&nbsp;
<!-- *************************************************************************** -->
<!-- MARKER PAGE="sheet: 14; page: 14" -->
<TABLE cellSpacing=0 cellPadding=0 width="100%">
<TR vAlign=top>
<TD width="5%"><FONT face="Times New Roman, Times, Serif" size=2>&nbsp; </FONT></TD>
<TD width="95%"><FONT face="Times New Roman, Times, Serif" size=2><B><I>Common Stock Warrants</I></B> &#150; At March 31, 2004, warrants were outstanding to purchase an aggregate of 567,135 shares of common stock at a weighted average exercise price of $6.78 per share expiring through May 2007. </FONT></TD></TR>
</TABLE>

<BR>
<!-- MARKER FORMAT-SHEET="Para Flush Level 1" FSL="Default" -->
<TABLE cellSpacing=0 cellPadding=0 width="100%">
<TR vAlign=top>
<TD width="5%"><FONT face="Times New Roman, Times, Serif" size=2>&nbsp; </FONT></TD>
<TD width="95%"><FONT face="Times New Roman, Times, Serif" size=2><B><I>Stock Option Plan</I></B> &#150; The Company&#146;s stock-based compensation plans are described below. </FONT></TD></TR>
</TABLE>

<BR>
<!-- MARKER FORMAT-SHEET="Para Flush Level 1" FSL="Default" -->
<TABLE cellSpacing=0 cellPadding=0 width="100%">
<TR vAlign=top>
<TD width="5%"><FONT face="Times New Roman, Times, Serif" size=2>&nbsp; </FONT></TD>
<TD width="95%"><FONT face="Times New Roman, Times, Serif" size=2><B>1998 Stock Option Plan</B> </FONT></TD></TR>
</TABLE>

<BR>
<!-- MARKER FORMAT-SHEET="Para Flush Level 1" FSL="Default" -->
<TABLE cellSpacing=0 cellPadding=0 width="100%">
<TR vAlign=top>
<TD width="5%"><FONT face="Times New Roman, Times, Serif" size=2>&nbsp; </FONT></TD>
<TD width="95%"><FONT face="Times New Roman, Times, Serif" size=2>Under the Company&#146;s 1998 Stock Option Plan (the Option Plan), options to purchase common stock may be granted to employees and consultants. Options granted under the Option Plan may be either incentive stock options or nonqualified stock options. Incentive stock options are granted at no less than the fair market value of the common stock on the date of grant, and nonqualified stock options are granted at no less than 85% of the current fair market value of the common stock on the date of grant. The stock options generally expire ten years from the date of grant and normally become exercisable ratably over four years. </FONT></TD></TR>
</TABLE>

<BR>
<!-- MARKER FORMAT-SHEET="Para Flush Level 1" FSL="Default" -->
<TABLE cellSpacing=0 cellPadding=0 width="100%">
<TR vAlign=top>
<TD width="5%"><FONT face="Times New Roman, Times, Serif" size=2>&nbsp; </FONT></TD>
<TD width="95%"><FONT face="Times New Roman, Times, Serif" size=2><B>1992 Outside Directors&#146; Stock Option Plan</B> </FONT></TD></TR>
</TABLE>

<BR>
<!-- MARKER FORMAT-SHEET="Para Flush Level 1" FSL="Default" -->
<TABLE cellSpacing=0 cellPadding=0 width="100%">
<TR vAlign=top>
<TD width="5%"><FONT face="Times New Roman, Times, Serif" size=2>&nbsp; </FONT></TD>
<TD width="95%"><FONT face="Times New Roman, Times, Serif" size=2>Under the Company&#146;s 1992 Outside Directors&#146; Stock Option Plan (the Directors&#146; Plan), options to purchase 4,000 shares of common stock are automatically granted, annually, to directors of Abaxis who are not employees. Options under the Directors&#146; Plan are nonqualified stock options and are granted at the fair market value on the date of grant and expire ten years from the date of grant. The time period for granting options under the 1992 Directors&#146; Plan expired in accordance with the terms of the Directors&#146; Plan in June 2002. </FONT></TD></TR>
</TABLE>

<BR>
<!-- MARKER FORMAT-SHEET="Para Flush Level 1" FSL="Default" -->
<TABLE cellSpacing=0 cellPadding=0 width="100%">
<TR vAlign=top>
<TD width="5%"><FONT face="Times New Roman, Times, Serif" size=2>&nbsp; </FONT></TD>
<TD width="95%"><FONT face="Times New Roman, Times, Serif" size=2><B>Stock-based Compensation</B> </FONT></TD></TR>
</TABLE>

<BR>
<!-- MARKER FORMAT-SHEET="Para Flush Level 1" FSL="Default" -->
<TABLE cellSpacing=0 cellPadding=0 width="100%">
<TR vAlign=top>
<TD width="5%"><FONT face="Times New Roman, Times, Serif" size=2>&nbsp; </FONT></TD>
<TD width="95%"><FONT face="Times New Roman, Times, Serif" size=2>During fiscal 2004, the Company recorded compensation expense of $24,000 for non-employee options granted prior to fiscal 2004 using the Black-Scholes option pricing model with the following assumption: contractual life 10 years; stock volatility of 58-62%, risk free interest rates of 2.78-4.43%, and no dividends during the expected term. The options vest ratably over one to four year terms and 146 shares remained unvested at March&nbsp;31, 2004. </FONT></TD></TR>
</TABLE>

<BR>
<!-- MARKER FORMAT-SHEET="Para Flush Level 1" FSL="Default" -->
<TABLE cellSpacing=0 cellPadding=0 width="100%">
<TR vAlign=top>
<TD width="5%"><FONT face="Times New Roman, Times, Serif" size=2>&nbsp; </FONT></TD>
<TD width="95%"><FONT face="Times New Roman, Times, Serif" size=2>During fiscal 2003 and 2002, the Company granted 6,000 and 9,000, respectively, of non-statutory stock options to consultants, the values of which were originally estimated at $16,000 and $38,000, respectively. The values of these non-statutory stock options granted to consultants were originally determined using the Black-Scholes option pricing model with the following assumptions: contractual life 10 years; stock volatility of 62% and 79% for fiscal 2003 and 2002, respectively; risk free interest rates of 4.07% and 5.53% for fiscal 2003 and 2002, respectively; and no dividends during the expected term. The options vested ratably over one to four year terms and are fully vested at March&nbsp;31, 2004. The values attributable to these options have been amortized over the service period on a graded vesting method and the vested portion of these options were remeasured based on current fair values at each vesting date. </FONT></TD></TR>
</TABLE>

<BR>
<!-- MARKER FORMAT-SHEET="Para Flush Level 1" FSL="Default" -->
<TABLE cellSpacing=0 cellPadding=0 width="100%">
<TR vAlign=top>
<TD width="5%"><FONT face="Times New Roman, Times, Serif" size=2>&nbsp; </FONT></TD>
<TD width="95%"><FONT face="Times New Roman, Times, Serif" size=2>Information with respect to stock option activity is summarized as follows: </FONT></TD></TR>
</TABLE>

<BR>
<TABLE width="100%">
<TR>
<TD align=center><FONT size=2>48</FONT></TD></TR>
</TABLE>



<P>
<HR align=left noshade SIZE=5>


<P>&nbsp;
<!-- *************************************************************************** -->
<!-- MARKER PAGE="sheet: 14; page: 14" -->

<P>
<TABLE cellSpacing=0 cellPadding=0 width="100%" border=0>
<TR>
<TD vAlign=bottom nowrap width="78%"><FONT face="Times New Roman" size=2><B>&nbsp;</B></FONT></TD>
<TD vAlign=bottom nowrap colSpan=3>
<DIV align=center><FONT face="Times New Roman" size=2><B>Options Outstanding</B></FONT><BR>
<HR align=center noshade SIZE=1>
</DIV></TD></TR>
<TR>
<TD vAlign=bottom nowrap width="78%"><FONT face="Times New Roman" size=2><B>&nbsp;</B></FONT></TD>
<TD vAlign=bottom nowrap width="10%">
<DIV align=center><FONT face="Times New Roman" size=2><B>Number of<BR>Common Shares</B></FONT> </DIV>
<HR align=center noshade SIZE=1>
</TD>
<TD vAlign=bottom nowrap width="1%">&nbsp;</TD>
<TD vAlign=bottom nowrap width="11%">
<DIV align=center><FONT face="Times New Roman" size=2><B>Weighted<BR>Average<BR>Exercise Price</B></FONT> </DIV>
<HR align=center noshade SIZE=1>
</TD></TR>
<TR>
<TD vAlign=bottom width="78%"><FONT face="Times New Roman" size=2>Balance at April 1, 2001</FONT></TD>
<TD vAlign=bottom nowrap width="10%">
<DIV align=right><FONT face="Times New Roman" size=2>2,094,076 </FONT></DIV></TD>
<TD vAlign=bottom nowrap width="1%">&nbsp;&nbsp;</TD>
<TD vAlign=bottom nowrap width="11%">
<DIV align=right><FONT face="Times New Roman" size=2>$4.45 </FONT></DIV></TD></TR>
<TR>
<TD vAlign=bottom nowrap width="78%"><FONT face="Times New Roman" size=2>Granted (weighted average fair value of $3.54 per share)</FONT></TD>
<TD vAlign=bottom nowrap width="10%">
<DIV align=right><FONT face="Times New Roman" size=2>749,000 </FONT></DIV></TD>
<TD vAlign=bottom nowrap width="1%">&nbsp;</TD>
<TD vAlign=bottom nowrap width="11%">
<DIV align=right><FONT face="Times New Roman" size=2>4.96 </FONT></DIV></TD></TR>
<TR>
<TD vAlign=bottom nowrap width="78%"><FONT face="Times New Roman" size=2>Exercised</FONT></TD>
<TD vAlign=bottom nowrap width="10%">
<DIV align=right><FONT face="Times New Roman" size=2>(133,901)</FONT></DIV></TD>
<TD vAlign=bottom nowrap width="1%">&nbsp;</TD>
<TD vAlign=bottom nowrap width="11%">
<DIV align=right><FONT face="Times New Roman" size=2>2.96 </FONT></DIV></TD></TR>
<TR>
<TD vAlign=bottom nowrap width="78%"><FONT face="Times New Roman" size=2>Canceled</FONT></TD>
<TD vAlign=bottom nowrap width="10%">
<DIV align=right><FONT face="Times New Roman" size=2>(207,850)</FONT></DIV></TD>
<TD vAlign=bottom nowrap width="1%">&nbsp;</TD>
<TD vAlign=bottom nowrap width="11%">
<DIV align=right><FONT face="Times New Roman" size=2>5.30 </FONT></DIV></TD></TR>
<TR>
<TD vAlign=bottom nowrap width="78%"><FONT face="Times New Roman" size=2>&nbsp;</FONT></TD>
<TD vAlign=bottom nowrap width="10%">
<HR align=right noshade SIZE=1>
</TD>
<TD vAlign=bottom nowrap width="1%">&nbsp;</TD>
<TD vAlign=bottom nowrap width="11%">
<DIV align=right><FONT face="Times New Roman" size=2></FONT>&nbsp;</DIV></TD></TR>
<TR>
<TD vAlign=bottom width="78%"><FONT face="Times New Roman" size=2>Balance at March 31, 2002 (1,422,264 shares vested at a weighted average exercise price of $4.15 per share)</FONT></TD>
<TD vAlign=bottom nowrap width="10%">
<DIV align=right><FONT face="Times New Roman" size=2>2,501,325 </FONT></DIV></TD>
<TD vAlign=bottom nowrap width="1%">&nbsp;</TD>
<TD vAlign=bottom nowrap width="11%">
<DIV align=right><FONT face="Times New Roman" size=2>$4.61 </FONT></DIV></TD></TR>
<TR>
<TD vAlign=bottom nowrap width="78%"><FONT face="Times New Roman" size=2>Granted (weighted average fair value of $2.43 per share)</FONT></TD>
<TD vAlign=bottom nowrap width="10%">
<DIV align=right><FONT face="Times New Roman" size=2>353,504 </FONT></DIV></TD>
<TD vAlign=bottom nowrap width="1%">&nbsp;</TD>
<TD vAlign=bottom nowrap width="11%">
<DIV align=right><FONT face="Times New Roman" size=2>3.98 </FONT></DIV></TD></TR>
<TR>
<TD vAlign=bottom nowrap width="78%"><FONT face="Times New Roman" size=2>Exercised</FONT></TD>
<TD vAlign=bottom nowrap width="10%">
<DIV align=right><FONT face="Times New Roman" size=2>(88,916)</FONT></DIV></TD>
<TD vAlign=bottom nowrap width="1%">&nbsp;</TD>
<TD vAlign=bottom nowrap width="11%">
<DIV align=right><FONT face="Times New Roman" size=2>2.03 </FONT></DIV></TD></TR>
<TR>
<TD vAlign=bottom nowrap width="78%"><FONT face="Times New Roman" size=2>Canceled</FONT></TD>
<TD vAlign=bottom nowrap width="10%">
<DIV align=right><FONT face="Times New Roman" size=2>(257,118)</FONT></DIV></TD>
<TD vAlign=bottom nowrap width="1%">&nbsp;</TD>
<TD vAlign=bottom nowrap width="11%">
<DIV align=right><FONT face="Times New Roman" size=2>5.50 </FONT></DIV></TD></TR>
<TR>
<TD vAlign=bottom nowrap width="78%"><FONT face="Times New Roman" size=2>&nbsp;</FONT></TD>
<TD vAlign=bottom nowrap width="10%">
<DIV align=right></DIV>
<HR align=right noshade SIZE=1>
</TD>
<TD vAlign=bottom nowrap width="1%">&nbsp;</TD>
<TD vAlign=bottom nowrap width="11%">
<DIV align=right><FONT face="Times New Roman" size=2></FONT>&nbsp;</DIV></TD></TR>
<TR>
<TD vAlign=bottom width="78%"><FONT face="Times New Roman" size=2>Balance at March 31, 2003 (1,762,949 shares vested at a weighted average exercise price of $4.36 per share)</FONT></TD>
<TD vAlign=bottom nowrap width="10%">
<DIV align=right><FONT face="Times New Roman" size=2>2,508,795 </FONT></DIV></TD>
<TD vAlign=bottom nowrap width="1%">&nbsp;</TD>
<TD vAlign=bottom nowrap width="11%">
<DIV align=right><FONT face="Times New Roman" size=2>$4.52 </FONT></DIV></TD></TR>
<TR>
<TD vAlign=bottom nowrap width="78%"><FONT face="Times New Roman" size=2>Granted (weighted average fair value of $3.57 per share)</FONT></TD>
<TD vAlign=bottom nowrap width="10%">
<DIV align=right><FONT face="Times New Roman" size=2>573,750 </FONT></DIV></TD>
<TD vAlign=bottom nowrap width="1%">&nbsp;</TD>
<TD vAlign=bottom nowrap width="11%">
<DIV align=right><FONT face="Times New Roman" size=2>5.91 </FONT></DIV></TD></TR>
<TR>
<TD vAlign=bottom nowrap width="78%"><FONT face="Times New Roman" size=2>Exercised</FONT></TD>
<TD vAlign=bottom nowrap width="10%">
<DIV align=right><FONT face="Times New Roman" size=2>(266,327)</FONT></DIV></TD>
<TD vAlign=bottom nowrap width="1%">&nbsp;</TD>
<TD vAlign=bottom nowrap width="11%">
<DIV align=right><FONT face="Times New Roman" size=2>4.31 </FONT></DIV></TD></TR>
<TR>
<TD vAlign=bottom nowrap width="78%"><FONT face="Times New Roman" size=2>Canceled</FONT></TD>
<TD vAlign=bottom nowrap width="10%">
<DIV align=right><FONT face="Times New Roman" size=2>(151,994)</FONT></DIV></TD>
<TD vAlign=bottom nowrap width="1%">&nbsp;</TD>
<TD vAlign=bottom nowrap width="11%">
<DIV align=right><FONT face="Times New Roman" size=2>3.71 </FONT></DIV></TD></TR>
<TR>
<TD vAlign=bottom width="78%">&nbsp;</TD>
<TD vAlign=bottom nowrap width="10%">
<HR align=right noshade SIZE=1>
</TD>
<TD vAlign=bottom nowrap width="1%">&nbsp;</TD>
<TD vAlign=bottom nowrap width="11%">
<DIV align=right></DIV></TD></TR>
<TR>
<TD vAlign=bottom width="78%"><FONT face="Times New Roman" size=2>Balance at March 31, 2004</FONT></TD>
<TD vAlign=bottom nowrap width="10%">
<DIV align=right><FONT face="Times New Roman" size=2>2,664,224 </FONT></DIV></TD>
<TD vAlign=bottom nowrap width="1%">&nbsp;</TD>
<TD vAlign=bottom nowrap width="11%">
<DIV align=right><FONT face="Times New Roman" size=2>4.88 </FONT></DIV></TD></TR>
<TR>
<TD vAlign=bottom width="78%">&nbsp;</TD>
<TD vAlign=bottom nowrap width="10%">
<HR align=right noshade SIZE=2>
</TD>
<TD vAlign=bottom nowrap width="1%">&nbsp;</TD>
<TD vAlign=bottom nowrap width="11%">
<DIV align=right></DIV></TD></TR>
</TABLE>



<P><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Additional information regarding options outstanding as of March&nbsp;31, 2004 is as follows: </FONT></P>


<P>
<TABLE cellSpacing=0 cellPadding=0 width="75%" border=0>
<TR align=center>
<TD vAlign=bottom colSpan=5>&nbsp; </TD>
<TD vAlign=bottom colSpan=5><FONT face="Times New Roman" size=2><B><FONT size=1>Options Outstanding<BR></FONT></B></FONT>
<HR align=right noshade SIZE=1>
</TD>
<TD vAlign=bottom width="5%">&nbsp; </TD>
<TD vAlign=bottom colSpan=3><FONT face="Times New Roman" size=2><B><FONT size=1></FONT></B></FONT><FONT face="Times New Roman" size=2><B><FONT size=1>Options Exercisable<BR></FONT></B></FONT>
<HR align=right noshade SIZE=1>
</TD></TR>
<TR align=center>
<TD vAlign=bottom width="3%">&nbsp;</TD>
<TD vAlign=bottom colSpan=3><FONT face="Times New Roman" size=2><B><FONT face="Times New Roman" size=2><B><FONT size=1>Range of</FONT></B></FONT><FONT size=1><BR>Exercise Prices<BR></FONT></B></FONT>
<HR align=right noshade SIZE=1>
</TD>
<TD vAlign=bottom width="6%">&nbsp;&nbsp;</TD>
<TD vAlign=bottom width="11%"><FONT face="Times New Roman" size=2><B><FONT face="Times New Roman" size=2><B><FONT size=1>Number</FONT></B></FONT><FONT size=1><BR>Outstanding<BR></FONT></B></FONT>
<HR align=right noshade SIZE=1>
<FONT face="Times New Roman" size=2><B><FONT size=1></FONT></B></FONT></TD>
<TD vAlign=bottom width="7%">&nbsp;&nbsp;</TD>
<TD vAlign=bottom width="13%"><FONT face="Times New Roman" size=2><B><FONT face="Times New Roman" size=2><B><FONT face="Times New Roman" size=2><B><FONT face="Times New Roman" size=2><B><FONT face="Times New Roman" size=2><B><FONT size=1>Weighted</FONT></B></FONT><FONT size=1><BR>Average</FONT></B></FONT><FONT size=1><BR>Remaining</FONT></B></FONT><FONT size=1><BR>Contractual Life</FONT></B></FONT><FONT size=1><BR>(Years)<BR></FONT></B></FONT>
<HR align=right noshade SIZE=1>
<FONT face="Times New Roman" size=2><B><FONT size=1></FONT></B></FONT></TD>
<TD vAlign=bottom width="2%">&nbsp;&nbsp;</TD>
<TD vAlign=bottom width="10%"><FONT face="Times New Roman" size=2><B><FONT face="Times New Roman" size=2><B><FONT face="Times New Roman" size=2><B><FONT face="Times New Roman" size=2><B><FONT size=1>Weighted</FONT></B></FONT><BR><FONT size=1>Average</FONT></B></FONT><FONT size=1><BR>Exercise</FONT></B></FONT><BR><FONT size=1>Price<BR></FONT></B></FONT>
<HR align=right noshade SIZE=1>
<FONT face="Times New Roman" size=2><B><FONT size=1></FONT></B></FONT></TD>
<TD vAlign=bottom width="5%">&nbsp;&nbsp;</TD>
<TD vAlign=bottom width="11%"><FONT face="Times New Roman" size=2><B><FONT face="Times New Roman" size=2><B><FONT size=1>Number</FONT></B></FONT><BR><FONT size=1>Exercisable<BR></FONT></B></FONT>
<HR align=right noshade SIZE=1>
<FONT face="Times New Roman" size=2><B><FONT size=1></FONT></B></FONT></TD>
<TD vAlign=bottom width="2%">&nbsp;&nbsp;</TD>
<TD vAlign=bottom width="11%"><FONT face="Times New Roman" size=2><B><FONT face="Times New Roman" size=2><B><FONT face="Times New Roman" size=2><B><FONT face="Times New Roman" size=2><B><FONT size=1>Weighted</FONT></B></FONT><BR><FONT size=1>Average</FONT></B></FONT><FONT size=1><BR>Exercise</FONT></B></FONT><BR><FONT size=1>Price<BR></FONT></B></FONT>
<HR align=right noshade SIZE=1>
</TD></TR>
<TR>
<TD vAlign=bottom width="3%">&nbsp;</TD>
<TD vAlign=bottom align=right width="7%"><FONT size=2>$ 1.50 </FONT></TD>
<TD vAlign=bottom align=right width="2%"><FONT size=2>- </FONT></TD>
<TD vAlign=bottom align=right width="10%"><FONT size=2>$ 1.88 </FONT></TD>
<TD vAlign=bottom align=right width="6%">&nbsp; </TD>
<TD vAlign=bottom align=right width="11%"><FONT size=2>267,839 </FONT></TD>
<TD vAlign=bottom align=right width="7%">&nbsp; </TD>
<TD vAlign=bottom align=right width="13%"><FONT size=2>4.75 </FONT></TD>
<TD vAlign=bottom align=right width="2%">&nbsp; </TD>
<TD vAlign=bottom align=right width="10%"><FONT size=2>$ 1.62 </FONT></TD>
<TD vAlign=bottom align=right width="5%">&nbsp; </TD>
<TD vAlign=bottom align=right width="11%"><FONT size=2>267,839 </FONT></TD>
<TD vAlign=bottom align=right width="2%">&nbsp; </TD>
<TD vAlign=bottom align=right width="11%"><FONT size=2>$ 1.62 </FONT></TD></TR>
<TR>
<TD vAlign=bottom width="3%">&nbsp;</TD>
<TD vAlign=bottom align=right width="7%"><FONT size=2>1.88 </FONT></TD>
<TD vAlign=bottom align=right width="2%"><FONT size=2>- </FONT></TD>
<TD vAlign=bottom align=right width="10%"><FONT size=2>3.13 </FONT></TD>
<TD vAlign=bottom align=right width="6%">&nbsp; </TD>
<TD vAlign=bottom align=right width="11%"><FONT size=2>320,185 </FONT></TD>
<TD vAlign=bottom align=right width="7%">&nbsp; </TD>
<TD vAlign=bottom align=right width="13%"><FONT size=2>4.87 </FONT></TD>
<TD vAlign=bottom align=right width="2%">&nbsp; </TD>
<TD vAlign=bottom align=right width="10%"><FONT size=2>2.62 </FONT></TD>
<TD vAlign=bottom align=right width="5%">&nbsp; </TD>
<TD vAlign=bottom align=right width="11%"><FONT size=2>286,018 </FONT></TD>
<TD vAlign=bottom align=right width="2%">&nbsp; </TD>
<TD vAlign=bottom align=right width="11%"><FONT size=2>2.57 </FONT></TD></TR>
<TR>
<TD vAlign=bottom width="3%">&nbsp;</TD>
<TD vAlign=bottom align=right width="7%"><FONT size=2>3.15 </FONT></TD>
<TD vAlign=bottom align=right width="2%"><FONT size=2>- </FONT></TD>
<TD vAlign=bottom align=right width="10%"><FONT size=2>3.85 </FONT></TD>
<TD vAlign=bottom align=right width="6%">&nbsp; </TD>
<TD vAlign=bottom align=right width="11%"><FONT size=2>460,038 </FONT></TD>
<TD vAlign=bottom align=right width="7%">&nbsp; </TD>
<TD vAlign=bottom align=right width="13%"><FONT size=2>8.99 </FONT></TD>
<TD vAlign=bottom align=right width="2%">&nbsp; </TD>
<TD vAlign=bottom align=right width="10%"><FONT size=2>3.80 </FONT></TD>
<TD vAlign=bottom align=right width="5%">&nbsp; </TD>
<TD vAlign=bottom align=right width="11%"><FONT size=2>21,288 </FONT></TD>
<TD vAlign=bottom align=right width="2%">&nbsp; </TD>
<TD vAlign=bottom align=right width="11%"><FONT size=2>3.27 </FONT></TD></TR>
<TR>
<TD vAlign=bottom width="3%">&nbsp;</TD>
<TD vAlign=bottom align=right width="7%"><FONT size=2>3.88 </FONT></TD>
<TD vAlign=bottom align=right width="2%"><FONT size=2>- </FONT></TD>
<TD vAlign=bottom align=right width="10%"><FONT size=2>4.25 </FONT></TD>
<TD vAlign=bottom align=right width="6%">&nbsp; </TD>
<TD vAlign=bottom align=right width="11%"><FONT size=2>122,745 </FONT></TD>
<TD vAlign=bottom align=right width="7%">&nbsp; </TD>
<TD vAlign=bottom align=right width="13%"><FONT size=2>7.76 </FONT></TD>
<TD vAlign=bottom align=right width="2%">&nbsp; </TD>
<TD vAlign=bottom align=right width="10%"><FONT size=2>4.07 </FONT></TD>
<TD vAlign=bottom align=right width="5%">&nbsp; </TD>
<TD vAlign=bottom align=right width="11%"><FONT size=2>75,130 </FONT></TD>
<TD vAlign=bottom align=right width="2%">&nbsp; </TD>
<TD vAlign=bottom align=right width="11%"><FONT size=2>4.11 </FONT></TD></TR>
<TR>
<TD vAlign=bottom width="3%">&nbsp;</TD>
<TD vAlign=bottom align=right width="7%"><FONT size=2>4.30 </FONT></TD>
<TD vAlign=bottom align=right width="2%"><FONT size=2>- </FONT></TD>
<TD vAlign=bottom align=right width="10%"><FONT size=2>4.87 </FONT></TD>
<TD vAlign=bottom align=right width="6%">&nbsp; </TD>
<TD vAlign=bottom align=right width="11%"><FONT size=2>509,668 </FONT></TD>
<TD vAlign=bottom align=right width="7%">&nbsp; </TD>
<TD vAlign=bottom align=right width="13%"><FONT size=2>7.04 </FONT></TD>
<TD vAlign=bottom align=right width="2%">&nbsp; </TD>
<TD vAlign=bottom align=right width="10%"><FONT size=2>4.85 </FONT></TD>
<TD vAlign=bottom align=right width="5%">&nbsp; </TD>
<TD vAlign=bottom align=right width="11%"><FONT size=2>367,952 </FONT></TD>
<TD vAlign=bottom align=right width="2%">&nbsp; </TD>
<TD vAlign=bottom align=right width="11%"><FONT size=2>4.85 </FONT></TD></TR>
<TR>
<TD vAlign=bottom width="3%">&nbsp;</TD>
<TD vAlign=bottom align=right width="7%"><FONT size=2>4.94 </FONT></TD>
<TD vAlign=bottom align=right width="2%"><FONT size=2>- </FONT></TD>
<TD vAlign=bottom align=right width="10%"><FONT size=2>5.47 </FONT></TD>
<TD vAlign=bottom align=right width="6%">&nbsp; </TD>
<TD vAlign=bottom align=right width="11%"><FONT size=2>332,731 </FONT></TD>
<TD vAlign=bottom align=right width="7%">&nbsp; </TD>
<TD vAlign=bottom align=right width="13%"><FONT size=2>3.55 </FONT></TD>
<TD vAlign=bottom align=right width="2%">&nbsp; </TD>
<TD vAlign=bottom align=right width="10%"><FONT size=2>5.20 </FONT></TD>
<TD vAlign=bottom align=right width="5%">&nbsp; </TD>
<TD vAlign=bottom align=right width="11%"><FONT size=2>310,649 </FONT></TD>
<TD vAlign=bottom align=right width="2%">&nbsp; </TD>
<TD vAlign=bottom align=right width="11%"><FONT size=2>5.18 </FONT></TD></TR>
<TR>
<TD vAlign=bottom width="3%">&nbsp;</TD>
<TD vAlign=bottom align=right width="7%"><FONT size=2>5.50 </FONT></TD>
<TD vAlign=bottom align=right width="2%"><FONT size=2>- </FONT></TD>
<TD vAlign=bottom align=right width="10%"><FONT size=2>6.56 </FONT></TD>
<TD vAlign=bottom align=right width="6%">&nbsp; </TD>
<TD vAlign=bottom align=right width="11%"><FONT size=2>279,175 </FONT></TD>
<TD vAlign=bottom align=right width="7%">&nbsp; </TD>
<TD vAlign=bottom align=right width="13%"><FONT size=2>6.54 </FONT></TD>
<TD vAlign=bottom align=right width="2%">&nbsp; </TD>
<TD vAlign=bottom align=right width="10%"><FONT size=2>5.97 </FONT></TD>
<TD vAlign=bottom align=right width="5%">&nbsp; </TD>
<TD vAlign=bottom align=right width="11%"><FONT size=2>195,188 </FONT></TD>
<TD vAlign=bottom align=right width="2%">&nbsp; </TD>
<TD vAlign=bottom align=right width="11%"><FONT size=2>5.97 </FONT></TD></TR>
<TR>
<TD vAlign=bottom width="3%">&nbsp;</TD>
<TD vAlign=bottom align=right width="7%"><FONT size=2>6.69 </FONT></TD>
<TD vAlign=bottom align=right width="2%"><FONT size=2>- </FONT></TD>
<TD vAlign=bottom align=right width="10%"><FONT size=2>8.13 </FONT></TD>
<TD vAlign=bottom align=right width="6%">&nbsp; </TD>
<TD vAlign=bottom align=right width="11%"><FONT size=2>268,593 </FONT></TD>
<TD vAlign=bottom align=right width="7%">&nbsp; </TD>
<TD vAlign=bottom align=right width="13%"><FONT size=2>5.96 </FONT></TD>
<TD vAlign=bottom align=right width="2%">&nbsp; </TD>
<TD vAlign=bottom align=right width="10%"><FONT size=2>7.81 </FONT></TD>
<TD vAlign=bottom align=right width="5%">&nbsp; </TD>
<TD vAlign=bottom align=right width="11%"><FONT size=2>261,115 </FONT></TD>
<TD vAlign=bottom align=right width="2%">&nbsp; </TD>
<TD vAlign=bottom align=right width="11%"><FONT size=2>7.82 </FONT></TD></TR>
<TR>
<TD vAlign=bottom width="3%">&nbsp;</TD>
<TD vAlign=bottom align=right width="7%"><FONT size=2>8.19 </FONT></TD>
<TD vAlign=bottom align=right width="2%"><FONT size=2>- </FONT></TD>
<TD vAlign=bottom align=right width="10%"><FONT size=2>21.00 </FONT></TD>
<TD vAlign=bottom align=right width="6%">&nbsp; </TD>
<TD vAlign=bottom align=right width="11%"><FONT size=2>102,750 </FONT></TD>
<TD vAlign=bottom align=right width="7%">&nbsp; </TD>
<TD vAlign=bottom align=right width="13%"><FONT size=2>8.93 </FONT></TD>
<TD vAlign=bottom align=right width="2%">&nbsp; </TD>
<TD vAlign=bottom align=right width="10%"><FONT size=2>14.68 </FONT></TD>
<TD vAlign=bottom align=right width="5%">&nbsp; </TD>
<TD vAlign=bottom align=right width="11%"><FONT size=2>25,666 </FONT></TD>
<TD vAlign=bottom align=right width="2%">&nbsp; </TD>
<TD vAlign=bottom align=right width="11%"><FONT size=2>10.55 </FONT></TD></TR>
<TR>
<TD vAlign=bottom width="3%">&nbsp;</TD>
<TD vAlign=bottom align=right width="7%"><FONT size=2>22.80 </FONT></TD>
<TD vAlign=bottom align=right width="2%"><FONT size=2>- </FONT></TD>
<TD vAlign=bottom align=right width="10%"><FONT size=2>22.80 </FONT></TD>
<TD vAlign=bottom align=right width="6%">&nbsp; </TD>
<TD vAlign=bottom align=right width="11%"><FONT size=2>500 </FONT></TD>
<TD vAlign=bottom align=right width="7%">&nbsp; </TD>
<TD vAlign=bottom align=right width="13%"><FONT size=2>9.82 </FONT></TD>
<TD vAlign=bottom align=right width="2%">&nbsp; </TD>
<TD vAlign=bottom align=right width="10%"><FONT size=2>22.80 </FONT></TD>
<TD vAlign=bottom align=right width="5%">&nbsp; </TD>
<TD vAlign=bottom align=right width="11%"><FONT size=2>- </FONT></TD>
<TD vAlign=bottom align=right width="2%">&nbsp; </TD>
<TD vAlign=bottom align=right width="11%"><FONT size=2>- </FONT></TD></TR>
<TR>
<TD vAlign=bottom width="3%">&nbsp;</TD>
<TD vAlign=bottom align=right width="7%">&nbsp;</TD>
<TD vAlign=bottom align=right width="2%">&nbsp;</TD>
<TD vAlign=bottom align=right width="10%">&nbsp;</TD>
<TD vAlign=bottom align=right width="6%">&nbsp;</TD>
<TD vAlign=bottom align=right width="11%">
<HR align=right width=55 noshade SIZE=1>
</TD>
<TD vAlign=bottom align=right width="7%">&nbsp;</TD>
<TD vAlign=bottom align=right width="13%">&nbsp;</TD>
<TD vAlign=bottom align=right width="2%">&nbsp;</TD>
<TD vAlign=bottom align=right width="10%">&nbsp;</TD>
<TD vAlign=bottom align=right width="5%">&nbsp;</TD>
<TD vAlign=bottom align=right width="11%">
<HR align=right width=55 noshade SIZE=1>
</TD>
<TD vAlign=bottom align=right width="2%">&nbsp;</TD>
<TD vAlign=bottom align=right width="11%">&nbsp;</TD></TR>
<TR>
<TD vAlign=bottom width="3%">&nbsp;</TD>
<TD vAlign=bottom align=right width="7%"><FONT size=2>$ 1.50 </FONT></TD>
<TD vAlign=bottom align=right width="2%"><FONT size=2>- </FONT></TD>
<TD vAlign=bottom align=right width="10%"><FONT size=2>$ 22.80 </FONT></TD>
<TD vAlign=bottom align=right width="6%">&nbsp; </TD>
<TD vAlign=bottom align=right width="11%"><FONT size=2>2,664,224 </FONT></TD>
<TD vAlign=bottom align=right width="7%">&nbsp; </TD>
<TD vAlign=bottom align=right width="13%"><FONT size=2>6.40 </FONT></TD>
<TD vAlign=bottom align=right width="2%">&nbsp; </TD>
<TD vAlign=bottom align=right width="10%"><FONT size=2>$ 4.88 </FONT></TD>
<TD vAlign=bottom align=right width="5%">&nbsp; </TD>
<TD vAlign=bottom align=right width="11%"><FONT size=2>1,810,845 </FONT></TD>
<TD vAlign=bottom align=right width="2%">&nbsp; </TD>
<TD vAlign=bottom align=right width="11%"><FONT size=2>$ 4.65 </FONT></TD></TR>
<TR>
<TD vAlign=bottom width="3%">&nbsp;</TD>
<TD vAlign=bottom align=right width="7%">&nbsp;</TD>
<TD vAlign=bottom align=right width="2%">&nbsp;</TD>
<TD vAlign=bottom align=right width="10%">&nbsp;</TD>
<TD vAlign=bottom align=right width="6%">&nbsp;</TD>
<TD vAlign=bottom align=right width="11%">
<HR align=right width=55 noshade SIZE=2>
</TD>
<TD vAlign=bottom align=right width="7%">&nbsp;</TD>
<TD vAlign=bottom align=right width="13%">&nbsp;</TD>
<TD vAlign=bottom align=right width="2%">&nbsp;</TD>
<TD vAlign=bottom align=right width="10%">&nbsp;</TD>
<TD vAlign=bottom align=right width="5%">&nbsp;</TD>
<TD vAlign=bottom align=right width="11%">
<HR align=right width=55 noshade SIZE=2>
</TD>
<TD vAlign=bottom align=right width="2%">&nbsp;</TD>
<TD vAlign=bottom align=right width="11%">&nbsp;</TD></TR>
</TABLE>

<BR>
<TABLE cellSpacing=0 cellPadding=0 width="100%">
<TR vAlign=top>
<TD width="5%"><FONT face="Times New Roman, Times, Serif" size=2>&nbsp; </FONT></TD>
<TD width="95%"><FONT face="Times New Roman, Times, Serif" size=2>At March&nbsp;31, 2004, 610,932 shares of common stock were available for future grants under the Company&#146;s Option Plan. </FONT></TD></TR>
</TABLE>

<BR>
<!-- MARKER FORMAT-SHEET="Para Flush Level 1" FSL="Default" -->
<TABLE cellSpacing=0 cellPadding=0 width="100%">
<TR vAlign=top>
<TD width="5%"><FONT face="Times New Roman, Times, Serif" size=2>&nbsp; </FONT></TD>
<TD width="95%"><FONT face="Times New Roman, Times, Serif" size=2><I>Stock Purchase Rights </I>&#150; On April 22, 2003, the Board of Directors of the Company approved the adoption of a Shareholder Rights Plan. Under the terms of the plan, shareholders of record on May 8, 2003, received one preferred stock purchase right for each outstanding share of Common Stock held. Each right entitled the registered holder to purchase from the Company one one-thousandth of a share of the Company&#146;s Series RP Preferred Stock, $0.001 par value, at a price of $24.00 per share and becomes exercisable when a person or group acquires 15% or more of the Company&#146;s Common Stock without prior approval by the Board of Directors. </FONT></TD></TR>
</TABLE>

<BR>
<!-- MARKER FORMAT-SHEET="Para Flush Level 1" FSL="Default" -->
<TABLE cellSpacing=0 cellPadding=0 width="100%">
<TR vAlign=top>
<TD width="5%"><B><FONT face="Times New Roman, Times, Serif" size=2>12. </FONT></B></TD>
<TD width="95%"><B><FONT face="Times New Roman, Times, Serif" size=2>Net Income Per Share </FONT></B></TD></TR>
</TABLE>

<BR>
<!-- MARKER FORMAT-SHEET="Para Flush Level 1" FSL="Default" -->
<TABLE cellSpacing=0 cellPadding=0 width="100%">
<TR vAlign=top>
<TD width="5%"><FONT face="Times New Roman, Times, Serif" size=2>&nbsp; </FONT></TD>
<TD width="95%"><FONT face="Times New Roman, Times, Serif" size=2>The following is a reconciliation of the numerators and denominators used in computing basic and diluted net income per share: </FONT></TD></TR>
</TABLE>

<BR>
<TABLE width="100%">
<TR>
<TD align=center><FONT size=2>49</FONT></TD></TR>
</TABLE>



<P>
<HR align=left noshade SIZE=5>


<P>&nbsp;
<!-- *************************************************************************** -->
<!-- MARKER PAGE="sheet: 14; page: 14" -->

<P>
<TABLE cellSpacing=0 cellPadding=0 width="100%" border=0>
<TR>
<TD vAlign=bottom width="63%"><FONT size=2>&nbsp;</FONT></TD>
<TD vAlign=bottom colSpan=8>
<DIV align=center><FONT size=2><B>Year Ended March 31, </B></FONT></DIV>
<HR align=center noshade SIZE=1>
</TD></TR>
<TR>
<TD vAlign=bottom width="63%"><FONT size=2>&nbsp;</FONT></TD>
<TD vAlign=bottom width="10%">
<DIV align=center><FONT size=2><B>2004</B></FONT></DIV>
<HR align=center noshade SIZE=1>
</TD>
<TD vAlign=bottom width="1%"><FONT size=2></FONT></TD>
<TD vAlign=bottom width="3%"><FONT size=2></FONT></TD>
<TD vAlign=bottom width="9%">
<DIV align=center><FONT size=2><B>2003<BR></B></FONT></DIV>
<HR align=center noshade SIZE=1>
</TD>
<TD vAlign=bottom width="1%"><FONT size=2></FONT></TD>
<TD vAlign=bottom width="3%"><FONT size=2></FONT></TD>
<TD vAlign=bottom width="9%">
<DIV align=center><FONT size=2><B>2002 </B></FONT></DIV>
<HR align=center noshade SIZE=1>
</TD>
<TD vAlign=bottom width="1%"><FONT size=2></FONT></TD></TR>
<TR>
<TD vAlign=bottom width="63%"><FONT size=2>Net income</FONT></TD>
<TD vAlign=bottom align=right width="10%"><FONT size=2>$ 24,033,000 </FONT></TD>
<TD vAlign=bottom width="1%"><FONT size=2></FONT></TD>
<TD vAlign=bottom width="3%"><FONT size=2>&nbsp;&nbsp;</FONT></TD>
<TD vAlign=bottom align=right width="9%"><FONT size=2>$ 1,636,000 </FONT></TD>
<TD vAlign=bottom width="1%"><FONT size=2></FONT></TD>
<TD vAlign=bottom width="3%"><FONT size=2>&nbsp;&nbsp;</FONT></TD>
<TD vAlign=bottom align=right width="9%"><FONT size=2>$ 1,304,000 </FONT></TD>
<TD vAlign=bottom width="1%"><FONT size=2></FONT></TD></TR>
<TR>
<TD vAlign=bottom width="63%"><FONT size=2>Accrued preferred stock dividends</FONT></TD>
<TD vAlign=bottom align=right width="10%"><FONT size=2>(419,000</FONT></TD>
<TD vAlign=bottom width="1%"><FONT size=2>)</FONT></TD>
<TD vAlign=bottom width="3%"><FONT size=2></FONT></TD>
<TD vAlign=bottom align=right width="9%"><FONT size=2>(865,000</FONT></TD>
<TD vAlign=bottom width="1%"><FONT size=2>)</FONT></TD>
<TD vAlign=bottom width="3%"><FONT size=2></FONT></TD>
<TD vAlign=bottom align=right width="9%"><FONT size=2>(446,000</FONT></TD>
<TD vAlign=bottom width="1%"><FONT size=2>)</FONT></TD></TR>
<TR>
<TD vAlign=bottom width="63%"><FONT size=2>Accretion of value attributable to beneficial conversion feature</FONT></TD>
<TD vAlign=bottom align=right width="10%"><FONT size=2>&#151; </FONT></TD>
<TD vAlign=bottom width="1%"><FONT size=2></FONT></TD>
<TD vAlign=bottom width="3%"><FONT size=2></FONT></TD>
<TD vAlign=bottom align=right width="9%"><FONT size=2>(370,000</FONT></TD>
<TD vAlign=bottom width="1%"><FONT size=2>)</FONT></TD>
<TD vAlign=bottom width="3%"><FONT size=2></FONT></TD>
<TD vAlign=bottom align=right width="9%"><FONT size=2>(587,000</FONT></TD>
<TD vAlign=bottom width="1%"><FONT size=2>)</FONT></TD></TR>
<TR>
<TD vAlign=bottom width="63%"><FONT size=2></FONT></TD>
<TD vAlign=bottom align=right width="10%">
<HR noshade SIZE=1>
</TD>
<TD vAlign=bottom width="1%"><FONT size=2></FONT></TD>
<TD vAlign=bottom width="3%"><FONT size=2></FONT></TD>
<TD vAlign=bottom align=right width="9%">
<HR noshade SIZE=1>
</TD>
<TD vAlign=bottom width="1%"><FONT size=2></FONT></TD>
<TD vAlign=bottom width="3%"><FONT size=2></FONT></TD>
<TD vAlign=bottom align=right width="9%">
<HR noshade SIZE=1>
</TD>
<TD vAlign=bottom width="1%"><FONT size=2></FONT></TD></TR>
<TR>
<TD vAlign=bottom width="63%"><FONT size=2>Net income attributable to common shareholders</FONT></TD>
<TD vAlign=bottom align=right width="10%"><FONT size=2>&nbsp;</FONT></TD>
<TD vAlign=bottom width="1%"><FONT size=2></FONT></TD>
<TD vAlign=bottom width="3%"><FONT size=2></FONT></TD>
<TD vAlign=bottom align=right width="9%"><FONT size=2>&nbsp;</FONT></TD>
<TD vAlign=bottom width="1%"><FONT size=2></FONT></TD>
<TD vAlign=bottom width="3%"><FONT size=2></FONT></TD>
<TD vAlign=bottom align=right width="9%"><FONT size=2>&nbsp;</FONT></TD>
<TD vAlign=bottom width="1%"><FONT size=2></FONT></TD></TR>
<TR>
<TD vAlign=bottom width="63%"><FONT size=2></FONT></TD>
<TD vAlign=bottom align=right width="10%"><FONT size=2></FONT></TD>
<TD vAlign=bottom width="1%"><FONT size=2></FONT></TD>
<TD vAlign=bottom width="3%"><FONT size=2></FONT></TD>
<TD vAlign=bottom align=right width="9%"><FONT size=2></FONT></TD>
<TD vAlign=bottom width="1%"><FONT size=2></FONT></TD>
<TD vAlign=bottom width="3%"><FONT size=2></FONT></TD>
<TD vAlign=bottom align=right width="9%"><FONT size=2></FONT></TD>
<TD vAlign=bottom width="1%"><FONT size=2></FONT></TD></TR>
<TR>
<TD vAlign=bottom width="63%"><FONT size=2>(numerator) &#151; basic and diluted</FONT></TD>
<TD vAlign=bottom align=right width="10%"><FONT size=2>$ 23,614,000 </FONT></TD>
<TD vAlign=bottom width="1%"><FONT size=2></FONT></TD>
<TD vAlign=bottom width="3%"><FONT size=2></FONT></TD>
<TD vAlign=bottom align=right width="9%"><FONT size=2>$ 401,000 </FONT></TD>
<TD vAlign=bottom width="1%"><FONT size=2></FONT></TD>
<TD vAlign=bottom width="3%"><FONT size=2></FONT></TD>
<TD vAlign=bottom align=right width="9%"><FONT size=2>$ 271,000 </FONT></TD>
<TD vAlign=bottom width="1%"><FONT size=2></FONT></TD></TR>
<TR>
<TD vAlign=bottom width="63%"><FONT size=2>&nbsp;</FONT></TD>
<TD vAlign=bottom align=right width="10%">
<HR noshade SIZE=2>
<FONT size=2>&nbsp;</FONT></TD>
<TD vAlign=bottom width="1%"><FONT size=2></FONT></TD>
<TD vAlign=bottom width="3%"><FONT size=2></FONT></TD>
<TD vAlign=bottom align=right width="9%">
<HR noshade SIZE=2>
<FONT size=2>&nbsp;</FONT></TD>
<TD vAlign=bottom width="1%"><FONT size=2></FONT></TD>
<TD vAlign=bottom width="3%"><FONT size=2></FONT></TD>
<TD vAlign=bottom align=right width="9%">
<HR noshade SIZE=2>
<FONT size=2>&nbsp;</FONT></TD>
<TD vAlign=bottom width="1%"><FONT size=2></FONT></TD></TR>
<TR>
<TD vAlign=bottom width="63%"><FONT size=2>Shares (denominator):</FONT></TD>
<TD vAlign=bottom align=right width="10%"><FONT size=2>&nbsp;</FONT></TD>
<TD vAlign=bottom width="1%"><FONT size=2></FONT></TD>
<TD vAlign=bottom width="3%"><FONT size=2></FONT></TD>
<TD vAlign=bottom align=right width="9%"><FONT size=2>&nbsp;</FONT></TD>
<TD vAlign=bottom width="1%"><FONT size=2></FONT></TD>
<TD vAlign=bottom width="3%"><FONT size=2></FONT></TD>
<TD vAlign=bottom align=right width="9%"><FONT size=2>&nbsp;</FONT></TD>
<TD vAlign=bottom width="1%"><FONT size=2></FONT></TD></TR>
<TR>
<TD vAlign=bottom width="63%"><FONT size=2>Weighted average common shares outstanding &#151;</FONT></TD>
<TD vAlign=bottom align=right width="10%"><FONT size=2>&nbsp;</FONT></TD>
<TD vAlign=bottom width="1%"><FONT size=2></FONT></TD>
<TD vAlign=bottom width="3%"><FONT size=2></FONT></TD>
<TD vAlign=bottom align=right width="9%"><FONT size=2>&nbsp;</FONT></TD>
<TD vAlign=bottom width="1%"><FONT size=2></FONT></TD>
<TD vAlign=bottom width="3%"><FONT size=2></FONT></TD>
<TD vAlign=bottom align=right width="9%"><FONT size=2>&nbsp;</FONT></TD>
<TD vAlign=bottom width="1%"><FONT size=2></FONT></TD></TR>
<TR>
<TD vAlign=bottom width="63%"><FONT size=2>Denominator for basic net income per share</FONT></TD>
<TD vAlign=bottom align=right width="10%"><FONT size=2>18,128,181 </FONT></TD>
<TD vAlign=bottom width="1%"><FONT size=2></FONT></TD>
<TD vAlign=bottom width="3%"><FONT size=2></FONT></TD>
<TD vAlign=bottom align=right width="9%"><FONT size=2>16,634,447 </FONT></TD>
<TD vAlign=bottom width="1%"><FONT size=2></FONT></TD>
<TD vAlign=bottom width="3%"><FONT size=2></FONT></TD>
<TD vAlign=bottom align=right width="9%"><FONT size=2>16,264,153 </FONT></TD>
<TD vAlign=bottom width="1%"><FONT size=2></FONT></TD></TR>
<TR>
<TD vAlign=bottom width="63%"><FONT size=2>Effect of dilutive securities:</FONT></TD>
<TD vAlign=bottom align=right width="10%"><FONT size=2>&nbsp;</FONT></TD>
<TD vAlign=bottom width="1%"><FONT size=2></FONT></TD>
<TD vAlign=bottom width="3%"><FONT size=2></FONT></TD>
<TD vAlign=bottom align=right width="9%"><FONT size=2>&nbsp;</FONT></TD>
<TD vAlign=bottom width="1%"><FONT size=2></FONT></TD>
<TD vAlign=bottom width="3%"><FONT size=2></FONT></TD>
<TD vAlign=bottom align=right width="9%"><FONT size=2>&nbsp;</FONT></TD>
<TD vAlign=bottom width="1%"><FONT size=2></FONT></TD></TR>
<TR>
<TD vAlign=bottom width="63%"><FONT size=2>Stock options</FONT></TD>
<TD vAlign=bottom align=right width="10%"><FONT size=2>1,809,866 </FONT></TD>
<TD vAlign=bottom width="1%"><FONT size=2></FONT></TD>
<TD vAlign=bottom width="3%"><FONT size=2></FONT></TD>
<TD vAlign=bottom align=right width="9%"><FONT size=2>379,866 </FONT></TD>
<TD vAlign=bottom width="1%"><FONT size=2></FONT></TD>
<TD vAlign=bottom width="3%"><FONT size=2></FONT></TD>
<TD vAlign=bottom align=right width="9%"><FONT size=2>547,173 </FONT></TD>
<TD vAlign=bottom width="1%"><FONT size=2></FONT></TD></TR>
<TR>
<TD vAlign=bottom width="63%"><FONT size=2>Warrants</FONT></TD>
<TD vAlign=bottom align=right width="10%"><FONT size=2>449,120 </FONT></TD>
<TD vAlign=bottom width="1%"><FONT size=2></FONT></TD>
<TD vAlign=bottom width="3%"><FONT size=2></FONT></TD>
<TD vAlign=bottom align=right width="9%"><FONT size=2>&#151; </FONT></TD>
<TD vAlign=bottom width="1%"><FONT size=2></FONT></TD>
<TD vAlign=bottom width="3%"><FONT size=2></FONT></TD>
<TD vAlign=bottom align=right width="9%"><FONT size=2>&#151; </FONT></TD>
<TD vAlign=bottom width="1%"><FONT size=2></FONT></TD></TR>
<TR>
<TD vAlign=bottom width="63%"><FONT size=2></FONT></TD>
<TD vAlign=bottom align=right width="10%">
<HR noshade SIZE=1>
</TD>
<TD vAlign=bottom width="1%"><FONT size=2></FONT></TD>
<TD vAlign=bottom width="3%"><FONT size=2></FONT></TD>
<TD vAlign=bottom align=right width="9%">
<HR noshade SIZE=1>
</TD>
<TD vAlign=bottom width="1%"><FONT size=2></FONT></TD>
<TD vAlign=bottom width="3%"><FONT size=2></FONT></TD>
<TD vAlign=bottom align=right width="9%">
<HR noshade SIZE=1>
</TD>
<TD vAlign=bottom width="1%"><FONT size=2></FONT></TD></TR>
<TR>
<TD vAlign=bottom width="63%"><FONT size=2>Denominator for diluted net income per share</FONT></TD>
<TD vAlign=bottom align=right width="10%"><FONT size=2>20,387,167 </FONT></TD>
<TD vAlign=bottom width="1%"><FONT size=2></FONT></TD>
<TD vAlign=bottom width="3%"><FONT size=2></FONT></TD>
<TD vAlign=bottom align=right width="9%"><FONT size=2>17,014,313 </FONT></TD>
<TD vAlign=bottom width="1%"><FONT size=2></FONT></TD>
<TD vAlign=bottom width="3%"><FONT size=2></FONT></TD>
<TD vAlign=bottom align=right width="9%"><FONT size=2>16,811,326 </FONT></TD>
<TD vAlign=bottom width="1%"><FONT size=2></FONT></TD></TR>
<TR>
<TD vAlign=bottom width="63%"><FONT size=2>&nbsp;</FONT></TD>
<TD vAlign=bottom align=right width="10%">
<HR noshade>
<FONT size=2>&nbsp;</FONT></TD>
<TD vAlign=bottom width="1%"><FONT size=2></FONT></TD>
<TD vAlign=bottom width="3%"><FONT size=2></FONT></TD>
<TD vAlign=bottom align=right width="9%">
<HR noshade>
<FONT size=2>&nbsp;</FONT></TD>
<TD vAlign=bottom width="1%"><FONT size=2></FONT></TD>
<TD vAlign=bottom width="3%"><FONT size=2></FONT></TD>
<TD vAlign=bottom align=right width="9%">
<HR noshade>
<FONT size=2>&nbsp;</FONT></TD>
<TD vAlign=bottom width="1%"><FONT size=2></FONT></TD></TR>
<TR>
<TD vAlign=bottom width="63%"><FONT size=2>Net income per share:</FONT></TD>
<TD vAlign=bottom align=right width="10%"><FONT size=2>&nbsp;</FONT></TD>
<TD vAlign=bottom width="1%"><FONT size=2></FONT></TD>
<TD vAlign=bottom width="3%"><FONT size=2></FONT></TD>
<TD vAlign=bottom align=right width="9%"><FONT size=2>&nbsp;</FONT></TD>
<TD vAlign=bottom width="1%"><FONT size=2></FONT></TD>
<TD vAlign=bottom width="3%"><FONT size=2></FONT></TD>
<TD vAlign=bottom align=right width="9%"><FONT size=2>&nbsp;</FONT></TD>
<TD vAlign=bottom width="1%"><FONT size=2></FONT></TD></TR>
<TR>
<TD vAlign=bottom width="63%"><FONT size=2>Basic</FONT></TD>
<TD vAlign=bottom align=right width="10%"><FONT size=2>$ 1.30 </FONT></TD>
<TD vAlign=bottom width="1%"><FONT size=2></FONT></TD>
<TD vAlign=bottom width="3%"><FONT size=2></FONT></TD>
<TD vAlign=bottom align=right width="9%"><FONT size=2>$ 0.02 </FONT></TD>
<TD vAlign=bottom width="1%"><FONT size=2></FONT></TD>
<TD vAlign=bottom width="3%"><FONT size=2></FONT></TD>
<TD vAlign=bottom align=right width="9%"><FONT size=2>$ 0.02 </FONT></TD>
<TD vAlign=bottom width="1%"><FONT size=2></FONT></TD></TR>
<TR>
<TD vAlign=bottom width="63%"><FONT size=2></FONT></TD>
<TD vAlign=bottom align=right width="10%">
<HR noshade>
</TD>
<TD vAlign=bottom width="1%"><FONT size=2></FONT></TD>
<TD vAlign=bottom width="3%"><FONT size=2></FONT></TD>
<TD vAlign=bottom align=right width="9%">
<HR noshade>
</TD>
<TD vAlign=bottom width="1%"><FONT size=2></FONT></TD>
<TD vAlign=bottom width="3%"><FONT size=2></FONT></TD>
<TD vAlign=bottom align=right width="9%">
<HR noshade>
</TD>
<TD vAlign=bottom width="1%"><FONT size=2></FONT></TD></TR>
<TR>
<TD vAlign=bottom width="63%"><FONT size=2>Diluted</FONT></TD>
<TD vAlign=bottom align=right width="10%"><FONT size=2>$ 1.16 </FONT></TD>
<TD vAlign=bottom width="1%"><FONT size=2></FONT></TD>
<TD vAlign=bottom width="3%"><FONT size=2></FONT></TD>
<TD vAlign=bottom align=right width="9%"><FONT size=2>$ 0.02 </FONT></TD>
<TD vAlign=bottom width="1%"><FONT size=2></FONT></TD>
<TD vAlign=bottom width="3%"><FONT size=2></FONT></TD>
<TD vAlign=bottom align=right width="9%"><FONT size=2>$ 0.02 </FONT></TD>
<TD vAlign=bottom width="1%"><FONT size=2></FONT></TD></TR>
<TR>
<TD vAlign=bottom width="63%" height=2><FONT size=2></FONT></TD>
<TD vAlign=bottom align=right width="10%" height=2>
<HR noshade>
</TD>
<TD vAlign=bottom width="1%" height=2><FONT size=2></FONT></TD>
<TD vAlign=bottom width="3%" height=2><FONT size=2></FONT></TD>
<TD vAlign=bottom align=right width="9%" height=2>
<HR noshade>
</TD>
<TD vAlign=bottom width="1%" height=2><FONT size=2></FONT></TD>
<TD vAlign=bottom width="3%" height=2><FONT size=2></FONT></TD>
<TD vAlign=bottom align=right width="9%" height=2>
<HR noshade>
</TD>
<TD vAlign=bottom width="1%" height=2><FONT size=2></FONT></TD></TR>
</TABLE>

<BR>
<!-- MARKER FORMAT-SHEET="Para Flush Level 1" FSL="Default" -->
<TABLE cellSpacing=0 cellPadding=0 width="100%">
<TR vAlign=top>
<TD width="5%"><FONT face="Times New Roman, Times, Serif" size=2>&nbsp; </FONT></TD>
<TD width="95%"><FONT face="Times New Roman, Times, Serif" size=2>For the above mentioned periods, the Company had securities outstanding which could potentially dilute basic earnings per share in the future, but were excluded in the computation of diluted net income (loss) per share in the periods presented, as their effect would have been anti-dilutive. Such outstanding securities includes shares of the Company&#146;s Series D and Series E convertible preferred stock, which are listed below as assuming that the shares of the convertible preferred stock have in fact converted into shares of the Company&#146;s common stock, at the conversion price in effect at the initial issuance of the convertible preferred stock, such conversion price being subject to adjustment in the event that the Company effects a stock split, dividend, recapitalization or similar event. Such outstanding securities consist of the following: </FONT></TD></TR>
</TABLE>

<BR>

<P>
<TABLE cellSpacing=0 cellPadding=0 width="100%" border=0>
<TR>
<TD vAlign=bottom width="63%"><FONT face="Times New Roman" size=2>&nbsp;</FONT></TD>
<TD vAlign=bottom colSpan=5>
<DIV align=center><FONT face="Times New Roman" size=2><B>Year Ended March 31, </B></FONT></DIV>
<HR align=center noshade SIZE=1>
</TD></TR>
<TR>
<TD vAlign=bottom width="63%"><FONT face="Times New Roman" size=2><B>&nbsp;</B></FONT></TD>
<TD vAlign=bottom width="7%">
<DIV align=center><FONT face="Times New Roman" size=2><B>2004 </B></FONT></DIV>
<HR align=center noshade SIZE=1>
</TD>
<TD vAlign=bottom width="9%">
<DIV align=center>&nbsp;&nbsp;&nbsp;&nbsp;</DIV></TD>
<TD vAlign=bottom width="7%">
<DIV align=center><FONT face="Times New Roman" size=2><B>2003 </B></FONT></DIV>
<HR align=center noshade SIZE=1>
</TD>
<TD vAlign=bottom width="6%">
<DIV align=center>&nbsp;&nbsp;</DIV></TD>
<TD vAlign=bottom width="8%">
<DIV align=center><FONT face="Times New Roman" size=2><B>2002 </B></FONT></DIV>
<HR align=center noshade SIZE=1>
</TD></TR>
<TR>
<TD vAlign=bottom width="63%"><FONT face="Times New Roman" size=2>Convertible preferred stock</FONT></TD>
<TD vAlign=bottom align=right width="7%"><FONT face="Times New Roman" size=2>&#151; </FONT></TD>
<TD vAlign=bottom align=right width="9%">
<DIV align=right></DIV></TD>
<TD vAlign=bottom align=right width="7%"><FONT face="Times New Roman" size=2>1,786,639 </FONT></TD>
<TD vAlign=bottom align=right width="6%">
<DIV align=right></DIV></TD>
<TD vAlign=bottom align=right width="8%"><FONT face="Times New Roman" size=2>1,513,780 </FONT></TD></TR>
<TR>
<TD vAlign=bottom width="63%"><FONT face="Times New Roman" size=2>Outstanding options to purchase common stock</FONT></TD>
<TD vAlign=bottom align=right width="7%"><FONT face="Times New Roman" size=2>1,013,297 </FONT></TD>
<TD vAlign=bottom align=right width="9%">
<DIV align=right></DIV></TD>
<TD vAlign=bottom align=right width="7%"><FONT face="Times New Roman" size=2>2,139,354 </FONT></TD>
<TD vAlign=bottom align=right width="6%">
<DIV align=right></DIV></TD>
<TD vAlign=bottom align=right width="8%"><FONT face="Times New Roman" size=2>822,682 </FONT></TD></TR>
<TR>
<TD vAlign=bottom width="63%"><FONT face="Times New Roman" size=2>Warrants to purchase common stock</FONT></TD>
<TD vAlign=bottom align=right width="7%"><FONT face="Times New Roman" size=2>527,233 </FONT></TD>
<TD vAlign=bottom align=right width="9%">
<DIV align=right></DIV></TD>
<TD vAlign=bottom align=right width="7%"><FONT face="Times New Roman" size=2>1,277,452 </FONT></TD>
<TD vAlign=bottom align=right width="6%">
<DIV align=right></DIV></TD>
<TD vAlign=bottom align=right width="8%"><FONT face="Times New Roman" size=2>1,040,759 </FONT></TD></TR>
</TABLE>

<BR>
<TABLE cellSpacing=0 cellPadding=0 width="100%">
<TR vAlign=top>
<TD width="5%"><B><FONT face="Times New Roman, Times, Serif" size=2>13. </FONT></B></TD>
<TD width="95%"><B><FONT face="Times New Roman, Times, Serif" size=2>Income Tax Provision (Benefit) </FONT></B></TD></TR>
</TABLE>

<BR>
<!-- MARKER FORMAT-SHEET="Para Flush Level 1" FSL="Default" -->
<TABLE cellSpacing=0 cellPadding=0 width="100%">
<TR vAlign=top>
<TD width="5%"><FONT face="Times New Roman, Times, Serif" size=2>&nbsp; </FONT></TD>
<TD width="95%"><FONT face="Times New Roman, Times, Serif" size=2>The components of the Company&#146;s income tax provision (benefit) is summarized as follows: </FONT></TD></TR>
</TABLE>

<BR>

<P>
<TABLE cellSpacing=0 cellPadding=0 width="100%" border=0>
<TR>
<TD vAlign=bottom width="65%"><FONT face="Times New Roman" size=2>&nbsp;</FONT></TD>
<TD vAlign=bottom colSpan=6>
<DIV align=center><FONT face="Times New Roman" size=2><B>Year Ended March 31, </B></FONT></DIV>
<HR noshade SIZE=1>
</TD></TR>
<TR>
<TD vAlign=bottom width="65%"><FONT face="Times New Roman" size=2><B>&nbsp;</B></FONT></TD>
<TD vAlign=bottom width="10%">
<DIV align=center><FONT face="Times New Roman" size=2><B>2004 </B></FONT></DIV>
<HR align=center noshade SIZE=1>
<FONT face="Times New Roman" size=2><B></B></FONT></TD>
<TD vAlign=bottom width="2%">&nbsp;</TD>
<TD vAlign=bottom width="5%">&nbsp;</TD>
<TD vAlign=bottom width="7%">
<DIV align=center><FONT face="Times New Roman" size=2><B>2003 </B></FONT></DIV>
<HR align=center noshade SIZE=1>
<FONT face="Times New Roman" size=2><B></B></FONT></TD>
<TD vAlign=bottom width="4%">&nbsp;</TD>
<TD vAlign=bottom width="7%">
<DIV align=center><FONT face="Times New Roman" size=2><B>2002 </B></FONT></DIV>
<HR align=center noshade SIZE=1>
</TD></TR>
<TR>
<TD vAlign=bottom width="65%"><FONT face="Times New Roman" size=2>Current:</FONT></TD>
<TD vAlign=bottom width="10%"><FONT face="Times New Roman" size=2>&nbsp;</FONT></TD>
<TD vAlign=bottom width="2%">&nbsp;</TD>
<TD vAlign=bottom width="5%">&nbsp;&nbsp;</TD>
<TD vAlign=bottom width="7%"><FONT face="Times New Roman" size=2>&nbsp;</FONT></TD>
<TD vAlign=bottom width="4%">&nbsp;&nbsp;</TD>
<TD vAlign=bottom width="7%"><FONT face="Times New Roman" size=2>&nbsp;</FONT></TD></TR>
<TR>
<TD vAlign=bottom width="65%"><FONT face="Times New Roman" size=2>Federal</FONT></TD>
<TD vAlign=bottom align=right width="10%"><FONT face="Times New Roman" size=2>$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 118,000 </FONT></TD>
<TD vAlign=bottom width="2%">&nbsp;</TD>
<TD vAlign=bottom width="5%">&nbsp;</TD>
<TD vAlign=bottom align=right width="7%"><FONT face="Times New Roman" size=2>$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &#151; </FONT></TD>
<TD vAlign=bottom align=right width="4%">&nbsp;</TD>
<TD vAlign=bottom align=right width="7%"><FONT face="Times New Roman" size=2>$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &#151; </FONT></TD></TR>
<TR>
<TD vAlign=bottom width="65%"><FONT face="Times New Roman" size=2>State</FONT></TD>
<TD vAlign=bottom align=right width="10%"><FONT face="Times New Roman" size=2>124,000 </FONT></TD>
<TD vAlign=bottom width="2%">&nbsp;</TD>
<TD vAlign=bottom width="5%">&nbsp;</TD>
<TD vAlign=bottom align=right width="7%"><FONT face="Times New Roman" size=2>5,000 </FONT></TD>
<TD vAlign=bottom align=right width="4%">&nbsp;</TD>
<TD vAlign=bottom align=right width="7%"><FONT face="Times New Roman" size=2>16,000 </FONT></TD></TR>
<TR>
<TD vAlign=bottom width="65%">&nbsp;</TD>
<TD vAlign=bottom align=right width="10%">
<HR noshade SIZE=1>
</TD>
<TD vAlign=bottom width="2%">&nbsp;</TD>
<TD vAlign=bottom width="5%">&nbsp;</TD>
<TD vAlign=bottom align=right width="7%">
<HR noshade SIZE=1>
</TD>
<TD vAlign=bottom align=right width="4%">&nbsp;</TD>
<TD vAlign=bottom align=right width="7%">
<HR noshade SIZE=1>
</TD></TR>
<TR>
<TD vAlign=bottom width="65%"><FONT face="Times New Roman" size=2>Total current</FONT></TD>
<TD vAlign=bottom align=right width="10%"><FONT face="Times New Roman" size=2>242,000 </FONT></TD>
<TD vAlign=bottom width="2%">&nbsp;</TD>
<TD vAlign=bottom width="5%">&nbsp;</TD>
<TD vAlign=bottom align=right width="7%"><FONT face="Times New Roman" size=2>5,000 </FONT></TD>
<TD vAlign=bottom align=right width="4%">&nbsp;</TD>
<TD vAlign=bottom align=right width="7%"><FONT face="Times New Roman" size=2>16,000 </FONT></TD></TR>
<TR>
<TD vAlign=bottom width="65%">&nbsp;</TD>
<TD vAlign=bottom align=right width="10%">
<HR noshade SIZE=1>
</TD>
<TD vAlign=bottom width="2%">&nbsp;</TD>
<TD vAlign=bottom width="5%">&nbsp;</TD>
<TD vAlign=bottom align=right width="7%">
<HR noshade SIZE=1>
</TD>
<TD vAlign=bottom align=right width="4%">&nbsp;</TD>
<TD vAlign=bottom align=right width="7%">
<HR noshade SIZE=1>
</TD></TR>
<TR>
<TD vAlign=bottom width="65%"><FONT face="Times New Roman" size=2>Deferred:</FONT></TD>
<TD vAlign=bottom align=right width="10%"><FONT face="Times New Roman" size=2>&nbsp;</FONT></TD>
<TD vAlign=bottom width="2%">&nbsp;</TD>
<TD vAlign=bottom width="5%">&nbsp;</TD>
<TD vAlign=bottom align=right width="7%"><FONT face="Times New Roman" size=2>&nbsp;</FONT></TD>
<TD vAlign=bottom align=right width="4%">&nbsp;</TD>
<TD vAlign=bottom align=right width="7%"><FONT face="Times New Roman" size=2>&nbsp;</FONT></TD></TR>
<TR>
<TD vAlign=bottom width="65%"><FONT face="Times New Roman" size=2>Federal</FONT></TD>
<TD vAlign=bottom align=right width="10%"><FONT face="Times New Roman" size=2>(18,124,000</FONT></TD>
<TD vAlign=bottom width="2%"><FONT face="Times New Roman" size=2>)</FONT></TD>
<TD vAlign=bottom width="5%">&nbsp;</TD>
<TD vAlign=bottom align=right width="7%"><FONT face="Times New Roman" size=2>&#151; </FONT></TD>
<TD vAlign=bottom align=right width="4%">&nbsp;</TD>
<TD vAlign=bottom align=right width="7%"><FONT face="Times New Roman" size=2>&#151; </FONT></TD></TR>
<TR>
<TD vAlign=bottom width="65%"><FONT face="Times New Roman" size=2>State</FONT></TD>
<TD vAlign=bottom align=right width="10%"><FONT face="Times New Roman" size=2>(1,326,000</FONT></TD>
<TD vAlign=bottom width="2%"><FONT face="Times New Roman" size=2>)</FONT></TD>
<TD vAlign=bottom width="5%">&nbsp;</TD>
<TD vAlign=bottom align=right width="7%"><FONT face="Times New Roman" size=2>&#151; </FONT></TD>
<TD vAlign=bottom align=right width="4%">&nbsp;</TD>
<TD vAlign=bottom align=right width="7%"><FONT face="Times New Roman" size=2>&#151; </FONT></TD></TR>
<TR>
<TD vAlign=bottom width="65%">&nbsp;</TD>
<TD vAlign=bottom align=right width="10%">
<HR noshade SIZE=1>
</TD>
<TD vAlign=bottom width="2%">&nbsp;</TD>
<TD vAlign=bottom width="5%">&nbsp;</TD>
<TD vAlign=bottom align=right width="7%">
<HR noshade SIZE=1>
</TD>
<TD vAlign=bottom align=right width="4%">&nbsp;</TD>
<TD vAlign=bottom align=right width="7%">
<HR noshade SIZE=1>
</TD></TR>
<TR>
<TD vAlign=bottom width="65%"><FONT face="Times New Roman" size=2>Total deferred </FONT></TD>
<TD vAlign=bottom align=right width="10%"><FONT face="Times New Roman" size=2>(19,450,000</FONT></TD>
<TD vAlign=bottom width="2%"><FONT face="Times New Roman" size=2>)</FONT></TD>
<TD vAlign=bottom width="5%">&nbsp;</TD>
<TD vAlign=bottom align=right width="7%"><FONT face="Times New Roman" size=2>&#151; </FONT></TD>
<TD vAlign=bottom align=right width="4%">&nbsp;</TD>
<TD vAlign=bottom align=right width="7%"><FONT face="Times New Roman" size=2>&#151; </FONT></TD></TR>
<TR>
<TD vAlign=bottom width="65%">&nbsp;</TD>
<TD vAlign=bottom align=right width="10%">
<HR noshade SIZE=1>
</TD>
<TD vAlign=bottom width="2%">&nbsp;</TD>
<TD vAlign=bottom width="5%">&nbsp;</TD>
<TD vAlign=bottom align=right width="7%">
<HR noshade SIZE=1>
</TD>
<TD vAlign=bottom align=right width="4%">&nbsp;</TD>
<TD vAlign=bottom align=right width="7%">
<HR noshade SIZE=1>
</TD></TR>
<TR>
<TD vAlign=bottom width="65%"><FONT face="Times New Roman" size=2>Total Provision (Benefit)</FONT></TD>
<TD vAlign=bottom align=right width="10%"><FONT face="Times New Roman" size=2>$ (19,208,000</FONT></TD>
<TD vAlign=bottom width="2%"><FONT face="Times New Roman" size=2>)</FONT></TD>
<TD vAlign=bottom width="5%">&nbsp;</TD>
<TD vAlign=bottom align=right width="7%"><FONT face="Times New Roman" size=2>$&nbsp;&nbsp; 5,000 </FONT></TD>
<TD vAlign=bottom align=right width="4%">&nbsp;</TD>
<TD vAlign=bottom align=right width="7%"><FONT face="Times New Roman" size=2>$&nbsp;&nbsp; 16,000 </FONT></TD></TR>
<TR>
<TD vAlign=bottom width="65%">&nbsp;</TD>
<TD vAlign=bottom align=right width="10%">
<HR noshade>
</TD>
<TD vAlign=bottom width="2%">&nbsp;</TD>
<TD vAlign=bottom width="5%">&nbsp;</TD>
<TD vAlign=bottom align=right width="7%">
<HR noshade>
</TD>
<TD vAlign=bottom align=right width="4%">&nbsp;</TD>
<TD vAlign=bottom align=right width="7%">
<HR noshade>
</TD></TR>
</TABLE>

<BR>
<TABLE width="100%">
<TR>
<TD align=center><FONT size=2>50</FONT></TD></TR>
</TABLE>



<P>
<HR align=left noshade SIZE=5>


<P>&nbsp;
<!-- *************************************************************************** -->
<!-- MARKER PAGE="sheet: 14; page: 14" -->

<P><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company&#146;s amount of income tax provision recorded during fiscal 2004, 2003 and 2002 differs from the amount using the Federal statutory rate (35%) primarily due to the following: </FONT></P>


<P>
<TABLE cellSpacing=0 cellPadding=0 width="97%" border=0>
<TR>
<TD vAlign=bottom width="60%"><FONT face="Times New Roman" size=2>&nbsp;</FONT></TD>
<TD vAlign=bottom align=center colSpan=8><FONT face="Times New Roman" size=2><B>Year Ended March 31,<BR></B></FONT>
<HR noshade SIZE=1>
</TD></TR>
<TR>
<TD vAlign=bottom width="60%"><FONT face="Times New Roman" size=2><B>&nbsp;</B></FONT></TD>
<TD vAlign=bottom align=center colSpan=2><FONT face="Times New Roman" size=2><B>2004<BR></B></FONT>
<HR noshade SIZE=1>
</TD>
<TD vAlign=bottom align=center width="6%">&nbsp; </TD>
<TD vAlign=bottom align=center colSpan=2><FONT face="Times New Roman" size=2><B>2003<BR></B></FONT>
<HR noshade SIZE=1>
</TD>
<TD vAlign=bottom align=center width="2%">&nbsp; </TD>
<TD vAlign=bottom align=center colSpan=2><FONT face="Times New Roman" size=2><B>2002<BR></B></FONT>
<HR noshade SIZE=1>
</TD></TR>
<TR>
<TD vAlign=bottom width="60%"><FONT face="Times New Roman" size=2>Statutory Federal income tax rate</FONT></TD>
<TD vAlign=bottom align=right width="10%"><FONT face="Times New Roman" size=2>$ 1,689,000 </FONT></TD>
<TD vAlign=bottom width="2%">&nbsp;</TD>
<TD vAlign=bottom width="6%">&nbsp; </TD>
<TD vAlign=bottom align=right width="8%"><FONT face="Times New Roman" size=2>$ 587,000 </FONT></TD>
<TD vAlign=bottom width="2%">&nbsp;</TD>
<TD vAlign=bottom width="2%">&nbsp; </TD>
<TD vAlign=bottom align=right width="8%"><FONT face="Times New Roman" size=2>$ 471,000 </FONT></TD>
<TD vAlign=bottom width="2%">&nbsp;</TD></TR>
<TR>
<TD vAlign=bottom width="60%"><FONT face="Times New Roman" size=2>Statutory state income tax rate</FONT></TD>
<TD vAlign=bottom align=right width="10%"><FONT face="Times New Roman" size=2>285,000 </FONT></TD>
<TD vAlign=bottom width="2%">&nbsp;</TD>
<TD vAlign=bottom width="6%">&nbsp; </TD>
<TD vAlign=bottom align=right width="8%"><FONT face="Times New Roman" size=2>96,000 </FONT></TD>
<TD vAlign=bottom width="2%">&nbsp;</TD>
<TD vAlign=bottom width="2%">&nbsp; </TD>
<TD vAlign=bottom align=right width="8%"><FONT face="Times New Roman" size=2>77,000 </FONT></TD>
<TD vAlign=bottom width="2%">&nbsp;</TD></TR>
<TR>
<TD vAlign=bottom width="60%"><FONT face="Times New Roman" size=2>Credits</FONT></TD>
<TD vAlign=bottom align=right width="10%"><FONT face="Times New Roman" size=2>(31,000</FONT></TD>
<TD vAlign=bottom width="2%"><FONT face="Times New Roman" size=2>)</FONT></TD>
<TD vAlign=bottom width="6%">&nbsp; </TD>
<TD vAlign=bottom align=right width="8%"><FONT face="Times New Roman" size=2>(55,000</FONT></TD>
<TD vAlign=bottom width="2%"><FONT face="Times New Roman" size=2>)</FONT></TD>
<TD vAlign=bottom width="2%">&nbsp; </TD>
<TD vAlign=bottom align=right width="8%"><FONT face="Times New Roman" size=2>(200,000</FONT></TD>
<TD vAlign=bottom width="2%"><FONT face="Times New Roman" size=2>)</FONT></TD></TR>
<TR>
<TD vAlign=bottom width="60%"><FONT face="Times New Roman" size=2>Valuation allowance</FONT></TD>
<TD vAlign=bottom align=right width="10%"><FONT face="Times New Roman" size=2>(21,296,000</FONT></TD>
<TD vAlign=bottom width="2%"><FONT face="Times New Roman" size=2>)</FONT></TD>
<TD vAlign=bottom width="6%">&nbsp; </TD>
<TD vAlign=bottom align=right width="8%"><FONT face="Times New Roman" size=2>(556,000</FONT></TD>
<TD vAlign=bottom width="2%"><FONT face="Times New Roman" size=2>)</FONT></TD>
<TD vAlign=bottom width="2%">&nbsp; </TD>
<TD vAlign=bottom align=right width="8%"><FONT face="Times New Roman" size=2>(338,000</FONT></TD>
<TD vAlign=bottom width="2%"><FONT face="Times New Roman" size=2>)</FONT></TD></TR>
<TR>
<TD vAlign=bottom width="60%"><FONT face="Times New Roman" size=2>Non-deductible stock compensation</FONT></TD>
<TD vAlign=bottom align=right width="10%"><FONT face="Times New Roman" size=2>&#151; </FONT></TD>
<TD vAlign=bottom width="2%">&nbsp;</TD>
<TD vAlign=bottom width="6%">&nbsp; </TD>
<TD vAlign=bottom align=right width="8%"><FONT face="Times New Roman" size=2>&#151; </FONT></TD>
<TD vAlign=bottom width="2%">&nbsp;</TD>
<TD vAlign=bottom width="2%">&nbsp; </TD>
<TD vAlign=bottom align=right width="8%"><FONT face="Times New Roman" size=2>15,000 </FONT></TD>
<TD vAlign=bottom width="2%">&nbsp;</TD></TR>
<TR>
<TD vAlign=bottom width="60%"><FONT face="Times New Roman" size=2>Other</FONT></TD>
<TD vAlign=bottom align=right width="10%"><FONT face="Times New Roman" size=2>145,000 </FONT></TD>
<TD vAlign=bottom width="2%">&nbsp;</TD>
<TD vAlign=bottom width="6%">&nbsp; </TD>
<TD vAlign=bottom align=right width="8%"><FONT face="Times New Roman" size=2>(67,000</FONT></TD>
<TD vAlign=bottom width="2%"><FONT face="Times New Roman" size=2>)</FONT></TD>
<TD vAlign=bottom width="2%">&nbsp; </TD>
<TD vAlign=bottom align=right width="8%"><FONT face="Times New Roman" size=2>(9,000</FONT></TD>
<TD vAlign=bottom width="2%"><FONT face="Times New Roman" size=2>)</FONT></TD></TR>
<TR>
<TD vAlign=bottom width="60%">&nbsp;</TD>
<TD vAlign=bottom align=right width="10%">
<HR align=right width=70 noshade SIZE=1>
</TD>
<TD vAlign=bottom width="2%">&nbsp;</TD>
<TD vAlign=bottom width="6%">&nbsp;</TD>
<TD vAlign=bottom align=right width="8%">
<HR align=right width=40 noshade SIZE=1>
</TD>
<TD vAlign=bottom width="2%">&nbsp;</TD>
<TD vAlign=bottom width="2%">&nbsp;</TD>
<TD vAlign=bottom align=right width="8%">
<HR align=right width=45 noshade SIZE=1>
</TD>
<TD vAlign=bottom width="2%">&nbsp;</TD></TR>
<TR>
<TD vAlign=bottom width="60%"><FONT face="Times New Roman" size=2>&nbsp;</FONT></TD>
<TD vAlign=bottom align=right width="10%"><FONT face="Times New Roman" size=2>$ (19,208,000</FONT></TD>
<TD vAlign=bottom width="2%"><FONT face="Times New Roman" size=2>)</FONT></TD>
<TD vAlign=bottom width="6%">&nbsp; </TD>
<TD vAlign=bottom align=right width="8%"><FONT face="Times New Roman" size=2>$ 5,000 </FONT></TD>
<TD vAlign=bottom width="2%">&nbsp;</TD>
<TD vAlign=bottom width="2%">&nbsp; </TD>
<TD vAlign=bottom align=right width="8%"><FONT face="Times New Roman" size=2>$ 16,000 </FONT></TD>
<TD vAlign=bottom width="2%">&nbsp;</TD></TR>
<TR>
<TD vAlign=bottom width="60%">&nbsp;</TD>
<TD vAlign=bottom align=right width="10%">
<HR align=right width=70 noshade SIZE=2>
</TD>
<TD vAlign=bottom width="2%">&nbsp;</TD>
<TD vAlign=bottom width="6%">&nbsp;</TD>
<TD vAlign=bottom align=right width="8%">
<HR align=right width=40 noshade SIZE=2>
</TD>
<TD vAlign=bottom width="2%">&nbsp;</TD>
<TD vAlign=bottom width="2%">&nbsp;</TD>
<TD vAlign=bottom align=right width="8%">
<HR align=right width=45 noshade SIZE=2>
</TD>
<TD vAlign=bottom width="2%">&nbsp;</TD></TR>
</TABLE>



<P><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Significant components of the Company&#146;s deferred tax assets are as follows: </FONT></P>


<P>
<TABLE cellSpacing=0 cellPadding=0 width="97%" border=0>
<TR>
<TD vAlign=bottom nowrap width="61%"><FONT face="Times New Roman" size=2>&nbsp;</FONT></TD>
<TD vAlign=bottom align=center colSpan=8><FONT face="Times New Roman" size=2><B>Year Ended March 31,</B></FONT>
<HR noshade SIZE=1>
</TD></TR>
<TR>
<TD vAlign=bottom nowrap width="61%"><FONT face="Times New Roman" size=2><B>&nbsp;</B></FONT></TD>
<TD vAlign=bottom align=center width="10%"><FONT face="Times New Roman" size=2><B>2004<BR></B></FONT>
<HR noshade SIZE=1>
</TD>
<TD vAlign=bottom align=center width="1%">&nbsp;</TD>
<TD vAlign=bottom align=center width="5%">&nbsp; </TD>
<TD vAlign=bottom align=center width="9%"><FONT face="Times New Roman" size=2><B>2003<BR></B></FONT>
<HR noshade SIZE=1>
</TD>
<TD vAlign=bottom align=center width="2%">&nbsp;</TD>
<TD vAlign=bottom align=center width="1%">&nbsp; </TD>
<TD vAlign=bottom align=center width="10%"><FONT face="Times New Roman" size=2><B>2002<BR></B></FONT>
<HR noshade SIZE=1>
</TD>
<TD vAlign=bottom align=center width="1%">&nbsp;</TD></TR>
<TR>
<TD vAlign=bottom nowrap width="61%"><FONT face="Times New Roman" size=2>Deferred tax assets:</FONT></TD>
<TD vAlign=bottom width="10%"><FONT face="Times New Roman" size=2>&nbsp;</FONT></TD>
<TD vAlign=bottom width="1%">&nbsp;</TD>
<TD vAlign=bottom width="5%">&nbsp;&nbsp;</TD>
<TD vAlign=bottom width="9%"><FONT face="Times New Roman" size=2>&nbsp;</FONT></TD>
<TD vAlign=bottom width="2%">&nbsp;</TD>
<TD vAlign=bottom width="1%">&nbsp;&nbsp;</TD>
<TD vAlign=bottom width="10%"><FONT face="Times New Roman" size=2>&nbsp;</FONT></TD>
<TD vAlign=bottom width="1%">&nbsp;</TD></TR>
<TR>
<TD vAlign=bottom nowrap width="61%"><FONT face="Times New Roman" size=2>Net operating loss carryforwards</FONT></TD>
<TD vAlign=bottom align=right width="10%"><FONT face="Times New Roman" size=2>$ 17,345,000 </FONT></TD>
<TD vAlign=bottom width="1%">&nbsp;</TD>
<TD vAlign=bottom width="5%">&nbsp;</TD>
<TD vAlign=bottom align=right width="9%"><FONT face="Times New Roman" size=2>$ 18,157,000 </FONT></TD>
<TD vAlign=bottom width="2%">&nbsp;</TD>
<TD vAlign=bottom width="1%">&nbsp;</TD>
<TD vAlign=bottom align=right width="10%"><FONT face="Times New Roman" size=2>$ 18,812,000 </FONT></TD>
<TD vAlign=bottom width="1%">&nbsp;</TD></TR>
<TR>
<TD vAlign=bottom nowrap width="61%"><FONT face="Times New Roman" size=2>Research and development tax credit carryforwards</FONT></TD>
<TD vAlign=bottom align=right width="10%"><FONT face="Times New Roman" size=2>3,151,000 </FONT></TD>
<TD vAlign=bottom width="1%">&nbsp;</TD>
<TD vAlign=bottom width="5%">&nbsp;</TD>
<TD vAlign=bottom align=right width="9%"><FONT face="Times New Roman" size=2>3,115,000 </FONT></TD>
<TD vAlign=bottom width="2%">&nbsp;</TD>
<TD vAlign=bottom width="1%">&nbsp;</TD>
<TD vAlign=bottom align=right width="10%"><FONT face="Times New Roman" size=2>3,608,000 </FONT></TD>
<TD vAlign=bottom width="1%">&nbsp;</TD></TR>
<TR>
<TD vAlign=bottom nowrap width="61%"><FONT face="Times New Roman" size=2>Capitalized research and development</FONT></TD>
<TD vAlign=bottom align=right width="10%"><FONT face="Times New Roman" size=2>345,000 </FONT></TD>
<TD vAlign=bottom width="1%">&nbsp;</TD>
<TD vAlign=bottom width="5%">&nbsp;</TD>
<TD vAlign=bottom align=right width="9%"><FONT face="Times New Roman" size=2>446,000 </FONT></TD>
<TD vAlign=bottom width="2%">&nbsp;</TD>
<TD vAlign=bottom width="1%">&nbsp;</TD>
<TD vAlign=bottom align=right width="10%"><FONT face="Times New Roman" size=2>570,000 </FONT></TD>
<TD vAlign=bottom width="1%">&nbsp;</TD></TR>
<TR>
<TD vAlign=bottom nowrap width="61%"><FONT face="Times New Roman" size=2>Other, net</FONT></TD>
<TD vAlign=bottom align=right width="10%"><FONT face="Times New Roman" size=2>1,141,000 </FONT></TD>
<TD vAlign=bottom width="1%">&nbsp;</TD>
<TD vAlign=bottom width="5%">&nbsp;</TD>
<TD vAlign=bottom align=right width="9%"><FONT face="Times New Roman" size=2>1,055,000 </FONT></TD>
<TD vAlign=bottom width="2%">&nbsp;</TD>
<TD vAlign=bottom width="1%">&nbsp;</TD>
<TD vAlign=bottom align=right width="10%"><FONT face="Times New Roman" size=2>1,482,000 </FONT></TD>
<TD vAlign=bottom width="1%">&nbsp;</TD></TR>
<TR>
<TD vAlign=bottom nowrap width="61%">&nbsp;</TD>
<TD vAlign=bottom align=right width="10%">
<HR noshade SIZE=1>
</TD>
<TD vAlign=bottom width="1%">&nbsp;</TD>
<TD vAlign=bottom width="5%">&nbsp;</TD>
<TD vAlign=bottom align=right width="9%">
<HR noshade SIZE=1>
</TD>
<TD vAlign=bottom width="2%">&nbsp;</TD>
<TD vAlign=bottom width="1%">&nbsp;</TD>
<TD vAlign=bottom align=right width="10%">
<HR noshade SIZE=1>
</TD>
<TD vAlign=bottom width="1%">&nbsp;</TD></TR>
<TR>
<TD vAlign=bottom nowrap width="61%"><FONT face="Times New Roman" size=2>&nbsp;</FONT></TD>
<TD vAlign=bottom align=right width="10%"><FONT face="Times New Roman" size=2>21,982,000 </FONT></TD>
<TD vAlign=bottom width="1%">&nbsp;</TD>
<TD vAlign=bottom width="5%">&nbsp;</TD>
<TD vAlign=bottom align=right width="9%"><FONT face="Times New Roman" size=2>22,773,000 </FONT></TD>
<TD vAlign=bottom width="2%">&nbsp;</TD>
<TD vAlign=bottom width="1%">&nbsp;</TD>
<TD vAlign=bottom align=right width="10%"><FONT face="Times New Roman" size=2>24,472,000 </FONT></TD>
<TD vAlign=bottom width="1%">&nbsp;</TD></TR>
<TR>
<TD vAlign=bottom nowrap width="61%"><FONT face="Times New Roman" size=2>Valuation allowance for deferred tax assets</FONT></TD>
<TD vAlign=bottom align=right width="10%"><FONT face="Times New Roman" size=2>(749,000</FONT></TD>
<TD vAlign=bottom width="1%"><FONT face="Times New Roman" size=2>) </FONT></TD>
<TD vAlign=bottom width="5%">&nbsp;</TD>
<TD vAlign=bottom align=right width="9%"><FONT face="Times New Roman" size=2>(22,773,000 </FONT></TD>
<TD vAlign=bottom width="2%"><FONT face="Times New Roman" size=2>)</FONT></TD>
<TD vAlign=bottom width="1%">&nbsp;</TD>
<TD vAlign=bottom align=right width="10%"><FONT face="Times New Roman" size=2>(24,472,000</FONT></TD>
<TD vAlign=bottom width="1%"><FONT face="Times New Roman" size=2>) </FONT></TD></TR>
<TR>
<TD vAlign=bottom nowrap width="61%">&nbsp;</TD>
<TD vAlign=bottom align=right width="10%">
<HR noshade SIZE=1>
</TD>
<TD vAlign=bottom width="1%">&nbsp;</TD>
<TD vAlign=bottom width="5%">&nbsp;</TD>
<TD vAlign=bottom align=right width="9%">
<HR noshade SIZE=1>
</TD>
<TD vAlign=bottom width="2%">&nbsp;</TD>
<TD vAlign=bottom width="1%">&nbsp;</TD>
<TD vAlign=bottom align=right width="10%">
<HR noshade SIZE=1>
</TD>
<TD vAlign=bottom width="1%">&nbsp;</TD></TR>
<TR>
<TD vAlign=bottom nowrap width="61%"><FONT face="Times New Roman" size=2>Net deferred tax assets</FONT></TD>
<TD vAlign=bottom align=right width="10%"><FONT face="Times New Roman" size=2>$ 21,233,000 </FONT></TD>
<TD vAlign=bottom width="1%">&nbsp;</TD>
<TD vAlign=bottom width="5%">&nbsp;</TD>
<TD vAlign=bottom align=right width="9%"><FONT face="Times New Roman" size=2>$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#151; </FONT></TD>
<TD vAlign=bottom width="2%">&nbsp;</TD>
<TD vAlign=bottom width="1%">&nbsp;</TD>
<TD vAlign=bottom align=right width="10%"><FONT face="Times New Roman" size=2>$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &#151; </FONT></TD>
<TD vAlign=bottom width="1%">&nbsp;</TD></TR>
<TR>
<TD vAlign=bottom nowrap width="61%">&nbsp;</TD>
<TD vAlign=bottom align=right width="10%">
<HR noshade SIZE=2>
</TD>
<TD vAlign=bottom width="1%">&nbsp;</TD>
<TD vAlign=bottom width="5%">&nbsp;</TD>
<TD vAlign=bottom align=right width="9%">
<HR noshade SIZE=2>
</TD>
<TD vAlign=bottom width="2%">&nbsp;</TD>
<TD vAlign=bottom width="1%">&nbsp;</TD>
<TD vAlign=bottom align=right width="10%">
<HR noshade SIZE=2>
</TD>
<TD vAlign=bottom width="1%">&nbsp;</TD></TR>
</TABLE>

<BR>
<!-- MARKER FORMAT-SHEET="Para Flush Level 1" FSL="Default" -->
<TABLE cellSpacing=0 cellPadding=0 width="100%">
<TR vAlign=top>
<TD width="5%"><FONT face="Times New Roman, Times, Serif" size=2>&nbsp; </FONT></TD>
<TD width="95%"><FONT face="Times New Roman, Times, Serif" size=2>A valuation allowance against deferred tax assets is provided when it is more likely than not that some portion of the deferred tax assets will not be realized. The Company established a 100% valuation allowance at March&nbsp;31, 2003 and 2002 due to the uncertainty of realizing future tax benefits from its net operating loss carryforwards and other deferred tax assets. At March 31, 2004, the Company eliminated the valuation allowance previously maintained against deferred tax assets to the extent that it is more likely than not that the deferred tax assets will be realized in the future. The valuation allowance of ($21,296,000) reflected in the reconciliation of the income tax provision to the Federal statutory rate for the year ended March 31, 2004 consists of the ($22,024,000) change in the valuation allowance for the year ended March 31, 2004 and $728,000 attributable to deductions relating to stock options that are included in the
net operating loss carryforward deferred tax asset. </FONT></TD></TR>
</TABLE>

<BR>
<!-- MARKER FORMAT-SHEET="Para Flush Level 1" FSL="Default" -->
<TABLE cellSpacing=0 cellPadding=0 width="100%">
<TR vAlign=top>
<TD width="5%"><FONT face="Times New Roman, Times, Serif" size=2>&nbsp; </FONT></TD>
<TD width="95%"><FONT face="Times New Roman, Times, Serif" size=2>As of March&nbsp;31, 2004, the Company had federal and state net operating loss carryforwards of approximately $48,468,000 and $6,631,000, respectively. The Company also had federal and state research and development tax credit carryforwards of approximately $2,399,000 and $752,000, respectively. The net operating loss and credit carryforwards will expire at various dates from 2005 through 2023, if not utilized. </FONT></TD></TR>
</TABLE>

<BR>
<!-- MARKER FORMAT-SHEET="Para Flush Level 1" FSL="Default" -->
<TABLE cellSpacing=0 cellPadding=0 width="100%">
<TR vAlign=top>
<TD width="5%"><FONT face="Times New Roman, Times, Serif" size=2>&nbsp; </FONT></TD>
<TD width="95%"><FONT face="Times New Roman, Times, Serif" size=2>Internal Revenue Code Section&nbsp;382 places a limitation on the amount of taxable income which can be offset by net operating loss (&#147;NOL&#148;) carryforwards after a change in control (generally greater than 50% change in ownership) of a loss corporation. The State of California has similar rules. Generally, after a change in control, a loss corporation cannot deduct NOL carryforwards in excess of the Section&nbsp;382 limitation. Due to these &#147;change in ownership&#148; provisions, utilization of NOL and tax credit carryforwards may be subject to an annual limitation regarding their utilization against taxable income in future periods. </FONT></TD></TR>
</TABLE>


<H1 align=left><FONT face="Times New Roman, Times, Serif" size=2>14. Customer and Geographic Information </FONT></H1>

<!-- MARKER FORMAT-SHEET="Para Flush Level 1" FSL="Default" -->
<TABLE cellSpacing=0 cellPadding=0 width="100%">
<TR vAlign=top>
<TD width="5%"><FONT face="Times New Roman, Times, Serif" size=2>&nbsp; </FONT></TD>
<TD width="95%"><FONT face="Times New Roman, Times, Serif" size=2>The Company currently operates in one segment and develops, manufactures and markets portable blood analysis systems for use in any veterinary or human patient-care setting to provide clinicians with rapid blood constituent measurements. The following is a summary of revenues from external customers for products and services provided by the Company: </FONT></TD></TR>
</TABLE>

<BR>
<TABLE width="100%">
<TR>
<TD align=center><FONT size=2>51</FONT></TD></TR>
</TABLE>



<P>
<HR align=left noshade SIZE=5>


<P>&nbsp;
<!-- *************************************************************************** -->
<!-- MARKER PAGE="sheet: 14; page: 14" -->

<P>
<TABLE cellSpacing=0 cellPadding=0 width="100%" border=0>
<TR>
<TD vAlign=bottom nowrap width="69%"><FONT face="Times New Roman" size=2>&nbsp;</FONT></TD>
<TD vAlign=bottom nowrap align=center colSpan=5><FONT face="Times New Roman" size=2><B>Year Ended March 31,<BR></B></FONT>
<HR noshade SIZE=1>
</TD></TR>
<TR>
<TD vAlign=bottom nowrap width="69%"><FONT face="Times New Roman" size=2><B>&nbsp;</B></FONT></TD>
<TD vAlign=bottom nowrap align=center width="9%"><FONT face="Times New Roman" size=2><B>2004<BR></B></FONT>
<HR noshade SIZE=1>
<FONT face="Times New Roman" size=2><B></B></FONT></TD>
<TD vAlign=bottom nowrap align=center width="1%">&nbsp;</TD>
<TD vAlign=bottom nowrap align=center width="9%"><FONT face="Times New Roman" size=2><B>2003<BR></B></FONT>
<HR noshade SIZE=1>
<FONT face="Times New Roman" size=2><B></B></FONT></TD>
<TD vAlign=bottom nowrap align=center width="1%">&nbsp;</TD>
<TD vAlign=bottom nowrap align=center width="11%"><FONT face="Times New Roman" size=2><B>2002<BR></B></FONT>
<HR noshade SIZE=1>
</TD></TR>
<TR>
<TD vAlign=bottom nowrap width="69%"><FONT face="Times New Roman" size=2>Blood chemistry analyzers</FONT></TD>
<TD vAlign=bottom nowrap align=right width="9%"><FONT face="Times New Roman" size=2>$ 16,194,000 </FONT></TD>
<TD vAlign=bottom nowrap align=right width="1%">&nbsp;</TD>
<TD vAlign=bottom nowrap align=right width="9%"><FONT face="Times New Roman" size=2>$ 10,735,000 </FONT></TD>
<TD vAlign=bottom nowrap align=right width="1%">&nbsp;</TD>
<TD vAlign=bottom nowrap align=right width="11%"><FONT face="Times New Roman" size=2>$ 9,895,000 </FONT></TD></TR>
<TR>
<TD vAlign=bottom nowrap width="69%"><FONT face="Times New Roman" size=2>Reagent discs</FONT></TD>
<TD vAlign=bottom nowrap align=right width="9%"><FONT face="Times New Roman" size=2>28,144,000 </FONT></TD>
<TD vAlign=bottom nowrap align=right width="1%">&nbsp;</TD>
<TD vAlign=bottom nowrap align=right width="9%"><FONT face="Times New Roman" size=2>21,893,000 </FONT></TD>
<TD vAlign=bottom nowrap align=right width="1%">&nbsp;</TD>
<TD vAlign=bottom nowrap align=right width="11%"><FONT face="Times New Roman" size=2>18,206,000 </FONT></TD></TR>
<TR>
<TD vAlign=bottom nowrap width="69%"><FONT face="Times New Roman" size=2>Other</FONT></TD>
<TD vAlign=bottom nowrap align=right width="9%"><FONT face="Times New Roman" size=2>2,261,000 </FONT></TD>
<TD vAlign=bottom nowrap align=right width="1%">&nbsp;</TD>
<TD vAlign=bottom nowrap align=right width="9%"><FONT face="Times New Roman" size=2>1,904,000 </FONT></TD>
<TD vAlign=bottom nowrap align=right width="1%">&nbsp;</TD>
<TD vAlign=bottom nowrap align=right width="11%"><FONT face="Times New Roman" size=2>2,317,000 </FONT></TD></TR>
<TR>
<TD vAlign=bottom nowrap width="69%">&nbsp;</TD>
<TD vAlign=bottom nowrap align=right width="9%">
<HR noshade SIZE=1>
</TD>
<TD vAlign=bottom nowrap align=right width="1%">&nbsp;</TD>
<TD vAlign=bottom nowrap align=right width="9%">
<HR noshade SIZE=1>
</TD>
<TD vAlign=bottom nowrap align=right width="1%">&nbsp;</TD>
<TD vAlign=bottom nowrap align=right width="11%">
<HR noshade SIZE=1>
</TD></TR>
<TR>
<TD vAlign=bottom nowrap width="69%"><FONT face="Times New Roman" size=2>Product sales, net</FONT></TD>
<TD vAlign=bottom nowrap align=right width="9%"><FONT face="Times New Roman" size=2>46,599,000 </FONT></TD>
<TD vAlign=bottom nowrap align=right width="1%">&nbsp;</TD>
<TD vAlign=bottom nowrap align=right width="9%"><FONT face="Times New Roman" size=2>34,532,000 </FONT></TD>
<TD vAlign=bottom nowrap align=right width="1%">&nbsp;</TD>
<TD vAlign=bottom nowrap align=right width="11%"><FONT face="Times New Roman" size=2>30,418,000 </FONT></TD></TR>
<TR>
<TD vAlign=bottom nowrap width="69%"><FONT face="Times New Roman" size=2>Development and licensing revenue</FONT></TD>
<TD vAlign=bottom nowrap align=right width="9%"><FONT face="Times New Roman" size=2>275,000 </FONT></TD>
<TD vAlign=bottom nowrap align=right width="1%">&nbsp;</TD>
<TD vAlign=bottom nowrap align=right width="9%"><FONT face="Times New Roman" size=2>248,000 </FONT></TD>
<TD vAlign=bottom nowrap align=right width="1%">&nbsp;</TD>
<TD vAlign=bottom nowrap align=right width="11%"><FONT face="Times New Roman" size=2>213,000 </FONT></TD></TR>
<TR>
<TD vAlign=bottom nowrap width="69%">&nbsp;</TD>
<TD vAlign=bottom nowrap align=right width="9%">
<HR noshade SIZE=1>
</TD>
<TD vAlign=bottom nowrap align=right width="1%">&nbsp;</TD>
<TD vAlign=bottom nowrap align=right width="9%">
<HR noshade SIZE=1>
</TD>
<TD vAlign=bottom nowrap align=right width="1%">&nbsp;</TD>
<TD vAlign=bottom nowrap align=right width="11%">
<HR noshade SIZE=1>
</TD></TR>
<TR>
<TD vAlign=bottom nowrap width="69%"><FONT face="Times New Roman" size=2>Total revenues</FONT></TD>
<TD vAlign=bottom nowrap align=right width="9%"><FONT face="Times New Roman" size=2>$ 46,874,000 </FONT></TD>
<TD vAlign=bottom nowrap align=right width="1%">&nbsp;</TD>
<TD vAlign=bottom nowrap align=right width="9%"><FONT face="Times New Roman" size=2>$ 34,780,000 </FONT></TD>
<TD vAlign=bottom nowrap align=right width="1%">&nbsp;</TD>
<TD vAlign=bottom nowrap align=right width="11%"><FONT face="Times New Roman" size=2>$ 30,631,000 </FONT></TD></TR>
<TR>
<TD vAlign=bottom nowrap width="69%">&nbsp;</TD>
<TD vAlign=bottom nowrap align=right width="9%">
<HR noshade SIZE=2>
</TD>
<TD vAlign=bottom nowrap align=right width="1%">&nbsp;</TD>
<TD vAlign=bottom nowrap align=right width="9%">
<HR noshade SIZE=2>
</TD>
<TD vAlign=bottom nowrap align=right width="1%">&nbsp;</TD>
<TD vAlign=bottom nowrap align=right width="11%">
<HR noshade SIZE=2>
</TD></TR>
</TABLE>



<P><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The following is a summary of revenues by customer group: </FONT></P>


<P>
<TABLE cellSpacing=0 cellPadding=0 width="100%" border=0>
<TR>
<TD vAlign=bottom nowrap width="73%">&nbsp; </TD>
<TD vAlign=bottom nowrap align=center colSpan=5><FONT face="Times New Roman" size=2><B>Year Ended March 31,<BR></B></FONT>
<HR noshade SIZE=1>
<FONT face="Times New Roman" size=2><B></B></FONT></TD></TR>
<TR>
<TD vAlign=bottom nowrap width="73%">&nbsp; </TD>
<TD vAlign=bottom nowrap align=center width="8%"><FONT face="Times New Roman" size=2><B>2004<BR></B></FONT>
<HR noshade SIZE=1>
<FONT face="Times New Roman" size=2><B></B></FONT></TD>
<TD vAlign=bottom nowrap align=center width="1%">&nbsp;</TD>
<TD vAlign=bottom nowrap align=center width="9%"><FONT face="Times New Roman" size=2><B>2003<BR></B></FONT>
<HR noshade SIZE=1>
<FONT face="Times New Roman" size=2><B></B></FONT></TD>
<TD vAlign=bottom nowrap align=center width="1%">&nbsp;</TD>
<TD vAlign=bottom nowrap align=center width="8%"><FONT face="Times New Roman" size=2><B>2002<BR></B></FONT>
<HR noshade SIZE=1>
</TD></TR>
<TR>
<TD vAlign=bottom nowrap width="73%"><FONT face="Times New Roman" size=2>Medical Market </FONT></TD>
<TD vAlign=bottom nowrap align=right width="8%"><FONT face="Times New Roman" size=2>$ 7,119,000 </FONT></TD>
<TD vAlign=bottom nowrap align=right width="1%">
<DIV align=right>&nbsp;&nbsp;</DIV></TD>
<TD vAlign=bottom nowrap align=right width="9%"><FONT face="Times New Roman" size=2>$ 3,037,000 </FONT></TD>
<TD vAlign=bottom nowrap align=right width="1%">
<DIV align=right>&nbsp;&nbsp;</DIV></TD>
<TD vAlign=bottom nowrap align=right width="8%"><FONT face="Times New Roman" size=2>$ 1,586,000 </FONT></TD></TR>
<TR>
<TD vAlign=bottom nowrap width="73%"><FONT face="Times New Roman" size=2>Veterinary Market </FONT></TD>
<TD vAlign=bottom nowrap align=right width="8%"><FONT face="Times New Roman" size=2>37,875,000 </FONT></TD>
<TD vAlign=bottom nowrap align=right width="1%">
<DIV align=right></DIV></TD>
<TD vAlign=bottom nowrap align=right width="9%"><FONT face="Times New Roman" size=2>30,313,000 </FONT></TD>
<TD vAlign=bottom nowrap align=right width="1%">
<DIV align=right></DIV></TD>
<TD vAlign=bottom nowrap align=right width="8%"><FONT face="Times New Roman" size=2>27,312,000 </FONT></TD></TR>
<TR>
<TD vAlign=bottom nowrap width="73%"><FONT face="Times New Roman" size=2>Other</FONT></TD>
<TD vAlign=bottom nowrap align=right width="8%"><FONT face="Times New Roman" size=2>1,880,000 </FONT></TD>
<TD vAlign=bottom nowrap align=right width="1%">
<DIV align=right></DIV></TD>
<TD vAlign=bottom nowrap align=right width="9%"><FONT face="Times New Roman" size=2>1,430,000 </FONT></TD>
<TD vAlign=bottom nowrap align=right width="1%">
<DIV align=right></DIV></TD>
<TD vAlign=bottom nowrap align=right width="8%"><FONT face="Times New Roman" size=2>1,733,000 </FONT></TD></TR>
<TR>
<TD vAlign=bottom nowrap width="73%">&nbsp;</TD>
<TD vAlign=bottom nowrap align=right width="8%">
<HR noshade SIZE=1>
</TD>
<TD vAlign=bottom nowrap align=right width="1%">&nbsp;</TD>
<TD vAlign=bottom nowrap align=right width="9%">
<HR noshade SIZE=1>
</TD>
<TD vAlign=bottom nowrap align=right width="1%">&nbsp;</TD>
<TD vAlign=bottom nowrap align=right width="8%">
<HR noshade SIZE=1>
</TD></TR>
<TR>
<TD vAlign=bottom nowrap width="73%"><FONT face="Times New Roman" size=2>Total revenues </FONT></TD>
<TD vAlign=bottom nowrap align=right width="8%"><FONT face="Times New Roman" size=2>$ 46,874,000 </FONT></TD>
<TD vAlign=bottom nowrap align=right width="1%">
<DIV align=right></DIV></TD>
<TD vAlign=bottom nowrap align=right width="9%"><FONT face="Times New Roman" size=2>$ 34,780,000 </FONT></TD>
<TD vAlign=bottom nowrap align=right width="1%">
<DIV align=right></DIV></TD>
<TD vAlign=bottom nowrap align=right width="8%"><FONT face="Times New Roman" size=2>$ 30,631,000 </FONT></TD></TR>
<TR>
<TD vAlign=bottom nowrap width="73%">&nbsp;</TD>
<TD vAlign=bottom nowrap align=right width="8%">
<HR noshade SIZE=2>
</TD>
<TD vAlign=bottom nowrap align=right width="1%">&nbsp;</TD>
<TD vAlign=bottom nowrap align=right width="9%">
<HR noshade SIZE=2>
</TD>
<TD vAlign=bottom nowrap align=right width="1%">&nbsp;</TD>
<TD vAlign=bottom nowrap align=right width="8%">
<HR noshade SIZE=2>
</TD></TR>
</TABLE>

<BR>
<!-- MARKER FORMAT-SHEET="Para Flush Level 1" FSL="Default" -->
<TABLE cellSpacing=0 cellPadding=0 width="100%">
<TR vAlign=top>
<TD width="5%"><FONT face="Times New Roman, Times, Serif" size=2>&nbsp; </FONT></TD>
<TD width="95%"><FONT face="Times New Roman, Times, Serif" size=2>Two distributors, Vedco Inc. and DVM Resources accounted for 27% and 16%, respectively, of total revenues for fiscal 2004, 36% and 11%, respectively, of total revenues for fiscal 2003, and 41% and 8%, respectively, of total revenues for fiscal 2002. The following is a summary of revenues by geographic region based on customer location: </FONT></TD></TR>
</TABLE>

<BR>

<P>
<TABLE cellSpacing=0 cellPadding=0 width="100%" border=0>
<TR>
<TD vAlign=bottom nowrap width="71%"><FONT face="Times New Roman" size=2>&nbsp;</FONT></TD>
<TD vAlign=bottom nowrap align=center colSpan=5><FONT face="Times New Roman" size=2><B>Year Ended March 31,<BR></B></FONT>
<HR noshade SIZE=1>
<FONT face="Times New Roman" size=2><B></B></FONT></TD></TR>
<TR>
<TD vAlign=bottom nowrap width="71%"><FONT face="Times New Roman" size=2><B>&nbsp;</B></FONT></TD>
<TD vAlign=bottom nowrap align=center width="9%"><FONT face="Times New Roman" size=2><B>2004<BR></B></FONT>
<HR noshade SIZE=1>
<FONT face="Times New Roman" size=2><B></B></FONT></TD>
<TD vAlign=bottom nowrap align=center width="1%">&nbsp;</TD>
<TD vAlign=bottom nowrap align=center width="9%"><FONT face="Times New Roman" size=2><B>2003<BR></B></FONT>
<HR noshade SIZE=1>
<FONT face="Times New Roman" size=2><B></B></FONT></TD>
<TD vAlign=bottom nowrap align=center width="1%">&nbsp;</TD>
<TD vAlign=bottom nowrap align=center width="9%"><FONT face="Times New Roman" size=2><B>2002<BR></B></FONT>
<HR noshade SIZE=1>
</TD></TR>
<TR>
<TD vAlign=bottom nowrap width="71%"><FONT face="Times New Roman" size=2>United States</FONT></TD>
<TD vAlign=bottom nowrap align=right width="9%"><FONT face="Times New Roman" size=2>$ 40,000,000 </FONT></TD>
<TD vAlign=bottom nowrap align=right width="1%">
<DIV align=right></DIV></TD>
<TD vAlign=bottom nowrap align=right width="9%"><FONT face="Times New Roman" size=2>$ 29,029,000 </FONT></TD>
<TD vAlign=bottom nowrap align=right width="1%">
<DIV align=right></DIV></TD>
<TD vAlign=bottom nowrap align=right width="9%"><FONT face="Times New Roman" size=2>$ 26,463,000 </FONT></TD></TR>
<TR>
<TD vAlign=bottom nowrap width="71%"><FONT face="Times New Roman" size=2>Europe</FONT></TD>
<TD vAlign=bottom nowrap align=right width="9%"><FONT face="Times New Roman" size=2>5,005,000 </FONT></TD>
<TD vAlign=bottom nowrap align=right width="1%">
<DIV align=right></DIV></TD>
<TD vAlign=bottom nowrap align=right width="9%"><FONT face="Times New Roman" size=2>3,866,000 </FONT></TD>
<TD vAlign=bottom nowrap align=right width="1%">
<DIV align=right></DIV></TD>
<TD vAlign=bottom nowrap align=right width="9%"><FONT face="Times New Roman" size=2>2,780,000 </FONT></TD></TR>
<TR>
<TD vAlign=bottom nowrap width="71%"><FONT face="Times New Roman" size=2>Asia and Latin America</FONT></TD>
<TD vAlign=bottom nowrap align=right width="9%"><FONT face="Times New Roman" size=2>1,869,000 </FONT></TD>
<TD vAlign=bottom nowrap align=right width="1%">
<DIV align=right></DIV></TD>
<TD vAlign=bottom nowrap align=right width="9%"><FONT face="Times New Roman" size=2>1,885,000 </FONT></TD>
<TD vAlign=bottom nowrap align=right width="1%">
<DIV align=right></DIV></TD>
<TD vAlign=bottom nowrap align=right width="9%"><FONT face="Times New Roman" size=2>1,388,000 </FONT></TD></TR>
<TR>
<TD vAlign=bottom nowrap width="71%">&nbsp;</TD>
<TD vAlign=bottom nowrap align=right width="9%">
<HR noshade SIZE=1>
</TD>
<TD vAlign=bottom nowrap align=right width="1%">&nbsp;</TD>
<TD vAlign=bottom nowrap align=right width="9%">
<HR noshade SIZE=1>
</TD>
<TD vAlign=bottom nowrap align=right width="1%">&nbsp;</TD>
<TD vAlign=bottom nowrap align=right width="9%">
<HR noshade SIZE=1>
</TD></TR>
<TR>
<TD vAlign=bottom nowrap width="71%"><FONT face="Times New Roman" size=2>Total revenues</FONT></TD>
<TD vAlign=bottom nowrap align=right width="9%"><FONT face="Times New Roman" size=2>$ 46,874,000 </FONT></TD>
<TD vAlign=bottom nowrap align=right width="1%">
<DIV align=right></DIV></TD>
<TD vAlign=bottom nowrap align=right width="9%"><FONT face="Times New Roman" size=2>$ 34,780,000 </FONT></TD>
<TD vAlign=bottom nowrap align=right width="1%">
<DIV align=right></DIV></TD>
<TD vAlign=bottom nowrap align=right width="9%"><FONT face="Times New Roman" size=2>$ 30,631,000 </FONT></TD></TR>
<TR>
<TD vAlign=bottom nowrap width="71%">&nbsp;</TD>
<TD vAlign=bottom nowrap align=right width="9%">
<HR noshade SIZE=2>
</TD>
<TD vAlign=bottom nowrap align=right width="1%">&nbsp;</TD>
<TD vAlign=bottom nowrap align=right width="9%">
<HR noshade SIZE=2>
</TD>
<TD vAlign=bottom nowrap align=right width="1%">&nbsp;</TD>
<TD vAlign=bottom nowrap align=right width="9%">
<HR noshade SIZE=2>
</TD></TR>
</TABLE>


<TABLE cellSpacing=0 cellPadding=0 width="100%">
<TR vAlign=top>
<TD width="5%"><FONT face="Times New Roman, Times, Serif" size=2>&nbsp; </FONT></TD>
<TD width="95%"><FONT face="Times New Roman, Times, Serif" size=2>Substantially all of the Company&#146;s long-lived assets are located in the United States. </FONT></TD></TR>
</TABLE>

<BR>
<!-- MARKER FORMAT-SHEET="Para Flush Level 1" FSL="Default" -->
<TABLE cellSpacing=0 cellPadding=0 width="100%">
<TR vAlign=top>
<TD width="5%"><B><FONT face="Times New Roman, Times, Serif" size=2>15. </FONT></B></TD>
<TD width="95%"><B><FONT face="Times New Roman, Times, Serif" size=2>Quarterly Results of Operations (Unaudited) </FONT></B></TD></TR>
</TABLE>

<BR>
<!-- MARKER FORMAT-SHEET="Para Flush Level 1" FSL="Default" -->
<TABLE cellSpacing=0 cellPadding=0 width="100%">
<TR vAlign=top>
<TD width="5%"><FONT face="Times New Roman, Times, Serif" size=2>&nbsp; </FONT></TD>
<TD width="95%"><FONT face="Times New Roman, Times, Serif" size=2>The following is a summary of the unaudited quarterly results of operations for fiscal 2004 and 2003 (in thousands, except per share data): </FONT></TD></TR>
</TABLE>

<BR>
<TABLE width="100%">
<TR>
<TD align=center><FONT size=2>52</FONT></TD></TR>
</TABLE>



<P>
<HR align=left noshade SIZE=5>


<P>&nbsp;
<!-- *************************************************************************** -->
<!-- MARKER PAGE="sheet: 14; page: 14" -->

<P>
<TABLE cellSpacing=0 cellPadding=0 width="100%" border=0>
<TR>
<TD vAlign=bottom nowrap width="61%"><FONT face="Times New Roman" size=2><B>&nbsp;</B></FONT></TD>
<TD vAlign=bottom nowrap align=center width="9%"><FONT face="Times New Roman" size=2><B><FONT size=1><BR></FONT><FONT face="Times New Roman" size=2><B><FONT size=1>Quarter Ended</FONT></B></FONT><BR><FONT size=1>June 30<BR></FONT></B></FONT>
<HR noshade SIZE=1>
<FONT face="Times New Roman" size=2><B><FONT size=1></FONT></B></FONT></TD>
<TD vAlign=bottom nowrap align=center width="1%">&nbsp;</TD>
<TD vAlign=bottom nowrap align=center width="9%"><FONT face="Times New Roman" size=2><B><FONT size=1></FONT><FONT face="Times New Roman" size=2><B><FONT size=1>Quarter Ended</FONT></B></FONT><FONT size=1><BR>September 30<BR></FONT></B></FONT>
<HR noshade SIZE=1>
<FONT face="Times New Roman" size=2><B><FONT size=1></FONT></B></FONT></TD>
<TD vAlign=bottom nowrap align=center width="1%">&nbsp;</TD>
<TD vAlign=bottom nowrap align=center width="9%"><FONT face="Times New Roman" size=2><B><FONT size=1><BR></FONT><FONT face="Times New Roman" size=2><B><FONT size=1>Quarter Ended</FONT></B></FONT><BR><FONT size=1>December 31</FONT></B></FONT>
<HR noshade SIZE=1>
</TD>
<TD vAlign=bottom nowrap align=center width="1%">&nbsp;</TD>
<TD vAlign=bottom nowrap align=center width="9%"><FONT face="Times New Roman" size=2><B><FONT face="Times New Roman" size=2><B><FONT size=1>Quarter Ended</FONT></B></FONT><FONT size=1><BR>March 31</FONT></B></FONT>
<HR noshade SIZE=1>
</TD></TR>
<TR>
<TD vAlign=bottom nowrap width="61%"><FONT face="Times New Roman" size=2><B>Year ended March 31, 2004:</B></FONT></TD>
<TD vAlign=bottom nowrap width="9%">
<DIV align=right><FONT face="Times New Roman" size=2></FONT>&nbsp;</DIV></TD>
<TD vAlign=bottom nowrap width="1%">
<DIV align=right></DIV></TD>
<TD vAlign=bottom nowrap width="9%">
<DIV align=right><FONT face="Times New Roman" size=2></FONT>&nbsp;</DIV></TD>
<TD vAlign=bottom nowrap width="1%">
<DIV align=right></DIV></TD>
<TD vAlign=bottom nowrap width="9%">
<DIV align=right><FONT face="Times New Roman" size=2></FONT>&nbsp;</DIV></TD>
<TD vAlign=bottom nowrap width="1%">
<DIV align=right></DIV></TD>
<TD vAlign=bottom nowrap width="9%">
<DIV align=right><FONT face="Times New Roman" size=2></FONT>&nbsp;</DIV></TD></TR>
<TR>
<TD vAlign=bottom nowrap width="61%"><FONT face="Times New Roman" size=2>&nbsp;</FONT></TD>
<TD vAlign=bottom nowrap width="9%">
<DIV align=right><FONT face="Times New Roman" size=2></FONT>&nbsp;</DIV></TD>
<TD vAlign=bottom nowrap width="1%">
<DIV align=right>&nbsp;&nbsp;</DIV></TD>
<TD vAlign=bottom nowrap width="9%">
<DIV align=right><FONT face="Times New Roman" size=2></FONT>&nbsp;</DIV></TD>
<TD vAlign=bottom nowrap width="1%">
<DIV align=right>&nbsp;&nbsp;</DIV></TD>
<TD vAlign=bottom nowrap width="9%">
<DIV align=right><FONT face="Times New Roman" size=2></FONT>&nbsp;</DIV></TD>
<TD vAlign=bottom nowrap width="1%">
<DIV align=right>&nbsp;&nbsp;</DIV></TD>
<TD vAlign=bottom nowrap width="9%">
<DIV align=right><FONT face="Times New Roman" size=2></FONT>&nbsp;</DIV></TD></TR>
<TR>
<TD vAlign=bottom nowrap width="61%"><FONT face="Times New Roman" size=2>Net revenues</FONT></TD>
<TD vAlign=bottom nowrap width="9%">
<DIV align=right><FONT face="Times New Roman" size=2>$ 10,326 </FONT></DIV></TD>
<TD vAlign=bottom nowrap width="1%">
<DIV align=right></DIV></TD>
<TD vAlign=bottom nowrap width="9%">
<DIV align=right><FONT face="Times New Roman" size=2>$ 11,523 </FONT></DIV></TD>
<TD vAlign=bottom nowrap width="1%">
<DIV align=right></DIV></TD>
<TD vAlign=bottom nowrap width="9%">
<DIV align=right><FONT face="Times New Roman" size=2>$ 12,280 </FONT></DIV></TD>
<TD vAlign=bottom nowrap width="1%">
<DIV align=right></DIV></TD>
<TD vAlign=bottom nowrap width="9%">
<DIV align=right><FONT face="Times New Roman" size=2>$ 12,745 </FONT></DIV></TD></TR>
<TR>
<TD vAlign=bottom nowrap width="61%"><FONT face="Times New Roman" size=2>Gross profit</FONT></TD>
<TD vAlign=bottom nowrap width="9%">
<DIV align=right><FONT face="Times New Roman" size=2>5,106 </FONT></DIV></TD>
<TD vAlign=bottom nowrap width="1%">
<DIV align=right></DIV></TD>
<TD vAlign=bottom nowrap width="9%">
<DIV align=right><FONT face="Times New Roman" size=2>5,882 </FONT></DIV></TD>
<TD vAlign=bottom nowrap width="1%">
<DIV align=right></DIV></TD>
<TD vAlign=bottom nowrap width="9%">
<DIV align=right><FONT face="Times New Roman" size=2>6,125 </FONT></DIV></TD>
<TD vAlign=bottom nowrap width="1%">
<DIV align=right></DIV></TD>
<TD vAlign=bottom nowrap width="9%">
<DIV align=right><FONT face="Times New Roman" size=2>6,795 </FONT></DIV></TD></TR>
<TR>
<TD vAlign=bottom nowrap width="61%"><FONT face="Times New Roman" size=2>Net income </FONT></TD>
<TD vAlign=bottom nowrap width="9%">
<DIV align=right><FONT face="Times New Roman" size=2>863 </FONT></DIV></TD>
<TD vAlign=bottom nowrap width="1%">
<DIV align=right></DIV></TD>
<TD vAlign=bottom nowrap width="9%">
<DIV align=right><FONT face="Times New Roman" size=2>1,066 </FONT></DIV></TD>
<TD vAlign=bottom nowrap width="1%">
<DIV align=right></DIV></TD>
<TD vAlign=bottom nowrap width="9%">
<DIV align=right><FONT face="Times New Roman" size=2>1,173 </FONT></DIV></TD>
<TD vAlign=bottom nowrap width="1%">
<DIV align=right></DIV></TD>
<TD vAlign=bottom nowrap width="9%">
<DIV align=right><FONT face="Times New Roman" size=2>20,931 </FONT></DIV></TD></TR>
<TR>
<TD vAlign=bottom nowrap width="61%">&nbsp;</TD>
<TD vAlign=bottom nowrap width="9%">
<DIV align=right>
<HR noshade SIZE=1>
</DIV></TD>
<TD vAlign=bottom nowrap width="1%">
<DIV align=right></DIV></TD>
<TD vAlign=bottom nowrap width="9%">
<DIV align=right>
<HR noshade SIZE=1>
</DIV></TD>
<TD vAlign=bottom nowrap width="1%">
<DIV align=right></DIV></TD>
<TD vAlign=bottom nowrap width="9%">
<DIV align=right>
<HR noshade SIZE=1>
</DIV></TD>
<TD vAlign=bottom nowrap width="1%">
<DIV align=right></DIV></TD>
<TD vAlign=bottom nowrap width="9%">
<DIV align=right>
<HR noshade SIZE=1>
</DIV></TD></TR>
<TR>
<TD vAlign=bottom nowrap width="61%"><FONT face="Times New Roman" size=2>Net income attributable to common shareholders</FONT></TD>
<TD vAlign=bottom nowrap width="9%">
<DIV align=right><FONT face="Times New Roman" size=2>$ 659 </FONT></DIV></TD>
<TD vAlign=bottom nowrap width="1%">
<DIV align=right></DIV></TD>
<TD vAlign=bottom nowrap width="9%">
<DIV align=right><FONT face="Times New Roman" size=2>$ 879 </FONT></DIV></TD>
<TD vAlign=bottom nowrap width="1%">
<DIV align=right></DIV></TD>
<TD vAlign=bottom nowrap width="9%">
<DIV align=right><FONT face="Times New Roman" size=2>$ 1,145 </FONT></DIV></TD>
<TD vAlign=bottom nowrap width="1%">
<DIV align=right></DIV></TD>
<TD vAlign=bottom nowrap width="9%">
<DIV align=right><FONT face="Times New Roman" size=2>$ 20,931 </FONT></DIV></TD></TR>
<TR>
<TD vAlign=bottom nowrap width="61%">&nbsp;</TD>
<TD vAlign=bottom nowrap width="9%">
<DIV align=right>
<HR noshade SIZE=2>
</DIV></TD>
<TD vAlign=bottom nowrap width="1%">
<DIV align=right></DIV></TD>
<TD vAlign=bottom nowrap width="9%">
<DIV align=right>
<HR noshade SIZE=2>
</DIV></TD>
<TD vAlign=bottom nowrap width="1%">
<DIV align=right></DIV></TD>
<TD vAlign=bottom nowrap width="9%">
<DIV align=right>
<HR noshade SIZE=2>
</DIV></TD>
<TD vAlign=bottom nowrap width="1%">
<DIV align=right></DIV></TD>
<TD vAlign=bottom nowrap width="9%">
<DIV align=right>
<HR noshade SIZE=2>
</DIV></TD></TR>
<TR>
<TD vAlign=bottom nowrap width="61%"><FONT face="Times New Roman" size=2>Net income per share - basic </FONT></TD>
<TD vAlign=bottom nowrap width="9%">
<DIV align=right><FONT face="Times New Roman" size=2>$ 0.04 </FONT></DIV></TD>
<TD vAlign=bottom nowrap width="1%">
<DIV align=right></DIV></TD>
<TD vAlign=bottom nowrap width="9%">
<DIV align=right><FONT face="Times New Roman" size=2>$ 0.05 </FONT></DIV></TD>
<TD vAlign=bottom nowrap width="1%">
<DIV align=right></DIV></TD>
<TD vAlign=bottom nowrap width="9%">
<DIV align=right><FONT face="Times New Roman" size=2>$ 0.06 </FONT></DIV></TD>
<TD vAlign=bottom nowrap width="1%">
<DIV align=right></DIV></TD>
<TD vAlign=bottom nowrap width="9%">
<DIV align=right><FONT face="Times New Roman" size=2>$ 1.08 </FONT></DIV></TD></TR>
<TR>
<TD vAlign=bottom nowrap width="61%">&nbsp;</TD>
<TD vAlign=bottom nowrap width="9%">
<DIV align=right>
<HR noshade SIZE=2>
</DIV></TD>
<TD vAlign=bottom nowrap width="1%">
<DIV align=right></DIV></TD>
<TD vAlign=bottom nowrap width="9%">
<DIV align=right>
<HR noshade SIZE=2>
</DIV></TD>
<TD vAlign=bottom nowrap width="1%">
<DIV align=right></DIV></TD>
<TD vAlign=bottom nowrap width="9%">
<DIV align=right>
<HR noshade SIZE=2>
</DIV></TD>
<TD vAlign=bottom nowrap width="1%">
<DIV align=right></DIV></TD>
<TD vAlign=bottom nowrap width="9%">
<DIV align=right>
<HR noshade SIZE=2>
</DIV></TD></TR>
<TR>
<TD vAlign=bottom nowrap width="61%"><FONT face="Times New Roman" size=2>Net income per share - diluted</FONT></TD>
<TD vAlign=bottom nowrap width="9%">
<DIV align=right><FONT face="Times New Roman" size=2>$ 0.04 </FONT></DIV></TD>
<TD vAlign=bottom nowrap width="1%">
<DIV align=right></DIV></TD>
<TD vAlign=bottom nowrap width="9%">
<DIV align=right><FONT face="Times New Roman" size=2>$ 0.05 </FONT></DIV></TD>
<TD vAlign=bottom nowrap width="1%">
<DIV align=right></DIV></TD>
<TD vAlign=bottom nowrap width="9%">
<DIV align=right><FONT face="Times New Roman" size=2>$ 0.05 </FONT></DIV></TD>
<TD vAlign=bottom nowrap width="1%">
<DIV align=right></DIV></TD>
<TD vAlign=bottom nowrap width="9%">
<DIV align=right><FONT face="Times New Roman" size=2>$ 0.96 </FONT></DIV></TD></TR>
<TR>
<TD vAlign=bottom nowrap width="61%"><FONT face="Times New Roman" size=2>&nbsp;</FONT></TD>
<TD vAlign=bottom nowrap width="9%">
<DIV align=right>
<HR noshade SIZE=2>
<FONT face="Times New Roman" size=2>&nbsp;</FONT></DIV></TD>
<TD vAlign=bottom nowrap width="1%">
<DIV align=right></DIV></TD>
<TD vAlign=bottom nowrap width="9%">
<DIV align=right>
<HR noshade SIZE=2>
<FONT face="Times New Roman" size=2>&nbsp;</FONT></DIV></TD>
<TD vAlign=bottom nowrap width="1%">
<DIV align=right></DIV></TD>
<TD vAlign=bottom nowrap width="9%">
<DIV align=right>
<HR noshade SIZE=2>
<FONT face="Times New Roman" size=2>&nbsp;</FONT></DIV></TD>
<TD vAlign=bottom nowrap width="1%">
<DIV align=right></DIV></TD>
<TD vAlign=bottom nowrap width="9%">
<DIV align=right>
<HR noshade SIZE=2>
<FONT face="Times New Roman" size=2>&nbsp;</FONT></DIV></TD></TR>
<TR>
<TD vAlign=bottom nowrap width="61%"><FONT face="Times New Roman" size=2><B>Year ended March 31, 2003:</B></FONT></TD>
<TD vAlign=bottom nowrap width="9%">
<DIV align=right><FONT face="Times New Roman" size=2></FONT>&nbsp;</DIV></TD>
<TD vAlign=bottom nowrap width="1%">
<DIV align=right></DIV></TD>
<TD vAlign=bottom nowrap width="9%">
<DIV align=right><FONT face="Times New Roman" size=2></FONT>&nbsp;</DIV></TD>
<TD vAlign=bottom nowrap width="1%">
<DIV align=right></DIV></TD>
<TD vAlign=bottom nowrap width="9%">
<DIV align=right><FONT face="Times New Roman" size=2></FONT>&nbsp;</DIV></TD>
<TD vAlign=bottom nowrap width="1%">
<DIV align=right></DIV></TD>
<TD vAlign=bottom nowrap width="9%">
<DIV align=right><FONT face="Times New Roman" size=2></FONT>&nbsp;</DIV></TD></TR>
<TR>
<TD vAlign=bottom nowrap width="61%"><FONT face="Times New Roman" size=2>&nbsp;</FONT></TD>
<TD vAlign=bottom nowrap width="9%">
<DIV align=right><FONT face="Times New Roman" size=2></FONT>&nbsp;</DIV></TD>
<TD vAlign=bottom nowrap width="1%">
<DIV align=right></DIV></TD>
<TD vAlign=bottom nowrap width="9%">
<DIV align=right><FONT face="Times New Roman" size=2></FONT>&nbsp;</DIV></TD>
<TD vAlign=bottom nowrap width="1%">
<DIV align=right></DIV></TD>
<TD vAlign=bottom nowrap width="9%">
<DIV align=right><FONT face="Times New Roman" size=2></FONT>&nbsp;</DIV></TD>
<TD vAlign=bottom nowrap width="1%">
<DIV align=right></DIV></TD>
<TD vAlign=bottom nowrap width="9%">
<DIV align=right><FONT face="Times New Roman" size=2></FONT>&nbsp;</DIV></TD></TR>
<TR>
<TD vAlign=bottom nowrap width="61%"><FONT face="Times New Roman" size=2>Net revenues</FONT></TD>
<TD vAlign=bottom nowrap width="9%">
<DIV align=right><FONT face="Times New Roman" size=2>$ 7,416 </FONT></DIV></TD>
<TD vAlign=bottom nowrap width="1%">
<DIV align=right></DIV></TD>
<TD vAlign=bottom nowrap width="9%">
<DIV align=right><FONT face="Times New Roman" size=2>$ 8,700 </FONT></DIV></TD>
<TD vAlign=bottom nowrap width="1%">
<DIV align=right></DIV></TD>
<TD vAlign=bottom nowrap width="9%">
<DIV align=right><FONT face="Times New Roman" size=2>$ 8,488 </FONT></DIV></TD>
<TD vAlign=bottom nowrap width="1%">
<DIV align=right></DIV></TD>
<TD vAlign=bottom nowrap width="9%">
<DIV align=right><FONT face="Times New Roman" size=2>$ 10,176 </FONT></DIV></TD></TR>
<TR>
<TD vAlign=bottom nowrap width="61%"><FONT face="Times New Roman" size=2>Gross profit</FONT></TD>
<TD vAlign=bottom nowrap width="9%">
<DIV align=right><FONT face="Times New Roman" size=2>3,662 </FONT></DIV></TD>
<TD vAlign=bottom nowrap width="1%">
<DIV align=right></DIV></TD>
<TD vAlign=bottom nowrap width="9%">
<DIV align=right><FONT face="Times New Roman" size=2>3,966 </FONT></DIV></TD>
<TD vAlign=bottom nowrap width="1%">
<DIV align=right></DIV></TD>
<TD vAlign=bottom nowrap width="9%">
<DIV align=right><FONT face="Times New Roman" size=2>4,062 </FONT></DIV></TD>
<TD vAlign=bottom nowrap width="1%">
<DIV align=right></DIV></TD>
<TD vAlign=bottom nowrap width="9%">
<DIV align=right><FONT face="Times New Roman" size=2>5,087 </FONT></DIV></TD></TR>
<TR>
<TD vAlign=bottom nowrap width="61%"><FONT face="Times New Roman" size=2>Net income</FONT></TD>
<TD vAlign=bottom nowrap width="9%">
<DIV align=right><FONT face="Times New Roman" size=2>305 </FONT></DIV></TD>
<TD vAlign=bottom nowrap width="1%">
<DIV align=right></DIV></TD>
<TD vAlign=bottom nowrap width="9%">
<DIV align=right><FONT face="Times New Roman" size=2>101 </FONT></DIV></TD>
<TD vAlign=bottom nowrap width="1%">
<DIV align=right></DIV></TD>
<TD vAlign=bottom nowrap width="9%">
<DIV align=right><FONT face="Times New Roman" size=2>365 </FONT></DIV></TD>
<TD vAlign=bottom nowrap width="1%">
<DIV align=right></DIV></TD>
<TD vAlign=bottom nowrap width="9%">
<DIV align=right><FONT face="Times New Roman" size=2>865 </FONT></DIV></TD></TR>
<TR>
<TD vAlign=bottom nowrap width="61%">&nbsp;</TD>
<TD vAlign=bottom nowrap width="9%">
<DIV align=right>
<HR noshade SIZE=1>
</DIV></TD>
<TD vAlign=bottom nowrap width="1%">
<DIV align=right></DIV></TD>
<TD vAlign=bottom nowrap width="9%">
<DIV align=right>
<HR noshade SIZE=1>
</DIV></TD>
<TD vAlign=bottom nowrap width="1%">
<DIV align=right></DIV></TD>
<TD vAlign=bottom nowrap width="9%">
<DIV align=right>
<HR noshade SIZE=1>
</DIV></TD>
<TD vAlign=bottom nowrap width="1%">
<DIV align=right></DIV></TD>
<TD vAlign=bottom nowrap width="9%">
<DIV align=right>
<HR noshade SIZE=1>
</DIV></TD></TR>
<TR>
<TD vAlign=bottom nowrap width="61%"><FONT face="Times New Roman" size=2>Net income (loss) attributable to common shareholders</FONT></TD>
<TD vAlign=bottom nowrap width="9%">
<DIV align=right><FONT face="Times New Roman" size=2>$ (290)</FONT></DIV></TD>
<TD vAlign=bottom nowrap width="1%">
<DIV align=right></DIV></TD>
<TD vAlign=bottom nowrap width="9%">
<DIV align=right><FONT face="Times New Roman" size=2>$ (131)</FONT></DIV></TD>
<TD vAlign=bottom nowrap width="1%">
<DIV align=right></DIV></TD>
<TD vAlign=bottom nowrap width="9%">
<DIV align=right><FONT face="Times New Roman" size=2>$ 161 </FONT></DIV></TD>
<TD vAlign=bottom nowrap width="1%">
<DIV align=right></DIV></TD>
<TD vAlign=bottom nowrap width="9%">
<DIV align=right><FONT face="Times New Roman" size=2>$ 661 </FONT></DIV></TD></TR>
<TR>
<TD vAlign=bottom nowrap width="61%">&nbsp;</TD>
<TD vAlign=bottom nowrap width="9%">
<DIV align=right>
<HR noshade SIZE=2>
</DIV></TD>
<TD vAlign=bottom nowrap width="1%">
<DIV align=right></DIV></TD>
<TD vAlign=bottom nowrap width="9%">
<DIV align=right>
<HR noshade SIZE=2>
</DIV></TD>
<TD vAlign=bottom nowrap width="1%">
<DIV align=right></DIV></TD>
<TD vAlign=bottom nowrap width="9%">
<DIV align=right>
<HR noshade SIZE=2>
</DIV></TD>
<TD vAlign=bottom nowrap width="1%">
<DIV align=right></DIV></TD>
<TD vAlign=bottom nowrap width="9%">
<DIV align=right>
<HR noshade SIZE=2>
</DIV></TD></TR>
<TR>
<TD vAlign=bottom nowrap width="61%"><FONT face="Times New Roman" size=2>Net income (loss) per share - basic</FONT></TD>
<TD vAlign=bottom nowrap width="9%">
<DIV align=right><FONT face="Times New Roman" size=2>$ (0.02)</FONT></DIV></TD>
<TD vAlign=bottom nowrap width="1%">
<DIV align=right></DIV></TD>
<TD vAlign=bottom nowrap width="9%">
<DIV align=right><FONT face="Times New Roman" size=2>$ (0.01)</FONT></DIV></TD>
<TD vAlign=bottom nowrap width="1%">
<DIV align=right></DIV></TD>
<TD vAlign=bottom nowrap width="9%">
<DIV align=right><FONT face="Times New Roman" size=2>$ 0.01 </FONT></DIV></TD>
<TD vAlign=bottom nowrap width="1%">
<DIV align=right></DIV></TD>
<TD vAlign=bottom nowrap width="9%">
<DIV align=right><FONT face="Times New Roman" size=2>$ 0.04 </FONT></DIV></TD></TR>
<TR>
<TD vAlign=bottom nowrap width="61%">&nbsp;</TD>
<TD vAlign=bottom nowrap width="9%">
<DIV align=right>
<HR noshade SIZE=2>
</DIV></TD>
<TD vAlign=bottom nowrap width="1%">
<DIV align=right></DIV></TD>
<TD vAlign=bottom nowrap width="9%">
<DIV align=right>
<HR noshade SIZE=2>
</DIV></TD>
<TD vAlign=bottom nowrap width="1%">
<DIV align=right></DIV></TD>
<TD vAlign=bottom nowrap width="9%">
<DIV align=right>
<HR noshade SIZE=2>
</DIV></TD>
<TD vAlign=bottom nowrap width="1%">
<DIV align=right></DIV></TD>
<TD vAlign=bottom nowrap width="9%">
<DIV align=right>
<HR noshade SIZE=2>
</DIV></TD></TR>
<TR>
<TD vAlign=bottom nowrap width="61%"><FONT face="Times New Roman" size=2>Net income (loss) per share - diluted</FONT></TD>
<TD vAlign=bottom nowrap width="9%">
<DIV align=right><FONT face="Times New Roman" size=2>$ (0.02)</FONT></DIV></TD>
<TD vAlign=bottom nowrap width="1%">
<DIV align=right></DIV></TD>
<TD vAlign=bottom nowrap width="9%">
<DIV align=right><FONT face="Times New Roman" size=2>$ (0.01)</FONT></DIV></TD>
<TD vAlign=bottom nowrap width="1%">
<DIV align=right></DIV></TD>
<TD vAlign=bottom nowrap width="9%">
<DIV align=right><FONT face="Times New Roman" size=2>$ 0.01 </FONT></DIV></TD>
<TD vAlign=bottom nowrap width="1%">
<DIV align=right></DIV></TD>
<TD vAlign=bottom nowrap width="9%">
<DIV align=right><FONT face="Times New Roman" size=2>$ 0.04 </FONT></DIV></TD></TR>
<TR>
<TD vAlign=bottom nowrap width="61%">&nbsp;</TD>
<TD vAlign=bottom nowrap width="9%">
<DIV align=right>
<HR noshade SIZE=2>
</DIV></TD>
<TD vAlign=bottom nowrap width="1%">
<DIV align=right></DIV></TD>
<TD vAlign=bottom nowrap width="9%">
<DIV align=right>
<HR noshade SIZE=2>
</DIV></TD>
<TD vAlign=bottom nowrap width="1%">
<DIV align=right></DIV></TD>
<TD vAlign=bottom nowrap width="9%">
<DIV align=right>
<HR noshade SIZE=2>
</DIV></TD>
<TD vAlign=bottom nowrap width="1%">
<DIV align=right></DIV></TD>
<TD vAlign=bottom nowrap width="9%">
<DIV align=right>
<HR noshade SIZE=2>
</DIV></TD></TR>
</TABLE>


<H1><FONT size=2>ITEM 9.&nbsp;&nbsp;CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE </FONT>
<!-- MARKER FORMAT-SHEET="Head Sub 2 Left" FSL="Default" --></H1>

<P align=left><FONT face="Times New Roman, Times, Serif" size=2><I>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Not applicable.</I> </FONT></P>

<H1 align=left><FONT face="Times New Roman, Times, Serif" size=2>ITEM 9A.&nbsp;&nbsp;CONTROLS AND PROCEDURES </FONT></H1>


<P><FONT face="Times New Roman, Times, Serif" size=2><I>Evaluation of Disclosure Controls and Procedures.</I> Based on our management&#146;s evaluation (with the participation of our principal executive officer and principal financial officer), as of the end of the period covered by this report, our principal executive officer and principal financial officer have concluded that our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended, (the &#147;Exchange Act&#148;) are effective to ensure that information required to be disclosed by us in reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in Securities and Exchange Commission rules and forms. </FONT></P>


<P><FONT face="Times New Roman, Times, Serif" size=2><I>Changes in Internal Control over Financial Reporting</I>. There was no change in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) during our fourth fiscal quarter that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting. </FONT></P>

<H1 align=left><FONT face="Times New Roman, Times, Serif" size=2>ITEM 9B.&nbsp;&nbsp;OTHER INFORMATION </FONT></H1>

<!-- MARKER FORMAT-SHEET="Head Sub 2 Left" FSL="Default" -->
<P align=left><FONT face="Times New Roman, Times, Serif" size=2><I>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;None.</I> </FONT></P>

<TABLE width="100%">
<TR>
<TD align=center><FONT size=2>53</FONT></TD></TR>
</TABLE>



<P>
<HR align=left noshade SIZE=5>


<P>&nbsp;
<!-- *************************************************************************** -->
<!-- MARKER PAGE="sheet: 14; page: 14" -->
<H1 align=center><FONT face="Times New Roman, Times, Serif" size=2>PART III </FONT></H1>

<H1 align=left><FONT face="Times New Roman, Times, Serif" size=2>ITEM 10.&nbsp;&nbsp;DIRECTORS AND EXECUTIVE OFFICERS OF THE REGISTRANT </FONT></H1>


<P><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The following table sets forth certain information concerning our directors and executive officers: </FONT></P>


<P>
<TABLE cellSpacing=0 cellPadding=0 width="100%" border=0>
<TR>
<TD vAlign=top width="34%">

<P><FONT face="Times New Roman" size=2><B><FONT face="Times New Roman Bold">Name</FONT></B></FONT></P>
</TD>
<TD vAlign=top width="1%">&nbsp;</TD>
<TD vAlign=top width="8%">
<P align=center><FONT face="Times New Roman" size=2><B><FONT face="Times New Roman Bold">Age</FONT></B></FONT></P>
</TD>
<TD vAlign=top width="4%">&nbsp;</TD>
<TD vAlign=top width="53%">

<P><FONT face="Times New Roman" size=2><B><FONT face="Times New Roman Bold">Title</FONT></B></FONT></P>
</TD></TR>
<TR>
<TD vAlign=top colSpan=5>
<HR noshade SIZE=1>
</TD></TR>
<TR>
<TD vAlign=top width="34%">

<P><FONT face="Times New Roman" size=2>Clinton H. Severson</FONT></P>
</TD>
<TD vAlign=top width="1%">&nbsp;</TD>
<TD vAlign=top width="8%">
<P align=center><FONT face="Times New Roman" size=2>56</FONT></P>
</TD>
<TD vAlign=top width="4%">&nbsp;</TD>
<TD vAlign=top width="53%">
<P align=left><FONT face="Times New Roman" size=2>Chairman of the Board, President and Chief Executive Officer</FONT></P>
</TD></TR>
<TR>
<TD vAlign=top width="34%">

<P><FONT face="Times New Roman" size=2>Richard J. Bastiani, Ph.D. <SUP><FONT face="Times New Roman Bold">(1)(2)</FONT></SUP></FONT></P>
</TD>
<TD vAlign=top width="1%">&nbsp;</TD>
<TD vAlign=top width="8%">
<P align=center><FONT face="Times New Roman" size=2>61</FONT></P>
</TD>
<TD vAlign=top width="4%">&nbsp;</TD>
<TD vAlign=top width="53%">

<P><FONT face="Times New Roman" size=2>Director</FONT></P>
</TD></TR>
<TR>
<TD vAlign=top width="34%">

<P><FONT face="Times New Roman" size=2>Brenton G. A. Hanlon <SUP><FONT face="Times New Roman Bold">(1) (2)</FONT></SUP></FONT></P>
</TD>
<TD vAlign=top width="1%">&nbsp;</TD>
<TD vAlign=top width="8%">
<P align=center><FONT face="Times New Roman" size=2>58</FONT></P>
</TD>
<TD vAlign=top width="4%">&nbsp;</TD>
<TD vAlign=top width="53%">

<P><FONT face="Times New Roman" size=2>Director</FONT></P>
</TD></TR>
<TR>
<TD vAlign=top width="34%">

<P><FONT face="Times New Roman" size=2>Prithipal Singh, Ph.D. <SUP><FONT face="Times New Roman Bold">(1)</FONT></SUP></FONT></P>
</TD>
<TD vAlign=top width="1%">&nbsp;</TD>
<TD vAlign=top width="8%">
<P align=center><FONT face="Times New Roman" size=2>65</FONT></P>
</TD>
<TD vAlign=top width="4%">&nbsp;</TD>
<TD vAlign=top width="53%">

<P><FONT face="Times New Roman" size=2>Director</FONT></P>
</TD></TR>
<TR>
<TD vAlign=top width="34%">

<P><FONT face="Times New Roman" size=2>Ernest S. Tucker, III, M.D. <SUP><FONT face="Times New Roman Bold">(1)</FONT></SUP></FONT></P>
</TD>
<TD vAlign=top width="1%">&nbsp;</TD>
<TD vAlign=top width="8%">
<P align=center><FONT face="Times New Roman" size=2>71</FONT></P>
</TD>
<TD vAlign=top width="4%">&nbsp;</TD>
<TD vAlign=top width="53%">

<P><FONT face="Times New Roman" size=2>Director</FONT></P>
</TD></TR>
<TR>
<TD vAlign=top width="34%">

<P><FONT face="Times New Roman" size=2>Henk J. Evenhuis <SUP><FONT face="Times New Roman Bold">(1)</FONT></SUP></FONT></P>
</TD>
<TD vAlign=top width="1%">&nbsp;</TD>
<TD vAlign=top width="8%">
<P align=center><FONT face="Times New Roman" size=2>61</FONT></P>
</TD>
<TD vAlign=top width="4%">&nbsp;</TD>
<TD vAlign=top width="53%">

<P><FONT face="Times New Roman" size=2>Director</FONT></P>
</TD></TR>
<TR>
<TD vAlign=top width="34%">

<P><FONT face="Times New Roman" size=2>Alberto R. Santa Ines</FONT></P>
</TD>
<TD vAlign=top width="1%">&nbsp;</TD>
<TD vAlign=top width="8%">
<P align=center><FONT face="Times New Roman" size=2>57</FONT></P>
</TD>
<TD vAlign=top width="4%">&nbsp;</TD>
<TD vAlign=top width="53%">
<P align=left><FONT face="Times New Roman" size=2>Chief Financial Officer and Vice President of Finance</FONT></P>
</TD></TR>
<TR>
<TD vAlign=top width="34%">

<P><FONT face="Times New Roman" size=2>Kenneth P. Aron, Ph.D.</FONT></P>
</TD>
<TD vAlign=top width="1%">&nbsp;</TD>
<TD vAlign=top width="8%">
<P align=center><FONT face="Times New Roman" size=2>51</FONT></P>
</TD>
<TD vAlign=top width="4%">&nbsp;</TD>
<TD vAlign=top width="53%">

<P><FONT face="Times New Roman" size=2>Vice President of Research and Development</FONT></P>
</TD></TR>
<TR>
<TD vAlign=top width="34%">

<P><FONT face="Times New Roman" size=2>Robert B. Milder</FONT></P>
</TD>
<TD vAlign=top width="1%">&nbsp;</TD>
<TD vAlign=top width="8%">
<P align=center><FONT face="Times New Roman" size=2>54</FONT></P>
</TD>
<TD vAlign=top width="4%">&nbsp;</TD>
<TD vAlign=top width="53%">

<P><FONT face="Times New Roman" size=2>Chief Operations Officer</FONT></P>
</TD></TR>
<TR>
<TD vAlign=top width="34%">

<P><FONT face="Times New Roman" size=2>Vladimir E. Ostoich, Ph.D.</FONT></P>
</TD>
<TD vAlign=top width="1%">&nbsp;</TD>
<TD vAlign=top width="8%">
<P align=center><FONT face="Times New Roman" size=2>58</FONT></P>
</TD>
<TD vAlign=top width="4%">&nbsp;</TD>
<TD vAlign=top width="53%">
<P align=left><FONT face="Times New Roman" color=black size=2>Vice President of Government Affairs and Vice President of Marketing for the Pacific Rim, Founder</FONT></P>
</TD></TR>
<TR>
<TD vAlign=top width="34%">

<P><FONT face="Times New Roman" size=2>Richard L. Schoen</FONT></P>
</TD>
<TD vAlign=top width="1%">&nbsp;</TD>
<TD vAlign=top width="8%">
<P align=center><FONT face="Times New Roman" size=2>54</FONT></P>
</TD>
<TD vAlign=top width="4%">&nbsp;</TD>
<TD vAlign=top width="53%">

<P><FONT face="Times New Roman" size=2>Vice President of Domestic Marketing and Sales</FONT></P>
</TD></TR>
</TABLE>


<P align=left><FONT face="Times New Roman, Times, Serif" size=2><SUP>(1)</SUP> Member of the Audit Committee </FONT></P>

<P align=left><FONT face="Times New Roman, Times, Serif" size=2><SUP>(2)</SUP> Member of the Compensation Committee </FONT></P>


<P><FONT face="Times New Roman, Times, Serif" size=2><I>Clinton H. Severson</I> has served as our President, Chief Executive Officer and one of our directors since June 1996. He was appointed Chairman of the Board in May 1998. From February 1989 to May 1996, Mr.&nbsp;Severson served as President and Chief Executive Officer of MAST Immunosystems, Inc., a privately held medical diagnostic company. </FONT></P>


<P><FONT face="Times New Roman, Times, Serif" size=2><I>Richard J. Bastiani, Ph.D.</I> joined our Board of Directors in September 1995. Dr.&nbsp;Bastiani has also served as Chairman of the Board of Directors of ID Biomedical Corporation (NASDAQ: IDBE) since August 1998, after having been appointed to the Board of Directors of ID Biomedical Corporation in October 1996. Dr.&nbsp;Bastiani was President of Dendreon (NASDAQ: DNDN), a biotechnology company from September 1995 to September 1998. From 1971 until 1995, Dr.&nbsp;Bastiani held a number of positions with Syva Company, including as President from 1991 until Syva was acquired by a subsidiary of Hoechst AG of Germany in 1995. Dr.&nbsp;Bastiani is also a member of the board of directors of a privately held company. </FONT></P>


<P><FONT face="Times New Roman, Times, Serif" size=2><I>Brenton G. A. Hanlon</I> joined our Board of Directors in November 1996. Since January 2001, Mr.&nbsp;Hanlon has been President and Chief Executive Officer of Hitachi Chemical Diagnostics, a manufacturer of in vitro allergy diagnostic products. Concurrently, from December 1996 until the present, Mr.&nbsp;Hanlon has served as President and Chief Operating Officer of Tri-Continent Scientific, a subsidiary of Hitachi Chemical. From 1989 to December 1996, Mr.&nbsp;Hanlon was Vice President and General Manager of Tri-Continent Scientific. Mr.&nbsp;Hanlon serves on the board of directors of two privately held companies. </FONT></P>


<P><FONT face="Times New Roman, Times, Serif" size=2><I>Prithipal Singh, Ph.D.</I> joined our Board of Directors in June 1992. He has been the Founder, Chairman and Chief Executive Officer of ChemTrak Inc. (Pink Sheets: CMTR) from 1988 to 1998. Prior to this, he was an Executive Vice President of Idetec Corporation from 1985 to 1988 and a Vice President of Syva Corporation from 1977 to 1985. Dr. Singh is also on the board of a privately held company. </FONT></P>


<P><FONT face="Times New Roman, Times, Serif" size=2><I>Ernest S. Tucker, III, M.D</I>. joined our Board of Directors in September 1995. Dr.&nbsp;Tucker currently serves as a self-employed healthcare consultant after having retired as Chief Compliance Officer for Scripps Health in San Diego in September 2000, a position </FONT></P>

<TABLE width="100%">
<TR>
<TD align=center><FONT size=2>54</FONT></TD></TR>
</TABLE>



<P>
<HR align=left noshade SIZE=5>


<P>&nbsp;
<!-- *************************************************************************** -->
<!-- MARKER PAGE="sheet: 14; page: 14" -->

<P><FONT face="Times New Roman, Times, Serif" size=2>which he assumed in April 1998. Dr.&nbsp;Tucker was Chairman of Pathology at Scripps Clinic and Research Foundation from 1992 to April 1998 and Chair of Pathology at California Pacific Medical Center in San Francisco from 1989 to 1992. </FONT></P>


<P><FONT face="Times New Roman, Times, Serif" size=2><I>Henk J. Evenhuis</I> joined our Board of Directors in November 2002. Mr. Evenhuis currently serves as a Director of Credence Systems Corporation (NASDAQ: CMOS), a semiconductor equipment manufacturer. Mr. Evenhuis served as Chief Financial Officer of Fair Isaac Corporation (NYSE: FIC), a global provider of analytic software products to the financial services, insurance and health care industries from October 1999 to October 2002. From 1987 to 1998, he was Executive Vice President and Chief Financial Officer of Lam Research Corporation (NASDAQ: LRCX), a semiconductor equipment manufacturer. </FONT></P>


<P><FONT face="Times New Roman, Times, Serif" size=2><I>Alberto R. Santa Ines</I> has served as our Chief Financial Officer and Vice President of Finance since April 2002. Mr.&nbsp;Santa Ines joined us in February 2000 as Finance Manager. In April 2001, Mr.&nbsp;Santa Ines was promoted to Interim Chief Financial Officer and Director of Finance, and in April 2002 he was promoted to his current position. From March 1998 to January 2000, Mr. Santa Ines was a self-employed consultant to several companies. From August 1997 to March 1998, Mr.&nbsp;Santa Ines was the Controller of Unisil (Pink Sheets: USIL), a semiconductor company. From April 1994 to August 1997, he was a Senior Finance Manager at Lam Research Corporation (NASDAQ: LRCX), a semiconductor equipment manufacturer. </FONT></P>


<P><FONT face="Times New Roman, Times, Serif" size=2><I>Kenneth P. Aron, Ph.D</I>. joined us in February 2000 as Vice President of Research and Development. From April 1998 to November 1999, Dr.&nbsp;Aron was Vice President of Engineering and Technology of Incyte Pharmaceuticals (NASDAQ: INCY), a genomic information company. From April 1996 to April 1998, Dr. Aron was Vice President, Research, Development and Engineering for Cardiogenesis Corporation (NASDAQ: CGCP), a manufacturer of laser-based cardiology surgical products. </FONT></P>


<P><FONT face="Times New Roman, Times, Serif" size=2><I>Robert B. Milder</I> has served as our Chief Operations Officer since April 2000. Mr.&nbsp;Milder joined us in May 1998 as Vice President of Operations. From December 1996 to May 1998, Mr.&nbsp;Milder was the Vice President of Manufacturing for Nidek, Inc., a manufacturer of opthalmic and surgical lasers. From March 1992 to January 1996, Mr.&nbsp;Milder was Vice President of Operations for Heraeus Surgical, Inc., a surgical capital equipment manufacturer. </FONT></P>


<P><FONT face="Times New Roman, Times, Serif" size=2><I>Vladimir E. Ostoich, Ph.D.,</I> one of our co-founders, is currently our Vice President of Government Affairs and Vice President of Marketing for the Pacific Rim. Dr.&nbsp;Ostoich has served as Vice President in various capacities at Abaxis since our inception, including as Vice President of Research and Development, Senior Vice President of Research and Development, Vice President of Engineering and Instrument Manufacturing and Vice President of Marketing and Sales for the United States and Canada. </FONT></P>


<P><FONT face="Times New Roman, Times, Serif" size=2><I>Richard L. Schoen</I> joined us in November 2002 as Vice President of Marketing and Sales. Prior to Abaxis, Mr. Schoen was Vice President, Business Development from October 1999 to November 2002 at Colorado MEDtech, Inc., a full service outsource provider of medical device product development and manufacturing. From March 1972 to April 1998, Mr. Schoen held several key positions with Beckman Coulter, a major manufacturer of in vitro laboratory instrumentation and biomedical systems, that included program management, sales and marketing management and general management where he was responsible for Beckman&#146;s point-of-care testing products. </FONT></P>


<P><FONT face="Times New Roman, Times, Serif" size=2>All directors hold office until the next annual meeting of shareholders of Abaxis and until their successors have been elected and qualified. Our Bylaws authorize the Board of Directors to fix the number of directors at not less than four or more than seven. The number of directors of the Company is currently six. </FONT></P>


<P><FONT face="Times New Roman, Times, Serif" size=2>Each officer serves at the discretion of the Board of Directors. There are no family relationships among any of our directors or officers. </FONT></P>

<H1 align=left><FONT face="Times New Roman, Times, Serif" size=2>Identification of Audit Committee and Financial Expert </FONT></H1>


<P><FONT size=2>The Audit Committee of the Board of Directors oversees Abaxis's corporate accounting and financial reporting process. The outside directors comprise the Audit Committee: Messrs. Bastiani, Hanlon, Tucker, Evenhuis and Singh. Mr. Evenhuis serves as Chairman of the Audit Committee. </FONT></P>


<P><FONT face="Times New Roman, Times, Serif" size=2>The Board of Directors annually reviews the Nasdaq National Market listing standards definition of independence for Audit Committee members and has determined that all members of the Abaxis Audit Committee are independent (as independence is currently defined in Rule 4350(d)(2)(A)(i) and (ii) of the Nasdaq National Market listing standards). Securities and Exchange Commission, or SEC, regulations require Abaxis to disclose whether a director qualifying as an &#147;audit committee financial expert&#148; serves on the Audit Committee. The Board of Directors has determined that Mr. Evenhuis qualifies as an &#147;audit committee financial expert,&#148; as defined in applicable SEC rules. The Board of Directors made a qualitative assessment of Mr. Evenhuis&#146;s level of knowledge and experience based on a number of factors, including his formal education and experience as a chief financial officer for public reporting companies. </FONT></P>

<TABLE width="100%">
<TR>
<TD align=center><FONT size=2>55</FONT></TD></TR>
</TABLE>



<P>
<HR align=left noshade SIZE=5>


<P>&nbsp;
<!-- *************************************************************************** -->
<!-- MARKER PAGE="sheet: 14; page: 14" -->
<H1 align=left><FONT face="Times New Roman, Times, Serif" size=2>Section&nbsp;16(a) Beneficial Ownership Reporting Compliance </FONT></H1>


<P><FONT face="Times New Roman, Times, Serif" size=2>Section&nbsp;16(a)&nbsp;&nbsp;&nbsp;&nbsp; of the Securities Exchange Act of 1934 requires our executive officers, directors and persons who beneficially own more than 10% of our common stock to file initial reports of ownership and reports of changes in ownership with the Securities and Exchange Commission. Such persons are required by SEC regulations to furnish us with copies of all Section&nbsp;16(a) forms filed by such persons. </FONT></P>


<P><FONT face="Times New Roman, Times, Serif" size=2>Based solely on our review of the copies of Forms 3, 4 and 5 and amendments thereto received by us, we believe that during the period from April&nbsp;1, 2003 through March&nbsp;31, 2004, our officers and directors complied with all applicable filing requirements except with respect to seven late filings by our executive officers. </FONT></P>

<H1 align=left><FONT face="Times New Roman, Times, Serif" size=2>Code of Business Conduct and Ethics </FONT></H1>


<P><FONT face="Times New Roman, Times, Serif" size=2>Abaxis has adopted a Code of Business Conduct and Ethics that applies to all our executive officers, directors and employees. The Code of Business Conduct and Ethics is available on our website at <I>www.abaxis.com</I>. If we make any amendments to the Code of Business Conduct and Ethics or grant any waiver from a provision of the code to any executive officer or director, we will promptly disclose the nature of the amendment or waiver on our website. </FONT></P>

<H1 align=left><FONT face="Times New Roman, Times, Serif" size=2>Employment Agreements </FONT></H1>


<P><FONT face="Times New Roman, Times, Serif" size=2>In March 1997, we entered into an employment agreement with Clinton H. Severson, our President, Chief Executive Officer, and Chairman of our Board of Directors, which provides Mr.&nbsp;Severson with six months of salary and benefits if his employment with us is terminated for other than cause. In April 2001, this agreement was modified to increase the length of term from six months to two years. </FONT></P>


<P><FONT face="Times New Roman, Times, Serif" size=2>In April 2001, we entered into an Employee Retention Incentive Agreement with Alberto R. Santa Ines, which provided that Mr.&nbsp;Santa Ines, then our Interim Chief Financial Officer and Director of Finance, would receive a lump sum cash payment equal to nine months of salary and benefits if his employment with us was terminated for other than cause. In May 2002, Mr.&nbsp;Santa Ines was appointed as our Chief Financial Officer and Vice President of Finance and concurrently Mr.&nbsp;Santa Ines&#146; employment agreement was amended to provide that Mr.&nbsp;Santa Ines will receive a lump sum cash payment equal to nine months of salary and benefits if his employment with us is terminated for other than cause before April 2004 or upon providing services to Abaxis for a period of three years. </FONT></P>

<H1 align=left><FONT face="Times New Roman, Times, Serif" size=2>ITEM 11.&nbsp;&nbsp;EXECUTIVE COMPENSATION AND OTHER MATTERS </FONT></H1>


<P><FONT face="Times New Roman, Times, Serif" size=2>The following table sets forth information concerning the compensation during fiscal 2004, 2003 and 2002 of our Chief Executive Officer and our four other most highly compensated executive officers whose total salary and bonus for our fiscal 2004 exceeded $100,000, for services in all capacities to us, during our fiscal 2004. </FONT></P>

<!-- MARKER FORMAT-SHEET="Head Sub 3 Left" FSL="Default" -->
<H1 align=center>&nbsp;</H1>

<TABLE width="100%">
<TR>
<TD align=center><FONT size=2>56</FONT></TD></TR>
</TABLE>



<P>
<HR align=left noshade SIZE=5>


<P>&nbsp;
<!-- *************************************************************************** -->
<!-- MARKER PAGE="sheet: 14; page: 14" -->

<P>
<TABLE cellSpacing=0 cellPadding=0 width="100%" border=0>
<TR align=center>
<TD vAlign=top colSpan=9><FONT face="Times New Roman" size=2><B><FONT face="Times New Roman Bold">SUMMARY COMPENSATION TABLE</FONT></B></FONT></TD></TR>
<TR>
<TD vAlign=top width="66%"><FONT face="Times New Roman" size=2><B>&nbsp;</B></FONT></TD>
<TD vAlign=top width="1%">&nbsp;</TD>
<TD vAlign=bottom align=center width="5%"><FONT face="Times New Roman" size=2><B>&nbsp;</B></FONT></TD>
<TD vAlign=bottom align=center width="1%"><FONT face="Times New Roman" size=2><B>&nbsp;</B></FONT></TD>
<TD vAlign=bottom align=center colSpan=4><FONT face="Times New Roman" size=2><B>&nbsp;</B></FONT><FONT face="Times New Roman" size=2><B>&nbsp;</B></FONT><FONT face="Times New Roman" size=2><B>Annual Compensation ($)<BR></B></FONT>
<HR noshade SIZE=1>
<FONT face="Times New Roman" size=2><B></B></FONT></TD>
<TD vAlign=bottom align=center width="11%"><FONT face="Times New Roman" size=2><B>Long-Term<BR>Compensation<BR></B></FONT><FONT face="Times New Roman" size=2><B>Awards</B></FONT>
<HR noshade SIZE=1>
</TD></TR>
<TR>
<TD vAlign=bottom width="66%"><FONT face="Times New Roman" size=2><B>&nbsp;</B></FONT><FONT face="Times New Roman" size=2><B>&nbsp;</B></FONT><FONT face="Times New Roman" size=2><B>Name and Principal Position<BR></B></FONT>
<HR noshade SIZE=1>
<FONT face="Times New Roman" size=2><B></B></FONT></TD>
<TD vAlign=bottom width="1%">&nbsp;</TD>
<TD vAlign=bottom align=center width="5%"><FONT face="Times New Roman" size=2><B>&nbsp;</B></FONT><FONT face="Times New Roman" size=2><B>Fiscal<BR>Year<BR></B></FONT>
<HR noshade SIZE=1>
<FONT face="Times New Roman" size=2><B></B></FONT></TD>
<TD vAlign=bottom align=center width="1%">&nbsp; </TD>
<TD vAlign=bottom align=center width="8%"><FONT face="Times New Roman" size=2><B>&nbsp;</B></FONT><FONT face="Times New Roman" size=2><B>Salary<BR></B></FONT>
<HR noshade SIZE=1>
<FONT face="Times New Roman" size=2><B></B></FONT></TD>
<TD vAlign=bottom align=center width="1%">&nbsp;</TD>
<TD vAlign=bottom align=center width="6%"><FONT face="Times New Roman" size=2><B>&nbsp;</B></FONT><FONT face="Times New Roman" size=2><B>Bonus<BR></B></FONT>
<HR noshade SIZE=1>
<FONT face="Times New Roman" size=2><B></B></FONT></TD>
<TD vAlign=bottom align=center width="1%">&nbsp;</TD>
<TD vAlign=bottom align=center width="11%"><FONT face="Times New Roman" size=2><B>Securities<BR>Underlying<BR>Options (#)<BR></B></FONT>
<HR noshade SIZE=1>
</TD></TR>
<TR>
<TD vAlign=top width="66%"><FONT face="Times New Roman" size=2><B>Clinton H. Severson<BR></B></FONT><FONT face="Times New Roman" size=2>President, Chief Executive Officer and<BR>Chairman of the Board</FONT></TD>
<TD vAlign=top width="1%">&nbsp;&nbsp;</TD>
<TD vAlign=top width="5%">
<DIV align=center><FONT face="Times New Roman" size=2>2004</FONT><FONT face="Times New Roman" size=2><BR>2003</FONT><FONT face="Times New Roman" size=2><BR>2002</FONT></DIV></TD>
<TD vAlign=top width="1%">
<DIV align=right>&nbsp;&nbsp;</DIV></TD>
<TD vAlign=top width="8%">
<DIV align=right><FONT face="Times New Roman" size=2>$285,000</FONT><FONT face="Times New Roman" size=2><BR>265,000</FONT><FONT face="Times New Roman" size=2><BR>265,000</FONT></DIV></TD>
<TD vAlign=top width="1%">&nbsp;&nbsp;</TD>
<TD vAlign=top width="6%">
<DIV align=right><FONT face="Times New Roman" size=2>$461,000</FONT><FONT face="Times New Roman" size=2><BR>187,000</FONT><FONT face="Times New Roman" size=2><BR>82,500</FONT></DIV></TD>
<TD vAlign=top width="1%">&nbsp;&nbsp;</TD>
<TD vAlign=top align=center width="11%">
<DIV align=center><FONT face="Times New Roman" size=2>&nbsp;&nbsp;50,000</FONT><FONT face="Times New Roman" size=2><BR>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#151;</FONT><FONT face="Times New Roman" size=2><BR>164,000</FONT></DIV></TD></TR>
<TR>
<TD vAlign=top width="66%"><FONT face="Times New Roman" size=2><B>Alberto R. Santa Ines</B><BR>Chief Financial Officer and Vice<BR>President of Finance</FONT></TD>
<TD vAlign=top width="1%">&nbsp;</TD>
<TD vAlign=top width="5%">
<DIV align=center><FONT face="Times New Roman" size=2>2004</FONT><FONT face="Times New Roman" size=2><BR>2003</FONT><FONT face="Times New Roman" size=2><BR>2002</FONT></DIV></TD>
<TD vAlign=top width="1%">
<DIV align=right></DIV></TD>
<TD vAlign=top width="8%">
<DIV align=right><FONT face="Times New Roman" size=2>$150,000<BR></FONT><FONT face="Times New Roman" size=2>131,000<BR></FONT><FONT face="Times New Roman" size=2>110,000</FONT></DIV></TD>
<TD vAlign=top width="1%">&nbsp;</TD>
<TD vAlign=top width="6%">
<DIV align=right><FONT face="Times New Roman" size=2>$406,000</FONT><FONT face="Times New Roman" size=2><BR>125,000<BR></FONT><FONT face="Times New Roman" size=2>22,000</FONT></DIV></TD>
<TD vAlign=top width="1%">&nbsp;</TD>
<TD vAlign=top align=center width="11%">
<DIV align=center><FONT face="Times New Roman" size=2>&nbsp;&nbsp;40,000</FONT><FONT face="Times New Roman" size=2><BR>&nbsp;&nbsp;50,000</FONT><FONT face="Times New Roman" size=2><BR>&nbsp;&nbsp;22,000</FONT></DIV></TD></TR>
<TR>
<TD vAlign=top width="66%"><FONT face="Times New Roman" size=2><B>Kenneth P. Aron, Ph.D.</B><BR></FONT><FONT face="Times New Roman" size=2>Vice President of Research and<BR>Development</FONT></TD>
<TD vAlign=top width="1%">&nbsp;</TD>
<TD vAlign=top width="5%">
<DIV align=center><FONT face="Times New Roman" size=2>2004</FONT><FONT face="Times New Roman" size=2><BR>2003</FONT><FONT face="Times New Roman" size=2><BR>2002</FONT></DIV></TD>
<TD vAlign=top width="1%">
<DIV align=right></DIV></TD>
<TD vAlign=top width="8%">
<DIV align=right><FONT face="Times New Roman" size=2>$160,000</FONT><FONT face="Times New Roman" size=2><BR>150,000</FONT><FONT face="Times New Roman" size=2><BR>150,000</FONT></DIV></TD>
<TD vAlign=top width="1%">&nbsp;</TD>
<TD vAlign=top width="6%">
<DIV align=right><FONT face="Times New Roman" size=2>$302,000</FONT><FONT face="Times New Roman" size=2><BR>125,000</FONT><FONT face="Times New Roman" size=2><BR>55,000</FONT></DIV></TD>
<TD vAlign=top width="1%">&nbsp;</TD>
<TD vAlign=top align=center width="11%">
<DIV align=center><FONT face="Times New Roman" size=2>&nbsp;&nbsp;40,000</FONT><FONT face="Times New Roman" size=2><BR>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#151;</FONT><FONT face="Times New Roman" size=2><BR>&nbsp;&nbsp;55,000</FONT></DIV></TD></TR>
<TR>
<TD vAlign=top width="66%"><FONT face="Times New Roman" size=2><B>Robert B. Milder</B><BR></FONT><FONT face="Times New Roman" size=2>Chief Operations Officer</FONT></TD>
<TD vAlign=top width="1%">&nbsp;</TD>
<TD vAlign=top width="5%">
<DIV align=center><FONT face="Times New Roman" size=2>2004</FONT><FONT face="Times New Roman" size=2><BR>2003</FONT><FONT face="Times New Roman" size=2><BR>2002</FONT></DIV></TD>
<TD vAlign=top width="1%">
<DIV align=right></DIV></TD>
<TD vAlign=top width="8%">
<DIV align=right><FONT face="Times New Roman" size=2>$175,000</FONT><FONT face="Times New Roman" size=2><BR>165,000</FONT><FONT face="Times New Roman" size=2><BR>165,000</FONT></DIV></TD>
<TD vAlign=top width="1%">&nbsp;</TD>
<TD vAlign=top width="6%">
<DIV align=right><FONT face="Times New Roman" size=2>$360,000</FONT><FONT face="Times New Roman" size=2><BR>149,000</FONT><FONT face="Times New Roman" size=2><BR>66,000</FONT></DIV></TD>
<TD vAlign=top width="1%">&nbsp;</TD>
<TD vAlign=top align=center width="11%">
<DIV align=center><FONT face="Times New Roman" size=2>&nbsp;&nbsp;40,000</FONT><FONT face="Times New Roman" size=2><BR>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#151;</FONT><FONT face="Times New Roman" size=2><BR>&nbsp;&nbsp;62,000</FONT></DIV></TD></TR>
<TR>
<TD vAlign=top width="66%"><FONT face="Times New Roman" size=2><B>Vladimir E. Ostoich, Ph.D.</B></FONT><FONT face="Times New Roman" size=2><BR>Vice President of Government Affairs<BR>and Vice President of Marketing for the<BR>Pacific Rim</FONT></TD>
<TD vAlign=top width="1%">&nbsp;</TD>
<TD vAlign=top width="5%">
<DIV align=center><FONT face="Times New Roman" size=2>2004</FONT><FONT face="Times New Roman" size=2><BR>2003</FONT><FONT face="Times New Roman" size=2><BR>2002</FONT></DIV></TD>
<TD vAlign=top width="1%">
<DIV align=right></DIV></TD>
<TD vAlign=top width="8%">
<DIV align=right><FONT face="Times New Roman" size=2>$170,000</FONT><FONT face="Times New Roman" size=2><BR>160,000</FONT><FONT face="Times New Roman" size=2><BR>160,000</FONT></DIV></TD>
<TD vAlign=top width="1%">&nbsp;</TD>
<TD vAlign=top width="6%">
<DIV align=right><FONT face="Times New Roman" size=2>$302,000</FONT><FONT face="Times New Roman" size=2><BR>125,000</FONT><FONT face="Times New Roman" size=2><BR>55,000</FONT></DIV></TD>
<TD vAlign=top width="1%">&nbsp;</TD>
<TD vAlign=top align=center width="11%">
<DIV align=center><FONT face="Times New Roman" size=2>&nbsp;&nbsp;40,000<BR></FONT><FONT face="Times New Roman" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#151;</FONT><FONT face="Times New Roman" size=2> <BR>&nbsp;&nbsp;59,500</FONT></DIV></TD></TR>
</TABLE>


<H1 align=left><FONT face="Times New Roman, Times, Serif" size=2>Stock Options Granted in Fiscal 2004 </FONT></H1>


<P><FONT face="Times New Roman, Times, Serif" size=2>The following table provides the specified information concerning grants of options to purchase our common stock made during fiscal 2004, made to the persons named in the Summary Compensation Table. </FONT></P>

<!-- MARKER FORMAT-SHEET="Head Sub 3 Left" FSL="Default" -->
<P align=center><FONT face="Times New Roman, Times, Serif" size=2><B>OPTION GRANTS IN FISCAL 2004</B></FONT></P>

<TABLE cellSpacing=0 cellPadding=0 width="100%" border=0>
<TR vAlign=bottom align=center>
<TD width="21%">&nbsp;</TD>
<TD width="1%">&nbsp;</TD>
<TD colSpan=7><FONT face="Times New Roman" size=2><B>Individual Grants in Fiscal 2004</B></FONT>
<HR noshade SIZE=1>
</TD>
<TD width="3%">&nbsp;</TD>
<TD colSpan=3>&nbsp;</TD></TR>
<TR vAlign=bottom>
<TD width="21%" rowSpan=2><FONT face="Times New Roman" size=2><B>Name</B></FONT>
<HR noshade SIZE=1>
</TD>
<TD width="1%" rowSpan=2>&nbsp;&nbsp;</TD>
<TD align=center width="18%" rowSpan=2><FONT face="Times New Roman" size=2><B>&nbsp;</B></FONT><FONT face="Times New Roman" size=2><B>Number of </B></FONT><FONT face="Times New Roman" size=2><B>Securities<BR></B></FONT><FONT face="Times New Roman" size=2><B>Underlying </B></FONT><FONT face="Times New Roman" size=2><B>Options<BR></B></FONT><FONT face="Times New Roman" size=2><B>Granted </B></FONT><FONT face="Times New Roman" size=2><B>(#) <SUP>(2)</SUP></B></FONT>
<HR noshade SIZE=1>
</TD>
<TD width="1%" rowSpan=2>&nbsp;&nbsp;</TD>
<TD align=center width="17%" rowSpan=2><FONT face="Times New Roman" size=2><B>% of Total Options <BR>Granted to Employees<BR>in Fiscal Year</B></FONT>
<HR noshade SIZE=1>
</TD>
<TD align=center width="1%" rowSpan=2>&nbsp;&nbsp;</TD>
<TD align=center width="9%" rowSpan=2><FONT face="Times New Roman" size=2><B>Exercise <BR>Base Price<BR>($/Sh)</B><SUP> <B>(3)</B></SUP></FONT>
<HR noshade SIZE=1>
</TD>
<TD align=center width="1%" rowSpan=2>&nbsp;&nbsp;</TD>
<TD align=center width="11%" rowSpan=2><FONT face="Times New Roman" size=2><B>Expiration Date</B></FONT>
<HR noshade SIZE=1>
</TD>
<TD width="3%" rowSpan=2><FONT face="Times New Roman" size=2>&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD align=center colSpan=3><FONT face="Times New Roman" size=2><B>&nbsp;</B></FONT><FONT face="Times New Roman" size=2><B>Potential Realizable Value at Assumed Annual Rates of Stock Price Appreciation for Option Term <SUP>(1)</SUP></B></FONT><FONT face="Times New Roman" size=2><B> </B></FONT></TD></TR>
<TR>
<TD vAlign=bottom align=center width="7%"><FONT face="Times New Roman" size=2><B>5% ($)</B></FONT>
<HR noshade SIZE=1>
</TD>
<TD vAlign=bottom align=center width="1%">&nbsp;&nbsp;</TD>
<TD vAlign=bottom align=center width="9%"><FONT face="Times New Roman" size=2><B>10% ($)</B></FONT>
<HR noshade SIZE=1>
</TD></TR>
<TR>
<TD vAlign=top width="21%"><FONT face="Times New Roman" size=2><B>Clinton H. Severson</B></FONT></TD>
<TD vAlign=top width="1%">&nbsp;</TD>
<TD vAlign=top align=center width="18%"><FONT face="Times New Roman" size=2>50,000</FONT></TD>
<TD vAlign=top align=center width="1%">&nbsp;</TD>
<TD vAlign=top align=center width="17%"><FONT face="Times New Roman" size=2>8.9%</FONT></TD>
<TD vAlign=top align=center width="1%">&nbsp;</TD>
<TD vAlign=top align=center width="9%"><FONT face="Times New Roman" size=2>$ 3.85</FONT></TD>
<TD vAlign=top align=center width="1%">&nbsp;</TD>
<TD vAlign=top align=center width="11%"><FONT face="Times New Roman" size=2>4/22/2013</FONT></TD>
<TD vAlign=top align=center width="3%"><FONT face="Times New Roman" size=2>&nbsp;</FONT></TD>
<TD vAlign=top align=center width="7%"><FONT face="Times New Roman" size=2>$ 121,062</FONT></TD>
<TD vAlign=top align=center width="1%">&nbsp;</TD>
<TD vAlign=top align=center width="9%"><FONT face="Times New Roman" size=2>$ 306,795</FONT></TD></TR>
<TR>
<TD vAlign=top width="21%"><FONT face="Times New Roman" size=2><B>Alberto R. Santa Ines</B></FONT></TD>
<TD vAlign=top width="1%">&nbsp;</TD>
<TD vAlign=top align=center width="18%"><FONT face="Times New Roman" size=2>40,000</FONT></TD>
<TD vAlign=top align=center width="1%">&nbsp;</TD>
<TD vAlign=top align=center width="17%"><FONT face="Times New Roman" size=2>7.1%</FONT></TD>
<TD vAlign=top align=center width="1%">&nbsp;</TD>
<TD vAlign=top align=center width="9%"><FONT face="Times New Roman" size=2>$ 3.85</FONT></TD>
<TD vAlign=top align=center width="1%">&nbsp;</TD>
<TD vAlign=top align=center width="11%"><FONT face="Times New Roman" size=2>4/22/2013</FONT></TD>
<TD vAlign=top align=center width="3%"><FONT face="Times New Roman" size=2>&nbsp;</FONT></TD>
<TD vAlign=top align=center width="7%"><FONT face="Times New Roman" size=2>$&nbsp;&nbsp; 96,850</FONT></TD>
<TD vAlign=top align=center width="1%">&nbsp;</TD>
<TD vAlign=top align=center width="9%"><FONT face="Times New Roman" size=2>$ 245,436</FONT></TD></TR>
<TR>
<TD vAlign=top width="21%"><FONT face="Times New Roman" size=2><B>Kenneth P. Aron, Ph.D.</B></FONT></TD>
<TD vAlign=top width="1%">&nbsp;</TD>
<TD vAlign=top align=center width="18%"><FONT face="Times New Roman" size=2>40,000</FONT></TD>
<TD vAlign=top align=center width="1%">&nbsp;</TD>
<TD vAlign=top align=center width="17%"><FONT face="Times New Roman" size=2>7.1%</FONT></TD>
<TD vAlign=top align=center width="1%">&nbsp;</TD>
<TD vAlign=top align=center width="9%"><FONT face="Times New Roman" size=2>$ 3.85</FONT></TD>
<TD vAlign=top align=center width="1%">&nbsp;</TD>
<TD vAlign=top align=center width="11%"><FONT face="Times New Roman" size=2>4/22/2013</FONT></TD>
<TD vAlign=top align=center width="3%"><FONT face="Times New Roman" size=2>&nbsp;</FONT></TD>
<TD vAlign=top align=center width="7%"><FONT face="Times New Roman" size=2>$&nbsp;&nbsp; 96,850</FONT></TD>
<TD vAlign=top align=center width="1%">&nbsp;</TD>
<TD vAlign=top align=center width="9%"><FONT face="Times New Roman" size=2>$ 245,436</FONT></TD></TR>
<TR>
<TD vAlign=top width="21%"><FONT face="Times New Roman" size=2><B>Robert B. Milder</B></FONT></TD>
<TD vAlign=top width="1%">&nbsp;</TD>
<TD vAlign=top align=center width="18%"><FONT face="Times New Roman" size=2>40,000</FONT></TD>
<TD vAlign=top align=center width="1%">&nbsp;</TD>
<TD vAlign=top align=center width="17%"><FONT face="Times New Roman" size=2>7.1%</FONT></TD>
<TD vAlign=top align=center width="1%">&nbsp;</TD>
<TD vAlign=top align=center width="9%"><FONT face="Times New Roman" size=2>$ 3.85</FONT></TD>
<TD vAlign=top align=center width="1%">&nbsp;</TD>
<TD vAlign=top align=center width="11%"><FONT face="Times New Roman" size=2>4/22/2013</FONT></TD>
<TD vAlign=top align=center width="3%"><FONT face="Times New Roman" size=2>&nbsp;</FONT></TD>
<TD vAlign=top align=center width="7%"><FONT face="Times New Roman" size=2>$&nbsp;&nbsp; 96,850</FONT></TD>
<TD vAlign=top align=center width="1%">&nbsp;</TD>
<TD vAlign=top align=center width="9%"><FONT face="Times New Roman" size=2>$ 245,436</FONT></TD></TR>
<TR>
<TD vAlign=top width="21%"><FONT face="Times New Roman" size=2><B>Vladimir E. Ostoich, Ph.D.</B></FONT></TD>
<TD vAlign=top width="1%">&nbsp;</TD>
<TD vAlign=top align=center width="18%"><FONT face="Times New Roman" size=2>40,000</FONT></TD>
<TD vAlign=top align=center width="1%">&nbsp;</TD>
<TD vAlign=top align=center width="17%"><FONT face="Times New Roman" size=2>7.1%</FONT></TD>
<TD vAlign=top align=center width="1%">&nbsp;</TD>
<TD vAlign=top align=center width="9%"><FONT face="Times New Roman" size=2>$ 3.85</FONT></TD>
<TD vAlign=top align=center width="1%">&nbsp;</TD>
<TD vAlign=top align=center width="11%"><FONT face="Times New Roman" size=2>4/22/2013</FONT></TD>
<TD vAlign=top align=center width="3%"><FONT face="Times New Roman" size=2>&nbsp;</FONT></TD>
<TD vAlign=top align=center width="7%"><FONT face="Times New Roman" size=2>$&nbsp;&nbsp; 96,850</FONT></TD>
<TD vAlign=top align=center width="1%">&nbsp;</TD>
<TD vAlign=top align=center width="9%"><FONT face="Times New Roman" size=2>$ 245,436</FONT></TD></TR>
<TR>
<TD vAlign=top colSpan=13>
<HR noshade SIZE=1>
</TD></TR>
</TABLE>


<TABLE cellSpacing=0 cellPadding=0 width="100%">
<TR vAlign=top>
<TD align=left width="3%"><FONT face="Times New Roman, Times, Serif" size=2><SUP>(1) </SUP></FONT></TD>
<TD width="97%">
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>Potential gains are net of exercise price, but before taxes associated with exercise. These amounts represent certain assumed rates of appreciation only, based on the Securities and Exchange Commission rules. Actual gains, if any, on stock option exercise are dependent on the future performance of the common stock, overall market conditions and the option holders&#146; continued employment through the vesting period. The amounts reflected in this table may not necessarily be achieved. </FONT></P>
</TD></TR>
</TABLE>

<BR>
<TABLE cellSpacing=0 cellPadding=0 width="100%">
<TR vAlign=top>
<TD align=left width="3%"><FONT face="Times New Roman, Times, Serif" size=2><SUP>(2)</SUP> </FONT></TD>
<TD width="97%">
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>All options granted in fiscal 2004 were granted pursuant to our 1998 Stock Option Plan. The options vest and become exercisable at the rate of one-fourth on the first anniversary of the date of grant and 1/48 per month thereafter for each full month of the optionee&#146;s continuous employment by us. Under our 1998 Stock Option Plan, the Board retains discretion to modify the terms, including the price, of outstanding options. For additional information regarding options, see &#147;Change of Control Arrangements.&#148; </FONT></P>
</TD></TR>
</TABLE>

<BR>
<TABLE cellSpacing=0 cellPadding=0 width="100%">
<TR vAlign=top>
<TD width="3%"><FONT face="Times New Roman, Times, Serif" size=2><SUP>(3)</SUP></FONT></TD>
<TD width="97%"><FONT face="Times New Roman, Times, Serif" size=2>All options were granted at market value on the date of grant. </FONT></TD></TR>
</TABLE>


<!-- MARKER FORMAT-SHEET="Head Minor Center Bold" FSL="Default" -->
<H1 align=center><FONT face="Times New Roman, Times, Serif" size=2>OPTION EXERCISES IN FISCAL 2004 AND OPTION VALUES AT MARCH 31, 2004 </FONT></H1>


<P><FONT face="Times New Roman, Times, Serif" size=2>The following table provides the specified information concerning exercises of options to purchase our common stock in the fiscal year ended March&nbsp;31, 2004, and unexercised options held as of March&nbsp;31, 2004, by the persons named in the Summary Compensation Table. </FONT></P>

<TABLE width="100%">
<TR>
<TD align=center><FONT size=2>57</FONT></TD></TR>
</TABLE>



<P>
<HR align=left noshade SIZE=5>


<P>&nbsp;
<!-- *************************************************************************** -->
<!-- MARKER PAGE="sheet: 14; page: 14" -->
<TABLE cellSpacing=0 cellPadding=0 width="100%" border=0>
<TR vAlign=bottom align=center>
<TD width="18%"><FONT face="Times New Roman" size=2></FONT></TD>
<TD width="11%"><FONT face="Times New Roman" size=2><B>Shares<BR>Acquired<BR>on<BR>Exercise<BR></B></FONT></TD>
<TD width="2%">&nbsp;&nbsp;</TD>
<TD width="9%"><FONT face="Times New Roman" size=2><B>Value<BR>Realized<BR></B></FONT></TD>
<TD width="2%">&nbsp;&nbsp;</TD>
<TD colSpan=3><FONT face="Times New Roman" size=2><B>Number of Unexercised Options<BR>at 3/31/04 <SUP>(2)</SUP><SUP></SUP></B></FONT>&nbsp;&nbsp;<FONT face="Times New Roman" size=2></FONT></TD>
<TD width="4%">&nbsp;&nbsp;</TD>
<TD colSpan=3><FONT face="Times New Roman" size=2></FONT><FONT face="Times New Roman" size=2><B>Value of Unexercised<BR></B></FONT><FONT face="Times New Roman" size=2><B>In&#151;the&#151;Money Options at 3/31/04<BR>($) <SUP>(3)</SUP></B></FONT></TD></TR>
<TR align=center>
<TD vAlign=top width="18%"><FONT face="Times New Roman" size=2><B>Name</B></FONT></TD>
<TD vAlign=top width="11%"><FONT face="Times New Roman" size=2><B>(#)</B></FONT></TD>
<TD vAlign=top width="2%">&nbsp;</TD>
<TD vAlign=top width="9%"><FONT face="Times New Roman" size=2><B>($)<SUP>(1)</SUP></B></FONT></TD>
<TD vAlign=top width="2%">&nbsp;</TD>
<TD vAlign=top width="13%"><FONT face="Times New Roman" size=2><B>Exercisable<SUP></SUP></B></FONT></TD>
<TD vAlign=top width="2%">&nbsp;</TD>
<TD vAlign=top width="16%"><FONT face="Times New Roman" size=2><B>Unexercisable</B></FONT></TD>
<TD vAlign=top width="4%">&nbsp;</TD>
<TD vAlign=top width="10%"><FONT face="Times New Roman" size=2><B>Exercisable</B></FONT></TD>
<TD vAlign=top width="1%">&nbsp;&nbsp;</TD>
<TD vAlign=top width="12%"><FONT face="Times New Roman" size=2><B>Unexercisable</B></FONT></TD></TR>
<TR>
<TD vAlign=top colSpan=12>
<HR noshade SIZE=1>
</TD></TR>
<TR>
<TD vAlign=top width="18%"><FONT face="Times New Roman" size=2><B>Clinton H. Severson </B></FONT></TD>
<TD vAlign=top align=center width="11%"><FONT face="Times New Roman" size=2>&#151;</FONT></TD>
<TD vAlign=top width="2%">&nbsp;</TD>
<TD vAlign=top align=center width="9%"><FONT face="Times New Roman" size=2>&#151;</FONT></TD>
<TD vAlign=top width="2%">&nbsp;</TD>
<TD vAlign=top width="13%">
<DIV align=center><FONT face="Times New Roman" size=2>623,375</FONT></DIV></TD>
<TD vAlign=top width="2%">
<DIV align=center>&nbsp;&nbsp;</DIV></TD>
<TD vAlign=top align=center width="16%"><FONT face="Times New Roman" size=2>90,625</FONT></TD>
<TD vAlign=top width="4%">
<DIV align=right></DIV></TD>
<TD vAlign=top align=center width="10%">
<DIV align=center><FONT face="Times New Roman" size=2>$10,307,744</FONT></DIV></TD>
<TD vAlign=top width="1%">
<DIV align=right></DIV></TD>
<TD vAlign=top width="12%">
<DIV align=center><FONT face="Times New Roman" size=2>$1,451,156</FONT></DIV></TD></TR>
<TR>
<TD vAlign=top width="18%"><FONT face="Times New Roman" size=2><B>Alberto R. Santa Ines</B></FONT></TD>
<TD vAlign=top align=center width="11%"><FONT face="Times New Roman" size=2>&#151;</FONT></TD>
<TD vAlign=top width="2%">&nbsp;</TD>
<TD vAlign=top align=center width="9%"><FONT face="Times New Roman" size=2>&#151;</FONT></TD>
<TD vAlign=top width="2%">&nbsp;</TD>
<TD vAlign=top width="13%">
<DIV align=center><FONT face="Times New Roman" size=2>54,312</FONT></DIV></TD>
<TD vAlign=top width="2%">
<DIV align=center></DIV></TD>
<TD vAlign=top align=center width="16%"><FONT face="Times New Roman" size=2>74,688</FONT></TD>
<TD vAlign=top width="4%">
<DIV align=right></DIV></TD>
<TD vAlign=top align=center width="10%">
<DIV align=center><FONT face="Times New Roman" size=2>$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;817,106</FONT></DIV></TD>
<TD vAlign=top width="1%">
<DIV align=right></DIV></TD>
<TD vAlign=top width="12%">
<DIV align=center><FONT face="Times New Roman" size=2>$1,248,959</FONT></DIV></TD></TR>
<TR>
<TD vAlign=top width="18%"><FONT face="Times New Roman" size=2><B>Kenneth P. Aron, Ph.D.</B></FONT></TD>
<TD vAlign=top align=center width="11%"><FONT face="Times New Roman" size=2>500</FONT></TD>
<TD vAlign=top width="2%">&nbsp;</TD>
<TD vAlign=top align=center width="9%"><FONT face="Times New Roman" size=2>$7,160</FONT></TD>
<TD vAlign=top width="2%">&nbsp;</TD>
<TD vAlign=top width="13%">
<DIV align=center><FONT face="Times New Roman" size=2>143,666</FONT></DIV></TD>
<TD vAlign=top width="2%">
<DIV align=center></DIV></TD>
<TD vAlign=top align=center width="16%"><FONT face="Times New Roman" size=2>60,834</FONT></TD>
<TD vAlign=top width="4%">
<DIV align=right></DIV></TD>
<TD vAlign=top align=center width="10%">
<DIV align=center><FONT face="Times New Roman" size=2>$&nbsp;&nbsp;1,993,890</FONT></DIV></TD>
<TD vAlign=top width="1%">
<DIV align=right></DIV></TD>
<TD vAlign=top width="12%">
<DIV align=center><FONT face="Times New Roman" size=2>$&nbsp;&nbsp;&nbsp;970,185</FONT></DIV></TD></TR>
<TR>
<TD vAlign=top width="18%"><FONT face="Times New Roman" size=2><B>Robert B. Milder</B></FONT></TD>
<TD vAlign=top align=center width="11%"><FONT face="Times New Roman" size=2>&#151;</FONT></TD>
<TD vAlign=top width="2%">&nbsp;</TD>
<TD vAlign=top align=center width="9%"><FONT face="Times New Roman" size=2>&#151;</FONT></TD>
<TD vAlign=top width="2%">&nbsp;</TD>
<TD vAlign=top width="13%">
<DIV align=center><FONT face="Times New Roman" size=2>175,458</FONT></DIV></TD>
<TD vAlign=top width="2%">
<DIV align=center></DIV></TD>
<TD vAlign=top align=center width="16%"><FONT face="Times New Roman" size=2>53,542</FONT></TD>
<TD vAlign=top width="4%">
<DIV align=right></DIV></TD>
<TD vAlign=top align=center width="10%">
<DIV align=center><FONT face="Times New Roman" size=2>$&nbsp;&nbsp;2,745,231</FONT></DIV></TD>
<TD vAlign=top width="1%">
<DIV align=right></DIV></TD>
<TD vAlign=top width="12%">
<DIV align=center><FONT face="Times New Roman" size=2>$&nbsp;&nbsp;&nbsp;868,024</FONT></DIV></TD></TR>
<TR>
<TD vAlign=top width="18%"><FONT face="Times New Roman" size=2><B>Vladimir E. Ostoich, Ph.D.</B></FONT></TD>
<TD vAlign=top align=center width="11%"><FONT face="Times New Roman" size=2>25,625</FONT></TD>
<TD vAlign=top width="2%">&nbsp;</TD>
<TD vAlign=top align=center width="9%"><FONT face="Times New Roman" size=2>$326,481</FONT></TD>
<TD vAlign=top width="2%">&nbsp;</TD>
<TD vAlign=top width="13%">
<DIV align=center><FONT face="Times New Roman" size=2>185,958</FONT></DIV></TD>
<TD vAlign=top width="2%">
<DIV align=center></DIV></TD>
<TD vAlign=top align=center width="16%"><FONT face="Times New Roman" size=2>53,542</FONT></TD>
<TD vAlign=top width="4%">
<DIV align=right></DIV></TD>
<TD vAlign=top align=center width="10%">
<DIV align=center><FONT face="Times New Roman" size=2>$&nbsp;&nbsp;2,846,026</FONT></DIV></TD>
<TD vAlign=top width="1%">
<DIV align=right></DIV></TD>
<TD vAlign=top width="12%">
<DIV align=center><FONT face="Times New Roman" size=2>$&nbsp;&nbsp;&nbsp;868,024</FONT></DIV></TD></TR>
</TABLE>

<BR>
<TABLE cellSpacing=0 cellPadding=0 width="100%">
<TR vAlign=top>
<TD align=left width="3%"><FONT face="Times New Roman, Times, Serif" size=2><SUP>(1)</SUP> </FONT></TD>
<TD width="97%">
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>Amounts shown under the column &#147;Value Realized&#148; are based on the fair market value of our common stock on the exercise date as reported on the Nasdaq National Market less the aggregate exercise price. </FONT></P>
</TD></TR>
</TABLE>

<BR>
<TABLE cellSpacing=0 cellPadding=0 width="100%">
<TR vAlign=top>
<TD align=left width="3%"><FONT face="Times New Roman, Times, Serif" size=2><SUP>(2)</SUP> </FONT></TD>
<TD width="97%">
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>Options to purchase our common stock generally vest as to one-fourth of the option grant on the first anniversary of the date of grant and 1/48 per month thereafter for each full month of the optionee&#146;s continuous employment with Abaxis. All options are exercisable only to the extent vested. </FONT></P>
</TD></TR>
</TABLE>

<BR>
<TABLE cellSpacing=0 cellPadding=0 width="100%">
<TR vAlign=top>
<TD align=left width="3%"><FONT face="Times New Roman, Times, Serif" size=2><SUP>(3)</SUP> </FONT></TD>
<TD width="97%">
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>The value of the unexercised in-the-money options is based on the reported closing price of our common stock ($20.32 per share) on the Nasdaq National Market on March&nbsp;31, 2004, the last trading day in our fiscal year ended March 31, 2004, and is net of the exercise price of such options. </FONT></P>
</TD></TR>
</TABLE>


<H1 align=left><FONT face="Times New Roman, Times, Serif" size=2>Compensation of Directors </FONT></H1>


<P><FONT face="Times New Roman, Times, Serif" size=2>In fiscal 2004, all of our non-employee directors received compensation in the amount of $2,258 per Board meeting they attended plus reimbursement of reasonable travel expenses incurred. Each of our non-employee directors also receives an automatic annual grant of options to purchase 4,000 shares of our common stock under our 1998 Stock Option Plan. </FONT></P>

<H1 align=left><FONT face="Times New Roman, Times, Serif" size=2>Change of Control Arrangements </FONT></H1>


<P><FONT face="Times New Roman, Times, Serif" size=2>Our 1998 Stock Option Plan and 1992 Outside Directors Stock Option Plan provide that, in the event of a transfer of control of Abaxis, the surviving, continuing, successor or purchasing corporation or a parent corporation thereof, as the case may be, which is referred to as the acquiring corporation, shall either assume our rights and obligations under stock option agreements outstanding under our option plans or substitute options for the acquiring corporation&#146;s stock for such outstanding options. In the event the acquiring corporation elects not to assume or substitute for such outstanding options in connection with a merger constituting a transfer of control, our Board shall provide that any unexercisable and/or unvested portion of the outstanding options shall be immediately exercisable and vested as of a date prior to the transfer of control, as our Board so determines. Any options which are neither assumed by the acquiring corporation,
nor exercised as of the date of the transfer of control, shall terminate effective as of the date of the transfer of control. Options which are assumed by the acquiring corporation shall become exercisable and vested as provided under the relevant stock option agreements under the option plans, unless the acquiring corporation terminates the option holder under certain circumstances defined in the option plans. Under such circumstances, the holder&#146;s options shall become immediately exercisable and vested as of the date of termination. </FONT></P>

<H1 align=left><FONT face="Times New Roman, Times, Serif" size=2>ITEM 12. &nbsp;SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT </FONT></H1>


<P><FONT face="Times New Roman, Times, Serif" size=2>The following table sets forth as of June 1, 2004 certain information with respect to the beneficial ownership of our common stock by (i) the persons named in the Summary Compensation Table; (ii) each of our directors, and (iii) all of our executive officers and directors as a group. There are no persons known to us that are the beneficial owners of more than 5% of our outstanding common stock. </FONT></P>

<TABLE width="100%">
<TR>
<TD align=center><FONT size=2>58</FONT></TD></TR>
</TABLE>



<P>
<HR align=left noshade SIZE=5>


<P>&nbsp;
<!-- *************************************************************************** -->
<!-- MARKER PAGE="sheet: 14; page: 14" -->
<TABLE cellSpacing=0 cellPadding=0 width="100%" border=0>
<TR vAlign=bottom>
<TD width="36%">
<DIV align=center><FONT face="Times New Roman" size=2><B>&nbsp;</B></FONT><FONT face="Times New Roman" size=2><B>&nbsp;</B></FONT><FONT face="Times New Roman" size=2><B>Name and Address of Beneficial Owner <SUP>(1)<BR></SUP></B></FONT></DIV>
<HR align=center noshade SIZE=1>
</TD>
<TD width="33%">&nbsp;</TD>
<TD width="13%">
<DIV align=center><FONT face="Times New Roman" size=2><B>Shares<BR>Beneficially<BR>Owned<BR></B></FONT></DIV>
<HR align=center noshade SIZE=1>
<FONT face="Times New Roman" size=2><B></B></FONT></TD>
<TD width="6%">&nbsp;</TD>
<TD width="12%">
<DIV align=center><FONT face="Times New Roman" size=2><B>Percent of Abaxis<BR>Common Stock<BR>Outstanding <SUP>(2)<BR></SUP></B></FONT></DIV>
<HR align=center noshade SIZE=1>
</TD></TR>
<TR>
<TD vAlign=top width="36%">&nbsp; </TD>
<TD vAlign=top width="33%">&nbsp;</TD>
<TD vAlign=top width="13%">&nbsp; </TD>
<TD vAlign=top width="6%">&nbsp;</TD>
<TD vAlign=top width="12%">&nbsp; </TD></TR>
<TR>
<TD vAlign=top width="36%"><FONT face="Times New Roman" size=2>Executive Officers</FONT></TD>
<TD vAlign=top width="33%">&nbsp;</TD>
<TD vAlign=top width="13%">
<DIV align=center></DIV></TD>
<TD vAlign=top width="6%">&nbsp;</TD>
<TD vAlign=top width="12%">
<DIV align=center></DIV></TD></TR>
<TR>
<TD vAlign=top width="36%" height=20><FONT face="Times New Roman" size=2>Clinton H. Severson <SUP>(3)</SUP></FONT></TD>
<TD vAlign=top width="33%" height=20>&nbsp;</TD>
<TD vAlign=top width="13%" height=20>
<DIV align=center><FONT face="Times New Roman" size=2>824,917</FONT></DIV></TD>
<TD vAlign=top width="6%" height=20>&nbsp;</TD>
<TD vAlign=top width="12%" height=20>
<DIV align=center><FONT face="Times New Roman" size=2>4.2%</FONT></DIV></TD></TR>
<TR>
<TD vAlign=top width="36%"><FONT face="Times New Roman" size=2>Vladimir E. Ostoich, Ph.D. <SUP>(4)</SUP></FONT></TD>
<TD vAlign=top width="33%">&nbsp;</TD>
<TD vAlign=top width="13%">
<DIV align=center><FONT face="Times New Roman" size=2>444,593</FONT></DIV></TD>
<TD vAlign=top width="6%">&nbsp;</TD>
<TD vAlign=top width="12%">
<DIV align=center><FONT face="Times New Roman" size=2>2.3%</FONT></DIV></TD></TR>
<TR>
<TD vAlign=top width="36%"><FONT face="Times New Roman" size=2>Robert B. Milder <SUP>(5)</SUP></FONT></TD>
<TD vAlign=top width="33%">&nbsp;</TD>
<TD vAlign=top width="13%">
<DIV align=center><FONT face="Times New Roman" size=2>238,860</FONT></DIV></TD>
<TD vAlign=top width="6%">&nbsp;</TD>
<TD vAlign=top width="12%">
<DIV align=center><FONT face="Times New Roman" size=2>1.2%</FONT></DIV></TD></TR>
<TR>
<TD vAlign=top width="36%"><FONT face="Times New Roman" size=2>Kenneth P. Aron, Ph.D. <SUP>(6)</SUP></FONT></TD>
<TD vAlign=top width="33%">&nbsp;</TD>
<TD vAlign=top width="13%">
<DIV align=center><FONT face="Times New Roman" size=2>173,631</FONT></DIV></TD>
<TD vAlign=top width="6%">&nbsp;</TD>
<TD vAlign=top width="12%">
<DIV align=center><FONT face="Times New Roman" size=2>*</FONT></DIV></TD></TR>
<TR>
<TD vAlign=top width="36%"><FONT face="Times New Roman" size=2>Alberto R. Santa Ines <SUP>(7)</SUP></FONT></TD>
<TD vAlign=top width="33%">&nbsp;</TD>
<TD vAlign=top width="13%">
<DIV align=center><FONT face="Times New Roman" size=2>90,565</FONT></DIV></TD>
<TD vAlign=top width="6%">&nbsp;</TD>
<TD vAlign=top width="12%">
<DIV align=center><FONT face="Times New Roman" size=2>*</FONT></DIV></TD></TR>
<TR>
<TD vAlign=top width="36%">&nbsp; </TD>
<TD vAlign=top width="33%">&nbsp;</TD>
<TD vAlign=top width="13%">
<DIV align=center></DIV></TD>
<TD vAlign=top width="6%">&nbsp;</TD>
<TD vAlign=top width="12%">
<DIV align=center></DIV></TD></TR>
<TR>
<TD vAlign=top width="36%"><FONT face="Times New Roman" size=2>Outside Directors</FONT></TD>
<TD vAlign=top width="33%">&nbsp;</TD>
<TD vAlign=top width="13%">
<DIV align=center></DIV></TD>
<TD vAlign=top width="6%">&nbsp;</TD>
<TD vAlign=top width="12%">
<DIV align=center></DIV></TD></TR>
<TR>
<TD vAlign=top width="36%"><FONT face="Times New Roman" size=2>Richard J. Bastiani, Ph.D. <SUP>(8)</SUP></FONT></TD>
<TD vAlign=top width="33%">&nbsp;</TD>
<TD vAlign=top width="13%">
<DIV align=center><FONT face="Times New Roman" size=2>65,333</FONT></DIV></TD>
<TD vAlign=top width="6%">&nbsp;</TD>
<TD vAlign=top width="12%">
<DIV align=center><FONT face="Times New Roman" size=2>*</FONT></DIV></TD></TR>
<TR>
<TD vAlign=top width="36%"><FONT face="Times New Roman" size=2>Ernest S. Tucker, III, M.D. <SUP>(9)</SUP></FONT></TD>
<TD vAlign=top width="33%">&nbsp;</TD>
<TD vAlign=top width="13%">
<DIV align=center><FONT face="Times New Roman" size=2>48,333</FONT></DIV></TD>
<TD vAlign=top width="6%">&nbsp;</TD>
<TD vAlign=top width="12%">
<DIV align=center><FONT face="Times New Roman" size=2>*</FONT></DIV></TD></TR>
<TR>
<TD vAlign=top width="36%"><FONT face="Times New Roman" size=2>Prithipal Singh, Ph.D. <SUP>(10)</SUP></FONT></TD>
<TD vAlign=top width="33%">&nbsp;</TD>
<TD vAlign=top width="13%">
<DIV align=center><FONT face="Times New Roman" size=2>38,000</FONT></DIV></TD>
<TD vAlign=top width="6%">&nbsp;</TD>
<TD vAlign=top width="12%">
<DIV align=center><FONT face="Times New Roman" size=2>*</FONT></DIV></TD></TR>
<TR>
<TD vAlign=top width="36%"><FONT face="Times New Roman" size=2>Brenton G. A. Hanlon <SUP>(11)</SUP></FONT></TD>
<TD vAlign=top width="33%">&nbsp;</TD>
<TD vAlign=top width="13%">
<DIV align=center><FONT face="Times New Roman" size=2>36,667</FONT></DIV></TD>
<TD vAlign=top width="6%">&nbsp;</TD>
<TD vAlign=top width="12%">
<DIV align=center><FONT face="Times New Roman" size=2>*</FONT></DIV></TD></TR>
<TR>
<TD vAlign=top width="36%"><FONT face="Times New Roman" size=2>Henk J. Evenhuis<SUP>(12)</SUP></FONT></TD>
<TD vAlign=top width="33%">&nbsp;</TD>
<TD vAlign=top width="13%">
<DIV align=center><FONT face="Times New Roman" size=2>6,667</FONT></DIV></TD>
<TD vAlign=top width="6%">&nbsp;</TD>
<TD vAlign=top width="12%">
<DIV align=center><FONT face="Times New Roman" size=2>*</FONT></DIV></TD></TR>
<TR>
<TD vAlign=top width="36%">&nbsp; </TD>
<TD vAlign=top width="33%">&nbsp;</TD>
<TD vAlign=top width="13%">
<DIV align=center></DIV></TD>
<TD vAlign=top width="6%">&nbsp;</TD>
<TD vAlign=top width="12%">
<DIV align=center></DIV></TD></TR>
<TR>
<TD vAlign=top width="36%"><FONT face="Times New Roman" size=2><B>Executive officers and directors as a group (10 persons)</B> <B><SUP>(13)</SUP></B></FONT></TD>
<TD vAlign=top width="33%">&nbsp;</TD>
<TD vAlign=top width="13%">
<DIV align=center><FONT face="Times New Roman" size=2>1,967,566</FONT></DIV></TD>
<TD vAlign=top width="6%">&nbsp;</TD>
<TD vAlign=top width="12%">
<DIV align=center><FONT face="Times New Roman" size=2>10.1%</FONT></DIV></TD></TR>
<TR>
<TD vAlign=top width="36%">&nbsp; </TD>
<TD vAlign=top width="33%">&nbsp;</TD>
<TD vAlign=top width="13%">&nbsp; </TD>
<TD vAlign=top width="6%">&nbsp;</TD>
<TD vAlign=top width="12%">&nbsp; </TD></TR>
</TABLE>


<P align=left><FONT face="Times New Roman, Times, Serif" size=2>* Less than 1% </FONT></P>

<!-- MARKER FORMAT-SHEET="Para (List) Hang Level 2" FSL="Default" -->
<TABLE cellSpacing=0 cellPadding=0 width="100%" border=0>
<TR>
<TD vAlign=top width="4%">

<P><FONT size=2><B><SUP>(1)</SUP></B></FONT></P>
</TD>
<TD vAlign=top colSpan=2>
<P align=left><FONT size=2>The persons named in the table above have sole voting and investment power with respect to all shares of Common Stock shown as beneficially owned by them, subject to community property laws where applicable and to the information contained in the footnotes to this table. The business address of each of the beneficial owners listed is c/o Abaxis, Inc., 3240 Whipple Road, Union City, CA 94587.</FONT></P>
</TD></TR>
<TR>
<TD vAlign=top width="4%">&nbsp;</TD>
<TD vAlign=top colSpan=2>&nbsp;</TD></TR>
<TR>
<TD vAlign=top width="4%">

<P><FONT size=2><B><SUP>(2)</SUP></B></FONT></P>
</TD>
<TD vAlign=top colSpan=2>
<P align=left><FONT size=2>The percentages shown in this column are calculated from the 19,520,237 shares of common stock outstanding on March 31, 2004, exercise of warrants and options held by that person that are currently exercisable or which are exercisable within sixty calendar days of June 1, 2004, and are deemed outstanding in accordance with the rules of the Securities and Exchange Commission.</FONT></P>
</TD></TR>
<TR>
<TD vAlign=top width="4%">&nbsp;</TD>
<TD vAlign=top colSpan=2>&nbsp;</TD></TR>
<TR>
<TD vAlign=top width="4%">

<P><FONT size=2><B><SUP>(3)</SUP></B></FONT></P>
</TD>
<TD vAlign=top colSpan=2>

<P><FONT size=2>Includes:<FONT size=1> </FONT></FONT></P>
</TD></TR>
<TR>
<TD vAlign=top width="4%">&nbsp;</TD>
<TD vAlign=top align=right width="3%"><FONT size=2>&#149;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD vAlign=top width="93%"><FONT size=2>163,517 shares;</FONT></TD></TR>
<TR>
<TD vAlign=top width="4%">&nbsp;</TD>
<TD vAlign=top align=right width="3%"><FONT size=2>&#149;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD vAlign=top width="93%"><FONT size=2>9,900 shares issuable upon the exercise of warrants; and</FONT></TD></TR>
<TR>
<TD vAlign=top width="4%">&nbsp;</TD>
<TD vAlign=top align=right width="3%"><FONT size=2>&#149;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD vAlign=top width="93%"><FONT size=2>651,500 shares subject to stock options exercisable by Mr.&nbsp;Severson within sixty days of June 1, 2004.</FONT></TD></TR>
<TR>
<TD vAlign=top width="4%">&nbsp;</TD>
<TD vAlign=top colSpan=2>&nbsp;</TD></TR>
<TR>
<TD vAlign=top width="4%">

<P><FONT size=2><B><SUP>(4) </SUP></B></FONT></P>
</TD>
<TD vAlign=top colSpan=2>

<P><FONT size=2>Includes:<FONT size=1> </FONT></FONT></P>
</TD></TR>
<TR>
<TD vAlign=top width="4%">&nbsp;</TD>
<TD vAlign=top align=right width="3%"><FONT size=2>&#149;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD vAlign=top width="93%"><FONT size=2>56,040 shares;</FONT></TD></TR>
<TR>
<TD vAlign=top width="4%">&nbsp;</TD>
<TD vAlign=top align=right width="3%"><FONT size=2>&#149;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD vAlign=top width="93%"><FONT size=2>31,500 shares held by Dr.&nbsp;Ostoich&#146;s IRA;</FONT></TD></TR>
<TR>
<TD vAlign=top width="4%">&nbsp;</TD>
<TD vAlign=top align=right width="3%"><FONT size=2>&#149;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD vAlign=top width="93%"><FONT size=2>29,500 shares held by Mrs.&nbsp;Ostoich&#146;s IRA;</FONT></TD></TR>
<TR>
<TD vAlign=top width="4%">&nbsp;</TD>
<TD vAlign=top align=right width="3%"><FONT size=2>&#149;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD vAlign=top width="93%"><FONT size=2>117,328 shares held by the Vladimir Ostoich and Liliana Ostoich Trust Fund, for the benefit of Dr.&nbsp;Ostoich and his wife;</FONT></TD></TR>
<TR>
<TD vAlign=top width="4%">&nbsp;</TD>
<TD vAlign=top align=right width="3%"><FONT size=2>&#149;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD vAlign=top width="93%"><FONT size=2>7,600 shares issuable upon the exercise of warrants; and</FONT></TD></TR>
<TR>
<TD vAlign=top width="4%">&nbsp;</TD>
<TD vAlign=top align=right width="3%"><FONT size=2>&#149;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD vAlign=top width="93%"><FONT size=2>202,625 shares subject to stock options exercisable by Dr.&nbsp;Ostoich within sixty days of June 1, 2004.</FONT></TD></TR>
<TR>
<TD vAlign=top width="4%">&nbsp;</TD>
<TD vAlign=top colSpan=2>&nbsp;</TD></TR>
<TR>
<TD vAlign=top width="4%">

<P><FONT size=2><B><SUP>(5)</SUP></B></FONT></P>
</TD>
<TD vAlign=top colSpan=2>
<P align=left><FONT size=2>Includes: <FONT size=1></FONT></FONT></P>
</TD></TR>
<TR>
<TD vAlign=top width="4%">&nbsp;</TD>
<TD vAlign=top align=right width="3%"><FONT size=2>&#149;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD vAlign=top width="93%"><FONT size=2>46,735 shares;</FONT></TD></TR>
<TR>
<TD vAlign=top width="4%">&nbsp;</TD>
<TD vAlign=top align=right width="3%"><FONT size=2>&#149;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD vAlign=top width="93%"><FONT size=2>192,125 shares subject to stock options exercisable by Mr.&nbsp;Milder within sixty days of June 1, 2004.</FONT></TD></TR>
<TR>
<TD vAlign=top width="4%">&nbsp;</TD>
<TD vAlign=top colSpan=2>&nbsp;</TD></TR>
<TR>
<TD vAlign=top width="4%">

<P><FONT size=2><B><SUP>(6)</SUP></B></FONT></P>
</TD>
<TD vAlign=top colSpan=2>
<P align=left><FONT size=2>Includes:</FONT> <FONT size=2><FONT size=1></FONT></FONT></P>
</TD></TR>
<TR>
<TD vAlign=top width="4%">&nbsp;</TD>
<TD vAlign=top align=right width="3%"><FONT size=2>&#149;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD vAlign=top width="93%"><FONT size=2>9,131 shares;</FONT></TD></TR>
<TR>
<TD vAlign=top width="4%">&nbsp;</TD>
<TD vAlign=top align=right width="3%"><FONT size=2>&#149;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD vAlign=top width="93%"><FONT size=2>164,500 shares subject to stock options exercisable by Dr.&nbsp;Aron within sixty days of June 1, 2004.</FONT></TD></TR>
<TR>
<TD vAlign=top width="4%">&nbsp;</TD>
<TD vAlign=top colSpan=2>&nbsp;</TD></TR>
<TR>
<TD vAlign=top width="4%">

<P><FONT size=2><B><SUP>(7)</SUP></B></FONT></P>
</TD>
<TD vAlign=top colSpan=2>

<P><FONT size=2>Includes: <FONT size=1></FONT></FONT></P>
</TD></TR>
<TR>
<TD vAlign=top width="4%">&nbsp;</TD>
<TD vAlign=top align=right width="3%"><FONT size=2>&#149;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD vAlign=top width="93%"><FONT size=2>17,815 shares;</FONT></TD></TR>
<TR>
<TD vAlign=top width="4%">&nbsp;</TD>
<TD vAlign=top align=right width="3%"><FONT size=2>&#149;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD vAlign=top width="93%"><FONT size=2>72,750 shares subject to stock options exercisable by Mr.&nbsp;Santa Ines within sixty days of June 1, 2004.</FONT></TD></TR>
<TR>
<TD vAlign=top width="4%">&nbsp;</TD>
<TD vAlign=top colSpan=2>&nbsp;</TD></TR>
<TR>
<TD vAlign=top width="4%">

<P><FONT size=2><B><SUP>(8)</SUP></B></FONT></P>
</TD>
<TD vAlign=top colSpan=2>

<P><FONT size=2>Includes: <FONT size=1></FONT></FONT></P>
</TD></TR>
<TR>
<TD vAlign=top width="4%">&nbsp;</TD>
<TD vAlign=top align=right width="3%"><FONT size=2>&#149;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD vAlign=top width="93%"><FONT size=2>42,000 shares;</FONT></TD></TR>
<TR>
<TD vAlign=top width="4%">&nbsp;</TD>
<TD vAlign=top align=right width="3%"><FONT size=2>&#149;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD vAlign=top width="93%"><FONT size=2>23,333 shares subject to stock options exercisable by Dr.&nbsp;Bastiani within sixty days of June 1, 2004.</FONT></TD></TR>
<TR>
<TD vAlign=top width="4%">&nbsp;</TD>
<TD vAlign=top colSpan=2>&nbsp;</TD></TR>
<TR>
<TD vAlign=top width="4%">

<P><FONT size=2><B><SUP>(9)</SUP></B></FONT></P>
</TD>
<TD vAlign=top colSpan=2>

<P><FONT size=2>Includes 48,333 shares subject to stock options exercisable by Dr.&nbsp;Tucker within sixty days of June 1, 2004.</FONT></P>
</TD></TR>
<TR>
<TD vAlign=top width="4%">&nbsp;</TD>
<TD vAlign=top colSpan=2>&nbsp;</TD></TR>
<TR>
<TD vAlign=top width="4%">

<P><FONT size=2><B><SUP>(10)</SUP></B></FONT></P>
</TD>
<TD vAlign=top colSpan=2>

<P><FONT size=2>Includes: <FONT size=1></FONT></FONT></P>
</TD></TR>
<TR>
<TD vAlign=top width="4%">&nbsp;</TD>
<TD vAlign=top align=right width="3%"><FONT size=2>&#149;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD vAlign=top width="93%"><FONT size=2>16,000 shares;</FONT></TD></TR>
<TR>
<TD vAlign=top width="4%">&nbsp;</TD>
<TD vAlign=top align=right width="3%"><FONT size=2>&#149;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD vAlign=top width="93%"><FONT size=2>22,000 shares subject to stock options exercisable by Dr.&nbsp;Singh within sixty days of June 1, 2004.</FONT></TD></TR>
</TABLE>

<BR><BR>
<TABLE width="100%">
<TR>
<TD align=center><FONT size=2>59</FONT></TD></TR>
</TABLE>



<P>
<HR align=left noshade SIZE=5>


<P>&nbsp;
<!-- *************************************************************************** -->
<!-- MARKER PAGE="sheet: 14; page: 14" -->
<TABLE cellSpacing=0 cellPadding=0 width="100%" border=0>
<TR>
<TD vAlign=top width="4%">

<P><FONT size=2><B><SUP>(11)</SUP></B></FONT></P>
</TD>
<TD vAlign=top colSpan=2>

<P><FONT size=2>Includes: <FONT size=1></FONT></FONT></P>
</TD></TR>
<TR>
<TD vAlign=top width="4%">&nbsp;</TD>
<TD vAlign=top align=right width="3%"><FONT size=2>&#149;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD vAlign=top width="93%"><FONT size=2>14,000 shares;</FONT></TD></TR>
<TR>
<TD vAlign=top width="4%">&nbsp;</TD>
<TD vAlign=top align=right width="3%"><FONT size=2>&#149;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD vAlign=top width="93%"><FONT size=2>22,667 shares subject to stock options exercisable by Mr.&nbsp;Hanlon within sixty days of June 1, 2004.</FONT></TD></TR>
<TR>
<TD vAlign=top width="4%">&nbsp;</TD>
<TD vAlign=top colSpan=2>&nbsp;</TD></TR>
<TR>
<TD vAlign=top width="4%">

<P><FONT size=2><B><SUP>&nbsp;(12)</SUP></B></FONT></P>
</TD>
<TD vAlign=top colSpan=2>

<P><FONT size=2>Includes 6,667 shares subject to stock options exercisable by Mr.&nbsp;Evenhuis within sixty days of June 1, 2004.</FONT></P>
</TD></TR>
<TR>
<TD vAlign=top width="4%">

<P><FONT size=2><B><SUP></SUP></B></FONT>&nbsp;</P>
</TD>
<TD vAlign=top colSpan=2>

<P>&nbsp;</P>
</TD></TR>
<TR>
<TD vAlign=top width="4%">

<P><FONT size=2><B><SUP>(13)</SUP></B></FONT></P>
</TD>
<TD vAlign=top colSpan=2>

<P><FONT size=2>Includes: <FONT size=1></FONT></FONT></P>
</TD></TR>
<TR>
<TD vAlign=top width="4%">&nbsp;</TD>
<TD vAlign=top align=right width="3%"><FONT size=2>&#149;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD vAlign=top width="93%"><FONT size=2>543,566 shares;</FONT></TD></TR>
<TR>
<TD vAlign=top width="4%">&nbsp;</TD>
<TD vAlign=top align=right width="3%"><FONT size=2>&#149;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD vAlign=top width="93%"><FONT size=2>17,500 shares issuable upon the exercise of warrants held individually; and</FONT></TD></TR>
<TR>
<TD vAlign=top width="4%">&nbsp;</TD>
<TD vAlign=top align=right width="3%"><FONT size=2>&#149;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD vAlign=top width="93%"><FONT size=2>1,406,500 shares subject to options exercisable within sixty days of June 1, 2004.</FONT></TD></TR>
</TABLE>


<H2><FONT face="Times New Roman, Times, Serif" size=2>ITEM 13. &nbsp;CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS </FONT></H2>

<P align=left><FONT face="Times New Roman, Times, Serif" size=2>None. </FONT></P>

<!-- MARKER FORMAT-SHEET="Head Sub 1 Left" FSL="Default" -->
<H1 align=left><FONT face="Times New Roman, Times, Serif" size=2>ITEM 14.&nbsp; PRINCIPAL ACCOUNTANT FEES AND SERVICES </FONT></H1>


<P><FONT face="Times New Roman, Times, Serif" size=2>The following table sets forth the aggregate fees billed to Abaxis for fiscal 2004 and 2003 by Deloitte &amp; Touche LLP: </FONT></P>

<TABLE cellSpacing=0 cellPadding=0 width="100%" border=0>
<TR>
<TD vAlign=top width="15%">&nbsp;</TD>
<TD vAlign=bottom width="35%">&nbsp;</TD>
<TD vAlign=bottom align=center colSpan=4><FONT face="Times New Roman" size=2><B><U>Year Ended March 31,</U></B></FONT></TD>
<TD vAlign=top width="18%">&nbsp;</TD></TR>
<TR>
<TD vAlign=top width="15%">

<P>&nbsp;</P>
</TD>
<TD vAlign=bottom width="35%">&nbsp;</TD>
<TD vAlign=bottom align=center colSpan=2>
<P align=center><FONT face="Times New Roman" size=2><B><U>2004</U></B></FONT></P>
</TD>
<TD vAlign=bottom align=center colSpan=2>
<P align=center><FONT face="Times New Roman" size=2><B><U>200</U></B><B><U>3</U></B></FONT></P>
</TD>
<TD vAlign=top width="18%">&nbsp;</TD></TR>
<TR>
<TD vAlign=top width="15%">&nbsp;</TD>
<TD vAlign=bottom colSpan=5>
<HR noshade SIZE=1>
</TD>
<TD vAlign=top width="18%">&nbsp;</TD></TR>
<TR>
<TD vAlign=top width="15%">&nbsp;</TD>
<TD vAlign=bottom width="35%">

<P><FONT face="Times New Roman" size=2>Audit Fees</FONT></P>
</TD>
<TD vAlign=bottom align=right width="11%"><FONT face="Times New Roman" size=2>$ 241,000</FONT></TD>
<TD vAlign=bottom align=center width="6%">&nbsp;</TD>
<TD vAlign=bottom align=right width="10%"><FONT face="Times New Roman" size=2>$ 238,000</FONT></TD>
<TD vAlign=bottom align=center width="5%">&nbsp;</TD>
<TD vAlign=top width="18%">&nbsp;</TD></TR>
<TR>
<TD vAlign=top width="15%">&nbsp;</TD>
<TD vAlign=bottom width="35%">

<P><FONT face="Times New Roman" size=2>Audit-Related Fees</FONT></P>
</TD>
<TD vAlign=bottom align=right width="11%"><FONT face="Times New Roman" size=2>9,000</FONT></TD>
<TD vAlign=bottom align=center width="6%">&nbsp;</TD>
<TD vAlign=bottom align=right width="10%"><FONT face="Times New Roman" size=2>67,000</FONT></TD>
<TD vAlign=bottom align=center width="5%">&nbsp;</TD>
<TD vAlign=top width="18%">&nbsp;</TD></TR>
<TR>
<TD vAlign=top width="15%">&nbsp;</TD>
<TD vAlign=bottom width="35%">

<P><FONT face="Times New Roman" size=2>Tax Fees</FONT></P>
</TD>
<TD vAlign=bottom align=right width="11%"><FONT face="Times New Roman" size=2>86,000</FONT></TD>
<TD vAlign=bottom align=center width="6%">&nbsp;</TD>
<TD vAlign=bottom align=right width="10%"><FONT face="Times New Roman" size=2>90,000</FONT></TD>
<TD vAlign=bottom align=center width="5%">&nbsp;</TD>
<TD vAlign=top width="18%">&nbsp;</TD></TR>
<TR>
<TD vAlign=top width="15%">&nbsp;</TD>
<TD vAlign=bottom width="35%">

<P><FONT face="Times New Roman" size=2>All Other Fees</FONT></P>
</TD>
<TD vAlign=bottom align=right width="11%"><FONT face="Times New Roman" size=2>8,000</FONT></TD>
<TD vAlign=bottom align=center width="6%">&nbsp;</TD>
<TD vAlign=bottom align=right width="10%"><FONT face="Times New Roman" size=2>-</FONT></TD>
<TD vAlign=bottom align=center width="5%">&nbsp;</TD>
<TD vAlign=top width="18%">&nbsp;</TD></TR>
<TR>
<TD vAlign=top width="15%">&nbsp;</TD>
<TD vAlign=bottom colSpan=5>
<HR noshade SIZE=1>
</TD>
<TD vAlign=top width="18%">&nbsp;</TD></TR>
<TR>
<TD vAlign=top width="15%">&nbsp;</TD>
<TD vAlign=bottom width="35%">

<P><FONT face="Times New Roman" size=2>Total All Fees</FONT></P>
</TD>
<TD vAlign=bottom align=right width="11%"><FONT face="Times New Roman" size=2>$ 344,000</FONT></TD>
<TD vAlign=bottom align=center width="6%">&nbsp;</TD>
<TD vAlign=bottom align=right width="10%"><FONT face="Times New Roman" size=2>$ 395,000</FONT></TD>
<TD vAlign=bottom align=center width="5%">&nbsp;</TD>
<TD vAlign=top width="18%">&nbsp;</TD></TR>
<TR>
<TD vAlign=top width="15%">&nbsp;</TD>
<TD vAlign=bottom colSpan=5>
<HR noshade SIZE=1>
</TD>
<TD vAlign=top width="18%">&nbsp;</TD></TR>
</TABLE>



<P><FONT face="Times New Roman, Times, Serif" size=2>&#147;Audit-related fees&#148; billed during fiscal 2004 and 2003 were for services related to accounting consultation and review of documents filed with the Securities and Exchange Commission. &#147;Tax Fees&#148; consist of fees billed for professional services rendered for preparation and review of income tax returns, tax compliance and tax advice. &#147;All Other Fees&#148; consist of fees for products and services other than the services reported above. In fiscal 2004, this category included fees related to an informational workshop on internal controls. </FONT></P>


<P><FONT face="Times New Roman, Times, Serif" size=2>The Audit Committee has adopted a policy for the pre-approval of all audit and non-audit services to be performed for the Company by its independent auditor. The Audit Committee has considered the role of Deloitte &amp; Touche LLP in providing audit, audit-related and tax services to Abaxis and has concluded that such services are compatible with Deloitte &amp; Touche&#146;s role as Abaxis&#146; independent auditor. </FONT></P>

<H1 align=center><FONT face="Times New Roman, Times, Serif" size=2>PART IV </FONT></H1>

<H1><FONT size=2>ITEM 15. EXHIBITS, FINANCIAL STATEMENT SCHEDULES AND REPORTS ON FORM 8-K </FONT></H1>


<P>
<!-- MARKER FORMAT-SHEET="Para (List) Hang " FSL="Default" --></P>

<TABLE cellSpacing=0 cellPadding=0 width="100%">
<TR vAlign=top>
<TD align=left width="3%"><FONT face="Times New Roman, Times, Serif" size=2>(a) </FONT></TD>
<TD width="97%">
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp; List of documents filed as part of this report: </FONT></P>
</TD></TR>
</TABLE>

<BR>
<!-- MARKER FORMAT-SHEET="Para (List) Hang Level 2" FSL="Default" -->
<TABLE cellSpacing=0 cellPadding=0 width="100%">
<TR vAlign=top>
<TD align=right width="6%"><FONT face="Times New Roman, Times, Serif" size=2>1. </FONT></TD>
<TD align=left width="3%"><FONT face="Times New Roman, Times, Serif" size=2>&nbsp; </FONT></TD>
<TD width="91%">
<P align=left><FONT face="Times New Roman, Times, Serif" size=2><I>Financial Statements </I></FONT></P>
</TD></TR>
</TABLE>

<BR>
<!-- MARKER FORMAT-SHEET="Para (List) Hang Level 2" FSL="Default" -->
<TABLE cellSpacing=0 cellPadding=0 width="100%">
<TR vAlign=top>
<TD align=right width="6%"><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
<TD align=left width="3%"><FONT face="Times New Roman, Times, Serif" size=2>&nbsp; </FONT></TD>
<TD width="91%">
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>Reference is made to the Index to Financial Statements under Item 8 of Part II of this report, where these documents are included. </FONT></P>
</TD></TR>
</TABLE>

<BR>
<!-- MARKER FORMAT-SHEET="Para (List) Hang Level 2" FSL="Default" -->
<TABLE cellSpacing=0 cellPadding=0 width="100%">
<TR vAlign=top>
<TD align=right width="6%"><FONT face="Times New Roman, Times, Serif" size=2>2. </FONT></TD>
<TD align=left width="3%"><FONT face="Times New Roman, Times, Serif" size=2>&nbsp; </FONT></TD>
<TD width="91%">
<P align=left><FONT face="Times New Roman, Times, Serif" size=2><I>Financial Statement Schedules </I></FONT></P>
</TD></TR>
</TABLE>

<BR>
<!-- MARKER FORMAT-SHEET="Para (List) Hang Level 2" FSL="Default" -->
<TABLE cellSpacing=0 cellPadding=0 width="100%">
<TR vAlign=top>
<TD align=right width="6%"><FONT face="Times New Roman, Times, Serif" size=2><I></I></FONT></TD>
<TD align=left width="3%"><FONT face="Times New Roman, Times, Serif" size=2>&nbsp; </FONT></TD>
<TD width="91%">
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>Report of Independent Registered Public Accounting Firm </FONT></P>
</TD></TR>
</TABLE>

<BR>
<!-- MARKER FORMAT-SHEET="Para (List) Hang Level 2" FSL="Default" -->
<TABLE cellSpacing=0 cellPadding=0 width="100%">
<TR vAlign=top>
<TD align=right width="6%"></TD>
<TD align=left width="3%"><FONT face="Times New Roman, Times, Serif" size=2>&nbsp; </FONT></TD>
<TD width="91%">
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>Schedule II &#150; Valuation and Qualifying Accounts and Reserves </FONT></P>
</TD></TR>
</TABLE>

<BR>
<TABLE width="100%">
<TR>
<TD align=center><FONT size=2>60</FONT></TD></TR>
</TABLE>



<P>
<HR align=left noshade SIZE=5>


<P>&nbsp;
<!-- *************************************************************************** -->
<!-- MARKER PAGE="sheet: 14; page: 14" --></P>


<P>&nbsp;
<!-- *************************************************************************** -->
<TABLE cellSpacing=0 cellPadding=0 width="100%">
<TR vAlign=top>
<TD width="5%"><FONT face="Times New Roman, Times, Serif" size=2>&nbsp; </FONT></TD>
<TD width="95%"><FONT face="Times New Roman, Times, Serif" size=2>Other financial statement schedules are not included because they are not required or the information is otherwise shown in the financial statements or notes thereto. </FONT></TD></TR>
</TABLE>

<BR>
<!-- MARKER FORMAT-SHEET="Para Flush Level 1" FSL="Default" -->
<TABLE cellSpacing=0 cellPadding=0 width="100%">
<TR vAlign=top>
<TD width="5%"><FONT face="Times New Roman, Times, Serif" size=2>&nbsp; </FONT></TD>
<TD width="95%"><FONT face="Times New Roman, Times, Serif" size=2>3.&nbsp;<I>Exhibits filed with this Report on Form 10-K</I> </FONT></TD></TR>
</TABLE>

<BR>
<!-- MARKER FORMAT-SHEET="Para Flush Level 1" FSL="Default" -->
<TABLE cellSpacing=0 cellPadding=0 width="100%">
<TR vAlign=top>
<TD width="5%"><FONT face="Times New Roman, Times, Serif" size=2>&nbsp; </FONT></TD>
<TD width="95%"><FONT face="Times New Roman, Times, Serif" size=2>The exhibits listed on the accompanying Exhibit Index are filed as part of, or are incorporated by reference into, this report. </FONT></TD></TR>
</TABLE>

<BR>
<!-- MARKER FORMAT-SHEET="Para Hang" FSL="Default" -->
<TABLE cellSpacing=0 cellPadding=0 width="100%">
<TR vAlign=top>
<TD width="5%"><FONT face="Times New Roman, Times, Serif" size=2>(b) </FONT></TD>
<TD colSpan=2><FONT face="Times New Roman, Times, Serif" size=2>Reports on Form 8-K </FONT></TD></TR>
</TABLE>

<BR>
<!-- MARKER FORMAT-SHEET="Para Flush Level 1" FSL="Default" -->
<TABLE cellSpacing=0 cellPadding=0 width="100%">
<TR vAlign=top>
<TD width="5%"><FONT face="Times New Roman, Times, Serif" size=2>&nbsp; </FONT></TD>
<TD width="95%"><FONT face="Times New Roman, Times, Serif" size=2>On January 29, 2004, we filed a Current Report on Form 8-K to release our quarterly earnings announcement. </FONT></TD></TR>
</TABLE>

<BR>
<TABLE width="100%">
<TR>
<TD align=center><FONT size=2>61</FONT></TD></TR>
</TABLE>



<P>
<HR align=left noshade SIZE=5>


<P>&nbsp;
<!-- *************************************************************************** -->
<!-- MARKER PAGE="sheet: 14; page: 14" -->
<H1 align=center><FONT face="Times New Roman, Times, Serif" size=2>SIGNATURES </FONT></H1>


<P><FONT face="Times New Roman, Times, Serif" size=2>Pursuant to the requirements of Section&nbsp;13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized, on June 14, 2004. </FONT></P>

<TABLE width="100%" border=0>
<TR>
<TD width="56%"></TD>
<TD width="10%"></TD>
<TD width="2%"></TD>
<TD width="32%"><FONT face="Times New Roman" size=2>ABAXIS, INC.</FONT></TD></TR>
<TR>
<TD width="56%"></TD>
<TD vAlign=top align=right width="10%"><FONT face="Times New Roman" size=2>BY</FONT></TD>
<TD vAlign=top width="2%"></TD>
<TD vAlign=top width="32%"><FONT face="Times New Roman" size=2>/s/ Clinton H. Severson<BR></FONT>
<HR noshade SIZE=1>
</TD></TR>
<TR>
<TD width="56%"></TD>
<TD width="10%"></TD>
<TD width="2%"></TD>
<TD width="32%"><FONT face="Times New Roman" size=2>Clinton H. Severson</FONT></TD></TR>
<TR>
<TD width="56%"></TD>
<TD width="10%"></TD>
<TD width="2%"></TD>
<TD width="32%"><FONT face="Times New Roman" size=2>Chairman of the Board, President and Chief Executive Officer</FONT></TD></TR>
</TABLE>



<P><FONT face="Times New Roman" size=2>Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.</FONT></P>

<TABLE cellSpacing=0 cellPadding=0 width="100%" border=0>
<TR>
<TD vAlign=top align=center colSpan=3><FONT face="Times New Roman" size=2><B>Signature</B></FONT></TD>
<TD vAlign=top width="1%">&nbsp;</TD>
<TD vAlign=top width="36%"><FONT face="Times New Roman" size=2><B>Title</B></FONT></TD>
<TD vAlign=top width="7%"></TD>
<TD vAlign=top align=center width="32%"><FONT face="Times New Roman" size=2><B>Date</B></FONT></TD></TR>
<TR>
<TD vAlign=top colSpan=7>
<HR noshade SIZE=1>
</TD></TR>
<TR>
<TD vAlign=bottom colSpan=3><FONT face="Times New Roman" size=2>/s/ Clinton H. Severson</FONT>
<HR noshade SIZE=1>
</TD>
<TD vAlign=top width="1%">&nbsp;</TD>
<TD vAlign=top width="36%"><FONT face="Times New Roman" size=2>President, Chief Executive Officer and<BR>Director (Principal Executive Officer)</FONT></TD>
<TD vAlign=top width="7%"></TD>
<TD vAlign=top align=center width="32%"><FONT face="Times New Roman" size=2>June&nbsp;14, 2004</FONT></TD></TR>
<TR>
<TD vAlign=bottom colSpan=3><FONT face="Times New Roman" size=2>Clinton H. Severson</FONT></TD>
<TD vAlign=top width="1%">&nbsp;</TD>
<TD vAlign=top width="36%"></TD>
<TD vAlign=top width="7%"></TD>
<TD vAlign=top align=center width="32%"></TD></TR>
<TR>
<TD vAlign=bottom colSpan=3></TD>
<TD vAlign=top width="1%"></TD>
<TD vAlign=top width="36%"></TD>
<TD vAlign=top width="7%"></TD>
<TD vAlign=top align=center width="32%"></TD></TR>
<TR>
<TD vAlign=bottom colSpan=3>&nbsp;</TD>
<TD vAlign=top width="1%">&nbsp;</TD>
<TD vAlign=top width="36%">&nbsp;</TD>
<TD vAlign=top width="7%">&nbsp;</TD>
<TD vAlign=top align=center width="32%">&nbsp;</TD></TR>
<TR>
<TD vAlign=bottom colSpan=3><FONT face="Times New Roman" size=2>&nbsp;</FONT><FONT face="Times New Roman" size=2>/s/ Alberto R. Santa Ines<BR></FONT>
<HR noshade SIZE=1>
<FONT face="Times New Roman" size=2></FONT></TD>
<TD vAlign=top width="1%">&nbsp;</TD>
<TD vAlign=top width="36%"><FONT face="Times New Roman" size=2>Chief Financial Officer and</FONT><FONT face="Times New Roman" size=2><BR>Vice President of Finance (Principal<BR>Financial and Accounting Officer)</FONT></TD>
<TD vAlign=top width="7%">&nbsp;</TD>
<TD vAlign=top align=center width="32%"><FONT face="Times New Roman" size=2>June&nbsp;14, 2004</FONT></TD></TR>
<TR>
<TD vAlign=bottom colSpan=3 height=13><FONT face="Times New Roman" size=2>Alberto R. Santa Ines</FONT></TD>
<TD vAlign=top width="1%" height=13>&nbsp;</TD>
<TD vAlign=top width="36%" height=13></TD>
<TD vAlign=top width="7%" height=13></TD>
<TD vAlign=middle align=center width="32%" height=13><FONT face="Times New Roman" size=2>&nbsp;</FONT></TD></TR>
<TR>
<TD vAlign=bottom colSpan=3></TD>
<TD vAlign=top width="1%"></TD>
<TD vAlign=top width="36%"></TD>
<TD vAlign=top width="7%"></TD>
<TD vAlign=middle align=center width="32%"></TD></TR>
<TR>
<TD vAlign=bottom colSpan=3>&nbsp;</TD>
<TD vAlign=top width="1%">&nbsp;</TD>
<TD vAlign=top width="36%">&nbsp;</TD>
<TD vAlign=top width="7%"></TD>
<TD vAlign=middle align=center width="32%">&nbsp;</TD></TR>
<TR>
<TD vAlign=bottom colSpan=3><FONT face="Times New Roman" size=2>/s/ Richard J. Bastiani, Ph.D.<BR></FONT>
<HR noshade SIZE=1>
</TD>
<TD vAlign=top width="1%">&nbsp;</TD>
<TD vAlign=top width="36%"><FONT face="Times New Roman" size=2>Director</FONT></TD>
<TD vAlign=top width="7%"></TD>
<TD vAlign=top align=center width="32%"><FONT face="Times New Roman" size=2>June&nbsp;14, 2004</FONT></TD></TR>
<TR>
<TD vAlign=bottom colSpan=3><FONT face="Times New Roman" size=2>Richard Bastiani</FONT></TD>
<TD vAlign=top width="1%">&nbsp;</TD>
<TD vAlign=top width="36%"></TD>
<TD vAlign=top width="7%"></TD>
<TD vAlign=top align=center width="32%"></TD></TR>
<TR>
<TD vAlign=bottom colSpan=3></TD>
<TD vAlign=top width="1%"></TD>
<TD vAlign=top width="36%"></TD>
<TD vAlign=top width="7%"></TD>
<TD vAlign=top align=center width="32%"></TD></TR>
<TR>
<TD vAlign=bottom colSpan=3>&nbsp;</TD>
<TD vAlign=top width="1%">&nbsp;</TD>
<TD vAlign=top width="36%">&nbsp;</TD>
<TD vAlign=top width="7%"></TD>
<TD vAlign=top align=center width="32%">&nbsp;</TD></TR>
<TR>
<TD vAlign=bottom colSpan=3><FONT face="Times New Roman" size=2>/s/ Henk J. Evenhuis<BR></FONT>
<HR noshade SIZE=1>
</TD>
<TD vAlign=top width="1%">&nbsp;</TD>
<TD vAlign=top width="36%"><FONT face="Times New Roman" size=2>Director</FONT></TD>
<TD vAlign=top width="7%"></TD>
<TD vAlign=top align=center width="32%"><FONT face="Times New Roman" size=2>June&nbsp;14, 2004</FONT></TD></TR>
<TR>
<TD vAlign=bottom colSpan=3><FONT face="Times New Roman" size=2>Henk J. Evenhuis </FONT></TD>
<TD vAlign=top width="1%">&nbsp;</TD>
<TD vAlign=top width="36%"></TD>
<TD vAlign=top width="7%"></TD>
<TD vAlign=top align=center width="32%"></TD></TR>
<TR>
<TD vAlign=bottom colSpan=3></TD>
<TD vAlign=top width="1%"></TD>
<TD vAlign=top width="36%"></TD>
<TD vAlign=top width="7%"></TD>
<TD vAlign=top align=center width="32%"></TD></TR>
<TR>
<TD vAlign=bottom colSpan=3>&nbsp;</TD>
<TD vAlign=top width="1%">&nbsp;</TD>
<TD vAlign=top width="36%">&nbsp;</TD>
<TD vAlign=top width="7%"></TD>
<TD vAlign=top align=center width="32%">&nbsp;</TD></TR>
<TR>
<TD vAlign=bottom colSpan=3><FONT face="Times New Roman" size=2>/s/ Brenton G. A. Hanlon<BR></FONT>
<HR noshade SIZE=1>
</TD>
<TD vAlign=top width="1%">&nbsp;</TD>
<TD vAlign=top width="36%"><FONT face="Times New Roman" size=2>Director</FONT></TD>
<TD vAlign=top width="7%"></TD>
<TD vAlign=top align=center width="32%"><FONT face="Times New Roman" size=2>June&nbsp;14, 2004</FONT></TD></TR>
<TR>
<TD vAlign=bottom colSpan=3><FONT face="Times New Roman" size=2>Brenton G. A. Hanlon</FONT></TD>
<TD vAlign=top width="1%">&nbsp;</TD>
<TD vAlign=top width="36%"></TD>
<TD vAlign=top width="7%"></TD>
<TD vAlign=top align=center width="32%"></TD></TR>
<TR>
<TD vAlign=bottom colSpan=3></TD>
<TD vAlign=top width="1%"></TD>
<TD vAlign=top width="36%"></TD>
<TD vAlign=top width="7%"></TD>
<TD vAlign=top align=center width="32%"></TD></TR>
<TR>
<TD vAlign=bottom colSpan=3>&nbsp;</TD>
<TD vAlign=top width="1%">&nbsp;</TD>
<TD vAlign=top width="36%">&nbsp;</TD>
<TD vAlign=top width="7%"></TD>
<TD vAlign=top align=center width="32%">&nbsp;</TD></TR>
<TR>
<TD vAlign=bottom colSpan=3><FONT face="Times New Roman" size=2>/s/ Prithipal Singh, Ph.D.<BR></FONT>
<HR noshade SIZE=1>
</TD>
<TD vAlign=top width="1%">&nbsp;</TD>
<TD vAlign=top width="36%"><FONT face="Times New Roman" size=2>Director</FONT></TD>
<TD vAlign=top width="7%"></TD>
<TD vAlign=top align=center width="32%"><FONT face="Times New Roman" size=2>June&nbsp;14, 2004</FONT></TD></TR>
<TR>
<TD vAlign=bottom colSpan=3><FONT face="Times New Roman" size=2>Prithipal Singh, Ph.D.</FONT></TD>
<TD vAlign=top width="1%">&nbsp;</TD>
<TD vAlign=top width="36%"></TD>
<TD vAlign=top width="7%"></TD>
<TD vAlign=top align=center width="32%"></TD></TR>
<TR>
<TD vAlign=bottom colSpan=3></TD>
<TD vAlign=top width="1%"></TD>
<TD vAlign=top width="36%"></TD>
<TD vAlign=top width="7%"></TD>
<TD vAlign=top align=center width="32%"></TD></TR>
<TR>
<TD vAlign=bottom colSpan=3>&nbsp;</TD>
<TD vAlign=top width="1%">&nbsp;</TD>
<TD vAlign=top width="36%">&nbsp;</TD>
<TD vAlign=top width="7%"></TD>
<TD vAlign=top align=center width="32%">&nbsp;</TD></TR>
<TR>
<TD vAlign=bottom colSpan=3><FONT face="Times New Roman" size=2>/s/ Ernest S. Tucker III<BR></FONT>
<HR noshade SIZE=1>
</TD>
<TD vAlign=top width="1%">&nbsp;</TD>
<TD vAlign=top width="36%"><FONT face="Times New Roman" size=2>Director</FONT></TD>
<TD vAlign=top width="7%"></TD>
<TD vAlign=top align=center width="32%"><FONT face="Times New Roman" size=2>June&nbsp;14, 2004</FONT></TD></TR>
<TR>
<TD vAlign=bottom colSpan=3><FONT face="Times New Roman" size=2>Ernest S. Tucker III</FONT></TD>
<TD vAlign=top width="1%">&nbsp;</TD>
<TD vAlign=top width="36%"></TD>
<TD vAlign=top width="7%"></TD>
<TD vAlign=middle align=center width="32%"></TD></TR>
</TABLE>


<TABLE width="100%">
<TR>
<TD align=center><FONT size=2>62</FONT></TD></TR>
</TABLE>



<P>
<HR align=left noshade SIZE=5>


<P>&nbsp;
<!-- *************************************************************************** -->
<!-- MARKER PAGE="sheet: 14; page: 14" -->
<H1 align=left><FONT face="Times New Roman, Times, Serif" size=2>REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM </FONT></H1>


<P><FONT face="Times New Roman, Times, Serif" size=2>To the Board of Directors and Shareholders of Abaxis, Inc.: </FONT></P>


<P><FONT face="Times New Roman, Times, Serif" size=2>We have audited the financial statements of Abaxis, Inc. (the &#147;Company&#148;) as of March&nbsp;31, 2004 and 2003, and for each of the three years in the period ended March&nbsp;31, 2004, and have issued our report thereon dated June 11, 2004; such report is included elsewhere in this Annual Report on Form 10-K. Our audits also included the financial statement schedule listed in Item 15(a)(2). This financial statement schedule is the responsibility of the Company&#146;s management. Our responsibility is to express an opinion based on our audits. In our opinion, such financial statement schedule, when considered in relation to the basic financial statements taken as a whole, presents fairly in all material respects the information set forth therein. </FONT></P>

<P align=left><FONT face="Times New Roman, Times, Serif" size=2>/s/ DELOITTE &amp; TOUCHE LLP </FONT></P>

<P align=left><FONT face="Times New Roman, Times, Serif" size=2>San Jose, California </FONT></P>

<P align=left><FONT face="Times New Roman, Times, Serif" size=2>June 11, 2004 </FONT></P>

<TABLE width="100%">
<TR>
<TD align=center><FONT size=2>63</FONT></TD></TR>
</TABLE>



<P>
<HR align=left noshade SIZE=5>


<P>&nbsp;
<!-- *************************************************************************** -->
<!-- MARKER PAGE="sheet: 14; page: 14" -->
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>Schedule II </FONT></P>

<P align=center><FONT face="Times New Roman, Times, Serif" size=2>Abaxis, Inc. </FONT></P>

<P align=center><FONT face="Times New Roman, Times, Serif" size=2>Valuation and Qualifying Accounts and Reserves </FONT></P>

<TABLE cellSpacing=0 cellPadding=0 width="100%" border=0>
<TR>
<TD vAlign=bottom width="34%">
<P align=center><FONT face="Times New Roman" size=2><B>Description</B></FONT></P>
</TD>
<TD vAlign=bottom width="18%">
<P align=center><FONT face="Times New Roman" size=2><B>Balance at <BR>Beginning <BR>of Year</B></FONT></P>
</TD>
<TD vAlign=bottom width="17%">
<P align=center><FONT face="Times New Roman" size=2><B>Additions <BR>Charged to <BR>Expenses</B></FONT></P>
</TD>
<TD vAlign=bottom width="15%">
<P align=center><FONT face="Times New Roman" size=2><B>Deductions <BR>from Reserves</B></FONT></P>
</TD>
<TD vAlign=bottom width="16%">
<P align=center><FONT face="Times New Roman" size=2><B>Balance at <BR>End of Year</B></FONT></P>
</TD></TR>
<TR>
<TD vAlign=bottom colSpan=5>
<HR noshade SIZE=1>
</TD></TR>
<TR>
<TD vAlign=bottom width="34%">
<P align=left><FONT face="Times New Roman" size=2><B>Reserve for Doubtful Accounts &amp; Sales Allowances</B></FONT></P>
</TD>
<TD vAlign=bottom nowrap width="18%">
<P align=left><FONT face="Times New Roman" size=2></FONT>&nbsp;</P>
</TD>
<TD vAlign=bottom nowrap width="17%">
<P align=left><FONT face="Times New Roman" size=2></FONT>&nbsp;</P>
</TD>
<TD vAlign=bottom nowrap width="15%">
<P align=left><FONT face="Times New Roman" size=2></FONT>&nbsp;</P>
</TD>
<TD vAlign=bottom nowrap width="16%">
<P align=left><FONT face="Times New Roman" size=2></FONT>&nbsp;</P>
</TD></TR>
<TR>
<TD vAlign=bottom width="34%">
<P align=left><FONT face="Times New Roman" size=2>Year ended March 31, 2004</FONT></P>
</TD>
<TD vAlign=bottom nowrap width="18%">
<P align=center><FONT face="Times New Roman" size=2>$ 267,000 </FONT></P>
</TD>
<TD vAlign=bottom nowrap width="17%">
<P align=center><FONT face="Times New Roman" size=2>$ 586,000 </FONT></P>
</TD>
<TD vAlign=bottom nowrap width="15%">
<P align=center><FONT face="Times New Roman" size=2>$ 596,000 </FONT></P>
</TD>
<TD vAlign=bottom nowrap width="16%">
<P align=center><FONT face="Times New Roman" size=2>$ 257,000 </FONT></P>
</TD></TR>
<TR>
<TD vAlign=bottom width="34%">
<P align=left><FONT face="Times New Roman" size=2>Year ended March 31, 2003</FONT></P>
</TD>
<TD vAlign=bottom nowrap width="18%">
<P align=center><FONT face="Times New Roman" size=2>&nbsp;&nbsp;&nbsp;244,000 </FONT></P>
</TD>
<TD vAlign=bottom nowrap width="17%">
<P align=center><FONT face="Times New Roman" size=2>&nbsp;&nbsp;&nbsp;422,000 </FONT></P>
</TD>
<TD vAlign=bottom nowrap width="15%">
<P align=center><FONT face="Times New Roman" size=2>&nbsp;&nbsp;&nbsp;399,000 </FONT></P>
</TD>
<TD vAlign=bottom nowrap width="16%">
<P align=center><FONT face="Times New Roman" size=2>&nbsp;&nbsp;&nbsp;267,000 </FONT></P>
</TD></TR>
<TR>
<TD vAlign=bottom width="34%">
<P align=left><FONT face="Times New Roman" size=2>Year ended March 31, 2002</FONT></P>
</TD>
<TD vAlign=bottom nowrap width="18%">
<P align=center><FONT face="Times New Roman" size=2>&nbsp;&nbsp;&nbsp;357,000 </FONT></P>
</TD>
<TD vAlign=bottom nowrap width="17%">
<P align=center><FONT face="Times New Roman" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;52,000 </FONT></P>
</TD>
<TD vAlign=bottom nowrap width="15%">
<P align=center><FONT face="Times New Roman" size=2>&nbsp;&nbsp;&nbsp;165,000 </FONT></P>
</TD>
<TD vAlign=bottom nowrap width="16%">
<P align=center><FONT face="Times New Roman" size=2>&nbsp;&nbsp;&nbsp;244,000 </FONT></P>
</TD></TR>
</TABLE>


<!-- MARKER FORMAT-SHEET="Head Sub 3 Left" FSL="Default" -->
<P align=center><FONT face="Times New Roman, Times, Serif" size=2><B>EXHIBIT INDEX </B></FONT></P>

<TABLE cellSpacing=0 cellPadding=0 width="100%" border=0>
<TR>
<TD vAlign=top width="8%"><FONT face="Times New Roman" size=2><B>Exhibit No. </B></FONT>
<HR noshade SIZE=1>
</TD>
<TD vAlign=top width="3%">&nbsp;</TD>
<TD vAlign=top width="89%"><FONT face="Times New Roman" size=2><B>Description of Document<BR></B></FONT>
<HR noshade SIZE=1>
</TD></TR>
<TR>
<TD vAlign=top width="8%"><FONT face="Times New Roman" size=2><B>3.1</B></FONT></TD>
<TD vAlign=top width="3%">&nbsp;</TD>
<TD vAlign=top width="89%"><FONT face="Times New Roman" size=2>Restated Articles of Incorporation <SUP><FONT face="Times New Roman Bold">(4)</FONT></SUP></FONT></TD></TR>
<TR>
<TD vAlign=top width="8%"><FONT face="Times New Roman" size=2><B>3.2</B></FONT></TD>
<TD vAlign=top width="3%">&nbsp;</TD>
<TD vAlign=top width="89%"><FONT face="Times New Roman" size=2>By-laws <SUP>(2)</SUP></FONT></TD></TR>
<TR>
<TD vAlign=top width="8%"><FONT face="Times New Roman" size=2><B>4.2</B></FONT></TD>
<TD vAlign=top width="3%">&nbsp;</TD>
<TD vAlign=top width="89%"><FONT face="Times New Roman" size=2>Form of Warrant Agreement issued to purchasers of Series D Convertible Preferred Stock<SUP><FONT face="Times New Roman">(7)</FONT></SUP></FONT></TD></TR>
<TR>
<TD vAlign=top width="8%"><FONT face="Times New Roman" size=2><B>4.4</B></FONT></TD>
<TD vAlign=top width="3%">&nbsp;</TD>
<TD vAlign=top width="89%"><FONT face="Times New Roman" size=2>Registration Rights Agreement dated as of March&nbsp;29, 2002 <SUP><FONT face="Times New Roman">(10)</FONT></SUP></FONT></TD></TR>
<TR>
<TD vAlign=top width="8%"><FONT face="Times New Roman" size=2><B>4.5</B></FONT></TD>
<TD vAlign=top width="3%">&nbsp;</TD>
<TD vAlign=top width="89%"><FONT face="Times New Roman" size=2>Form of Warrant Agreement issued to purchasers of Series E Convertible Preferred Stock<SUP><FONT face="Times New Roman">(10)</FONT></SUP></FONT></TD></TR>
<TR>
<TD vAlign=top width="8%"><FONT face="Times New Roman" size=2><B>10.5</B></FONT></TD>
<TD vAlign=top width="3%">&nbsp;</TD>
<TD vAlign=top width="89%"><FONT face="Times New Roman" size=2>1989 Stock Option Plan, as amended and restated as the 1998 Stock Option Plan, and forms of agreement <SUP><FONT face="Times New Roman">(3)</FONT></SUP></FONT></TD></TR>
<TR>
<TD vAlign=top width="8%"><FONT face="Times New Roman" size=2><B>10.6</B></FONT></TD>
<TD vAlign=top width="3%">&nbsp;</TD>
<TD vAlign=top width="89%"><FONT face="Times New Roman" size=2>1992 Outside Directors Stock Option Plan and forms of agreement <SUP><FONT face="Times New Roman">(4)</FONT></SUP></FONT></TD></TR>
<TR>
<TD vAlign=top width="8%"><FONT face="Times New Roman" size=2><B>10.7</B></FONT></TD>
<TD vAlign=top width="3%">&nbsp;</TD>
<TD vAlign=top width="89%"><FONT face="Times New Roman" size=2>401(k) Defined Contribution Plan <SUP><FONT face="Times New Roman">(2)</FONT></SUP></FONT></TD></TR>
<TR>
<TD vAlign=top width="8%"><FONT face="Times New Roman" size=2><B>10.13</B></FONT></TD>
<TD vAlign=top width="3%">&nbsp;</TD>
<TD vAlign=top width="89%"><FONT face="Times New Roman" size=2>Exclusive Distribution Agreement dated September&nbsp;20, 1991 between the Company and Teramecs <SUP><FONT face="Times New Roman">(1)(2)</FONT></SUP></FONT></TD></TR>
<TR>
<TD vAlign=top width="8%"><FONT face="Times New Roman" size=2><B>10.14</B></FONT></TD>
<TD vAlign=top width="3%">&nbsp;</TD>
<TD vAlign=top width="89%"><FONT face="Times New Roman" size=2>Sponsored Research Agreement dated as of September&nbsp;20, 1991 between the Company and Teramecs <SUP><FONT face="Times New Roman">(1)(2)</FONT></SUP></FONT></TD></TR>
<TR>
<TD vAlign=top width="8%"><FONT face="Times New Roman" size=2><B>10.15</B></FONT></TD>
<TD vAlign=top width="3%">&nbsp;</TD>
<TD vAlign=top width="89%"><FONT face="Times New Roman" size=2>Development Agreement between the Company and Becton Dickinson and Company (through its Becton Dickinson Immunocytometry Systems Division) dated April&nbsp;9, 1993 <SUP><FONT face="Times New Roman">(1)(4)</FONT></SUP></FONT></TD></TR>
<TR>
<TD vAlign=top width="8%"><FONT face="Times New Roman" size=2><B>10.17</B></FONT></TD>
<TD vAlign=top width="3%">&nbsp;</TD>
<TD vAlign=top width="89%"><FONT face="Times New Roman" size=2>Supply Agreement between the Company and Becton Dickinson and Company (through its Becton Dickinson Immunocytometry Systems Division) dated September&nbsp;16, 1994 <SUP><FONT face="Times New Roman">(1)(5)</FONT></SUP></FONT></TD></TR>
<TR>
<TD vAlign=top width="8%"><FONT face="Times New Roman" size=2><B>10.18</B></FONT></TD>
<TD vAlign=top width="3%">&nbsp;</TD>
<TD vAlign=top width="89%"><FONT face="Times New Roman" size=2>Licensing agreement between the Company and Pharmacia Biotech, Inc. dated October&nbsp;1, 1994 <SUP><FONT face="Times New Roman">(1)(5)</FONT></SUP></FONT></TD></TR>
<TR>
<TD vAlign=top width="8%"><FONT face="Times New Roman" size=2><B>10.20</B></FONT></TD>
<TD vAlign=top width="3%">&nbsp;</TD>
<TD vAlign=top width="89%"><FONT face="Times New Roman" size=2>Employment Agreement with Mr.&nbsp;Clinton H. Severson dated March&nbsp;31, 1997.<SUP><FONT face="Times New Roman">(6)</FONT></SUP></FONT></TD></TR>
<TR>
<TD vAlign=top width="8%"><FONT face="Times New Roman" size=2><B>10.25</B></FONT></TD>
<TD vAlign=top width="3%">&nbsp;</TD>
<TD vAlign=top width="89%"><FONT face="Times New Roman" size=2>Lease Agreement with Principal Development Investors, LLC, dated June&nbsp;21, 2000 <SUP><FONT face="Times New Roman">(9)</FONT></SUP></FONT></TD></TR>
<TR>
<TD vAlign=top width="8%"><FONT face="Times New Roman" size=2><B>10.26</B></FONT></TD>
<TD vAlign=top width="3%">&nbsp;</TD>
<TD vAlign=top width="89%"><FONT face="Times New Roman" size=2>Employee Retention Incentive Agreement with Mr.&nbsp;Alberto R. Santa Ines, as amended, as of May 1, 2002.<B><SUP><FONT face="Times New Roman"> </FONT></SUP></B><SUP><FONT face="Times New Roman">(11)</FONT></SUP></FONT></TD></TR>
<TR>
<TD vAlign=top width="8%"><FONT face="Times New Roman" size=2><B>10.27</B></FONT></TD>
<TD vAlign=top width="3%">&nbsp;</TD>
<TD vAlign=top width="89%"><FONT face="Times New Roman" size=2>Joint Defense Agreement by and between Abaxis, Inc. and S.A. Scientific, Inc. dated as of May 8, 2002<SUP><FONT face="Times New Roman">(11)</FONT></SUP></FONT></TD></TR>
<TR>
<TD vAlign=top width="8%"><FONT face="Times New Roman" size=2><B>10.28</B></FONT></TD>
<TD vAlign=top width="3%">&nbsp;</TD>
<TD vAlign=top width="89%"><FONT face="Times New Roman" size=2>Loan and Security Agreement with Comerica Bank - California dated March 13, 2002 <SUP><FONT face="Times New Roman">(12)</FONT></SUP></FONT></TD></TR>
<TR>
<TD vAlign=top width="8%"><FONT face="Times New Roman" size=2><B>10.29</B></FONT></TD>
<TD vAlign=top width="3%">&nbsp;</TD>
<TD vAlign=top width="89%"><FONT face="Times New Roman" size=2>First and Second Modification to Loan and Security Agreement with Comerica Bank - California dated March 29, 2002 <SUP><FONT face="Times New Roman">(12)</FONT></SUP></FONT></TD></TR>
<TR>
<TD vAlign=top width="8%"><FONT face="Times New Roman" size=2><B>10.30</B></FONT></TD>
<TD vAlign=top width="3%">&nbsp;</TD>
<TD vAlign=top width="89%"><FONT face="Times New Roman" size=2>Loan Revision/Extension Agreement with Comerica Bank - California dated March 29, 2002 <SUP><FONT face="Times New Roman">(12)</FONT></SUP></FONT></TD></TR>
<TR>
<TD vAlign=top width="8%"><FONT face="Times New Roman" size=2><B>10.31</B></FONT></TD>
<TD vAlign=top width="3%">&nbsp;</TD>
<TD vAlign=top width="89%"><FONT face="Times New Roman" size=2>Loan Revision/Extension Agreement with Comerica Bank - California dated September 23, 2002 <SUP><FONT face="Times New Roman">(13)</FONT></SUP></FONT></TD></TR>
<TR>
<TD vAlign=top width="8%"><FONT face="Times New Roman" size=2><B>10.32+</B></FONT></TD>
<TD vAlign=top width="3%">&nbsp;</TD>
<TD vAlign=top width="89%"><FONT face="Times New Roman" size=2>Letter Setting Forth Additional Terms of Relationship Between Abaxis and Pharmacia Biotech dated as of June 9, 1997 <SUP><FONT face="Times New Roman">(13)</FONT></SUP></FONT></TD></TR>
<TR>
<TD vAlign=top width="8%"><FONT face="Times New Roman" size=2><B>10.33</B></FONT></TD>
<TD vAlign=top width="3%">&nbsp;</TD>
<TD vAlign=top width="89%"><FONT face="Times New Roman" size=2>Letter from Abaxis to Becton Dickinson and Company dated December 12, 1997 <SUP><FONT face="Times New Roman">(13)</FONT></SUP></FONT></TD></TR>
</TABLE>

<BR>
<TABLE width="100%">
<TR>
<TD align=center><FONT size=2>64</FONT></TD></TR>
</TABLE>



<P>
<HR align=left noshade SIZE=5>


<P>&nbsp;
<!-- *************************************************************************** -->
<!-- MARKER PAGE="sheet: 14; page: 14" -->
<TABLE cellSpacing=0 cellPadding=0 width="100%" border=0>
<TR>
<TD vAlign=top width="7%"><FONT face="Times New Roman" size=2><B>10.34</B></FONT></TD>
<TD vAlign=top width="1%">&nbsp;</TD>
<TD vAlign=top width="92%"><FONT face="Times New Roman" size=2>Distribution Agreement by and between Diatron Messtechnik GmbH and Abaxis, dated November 13, 2003<SUP><FONT face="Times New Roman">(16)</FONT></SUP><B><SUP><FONT face="Times New Roman"> </FONT></SUP></B></FONT></TD></TR>
<TR>
<TD vAlign=top width="7%"><FONT face="Times New Roman" size=2><B>10.35</B></FONT></TD>
<TD vAlign=top width="1%">&nbsp;</TD>
<TD vAlign=top width="92%"><FONT face="Times New Roman" size=2>Distribution Agreement by and between Scil Animal Care Company GmbH and Abaxis, Inc., dated September 1, 2001<SUP><FONT face="Times New Roman">(15)</FONT></SUP></FONT></TD></TR>
<TR>
<TD vAlign=top width="7%"><FONT face="Times New Roman" size=2><B>10.36</B></FONT></TD>
<TD vAlign=top width="1%">&nbsp;</TD>
<TD vAlign=top width="92%"><FONT face="Times New Roman" size=2>Loan and Security Agreement by and between Abaxis and Comerica Bank-California dated as of September 8, 2003 <SUP><FONT face="Times New Roman">(14)</FONT></SUP></FONT></TD></TR>
<TR>
<TD vAlign=top width="7%"><FONT face="Times New Roman" size=2><B>14.1</B></FONT></TD>
<TD vAlign=top width="1%">&nbsp;</TD>
<TD vAlign=top width="92%"><FONT face="Times New Roman" size=2>Code of Ethics</FONT></TD></TR>
<TR>
<TD vAlign=top width="7%"><FONT face="Times New Roman" size=2><B>21.1</B></FONT></TD>
<TD vAlign=top width="1%">&nbsp;</TD>
<TD vAlign=top width="92%"><FONT face="Times New Roman" size=2>Subsidiaries of Registrant</FONT></TD></TR>
<TR>
<TD vAlign=top width="7%"><FONT face="Times New Roman" size=2><B>23.1</B></FONT></TD>
<TD vAlign=top width="1%">&nbsp;</TD>
<TD vAlign=top width="92%"><FONT face="Times New Roman" size=2>Consent of Independent Registered Public Accounting Firm</FONT></TD></TR>
<TR>
<TD vAlign=top width="7%"><FONT face="Times New Roman" size=2><B>31.1</B></FONT></TD>
<TD vAlign=top width="1%">&nbsp;</TD>
<TD vAlign=top width="92%"><FONT face="Times New Roman" size=2>Certification of President and Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</FONT></TD></TR>
<TR>
<TD vAlign=top width="7%"><FONT face="Times New Roman" size=2><B>31.2</B></FONT></TD>
<TD vAlign=top width="1%">&nbsp;</TD>
<TD vAlign=top width="92%"><FONT face="Times New Roman" size=2>Certification of Chief Financial Officer and Vice President of Finance pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</FONT></TD></TR>
<TR>
<TD vAlign=top width="7%"><FONT face="Times New Roman" size=2><B>32.1</B></FONT></TD>
<TD vAlign=top width="1%">&nbsp;</TD>
<TD vAlign=top width="92%"><FONT face="Times New Roman" size=2>Certification of President and Chief Executive Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</FONT></TD></TR>
<TR>
<TD vAlign=top width="7%"><FONT face="Times New Roman" size=2><B>32.2</B></FONT></TD>
<TD vAlign=top width="1%">&nbsp;</TD>
<TD vAlign=top width="92%"><FONT face="Times New Roman" size=2>Certification of Chief Financial Officer and Vice President of Finance pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</FONT></TD></TR>
</TABLE>

<BR>
<TABLE cellSpacing=0 cellPadding=0 width="100%">
<TR vAlign=top>
<TD align=left width="3%"><FONT face="Times New Roman, Times, Serif" size=2>(1) </FONT></TD>
<TD width="97%">
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>Confidential treatment of certain portions of these agreements has been granted by the Securities and Exchange Commission. </FONT></P>
</TD></TR>
</TABLE>

<BR>
<TABLE cellSpacing=0 cellPadding=0 width="100%">
<TR vAlign=top>
<TD align=left width="3%"><FONT face="Times New Roman, Times, Serif" size=2>(2) </FONT></TD>
<TD width="97%">
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>Incorporated by reference from Registration Statement No. 33-44326 filed December&nbsp;11, 1991. </FONT></P>
</TD></TR>
</TABLE>

<BR>
<TABLE cellSpacing=0 cellPadding=0 width="100%">
<TR vAlign=top>
<TD align=left width="3%"><FONT face="Times New Roman, Times, Serif" size=2>(3) </FONT></TD>
<TD width="97%">
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>Incorporated by reference to the exhibit filed with our Annual Report on Form 10-K for the fiscal year ended March&nbsp;31, 1992. </FONT></P>
</TD></TR>
</TABLE>

<BR>
<TABLE cellSpacing=0 cellPadding=0 width="100%">
<TR vAlign=top>
<TD align=left width="3%"><FONT face="Times New Roman, Times, Serif" size=2>(4) </FONT></TD>
<TD width="97%">
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>Incorporated by reference to the exhibit filed with our Annual Report on Form 10-K for the fiscal year ended March&nbsp;31, 1993. </FONT></P>
</TD></TR>
</TABLE>

<BR>
<TABLE cellSpacing=0 cellPadding=0 width="100%">
<TR vAlign=top>
<TD align=left width="3%"><FONT face="Times New Roman, Times, Serif" size=2>(5) </FONT></TD>
<TD width="97%">
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>Incorporated by reference to the exhibit filed with our Quarterly Report on Form 10-Q for the quarter ended September&nbsp;30, 1994. </FONT></P>
</TD></TR>
</TABLE>

<BR>
<TABLE cellSpacing=0 cellPadding=0 width="100%">
<TR vAlign=top>
<TD align=left width="3%"><FONT face="Times New Roman, Times, Serif" size=2>(6) </FONT></TD>
<TD width="97%">
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>Incorporated by reference to the exhibit filed with our Annual Report on Form 10-K for the fiscal year ended March&nbsp;31, 1997. </FONT></P>
</TD></TR>
</TABLE>

<BR>
<TABLE cellSpacing=0 cellPadding=0 width="100%">
<TR vAlign=top>
<TD align=left width="3%"><FONT face="Times New Roman, Times, Serif" size=2>(7) </FONT></TD>
<TD width="97%">
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>Incorporated by reference to the exhibit filed with our Current Report on Form 8-K on October&nbsp;19, 2000. </FONT></P>
</TD></TR>
</TABLE>

<BR>
<TABLE cellSpacing=0 cellPadding=0 width="100%">
<TR vAlign=top>
<TD align=left width="3%"><FONT face="Times New Roman, Times, Serif" size=2>(8) </FONT></TD>
<TD width="97%">
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>Incorporated by reference to the exhibit filed with our Amended Current Report on Form 8-K/A on January&nbsp;5, 2000. </FONT></P>
</TD></TR>
</TABLE>

<BR>
<TABLE cellSpacing=0 cellPadding=0 width="100%">
<TR vAlign=top>
<TD align=left width="3%"><FONT face="Times New Roman, Times, Serif" size=2>(9) </FONT></TD>
<TD width="97%">
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>Incorporated by reference to the exhibit filed with our Registration Statement on Form S-3 on January&nbsp;10, 2000. </FONT></P>
</TD></TR>
</TABLE>

<BR>
<TABLE cellSpacing=0 cellPadding=0 width="100%">
<TR vAlign=top>
<TD align=left width="3%"><FONT face="Times New Roman, Times, Serif" size=2>(10) </FONT></TD>
<TD width="97%">
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>Incorporated by reference to the exhibit filed with our Current Report on Form 8-K on May&nbsp;13, 2002. </FONT></P>
</TD></TR>
</TABLE>

<BR>
<TABLE cellSpacing=0 cellPadding=0 width="100%">
<TR vAlign=top>
<TD align=left width="3%"><FONT face="Times New Roman, Times, Serif" size=2>(11) </FONT></TD>
<TD width="97%">
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>Incorporated by reference to the exhibit filed with our annual report on Form 10-K for the year ended March 31, 2002. </FONT></P>
</TD></TR>
</TABLE>

<BR>
<TABLE cellSpacing=0 cellPadding=0 width="100%">
<TR vAlign=top>
<TD align=left width="3%"><FONT face="Times New Roman, Times, Serif" size=2>(12) </FONT></TD>
<TD width="97%">
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>Incorporated by reference to the exhibit filed with our quarterly report on Form 10-Q for the quarter ended June 30, 2002. </FONT></P>
</TD></TR>
</TABLE>

<BR>
<TABLE cellSpacing=0 cellPadding=0 width="100%">
<TR vAlign=top>
<TD align=left width="3%"><FONT face="Times New Roman, Times, Serif" size=2>(13) </FONT></TD>
<TD width="97%">
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>Incorporated by reference to the exhibit filed with our quarterly report on Form 10-Q for the quarter ended September 30, 2002. </FONT></P>
</TD></TR>
</TABLE>

<BR>
<TABLE cellSpacing=0 cellPadding=0 width="100%">
<TR vAlign=top>
<TD align=left width="3%"><FONT face="Times New Roman, Times, Serif" size=2>(14) </FONT></TD>
<TD width="97%">
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>Incorporated by reference to the exhibit filed with our quarterly report on Form 10-Q for the quarter ended September 30, 2003. </FONT></P>
</TD></TR>
</TABLE>

<BR>
<TABLE cellSpacing=0 cellPadding=0 width="100%">
<TR vAlign=top>
<TD align=left width="3%"><FONT face="Times New Roman, Times, Serif" size=2>(15) </FONT></TD>
<TD width="97%">
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>Incorporated by reference to the exhibit filed with Amendment Number One to our annual report on Form 10K/A for the year ended March 31, 2002, as filed with the Security and Exchange Commission on December 24, 2002. </FONT></P>
</TD></TR>
</TABLE>

<BR>
<TABLE cellSpacing=0 cellPadding=0 width="100%">
<TR vAlign=top>
<TD align=left width="3%"><FONT face="Times New Roman, Times, Serif" size=2>(16) </FONT></TD>
<TD width="97%">
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>Confidential treatment of certain portions of this agreements has been requested from the Securities and Exchange Commission. </FONT></P>
</TD></TR>
</TABLE>

<BR>

<P><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;All Schedules have been omitted because the information required to be set forth therein is not applicable or is shown in the Financial Statements or notes thereto. </FONT></P>

<TABLE width="100%">
<TR>
<TD align=center><FONT size=2>65</FONT></TD></TR>
</TABLE>



<P>
<HR align=left noshade SIZE=5>


<P>&nbsp;
<!-- *************************************************************************** -->
<!-- MARKER PAGE="sheet: 14; page: 14" -->

<P><FONT face="Times New Roman, Times, Serif" size=2>+ Confidential treatment has been<B> </B>granted as to a portion of this Exhibit. </FONT></P>

<HR align=left noshade SIZE=5>


<P>&nbsp;</P>

</BODY>

</HTML>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.34
<SEQUENCE>2
<FILENAME>e18184ex10-34.txt
<DESCRIPTION>MANUFACTURING AND SUPPLY AGREEMENT
<TEXT>
                                                                   Exhibit 10.34

- --------------------------------------------------------------------------------
*** Confidential treatment has been requested for portions of this exhibit. The
copy filed herewith omits the information subject to the confidentiality
request. Omissions are designated as [****]. A complete version of this exhibit
has been filed separately with the Securities and Exchange Commission.
- --------------------------------------------------------------------------------

                PRIVATE LABEL MANUFACTURING AND SUPPLY AGREEMENT

      THIS PRIVATE LABEL MANUFACTURING AND SUPPLY AGREEMENT (this "Agreement")
is made as of this 13th day of November, 2003 (the "Effective Date"), by and
between Diatron Messtechnik GmbH., a corporation organized under the laws of
Austria and having its principal place of business at Ameisgasse 49-51/2A, 1140
Vienna ("Supplier"), and Abaxis, Inc., a California corporation having its
principal place of business at 3240 Whipple Road, Union City, California 94587,
USA ("Purchaser").

                                   BACKGROUND

      Supplier is a supplier of hematology analyzers for use in the human and
veterinary blood analysis market and Purchaser wishes to purchase Supplier's
products for use in the veterinary market. Supplier agrees to sell to Purchaser,
and Purchaser agrees to purchase, the products described below, subject to the
terms and conditions contained in this Agreement, for distribution by Purchaser
under its own trademarks and tradenames.

                                    AGREEMENT

      Supplier and Purchaser agree as follows:

      1. Purchase and Sale Obligations.

            1.1 General. Supplier hereby appoints Purchaser as Supplier's
reseller of the products specified on Schedule A (Products) attached to this
Agreement and incorporated herein by this reference (the "Products"). Subject to
the terms and conditions of this Agreement, Purchaser agrees to purchase, and
Supplier agrees to sell the Products. With respect to the HMII Hematology
Analyzer described on Schedule A (Products) as of the Effective Date, Supplier
appoints Purchase as Supplier's exclusive worldwide distributor. The parties may
modify the Products subject to this Agreement from time to time by annexing a
revised Schedule A (Products) to this Agreement. Supplier agrees that Supplier
will not (and will not permit any third party to) distribute any other products
of Supplier which are hematology products, in the veterinary market in the
United States, Canada, Australia, New Zealand, Japan and/or in such other
geographic territories as the parties may mutually agree in writing.

            1.2 Minimum Purchase Commitment and Exclusivity. Purchaser agrees to
order from Supplier for delivery during each Contract Year during the term of
this Agreement, the minimum number of Products, per Contract Year, as is
specified on Schedule B attached hereto and incorporated herein (the "Minimum
Purchase Commitment"). Contract Year shall mean each twelve (12)-month period
commencing with the date Products are first available for


                                     Page 1
<PAGE>

shipment to Purchaser. Supplier agrees, subject to Purchaser's strict compliance
with the terms and conditions of this Agreement including, without limitation,
Purchaser's compliance with the Minimum Purchase Commitment, that it will not,
directly or indirectly, knowingly sell products with the same form, fit and
function of the Products into the veterinary market in competition with the
Products. The failure to meet the Minimum Purchase Commitment shall not
constitute an Event of Default as defined in Section 14.2 (Termination Upon
Event of Default) of this Agreement unless and/or until the amount Purchaser
orders for delivery during any Contract Year falls below seventy-five percent
(75%) of the then applicable Minimum Purchase Commitment. Supplier agrees to
disclose to Purchaser any inquiries, sales leads or information it receives from
potential purchasers of Products in territories set forth in Section 1.1
(General).

            1.3 Governmental Rules and Regulations. Supplier's obligation to
ship orders to Purchaser under this Agreement shall be subject to Supplier's
right and ability to make such sales and obtain required licenses and permits,
under all applicable decrees, statutes, rules and regulations of a government
and/or agency with competent jurisdiction presently in effect or which may be in
effect hereafter.

      2. Orders, Payment and Delivery.

            2.1 Orders. Purchaser shall order Products from Supplier under this
Agreement by submitting to Supplier a written purchase order specifying the
Products, quantities and requested delivery dates required to enable Supplier to
fill the order. Each purchase order submitted to Supplier is subject to
acceptance by Supplier at its offices to which such order was submitted.
Supplier shall have no liability to Purchaser with respect to orders which are
not accepted by Supplier; provided, however, that Supplier will not unreasonably
reject any orders for Products which do not require any modifications or
additions, other than the modifications of Supplier's products specified in
Section 3.1 (Customization for the Veterinary Market) hereto. Subject to the
foregoing, Supplier may reject, in its sole discretion, any order for customized
Products. In the event Supplier has not given Purchaser notice of acceptance or
rejection of a purchase order within ten (10) business days of receipt thereof,
such order shall be deemed accepted. The purpose of the purchase order to be
issued under this Agreement is for specifying the Products, quantities and
requested delivery dates only; no terms and conditions of Purchaser's purchase
orders, Supplier's order acknowledgment or any other document or instrument of
Purchaser or Supplier shall be binding upon the other party or amend or modify
this Agreement in any manner.

            2.2 Prices. The purchase price for Products sold under this
Agreement shall be determined in accordance with Schedule A (Products) hereto
from the date hereof until the end of the first Contract Year. After the first
Contract Year, Supplier may modify the prices for Products, upon notice to the
Purchaser; provided such prices do not increase more than five percent (5%) in
any one Contract Year, unless justified by cost increases incurred by Supplier
from third-party suppliers. Supplier agrees to provide Purchaser with ninety
(90) days prior written notice of any price change and Supplier agrees to honor
the price in effect prior to any notice with respect to orders (i) placed prior
to the price change effective date and (ii) not modified or canceled by
Purchaser. All sales are F.O.B. Vienna or Budapest (Incoterms 2000). Purchaser
agrees to separately pay all expenses incurred by Supplier in the shipment and
delivery


                                     Page 2
<PAGE>

of ordered Products, including without limitation freight charges, import duties
and insurance premiums. Purchaser shall determine, in its sole discretion, the
price at which Purchaser resells Products to Purchaser's customers.

            2.3 Shipment and Delivery. Shipments will be made to the warehouse
facilities of Purchaser in Union City, California, USA or Darmstadt, Germany, as
designated by Purchaser in advance of each shipment. Shipments will be made by
air to Union City and by truck to Darmstadt. In the event Purchaser requests
express delivery or shipment by air instead of by truck or by courier service,
Purchaser agrees to pay all additional expenses required by such request.
Supplier will use commercially reasonable efforts to meet Purchaser's requested
delivery schedules for Products. For Supplier's first purchase order, the latest
shipment date shall be 90 days after receipt of purchase order. In any other
event, Supplier agrees to ship the ordered quantity of Products within thirty
(30) days after receipt of the applicable purchase order, unless the quantity of
Products ordered in such purchase order exceeds the number of products
forecasted (pursuant to Section 2.6 (Forecasts)) by twenty-five percent (25%) or
greater, in which case, Supplier agrees to ship those Products ordered in excess
of the forecast within ninety (90) days after receipt of such purchase order.
Should orders for Products exceed Supplier's available inventory, Supplier will
allocate its available inventory and make deliveries on such basis as Supplier
deems equitable, as agreed to by both parties. Unless otherwise specified in
Purchaser's purchase order, Supplier shall be authorized to make deliveries in
installments. Purchaser shall make any claims for shortage or damage of Products
with the common carrier promptly upon receipt of the order and provide Supplier
with written notice of such a claim. Except in the case of negligence on the
part of Supplier or Supplier's failure to package Products as set forth below,
Supplier will not have responsibility for Products damaged in shipment and
Purchaser must handle all claims for damage with the carrier. As between
Supplier and Purchaser, Products shall be deemed accepted by Purchaser unless,
within ninety (90) days of delivery of the Products, Purchaser affirmatively
rejects the Products, by written notice detailing the reasons for rejections.
The parties acknowledge that they may mutually agree in writing in the future
that the foregoing period of time be reduced. Such reasons for rejection may be
non-conformance of the Products to the technical specifications described on
Schedule A (Products), damage in connection with bodily injury and property
damage arising out of any defect in the Products made intentionally,
unintentionally or negligently by Supplier during manufacturing and packaging,
and the breach of any material provision of this agreement by Supplier. If no
such notice of rejection is received, Purchaser shall be deemed to have accepted
delivery provided, however, the acceptance of delivery shall in no way diminish
or affect the product warranty given by Supplier in Section 6 (Warranty and
Repairs). If Purchaser rejects a shipment, Purchaser shall promptly return a
sample of the defective Product to Supplier in accordance with Supplier's
instructions, to enable Supplier to, within thirty (30) days, inspect and
determine whether the Product is defective; provided that Purchaser shall retain
the rest of the Products pending such determination. It is Purchaser's
responsibility to properly store and handle all Products pending inspection
and/or return. If rejection was timely effected and Supplier determines the
Products to be defective, Supplier agrees to repair or replace the Products or
cancel an unpaid invoice or refund the amounts paid with respect to such
defective Product which is returned to Supplier, at Supplier's option.


                                     Page 3
<PAGE>

      All shipments shall be accompanied by a quality control release report
(the form and contents of which shall be mutually agreed upon by the parties)
for each unit of Product shipped by Supplier. Unless Purchaser requests
otherwise, all Products ordered by Purchaser shall be packed for shipment and
storage in accordance with Schedule A (Products). It is Purchaser's obligation
to notify Supplier of any special packaging requirements (which shall be at
Purchaser's expense).

            2.4 Payment. Purchaser agrees to pay amounts invoiced by Supplier
for Products without offset or deduction for any reason whatsoever except as
otherwise provided in Section 2.3 (Shipment and Delivery), within thirty (30)
days from the date of invoice payable in Euro. If Purchaser fails to pay any
amount when due, Purchaser agrees to pay all costs and expenses, including
without limitation reasonable attorney's fees, incurred by Supplier in
collecting such overdue amounts, together with interest on such unpaid amount at
the lesser of one and one-half percent (1-1/2%) per month or the greatest amount
permitted by applicable law. Supplier reserves the right at any time after
Purchaser fails to make any payment within sixty (60) days after the due date,
to require payment for all Products delivered hereunder to be made by
irrevocable letter of credit. If Supplier elects to have payment made by letter
of credit, Purchaser shall select the issuing bank, which must be acceptable to
Supplier. Any such letter of credit shall be governed by Uniform Customs and
Practice for Documentary Credits (UPC) 500.

            2.5 Title and Risk of Loss. Title to and risk of loss of the
Products shall pass to Purchaser upon the earlier of delivery of the Products to
Purchaser or to a carrier at Supplier's point of shipment.

            2.6 Forecasts. Purchaser shall submit a rolling twelve (12)-month
sales forecast to Supplier every three (3) months on the first day of each
calendar quarter first following the Effective Date of this Agreement (or, if
the Effective Date of this Agreement is within thirty (30) days before any of
such dates, commencing on the second such date after the Effective Date of this
Agreement). Such sales forecast shall include expected sales quantities per
month, order dates, shipping dates and Product requirements. If the most recent
forecast becomes materially inaccurate at any time, Purchaser shall promptly
provide Supplier with updated information. The forecast information for months
four (4) through twelve (12) of the sales forecast shall be for planning
purposes only and Purchaser is not required to purchase the Products projected
to be sold on the sales forecast. The Purchaser shall issue a purchase order and
purchase the Products included in the first three (3) months of each forecast,
in accordance with the provisions of Section 2.1 (Orders).

      3. Substitutions and Modifications; Discontinued Products; Quality
Assurance.

            3.1 Customization for the Veterinary Market. Supplier agrees to
modify Supplier's product in accordance with the technical specifications set
forth on Schedule A (Products). It is anticipated that this work will include
modifications to the embedded software and/or the keypad and/or the interface.
Supplier and Purchaser shall collaborate to ensure the proper interface,
connection and interoperability between the software of Supplier's product and
that of the VetScan, a product of Purchaser. Technical specifications of the
interfaces of Supplier's products and their modifications according to
Purchaser's requirements for the


                                     Page 4
<PAGE>

Products are set forth on Schedule D (Interface). Purchaser agrees to assist
Supplier in the translations, revisions and editing work to provide an operating
manual in English for the Products.

            3.2 Reagents for Products. Purchaser shall be responsible for
producing or procuring from third parties reagents for use in the Products.
Supplier shall assist Purchaser in the procurement of reagents as well as inform
Purchaser in writing of any changes in the performance of the Products that
affect the specifications of the then-current reagent used on the Products with
at least ninety (90) days prior notice.

            3.3 Product Changes. Except with respect to Products ordered
pursuant to a purchase order which has been accepted by Supplier as described in
Section 2.1 (Orders) Supplier shall have the right, at any time and from time to
time, to make substitutions and modifications to the Products (including
software improvements); provided, however, that Supplier agrees to consider that
Purchaser's use of the Products is in the veterinary market in making any such
substitutions or modifications. In the event that any proposed substitution or
modification affects, in Supplier's reasonable judgment, the form, fit or
function of a Product, Supplier shall give Purchaser written notice of such
proposed substitution or modification at least thirty (30) days prior to its
taking effect and Purchaser shall have the right, during such thirty (30)-day
period, to order Products without such substitution or modification for delivery
within fifteen (15) days after the expiration of such thirty (30)-day period.
Any changes that affect the Product performance, operation or documentation
shall be provided to the Purchaser in writing with no less than ninety (90) days
notice. Purchaser shall have the right, at any time and from time to time to
request substitution and/or modification to the Products. In the event of such
request Supplier agrees to review and consider the requested modifications and
notify Purchaser whether it is feasible and/or practical to make the
modifications requested. In the event Supplier notifies Purchaser the
modifications are feasible and practical, it will also notify Purchaser of the
estimated modification costs and estimated time for manufacturing the modified
Product. All work requested by Purchaser, other than that set forth in Sections
3.1 (Customizations for the Veterinary Market), 6 (Warranty and Repairs) and 8.1
(Clinical Studies), will be charged on a time and materials basis, at an initial
rate of fifty Euros ((euro)50) per employee per hour, for a minimum of 3.5 hours
for each request (or as may be otherwise mutually agreed upon by the parties).

            3.4 Discontinued Products. Supplier agrees to notify Purchaser in
writing not less than one (1) year in advance of the discontinuance of any
Product. In the event Supplier is unable to manufacture the Products for
Purchaser (due to bankruptcy, fire, or other event of force majeure), then
Purchaser will have the right to manufacture the Products (or have the Products
manufactured for Purchaser), and, in exchange, pay a reasonable royalty or
license fee for such right. The parties will establish an escrow account
providing for the deposit of updated copies of all information reasonably
necessary for the manufacture of the Products with a third party (to be agreed
upon by the parties) under terms to be agreed upon in good faith between the
parties and such third party. Purchaser agrees to cover the costs for
establishing and maintaining of said escrow account. Supplier will deposit in
the escrow account all information reasonably necessary for the manufacture of
the Products prior to shipment of the first order of Products.


                                     Page 5
<PAGE>

The conditions for the transfer of know-how related to such manufacture shall be
agreed upon separately in good faith by the parties.

            3.5 Quality Assurance. The Product shall be manufactured in
accordance with ISO 9001 standards. Purchaser shall be permitted to inspect
facilities in which the Products are developed and produced upon reasonable
advance written notice to Supplier, during business hours at times reasonably
convenient to both parties; provided, however, that Purchaser acknowledges that
all information obtained in the course of any such inspection shall be deemed
proprietary information pursuant to Section 4 (Confidentiality) of this
Agreement. Supplier shall be permitted to inspect Purchaser's storage and
handling procedures of the Product upon reasonable advance written notice to
Purchaser during business hours at times reasonably convenient to both parties;
provided, however, that Supplier acknowledges that all information obtained in
the course of any such inspection shall be deemed proprietary information
pursuant to Section 4 (Confidentiality) of this Agreement.

      4. Confidentiality. Supplier and Purchaser agree that certain information
supplied by each to the other during the term of this Agreement, including,
without limitation, the Products, the documentation and the intellectual
property and technology underlying the Products, the information for
customization pursuant to Section 3.1 (Customization for the Veterinary Market)
and information contained on purchase orders or regarding Purchaser's ordering
or delivery patterns is proprietary, secret, confidential or non-public. All
such information shall be held in confidence by the receiving party, shall be
used only for the purposes of this Agreement and shall not be disclosed to any
person other than an employee with a need to know the information in order to
fulfill the obligations of the receiving party hereunder. Information shall not
be subject to the provisions of this Section 4 (Confidentiality) if shown by
recipient's records to be: (i) in the public domain at the time of disclosure or
thereafter through no fault of the recipient; (ii) known to the receiving party
at the time of disclosure; (iii) disclosed to the receiving party without an
obligation of confidentiality by a third party with the legal right to make such
free disclosure; (iv) developed independently by the receiving party by
personnel without access to or knowledge of the information disclosed; or (v)
clinical studies set forth in Section 8.1 (Clinical Studies) and other
developments and improvements of products, parts, programs and interfaces which
are not specifically proprietary or confidential information of Purchaser or any
third party. The receiving party may disclose information to the extent
requested or required by a governmental or judicial entity, provided such
disclosure is limited to the fullest extent permitted by applicable law.

      All documentation with respect to the Products (except information
contained in or for use in manuals, promotional materials or educational
materials to be provided to Purchaser's customers), are furnished solely for
Purchaser's internal use. Purchaser may make copies of such documentation to
satisfy its internal requirements, provided that all such copies include
appropriate copyright and proprietary information notices. No other copies or
use of such documentation, or any portion thereof, shall be made without the
prior written approval of Supplier. From time to time, Purchaser shall provide
Supplier with feedback, comments or suggestions regarding the Products
(collectively, "Feedback"). Feedback, if any, will be the property of the
Supplier and may be freely used by Supplier in Supplier's business. Feedback
specifically excludes any proprietary or Confidential Information of Purchaser.


                                     Page 6
<PAGE>

      Upon termination of this Agreement, Purchaser shall return or, at
Supplier's request, destroy all confidential, proprietary or secret information
of Supplier in Purchaser's possession. The obligations of the parties pursuant
to this Section 4 (Confidentiality) shall survive the expiration or earlier
termination of this Agreement for a period of five (5) years.

      5. Product Trademarks and Copyrights.

            5.1 Trademark Usage. Purchaser agrees that the Products purchased
and/or licensed hereunder shall be sold or leased by Purchaser only under the
trademarks, tradenames or logos (collectively the "Purchaser Marks") of
Purchaser.

            5.2 Notices. Purchaser shall not alter or remove any copyright,
trademark, trade secret, proprietary and/or other legal notices of Supplier or
third parties contained on or in the Products. The existence of any such
copyright notice shall not be construed as an admission, or be deemed to create
a presumption, that any publication of such Products has occurred.

            5.3 Logos. Supplier shall label all Products with Product serial
numbers, Product electrical data, Purchaser Marks and such other label
information as may be specified by Purchaser. Purchaser shall provide Supplier
with camera-ready artwork necessary for the labeling of the Products, which
shall include, without limitation: Purchaser Marks, Product serial numbers,
electrical data label information, and such additional information as may be
specified by Purchaser. Supplier shall be responsible for the costs of such
labeling. Supplier shall be responsible for ensuring that the Products and all
labeling conform to applicable rules and regulations with respect to electrical
standards established by Underwriter's Laboratories ("UL") for the United States
and Canada and by Conformite Europeen ("CE"). Purchaser shall be responsible for
the costs of registration. The parties will discuss in good faith the
apportionment of costs for ensuring conformity of the Products to rules of other
applicable standard setting organizations in the applicable jurisdictions.
Purchaser shall be responsible for the costs of registration with such other
standard setting organizations in the applicable jurisdictions.

            5.4 Trademark License. Purchaser hereby grants to Supplier a
non-exclusive, non-transferable right to use the Purchaser Marks solely on the
Products ordered by Purchaser hereunder and associated packaging. Supplier
agrees to the following:

                  (a) to comply with Purchaser's guidelines and instructions
regarding use of the Purchaser Marks as communicated to Supplier from time to
time;

                  (b) in the event Purchaser notifies Supplier that such use is
not in conformance with Purchaser's guidelines and instructions, to promptly
bring such use into conformance;

                  (c) to ensure that all use of the Purchaser Marks will not
reflect adversely upon the good name or good will of Purchaser and that all
Products in connection with which the Purchaser Marks are used are of high
standard and workmanship and of such nature,


                                     Page 7
<PAGE>

style, appearance and quality as shall be adequate and suited to the protection
of the Purchaser Marks and the goodwill associated therewith;

                  (d) not to use the Purchaser Marks (or any part thereof) as
part of, or in combination with, any other names or trademarks without
Purchaser's prior written approval;

                  (e) not to register (or aid any third party in registering)
the Purchaser Marks (or confusingly similar mark) or take any action
inconsistent with Purchaser's ownership of the Purchaser Marks in any
jurisdiction; and

                  (f) that all usage of the Purchaser Marks will be on behalf
of, and inure to the benefit of, Purchaser.

      6. Warranty and Repairs.

            6.1 Warranty. Supplier warrants that the Products manufactured and
sold by it will be free from defects in material and workmanship, and will
substantially conform to the technical specifications described in Schedule A
(Products), in normal use and service for a period and under the terms set forth
in Schedule C (Warranty Terms), annexed hereto and made a part hereof. The
warranty set forth in this Section 6.1 (Warranty) shall be void to the extent of
(i) any modification of a Product (except for repairs made by Purchaser) by any
person or entity other than Supplier, (ii) misuse or abuse of a Product or
documentation by Purchaser or Purchaser's customers or end users, (iii)
negligence or wrongdoing of Purchaser or Purchaser's customers or end users,
(iv) accident, disaster or event of force majeure, (v) use of a Product or
documentation in any manner inconsistent with this Agreement, (vi) causes
external to a Product such as, but not limited to, power failure or electrical
power surges, (vii) improper storage of a Product, (vii) use of a Product in
combination with products, equipment or software not supplied by Supplier or by
Purchaser or (viii) use of a Product in combination with products, equipment or
software supplied by Purchaser without Supplier's technical approval. Purchaser
shall pay Supplier for services performed by Supplier not covered by this
Section 6.1 (Warranty) at Supplier's then current time and materials rates.

            6.2 Repairs. Purchaser shall be responsible for proper installation,
service, maintenance and repair of the Products as well as for coordinating
repair requests from Purchaser's customers or end users and for resolution of
such repair requests. If Purchaser cannot resolve a repair request through
Purchaser's technical support personnel or by providing spare parts, Purchaser
shall first coordinate with Supplier's technical support personnel for
resolution of such repair request. In exceptional cases and after thorough
troubleshooting Purchaser shall ask for written authorization to return Products
to Supplier for repair. It is Supplier's option to choose the carrier when
Supplier is responsible for transportation costs. Except for rejected Products
set forth in Section 2.3 (Shipment and Delivery) and for Products covered by the
warranty in Section 6.1 (Warranty) which are returned within the one (1)-year
warranty period, Purchaser shall be responsible for (a) paying the cost of
mailing the Products to repair facilities designated by Supplier, (b) paying
Supplier for its labor costs at Supplier's then current time rates and (c)
providing replacement Products on a loan basis to Purchaser's customers or end
users. Supplier shall return repaired Products to Purchaser within thirty (30)


                                     Page 8
<PAGE>

days of receipt of such Products and pay the cost or return mailing for Products
received prior to the end of the one (1)-year warranty period; otherwise
Purchaser shall be responsible for paying the cost of return mailing for
Products received after the one (1)-year warranty period as well as paying
Supplier for its services at Supplier's then current time and materials rates.
If any Product is returned to an authorized Supplier service location specified
by Supplier within the warranty period set forth above, and upon examination
Supplier determines to its satisfaction that such Product is covered by the
warranty in Section 6.1 (Warranty), within the warranty period set forth herein,
Supplier will, at its option and as Purchaser's sole and exclusive remedy for a
breach of this warranty, repair or replace the Product or the defective part
hereof or refund the original purchase price of the Product to the Purchaser
within thirty (30) days after receipt of the defective Product. Purchaser agrees
to purchase an adequate stock of spare parts for the Products and Products to be
loaned to Purchaser's customers of the Products, for use during servicing of
Products under warranty repair.

            6.3 Disclaimer. Except for the warranty set forth in this Section 6
(Warranty and Repairs) and Section 11 (Representations and Warranties), Supplier
disclaims all warranties, whether express or implied, oral or written, with
respect to the Products, including without limitation, all implied warranties of
merchantability or fitness for any particular purpose. Laws from time to time in
force in certain jurisdictions may imply warranties that cannot be excluded or
can only be excluded to a limited extent, and this Agreement shall be read and
construed subject to any such statutory provisions. Purchaser shall be
responsible for any warranty it extends, either directly or indirectly,
expressly or by operation of law, beyond the warranty expressly granted in this
Section 6 (Warranty and Repairs). Supplier is not responsible for (i) damages
caused by Purchaser's failure to perform Purchaser's responsibilities or (ii)
damages due to deterioration during periods of storage by Purchaser longer than
those periods set forth in the Product documentation.

      7. Consequential Damages Waiver; Limitation of Liability. EXCEPT FOR
LIABILITY ARISING UNDER SECTION 4 (CONFIDENTIALITY) AND A PARTY'S OBLIGATIONS
UNDER SECTION 12 (INDEMNITIES) IN NO EVENT SHALL EITHER PARTY BE LIABLE TO THE
OTHER FOR SPECIAL, INDIRECT, INCIDENTAL OR CONSEQUENTIAL DAMAGES, EVEN IF SUCH
PARTY SHALL HAVE BEEN ADVISED OF THE POSSIBILITY OF THE SAME.

      8. Supplier's Support Obligations.

            8.1 Clinical Studies. Supplier agrees to complete, at its own
expense, clinical studies to establish and validate normal dosages, ranges and
studies (i) for the species ferret, mouse, rabbit and rat within six (6) months
of Effective Date; (ii) for other species to include (without limitation) sheep,
goat, pig, monkey (species to be identified and subject to availability for
Supplier) and cow within twelve (12) months of Effective Date; and (iii) for
such other species as the parties may mutually agree, in the time frames for
which the parties may mutually agree. In each case, Supplier will deliver
Purchaser a copy of the results and data from said studies, upon the completion
of said results.


                                     Page 9
<PAGE>

            8.2 Training. Supplier agrees to provide to Purchaser five (5) days
of service and technical training for Purchaser personnel at Supplier's
production facility in Budapest. For service training and technical training,
Supplier will provide the training facility, training materials and training
personnel. Purchaser shall be responsible for the travel, hotel, and other
living expenses of its personnel being trained. In the event that Purchaser
requires or requests training in excess of that specified in this Section 8.2
(Training), all required training will occur within the first year of this
Agreement, on dates mutually agreed between the parties.

            8.3 Post-Warranty Service. For a period of two (2) years after the
last to expire of the warranty periods of the Products ordered during the term
of this Agreement, Supplier agrees to provide reasonable e-mail technical
support to Purchaser with respect to high level, complex issues which require
personnel experienced in the field of hematology for resolution. Purchaser shall
be responsible to its customers and end users for all post-warranty support and
maintenance. In the event Purchaser requests provision of post-warranty service
by Supplier other than as expressly provided in this Agreement, such will be
provided, at Supplier's discretion, on a time and materials basis. Supplier
shall make available to the Purchaser spare parts and assemblies for seven (7)
years after the date of the last unit shipped to Purchaser. A list of Supplier's
current standard prices for spare parts is attached hereto as Schedule E (Spare
Parts Price List).

            8.4 Marketing and Promotional Materials. Supplier shall provide
existing promotional materials and technical consultation to Purchaser for
Purchaser's development of its own internal promotional and educational
materials. Purchaser shall be solely responsible for the costs of developing
promotional and educational materials for Purchaser's customers and end users.

      9. Product Recalls. Supplier shall be responsible for all Product recalls.
Supplier agrees to take any and all actions, at its sole cost and expense, which
are reasonably necessary and appropriate to effectuate a Product corrective
action, including, without limitation, a Product recall, provided, however that
Purchaser agrees to cooperate with Supplier in such action, including, without
limitation contacting customers and assisting in the transfer of Products, as
directed by Supplier, if necessary. Supplier agrees to respond within a
reasonable period to any question or request for information received by
Purchaser from its customers pertaining to the production of Product. Each party
agrees to provide to the other party all necessary information in its possession
arising out of a recall or corrective action program or similar program,
including a Supplier quality assurance program. Upon thirty (30) business days
written notice, each party shall, at a time and place mutually agreeable to the
parties, have the right to audit and inspect the other's facilities and/or
records relating to such party's obligations under this Agreement and with
respect to the Products. All information that the inspecting party obtains in
the course of such inspection or audit shall be treated as "Confidential
Information," in accordance with Section 4 (Confidentiality) of this Agreement.

      10. Software.

            10.1 Title. Notwithstanding the references in this Agreement to the
purchase of Products by Purchaser, the parties intend and agree that the
veterinary software programs


                                    Page 10
<PAGE>

included or embedded in the Products (the "Programs") necessary for the
operation of the Products are being licensed by Supplier to Purchaser on an
exclusive basis, and are not being sold by Supplier or purchased by Purchaser.
Supplier or the ultimate owner of the Programs, as the case may be, shall retain
title to the Programs.

            10.2 Limited Use License. Supplier hereby grants to Purchaser a
nontransferable, royalty-free license (with right of sublicense through
Purchaser's channels of distribution) to use the Programs in connection with the
use, sale and/or distribution of Products. Purchaser shall retain and shall not
alter or obscure any notices, markings or other insignia which are affixed to
the Programs, related documentation or any part thereof. Purchaser shall not
have the right to disassemble, decompose or otherwise reverse engineer the
Programs. The foregoing license as to Purchaser (but not as to any customers or
end users who have purchased the Products) shall terminate upon the expiration
or earlier termination or expiration of this Agreement.

      11. Representation and Warranties. Each party hereby represents and
warrants to the other party as of the Effective Date as follows:

            11.1 Authorization. Such party (i) has the corporate power and
authority and the legal right to enter into the Agreement and perform its
obligations hereunder, and (ii) has taken all necessary corporate action on its
part required to authorize the execution and delivery of the Agreement and the
performance of its obligations hereunder. The Agreement has been duly executed
and delivered on behalf of such party, and constitutes a legal, valid, binding
obligation of such party and is enforceable against it in accordance with its
terms subject to the effects of bankruptcy, insolvency or other laws of general
application affecting the enforcement of creditor rights and judicial principles
affecting the availability of specific performance and general principles of
equity whether enforceability is considered a proceeding at law or equity.

            11.2 Absence of Litigation. Supplier is not aware of any pending or
threatened litigation (and has not received any communication) which alleges
that the Products infringe upon any intellectual property rights of a third
party.

            11.3 Consents. All necessary consents, approvals and authorizations
of all governmental authorities and other persons or entities required to be
obtained by such party in connection with the Agreement have been obtained.

            11.4 Intellectual Property. To the best of Supplier's knowledge,
Supplier has sufficient legal and/or beneficial title and ownership under
Supplier's intellectual property rights or sufficient license rights necessary
for Supplier to fulfill Supplier's obligations under this Agreement and that
Supplier is not aware of any communication alleging that Supplier has infringed
the intellectual property rights of any third party. In the event that Supplier
becomes aware that a Product may infringe a patent of a third party, Supplier
agrees to disclose such patent to Purchaser. Supplier further agrees (i) to
inquire of the applicable third party as to whether a license under such patent
is available, and if so, (ii) to negotiate, in good faith, a license under such
patent which would permit Purchaser to distribute the applicable Product as
contemplated hereunder. If Supplier does not negotiate such a license in good
faith and


                                    Page 11
<PAGE>

Purchaser in good faith believes, from a business perspective, that a license
under such patent is appropriate, Supplier agrees that Purchaser may contact the
applicable third party in order to negotiate a license under such patent and
Supplier agrees to reimburse Purchaser for any monies paid by Purchaser to the
applicable third party under such patent license. As used herein, "intellectual
property rights" means all patent rights, copyrights, trademarks, trade secret
rights, and know-how rights necessary or useful to make, have made, use, offer
for sale, sell, have sold, import and export the Products.

      12. Indemnities.

            12.1 By Supplier. Supplier shall indemnify, defend and hold
Purchaser harmless from and against any damages, claims, suits, actions, causes
of action, demands, liabilities, losses, costs and expenses (including without
limitation reasonable attorneys' fees and disbursements and court costs) as a
result of or arising out of any claim (a) that the Products supplied hereunder
infringe any patent or valid copyright of a third party; or (b) the Products
supplied hereunder have caused bodily injury or property damage provided that
(i) Purchaser shall have promptly provided Supplier written notice of such claim
and reasonable cooperation, information and assistance in connection therewith
and (ii) Supplier shall have sole control and authority with respect to the
defense, settlement, or compromise thereof. Should any Product delivered
hereunder become or, in Supplier's opinion be likely to become, the subject of
such a claim under subsection (a), above, Supplier may, at its option, either
procure for Purchaser the right to continue purchasing and using such Products,
or replace or modify such Products so that they become non-infringing. In the
event neither of these options is practicable, Supplier may accept the return of
the infringing or potentially infringing Products, in exchange for a refund of
the purchase price therefor, amortized over a period of three (3) years. In any
such event, Supplier may withhold further shipments of infringing or potentially
infringing Products.

      Supplier shall have no liability or obligation to Purchaser hereunder with
respect to any infringement or claim thereof based upon (i) compliance with
designs, plans or specifications of Purchaser, (ii) use of the Products by
Purchaser in combination with devices or products not purchased hereunder where
the Products would not themselves be infringing, (iii) use of Products by
Purchaser in an application or environment for which such Products were not
designed or contemplated as specified in Schedule A (Products), (iv)
modifications of the Products by anyone other than Supplier where such
modifications directly are the cause of the infringement. The foregoing states
the entire liability of Supplier with respect to infringement of intellectual
property rights by the Products.

            12.2 By Purchaser. Purchaser shall indemnify, defend and hold
Supplier harmless from and against any damages, claims, suits, actions, causes
of action, demands, liabilities, losses, costs and expenses (including without
limitation reasonable attorneys' fees and disbursements and court costs) as a
result of or arising from any representations or warranties made by Purchaser to
customers or end users which (a) exceed the scope of the representations or
warranties made by Supplier to Purchaser pursuant to Sections 6 (Warranty and
Repairs) and 11 (Representations and Warranties) of this Agreement; or (b)
contradict the documentation and/or information made available to Purchaser by
Supplier regarding specifications, performance and intended use of the Products,
provided that (i) Supplier shall have promptly


                                    Page 12
<PAGE>

provided Purchaser written notice thereof and reasonable cooperation,
information and assistance in connection therewith, and (ii) Purchaser shall
have sole control and authority with respect to the defense, settlement or
compromise thereof.

      13. Compliance with Laws. Purchaser shall comply with all laws, rules,
regulations, governmental requirements and industry standards applicable to the
purchase, sale, leasing, licensing, marketing, demonstration, installation,
servicing, repair or use of the Products supplied to Purchaser hereunder,
including, without limitation those relating to the maintenance and availability
of records. Without in any way limiting the foregoing, Purchaser shall not
export any Product documentation or technical data relating thereto to any
jurisdiction without first obtaining all necessary export permits and
clearances, and in no event shall Purchaser export any Product in violation of
any applicable law or regulation, whether foreign or domestic. In furtherance
of, but without limiting the foregoing, Purchaser represents and covenants that
it has read, understood and will comply with the anti-bribery provisions of the
US Foreign Corrupt Practices Act.

      14. Term and Termination.

            14.1 Term. Unless earlier terminated pursuant to this Section 14
(Term and Termination) or renewed for one (1)-year terms by written agreement of
the parties hereto, this Agreement shall terminate five (5) years from the
Effective Date.

            14.2 Termination Upon Event of Default. Upon the occurrence of an
Event of Default (as defined below), the non-defaulting party, in its sole
discretion, shall have the right to terminate this Agreement, in addition to any
other remedy or remedies which may be available to it under this Agreement, at
law or in equity. In addition, upon the occurrence of an Event of Default by
Purchaser, Supplier shall have the right to cancel any or all unfilled orders
for Products submitted by Purchaser.

      The following events shall be deemed "Events of Default" with respect to
the party engage in such activity:

                  (a) Either party breaches its obligations under Section 4
(Confidentiality) or 10 (Software);

                  (b) Either party fails to perform any of its covenants,
obligations or responsibilities under this Agreement which failure remains
uncured for thirty (30) days after notice thereof from the non-defaulting party;
provided that the non-defaulting party delivers written notice to the defaulting
party within ninety (90) days of the alleged default;

                  (c) The dissolution, termination of existence, liquidation,
insolvency or business failure of either party, or the appointment of a
custodian or receiver for either party or any part of its property if such
appointment is not terminated or dismissed within sixty (60) days;

                  (d) The institution by either party of any proceeding under
the United States Bankruptcy Code or any other federal, national or state
bankruptcy, reorganization,


                                    Page 13
<PAGE>

receivership, insolvency or other similar law affecting the rights of creditors
generally or the making by either party of a composition or any assignment or
trust mortgage for the benefit of creditors; and

                  (e) The institution against either party of a proceeding under
the United States Bankruptcy Code or any other federal, national or state
bankruptcy, reorganization, receivership, insolvency or other similar law
affecting the rights of creditors generally, which proceeding is not dismissed
within sixty (60) days of filing.

            14.3 Termination for Convenience. Either party may terminate this
Agreement upon twelve (12) months prior notice to the other.

            14.4 Duties Upon Termination. Upon the termination of this Agreement
for any reason whatsoever:

                  (a) Purchaser shall pay to Supplier in full within thirty (30)
days of such termination, all amounts owed to Supplier. Supplier shall be
entitled to set off and deduct from any money due Purchaser under this
Agreement, any and all amounts due Supplier from Purchaser; and

                  (b) Purchaser shall promptly return to Supplier any and all
Supplier-owned Products or other equipment, materials, documentation or data in
the possession of Purchaser for whatever reason or purpose, such Products,
equipment, materials, documentation and data to be in the same condition as when
delivered to Purchaser, reasonable use, wear and tear excepted; and

                  (c) Supplier shall promptly return to Purchaser any and all
Purchaser-owned equipment, materials, documentation or data in the possession of
Supplier for whatever reason or purpose, such equipment, materials,
documentation and data to be in the same condition as when delivered to
Supplier, reasonable use, wear and tear excepted.

            14.5 Survival. Notwithstanding anything to the contrary in this
Agreement, the parties agree that the following provisions shall survive
expiration or earlier termination of this Agreement: 4 (Confidentiality), 6
(Warranty and Repairs), 7 (Consequential Damages Waiver; Limitation of
Liability), 8.3 (Post-Warranty Service), 9 (Product Recalls), 12 (Indemnities),
14.4 (Duties Upon Termination), and 15 (Miscellaneous).

      15. Miscellaneous.

            15.1 Force Majeure. Supplier shall not be liable in any respect for
failure to ship or for delay in shipment of Products pursuant to accepted orders
where such failure or delay shall have been due wholly or in part to the
elements, acts of God, acts of Purchaser, acts or civil or military authority,
fires, floods, epidemics, quarantine restrictions, war, armed hostilities,
riots, strikes, lockouts, breakdown, differences with workers, accidents to
machinery, delays in transportation, delays in delivery by Supplier suppliers or
any other cause beyond the reasonable control of Supplier. Upon such occurrence,
Supplier shall immediately notify Purchaser as soon as practicable of such
inability and of the period for which such inability is expected to continue,


                                    Page 14
<PAGE>

and any time for performance hereunder shall be extended by the actual time of
delay caused by the occurrence; provided, that the Supplier uses commercially
reasonable efforts to mitigate any damages incurred by the Purchaser. Products
on which delivery is delayed due to any cause within Purchaser's control may be
placed in storage by Supplier for Purchaser's account and at Purchaser's risk.
Purchaser shall be liable for all costs and expenses incurred by Supplier in
storing Products for Purchaser.

            15.2 Assignment and Corporate Reorganization. Neither this Agreement
nor any rights granted hereby may be assigned by either party voluntarily or by
operation of law without the other party's prior written consent (which will not
be unreasonably withheld) and any such attempted assignment shall be null and
void. For purposes of this Agreement, "assignment" shall be deemed to include
the transfer of all or substantially all of the assets of, or a majority
interest in the voting stock of, either party, or the merger of either party
with one or more entities. This Agreement shall inure to the benefit of and be
binding upon any successor or assign of either party.

            15.3 Equitable Relief. Nothing in this Agreement will prevent a
party from bringing an action for equitable or injunctive relief in any court of
competent jurisdiction to compel the other party to comply with its obligations
under the Agreement.

            15.4 Applicable Law and Jurisdiction. This Agreement shall be
governed by and construed in accordance with the internal laws of the State of
California without reference to the conflict of laws provisions thereof.

            15.5 Relationship of the Parties. Nothing contained in this
Agreement shall be deemed to constitute either party as the agent or
representative of the other party, or both parties as joint venturers or
partners for any purpose. Neither party shall be responsible for the acts or
omissions of the other party, and neither party will have authority to speak
for, represent or obligate the other party in any way without prior written
authority from the other party.

            15.6 Registration. In the event that this Agreement is required to
be registered with any governmental authority, Purchaser shall cause such
registration to be made and shall bear any expense or tax payable in respect
thereof.

            15.7 Entire Agreement. This Agreement constitutes the entire
agreement between Supplier and Purchaser and shall not be amended, altered or
changed except by a written agreement signed by the parties hereto. Any terms
and conditions in any purchase order or other instrument issued by Purchaser or
Supplier or any of Purchaser's customers in connection with this Agreement which
are in addition to or inconsistent with the terms and conditions of this
Agreement shall not be binding on either party and shall not be deemed to amend
or modify this Agreement. Each party acknowledges that it is not entering into
this Agreement on the basis of any representations not expressly contained
herein.

            15.8 Waivers. No delay or omission on the part of either party to
this Agreement in requiring performance by the other party or in exercising any
right hereunder shall operate as a waiver of any provision hereof or of any
right or rights hereunder; and the waiver,


                                    Page 15
<PAGE>

omission or delay in requiring performance or exercising any right hereunder on
any one occasion shall not be construed as a bar to or waiver of such
performance or right, or of any right or remedy under this Agreement, on any
future occasion. A waiver must be in writing, executed by the party against
which enforcement is sought, in order to be enforceable.

            15.9 Notices. Whenever, by the terms of this Agreement, notice,
demand or other communication shall or may be given to either party, the same
shall be in writing and shall be addressed to the other party at its address
first set forth above, or to such other address or addresses as shall from time
to time be designated by written notice by either party to the other in
accordance with this Section 15.9 (Notices). All notices shall be sent by
registered or certified mail, return receipt requested, by delivery or by
Federal Express or other comparable courier providing proof of delivery, and
shall be deemed duly given and received (i) if mailed, on the tenth business day
following the mailing thereof, or (ii) if sent by courier or if delivered, the
date of its receipt (or, if such day is not a business day, the next succeeding
business day).

            15.10 Section Heading. Section headings are for descriptive purposes
only and shall not control or alter the meaning of this Agreement.

            15.11 Rights and Remedies. All rights and remedies of either party
hereunder shall be cumulative and may be exercised singularly or concurrently.
The failure of either party, in any one or more instances, to enforce any of the
terms of this Agreement shall not be construed as a waiver of future enforcement
of that or any other term.

            15.12 Severability. If any provision of this Agreement shall for any
reason be held illegal or unenforceable, such provision shall be deemed
separable from the remaining provisions of this Agreement and shall in no way
affect or impair the validity or enforceability of the remaining provisions of
this Agreement, unless removal of the invalidated provision renders another
provision impossible to perform or inconsistent with the intent of the parties.

            15.13 Modifications, Amendments. Modifications and amendments to
this Agreement must be in writing, executed by the party against which
enforcement thereof is sought.

            15.14 No Rights by Implication. No rights or licenses with respect
to the Products are granted or deemed granted hereunder or in connection
herewith, other than those rights expressly granted in this Agreement.


                                    Page 16
<PAGE>

      IN WITNESS WHEREOF, Supplier and Purchaser hereby have duly executed this
Agreement under seal as of the day and year first above written.

PURCHASER                                      ABAXIS, INC.

                                               By:    /s/ Richard Schoen
                                                      --------------------------
                                               Name:  Richard Schoen

                                               Title: VP, Sales & Marketing

SUPPLIER                                       DIATRON MESSTECHNIK GMBH

                                               By:    /s/ Gabor Lengyel
                                                      --------------------------
                                               Name:  Gabor Lengyel

                                               Title: Managing Director

                                               November 24, 2003


                                    Page 17
<PAGE>

                                   Schedule A

- --------------------------------------------------------------------------------
*** Confidential treatment has been requested for portions of this exhibit. The
copy filed herewith omits the information subject to the confidentiality
request. Omissions are designated as [****]. A complete version of this exhibit
has been filed separately with the Securities and Exchange Commission.
- --------------------------------------------------------------------------------

                                   SCHEDULE A

                                    PRODUCTS

Product                                                           Price per Unit
- -------                                                           --------------
HMII Hematology Analyzer                                             [****]*
(including CE and UL markings, power cord,
English language operator manual, standard
accessories)

*Prices are to be understood as F.O.B. Vienna or Budapest (Incoterms 2000).

                          HMII TECHNICAL SPECIFICATIONS

                                     [****]


                                   Schedule A
<PAGE>

- --------------------------------------------------------------------------------
*** Confidential treatment has been requested for portions of this exhibit. The
copy filed herewith omits the information subject to the confidentiality
request. Omissions are designated as [****]. A complete version of this exhibit
has been filed separately with the Securities and Exchange Commission.
- --------------------------------------------------------------------------------

                                   SCHEDULE B

                          MINIMUM PURCHASE COMMITMENTS

1.    Minimum Purchase                          Units of Products

      First 12 months following availability    [****] unit order at beginning
      of Product for shipment to Purchaser      of First Contract Year
      ("Contract Year")

                                                [****] unit order in the second
                                                quarter of First Contract Year

                                                [****] unit order in the third
                                                quarter of First Contract Year

                                                [****] unit order in the fourth
                                                quarter of First Contract Year

      Second Contract Year                      [****] unit order in each
                                                quarter of Second Contract Year

      Third through Fifth Contract Years        Minimum of [****] units/month or
                                                such greater amount as the
                                                parties shall determine and
                                                agree

2.    Minimum Order Quantity                    [****] units/order


                                   Schedule B

<PAGE>

                                   SCHEDULE C

                                 WARRANTY TERMS

      The Supplier's warranty for the Products extends for the later of:

      (a)   twelve  months  (12)  from  the  date  the  product  is  shipped  to
            Purchaser, or

      (b)   twelve  months (12) from the date on which the Product is  installed
            for use by a veterinary  customer but no later than eighteen  months
            (18) from the date the  Product is shipped  to  Purchaser,  provided
            Purchaser sends Supplier an Installation Report as attached herewith
            within thirty (30) days from date of installation  including  serial
            number of the Product and date of installation.

o     The warranty gives Purchaser the right to have the defective part replaced
      free of charge  (labor,  travelling  expenses and other costs related with
      the repair not included).

o     All claims under  warranty have to be submitted to Supplier  within ninety
      (90) days after the malfunction has been observed.  Purchaser's  complaint
      shall  be  accompanied  by a  detailed  report  on the  defect  and on any
      measures  taken in order to rectify it. The report  shall  include  serial
      number and software  version of the Product and other data to be requested
      by Supplier (e.g. print-out of self-test,  measurement results,  data base
      tables, etc.).

o     Purchaser  shall inform  Supplier on  replacement  of following  parts and
      assemblies  if  replacement  was  carried out by using parts from stock or
      removed from an other instrument:

- -     PPB board and its parts
- -     COMB board
- -     Reagent Sensor board
- -     HV board
- -     Display
- -     Amplifier board
- -     Diluter block
- -     Microdiluter block
- -     XY movement block

o     Delicate parts such as printed circuit boards,  diluter  modules,  motors,
      apertures,  chambers,  parts  made of glass,  etc.  must be sent back in a
      suitable and protective packing.

o     Shipping  out  spare  or  repaired  parts  respectively  Products  will be
      Supplier's  responsibility.  Supplier is free to choose the  carrier.  The
      transportation  expenses of  returning  defective  parts or Products  from
      Purchaser to Supplier shall be Supplier's responsibility.

o     Supplier  reserves the right to inspect the defective  part or Products on
      its  return in order to  determine  the  origin of the  fault,  and if the
      defect is found not to be covered by the warranty,


                                   Schedule C

<PAGE>

      Supplier reserves the right to bill Purchaser for the spare part and labor
      required.  In any case any defective part is to be returned to Supplier in
      90 days  after  the  replacement  was  sent,  otherwise  Supplier  will be
      entitled to bill Purchaser for the supplied  material.  Purchaser shall be
      authorized to return  defective parts  accumulated in its inventory in one
      shipment quarterly or along with other regular shipment. Supplier will use
      commercially  reasonable  efforts to meet Purchaser's  requested  delivery
      schedules  for  warranty  replacements.   Unless  otherwise  specified  in
      Purchaser's  warranty  claims,   Supplier  shall  be  authorized  to  make
      deliveries  of spare parts  under  warranty  on  accumulated  basis in one
      shipment per month or along with other regular shipment.

o     After  having been  replaced  the  defective  part becomes the property of
      Supplier.

o     Supplier,  at its expense  and upon thirty (30) days notice to  Purchaser,
      will have the right to examine (during  Purchaser's  normal business hours
      and on a date to be mutually agreed upon)  Purchaser's  relevant books and
      records in order to verify Purchaser's compliance with Section 6 (Warranty
      and Repairs) and this Schedule C (Warranty Terms).  Such books and records
      will be made  available  at the place where these  records are kept in the
      ordinary course of business, and may not be copied or removed by Supplier.
      All  information  acquired by  Supplier in the course of such  examination
      will be treated as the Confidential  Information of Purchaser  pursuant to
      Section 4 (Confidentiality).


                                   Schedule C

<PAGE>

                               INSTALLATION REPORT

MODEL_________________________________________________________________

SERIAL No.____________________
INSTALLATION DATE_____________________________________________________

PURCHASER'S SIGNATURE_________________________________________________


                                   SCHEDULE C

<PAGE>

                                   SCHEDULE D

                                   INTERFACES

VetScan interface

Receive VetScan data.

Store received data temporarily, to avoid losing not printed VS data. Match
received VetScan data to stored hematology result. If matched include received
data in printout.

Sample ID dialog

Implement patient type "drop-down" list (integrated species selection).

Reorganize dialog (to include: Sample ID, Date, Patient ID, Patient Name,
Species selection, Age and Gender). Reorganize patient selection and limits
setting.

Icons with text

Replace symbols with texts, where needed, for English software version.

[GRAPHIC OMITTED]  EXIT                [GRAPHIC OMITTED]  SPECIES
[GRAPHIC OMITTED]  CANCEL              [GRAPHIC OMITTED]  OK
[GRAPHIC OMITTED]  REPEAT              [GRAPHIC OMITTED]  MENU
[GRAPHIC OMITTED]  PT. ID              [GRAPHIC OMITTED]  LIMITS


Standby Mode

Diatron will validate extended Standby Mode to allow customers to leave the
instrument on in this configuration when not in use. Recommendations on how
often to Shut Down the HMII will be provided based on Diatron findings.


                                   Schedule D

<PAGE>

Status / ready screen

                         [GRAPHIC OMITTED]  [GRAPHIC OMITTED]  [GRAPHIC OMITTED]

Implement streamlined User Ready Screen with Blank status and instructions to
begin analysis (as depicted).

Implement "screen saver" feature to indicate functions (as depicted).

             [GRAPHIC OMITTED] [GRAPHIC OMITTED] [GRAPHIC OMITTED]
                      [GRAPHIC OMITTED] [GRAPHIC OMITTED]

Screen saver should turn LCD backlight off.

Hide Lyse

Remove lyse option from user level
Enable lyse option on service level
Enable uploading patient type settings from media

Patient Results

All out of normal range results will be highlighted (inverse text on HMII
screen) for easy identification by the user.

Printout format

Make printout with numerical and graphical representation
Parameter - result - flag - numerical range (without brackets) - graphical range
Simplify printer settings
Implement printout options in printer settings: None / Text / Graph / Both

Help / info messages

All help and information messages will be reviewed and approved by Abaxis for
proper English terminology.


                                   Schedule D

<PAGE>

Measurement options

Move needle setting icon to be menu item in Measurement Local Menu Make needle
setting interactive (user defined tube types)

[GRAPHIC OMITTED]

[GRAPHIC OMITTED]

Reagent consumption and Preventive maintenance notifications

Instrument should keep track of used reagent volumes, and notify user when
reagents are calculated to run low. Instrument should instruct and help user to
perform preventive maintenance tasks, like cleaning bottom of washing head,
checking and / or replacing peristaltic pump, depending on uptime or measurement
cycles

QC profiles limited to 3

Current 6 QC levels (profiles) should be limited to three: Dog, Cat, Normal
Normal should be kept, as factory QC uses human control.

QC parameters tested out of range will be indicated by a highlighted (inverse
text on HMII screen) line for easy identification by the user.

Calibration

Default user

calibration method to be implemented as automatic calibration determined by 3
measures. Calibration parameters out of acceptable range will be indicated by a
highlighted (inverse text on HMII screen) line for easy identification by the
user.

Calibration measures producing error flags are considered unacceptable for
calibration and user will be notified of the rejection.


                                   Schedule D

<PAGE>

- --------------------------------------------------------------------------------
*** Confidential treatment has been requested for portions of this exhibit. The
copy filed herewith omits the information subject to the confidentiality
request. Omissions are designated as [****]. A complete version of this exhibit
has been filed separately with the Securities and Exchange Commission.
- --------------------------------------------------------------------------------

                                   SCHEDULE E

                             SPARE PARTS PRICE LIST

Prices are to be understood fob Vienna or Budapest
- --------------------------------------------------------------------------------
                                                                LIST PRICE
                                                                   EURO
                                                          ----------------------
     CODE                      ITEM                        NEW       REFURBISHED
- --------------------------------------------------------------------------------
     A133       HVB BOARD WITH INVERTER  (COMPL.)         [****]
- --------------------------------------------------------------------------------
     A136       LCD DISPLAY                               [****]
- --------------------------------------------------------------------------------
     A137       LAMP FOR LCD                              [****]
- --------------------------------------------------------------------------------
     A192       DIMMPC (CPU)                              [****]
- --------------------------------------------------------------------------------
     A193       HEAT SINK FOR DIMMPC                      [****]
- --------------------------------------------------------------------------------
     A302       STEPPER MOTOR                             [****]
- --------------------------------------------------------------------------------
     A304       TIMING PULLEY FOR X                       [****]
- --------------------------------------------------------------------------------
     A305       TIMING PULLEY FOR Y                       [****]
- --------------------------------------------------------------------------------
     A308       OPTO SWITCH I.                            [****]
- --------------------------------------------------------------------------------
     A309       OPTO SWITCH II.                           [****]
- --------------------------------------------------------------------------------
     A310       WASHING HEAD                              [****]
- --------------------------------------------------------------------------------
     A402       SEALING RING FOR CHAMBERS                 [****]
- --------------------------------------------------------------------------------
     A403       U-SHAPED METAL FIXING FOR APERT.          [****]
- --------------------------------------------------------------------------------
     A421       APERTURE 80 um                            [****]
- --------------------------------------------------------------------------------
     A422       GROUND ELECTRODE                          [****]
- --------------------------------------------------------------------------------
     A434       HGB MEASURING  HEAD (COMPLETE)            [****]
- --------------------------------------------------------------------------------
     A504       2/2 VALVE                                 [****]
- --------------------------------------------------------------------------------
     A505       3/2 VALVE                                 [****]
- --------------------------------------------------------------------------------
     A506       VALVE COIL FOR BOTH VALVES                [****]
- --------------------------------------------------------------------------------
     A507       2/2 VALVE HEAD                            [****]
- --------------------------------------------------------------------------------
     A508       3/2 VALVE HEAD                            [****]
- --------------------------------------------------------------------------------
     A509       VALVE MEMBRANE                            [****]
- --------------------------------------------------------------------------------
     A531       PRESSURE SENSOR                           [****]
- --------------------------------------------------------------------------------
     A541       4/2 PLASTIC TUBE (SILICON)                [****]
- --------------------------------------------------------------------------------
     A542       5/3 PLASTIC TUBE (SILICON)                [****]
- --------------------------------------------------------------------------------
     A543       4/1.8 TYGON TUBE                          [****]
- --------------------------------------------------------------------------------
     A544       5/3 REAGENT TUBE                          [****]
- --------------------------------------------------------------------------------
     A545       3,2 mm T CONNECTOR                        [****]
- --------------------------------------------------------------------------------
     A546       Y CONNECTOR                               [****]
- --------------------------------------------------------------------------------
     A551       COLOR LOCKING RING                        [****]
- --------------------------------------------------------------------------------
     A552       COLOR LOCK NUT (INSIDE)                   [****]
- --------------------------------------------------------------------------------
     A553       COLOR CODING RING (OUTSIDE)               [****]
- --------------------------------------------------------------------------------
     A554       LUER CONNECTOR FEMALE                     [****]
- --------------------------------------------------------------------------------
     A555       LUER CONNECTOR MALE                       [****]
- --------------------------------------------------------------------------------
     A556       2,3 mm T CONNECTOR                        [****]
- --------------------------------------------------------------------------------


                                   Schedule E

<PAGE>

- --------------------------------------------------------------------------------
*** Confidential treatment has been requested for portions of this exhibit. The
copy filed herewith omits the information subject to the confidentiality
request. Omissions are designated as [****]. A complete version of this exhibit
has been filed separately with the Securities and Exchange Commission.
- --------------------------------------------------------------------------------

- --------------------------------------------------------------------------------
     A560       PERISTALTIC PUMP                          [****]
- --------------------------------------------------------------------------------
     A561       TUBING FOR PERISTALTIC PUMP               [****]
- --------------------------------------------------------------------------------
     A563       CASSETTE FOR PUMP                         [****]
- --------------------------------------------------------------------------------
     A564       FIXING FOR PUMP (PAIR)                    [****]
- --------------------------------------------------------------------------------
     A565       CONNECTOR FOR PUMP (PAIR)                 [****]
- --------------------------------------------------------------------------------
     A640       INSTRUMENT FOOT                           [****]
- --------------------------------------------------------------------------------
     A701       POWER CORD  ( 220V )                      [****]
- --------------------------------------------------------------------------------
     A702       POWER CORD  ( 110V )                      [****]
- --------------------------------------------------------------------------------
     S800       THERMAL PRINTER (INTERNAL)                [****]
- --------------------------------------------------------------------------------
     S801       MECHANICS FOR INTERNAL PRINTER            [****]
- --------------------------------------------------------------------------------
     S802       ELECTRONICS FOR INTERNAL PRINTER          [****]        [****]
- --------------------------------------------------------------------------------
     S803       CASE FOR  INTERNAL PRINTER                [****]
- --------------------------------------------------------------------------------
     C400       MEASURING BLOCK EXCL. AMPLIFIER           [****]
- --------------------------------------------------------------------------------
     C510       BUFFER RESERVOIR                          [****]
- --------------------------------------------------------------------------------
     J100       POWER & PNEUMATIC BOARD                   [****]        [****]
- --------------------------------------------------------------------------------
     J110       CONTROL BOARD (COMB)                      [****]        [****]
- --------------------------------------------------------------------------------
     J111       CONTROL BOARD INCL. DIMMPC                [****]
- --------------------------------------------------------------------------------
     J132       FOIL KEYBOARD                             [****]
- --------------------------------------------------------------------------------
     J138       DISPLAY BOARD                             [****]        [****]
- --------------------------------------------------------------------------------
     J140       AMPLIFIER BOARD                           [****]        [****]
- --------------------------------------------------------------------------------
     J156       POWER SUPPLY                              [****]
- --------------------------------------------------------------------------------
     J157       MAINS SWITCH                              [****]
- --------------------------------------------------------------------------------
     J170       IDEEPROM BOARD                            [****]
- --------------------------------------------------------------------------------
     J214       DILUTER BOARD                             [****]
- --------------------------------------------------------------------------------
     J224       MICRODILUTER BOARD                        [****]
- --------------------------------------------------------------------------------
     J240       REAGENT SENSOR BOARD                      [****]
- --------------------------------------------------------------------------------
     J250       DILUTER BLOCK COMPLETE  W. 2 MOTORS       [****]        [****]
- --------------------------------------------------------------------------------
     J251       SYRINGE+PISTON (MOUNTED/2ML)              [****]
- --------------------------------------------------------------------------------
     J252       PISTON FIXING SCREW                       [****]
- --------------------------------------------------------------------------------
     J300       XY MOVMENT BLOCK                          [****]        [****]
- --------------------------------------------------------------------------------
     J301       TIMING BELT FOR X                         [****]
- --------------------------------------------------------------------------------
     J302       TIMING BELT FOR Y                         [****]
- --------------------------------------------------------------------------------
     J306       GEAR FOR Y OPTO                           [****]
- --------------------------------------------------------------------------------
     J307       H&V MOTOR OPTO BOARD                      [****]
- --------------------------------------------------------------------------------
     J311       ASPIRATOR TIP                             [****]
- --------------------------------------------------------------------------------
     J501       VALVE UNIT I. ( valve 1-5 )               [****]
- --------------------------------------------------------------------------------
     J502       VALVE UNIT. II. ( valve 11-15 )           [****]
- --------------------------------------------------------------------------------
     J503       VALVE UNIT. VET. II. ( valve 11-16 )      [****]
- --------------------------------------------------------------------------------
     J530       PRESSURE SENSOR (COMPLETE)                [****]
- --------------------------------------------------------------------------------
     J559       REAGENT TUBING SET (VET)                  [****]
- --------------------------------------------------------------------------------
     J610       MICRO SWITCH                              [****]
- --------------------------------------------------------------------------------
     J613       LED BOARD                                 [****]
- --------------------------------------------------------------------------------
     J721       AMPLIFIER BOARD CABLE                     [****]
- --------------------------------------------------------------------------------
     J750       CABLE SET                                 [****]
- --------------------------------------------------------------------------------
     J900       MICRODILUTER UNIT                         [****]        [****]
- --------------------------------------------------------------------------------
     J901       MICRO PISTON                              [****]
- --------------------------------------------------------------------------------
     J902       MICRO SYRINGE COVER                       [****]
- --------------------------------------------------------------------------------


                                   Schedule E

<PAGE>

- --------------------------------------------------------------------------------
*** Confidential treatment has been requested for portions of this exhibit. The
copy filed herewith omits the information subject to the confidentiality
request. Omissions are designated as [****]. A complete version of this exhibit
has been filed separately with the Securities and Exchange Commission.
- --------------------------------------------------------------------------------

- --------------------------------------------------------------------------------
- --------------------------------------------------------------------------------
     J903       ADAPTOR I.                                [****]
- --------------------------------------------------------------------------------
     J904       ADAPTOR II.                               [****]
- --------------------------------------------------------------------------------
     J905       ADAPTOR III.                              [****]
- --------------------------------------------------------------------------------
     S221       MACRO SYRINGE+PISTON                      [****]
- --------------------------------------------------------------------------------
     S222       LYSE SYRINGE+PISTON                       [****]
- --------------------------------------------------------------------------------
     S210       BEARING FOR DILUTOR                       [****]
- --------------------------------------------------------------------------------
     S211       SEEGER RING                               [****]
- --------------------------------------------------------------------------------

       Adaptor I: for 1-0,3 ml microtainers (Greiner, BD..) max. 011mm
       AdaptorII: for 3ml vacutainers max. 012,5mm, max height 76mm
       Adaptor III: for R&D 2ml blood control


                                   Schedule E

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-14.1
<SEQUENCE>3
<FILENAME>e18184ex14_1.htm
<DESCRIPTION>CODE OF ETHICS
<TEXT>
<html>
<head>
<title> </title>
</head>
<body>







<p><table width=100%><tr><td align=right><font size=2><B>EXHIBIT 14.1</B></font></td></tr></table>

<p><table width=100%><tr><td  align=center><font size=2><B>ABAXIS, INC.  <BR>CODE OF BUSINESS
CONDUCT AND ETHICS</B></font></td></tr></table>

<p><table width=100%><tr><td><font size=2><I>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our Code has traditionally embodied policies
encouraging individual and peer integrity, ethical behavior and our  responsibilities to
our employees, customers, suppliers, stockholders, and the public, and includes:</I></font></td></tr></table>

<br>
<table width=100%>
  <tr>
    <td width=3%></td>
    <td width=1% valign=top><font size=3>&#149;</font></td>
    <td width=3%></td>
    <td width=93%><FONT SIZE="2"><I>Prohibiting
conflicts of interest (including protecting corporate opportunities)</I></FONT></td></tr></table>

<table width=100%>
  <tr>
    <td width=3%></td>
    <td width=1% valign=top><font size=3>&#149;</font></td>
    <td width=3%></td>
    <td width=93%><FONT SIZE="2"><I>Protecting
our confidential and proprietary information and that of our customers&#146; and vendors&#146;</I></FONT></td></tr></table>

<table width=100%>
  <tr>
    <td width=3%></td>
    <td width=1% valign=top><font size=3>&#149;</font></td>
    <td width=3%></td>
    <td width=93%><FONT SIZE="2"><I>Treating
our employees, customers, suppliers and competitors fairly and with the outmost respect</I></FONT></td></tr></table>

<table width=100%>
  <tr>
    <td width=3%></td>
    <td width=1% valign=top><font size=3>&#149;</font></td>
    <td width=3%></td>
    <td width=93%><FONT SIZE="2"><I>Encouraging
full, fair, accurate, timely and understandable disclosur</I>e</FONT></td></tr></table>

<table width=100%>
  <tr>
    <td width=3%></td>
    <td width=1% valign=top><font size=3>&#149;</font></td>
    <td width=3%></td>
    <td width=93%><FONT SIZE="2"><I>Protecting
and properly using company assets</I></FONT></td></tr></table>

<table width=100%>
  <tr>
    <td width=3%></td>
    <td width=1% valign=top><font size=3>&#149;</font></td>
    <td width=3%></td>
    <td width=93%><FONT SIZE="2"><I>Complying
with laws, rules and regulations (including insider trading laws)</I></FONT></td></tr></table>

<table width=100%>
  <tr>
    <td width=3%></td>
    <td width=1% valign=top><font size=3>&#149;</font></td>
    <td width=3%></td>
    <td width=93%><FONT SIZE="2"><I>Encouraging
the reporting of any unlawful or unethical behavior</I></FONT></td></tr></table>

<br>
<table width=100%>
  <tr>
    <td width=100% colspan="4"><FONT SIZE="2"><I>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
      information below are those portions of our code of business conduct and
      ethics, which address the issues listed above.</I></FONT></td>
  </tr>
</table>

<p><table width=100%><tr><td><font size=2><B>Table of Content</B></font></td></tr></table>


<table 0 cellspacing=0 cellpadding=0 width=100%>
  <tr valign="top">
    <td colspan="6">
      <hr size="1" noshade>
    </td>
  </tr>
  <tr valign="top">
    <td width="49"> <font size="2">Section</font></td>
    <td width="21">&nbsp;</td>
    <td width="453"> <font size="2">Topic</font></td>
    <td width="38">&nbsp;</td>
    <td colspan="2" align="center"> <font size="2">Page</font></td>
  </tr>
  <tr valign="top">
    <td colspan="6">
      <hr size="1" noshade>
    </td>
  </tr>
  <tr valign="top">
    <td width="49"><font size="2"></font></td>
    <td width="21">&nbsp;</td>
    <td width="453"> <font size="2">Transmittal letter from President and CEO
      - "A Message About the Code from the President and CEO"</font></td>
    <td align="center" width="38">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</td>
    <td align="right" width="26"> <font size="2">2</font></td>
    <td align="center" width="13">&nbsp;&nbsp;</td>
  </tr>
  <tr valign="top">
    <td width="49"> <font size="2">1</font></td>
    <td width="21">&nbsp;&nbsp;</td>
    <td width="453"> <font size="2">Policy Statement</font></td>
    <td align="center" width="38">&nbsp;</td>
    <td align="right" width="26"> <font size="2">3</font></td>
    <td align="center" width="13">&nbsp;</td>
  </tr>
  <tr valign="top">
    <td width="49"> <font size="2">2</font></td>
    <td width="21">&nbsp;</td>
    <td width="453"> <font size="2">Compliance with Laws and Regulations</font></td>
    <td align="center" width="38">&nbsp;</td>
    <td align="right" width="26"> <font size="2">3</font></td>
    <td align="center" width="13">&nbsp;</td>
  </tr>
  <tr valign="top">
    <td width="49"> <font size="2">3</font></td>
    <td width="21">&nbsp;</td>
    <td width="453"> <font size="2">Full, Fair, Accurate, Timely and Understandable
      Disclosure</font></td>
    <td align="center" width="38">&nbsp;</td>
    <td align="right" width="26"> <font size="2">4</font></td>
    <td align="center" width="13">&nbsp;</td>
  </tr>
  <tr valign="top">
    <td width="49"> <font size="2">4</font></td>
    <td width="21">&nbsp;</td>
    <td width="453"> <font size="2">Special Ethics Obligations for Employees With
      Financial Reporting Responsibilities</font></td>
    <td align="center" width="38">&nbsp;</td>
    <td align="right" width="26"> <font size="2">4</font></td>
    <td align="center" width="13">&nbsp;</td>
  </tr>
  <tr valign="top">
    <td width="49"> <font size="2">5</font></td>
    <td width="21">&nbsp;</td>
    <td width="453"> <font size="2">Insider Trading</font></td>
    <td align="center" width="38">&nbsp;</td>
    <td align="right" width="26"> <font size="2">4</font></td>
    <td align="center" width="13">&nbsp;</td>
  </tr>
  <tr valign="top">
    <td width="49"> <font size="2">6</font></td>
    <td width="21">&nbsp;</td>
    <td width="453"> <font size="2">Conflicts of Interest and Corporate Opportunities
      </font></td>
    <td align="center" width="38">&nbsp;</td>
    <td align="right" width="26"> <font size="2">5</font></td>
    <td align="center" width="13">&nbsp;</td>
  </tr>
  <tr valign="top">
    <td width="49"> <font size="2">7</font></td>
    <td width="21">&nbsp;</td>
    <td width="453"> <font size="2">Confidentiality </font></td>
    <td align="center" width="38">&nbsp;</td>
    <td align="right" width="26"> <font size="2">6</font></td>
    <td align="center" width="13">&nbsp;</td>
  </tr>
  <tr valign="top">
    <td width="49"> <font size="2">8</font></td>
    <td width="21">&nbsp;</td>
    <td width="453"> <font size="2">Fair Dealing </font></td>
    <td align="center" width="38">&nbsp;</td>
    <td align="right" width="26"> <font size="2">6</font></td>
    <td align="center" width="13">&nbsp;</td>
  </tr>
  <tr valign="top">
    <td width="49"> <font size="2">9</font></td>
    <td width="21">&nbsp;</td>
    <td width="453"> <font size="2">Protection and Proper Use of Company Assets</font></td>
    <td align="center" width="38">&nbsp;</td>
    <td align="right" width="26"> <font size="2">6</font></td>
    <td align="center" width="13">&nbsp;</td>
  </tr>
  <tr valign="top">
    <td width="49"> <font size="2">10</font></td>
    <td width="21">&nbsp;</td>
    <td width="453"> <font size="2">Reporting Violations of Company Policies and
      Receipt of Complaints Regarding Financial Reporting or Accounting Issues
      </font></td>
    <td align="center" width="38">&nbsp;</td>
    <td align="right" width="26"> <font size="2">7</font></td>
    <td align="center" width="13">&nbsp;</td>
  </tr>
  <tr valign="top">
    <td width="49"> <font size="2">11</font></td>
    <td width="21">&nbsp;</td>
    <td width="453"> <font size="2">Compliance Procedures </font></td>
    <td align="center" width="38">&nbsp;</td>
    <td align="right" width="26"> <font size="2">8</font></td>
    <td align="center" width="13">&nbsp;</td>
  </tr>
  <tr valign="top">
    <td width="49"> <font size="2">12</font></td>
    <td width="21">&nbsp;</td>
    <td width="453"> <font size="2">Publication of the Code of Business Conduct
      and Ethics; Amendments and Waivers of the Code of Business Conduct and Ethics</font></td>
    <td align="center" width="38">&nbsp;</td>
    <td align="right" width="26"> <font size="2"> 10</font></td>
    <td align="center" width="13">&nbsp;</td>
  </tr>
  <tr valign="top">
    <td width="49"><font size="2"></font></td>
    <td width="21">&nbsp;</td>
    <td width="453"> <font size="2">Policy for Reporting Violations and Complaints</font></td>
    <td align="center" width="38">&nbsp;</td>
    <td align="right" width="26"> <font size="2">11</font></td>
    <td align="center" width="13">&nbsp;</td>
  </tr>
</table>
<p>&nbsp;</p><table width=100%><tr><td width=10% align=left><font size=1>&nbsp;</font></td><td width=80% align=center><font size="2">
1</font></td><td width=10% align=right><font size="1">&nbsp;</font></td></tr></table><p>&nbsp;<hr size=5 noshade width=100%align=LEFT><p>&nbsp;





<!-- *************************************************************************** -->
<!-- MARKER PAGE="sheet: 20; page: 20" -->



<p><table width=100%><tr><td><font size=2><B>Transmittal letter from President and CEO:</B></font></td></tr></table>

<p><table width=100%><tr><td><font size=2><B>A Message About the Code from the President
and CEO:</B></font></td></tr></table>

<p><table width=100%><tr><td><font size=2>To All Officers, Directors and Employees:</font></td></tr></table>

<p><table width=100%><tr><td><font size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;One of our
Company&#146;s most valuable assets is its integrity. Protecting  this asset is the job of
everyone in the Company. To that end, we have  established a Code of Business Conduct and
Ethics. The Code applies to every  officer, director and employee. We also expect that
those with whom we do  business (including our agents, consultants, suppliers and
customers) will also  adhere to the Code. Our Code is designed to help you comply with
the law and  maintain the highest standards of ethical conduct. The Code does not cover
every  issue that may arise, but it sets out basic principles and a methodology to help
guide you in the attainment of this common goal.</font></td></tr></table>

<p><table width=100%><tr><td><font size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;All of the
Company&#146;s officers, directors and employees must carry out  their duties in accordance
with the policies set forth in this Code and with  applicable laws and regulations. To
the extent that other Company polices and  procedures conflict with this Code, you should
follow this Code. Any violation  of applicable law or any deviation from the standards
embodied in this Code will  result in disciplinary action up to and including
termination. Disciplinary  action also may apply to an employee&#146;s supervisor who directs
or approves the  employee&#146;s improper actions, or is aware of those actions but does not
act  appropriately to correct them. In addition to imposing its own discipline, the
Company may also bring suspected violations of law to the attention of the  appropriate
law enforcement personnel. If you are in a situation which you  believe may violate or
lead to a violation of this Code, follow the procedures  described in Sections 10 and 11
of the Code.</font></td></tr></table>

<p>
<table width=100%>
  <tr>
    <td align=right width="293">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</td>
    <td align=left valign="bottom" width="295"><font size=2><B>Clint Severson
      <BR>
      President and Chief Executive Officer</B></font></td>
  </tr>
</table>


<p>&nbsp;
<table width=100%><tr><td width=10% align=left><font size=1>&nbsp;</font></td><td width=80% align=center><font size="2">
2</font></td><td width=10% align=right><font size="1">&nbsp;</font></td></tr></table><p>&nbsp;<hr size=5 noshade width=100%align=LEFT><p>&nbsp;





<!-- *************************************************************************** -->
<!-- MARKER PAGE="sheet: 21; page: 21" -->



<p><table width=100%><tr><td  align=center><font size=2><B>ABAXIS, INC.</B></font></td></tr></table>

<p><table width=100%><tr><td  align=center><font size=2><B>CODE OF BUSINESS CONDUCT AND
ETHICS</B></font></td></tr></table>

<p><table width=100%><tr>
    <td><font size=2><B>1. &nbsp;Policy Statement</B></font></td>
  </tr></table>

<p><table width=100%><tr><td><font size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Nasdaq rules
require that the Company provide a code of conduct for  all of its directors, officers
and employees. This Company is committed to being  a good corporate citizen. The
Company&#146;s policy is to conduct its business  affairs honestly and in an ethical manner.
That goal cannot be achieved unless  you individually accept your responsibility to
promote integrity and demonstrate  the highest level of ethical conduct in all of your
activities. Activities that  may call into question the Company&#146;s reputation or integrity
should be avoided.  The Company understands that not every situation is black and white.
The key to  compliance with the Code is exercising good judgment. This means following
the  spirit of this Code and the law, doing the &#147;right&#148; thing and acting
ethically  even when the law is not specific. When you are faced with a business
situation  where you must determine the right thing to do, you should ask the following
questions:</font></td></tr></table>

<br>
<table width=100%>
  <tr>
    <td width=3%></td>
    <td width=1% valign=top><font size=3>&#149;</font></td>
    <td width=3%></td>
    <td width=93%><font size=2>Am
I following the spirit, as well as the letter, of any law or Company  policy?</font></td></tr></table>

<table width=100%>
  <tr>
    <td width=3%></td>
    <td width=1% valign=top><font size=3>&#149;</font></td>
    <td width=3%></td>
    <td width=93%><font size=2>Would
I want my actions reported on 60 Minutes?</font></td></tr></table>

<table width=100%>
  <tr>
    <td width=3%></td>
    <td width=1% valign=top><font size=3>&#149;</font></td>
    <td width=3%></td>
    <td width=93%><font size=2>What
would my family, friends or neighbors think of my actions?</font></td></tr></table>

<table width=100%>
  <tr>
    <td width=3%></td>
    <td width=1% valign=top><font size=3>&#149;</font></td>
    <td width=3%></td>
    <td width=93%><font size=2>Will
there be any direct or indirect negative consequences for the Company?</font></td></tr></table>

<p><table width=100%><tr><td><font size=2>Managers set an example for other employees and
are often responsible for  directing the actions of others. Every manager and supervisor
is expected to  take necessary actions to ensure compliance with this Code, to provide
guidance  and assist employees in resolving questions concerning the Code and to permit
employees to express any concerns regarding compliance with this Code. No one  has the
authority to order another employee to act contrary to this Code.</font></td></tr></table>

<p><table width=100%><tr>
    <td><font size=2><B>2. &nbsp;Compliance with Laws and Regulations</B></font></td>
  </tr></table>

<p><table width=100%><tr><td>
<font size=2><B><I>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company
seeks to comply with both the letter and spirit of the laws and regulations in all
countries in which it operates.</I></B></font></td></tr></table>



<p><table width=100%><tr><td><font size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company is
committed to full compliance with the laws and  regulations of the cities, states and
countries in which it operates. You must  comply with all applicable laws, rules and
regulations in performing your duties  for the Company. Numerous federal, state and local
laws and regulations define  and establish obligations with which the Company, its
employees and agents must  comply. Under certain circumstances, local country law may
establish  requirements that differ from this Code. You are expected to comply with all
local country laws in conducting the Company&#146;s business. If you violate these  laws or
regulations in performing your duties for the Company, you not only risk  individual
indictment, prosecution and penalties, and civil actions and  penalties, you also subject
the Company to the same risks and penalties. If you  violate these laws in performing
your duties for the Company, you may be subject  to immediate disciplinary action,
including possible termination of your  employment or affiliation with the Company.</font></td></tr></table>

<p><table width=100%><tr><td><font size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As explained
below, you should always consult your manager or any  Company officers with any questions
about the legality of you or your  colleagues&#146; conduct.</font></td></tr></table>

<p><table width=100%><tr>
    <td><font size=2><B>3. &nbsp;Full, Fair, Accurate, Timely and Understandable
      Disclosure</B></font></td>
  </tr></table>

<p><table width=100%><tr><td><font size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;It is of paramount
importance to the Company that all disclosure in  reports and documents that the Company
files with, or submits to, the SEC, and  in other public communications made by the
Company is full, fair, accurate,  timely and understandable. You must take all steps
available to assist the  Company in these responsibilities consistent with your role
within the Company.  In particular, you are required to provide prompt and accurate
answers to all  inquiries made to you in connection with the Company&#146;s preparation of its
public  reports and disclosure.</font></td></tr></table>

<p><table width=100%><tr><td><font size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company&#146;s
Chief Executive Officer (&#147;CEO&#148;) and Chief Financial  Officer (&#147;CFO&#148;)
are responsible for designing, establishing, maintaining,  reviewing and evaluating on a
quarterly basis the effectiveness of the Company&#146;s  disclosure controls and procedures
(as such term is defined by applicable SEC  rules). The Company&#146;s CEO, CFO and such other
Company officers are designated  from time to time by the Audit Committee of the Board of
Directors shall be  deemed </font></td></tr></table>



<p>&nbsp;
<table width=100%><tr><td width=10% align=left><font size=1>&nbsp;</font></td><td width=80% align=center><font size="2">
3</font></td><td width=10% align=right><font size="1">&nbsp;</font></td></tr></table><p>&nbsp;<hr size=5 noshade width=100%align=LEFT><p>&nbsp;





<!-- *************************************************************************** -->
<!-- MARKER PAGE="sheet: 22; page: 22" -->



<p><table width=100%><tr><td><font size=2>the Senior Officers of the Company. Senior
Officers shall take all steps  necessary or advisable to ensure that all disclosure in
reports and documents  filed with or submitted to the SEC, and all disclosure in other
public  communication made by the Company is full, fair, accurate, timely and
understandable.</font></td></tr></table>

<p><table width=100%><tr><td><font size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Senior Officers
are also responsible for establishing and maintaining  adequate internal control over
financial reporting to provide reasonable  assurance regarding the reliability of
financial reporting and the preparation  of financial statements for external purposes in
accordance with generally  accepted accounting principles. The Senior Officers will take
all necessary  steps to ensure compliance with established accounting procedures, the
Company&#146;s  system of internal controls and generally accepted accounting principles.
Senior  Officers will ensure that the Company makes and keeps books, records, and
accounts, which, in reasonable detail, accurately and fairly reflect the  transactions
and dispositions of the assets of the Company. Senior Officers will  also ensure that the
Company devises and maintains a system of internal  accounting controls sufficient to
provide reasonable assurances that:</font></td></tr></table>

<br>
<table width=100%>
  <tr>
    <td width=3%></td>
    <td width=1% valign=top><font size=3>&#149;</font></td>
    <td width=3%></td>
    <td width=93%><font size=2>transactions
are executed in accordance with management&#146;s general or specific authorization;</font></td></tr></table>

<table width=100%>
  <tr>
    <td width=3%></td>
    <td width=1% valign=top><font size=3>&#149;</font></td>
    <td width=3%></td>
    <td width=93%><font size=2>transactions
are recorded as necessary (a) to permit preparation  of financial statements in
conformity with generally accepted  accounting principles or any other criteria
applicable to such  statements, and (b) to maintain accountability for assets;</font></td></tr></table>

<table width=100%>
  <tr>
    <td width=3%></td>
    <td width=1% valign=top><font size=3>&#149;</font></td>
    <td width=3%></td>
    <td width=93%><font size=2>access
to assets is permitted, and receipts and expenditures are  made, only in accordance with
management&#146;s general or specific  authorization; and</font></td></tr></table>

<table width=100%>
  <tr>
    <td width=3%></td>
    <td width=1% valign=top><font size=3>&#149;</font></td>
    <td width=3%></td>
    <td width=93%><font size=2>the
recorded accountability for assets is compared with the  existing assets at reasonable
intervals and appropriate action is  taken with respect to any differences, all to permit
prevention or  timely detection of unauthorized acquisition, use or disposition  of
assets that could have a material effect on the Company&#146;s  financial statements.</font></td></tr></table>

<p><table width=100%><tr><td><font size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Any attempt to
enter inaccurate or fraudulent information into the  Company&#146;s accounting system will not
be tolerated and will result in  disciplinary action, up to and including termination of
employment.</font></td></tr></table>

<p><table width=100%><tr>
    <td><font size=2><B>4. &nbsp;Special Ethics Obligations For Employees With
      Financial Reporting Responsibilities</B></font></td>
  </tr></table>

<p><table width=100%><tr><td><font size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Senior Officers
each bear a special responsibility for promoting  integrity throughout the Company.
Furthermore, the Senior Officers have a  responsibility to foster a culture throughout
the Company as a whole that  ensures the fair and timely reporting of the Company&#146;s
results of operation and  financial condition and other financial information.</font></td></tr></table>

<p><table width=100%><tr><td><font size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Because of this
special role, the Senior Officers are bound by the  following Financial Officer Code of
Ethics, and by accepting the Code of  Business Conduct and Ethics each agrees that he or
she will:</font></td></tr></table>

<br>
<table width=100%>
  <tr>
    <td width=3%></td>
    <td width=1% valign=top><font size=3>&#149;</font></td>
    <td width=3%></td>
    <td width=93%><font size=2>Perform
his or her duties in an honest and ethical manner.</font></td></tr></table>

<table width=100%>
  <tr>
    <td width=3%></td>
    <td width=1% valign=top><font size=3>&#149;</font></td>
    <td width=3%></td>
    <td width=93%><font size=2>Handle
all actual or apparent conflicts of interest between his or  her personal and
professional relationships in an ethical manner.</font></td></tr></table>

<table width=100%>
  <tr>
    <td width=3%></td>
    <td width=1% valign=top><font size=3>&#149;</font></td>
    <td width=3%></td>
    <td width=93%><font size=2>Take
all necessary actions to ensure full, fair, accurate, timely,  and understandable
disclosure in reports and documents that the  Company files with, or submits to,
government agencies and in  other public communications.</font></td></tr></table>

<table width=100%>
  <tr>
    <td width=3%></td>
    <td width=1% valign=top><font size=3>&#149;</font></td>
    <td width=3%></td>
    <td width=93%><font size=2>Comply
with all applicable laws, rules and regulations of federal, state and  local governments.</font></td></tr></table>

<table width=100%>
  <tr>
    <td width=3%></td>
    <td width=1% valign=top><font size=3>&#149;</font></td>
    <td width=3%></td>
    <td width=93%><font size=2>Proactively
promote and be an example of ethical behavior in the work  environment.</font></td></tr></table>

<p><table width=100%><tr>
    <td><font size=2><B>5. &nbsp;Insider Trading</B></font></td>
  </tr></table>

<p><table width=100%><tr><td><font size=2><i>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;You should
never trade securities on the basis of confidential  information acquired through your
employment or fiduciary relationship with the  Company.</i></font></td></tr></table>



<p>&nbsp;
<table width=100%><tr><td width=10% align=left><font size=1>&nbsp;</font></td><td width=80% align=center><font size="2">
4</font></td><td width=10% align=right><font size="1">&nbsp;</font></td></tr></table><p>&nbsp;<hr size=5 noshade width=100%align=LEFT><p>&nbsp;





<!-- *************************************************************************** -->
<!-- MARKER PAGE="sheet: 23; page: 23" -->



<p><table width=100%><tr><td><font size=2>You are prohibited under both federal law and
Company policy from purchasing or  selling Company stock, directly or indirectly, on the
basis of material  non-public information concerning the Company. Any person possessing
material  non-public information about the Company must not engage in transactions
involving Company securities until this information has been released to the  public.
Generally, material information is that which would be expected to  affect the investment
decisions of a reasonable investor or the market price of  the stock. You must also
refrain from trading in the stock of other publicly  held companies, such as existing or
potential customers or suppliers, on the  basis of material confidential information
obtained in the course of your  employment or service as a director. It is also illegal
to recommend a stock to  (i.e., &#147;tip&#148;) someone else on the basis of such
information. If you have a  question concerning appropriateness or legality of a
particular securities  transaction, consult with the Company&#146;s CFO or Human Resource
Administrator.  Officers, directors and certain other employees of the Company are
subject to  additional responsibilities under the Company&#146;s insider trading compliance
policy, a copy of which has been provided to each such officer, director and  employee,
and which can be obtained from the Company&#146;s Human Resource  Administrator.</font></td></tr></table>

<p><table width=100%><tr>
    <td><font size=2><B>6. &nbsp;Conflicts of Interest and Corporate Opportunities</B></font></td>
  </tr></table>

<p><table width=100%><tr><td><font size=2><i>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;You must avoid
any situation in which your personal interests conflict  or even appear to conflict with
the Company&#146;s interests. You owe a duty to the  Company not to compromise the Company&#146;s
legitimate interests and to advance such  interests when the opportunity to do so arises
in the course of your employment.</i></font></td></tr></table>

<p><table width=100%><tr><td><font size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;You shall perform
your duties to the Company in an honest and ethical  manner. You shall handle all actual
or apparent conflicts of interest between  your personal and professional relationships
in an ethical manner.</font></td></tr></table>

<p><table width=100%><tr><td><font size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;You should avoid
situations in which your personal, family or financial  interests conflict or even appear
to conflict with those of the Company. You may  not engage in activities that compete
with the Company or compromise its  interests. You should not take for your own benefit
opportunities discovered in  the course of employment that you have reason to know would
benefit the Company.  The following are examples of actual or potential conflicts:</font></td></tr></table>

<br>
<table width=100%>
  <tr>
    <td width=3%></td>
    <td width=1% valign=top><font size=3>&#149;</font></td>
    <td width=3%></td>
    <td width=93%><font size=2>you,
or a member of your family, receive improper personal benefits as a result of your
position in the Company;</font></td></tr></table>

<table width=100%>
  <tr>
    <td width=3%></td>
    <td width=1% valign=top><font size=3>&#149;</font></td>
    <td width=3%></td>
    <td width=93%><font size=2>you
use Company&#146;s property for your personal benefit;</font></td></tr></table>

<table width=100%>
  <tr>
    <td width=3%></td>
    <td width=1% valign=top><font size=3>&#149;</font></td>
    <td width=3%></td>
    <td width=93%><font size=2>you
engage in activities that interfere with your loyalty to the Company or your ability to
perform Company duties or  responsibilities effectively;</font></td></tr></table>

<table width=100%>
  <tr>
    <td width=3%></td>
    <td width=1% valign=top><font size=3>&#149;</font></td>
    <td width=3%></td>
    <td width=93%><font size=2>you
work simultaneously (whether as an employee or a consultant) for a competitor, customer
or supplier;</font></td></tr></table>

<table width=100%>
  <tr>
    <td width=3%></td>
    <td width=1% valign=top><font size=3>&#149;</font></td>
    <td width=3%></td>
    <td width=93%><font size=2>you,
or a member of your family, have a financial interest in a  customer, supplier, or
competitor which is significant enough to  cause divided loyalty with the Company or the
appearance of  divided loyalty (the significance of a financial interest depends  on many
factors, such as size of investment in relation to your  income, net worth and/or
financial needs, your potential to  influence decisions that could impact your interests,
and the  nature of the business or level of competition between the Company  and the
supplier, customer or competitor);</font></td></tr></table>

<table width=100%>
  <tr>
    <td width=3%></td>
    <td width=1% valign=top><font size=3>&#149;</font></td>
    <td width=3%></td>
    <td width=93%><font size=2>you,
or a member of your family, acquire an interest in property  (such as real estate, patent
or other intellectual property rights  or securities) in which you have reason to know
the Company has,  or might have, a legitimate interest;</font></td></tr></table>

<table width=100%>
  <tr>
    <td width=3%></td>
    <td width=1% valign=top><font size=3>&#149;</font></td>
    <td width=3%></td>
    <td width=93%><font size=2>you,
or a member of your family, receive a loan or a guarantee of  a loan from a customer,
supplier or competitor (other than a loan  from a financial institution made in the
ordinary course of  business and on an arm&#146;s-length basis);</font></td></tr></table>

<table width=100%>
  <tr>
    <td width=3%></td>
    <td width=1% valign=top><font size=3>&#149;</font></td>
    <td width=3%></td>
    <td width=93%><font size=2>you
divulge or use the Company&#146;s confidential information - such  as financial data, customer
information, or computer programs -  for your own personal or business purposes;</font></td></tr></table>

<table width=100%>
  <tr>
    <td width=3%></td>
    <td width=1% valign=top><font size=3>&#149;</font></td>
    <td width=3%></td>
    <td width=93%><font size=2>you
make gifts or payments, or provide special favors, to  customers, suppliers or
competitors (or their immediate family  members) with a value significant enough to cause
the customer,  supplier or competitor to </font></td></tr></table>



<p>&nbsp;
<table width=100%><tr><td width=10% align=left><font size=1>&nbsp;</font></td><td width=80% align=center><font size="2">
5</font></td><td width=10% align=right><font size="1">&nbsp;</font></td></tr></table><p>&nbsp;<hr size=5 noshade width=100%align=LEFT>
<p>&nbsp; <!-- *************************************************************************** -->
  <!-- MARKER PAGE="sheet: 24; page: 24" -->
<p>&nbsp;
<table width=100%>
  <tr>
    <td width=3%></td>
    <td width=1% valign=top><font size=3>&nbsp;</font></td>
    <td width=3%></td>
    <td width=93%><font size=2>make
a purchase, or take or forego other  action, which is beneficial to the Company and which
the customer,  supplier or competitor would not otherwise have taken; or</font></td></tr></table>

<table width=100%>
  <tr>
    <td width=3%></td>
    <td width=1% valign=top><font size=3>&#149;</font></td>
    <td width=3%></td>
    <td width=93%><font size=2>you
are given the right to buy stock in other companies or you  receive cash or other
payments in return for promoting the  services of an advisor, such as an investment
banker, to the  Company.</font></td></tr></table>

<p><table width=100%><tr><td><font size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Neither you, nor
members of your immediate family, are permitted to  solicit or accept valuable gifts,
payments, special favors or other  consideration from customers, suppliers or
competitors. Any gifts may be  accepted only on behalf of the Company with the approval
of your manager. Any  gifts should be turned over to Human Resources for appropriate
distribution. Any  exchange of gifts must be conducted so that there is no appearance of
impropriety. Gifts may be given only in compliance with the Foreign Corrupt  Practices
Act.</font></td></tr></table>

<p><table width=100%><tr><td><font size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Conflicts are not
always clear-cut. If you become aware of a conflict  described above or any other
conflict, potential conflict, or have a question as  to a potential conflict, you should
consult with the Company&#146;s Compliance  Officer and/or follow the procedures described in
Sections 10 and 11 of the  Code. If you become involved in a situation that gives rise to
an actual  conflict, you must inform the Company&#146;s Compliance Officer of the conflict.</font></td></tr></table>

<p><table width=100%><tr>
    <td><font size=2><B>7. &nbsp;Confidentiality</B></font></td>
  </tr></table>

<p><table width=100%><tr><td>
<font size=2><B><I>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;All
confidential information concerning the Company obtained by you is the property of the
Company and must be protected.</I></B></font></td></tr></table>

<p><table width=100%><tr><td><font size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Confidential
information includes all non-public information that might  be of use to competitors, or
harmful to the Company or its customers, if  disclosed. You must maintain the
confidentiality of such information entrusted  to you by the Company, its customers and
its suppliers, except when disclosure  is authorized by the Company or required by law.</font></td></tr></table>

<p><table width=100%><tr><td><font size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Examples of
confidential information include, but are not limited to:  the Company&#146;s trade secrets;
business trends and projections; information about  financial performance; new product or
marketing plans; research and development  ideas or information; manufacturing processes;
information about potential  acquisitions, divestitures and investments; stock splits,
public or private  securities offerings or changes in dividend policies or amounts;
significant  personnel changes; and existing or potential major contracts, orders,
suppliers,  customers or finance sources or the loss thereof.</font></td></tr></table>

<p><table width=100%><tr><td><font size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Your obligation
with respect to confidential information extends beyond  the workplace. In that respect,
it applies to communications with your family  members and continues to apply even after
your employment or director  relationship with the Company terminates.</font></td></tr></table>

<p><table width=100%><tr>
    <td><font size=2><B>8. &nbsp;Fair Dealing</B></font></td>
  </tr></table>

<p><table width=100%><tr><td>
<font size=2><B><I>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our goal is
to conduct our business with integrity.</I></B></font></td></tr></table>

<p><table width=100%><tr><td><font size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;You should
endeavor to deal honestly with the Company&#146;s customers,  suppliers, competitors, and
employees. Under federal and state laws, the Company  is prohibited from engaging in
unfair methods of competition, and unfair or  deceptive acts and practices. You should
not take unfair advantage of anyone  through manipulation, concealment, abuse of
privileged information,  misrepresentation of material facts, or any other unfair dealing.</font></td></tr></table>

<p><table width=100%><tr><td><font size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Examples of
prohibited conduct include, but are not limited to:</font></td></tr></table>

<br>
<table width=100%>
  <tr>
    <td width=3%></td>
    <td width=1% valign=top><font size=3>&#149;</font></td>
    <td width=3%></td>
    <td width=93%><font size=2>bribery
or payoffs to induce business or breaches of contracts by others;</font></td></tr></table>

<table width=100%>
  <tr>
    <td width=3%></td>
    <td width=1% valign=top><font size=3>&#149;</font></td>
    <td width=3%></td>
    <td width=93%><font size=2>acquiring
a competitor&#146;s trade secrets through bribery or theft;</font></td></tr></table>

<table width=100%>
  <tr>
    <td width=3%></td>
    <td width=1% valign=top><font size=3>&#149;</font></td>
    <td width=3%></td>
    <td width=93%><font size=2>making
false, deceptive or disparaging claims or comparisons about competitors or their products
or services; or</font></td></tr></table>

<table width=100%>
  <tr>
    <td width=3%></td>
    <td width=1% valign=top><font size=3>&#149;</font></td>
    <td width=3%></td>
    <td width=93%><font size=2>mislabeling
products or services.</font></td></tr></table>

<p>
<p>&nbsp;
<table width=100%><tr><td width=10% align=left><font size=1>&nbsp;</font></td><td width=80% align=center><font size="2">
6</font></td><td width=10% align=right><font size="1">&nbsp;</font></td></tr></table><p>&nbsp;<hr size=5 noshade width=100%align=LEFT>
<p>&nbsp; <!-- *************************************************************************** -->
  <!-- MARKER PAGE="sheet: 25; page: 25" -->
<p>&nbsp;
<table width=100%>
  <tr>
    <td><font size=2><b>9. &nbsp;Protection and Proper Use of Company Assets</b></font></td>
  </tr>
</table>
<br>
<table width=100%><tr><td>
<font size=2><B><I>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;You should
endeavor to protect the Company&#146;s assets and ensure their proper use.</I></B></font></td></tr></table>

<p><table width=100%><tr><td><font size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Company assets,
both tangible and intangible, are to be used only for  legitimate business purposes of
the Company and only by authorized employees or  consultants. Intangible assets include
intellectual property such as trade  secrets, patents, trademarks and copyrights,
business, marketing and service  plans, engineering and manufacturing ideas, designs,
databases, Company records,  salary information, and any unpublished financial data and
reports. Unauthorized  alteration, destruction, use, disclosure or distribution of
Company assets  violates Company policy and this Code. Theft or waste of, or carelessness
in  using, these assets have a direct adverse impact on the Company&#146;s operations and
profitability and will not be tolerated.</font></td></tr></table>

<p><table width=100%><tr><td><font size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company
provides computers, voice mail, electronic mail (e-mail),  and Internet access to certain
employees for the purpose of achieving the  Company&#146;s business objectives. As a result,
the Company has the right to access,  reprint, publish, or retain any information
created, sent or contained in any of  the Company&#146;s computers or e-mail systems of any
Company machine. You may not  use e-mail, the Internet or voice mail for any illegal
purpose or in any manner  that is contrary to the Company&#146;s policies or the standards
embodied in this  Code.</font></td></tr></table>

<p><table width=100%><tr><td><font size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;You should not
make copies of, or resell or transfer (externally or  internally), copyrighted
publications, including software, manuals, articles,  books, and databases being used in
the Company, that were created by another  entity and licensed to the Company, unless you
are authorized to do so under the  applicable license agreement. In no event should you
load or use, on any Company  computer, any software, third party content or database
without receiving the  prior written permission of the Information Systems Department to
do so. You  must refrain from transferring any data or information to any Company
computer  other than for Company use. You may use a handheld computing device or mobile
phone in connection with your work for the Company, but must not use such device  or
phone to access, load or transfer content, software or data in violation of  any
applicable law or regulation or without the permission of the owner of such  content,
software or data. If you should have any question as to what is  permitted in this
regard, please consult with the Company&#146;s Information Systems  Manager.</font></td></tr></table>

<p><table width=100%><tr>
    <td><font size=2><B>10. &nbsp;Reporting Violations of Company Policies and
      Receipt of Complaints Regarding Financial Reporting or <br>
      &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Accounting Issues</B></font></td>
  </tr></table>

<p><table width=100%><tr><td>
<font size=2><B><I>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;You should
report any violation or suspected violation of this Code to the appropriate Company
personnel or via the  Company&#146;s anonymous and confidential reporting procedures.</I></B></font></td></tr></table>

<p><table width=100%><tr><td><font size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company&#146;s
efforts to ensure observance of, and adherence to, the  goals and policies outlined in
this Code mandate that you promptly bring to the  attention of the Compliance Officer any
material transaction, relationship, act,  failure to act, occurrence or practice that you
believe, in good faith, is  inconsistent with, in violation, or reasonably could be
expected to give rise to  a violation, of this Code. You should report any suspected
violations of the  Company&#146;s financial reporting obligations or any complaints or
concerns about  questionable accounting practices in accordance with the procedures set
forth  below.</font></td></tr></table>

<p><table width=100%><tr><td><font size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Here are some
approaches to handling your reporting obligations:</font></td></tr></table>

<br>
<table width=100%>
  <tr>
    <td width=3%></td>
    <td width=1% valign=top><font size=3>&#149;</font></td>
    <td width=3%></td>
    <td width=93%><font size=2>In
the event you believe a violation of the Code, or a violation  of applicable laws and/or
governmental regulations has occurred or  you have observed or become aware of conduct
which appears to be  contrary to the Code, immediately report the situation to the
Company&#146;s Officers or the Compliance Officer.</font></td></tr></table>

<table width=100%>
  <tr>
    <td width=3%></td>
    <td width=1% valign=top><font size=3>&#149;</font></td>
    <td width=3%></td>
    <td width=93%><font size=2>If
you have or receive notice of a complaint or concern regarding  the Company&#146;s financial
disclosure, accounting practices, internal  accounting controls, or questionable
accounting matters, you must  immediately advise the Company&#146;s Officers or the Compliance
Officer.</font></td></tr></table>

<table width=100%>
  <tr>
    <td width=3%></td>
    <td width=1% valign=top><font size=3>&#149;</font></td>
    <td width=3%></td>
    <td width=93%><font size=2>If
you wish to report any such matters anonymously or confidentially, then you  may do so as
follows:</font></td></tr></table>

<table width=100%>
  <tr>
    <td width=3%></td>
    <td width=2% valign=top>&nbsp;</td>
    <td width=3% align="center"><font size=3>&#149;</font></td>
    <td width=3%>&nbsp;</td>
    <td width=89%><font size=2>Mail a description of the suspected violation or
      other complaint or concern to:</font></td>
  </tr>
</table>

<p>
<table width=100%>
  <tr>
    <td width="88">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</td>
    <td width="500"><font size=2><B>Abaxis, Inc. <BR>
      Attention: Compliance Officer <BR>
      3240 Whipple Road <BR>
      Union City, CA 94587</B></font></td>
  </tr>
</table>


<p>&nbsp;
<table width=100%><tr><td width=10% align=left><font size=1>&nbsp;</font></td><td width=80% align=center><font size="2">
7</font></td><td width=10% align=right><font size="1">&nbsp;</font></td></tr></table><p>&nbsp;<hr size=5 noshade width=100%align=LEFT>
<p>&nbsp; <!-- *************************************************************************** -->
  <!-- MARKER PAGE="sheet: 26; page: 26" -->
<p>&nbsp;
<table width=100%>
  <tr>
    <td width=3%></td>
    <td width=2% valign=top>&nbsp;</td>
    <td width=3% align="left" valign="top"><font size=3>&#149;</font></td>
    <td width=3% align="left" valign="top">&nbsp;</td>
    <td width=89% align="left" valign="top"><font size="2">Send an e-mail to:
      <b>complianceofficer@abaxis.com</b> <br>
      <b><i>NOTE: E-mails are <u>not</u> anonymous.</i></b></font></td>
  </tr>
  <tr>
    <td width=3%></td>
    <td width=2% valign=top>&nbsp;</td>
    <td width=3% align="center">&nbsp;</td>
    <td width=3%>&nbsp;</td>
    <td width=89%>&nbsp;</td>
  </tr>
  <tr>
    <td width=3%></td>
    <td width=2% valign=top>&nbsp;</td>
    <td width=3% align="left" valign="top"><font size=3>&#149;</font></td>
    <td width=3% align="left" valign="top">&nbsp;</td>
    <td width=89% align="left" valign="top"><font size="2">Calling our toll free
      Compliance Hotline: <b>1-800-822-2947</b>: <br>
      During business hours, ask to be directed to voice mailbox: <b>1400</b>;
      <br>
      During non-business hours, enter voice mailbox: <b>1400</b></font></td>
  </tr>
</table>
<br>
<table width=100%><tr><td><font size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Reports are
submitted to the Compliance Officer immediately upon  receipt.</font></td></tr></table>

<br>
<table width=100%>
  <tr>
    <td width=3%></td>
    <td width=1% valign=top><font size=3>&#149;</font></td>
    <td width=3%></td>
    <td width=93%><FONT SIZE="2"><U>Use
common sense and good judgment; Act in good faith</U>. You are expected to become familiar
with and to understand the requirements of the Code. If you become aware of a suspected
violation, don&#146;t try to investigate it or resolve it on your own. Prompt disclosure to
the appropriate parties is vital to ensuring a thorough and timely investigation and
resolution. The circumstances should be reviewed by appropriate personnel as promptly
as possible, and delay may affect the results of any investigation. A violation of the
Code, or of applicable laws and/or governmental regulations is a serious matter and
could have legal implications. Allegations of such behavior are not taken lightly and
should not be made to embarrass someone or put him or her in a false light. Reports of
suspected violations should always be made in good faith.</FONT></td></tr></table>

<table width=100%>
  <tr>
    <td width=3%></td>
    <td width=1% valign=top><font size=3>&#149;</font></td>
    <td width=3%></td>
    <td width=93%><FONT SIZE="2"><U>Internal
investigation</U>. When an alleged violation of the Code, applicable laws and/or
governmental regulations is reported, the Company will take appropriate action in
accordance with the compliance procedures outlined in Section 11 of the Code. You are
expected to cooperate in internal investigations of alleged misconduct or violations of
the Code or of applicable laws or regulations.</FONT></td></tr></table>

<table width=100%>
  <tr>
    <td width=3%></td>
    <td width=1% valign=top><font size=3>&#149;</font></td>
    <td width=3%></td>
    <td width=93%><FONT SIZE="2"><U>No
fear of retaliation</U>. It is Company policy that there be no intentional retaliation
against any person who provides truthful information to a Company or law enforcement
official concerning a possible violation of any law, regulation or Company policy,
including this Code. Persons who retaliate may be subject to civil, criminal and
administrative penalties, as well as disciplinary action, up to and including
termination of employment. In cases in which you report a suspected violation in good
faith and are not engaged in the questionable conduct, the Company will attempt to keep
its discussions with you confidential to the extent reasonably possible. In the course
of its investigation, the Company may find it necessary to share information with others
on a &#147;need to know&#148; basis. No retaliation shall be taken against you for
reporting alleged violations while acting in good faith.</FONT></td></tr></table>

<p><table width=100%><tr>
    <td><font size=2><B>11. &nbsp;Compliance Procedures</B></font></td>
  </tr></table>

<p><table width=100%><tr><td><font size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company has
established this Code as part of its overall policies  and procedures. To the extent that
other Company policies and procedures  conflict with this Code, you should follow this
Code. The Code applies to all  Company directors and Company employees, including all
officers, in all  locations.</font></td></tr></table>

<p><table width=100%><tr><td><font size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Code is based
on the Company&#146;s core values, good business practices  and applicable law. The existence
of a Code, however, does not ensure that  directors, officers and employees will comply
with it or act in a legal and  ethical manner. To achieve optimal legal and ethical
behavior, the individuals  subject to the Code must know and understand the Code as it
applies to them and  as it applies to others. You must champion the Code and assist
others in knowing  and understanding it.</font></td></tr></table>

<br>
<table width=100%>
  <tr>
    <td width=3%></td>
    <td width=1% valign=top><font size=3>&#149;</font></td>
    <td width=3%></td>
    <td width=93%><FONT SIZE="2"><U>Compliance</U>.
You are expected to become familiar with and understand the requirements of the Code.
Most importantly, you must comply with it.</FONT></td></tr></table>

<table width=100%>
  <tr>
    <td width=3%></td>
    <td width=1% valign=top><font size=3>&#149;</font></td>
    <td width=3%></td>
    <td width=93%><FONT SIZE="2"><U>CEO
Responsibility</U>. The Company&#146;s CEO shall be responsible for ensuring that the Code is
established and effectively communicated to all employees, officers and directors.
Although the day-to-day compliance issues will be the responsibility of the Company&#146;s
managers, the CEO has ultimate accountability with respect to the overall implementation
of and successful compliance with the Code.</FONT></td></tr></table>

<table width=100%>
  <tr>
    <td width=3%></td>
    <td width=1% valign=top><font size=3>&#149;</font></td>
    <td width=3%></td>
    <td width=93%><FONT SIZE="2"><U>Corporate
Compliance Management</U>. The Corporate Compliance Officer is Zara Thomas, who is
responsible for ensuring that the Code becomes an integral part of the Company&#146;s
culture. The Compliance Officer&#146;s charter is to ensure communication, training,
monitoring, and overall compliance with the Code. The Compliance Officer will, with the
assistance and cooperation of the Company&#146;s officers, directors and</FONT> </td></tr></table>



<p>&nbsp;
<table width=100%><tr><td width=10% align=left><font size=1>&nbsp;</font></td><td width=80% align=center><font size="2">
8</font></td><td width=10% align=right><font size="1">&nbsp;</font></td></tr></table><p>&nbsp;<hr size=5 noshade width=100%align=LEFT>
<p>&nbsp; <!-- *************************************************************************** -->
  <!-- MARKER PAGE="sheet: 27; page: 27" -->
<p>&nbsp;
<table width=100%>
  <tr>
    <td width=3%></td>
    <td width=1% valign=top><font size=3>&nbsp;</font></td>
    <td width=3%></td>
    <td width=93%><font size=2>managers,
foster an atmosphere where  employees are comfortable in communicating and/or reporting
concerns and possible Code violations.</font></td></tr></table>

<table width=100%>
  <tr>
    <td width=3%></td>
    <td width=1% valign=top><font size=3>&#149;</font></td>
    <td width=3%></td>
    <td width=93%><FONT SIZE="2"><U>Internal
Reporting of Violations</U>. The Company&#146;s efforts to ensure observance of, and adherence
to, the goals and policies outlined in this Code mandate that all employees, officers
and directors of the Company report suspected violations in accordance with Section 10
of this Code.</FONT></td></tr></table>

<table width=100%>
  <tr>
    <td width=3%></td>
    <td width=1% valign=top><font size=3>&#149;</font></td>
    <td width=3%></td>
    <td width=93%><FONT SIZE="2"><U>Screening
Of Employees</U>. The Company shall exercise due diligence when hiring and promoting
employees and, in particular, when conducting an employment search for a position
involving the exercise of substantial discretionary authority, such as a member of the
executive team, a senior management position or an employee with financial management
responsibilities. The Company shall make reasonable inquiries into the background of
each individual who is a candidate for such a position. All such inquiries shall be made
in accordance with applicable law and good business practice.</FONT></td></tr></table>

<table width=100%>
  <tr>
    <td width=3%></td>
    <td width=1% valign=top><font size=3>&#149;</font></td>
    <td width=3%></td>
    <td width=93%><FONT SIZE="2"><U>Access
to the Code</U>. The Company shall ensure that employees, officers and directors may access
the Code on the Company&#146;s website. In addition, each current employee will be provided
with a copy of the Code. New employees will receive a copy of the Code as part of their
new hire information.</FONT></td></tr></table>

<table width=100%>
  <tr>
    <td width=3%></td>
    <td width=1% valign=top><font size=3>&#149;</font></td>
    <td width=3%></td>
    <td width=93%><FONT SIZE="2"><U>Monitoring</U>.
The officers of the Company shall be responsible to review the Code with all of the
Company&#146;s managers. In turn, the Company&#146;s managers with supervisory responsibilities
should review the Code with his/her direct reports. Managers are the &#147;go to&#148;
persons for employee questions and concerns relating to the Code, especially in the
event of a potential violation. Managers or supervisors will immediately report any
violations or allegations of violations to the Compliance Officer. Managers will work
with the Compliance Officer in assessing areas of concern, potential violations, any
needs for enhancement of the Code or remedial actions to effect the Code&#146;s policies and
overall compliance with the Code and other related policies.</FONT></td></tr></table>

<table width=100%>
  <tr>
    <td width=3%></td>
    <td width=1% valign=top><font size=3>&#149;</font></td>
    <td width=3%></td>
    <td width=93%><FONT SIZE="2"><U>Internal
Investigation</U>. When an alleged violation of the Code is reported, the Company shall take
prompt and appropriate action in accordance with the law and regulations and otherwise
consistent with good business practice. If the suspected violation appears to involve
either a possible violation of law or an issue of significant corporate interest, or if
the report involves a complaint or concern of any person, whether employee, a shareholder
or other interested person regarding the Company&#146;s financial disclosure, internal
accounting controls, questionable accounting matters or practices or other issues
relating to the Company&#146;s accounting, then the manager or investigator should immediately
notify the Compliance Officer, -who, in turn, shall notify the Audit Committee, as
applicable. If a suspected violation involves any director or executive officer or if
the suspected violation concerns any fraud, whether or not material, involving
management or other employees who have a significant role in the Company&#146;s internal
controls, any person who received such report should immediately report the alleged
violation to the Compliance Officer, if appropriate, the Chief Executive Officer and/or
Chief Financial Officer, and, in every such case, the Audit Committee. The Compliance
Officer or the Audit Committee, as applicable, shall assess the situation and determine
the appropriate course of action. At a point in the process consistent with the need
not to compromise the investigation, a person who is suspected of a violation shall be
apprised of the alleged violation and shall have an opportunity to provide a response to
the investigator.</FONT></td></tr></table>

<table width=100%>
  <tr>
    <td width=3%></td>
    <td width=1% valign=top><font size=3>&#149;</font></td>
    <td width=3%></td>
    <td width=93%><FONT SIZE="2"><U>Disciplinary
Actions</U>. Subject to the following sentence, the Compliance Officer, after consultation
with Human Resources or outside Legal Counsel or the CEO, as applicable, shall be
responsible for implementing the appropriate disciplinary action in accordance with the
Company&#146;s policies and procedures for any employee who is found to have violated the
Code. If a violation has been reported to the Audit Committee or another committee of
the Board, that Committee shall be responsible for determining appropriate disciplinary
action. Any violation of applicable law or any deviation from the standards embodied in
this Code will result in disciplinary action, up to and including termination of
employment. Any employee engaged in the exercise of substantial discretionary authority,
including any Senior Officer, who is found to have engaged in a violation of law or
unethical conduct in connection with the performance of his or her duties for the
Company, shall be removed from his or her position and not assigned to any other position
involving the exercise of substantial discretionary authority. In addition to imposing
discipline upon employees involved in non-compliant conduct, the Company also will
impose discipline, as appropriate, upon an employee&#146;s supervisor, if any, who directs or
approves such employees&#146; improper actions, or is aware of those actions but does not act
appropriately to correct them, and upon other individuals who fail to report known
non-compliant conduct. In addition to imposing its own discipline, the Company will
bring any violations of law to the attention of appropriate law enforcement personnel.</FONT></td></tr></table>



<p>&nbsp;
<table width=100%><tr><td width=10% align=left><font size=1>&nbsp;</font></td><td width=80% align=center><font size="2">
9</font></td><td width=10% align=right><font size="1">&nbsp;</font></td></tr></table><p>&nbsp;<hr size=5 noshade width=100%align=LEFT>
<p>&nbsp; <!-- *************************************************************************** -->
  <!-- MARKER PAGE="sheet: 28; page: 28" -->
<p>&nbsp;
<table width=100%>
  <tr>
    <td width=3%></td>
    <td width=1% valign=top><font size=3>&#149;</font></td>
    <td width=3%></td>
    <td width=93%><FONT SIZE="2"><U>Retention
of Reports and Complaints</U>. All reports and complaints made to or received by Compliance
Officer shall be logged into a record maintained for this purpose by the Compliance
Officer and this record of such report shall be retained for five (5) years.</FONT></td></tr></table>

<table width=100%>
  <tr>
    <td width=3%></td>
    <td width=1% valign=top><font size=3>&#149;</font></td>
    <td width=3%></td>
    <td width=93%><FONT SIZE="2"><U>Required
Government Reporting</U>. Whenever conduct occurs that requires a report to the government,
the Compliance Officer shall be responsible for complying with such reporting
requirements.</FONT></td></tr></table>

<table width=100%>
  <tr>
    <td width=3%></td>
    <td width=1% valign=top><font size=3>&#149;</font></td>
    <td width=3%></td>
    <td width=93%><FONT SIZE="2"><U>Corrective
Actions</U>. Subject to the following sentence, in the event of a violation of the Code, the
manager and Compliance Officer should assess the situation to determine whether the
violation demonstrates a problem that requires remedial action as to Company policies
and procedures. If a violation has been reported to the Audit Committee or another
committee of the Board, that committee shall be responsible for determining appropriate
remedial or corrective actions. Such corrective action may include providing revised
public disclosure, retraining Company employees, modifying Company policies and
procedures, improving monitoring of compliance under existing procedures and other action
necessary to detect similar non-compliant conduct and prevent it from occurring in the
future. Such corrective action shall be documented, as appropriate.</FONT></td></tr></table>

<p><table width=100%><tr>
    <td><font size=2><B>12. &nbsp;Publication of the Code of Business Conduct
      and Ethics; Amendments and Waivers <br>
      &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; of the Code of Business Conduct
      and Ethics</B></font></td>
  </tr></table>

<p><table width=100%><tr><td><font size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The most current
version of this Code will be posted and maintained on  the Company&#146;s website and filed as
an exhibit to the Company&#146;s Annual Report on  Form 10-K. The Company&#146;s Annual Report on
Form 10-K shall disclose that the Code  is maintained on the website and shall disclose
that substantive amendments and  waivers will also be posted on the company&#146;s website.</font></td></tr></table>

<p><table width=100%><tr><td><font size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Any substantive
amendment or waiver of this Code (i.e., a material  departure from the requirements of
any provision) particularly applicable to or  directed at executive officers or directors
may be made only after approval by  the Board of Directors and will be disclosed within
five (5) business days of  such action (a) on the Company&#146;s website for a period of not
less than twelve  (12) months and (b) in a Form 8-K filed with the Securities and
Exchange  Commission. Such disclosure shall include the reasons for any waiver. The
Company shall retain the disclosure relating to any such amendment or waiver for  less
than five (5) years.</font></td></tr></table>



<p>&nbsp;
<table width=100%><tr><td width=10% align=left><font size=1>&nbsp;</font></td><td width=80% align=center><font size="2">
10</font></td><td width=10% align=right><font size="1">&nbsp;</font></td></tr></table><p>&nbsp;<hr size=5 noshade width=100%align=LEFT><p>&nbsp;





<!-- *************************************************************************** -->
<!-- MARKER PAGE="sheet: 29; page: 29" -->



<p><table width=100%><tr><td  align=center><font size=2><B>ABAXIS, INC.</B></font></td></tr></table>

<p><table width=100%><tr><td  align=center><font size=2><B>POLICY FOR REPORTING VIOLATIONS
AND COMPLAINTS</B></font></td></tr></table>

<p><table width=100%><tr>
    <td><FONT SIZE="2"><B>I.&nbsp; <U>Policy Statement</U></B></FONT></td>
  </tr></table>

<p><table width=100%><tr><td><font size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;One of our
Company&#146;s most valuable assets is its integrity. Protecting  this asset is the job of
everyone in the Company. We have established a Code of  Business Conduct and Ethics to
help our employees comply with the law and  regulations applicable to our business and to
maintain the highest standards of  ethical conduct. This policy is meant to supplement
our Code of Business Conduct  and Ethics by encouraging employees to report any suspected
violations or  concerns as to compliance with laws, regulations, our Code of Business
Conduct  and Ethics or other Company policies, or any complaints or concerns regarding
the Company&#146;s financial disclosure, accounting practices, internal accounting  controls,
or questionable accounting matters.</font></td></tr></table>

<p><table width=100%><tr>
    <td><FONT SIZE="2"><B>II.&nbsp; <U>Obligation to Report Suspected or Actual
      Violations; Anonymous Reporting</U></B></FONT></td>
  </tr></table>

<p><table width=100%><tr>
    <td><FONT SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;A.&nbsp; <U>Reporting Generally</U></FONT></td>
  </tr></table>

<p><table width=100%><tr><td><font size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;It is every
employee&#146;s obligation to report suspected or actual  violations of laws, government rules
and regulations, or the Company&#146;s Code of  Business Conduct and Ethics or other Company
policies. You must report any  suspected violations of the laws and rules that govern the
reporting of the  Company&#146;s financial performance, and any complaint or concern regarding
the  Company&#146;s financial disclosure, accounting practices, internal accounting  controls,
or questionable accounting matters.</font></td></tr></table>

<p><table width=100%><tr><td><font size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;You can report any
such matters by the procedures set forth below. As  noted below, supervisors and managers
are required to report to the Compliance  Officer (Zara Thomas) any time they receive a
report of a concern about our  compliance with laws, the Code of Business Conduct and
Ethics or other Company  policy, any notice of any suspected wrong-doing by any Company
employee, officer  or director, any complaint or concern about the Company&#146;s financial
disclosure,  accounting practices, internal accounting controls, or questionable
accounting  matters.</font></td></tr></table>

<p><table width=100%><tr>
    <td><FONT SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;B.&nbsp; A<U>nonymous Reporting</U></FONT></td>
  </tr></table>

<p><table width=100%><tr><td><font size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Alternatively, if
you wish to report any such matters anonymously, you  may do so as follows:</font></td></tr></table>

<p><table width=100%><tr><td><font size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Mail a description
of the suspected violation or other complaint or  concern to:</font></td></tr></table>

<p>
<table width=100%>
  <tr>
    <td width="76">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</td>
    <td width="512"><FONT SIZE="2"><B>Abaxis, Inc. <BR>
      Attention: Compliance Officer <BR>
      3240 Whipple Road <BR>
      Union City, CA 94587</B></FONT></td>
  </tr>
</table>

<br>
<table width=100%>
  <tr>
    <td width=3%></td>
    <td width=1% valign=top><font size=3>&#149;</font></td>
    <td width=3%></td>
    <td width=93%><FONT SIZE="2">Or
send an email to: <B>complianceofficer@abaxis.com</B> <BR><B><I>NOTE: E-mails are not anonymous</I></B>.</FONT></td></tr></table>

<table width=100%>
  <tr>
    <td width=3%></td>
    <td width=1% valign=top><font size=3>&#149;</font></td>
    <td width=3%></td>
    <td width=93%><FONT SIZE="2">Calling our toll free Compliance Hotline: <B>1-800-822-2947</B>:
      <BR>
      &nbsp;&nbsp;&nbsp;&nbsp;-During business hours, ask to be directed to voice
      mailbox: <B>1400</B> <BR>
      &nbsp;&nbsp;&nbsp;&nbsp;-During non-business hours, enter voice mailbox:
      <B>1400</B></FONT></td>
  </tr></table>

<p><table width=100%><tr><td><font size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Reports are
submitted to the Compliance Officer immediately upon  receipt.</font></td></tr></table>

<p><table width=100%><tr>
    <td><FONT SIZE="2"><B>III.&nbsp; <U>Treatment and Retention of Complaints
      and Reports</U></B></FONT></td>
  </tr></table>

<p><table width=100%><tr><td><font size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Each supervisor
and manager shall report any suspected violation,  concern or complaint reported to such
person by employees or other sources to  the Compliance Officer to assure proper
treatment and retention of complaints,  concerns or notices of potential violations. In
addition, employees should take  note that persons outside the Company may report
complaints or concerns about  suspected violations, or concerns regarding accounting
matters or internal  accounting controls. These concerns and complaints should be
reported  immediately on receipt to the Compliance Officer.</font></td></tr></table>

<p><table width=100%><tr><td><font size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Compliance
Officer shall promptly consider the information, reports  or notices received under this
policy or otherwise and take the appropriate  action, including investigation as
appropriate, in accordance with the law,  governmental </font></td></tr></table>


<p>&nbsp;
<table width=100%><tr><td width=10% align=left><font size=1>&nbsp;</font></td><td width=80% align=center><font size="2">
11</font></td><td width=10% align=right><font size="1">&nbsp;</font></td></tr></table><p>&nbsp;<hr size=5 noshade width=100%align=LEFT><p>&nbsp;





<!-- *************************************************************************** -->
<!-- MARKER PAGE="sheet: 30; page: 30" -->



<p><table width=100%><tr><td><font size=2>rules and regulations, the Company&#146;s Code of
Business Conduct and  Ethics and otherwise consistent with good business practice.</font></td></tr></table>

<p><table width=100%><tr><td><font size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Upon a report to
the Compliance Officer, all notices or reports of  suspected violations, complaints or
concerns received pursuant to this policy  shall be recorded in a log, indicating the
description of the matter reported,  the date of the report and the disposition thereof,
and the log shall be  retained for five years. This log shall be maintained by the
Compliance Officer.</font></td></tr></table>

<p><table width=100%><tr>
    <td><FONT SIZE="2"><B>IV.&nbsp; <U>Statement of Non-Retaliation</U></B></FONT></td>
  </tr></table>

<p><table width=100%><tr><td><font size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;It is a federal
crime for anyone to retaliate intentionally against any  person who provides truthful
information to a law enforcement official  concerning a possible violation of any federal
law. Moreover, the Company will  not permit any form of intimidation or retaliation by
any officer, employee,  contractor, subcontractor or agent of the Company against any
employee because  of any lawful act done by that employee to:</font></td></tr></table>

<br>
<table width=100%>
  <tr>
    <td width=3%></td>
    <td width=1% valign=top><font size=3>&#149;</font></td>
    <td width=3%></td>
    <td width=93%><font size=2>provide
information or assist in an investigation regarding any  conduct which the employee
reasonably believes constitutes a  violation of laws, rules, regulations, the Company&#146;s
Code of  Business Conduct and Ethics, or any Company policies; or</font></td></tr></table>

<table width=100%>
  <tr>
    <td width=3%></td>
    <td width=1% valign=top><font size=3>&#149;</font></td>
    <td width=3%></td>
    <td width=93%><font size=2>file,
testify, participate in, or otherwise assist in a proceeding  relating to a violation of
any law, rule or regulation.</font></td></tr></table>

<p><table width=100%><tr><td>
<font size=2><B><I>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Any such
action is a violation of Company policy and should be reported immediately under this
policy.</I></B></font></td></tr></table>

<p><table width=100%><tr>
    <td><FONT SIZE="2"><B>V. <U>&nbsp;Statement of Confidentialit</U>y</B></FONT></td>
  </tr></table>

<p><table width=100%><tr><td><font size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company will,
to the extent reasonably possible, keep confidential  both the information and concerns
reported under this policy, and its  discussions and actions in response to these reports
and concerns. In the course  of its investigation, however, the Company may find it
necessary to share  information with others on a &#147;need to know&#148; basis.</font></td></tr></table>


<p>&nbsp;
<table width=100%><tr><td width=10% align=left><font size=1>&nbsp;</font></td><td width=80% align=center><font size="2">
12</font></td><td width=10% align=right><font size="1">&nbsp;</font></td></tr></table><p>&nbsp;<hr size=5 noshade width=100%align=LEFT><p>&nbsp;


</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-21.1
<SEQUENCE>4
<FILENAME>e18184ex21_1.htm
<DESCRIPTION>SUBSIDIARIES OF REGISTRANT
<TEXT>
<html>
<head>
<title> </title>
</head>
<body>





<p><table width=100%><tr><td align=right><font size=2><B>EXHIBIT 21.1</B></font></td></tr></table>

<p><table width=100%><tr><td  align=center><font size=2><B>SUBSIDIARIES OF REGISTRANT</B></font></td></tr></table>

<p><table width=100%><tr>
    <td><font size=2>None.</font></td>
  </tr></table>


<p>&nbsp;
<table width=100%><tr><td width=10% align=left><font size=1>&nbsp;</font></td><td width=80% align=center><font size="2">
</font></td><td width=10% align=right><font size="1">&nbsp;</font></td></tr></table><p>&nbsp;<hr size=5 noshade width=100%align=LEFT><p>&nbsp;

</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>5
<FILENAME>e18184ex23_1.htm
<DESCRIPTION>CONSENT OF INDEPENDENT ACCOUNTANTS
<TEXT>
<html>
<head>
<title> </title>
</head>
<body>




<p><table width=100%>
  <tr align="right">
    <td><font size=2><b>EXHIBIT 23.1</b></font></td>
  </tr></table>

<p><table width=100%><tr>
    <td  align=center><font size=2><b>CONSENT OF INDEPENDENT REGISTERED PUBLIC
      ACCOUNTING FIRM</b></font></td>
  </tr></table>


<p><table width=100%><tr>
    <td><font size="2">We consent to the incorporation by reference in Registration
      Statements Nos. 33-49758, 33-85744, 333-07541, 333-85131, 333-65812, <br>
      333-84356, 333-102185 and 333-112815 on Form S-8 and Nos. 333-69999, 333-53484
      and 333-98475 on Form S-3 of Abaxis, Inc. of our reports dated June 11,
      2004, appearing in this Annual Report on Form 10-K of Abaxis, Inc. for the
      year ended March 31, 2004.</font></td>
  </tr></table>

<p><table width=100%><tr>
    <td height="15"><font size="2">/s/ DELOITTE &amp; TOUCHE LLP <br>
      San Jose, California <br>
      June 11, 2004 </font></td>
  </tr></table>

<p>
<p>
<p><font size="2"> </font>
<hr size=5 noshade width=100% align=LEFT><p>&nbsp;


</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>6
<FILENAME>e18184ex31_1.htm
<DESCRIPTION>CERTIFICATION
<TEXT>
<html>
<head>
<title> </title>
</head>
<body>




<p><table width=100%><tr><td  align=center><font size=2><B>EXHIBIT 31.1</B></font></td></tr></table>

<p><table width=100%><tr><td  align=center><font size=2><B>Sarbanes-Oxley Section 302(a)
Certification</B></font></td></tr></table>


<p><table width=100%><tr><td><font size=2>I, Clinton H. Severson, certify that:</font></td></tr></table>

<p><table width=100%><tr><td><font size=2>1. I have reviewed this Annual report on Form
10-K of Abaxis, Inc.;</font></td></tr></table>

<p><table width=100%><tr><td><font size=2>2. Based on my knowledge, this report does not
contain any untrue statement of a  material fact or omit to state a material fact
necessary to make the statements  made, in light of the circumstances under which such
statements were made, not  misleading with respect to the period covered by this report;</font></td></tr></table>

<p><table width=100%><tr><td><font size=2>3. Based on my knowledge, the financial
statements, and other financial  information included in this report, fairly present in
all material respects the  financial condition, results of operations and cash flows of
the registrant as  of, and for, the periods presented in this annual report;</font></td></tr></table>

<p><table width=100%><tr><td><font size=2>4. The registrant&#146;s other certifying officer and
I are responsible for  establishing and maintaining disclosure controls and procedures
(as defined in  Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and we
have:</font></td></tr></table>

<p><table width=100%><tr><td><font size=2>a) Designed such disclosure controls and
procedures, or caused such disclosure  controls and procedures to be designed under our
supervision, to ensure that  material information relating to the registrant, including
its consolidated  subsidiaries, is made known to us by others within those entities,
particularly  during the period in which this report is being prepared;</font></td></tr></table>

<p><table width=100%><tr><td><font size=2>b) Evaluated the effectiveness of the
registrant&#146;s disclosure controls and  procedures and presented in this report our
conclusions about the effectiveness  of the disclosure controls and procedures, as of the
end of the period covered  by this report based on such evaluation; and</font></td></tr></table>

<p><table width=100%><tr><td><font size=2>c) Disclosed in this report any change in the
registrant&#146;s internal control over  financial reporting that occurred during the
registrant&#146;s most recent fiscal  quarter (the registrant&#146;s fourth fiscal quarter in the
case of an annual report)  that has materially affected, or is reasonably likely to
materially affect, the  registrant&#146;s internal control over financial reporting; and</font></td></tr></table>

<p><table width=100%><tr><td><font size=2>5. The registrant&#146;s other certifying officer and
I have disclosed, based on our  most recent evaluation of internal control over financial
reporting, to the  registrant&#146;s auditors and the audit committee of the registrant&#146;s
board of  directors (or persons performing the equivalent functions):</font></td></tr></table>

<p><table width=100%><tr><td><font size=2>a) All significant deficiencies and material
weaknesses in the design or  operation of internal control over financial reporting which
are reasonably  likely to adversely affect the registrant&#146;s ability to record, process,
summarize and report financial information; and</font></td></tr></table>

<p><table width=100%><tr><td><font size=2>b) Any fraud, whether or not material, that
involves management or other  employees who have a significant role in the registrant&#146;s
internal control over  financial reporting.</font></td></tr></table>


<p>
<table width=100%>
  <tr align="left" valign="top">
    <td width="168"><font size=2>Date: June 14, 2004</font></td>
    <td width="96">&nbsp;&nbsp;&nbsp;&nbsp;</td>
    <td width="320"><font size=2> <u>/s/ Clinton H. Severson</u> <br>
      Clinton H. Severson <br>
      <i>President and Chief Executive Officer</i> </font></td>
  </tr>
</table>

<p><table width=100%><tr>
    <td>&nbsp;</td>
  </tr></table>



<p>&nbsp;
<table width=100%><tr><td width=10% align=left><font size=1>&nbsp;</font></td><td width=80% align=center><font size="2">
</font></td><td width=10% align=right><font size="1">&nbsp;</font></td></tr></table><p>&nbsp;<hr size=5 noshade width=100%align=LEFT><p>&nbsp;


</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>7
<FILENAME>e18184ex31_2.htm
<DESCRIPTION>CERTIFICATION
<TEXT>
<html>
<head>
<title> </title>
</head>
<body>







<p><table width=100%><tr><td align=right><font size=2><B>EXHIBIT 31.2</B></font></td></tr></table>

<p><table width=100%><tr><td  align=center><font size=2><B>Sarbanes-Oxley Section 302(a)
Certification</B></font></td></tr></table>

<p><table width=100%><tr><td><font size=2>I, Alberto R. Santa Ines, certify that:</font></td></tr></table>

<p><table width=100%><tr><td><font size=2>1. I have reviewed this Annual report on Form
10-K of Abaxis, Inc.;</font></td></tr></table>

<p><table width=100%><tr><td><font size=2>2. Based on my knowledge, this report does not
contain any untrue statement of a  material fact or omit to state a material fact
necessary to make the statements  made, in light of the circumstances under which such
statements were made, not  misleading with respect to the period covered by this report;</font></td></tr></table>

<p><table width=100%><tr><td><font size=2>3. Based on my knowledge, the financial
statements, and other financial  information included in this report, fairly present in
all material respects the  financial condition, results of operations and cash flows of
the registrant as  of, and for, the periods presented in this annual report;</font></td></tr></table>

<p><table width=100%><tr><td><font size=2>4. The registrant&#146;s other certifying officer and
I are responsible for  establishing and maintaining disclosure controls and procedures
(as defined in  Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and we
have:</font></td></tr></table>

<p><table width=100%><tr><td><font size=2>a) Designed such disclosure controls and
procedures, or caused such disclosure  controls and procedures to be designed under our
supervision, to ensure that  material information relating to the registrant, including
its consolidated  subsidiaries, is made known to us by others within those entities,
particularly  during the period in which this report is being prepared;</font></td></tr></table>

<p><table width=100%><tr><td><font size=2>b) Evaluated the effectiveness of the
registrant&#146;s disclosure controls and  procedures and presented in this report our
conclusions about the effectiveness  of the disclosure controls and procedures, as of the
end of the period covered  by this report based on such evaluation; and</font></td></tr></table>

<p><table width=100%><tr><td><font size=2>c) Disclosed in this report any change in the
registrant&#146;s internal control over  financial reporting that occurred during the
registrant&#146;s most recent fiscal  quarter (the registrant&#146;s fourth fiscal quarter in the
case of an annual report)  that has materially affected, or is reasonably likely to
materially affect, the  registrant&#146;s internal control over financial reporting; and</font></td></tr></table>

<p><table width=100%><tr><td><font size=2>5. The registrant&#146;s other certifying officer and
I have disclosed, based on our  most recent evaluation of internal control over financial
reporting, to the  registrant&#146;s auditors and the audit committee of the registrant&#146;s
board of  directors (or persons performing the equivalent functions):</font></td></tr></table>

<p><table width=100%><tr><td><font size=2>a) All significant deficiencies and material
weaknesses in the design or  operation of internal control over financial reporting which
are reasonably  likely to adversely affect the registrant&#146;s ability to record, process,
summarize and report financial information; and</font></td></tr></table>

<p><table width=100%><tr><td><font size=2>b) Any fraud, whether or not material, that
involves management or other  employees who have a significant role in the registrant&#146;s
internal control over  financial reporting.</font></td></tr></table>


<p>
<table width=100%>
  <tr align="left" valign="top">
    <td width="205"><font size=2>Date: June 14, 2004</font></td>
    <td width="66">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</td>
    <td width="313"><font size=2> <u>/s/ Alberto R. Santa Ines</u><br>
      Alberto R. Santa Ines <br>
      <i>Chief Financial Officer and Vice President of Finance</i></font></td>
  </tr>
</table>


<p>&nbsp;
<table width=100%><tr><td width=10% align=left><font size=1>&nbsp;</font></td><td width=80% align=center><font size="2">
</font></td><td width=10% align=right><font size="1">&nbsp;</font></td></tr></table><p>&nbsp;<hr size=5 noshade width=600 align=LEFT><p>&nbsp;


</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>8
<FILENAME>e18184ex32_1.htm
<DESCRIPTION>CERTIFICATION
<TEXT>
<html>
<head>
<title> </title>
</head>
<body>





<p><table width=100%><tr><td align=right><font size=2><B>EXHIBIT 32.1</B></font></td></tr></table>

<p><table width=100%><tr><td  align=center><font size=2><B>Certification of Chief
Executive Officer</B></font></td></tr></table>

<p><table width=100%><tr><td><font size=2>I, Clinton H. Severson, Chief Executive Officer
of Abaxis, Inc. (the &#147;Registrant&#148;), do hereby certify in accordance with  18
U.S.C. 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:</font></td></tr></table>

<P>
<table width=100%>
  <tr>
    <td width=5% valign=top>&nbsp;</td>
    <td width=5% valign="top" align="left"><font size="2">(1) </font></td>
    <td width=90% align="left" valign="top"><font size="2">the Annual Report on
      Form 10-K of the Registrant, to which this certification is attached as
      an exhibit (the &#147;Report&#148;), fully complies with the requirements
      of section 13(a) of the Securities Exchange Act of 1934 (15 U.S.C. 78m);
      and</font></td>
  </tr>
  <tr>
    <td width=5% valign=top>&nbsp;</td>
    <td width=5% valign="top" align="left">&nbsp;</td>
    <td width=90% align="left" valign="top">&nbsp;</td>
  </tr>
  <tr>
    <td width=5% valign=top>&nbsp;</td>
    <td width=5% valign="top" align="left"><font size="2">(2) </font></td>
    <td width=90% align="left" valign="top"><font size="2">the information contained
      in the Report fairly presents, in all material respects, the financial condition
      and results of operations of the Registrant.</font></td>
  </tr>
</table>

<p><table width=100%><tr><td><font size=2>Dated:  June 14, 2004</font></td></tr></table>

<p>
<table width=100%>
  <tr>
    <td width="302">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</td>
    <td width="286"><font size=2>By: <u>/s/ Clinton H. Severson</u> <br>
      Clinton H. Severson <br>
      President and Chief Executive Officer</font></td>
  </tr>
</table>



<p>&nbsp;
<table width=100%><tr><td width=10% align=left><font size=1>&nbsp;</font></td><td width=80% align=center><font size="2">
</font></td><td width=10% align=right><font size="1">&nbsp;</font></td></tr></table><p>&nbsp;<hr size=5 noshade width=100%align=LEFT><p>&nbsp;


</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>9
<FILENAME>e18184ex32_2.htm
<DESCRIPTION>CERTIFICATION
<TEXT>
<html>
<head>
<title> </title>
</head>
<body>

















<p><table width=100%><tr><td align=right><font size=2><B>EXHIBIT 32.2</B></font></td></tr></table>

<p><table width=100%><tr><td  align=center><font size=2><B>Certification of Chief
Financial Officer</B></font></td></tr></table>

<p><table width=100%><tr><td><font size=2>I, Alberto R. Santa Ines, Chief Financial
Officer of Abaxis, Inc. (the &#147;Registrant&#148;), do hereby certify in accordance
with 18 U.S.C. 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of
2002, that:</font></td></tr></table>

<P>
<table width=100%>
  <tr>
    <td width=5% valign=top>&nbsp;</td>
    <td width=5% valign="top" align="left"><font size="2">(1) </font></td>
    <td width=90% align="left" valign="top"><font size="2">the Annual Report on
      Form 10-K of the Registrant, to which this certification is attached as
      an exhibit (the &#147;Report&#148;), fully complies with the requirements
      of section 13(a) of the Securities Exchange Act of 1934 (15 U.S.C. 78m);
      and</font></td>
  </tr>
  <tr>
    <td width=5% valign=top>&nbsp;</td>
    <td width=5% valign="top" align="left">&nbsp;</td>
    <td width=90% align="left" valign="top">&nbsp;</td>
  </tr>
  <tr>
    <td width=5% valign=top>&nbsp;</td>
    <td width=5% valign="top" align="left"><font size="2">(2)</font></td>
    <td width=90% align="left" valign="top"><font size="2">the information contained
      in the Report fairly presents, in all material respects, the financial condition
      and results of operations of the Registrant.</font></td>
  </tr>
</table>

<P>
<p><table width=100%><tr><td><font size=2>Dated:  June 14, 2004</font></td></tr></table>

<p>
<table width=100%>
  <tr>
    <td width="276">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</td>
    <td width="312"><FONT SIZE="2">By: <U>/s/ Alberto R. Santa Ines</U> <BR>
      Alberto R. Santa Ines <BR>
      Vice President, Finance and Chief Financial Officer</FONT></td>
  </tr>
</table>



<p>&nbsp;
<table width=100%><tr><td width=10% align=left><font size=1>&nbsp;</font></td><td width=80% align=center><font size="2">
</font></td><td width=10% align=right><font size="1">&nbsp;</font></td></tr></table><p>&nbsp;<hr size=5 noshade width=100%align=LEFT><p>&nbsp;


</body>
</html>

</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
